<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30692699</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>ApoE attenuates unresolvable inflammation by complex formation with activated C1q.</ArticleTitle><Pagination><StartPage>496</StartPage><EndPage>506</EndPage><MedlinePgn>496-506</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-018-0336-8</ELocationID><Abstract><AbstractText>Apolipoprotein-E (ApoE) has been implicated in Alzheimer's disease, atherosclerosis, and other unresolvable inflammatory conditions but a common mechanism of action remains elusive. We found in ApoE-deficient mice that oxidized lipids activated the classical complement cascade (CCC), resulting in leukocyte infiltration of the choroid plexus (ChP). All human ApoE isoforms attenuated CCC activity via high-affinity binding to the activated CCC-initiating C1q protein (K<sub>D</sub>~140-580 pM) in vitro, and C1q-ApoE complexes emerged as markers for ongoing complement activity of diseased ChPs, A&#x3b2; plaques, and atherosclerosis in vivo. C1q-ApoE complexes in human ChPs, A&#x3b2; plaques, and arteries correlated with cognitive decline and atherosclerosis, respectively. Treatment with small interfering RNA (siRNA) against C5, which is formed by all complement pathways, attenuated murine ChP inflammation, A&#x3b2;-associated microglia accumulation, and atherosclerosis. Thus, ApoE is a direct checkpoint inhibitor of unresolvable inflammation, and reducing C5 attenuates disease burden.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Changjun</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1913-4477</Identifier><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany. changjun.yin@med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. changjun.yin@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ackermann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8179-5201</Identifier><AffiliationInfo><Affiliation>Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohanta</LastName><ForeName>Sarajo K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0001-6144-4092</Identifier><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chuankai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuanfang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nietzsche</LastName><ForeName>Sandor</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Electron Microscopy, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Electron Microscopy, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine of Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Desheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bontha</LastName><ForeName>Sai Vineela</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0001-8914-1966</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Tennessee, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srikakulapu</LastName><ForeName>Prasad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center (CVRC), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Information Technology, University Clinic Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Megens</LastName><ForeName>Remco T A</ForeName><Initials>RTA</Initials><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steffens</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildner</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Anatomy II, University Clinic Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halder</LastName><ForeName>Luke D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckstein</LastName><ForeName>Hans-Henning</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department for Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelisek</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department for Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roeber</LastName><ForeName>Sigrun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borodovsky</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alnylam Pharmaceuticals Cambridge, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habenicht</LastName><ForeName>Livia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Christoph J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Vienna and Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4610-8714</Identifier><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zipfel</LastName><ForeName>Peter F</ForeName><Initials>PF</Initials><Identifier Source="ORCID">0000-0002-6149-2411</Identifier><AffiliationInfo><Affiliation>Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedrich-Schiller-University, Faculty of Biological Sciences, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skerka</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2374-6473</Identifier><AffiliationInfo><Affiliation>Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany. christine.skerka@hki-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habenicht</LastName><ForeName>Andreas J R</ForeName><Initials>AJR</Initials><Identifier Source="ORCID">0000-0003-2901-3027</Identifier><AffiliationInfo><Affiliation>Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000936">Antigen-Antibody Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003182">Complement C5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2019 Mar;25(3):529. doi: 10.1038/s41591-019-0378-6.</RefSource><PMID Version="1">30718908</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Cardiol. 2019 May;16(5):259-260. doi: 10.1038/s41569-019-0182-5.</RefSource><PMID Version="1">30903022</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000936" MajorTopicYN="N">Antigen-Antibody Complex</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001011" MajorTopicYN="N">Aorta</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002339" MajorTopicYN="N">Carotid Arteries</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002340" MajorTopicYN="N">Carotid Artery Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="N">Choroid Plexus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003182" MajorTopicYN="N">Complement C5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003171" MajorTopicYN="N">Complement Pathway, Classical</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007962" MajorTopicYN="N">Leukocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074085" MajorTopicYN="N">Mice, Knockout, ApoE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests Statement</b>. C.Y., A.J.R.H., A.B., S.K.M., S.A., P.F.Z., and C.S. declare competing
financial interests. C.Y., S.K.M., and A.J.R.H. are owners of Easemedcontrol R
&amp; D GmbH &amp; Co KG Munich, Germany; A.B. is employed by Alnylam
Pharmaceuticals Cambridge; Cambridge, MA, USA; C.Y. and A.J.R.H. have been named
inventors on a pending patent application related to treatment and diagnosis of
unresolvable inflammatory diseases (EP18183584.4); A.B. has been named as an
inventor on patent applications related to C5 including PCT publication
WO2014160129, and applications and patents based thereon; S.A., P.F.Z., and C.S.
have been named inventors on a pending patent application (DE 10 2018 100
377.3).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30692699</ArticleId><ArticleId IdType="mid">EMS80920</ArticleId><ArticleId IdType="pmc">PMC6420126</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0336-8</ArticleId><ArticleId IdType="pii">10.1038/s41591-018-0336-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bell RD, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2 a006312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Xu H, Bu G. ApoE and A&#x3b2; in Alzheimer&#x2019;s disease: accidental encounters or partners? Neuron. 2014;81:740&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983361</ArticleId><ArticleId IdType="pubmed">24559670</ArticleId></ArticleIdList></Reference><Reference><Citation>Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995;267:1034&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">7863332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009;50(Suppl):S183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674716</ArticleId><ArticleId IdType="pubmed">19106071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol. 2013;70:440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414030</ArticleId><ArticleId IdType="pubmed">23400708</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron. 2012;76:871&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4891195</ArticleId><ArticleId IdType="pubmed">23217737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">21321594</ArticleId></ArticleIdList></Reference><Reference><Citation>Que X, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018;558:301&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6033669</ArticleId><ArticleId IdType="pubmed">29875409</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat Immunol. 2016;17:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun MP, Monuki ES, Lehtinen MK. Development and functions of the choroid plexus-cerebrospinal fluid system. Nat Rev Neurosci. 2015;16:445&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629451</ArticleId><ArticleId IdType="pubmed">26174708</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore GR, et al. Complement and humoral adaptive immunity in the human choroid plexus: roles for stromal concretions, basement membranes, and epithelium. J Neuropathol Exp Neurol. 2016;75:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4824036</ArticleId><ArticleId IdType="pubmed">26994633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903150</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 2014;33:7&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990679</ArticleId><ArticleId IdType="pubmed">24357543</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014;346:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol. 2016;16:485&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097710</ArticleId><ArticleId IdType="pubmed">27346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Weismann D, et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. 2011;478:76&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826616</ArticleId><ArticleId IdType="pubmed">21979047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9:729&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">19730437</ArticleId></ArticleIdList></Reference><Reference><Citation>Arlaud GJ, Biro A, Ling WL. Enzymatically modified low-density lipoprotein is recognized by C1q and activates the classical complement pathway. Journal of Lipids. 2011;2011 376092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066639</ArticleId><ArticleId IdType="pubmed">21490800</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo K, et al. Complement factor H binds to human serum apolipoprotein E and mediates complement regulation on high density lipoprotein particles. J Biol Chem. 2015;290:28977&#x2013;28987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4661410</ArticleId><ArticleId IdType="pubmed">26468283</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson C, et al. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 1991;252:1817&#x2013;1822.</Citation><ArticleIdList><ArticleId IdType="pubmed">2063194</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman Girija U, et al. Structural basis of the C1q/C1s interaction and its central role in assembly of the C1 complex of complement activation. Proc Natl Acad Sci U S A. 2013;110:13916&#x2013;13920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752233</ArticleId><ArticleId IdType="pubmed">23922389</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Soderberg O, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Meth. 2006;3:995&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072308</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:11183&#x2013;11186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45191</ArticleId><ArticleId IdType="pubmed">7972031</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, et al. A&#x3b2;42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO reports. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabner R, et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med. 2009;206:233&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626665</ArticleId><ArticleId IdType="pubmed">19139167</ArticleId></ArticleIdList></Reference><Reference><Citation>Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20:1177&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10807728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolev M, Friec GL, Kemper C. Complement - tapping into new sites and effector systems. Nat Rev Immunol. 2014;14:811&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">25394942</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasek MJ, et al. A complement&#x2013;microglial axis drives synapse loss during virus-induced memory impairment. Nature. 2016;534:538&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452615</ArticleId><ArticleId IdType="pubmed">27337340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajishengallis G, et al. Novel mechanisms and functions of complement. Nat Immunol. 2017;18:1288&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706779</ArticleId><ArticleId IdType="pubmed">29144501</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140:935&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752337</ArticleId><ArticleId IdType="pubmed">20303881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013;190</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623009</ArticleId><ArticleId IdType="pubmed">23564577</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339:166&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608517</ArticleId><ArticleId IdType="pubmed">23307734</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. The Journal of Neuroscience. 2004;24:6457&#x2013;6465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729885</ArticleId><ArticleId IdType="pubmed">15269255</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YA, Zhou B, Wernig M, Sudhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Abeta secretion. Cell. 2017;168:427&#x2013;441 e421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of beta-amyloidosis. Neuron. 2017;96:1013&#x2013;1023.e1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="pubmed">29216448</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96:1024&#x2013;1032.e1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215:1047&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018;24:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner AJ, Stevens B, Woodruff TM. New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. Mol Immunol. 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478444</ArticleId><ArticleId IdType="pubmed">29958698</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12:267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">25583619</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman A, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997;349:151&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">9111537</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo ACL, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Frontiers in Immunology. 2016;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764694</ArticleId><ArticleId IdType="pubmed">26941740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Knouff C, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103:1579&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408371</ArticleId><ArticleId IdType="pubmed">10359567</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008;18:484&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659377</ArticleId><ArticleId IdType="pubmed">18371174</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117:309&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910889</ArticleId><ArticleId IdType="pubmed">19184666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Timaran CH, McKinsey JF, Schneider PA, Littooy F. Reporting standards for carotid interventions from the Society for Vascular Surgery. J Vasc Surg. 2011;53:1679&#x2013;1695.</Citation><ArticleIdList><ArticleId IdType="pubmed">21609800</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott AL, et al. Systematic Review of Guidelines for the Management of Asymptomatic and Symptomatic Carotid Stenosis. Stroke. 2015;46:3288&#x2013;3301.</Citation><ArticleIdList><ArticleId IdType="pubmed">26451020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu D, et al. Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin &#x3b2; Receptors. Immunity. 2015;42:1100&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4678289</ArticleId><ArticleId IdType="pubmed">26084025</ArticleId></ArticleIdList></Reference><Reference><Citation>Greissel A, et al. Alternation of histone and DNA methylation in human atherosclerotic carotid plaques. Thromb Haemost. 2015;114:390&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">25993995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendorff C, et al. Carotid Plaque Morphology Is Significantly Associated With Sex, Age, and History of Neurological Symptoms. Stroke. 2015;46:3213&#x2013;3219.</Citation><ArticleIdList><ArticleId IdType="pubmed">26451032</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin K, George P. The Mouse Brain in Stereotaxic Coordinates, Compact. (3rd Edition) 2007</Citation></Reference><Reference><Citation>Zhao L, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004;10:966&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322539</ArticleId></ArticleIdList></Reference><Reference><Citation>Haege S, et al. CXC Chemokine Receptor 7 (CXCR7) Regulates CXCR4 Protein Expression and Capillary Tuft Development in Mouse Kidney. PLoS ONE. 2012;7 e42814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412803</ArticleId><ArticleId IdType="pubmed">22880115</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin C, et al. Generation of Aorta Transcript Atlases of Wild-Type and Apolipoprotein E-null Mice by Laser Capture Microdissection-Based mRNA Expression Microarrays. Methods Mol Biol. 2015;1339:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">26445797</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer M, et al. Laser-capture microdissection of hyperlipidemic/ApoE-/- mouse aorta atherosclerosis. Methods Mol Biol. 2011;755:417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">21761324</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch TK, et al. Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. PLoS One. 2012;7 e47638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3469469</ArticleId><ArticleId IdType="pubmed">23071827</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30699343</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>REST and Neural Gene Network Dysregulation in iPSC Models of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1112</StartPage><EndPage>1127.e9</EndPage><MedlinePgn>1112-1127.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2019.01.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(19)30032-4</ELocationID><Abstract><AbstractText>The molecular basis of the earliest neuronal changes that lead to Alzheimer's disease (AD) is unclear. Here, we analyze neural cells derived from sporadic AD (SAD), APOE4 gene-edited and control induced pluripotent stem cells (iPSCs). We observe major differences in iPSC-derived neural progenitor (NP) cells and neurons in gene networks related to neuronal differentiation, neurogenesis, and synaptic transmission. The iPSC-derived neural cells from SAD patients exhibit accelerated neural differentiation and reduced progenitor cell renewal. Moreover, a similar phenotype appears in NP cells and cerebral organoids derived from APOE4 iPSCs. Impaired function of the transcriptional repressor REST is strongly implicated in the altered transcriptome and differentiation state. SAD and APOE4 expression result in reduced REST nuclear translocation and chromatin binding, and disruption of the nuclear lamina. Thus, dysregulation of neural gene networks may set in motion the pathologic cascade that leads to AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drake</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Elaine T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>King-Hwa</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jinsoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yuan-Ta</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Susan C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Church</LastName><ForeName>George M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. Electronic address: bruce_yankner@hms.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH113279</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 HG008525</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 OD006849</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048056</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092779">RE1-silencing transcription factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065150" MajorTopicYN="N">Cellular Reprogramming</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="Y">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034881" MajorTopicYN="N">Nuclear Lamina</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">REST</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword><Keyword MajorTopicYN="N">epigenetic</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cell</Keyword><Keyword MajorTopicYN="N">neural differentiation</Keyword><Keyword MajorTopicYN="N">neural progenitor</Keyword><Keyword MajorTopicYN="N">neurogenesis</Keyword><Keyword MajorTopicYN="N">organoid</Keyword><Keyword MajorTopicYN="N">polycomb</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30699343</ArticleId><ArticleId IdType="mid">NIHMS1519914</ArticleId><ArticleId IdType="pmc">PMC6386196</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.01.023</ArticleId><ArticleId IdType="pii">S2211-1247(19)30032-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adeosun SO, Hou X, Zheng B, Stockmeier C, Ou X, Paul I, Mosley T, Weisgraber K, and Wang JM (2014). Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction. J. Biol. Chem 289, 2946&#x2013;2959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3908426</ArticleId><ArticleId IdType="pubmed">24324264</ArticleId></ArticleIdList></Reference><Reference><Citation>Akers KG, Martinez-Canabal A, Restivo L, Yiu AP, De Cristofaro A, Hsiang H-L, Wheeler AL, Guskjolen A, Niibori Y, Shoji, et al. (2014). Hippocampal neurogenesis regulates forgetting during adulthood and infancy.Science 344, 598&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">24812394</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexa A, and Rahnenfuhrer J (2016). topGO: Enrichment Analysis for Gene Ontology. R package, version 2.30.1 (Bioconductor).</Citation></Reference><Reference><Citation>Ashton NJ, Hye A, Leckey CA, Jones AR, Gardner A, Elliott C, Wetherell JL, Lenze EJ, Killick R, and Marchant NL (2017). Plasma REST: a novel candidate biomarker of Alzheimer&#x2019;s disease is modified by psychological intervention in an at-risk population. Transl. Psychiatry 7, e1148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5537638</ArticleId><ArticleId IdType="pubmed">28585932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballas N, and Mandel G (2005). The many faces of REST oversee epigenetic programming of neuronal genes. Curr. Opin. Neurobiol 15, 500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">16150588</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake SM, Strasser V, Andrade N, Duit S, Hofbauer R, Schneider WJ, and Nimpf J (2008). Thrombospondin-1 binds to ApoER2 and VLDL receptor and functions in postnatal neuronal migration. EMBO J. 27, 3069&#x2013;3080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585172</ArticleId><ArticleId IdType="pubmed">18946489</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, Kahler DJ, Yamaki M, Davidow L, et al. (2011). A functionally characterized test set of human induced pluripotent stem cells. Nat.Biotechnol 29, 279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229307</ArticleId><ArticleId IdType="pubmed">21293464</ArticleId></ArticleIdList></Reference><Reference><Citation>Calaora V, Chazal G, Nielsen PJ, Rougon G, and Moreau H (1996). mCD24 expression in the developing mouse brain and in zones of secondary neurogenesis in the adult. Neuroscience 73, 581&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">8783272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K-H, Multani PS, Sun K-H, Vincent F, de Pablo Y, Ghosh S, Gupta R, Lee H-P, Lee HG, Smith MA, and Shah K (2011). Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death.Mol. Biol. Cell 22, 1452&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084668</ArticleId><ArticleId IdType="pubmed">21389115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, and Ma&#x2019;ayan A (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong JA, Tapia-Ram&#xed;rez, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, Altshuller YM, Frohman MA, Kraner SD, and Mandel G (1995). REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 80, 949&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">7697725</ArticleId></ArticleIdList></Reference><Reference><Citation>Corley M, and Kroll KL (2015). The roles and regulation of Polycomb complexes in neural development. Cell Tissue Res. 359, 65&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286515</ArticleId><ArticleId IdType="pubmed">25367430</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, et al. (2005). Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175&#x2013;e175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283542</ArticleId><ArticleId IdType="pubmed">16284200</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean DC 3rd, Jerskey BA, Chen K, Protas H, Thiyyagura P, Roontiva A, O&#x2019;Muircheartaigh J, Dirks H, Waskiewicz N, Lehman K, et al. (2014). Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 71, 11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056558</ArticleId><ArticleId IdType="pubmed">24276092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich N, Lerdrup M, Landt E, Agrawal-Singh S, Bak M, Tommerup N, Rappsilber J, So&#xa8;dersten E, and Hansen K (2012). REST-mediated recruitment of polycomb repressor complexes in mammalian cells. PLoS Genet. 8, e1002494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3291536</ArticleId><ArticleId IdType="pubmed">22396653</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Hemberg M, Lewis J, and Feany MB (2014). Tau promotes neurodegeneration through global chromatin relaxation. Nat. Neurosci 17, 357&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012297</ArticleId><ArticleId IdType="pubmed">24464041</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Bardai FH, and Feany MB (2016). Lamin dysfunction mediates neurodegeneration in tauopathies. Curr. Biol 26, 129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713335</ArticleId><ArticleId IdType="pubmed">26725200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z, Ure K, Ding P, Nashaat M, Yuan L, Ma J, Henner RE, and Hsieh J (2011). The master regulator REST/NRSF controls adult neurogenesis by restraining the neurogenic program in quiescent cells. J. Neurosci 31, 9772&#x2013;9786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365553</ArticleId><ArticleId IdType="pubmed">21715642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleeson JG, Lin PT, Flanagan LA, and Walsh CA (1999). Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons. Neuron 23, 257&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe H-S, Wessner D, Beffert U, Becker AG, Matsuoka Y, and Rebeck GW (2005). F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol. Cell. Biol 25, 9259&#x2013;9268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265841</ArticleId><ArticleId IdType="pubmed">16227578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe H-S, Lee KJ, Carney RSE, Lee J, Markova A, Lee J-Y, Howell BW, Hyman BT, Pak DTS, Bu G, and Rebeck GW (2009). Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J. Neurosci 29, 7459&#x2013;7473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759694</ArticleId><ArticleId IdType="pubmed">19515914</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SMS, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. (2012). Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells.Nature 482, 216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoferle J, Yoon SY, Walker D, Leung L, Gillespie AK, Tong LM, Bien-Ly N, and Huang Y (2014). Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice. J. Neurosci 34, 14069&#x2013;14078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198545</ArticleId><ArticleId IdType="pubmed">25319703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, et al. (2013). Modeling Alzheimer&#x2019;s disease with iPSCs reveals stress phenotypes associated with intracellular A&#x3b2; and differential drug responsiveness. Cell Stem Cell 12, 487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalczyk A, Filipkowski RK, Rylski M, Wilczynski GM, Konopacki FA, Jaworski J, Ciemerych MA, Sicinski P, and Kaczmarek L (2004). The critical role of cyclin D2 in adult neurogenesis. J. Cell Biol 167, 209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172537</ArticleId><ArticleId IdType="pubmed">15504908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosawa H (2007). Methods for inducing embryoid body formation: in vitro differentiation system of embryonic stem cells. J. Biosci. Bioeng 103, 389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">17609152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster MA, Renner M, Martin C-A, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP, and Knoblich JA (2013). Cerebral organoids model human brain development and microcephaly. Nature 501, 373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Oh YM, Lu Y-L, Kim WK, and Yoo AS (2018). MicroRNAs overcome cell fate barrier by reducing EZH2-controlled REST stability during neuronal conversion of human adult fibroblasts. Dev. Cell 46, 73&#x2013;84.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6082428</ArticleId><ArticleId IdType="pubmed">29974865</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi O, Lu&#x20ac;tjohann D, Devir A, von Bergmann K, Hartmann T, and Michaelson DM (2005). Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. J. Neurochem 95, 987&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190879</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K, Halabisky B, Deng C, Mahley RW, and Huang Y (2009). GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 5, 634&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992822</ArticleId><ArticleId IdType="pubmed">19951691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-T, Seo J, Gao F, Feldman HM, Wen H-L, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, et al. (2018). APOE4 causes widespread molecular and cellular alterations associated with Alzheimer&#x2019;s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048952</ArticleId><ArticleId IdType="pubmed">29953873</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo&#xb4;pez-Toledano MA, and Shelanski ML (2007). Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind). J. Alzheimers Dis 12, 229&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang T-H, Kim H-M, Drake D, Liu XS, et al. (2014). REST and stress resistance in ageing and Alzheimer&#x2019;s disease. Nature 507, 448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, Paquola ACM, Ku M, Hatch E, Bo&#xa8;hnke L, Ladjevardi S, McGrath S, Campbell B, Lee H, Herdy JR, et al. (2015). Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell 17, 705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="pubmed">26456686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozzetta C, Pontis J, Fritsch L, Robin P, Portoso M, Proux C, Margueron R, and Ait-Si-Ali S (2014). The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing. Mol. Cell 53, 277&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">24389103</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LNP, Walsh DM, Selkoe DJ, and Young-Pearse TL (2014). The familial Alzheimer&#x2019;s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum. Mol. Genet 23, 3523&#x2013;3536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I-H, Lerou PH, Zhao R, Huo H, and Daley GQ (2008). Generation of human-induced pluripotent stem cells. Nat. Protoc 3, 1180&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18600223</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Comas-Herrera MA, Knapp M, Guerchet M, and Karagiannidou MM (2016). World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia: Coverage, Quality and Costs Now and in the Future (Alzheimer&#x2019;s Disease International; ).</Citation></Reference><Reference><Citation>Pruszak J, Ludwig W, Blak A, Alavian K, and Isacson O (2009). CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells 27, 2928&#x2013;2940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322476</ArticleId><ArticleId IdType="pubmed">19725119</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenherr CJ, and Anderson DJ (1995). The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 267, 1360&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">7871435</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, and Markesbery WR (2000). Linguistic ability in early life and the neuropathology of Alzheimer&#x2019;s disease and cerebrovascular disease. Findings from the Nun Study. Ann. N Y Acad. Sci 903, 34&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, Santa-Maria I, Zimmer M, Aubry S, Steele JW, et al. (2014). Characterization and molecular profiling of PSEN1 familial Alzheimer&#x2019;s disease iPSCderived neural progenitors. PLoS One 9, e84547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885572</ArticleId><ArticleId IdType="pubmed">24416243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M-C, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, and Chang HY (2010). Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967777</ArticleId><ArticleId IdType="pubmed">20616235</ArticleId></ArticleIdList></Reference><Reference><Citation>von Schimmelmann M, Feinberg PA, Sullivan JM, Ku SM, Badimon A, Duff MK, Wang Z, Lachmann A, Dewell S, Ma&#x2019;ayan A, et al. (2016). Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration. Nat. Neurosci 19, 1321&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088783</ArticleId><ArticleId IdType="pubmed">27526204</ArticleId></ArticleIdList></Reference><Reference><Citation>Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, and Rissman RA (2016). Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement. (Amst.) 3, 63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4925777</ArticleId><ArticleId IdType="pubmed">27408937</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, and Suzuki N (2011). Modeling familial Alzheimer&#x2019;s disease with induced pluripotent stem cells. Hum. Mol. Genet 20, 4530&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C-P, Gilley JA, Zhang G, and Kernie SG (2011). ApoE is required for maintenance of the dentate gyrus neural progenitor pool. Development 138, 4351&#x2013;4362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177307</ArticleId><ArticleId IdType="pubmed">21880781</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YJ, Baltus AE, Mathew RS, Murphy EA, Evrony GD, Gonzalez DM, Wang EP, Marshall-Walker CA, Barry BJ, Murn J, et al. (2012). Microcephaly gene links trithorax and REST/NRSF to control neural stem cell proliferation and differentiation. Cell 151, 1097&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567437</ArticleId><ArticleId IdType="pubmed">23178126</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J-T, Tan L, and Hardy J (2014). Apolipoprotein E in Alzheimer&#x2019;s disease: an update. Annu. Rev. Neurosci 37, 79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">24821312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, Vidal JG, Mu Y, Killian RL, Israel MA, et al. (2011). Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 6, e17540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Zhong M, Elder GA, Sano M, Holtzman DM, Gandy S, Cardozo C, Haroutunian V, Robakis NK, and Cai D (2015). Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer&#x2019;s disease pathogenesis. Proc. Natl. Acad. Sci. USA 112, 11965&#x2013;11970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586834</ArticleId><ArticleId IdType="pubmed">26372964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30715078</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.</ArticleTitle><Pagination><StartPage>542</StartPage><EndPage>551</EndPage><MedlinePgn>542-551</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2018.4693</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Mounting evidence suggests that sex differences exist in the pathologic trajectory of Alzheimer disease. Previous literature shows elevated levels of cerebrospinal fluid tau in women compared with men as a function of apolipoprotein E (APOE) &#x3b5;4 status and &#x3b2;-amyloid (A&#x3b2;). What remains unclear is the association of sex with regional tau deposition in clinically normal individuals.</AbstractText><AbstractText Label="OBJECTIVE">To examine sex differences in the cross-sectional association between A&#x3b2; and regional tau deposition as measured with positron emission tomography (PET).</AbstractText><AbstractText Label="DESIGN, SETTING AND PARTICIPANTS">This is a study of 2 cross-sectional, convenience-sampled cohorts of clinically normal individuals who received tau and A&#x3b2; PET scans. Data were collected between January 2016 and February 2018 from 193 clinically normal individuals from the Harvard Aging Brain Study (age range, 55-92 years; 118 women [61%]) who underwent carbon 11-labeled Pittsburgh Compound B and flortaucipir F18 PET and 103 clinically normal individuals from the Alzheimer's Disease Neuroimaging Initiative (age range, 63-94 years; 55 women [51%]) who underwent florbetapir and flortaucipir F 18 PET.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">A main association of sex with regional tau in the entorhinal cortices, inferior temporal lobe, and a meta-region of interest, which was a composite of regions in the temporal lobe. Associations between sex and global A&#x3b2; as well as sex and APOE &#x3b5;4 on these regions after controlling for age were also examined.</AbstractText><AbstractText Label="RESULTS">The mean (SD) age of all individuals was 74.2 (7.6) years (81 APOE &#x3b5;4 carriers&#x2009;[31%]; 89 individuals [30%] with high A&#x3b2;). There was no clear association of sex with regional tau that was replicated across studies. However, in both cohorts, clinically normal women exhibited higher entorhinal cortical tau than men (meta-analytic estimate: &#x3b2; [male]&#x2009;=&#x2009;-0.11 [0.05]; 95% CI, -0.21 to -0.02; P&#x2009;=&#x2009;.02), which was associated with individuals with higher A&#x3b2; burden. A sex by APOE &#x3b5;4 interaction was not associated with regional tau (meta-analytic estimate: &#x3b2; [male, APOE &#x3b5;4+]&#x2009;=&#x2009;-0.15 [0.09]; 95% CI, -0.32 to 0.01; P&#x2009;=&#x2009;.07).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Early tau deposition was elevated in women compared with men in individuals on the Alzheimer disease trajectory. These findings lend support to a growing body of literature that highlights a biological underpinning for sex differences in Alzheimer disease risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Rachel F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Florey Institute, The University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Psychological Science, University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabin</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohman</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Vanderbilt Memory &amp; Alzheimer's Center, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanseeuw</LastName><ForeName>Bernard J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Cliniques Universitaires St-Luc, Institute of Neuroscience, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Heidi I L</ForeName><Initials>HIL</Initials><AffiliationInfo><Affiliation>Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>Kathryn V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Properzi</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirn</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Harvard Aging Brain Study, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG061238</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG059941</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG061238</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059716</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049164</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG051718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Buckley is funded with the National Health and Medical Research Council Dementia Research Fellowship (APP1105576). Dr Mormino reports grants from the National Institutes of Health during the conduct of the study and personal fees from Eli Lilly and Biogen outside the submitted work. Dr Rabin is funded by the Canadian Institutes of Health Research Postdoctoral Fellowship. Dr Hohman is funded by the National Institutes of Health/National Institute on Aging (K01 AG049164). Dr Landau reports grants from the National Institutes of Health during the conduct of the study and personal fees from Cortexyme outside the submitted work. Dr Hanseeuw reports grants from the Belgian National Fund for Scientific Research, Belgian Foundation for Scientific Research (FNRS grant SPD28094292), and the Belgian Foundation for Alzheimer Research (SAO-FRA grant P16.008) during the conduct of the study and nonfinancial support from GE Healthcare outside the submitted work. Dr Jacobs received funding from the European Union&#x2019;s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant agreement (IF-2015-GF, 706714). Dr Papp has been a paid consultant for Biogen. Dr Schultz has been a paid consultant for Janssen Pharmaceuticals and Biogen. Dr Hedden reports grants from the National Institutes of Health during the conduct of the study and outside the submitted work. Dr Chhatwal is funded by the National Institutes of Health (K23 AG049087). Dr Rentz served as a consultant for Eli Lilly, Biogen, and Lundbeck Pharmaceuticals and serves as a member of the scientific advisory board for Neurotrack. Dr Johnson has served as a paid consultant for Bayer, GE Healthcare, Janssen Alzheimer Immunotherapy, Siemens Medical Solutions, Sanofi Genzyme, Novartis, Biogen, Roche, ISIS Pharma (now Ionis Pharmaceuticals Inc), AZTherapies, Lundberg, and AbbVie; is a site coinvestigator for Eli Lilly/Avid Radiopharmaceuticals, Pfizer, Janssen Immunotherapy, and Navidea; has spoken at symposia sponsored by Janssen Alzheimer Immunotherapy and Pfizer; and receives funding from the National Institutes of Health (grants R01EB014894, R21 AG038994, R01 AG026484, R01 AG034556, P50 AG00513421, U19 AG10483, P01 AG036694, R13 AG042201174210, R01 AG027435, and R01 AG037497) and the Alzheimer&#x2019;s Association (grant ZEN-10-174210). Dr Sperling has served as a paid consultant for AbbVie, Biogen, Bracket, Genentech, Lundbeck, Roche, and Sanofi; has served as a coinvestigator for Avid Radiopharmaceuticals, Eli Lilly, and Janssen Alzheimer Immunotherapy clinical trials; has spoken at symposia sponsored by Eli Lilly, Biogen, and Janssen Pharmaceuticals; receives research support from Janssen Pharmaceuticals and Eli Lilly (these relationships are not related to the content in the manuscript); and also receives research support from the following grants: P01 AG036694, U01 AG032438, U01 AG024904, R01 AG037497, R01 AG034556, K24 AG035007, P50 AG005134, U19 AG010483, R01 AG027435, Fidelity Biosciences, Harvard NeuroDiscovery Center, and the Alzheimer&#x2019;s Association.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30715078</ArticleId><ArticleId IdType="mid">NIHMS1029661</ArticleId><ArticleId IdType="pmc">PMC6515599</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2018.4693</ArticleId><ArticleId IdType="pii">2722842</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen K, Launer LJ, Dewey ME, et al. ; EURODEM Incidence Research Group . Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. Neurology. 1999;53(9):1992-1997. doi:10.1212/WNL.53.9.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.9.1992</ArticleId><ArticleId IdType="pubmed">10599770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xea;ne G, Beiser A, Au R, et al. . Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement. 2015;11(3):310-320. doi:10.1016/j.jalz.2013.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.10.005</ArticleId><ArticleId IdType="pmc">PMC4092061</ArticleId><ArticleId IdType="pubmed">24418058</ArticleId></ArticleIdList></Reference><Reference><Citation>Edland SD, Rocca WA, Petersen RC, Cha RH, Kokmen E. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol. 2002;59(10):1589-1593. doi:10.1001/archneur.59.10.1589</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.10.1589</ArticleId><ArticleId IdType="pubmed">12374497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer&#x2019;s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48. doi:10.2147/CLEP.S37929</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37929</ArticleId><ArticleId IdType="pmc">PMC3891487</ArticleId><ArticleId IdType="pubmed">24470773</ArticleId></ArticleIdList></Reference><Reference><Citation>Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer&#x2019;s disease. Horm Behav. 2013;63(2):301-307. doi:10.1016/j.yhbeh.2012.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yhbeh.2012.04.006</ArticleId><ArticleId IdType="pmc">PMC3413783</ArticleId><ArticleId IdType="pubmed">22554955</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Berti V, Quinn C, et al. . Sex differences in Alzheimer risk: brain imaging of endocrine vs chronologic aging. Neurology. 2017;89(13):1382-1390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652968</ArticleId><ArticleId IdType="pubmed">28855400</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws KR, Irvine K, Gale TM. Sex differences in Alzheimer&#x2019;s disease. Curr Opin Psychiatry. 2018;31(2):133-139. doi:10.1097/YCO.0000000000000401</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000401</ArticleId><ArticleId IdType="pubmed">29324460</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher DW, Bennett DA, Dong H. Sexual dimorphism in predisposition to Alzheimer&#x2019;s disease. Neurobiol Aging. 2018;70:308-324. doi:10.1016/j.neurobiolaging.2018.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.04.004</ArticleId><ArticleId IdType="pmc">PMC6368179</ArticleId><ArticleId IdType="pubmed">29754747</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Seeley WW, Zhou J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Gender modulates the APOE &#x3b5;4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012;32(24):8254-8262. doi:10.1523/JNEUROSCI.0305-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0305-12.2012</ArticleId><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="pubmed">22699906</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Dumitrescu L, Barnes LL, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium and the Alzheimer&#x2019;s Disease Neuroimaging Initiative . Sex-specific association of Apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75(8):989-998. doi:10.1001/jamaneurol.2018.0821</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0821</ArticleId><ArticleId IdType="pmc">PMC6142927</ArticleId><ArticleId IdType="pubmed">29801024</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD; Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators . Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563-573. doi:10.1002/ana.24135</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24135</ArticleId><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Wiste HJ, Weigand SD, et al. . Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012;79(15):1570-1577. doi:10.1212/WNL.0b013e31826e2696</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e2696</ArticleId><ArticleId IdType="pmc">PMC3475629</ArticleId><ArticleId IdType="pubmed">22972644</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131. doi:10.1002/ana.21843</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21843</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119. doi:10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, et al. . Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med. 2016;8(338):338ra66. doi:10.1126/scitranslmed.aaf2362</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf2362</ArticleId><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage. 2017;157:448-463. doi:10.1016/j.neuroimage.2017.05.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Disease Neuroimaging Initiative. http://adni.loni.usc.edu/. Accessed December 19, 2018.</Citation></Reference><Reference><Citation>Harvard Aging Brain Study. https://nmr.mgh.harvard.edu/lab/harvardagingbrain. Accessed December 19, 2018.</Citation></Reference><Reference><Citation>Aisen PS, Petersen RC, Donohue MC, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Clinical core of the Alzheimer&#x2019;s disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010;6(3):239-246. doi:10.1016/j.jalz.2010.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.006</ArticleId><ArticleId IdType="pmc">PMC2867843</ArticleId><ArticleId IdType="pubmed">20451872</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagley A, LaPoint M, Huijbers W, et al. . Harvard Aging Brain Study: dataset and accessibility. Neuroimage. 2017;144(pt B):255-258. doi:10.1016/j.neuroimage.2015.03.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.03.069</ArticleId><ArticleId IdType="pmc">PMC4592689</ArticleId><ArticleId IdType="pubmed">25843019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. . Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283. doi:10.1016/j.neurobiolaging.2010.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.007</ArticleId><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578-586. doi:10.1002/ana.23650</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study . Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767. doi:10.1212/WNL.0000000000000431</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000431</ArticleId><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Breault C, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid-&#x3b2; imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54(1):70-77. doi:10.2967/jnumed.112.109009</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.112.109009</ArticleId><ArticleId IdType="pmc">PMC3747730</ArticleId><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221-229. doi:10.1016/j.jalz.2010.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.003</ArticleId><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982. doi:10.1016/j.neuron.2016.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. . Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-1042. doi:10.1002/ana.22333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22333</ArticleId><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904-911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Labb&#xe9; C, Koepp M, Ashburner J, et al. . Absolute PET quantification with correction for partial volume effects within cerebral structures In: Carson RE, Herscovitch P, Daube-Witherspoon ME, eds. Quantitative Functional Brain Imaging with Positron Emission Tomography. Academic Press: Cambridge, UK;1998.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2016;43(6):1139-1150. doi:10.1007/s00259-015-3231-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-015-3231-2</ArticleId><ArticleId IdType="pmc">PMC4844651</ArticleId><ArticleId IdType="pubmed">26572762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-258. doi:10.1002/ana.24711</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24711</ArticleId><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie SJ, Cox SR, Shen X, et al. . Sex differences in the adult human brain: evidence from 5,216 UK Biobank participants. Cereb Cortex. 2018;28(8):2959-2975. doi:10.1093/cercor/bhy109</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhy109</ArticleId><ArticleId IdType="pmc">PMC6041980</ArticleId><ArticleId IdType="pubmed">29771288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. . Synergistic effect of &#x3b2;-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71(11):1379-1385. doi:10.1001/jamaneurol.2014.2031</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2031</ArticleId><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. ; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Alzheimer&#x2019;s Disease Cooperative Study . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970. doi:10.1001/jamaneurol.2014.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Amariglio RE, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study . Sex, amyloid, and APOE &#x3b5;4 and risk of cognitive decline in preclinical Alzheimer&#x2019;s disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018;14(9):1193-1203. doi:10.1016/j.jalz.2018.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.04.010</ArticleId><ArticleId IdType="pmc">PMC6131023</ArticleId><ArticleId IdType="pubmed">29803541</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Vogel JW, Gonneaud J, et al. ; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group . Proximity to parental symptom onset and amyloid-&#x3b2; burden in sporadic Alzheimer disease. JAMA Neurol. 2018;75(5):608-619. doi:10.1001/jamaneurol.2017.5135</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.5135</ArticleId><ArticleId IdType="pmc">PMC5885216</ArticleId><ArticleId IdType="pubmed">29482212</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA. Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol. 2018;136(6):887-900. doi:10.1007/s00401-018-1920-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1920-1</ArticleId><ArticleId IdType="pmc">PMC6279593</ArticleId><ArticleId IdType="pubmed">30334074</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A. Sex and gender differences in Alzheimer's disease: recommendations for future research. J Womens Health (Larchmt). 2012;21(10):1018-1023. doi:10.1089/jwh.2012.3789</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2012.3789</ArticleId><ArticleId IdType="pubmed">22917473</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-281. doi:10.1212/01.WNL.0000149519.47454.F2</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000149519.47454.F2</ArticleId><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer&#x2019;s disease. Front Neuroendocrinol. 2009;30(2):239-258. doi:10.1016/j.yfrne.2009.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2009.04.015</ArticleId><ArticleId IdType="pmc">PMC2728624</ArticleId><ArticleId IdType="pubmed">19427328</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Boueiz A, Abougergi MS, et al. . Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiol Aging. 2012;33(4):720-731. doi:10.1016/j.neurobiolaging.2010.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.017</ArticleId><ArticleId IdType="pmc">PMC2974952</ArticleId><ArticleId IdType="pubmed">20619505</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Pa J, Kukull W, et al. . Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol. 2017;74(10):1178-1189. doi:10.1001/jamaneurol.2017.2188</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2188</ArticleId><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Mormino EC; Alzheimer&#x2019;s Disease Neuroimaging Initiative . APOE genotype and early &#x3b2;-amyloid accumulation in older adults without dementia. Neurology. 2017;89(10):1028-1034. doi:10.1212/WNL.0000000000004336</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004336</ArticleId><ArticleId IdType="pmc">PMC5589795</ArticleId><ArticleId IdType="pubmed">28794245</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC. Augmented senile plaque load in aged female &#x3b2;-amyloid precursor protein-transgenic mice. Am J Pathol. 2001;158(3):1173-1177. doi:10.1016/S0002-9440(10)64064-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64064-3</ArticleId><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett DR, Richardson JC, Austin A, et al. . Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004;1017(1-2):130-136. doi:10.1016/j.brainres.2004.05.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.05.029</ArticleId><ArticleId IdType="pubmed">15261108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin W-L, et al. . Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293(5534):1487-1491. doi:10.1126/science.1058189</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1058189</ArticleId><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm A, Biliouris EE, Lang UE, G&#xf6;tz J, Mensah-Nyagan AG, Eckert A. Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-&#x3b2; or hyperphosphorylated tau protein. Cell Mol Life Sci. 2016;73(1):201-215. doi:10.1007/s00018-015-1988-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-1988-x</ArticleId><ArticleId IdType="pmc">PMC4700074</ArticleId><ArticleId IdType="pubmed">26198711</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. Perimenopause as a neurological transition state. Nat Rev Endocrinol. 2015;11(7):393-405. doi:10.1038/nrendo.2015.82</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2015.82</ArticleId><ArticleId IdType="pmc">PMC9934205</ArticleId><ArticleId IdType="pubmed">26007613</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen R, Martinussen T, Christiansen L, et al. . Increased effect of the ApoE gene on survival at advanced age in healthy and long-lived Danes: two nationwide cohort studies. Aging Cell. 2010;9(6):1004-1009. doi:10.1111/j.1474-9726.2010.00626.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2010.00626.x</ArticleId><ArticleId IdType="pmc">PMC2988163</ArticleId><ArticleId IdType="pubmed">20849521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30775436</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.</ArticleTitle><Pagination><StartPage>eaau7220</StartPage><MedlinePgn>eaau7220</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eaau7220</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.aau7220</ELocationID><Abstract><AbstractText>A blood-based assessment of preclinical disease would have huge potential in the enrichment of participants for Alzheimer's disease (AD) therapeutic trials. In this study, cognitively unimpaired individuals from the AIBL and KARVIAH cohorts were defined as A&#x3b2; negative or A&#x3b2; positive by positron emission tomography. Nontargeted proteomic analysis that incorporated peptide fractionation and high-resolution mass spectrometry quantified relative protein abundances in plasma samples from all participants. A protein classifier model was trained to predict A&#x3b2;-positive participants using feature selection and machine learning in AIBL and independently assessed in KARVIAH. A 12-feature model for predicting A&#x3b2;-positive participants was established and demonstrated high accuracy (testing area under the receiver operator characteristic curve = 0.891, sensitivity = 0.78, and specificity = 0.77). This extensive plasma proteomic study has unbiasedly highlighted putative and novel candidates for AD pathology that should be further validated with automated methodologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nevado-Holgado</LastName><ForeName>Alejo J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-9276-2720</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Imelda S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynham</LastName><ForeName>Steven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3756-6430</Identifier><AffiliationInfo><Affiliation>Proteomics Core Facility, James Black Centre, King's College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Veer</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Faculty of Health, Deakin University, 3220 VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatterjee</LastName><ForeName>Pratishtha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KaRa Institute of Neurological Diseases, Macquarie Park, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, 2109, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goozee</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3573-1554</Identifier><AffiliationInfo><Affiliation>KaRa Institute of Neurological Diseases, Macquarie Park, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, 2109, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Department, Anglicare, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychiatry and Clinical Neurosciences, University of Western Australia, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hone</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6708-3718</Identifier><AffiliationInfo><Affiliation>School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrini</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6409-8022</Identifier><AffiliationInfo><Affiliation>School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7800-1781</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Academic Unit for Psychiatry of Old Age, St. George's Hospital, University of Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0001-8259-9069</Identifier><AffiliationInfo><Affiliation>Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Florey Institute, University of Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><Identifier Source="ORCID">0000-0002-5832-9875</Identifier><AffiliationInfo><Affiliation>Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Academic Unit for Psychiatry of Old Age, St. George's Hospital, University of Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Ageing Research Institute, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0003-3072-7940</Identifier><AffiliationInfo><Affiliation>The Florey Institute, University of Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6314-216X</Identifier><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6124-439X</Identifier><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4828-9363</Identifier><AffiliationInfo><Affiliation>School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KaRa Institute of Neurological Diseases, Macquarie Park, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Macquarie University, 2109, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hye</LastName><ForeName>Abdul</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2237-4823</Identifier><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17215</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30775436</ArticleId><ArticleId IdType="pmc">PMC6365111</ArticleId><ArticleId IdType="doi">10.1126/sciadv.aau7220</ArticleId><ArticleId IdType="pii">aau7220</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baird A. L., Westwood S., Lovestone S., Blood-based proteomic biomarkers of Alzheimer&#x2019;s disease pathology. Front. Neurol. 6, 236 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644785</ArticleId><ArticleId IdType="pubmed">26635716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazenet C., Lovestone S., Plasma biomarkers for Alzheimer&#x2019;s disease: Much needed but tough to find. Biomark. Med. 6, 441&#x2013;454 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22917146</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr., Knopman D. S., Jagust W. J., Petersen R. C., Weiner M. W., Aisen P. S., Shaw L. M., Vemuri P., Wiste H. J., Weigand S. D., Lesnick T. G., Pankratz V. S., Donohue M. C., Trojanowski J. Q., Tracking pathophysiological processes in Alzheimer&#x2019;s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S., Sperling R., Fox N. C., Blennow K., Klunk W., Raskind M., Sabbagh M., Honig L. S., Porsteinsson A. P., Ferris S., Reichert M., Ketter N., Nejadnik B., Guenzler V., Miloslavsky M., Wang D., Lu Y., Lull J., Tudor I. C., Liu E., Grundman M., Yuen E., Black R., Brashear H. R., Bapineuzumab 301 and 302 Clinical Trial Investigators , Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N. Engl. J. Med. 370, 322&#x2013;333 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S., Stomrud E., Palmqvist S., Zetterberg H., van Westen D., Jeromin A., Song L., Hanlon D., Tan Hehir C. A., Baker D., Blennow K., Hansson O., Plasma &#x3b2;-amyloid in Alzheimer&#x2019;s disease and vascular disease. Sci. Rep. 6, 26801 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A., Kaneko N., Villemagne V. L., Kato T., Doecke J., Dor&#xe9; V., Fowler C., Li Q.-X., Martins R., Rowe C., Tomita T., Matsuzaki K., Ishii K., Ishii K., Arahata Y., Iwamoto S., Ito K., Tanaka K., Masters C. L., Yanagisawa K., High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature 554, 249&#x2013;254 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M., Tripaldi R., Riddoch-Contreras J., Hye A., An Y., Campbell J., Sojkova J., Kinsey A., Lynham S., Zhou Y., Ferrucci L., Wong D. F., Lovestone S., Resnick S. M., Proteome-based plasma markers of brain amyloid-&#x3b2; deposition in non-demented older individuals. J. Alzheimers Dis. 22, 1099&#x2013;1109 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125970</ArticleId><ArticleId IdType="pubmed">20930274</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwood S., Leoni E., Hye A., Lynham S., Khondoker M. R., Ashton N. J., Kiddle S. J., Baird A. L., Sainz-Fuertes R., Leung R., Graf J., Hehir C. T., Baker D., Cereda C., Bazenet C., Ward M., Thambisetty M., Lovestone S., Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J. Alzheimers Dis. 52, 561&#x2013;572 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5898378</ArticleId><ArticleId IdType="pubmed">27031486</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham S. C., Faux N. G., Wilson W., Laws S. M., Ames D., Bedo J., Bush A. I., Doecke J. D., Ellis K. A., Head R., Jones G., Kiiveri H., Martins R. N., Rembach A., Rowe C. C., Salvado O., Macaulay S. L., Masters C. L., Villemagne V. L., Alzheimer&#x2019;s Disease Neuroimaging Initiative, Australian Imaging, Biomarkers and Lifestyle Study Research Group , A blood-based predictor for neocortical A&#x3b2; burden in Alzheimer&#x2019;s disease: Results from the AIBL study. Mol. Psychiatry 19, 519&#x2013;526 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23628985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiddle S. J., Thambisetty M., Simmons A., Riddoch-Contreras J., Hye A., Westman E., Pike I., Ward M., Johnston C., Lupton M. K., Lunnon K., Soininen H., Kloszewska I., Tsolaki M., Vellas B., Mecocci P., Lovestone S., Newhouse S., Dobson R., Alzheimers Disease Neuroimaging Initiative , Plasma based markers of [11C] PiB-PET brain amyloid burden. PLOS ONE 7, e44260 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454385</ArticleId><ArticleId IdType="pubmed">23028511</ArticleId></ArticleIdList></Reference><Reference><Citation>Geyer P. E., Kulak N. A., Pichler G., Holdt L. M., Teupser D., Mann M., Plasma proteome profiling to assess human health and disease. Cell Syst. 2, 185&#x2013;195 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27135364</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., Mattsson N., Sch&#xf6;ll M., Hansson O., Zetterberg H., Amyloid biomarkers in Alzheimer&#x2019;s disease. Trends Pharmacol. Sci. 36, 297&#x2013;309 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn H. J., Chen Z. L., Zamolodchikov D., Norris E. H., Strickland S., Interactions of &#x3b2;-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer&#x2bc;s disease. Curr. Opin. Hematol. 24, 427&#x2013;431 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5540762</ArticleId><ArticleId IdType="pubmed">28661939</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F., Davis J., Miao J., Previti M. L., Romanov G., Ziegler K., van Nostrand W. E., Protease nexin-2/amyloid &#x3b2;-protein precursor limits cerebral thrombosis. Proc. Natl. Acad. Sci. U.S.A. 102, 18135&#x2013;18140 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1312400</ArticleId><ArticleId IdType="pubmed">16330760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W., Li H., Navaneetham D., Reichenbach Z. W., Tuma R. F., Walsh P. N., The Kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis. Blood 120, 671&#x2013;677 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3401218</ArticleId><ArticleId IdType="pubmed">22674803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush A. I., Martins R. N., Rumble B., Moir R., Fuller S., Milward E., Currie J., Ames D., Weidemann A., Fischer P., The amyloid precursor protein of Alzheimer&#x2019;s disease is released by human platelets. J. Biol. Chem. 265, 15977&#x2013;15983 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2118534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton N. J., Kiddle S. J., Graf J., Ward M., Baird A. L., Hye A., Westwood S., Wong K. V., Dobson R. J., Rabinovici G. D., Miller B. L., Rosen H. J., Torres A., Zhang Z., Thurfjell L., Covin A., Hehir C. T., Baker D., Bazenet C., Lovestone S., AIBL Research Group , Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimers Dement. 1, 48&#x2013;60 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876903</ArticleId><ArticleId IdType="pubmed">27239491</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B., Lautner R., Andreasson U., &#xd6;hrfelt A., Portelius E., Bjerke M., H&#xf6;ltt&#xe4; M., Ros&#xe9;n C., Olsson C., Strobel G., Wu E., Dakin K., Petzold M., Blennow K., Zetterberg H., CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Lancet Neurol. 15, 673&#x2013;684 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H., Plasma amyloid &#x3b2;&#x2014;Quo vadis? Neurobiol. Aging 36, 2671&#x2013;2673 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26234755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush A. I., Whyte S., Thomas L. D., Williamson T. G., van Tiggelen C. J., Currie J., Small D. H., Moir R. D., Li Q.-X., Rumble B., M&#xf6;nning U., Beyreuther K., Masters C. L., An abnormality of plasma amyloid protein precursor in Alzheimer&#x2019;s disease. Ann. Neurol. 32, 57&#x2013;65 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1642473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rembach A., Faux N. G., Watt A. D., Pertile K. K., Rumble R. L., Trounson B. O., Fowler C. J., Roberts B. R., Perez K. A., Li Q. X., Laws S. M., Taddei K., Rainey-Smith S., Robertson J. S., Vandijck M., Vanderstichele H., Barnham K. J., Ellis K. A., Szoeke C., Macaulay L., Rowe C. C., Villemagne V. L., Ames D., Martins R. N., Bush A. I., Masters C. L., AIBL research group , Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 10, 53&#x2013;61 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23491263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J., Barro C., Andreasson U., Derfuss T., Lindberg R., Sandelius &#xc5;., Liman V., Norgren N., Blennow K., Zetterberg H., Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 54, 1655&#x2013;1661 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N., Andreasson U., Zetterberg H., Blennow K., Alzheimer&#x2019;s Disease Neuroimaging Initiative , Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557&#x2013;566 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer J. D., Woollacott I. O. C., Dick K. M., Brotherhood E., Gordon E., Fellows A., Toombs J., Druyeh R., Cardoso M. J., Ourselin S., Nicholas J. M., Norgren N., Mead S., Andreasson U., Blennow K., Schott J. M., Fox N. C., Warren J. D., Zetterberg H., Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329&#x2013;1336 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas J. C., Karydas A., Bang J., Tsai R. M., Blennow K., Liman V., Kramer J. H., Rosen H., Miller B. L., Zetterberg H., Boxer A. L., Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann. Clin. Transl. Neurol. 3, 216&#x2013;225 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774256</ArticleId><ArticleId IdType="pubmed">27042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M., Price R. W., Andreasson U., Norgren N., Nilsson S., Hagberg L., Fuchs D., Spudich S., Blennow K., Zetterberg H., Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study. EBioMedicine 3, 135&#x2013;140 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Thathiah A., De Strooper B., The role of G protein-coupled receptors in the pathology of Alzheimer&#x2019;s disease. Nat. Rev. Neurosci. 12, 73&#x2013;87 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21248787</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Mattar P., Zinyk D., Singh K., Chaturvedi C. P., Kovach C., Dixit R., Kurrasch D. M., Ma Y. C., Chan J. A., Wallace V., Dilworth F. J., Brand M., Schuurmans C., GSK3 temporally regulates neurogenin 2 proneural activity in the neocortex. J. Neurosci. 32, 7791&#x2013;7805 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6620952</ArticleId><ArticleId IdType="pubmed">22674256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kele J., Simplicio N., Ferri A. L., Mira H., Guillemot F., Arenas E., Ang S.-L., Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons. Development 133, 495&#x2013;505 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16410412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolos M., Hu Y., Young K. M., Foa L., Small D. H., Neurogenin 2 mediates amyloid-&#x3b2; precursor protein-stimulated neurogenesis. J. Biol. Chem. 289, 31253&#x2013;31261 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223326</ArticleId><ArticleId IdType="pubmed">25217641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G. G., Milenkovic I., W&#xf6;hrer A., H&#xf6;ftberger R., Gelpi E., Haberler C., H&#xf6;nigschnabl S., Reiner-Concin A., Heinzl H., Jungwirth S., Krampla W., Fischer P., Budka H., Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series. Acta Neuropathol. 126, 365&#x2013;384 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H. L., Hooper C., Rijsdijk F., Tabrizi S. J., Banner S., Shaw C. E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R. G., Sham P., Ward M., Lovestone S., Proteome-based plasma biomarkers for Alzheimer&#x2019;s disease. Brain 129, 3042&#x2013;3050 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17071923</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S., Mattsson N., Hansson O., Alzheimer&#x2019;s Disease Neuroimaging Initiative , Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain 139, 1226&#x2013;1236 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S., Sch&#xf6;ll M., Strandberg O., Mattsson N., Stomrud E., Zetterberg H., Blennow K., Landau S., Jagust W., Hansson O., Earliest accumulation of &#x3b2;-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis K. A., Bush A. I., Darby D., de Fazio D., Foster J., Hudson P., Lautenschlager N. T., Lenzo N., Martins R. N., Maruff P., Masters C., Milner A., Pike K., Rowe C., Savage G., Szoeke C., Taddei K., Villemagne V., Woodward M., Ames D., AIBL Research Group , The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer&#x2019;s disease. Int. Psychogeriatr. 21, 672&#x2013;687 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe C. C., Ellis K. A., Rimajova M., Bourgeat P., Pike K. E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O&#x2019;Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C. L., Ames D., Villemagne V. L., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31, 1275&#x2013;1283 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G., Villemagne V. L., Villain N., Jones G., Ellis K. A., Ames D., Martins R. N., Masters C. L., Rowe C. C., AIBL Research Group , Accelerated cortical atrophy in cognitively normal elderly with high &#x3b2;-amyloid deposition. Neurology 78, 477&#x2013;484 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22302548</ArticleId></ArticleIdList></Reference><Reference><Citation>Goozee K., Chatterjee P., James I., Shen K., Sohrabi H. R., Asih P. R., Dave P., ManYan C., Taddei K., Ayton S. J., Garg M. L., Kwok J. B., Bush A. I., Chung R., Magnussen J. S., Martins R. N., Elevated plasma ferritin in elderly individuals with high neocortical amyloid-&#x3b2; load. Mol. Psychiatry 23, 1807&#x2013;1812 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28696433</ArticleId></ArticleIdList></Reference><Reference><Citation>Goozee K., Chatterjee P., James I., Shen K., Sohrabi H. R., Asih P. R., Dave P., Ball B., ManYan C., Taddei K., Chung R., Garg M. L., Martins R. N., Alterations in erythrocyte fatty acid composition in preclinical Alzheimer&#x2019;s disease. Sci. Rep. 7, 676 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429676</ArticleId><ArticleId IdType="pubmed">28386119</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J., Hastie T., Tibshirani R., Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1&#x2013;22 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30742114</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Mitophagy inhibits amyloid-&#x3b2; and tau pathology and reverses cognitive deficits in models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>412</EndPage><MedlinePgn>401-412</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-018-0332-9</ELocationID><Abstract><AbstractText>Accumulation of damaged mitochondria is a hallmark of aging and age-related neurodegeneration, including Alzheimer's disease (AD). The molecular mechanisms of impaired mitochondrial homeostasis in AD are being investigated. Here we provide evidence that mitophagy is impaired in the hippocampus of AD patients, in induced pluripotent stem cell-derived human AD neurons, and in animal AD models. In both amyloid-&#x3b2; (A&#x3b2;) and tau Caenorhabditis elegans models of AD, mitophagy stimulation (through NAD<sup>+</sup> supplementation, urolithin A, and actinonin) reverses memory impairment through PINK-1 (PTEN-induced kinase-1)-, PDR-1 (Parkinson's disease-related-1; parkin)-, or DCT-1 (DAF-16/FOXO-controlled germline-tumor affecting-1)-dependent pathways. Mitophagy diminishes insoluble A&#x3b2;<sub>1-42</sub> and A&#x3b2;<sub>1-40</sub> and prevents cognitive impairment in an APP/PS1 mouse model through microglial phagocytosis of extracellular A&#x3b2; plaques and suppression of neuroinflammation. Mitophagy enhancement abolishes AD-related tau hyperphosphorylation in human neuronal cells and reverses memory impairment in transgenic tau nematodes and mice. Our findings suggest that impaired removal of defective mitochondria is a pivotal event in AD pathogenesis and that mitophagy represents a potential therapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fang</LastName><ForeName>Evandro F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0003-0355-7202</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. e.f.fang@medisin.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, L&#xf8;renskog, Norway. e.f.fang@medisin.uio.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hou</LastName><ForeName>Yujun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Palikaras</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Sciences, Faculty of Medicine, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adriaanse</LastName><ForeName>Bryan A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Jesse S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Beimeng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lautrup</LastName><ForeName>Sofie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan-Olive</LastName><ForeName>Md Mahdi</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caponio</LastName><ForeName>Domenica</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3827-8943</Identifier><AffiliationInfo><Affiliation>Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dan</LastName><ForeName>Xiuli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockt&#xe4;schel</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croteau</LastName><ForeName>Deborah L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Mansour</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greig</LastName><ForeName>Nigel H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Medicine and Laboratory Sciences, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsen</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cader</LastName><ForeName>M Zameel</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavernarakis</LastName><ForeName>Nektarios</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5253-1466</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Sciences, Faculty of Medicine, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohr</LastName><ForeName>Vilhelm A</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0003-4823-6429</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. bohrv@grc.nia.nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark. bohrv@grc.nia.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_16034</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000726</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Autophagy. 2019 Jun;15(6):1112-1114. doi: 10.1080/15548627.2019.1596497.</RefSource><PMID Version="1">30922179</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063306" MajorTopicYN="Y">Mitophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30742114</ArticleId><ArticleId IdType="mid">NIHMS1018837</ArticleId><ArticleId IdType="pmc">PMC6693625</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0332-9</ArticleId><ArticleId IdType="pii">10.1038/s41593-018-0332-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheibye-Knudsen M, Fang EF, Croteau DL, Wilson DM 3rd &amp; Bohr VA Protecting the mitochondrial powerhouse. Trends Cell Biol. 25, 158&#x2013;170 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576887</ArticleId><ArticleId IdType="pubmed">25499735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr JS et al. Mitophagy and Alzheimer&#x2019;s disease: cellular and molecular mechanisms. Trends Neurosci. 40, 151&#x2013;166 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5341618</ArticleId><ArticleId IdType="pubmed">28190529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW et al. ABAD directly links A&#xdf; to mitochondrial toxicity in Alzheimer&#x2019;s disease. Science 304, 448&#x2013;452 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino V et al. Enhancing mitochondrial proteostasis reduces amyloid-&#x3b2; proteotoxicity. Nature 552, 187&#x2013;193 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5730497</ArticleId><ArticleId IdType="pubmed">29211722</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Prabhu BM, Galati DF, Avadhani NG &amp; Anandatheerthavarada HK Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer&#x2019;s disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26, 9057&#x2013;9068 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mairet-Coello G et al. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of A&#x3b2; oligomers through Tau phosphorylation. Neuron 78, 94&#x2013;108 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784324</ArticleId><ArticleId IdType="pubmed">23583109</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA et al. Tau reduction prevents A&#x3b2;-induced defects in axonal transport. Science 330, 198 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Stamer K, Vogel R, Thies E &amp; Mandelkow E Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24, 1079&#x2013;1085 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14643379</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE &amp; Holzbaur EL Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086&#x2013;1089 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Palikaras K, Lionaki E &amp; Tavernarakis N Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans. Nature 521, 525&#x2013;528 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25896323</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang EF et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. Cell 157, 882&#x2013;896 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625837</ArticleId><ArticleId IdType="pubmed">24813611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang EF et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566&#x2013;581 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777858</ArticleId><ArticleId IdType="pubmed">27732836</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant&#xf3; C et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458, 1056&#x2013;1060 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616311</ArticleId><ArticleId IdType="pubmed">19262508</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama EQ et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351, 275&#x2013;281 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852862</ArticleId><ArticleId IdType="pubmed">26816379</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan DF et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456&#x2013;461 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030664</ArticleId><ArticleId IdType="pubmed">21205641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarou M et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524, 309&#x2013;314 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018156</ArticleId><ArticleId IdType="pubmed">26266977</ArticleId></ArticleIdList></Reference><Reference><Citation>Handel AE et al. Assessing similarity to primary tissue and cortical layer identity in induced pluripotent stem cell-derived cortical neurons through single-cell transcriptomics. Hum. Mol. Genet. 25, 989&#x2013;1000 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754051</ArticleId><ArticleId IdType="pubmed">26740550</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P &amp; Livesey FJ Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 7, 1836&#x2013;1846 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies FM, Fleming A &amp; Rubinsztein DC Compromised autophagy and neurodegenerative diseases. Nat. Rev. Neurosci. 16, 345&#x2013;357 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25991442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S, Noda T &amp; Yoshimori T Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3, 452&#x2013;460 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17534139</ArticleId></ArticleIdList></Reference><Reference><Citation>Fivenson EM et al. Mitophagy in neurodegeneration and aging. Neurochem. Int. 109, 202&#x2013;209 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5565781</ArticleId><ArticleId IdType="pubmed">28235551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JH, Chung TD &amp; Oldenburg KR A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67&#x2013;73 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang EF et al. In vitro and in vivo detection of mitophagy in human cells, C. elegans, and mice. J. Vis. Exp. 10.3791/56301 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/56301</ArticleId><ArticleId IdType="pmc">PMC5755444</ArticleId><ArticleId IdType="pubmed">29286376</ArticleId></ArticleIdList></Reference><Reference><Citation>Aman Y, Qiu Y, Tao J &amp; Fang EF Therapeutic potential of boosting NAD+ in aging and age-related diseases. Transi. Med. Aging 2, 30&#x2013;37 (2018).</Citation></Reference><Reference><Citation>Fang EF et al. NAD+ in aging: molecular mechanisms and translational implications. Trends Mol. Med. 23, 899&#x2013;916 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494058</ArticleId><ArticleId IdType="pubmed">28899755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat. Med. 22, 879&#x2013;888 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27400265</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun N et al. Measuring in vivo mitophagy. Mol. Cell 60, 685&#x2013;696 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4656081</ArticleId><ArticleId IdType="pubmed">26549682</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatouros C et al. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum. Mol. Genet. 21, 3587&#x2013;3603 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22611162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin AL &amp; Link CD Alzheimer&#x2019;s disease drug discovery: in vivo screening using C. elegans as a model for &#x3b2;-amyloid peptide-induced toxicity. Drug Discov. Today Technol. 10, e115&#x2013;e119 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640579</ArticleId><ArticleId IdType="pubmed">24050239</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino HF et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540, 230&#x2013;235 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="pubmed">27929004</ArticleId></ArticleIdList></Reference><Reference><Citation>Voglis G &amp; Tavernarakis N A synaptic DEG/ENaC ion channel mediates learning in C. elegans by facilitating dopamine signalling. EMBO J. 27, 3288&#x2013;3299 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2609744</ArticleId><ArticleId IdType="pubmed">19037257</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ Alzheimer&#x2019;s disease is a synaptic failure. Science 298, 789&#x2013;791 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Babcock AA et al. Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice. Brain Behav. Immun. 48, 86&#x2013;101 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25774009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip WKE, Hoshi N, Shouval DS, Snapper S &amp; Medzhitov R Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 356, 513&#x2013;519 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260791</ArticleId><ArticleId IdType="pubmed">28473584</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG &amp; Goedert M Tau pathology and neurodegeneration. Lancet Neurol. 12, 609&#x2013;622 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 282, 23645&#x2013;23654 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17562708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y et al. NAD+ supplementation normalizes key Alzheimer&#x2019;s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc. Natl Acad. Sci. USA 115, E1876&#x2013;E1885 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828618</ArticleId><ArticleId IdType="pubmed">29432159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazure CM &amp; Swendsen J Sex differences in Alzheimer&#x2019;s disease and other dementias. Lancet Neurol. 15, 451&#x2013;452 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864429</ArticleId><ArticleId IdType="pubmed">26987699</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Burns JM &amp; Khan SM The Alzheimer&#x2019;s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta 1842, 1219&#x2013;1231 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962811</ArticleId><ArticleId IdType="pubmed">24071439</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Maestro P et al. Mitophagy failure in fibroblasts and iPSC-derived neurons of Alzheimer&#x2019;s disease-associated presenilin 1 mutation. Front. Mol. Neurosci. 10, 291 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5603661</ArticleId><ArticleId IdType="pubmed">28959184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Sun X, Starovoytov V &amp; Cai Q Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer&#x2019;s disease patient brains. Hum. Mol. Genet. 24, 2938&#x2013;2951 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406302</ArticleId><ArticleId IdType="pubmed">25678552</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton C, Bright NJ, Sastre M, Muckett PJ &amp; Carling D AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid p-peptide exposure. Biochem. J. 434, 503&#x2013;512 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21204788</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SO et al. JNK3 perpetuates metabolic stress induced by A&#x3b2; peptides. Neuron 75, 824&#x2013;837 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438522</ArticleId><ArticleId IdType="pubmed">22958823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlus H &amp; Heneka MT Microglia in Alzheimer&#x2019;s disease. J. Clin. Invest. 127, 3240&#x2013;3249 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C et al. Microglia-derived ASC specks cross-seed amyloid-&#x3b2; in Alzheimer&#x2019;s disease. Nature 552, 355&#x2013;361 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Du F et al. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer&#x2019;s disease. Brain 140, 3233&#x2013;3251 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841141</ArticleId><ArticleId IdType="pubmed">29077793</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandelwal PJ, Herman AM, Hoe HS, Rebeck GW &amp; Moussa CE Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated A&#x3b2; in AD models. Hum. Mol. Genet. 20, 2091&#x2013;2102 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090189</ArticleId><ArticleId IdType="pubmed">21378096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL et al. Blood-derived amyloid-&#x3b2; protein induces Alzheimer&#x2019;s disease pathologies. Mol. Psychiatry 23, 1&#x2013;9 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29086767</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S The genetics of Caenorhabditis elegans. Genetics 77, 71&#x2013;94 (1974).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Samara C, Syntichaki P &amp; Tavernarakis N Autophagy is required for necrotic cell death in Caenorhabditis elegans. Cell Death Differ. 15, 105&#x2013;112 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17901876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bargmann CI &amp; Horvitz HR Chemosensory neurons with overlapping functions direct chemotaxis to multiple chemicals in C. elegans. Neuron 7, 729&#x2013;742 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1660283</ArticleId></ArticleIdList></Reference><Reference><Citation>Palikaras K &amp; Tavernarakis N Assessing mitochondrial selective autophagy in the nematode Caenorhabditis elegans. Methods Mol. Biol. 1567, 349&#x2013;361 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28276029</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Ap and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorhees CV &amp; Williams MT Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1, 848&#x2013;858 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895266</ArticleId><ArticleId IdType="pubmed">17406317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosal K et al. Alzheimer&#x2019;s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl Acad. Sci. USA 106, 18367&#x2013;18372 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762847</ArticleId><ArticleId IdType="pubmed">19837693</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibye-Knudsen M et al. A high-fat diet and NAD+ activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 20, 840&#x2013;855 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261735</ArticleId><ArticleId IdType="pubmed">25440059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y et al. Smart Soup, a traditional Chinese medicine formula, ameliorates amyloid pathology and related cognitive deficits. PLoS One 9, e111215 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4227681</ArticleId><ArticleId IdType="pubmed">25386946</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman M et al. A screening-based platform for the assessment of cellular respiration in Caenorhabditis elegans. Nat. Protoc. 11, 1798&#x2013;1816 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5040492</ArticleId><ArticleId IdType="pubmed">27583642</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang EF et al. Tomatidine enhances lifespan and healthspan in C. elegans through mitophagy induction via the SKN-1/Nrf2 pathway. Sci. Rep. 7, 46208 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5387417</ArticleId><ArticleId IdType="pubmed">28397803</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer GJ &amp; Torricelli JR Isolation and culture of adult neurons and neurospheres. Nat. Protoc. 2, 1490&#x2013;1498 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17545985</ArticleId></ArticleIdList></Reference><Reference><Citation>Forester CM et al. Revealing nascent proteomics in signaling pathways and cell differentiation. Proc. Natl Acad. Sci. USA 115, 2353&#x2013;2358 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5877968</ArticleId><ArticleId IdType="pubmed">29467287</ArticleId></ArticleIdList></Reference><Reference><Citation>Skamagki M et al. ZSCAN10 expression corrects the genomic instability of iPSCs from aged donors. Nat. Cell Biol. 19, 1037&#x2013;1048 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5843481</ArticleId><ArticleId IdType="pubmed">28846095</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H et al. Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/SPECT imaging and flow cytometry. Nat. Protoc. 13, 392&#x2013;412 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5966297</ArticleId><ArticleId IdType="pubmed">29370158</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30767771</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy.</ArticleTitle><Pagination><StartPage>9</StartPage><MedlinePgn>9</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-019-0310-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">A G<sub>4</sub>C<sub>2</sub> hexanucleotide repeat expansion in the noncoding region of C9orf72 is the major genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis (c9FTD/ALS). Putative disease mechanisms underlying c9FTD/ALS include toxicity from sense G<sub>4</sub>C<sub>2</sub> and antisense G<sub>2</sub>C<sub>4</sub> repeat-containing RNA, and from dipeptide repeat (DPR) proteins unconventionally translated from these RNA products.</AbstractText><AbstractText Label="METHODS">Intracerebroventricular injections with adeno-associated virus (AAV) encoding 2 or 149 G<sub>4</sub>C<sub>2</sub> repeats were performed on postnatal day 0, followed by assessment of behavioral and neuropathological phenotypes.</AbstractText><AbstractText Label="RESULTS">Relative to control mice, gliosis and neurodegeneration accompanied by cognitive and motor deficits were observed in (G<sub>4</sub>C<sub>2</sub>)<sub>149</sub> mice by 6&#x2009;months of age. Recapitulating key pathological hallmarks, we also demonstrate that sense and antisense RNA foci, inclusions of poly(GA), poly(GP), poly(GR), poly(PR), and poly(PA) DPR proteins, and inclusions of endogenous phosphorylated TDP-43 (pTDP-43) developed in (G<sub>4</sub>C<sub>2</sub>)<sub>149</sub> mice but not control (G<sub>4</sub>C<sub>2</sub>)<sub>2</sub> mice. Notably, proteins that play a role in the regulation of stress granules - RNA-protein assemblies that form in response to translational inhibition and that have been implicated in c9FTD/ALS pathogenesis - were mislocalized in (G<sub>4</sub>C<sub>2</sub>)<sub>149</sub> mice as early as 3&#x2009;months of age. Specifically, we observed the abnormal deposition of stress granule components within inclusions immunopositive for poly(GR) and pTDP-43, as well as evidence of nucleocytoplasmic transport defects.</AbstractText><AbstractText Label="CONCLUSIONS">Our in vivo model of c9FTD/ALS is the first to robustly recapitulate hallmark features derived from both sense and antisense C9orf72 repeat-associated transcripts complete with neurodegeneration and behavioral impairments. More importantly, the early appearance of persistent pathological stress granules prior to significant pTDP-43 deposition implicates an aberrant stress granule response as a key disease mechanism driving TDP-43 proteinopathy in c9FTD/ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Rosso</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daughrity</LastName><ForeName>Lillian M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanedes-Casey</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stankowski</LastName><ForeName>Jeannette N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Disney</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Scripps Research Institute, Scripps Florida, 130 Scripps Way #3A1, Jupiter, Florida, 33458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Science Institute, Johns Hopkins University, 855 N Wolfe St, Baltimore, MD, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong-Jie</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA. zhang.yongjie@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA. zhang.yongjie@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA. petrucelli.leonard@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, 4500 San Pablo Rd, Jacksonville, Florida, 32224, USA. petrucelli.leonard@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Stress granules</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30767771</ArticleId><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="doi">10.1186/s13024-019-0310-z</ArticleId><ArticleId IdType="pii">10.1186/s13024-019-0310-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arzberger T, Schludi MH, Lehmer C, Schmid B, Edbauer D. RNA versus protein toxicity in C9orf72 ALS/FTLD. Acta Neuropathol. 2018;135:475&#x2013;479. doi: 10.1007/s00401-018-1823-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1823-1</ArticleId><ArticleId IdType="pubmed">29450647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, 3rd, Rademakers R, Boylan KB, Dickson DW, Petrucelli L. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Lee CW. Mouse models of C9orf72 Hexanucleotide repeat expansion in amyotrophic lateral sclerosis/ frontotemporal dementia. Front Cell Neurosci. 2017;11:196. doi: 10.3389/fncel.2017.00196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00196</ArticleId><ArticleId IdType="pmc">PMC5498553</ArticleId><ArticleId IdType="pubmed">28729824</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, Pulst SM, Taylor JP, Rigo F, Gitler AD. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43) J Biol Chem. 2012;287:23079&#x2013;23094. doi: 10.1074/jbc.M111.328757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.328757</ArticleId><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Kovacs D, Konijnenberg A, Timmerman E, Volkov A, Guharoy M, De Decker M, Jaspers T, Ryan VH, Janke AM, Baatsen P, Vercruysse T, Kolaitis RM, Daelemans D, Taylor JP, Kedersha N, Anderson P, Impens F, Sobott F, Schymkowitz J, Rousseau F, Fawzi NL, Robberecht W, Van Damme P, Tompa P, Van Den Bosch L. Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol Cell. 2017;65:1044&#x2013;1055. doi: 10.1016/j.molcel.2017.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.02.013</ArticleId><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Jansen K, Borchelt DR, Kim JY, Jankowsky JL, Golde TE, Levites Y. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One. 2013;8:e67680. doi: 10.1371/journal.pone.0067680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067680</ArticleId><ArticleId IdType="pmc">PMC3692458</ArticleId><ArticleId IdType="pubmed">23825679</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Mestre AA, Fu C, Makarem A, Xian F, Hayes LR, Lopez-Gonzalez R, Drenner K, Jiang J, Cleveland DW, Sun S. C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2alpha phosphorylation. Nat Commun. 2018;9:51. doi: 10.1038/s41467-017-02495-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02495-z</ArticleId><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang YJ, Castanedes-Casey M, Lee CW, Jansen-West K, Kurti A, Murray ME, Bieniek KF, Bauer PO, Whitelaw EC, Rousseau L, Stankowski JN, Stetler C, Daughrity LM, Perkerson EA, Desaro P, Johnston A, Overstreet K, Edbauer D, Rademakers R, Boylan KB, Dickson DW, Fryer JD, Petrucelli L. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348:1151&#x2013;1154. doi: 10.1126/science.aaa9344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa9344</ArticleId><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Clippinger AK, D'Alton S, Lin WL, Gendron TF, Howard J, Borchelt DR, Cannon A, Carlomagno Y, Chakrabarty P, Cook C, Golde TE, Levites Y, Ranum L, Schultheis PJ, Xu G, Petrucelli L, Sahara N, Dickson DW, Giasson B, Lewis J. Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta Neuropathol. 2013;126:39&#x2013;50. doi: 10.1007/s00401-013-1123-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1123-8</ArticleId><ArticleId IdType="pmc">PMC3690181</ArticleId><ArticleId IdType="pubmed">23666556</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, Manley JL. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. 2016;5. 10.7554/eLife.17820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Higginbottom A, Stopford MJ, Highley JR, Ince PG, Wharton SB, Pickering-Brown S, Kirby J, Hautbergue GM, Shaw PJ. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol. 2015;130:63&#x2013;75. doi: 10.1007/s00401-015-1429-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1429-9</ArticleId><ArticleId IdType="pmc">PMC4468790</ArticleId><ArticleId IdType="pubmed">25943887</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG, Vasilevich A, Murray ME, Rousseau L, Weesner R, Lucido A, Parsons M, Chew J, Josephs KA, Parisi JE, Knopman DS, Petersen RC, Boeve BF, Graff-Radford NR, de Boer J, Asmann YW, Petrucelli L, Boylan KB, Dickson DW, van Blitterswijk M, Rademakers R. In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol. 2017;134:255&#x2013;269. doi: 10.1007/s00401-017-1725-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1725-7</ArticleId><ArticleId IdType="pmc">PMC5508036</ArticleId><ArticleId IdType="pubmed">28508101</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Fay MM, Anderson PJ, Ivanov P. ALS/FTD-associated C9ORF72 repeat RNA promotes phase transitions in vitro and in cells. Cell Rep. 2017;21:3573&#x2013;3584. doi: 10.1016/j.celrep.2017.11.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.11.093</ArticleId><ArticleId IdType="pmc">PMC5741101</ArticleId><ArticleId IdType="pubmed">29262335</ArticleId></ArticleIdList></Reference><Reference><Citation>Flotte TR, Afione SA, Solow R, Drumm ML, Markakis D, Guggino WB, Zeitlin PL, Carter BJ. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem. 1993;268:3781&#x2013;3790.</Citation><ArticleIdList><ArticleId IdType="pubmed">7679117</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, Petrucelli L, Kim HJ, Gao FB, Taylor JP. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133. doi: 10.1038/nature14974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14974</ArticleId><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J, Cosio DM, van Blitterswijk M, Lee WC, Rademakers R, Boylan KB, Dickson DW, Petrucelli L. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126:829&#x2013;844. doi: 10.1007/s00401-013-1192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1192-8</ArticleId><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. Disease mechanisms of C9ORF72 repeat expansions. Cold Spring Harb Perspect Med. 2018;8. 10.1101/cshperspect.a024224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880161</ArticleId><ArticleId IdType="pubmed">28130314</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, Glineburg MR, Kearse MG, Flores BN, Linsalata AE, Fedak SJ, Goldstrohm AC, Barmada SJ, Todd PK. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Commun. 2017;8:2005. doi: 10.1038/s41467-017-02200-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02200-0</ArticleId><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lehmer C, Martinez-Sanchez A, Rudack T, Beck F, Hartmann H, Perez-Berlanga M, Frottin F, Hipp MS, Hartl FU, Edbauer D, Baumeister W, Fernandez-Busnadiego R. In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome recruitment. Cell. 2018;172:696&#x2013;705. doi: 10.1016/j.cell.2017.12.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.12.030</ArticleId><ArticleId IdType="pmc">PMC6035389</ArticleId><ArticleId IdType="pubmed">29398115</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, Rothstein JD, Wang J. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200. doi: 10.1038/nature13124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Vale RD. RNA phase transitions in repeat expansion disorders. Nature. 2017;546:243&#x2013;247. doi: 10.1038/nature22386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22386</ArticleId><ArticleId IdType="pmc">PMC5555642</ArticleId><ArticleId IdType="pubmed">28562589</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, Stauffer JE, Jafar-Nejad P, Drenner K, Schulte D, Chun S, Sun S, Ling SC, Myers B, Engelhardt J, Katz M, Baughn M, Platoshyn O, Marsala M, Watt A, Heyser CJ, Ard MC, De Muynck L, Daughrity LM, Swing DA, Tessarollo L, Jung CJ, Delpoux A, Utzschneider DT, Hedrick SM, de Jong PJ, Edbauer D, Van Damme P, Petrucelli L, Shaw CE, Bennett CF, Da Cruz S, Ravits J, Rigo F, Cleveland DW, Lagier-Tourenne C. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, 3rd, Sun S, Herdy JR, Bieri G, Kramer NJ, Gage FH, Van Den Bosch L, Robberecht W, Gitler AD. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;1229. doi: 10.1038/nn.4085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4085</ArticleId><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, Topp S, Gkazi AS, Miller J, Shaw CE, Kottlors M, Kirschner J, Pestronk A, Li YR, Ford AF, Gitler AD, Benatar M, King OD, Kimonis VE, Ross ED, Weihl CC, Shorter J, Taylor JP. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;473. doi: 10.1038/nature11922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11922</ArticleId><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM, Finkbeiner S, Gitler AD, Bonini NM. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014;46:152&#x2013;160. doi: 10.1038/ng.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2853</ArticleId><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, Grunke SD, Levites Y, Golde TE, Jankowsky JL. Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. J Vis Exp. 2014;51863. 10.3791/51863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199253</ArticleId><ArticleId IdType="pubmed">25286085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145. doi: 10.1126/science.1254917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254917</ArticleId><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, Troakes C, Nishimura AL, Scotter EL, Vance C, Adachi Y, Sardone V, Miller JW, Smith BN, Gallo JM, Ule J, Hirth F, Rogelj B, Houart C, Shaw CE. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186. doi: 10.1016/j.celrep.2013.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.10.049</ArticleId><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One. 2010;5:e13250. doi: 10.1371/journal.pone.0013250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013250</ArticleId><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum LP. C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron. 2016;90:521&#x2013;534. doi: 10.1016/j.neuron.2016.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng SM, Haass C, Kretzschmar HA, Edbauer D, Neumann M. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 2013;126:859&#x2013;879. doi: 10.1007/s00401-013-1181-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1181-y</ArticleId><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Grasser FA, Gendron TF, Petrucelli L, Cashman NR, Edbauer D, Kremmer E, Prudlo J, Troost D, Neumann M. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 2015;130:845&#x2013;861. doi: 10.1007/s00401-015-1476-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1476-2</ArticleId><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol. 2014;127:347&#x2013;357. doi: 10.1007/s00401-013-1232-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1232-4</ArticleId><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Nicholson AM, Sarkar M, Messing J, Purice MD, Pottier C, Annu K, Baker M, Perkerson RB, Kurti A, Matchett BJ, Mittag T, Temirov J, Hsiung GR, Krieger C, Murray ME, Kato M, Fryer JD, Petrucelli L, Zinman L, Weintraub S, Mesulam M, Keith J, Zivkovic SA, Hirsch-Reinshagen V, Roos RP, Zuchner S, Graff-Radford NR, Petersen RC, Caselli RJ, Wszolek ZK, Finger E, Lippa C, Lacomis D, Stewart H, Dickson DW, Kim HJ, Rogaeva E, Bigio E, Boylan KB, Taylor JP, Rademakers R. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and Alter stress granule dynamics. Neuron. 2017;95:808&#x2013;816. doi: 10.1016/j.neuron.2017.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId></ArticleIdList></Reference><Reference><Citation>Markmiller S, Soltanieh S, Server KL, Mak R, Jin W, Fang MY, Luo EC, Krach F, Yang D, Sen A, Fulzele A, Wozniak JM, Gonzalez DJ, Kankel MW, Gao FB, Bennett EJ, Lecuyer E, Yeo GW. Context-dependent and disease-specific diversity in protein interactions within stress granules. Cell. 2018;172:590&#x2013;604. doi: 10.1016/j.cell.2017.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.12.032</ArticleId><ArticleId IdType="pmc">PMC5969999</ArticleId><ArticleId IdType="pubmed">29373831</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, Grasser FA, Mori K, Kremmer E, Banzhaf-Strathmann J, Mann M, Meissner F, Edbauer D. C9orf72 FTLD/ALS-associated Gly-ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128:485&#x2013;503. doi: 10.1007/s00401-014-1329-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1329-4</ArticleId><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, Lee VM, Trojanowksi JQ, Van Deerlin VM, Lee EB, Bonini NM. Poly-a binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72. J Neuropathol Exp Neurol. 2014;73:837&#x2013;845. doi: 10.1097/NEN.0000000000000102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000102</ArticleId><ArticleId IdType="pmc">PMC4149258</ArticleId><ArticleId IdType="pubmed">25111021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IOC, Pietrzyk J, Cleverley K, Nicoll AJ, Pickering-Brown S, Dols J, Cabecinha M, Hendrich O, Fratta P, Fisher EMC, Partridge L, Isaacs AM. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194. doi: 10.1126/science.1256800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, Isaacs AM. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2013;857. doi: 10.1007/s00401-013-1200-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1200-z</ArticleId><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Grasser FA, Gijselinck I, May S, Rentzsch K, Weng SM, Schludi MH, van der Zee J, Cruts M, Van Broeckhoven C, Kremmer E, Kretzschmar HA, Haass C, Edbauer D. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126:881&#x2013;893. doi: 10.1007/s00401-013-1189-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1189-3</ArticleId><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Vemuri P, Preboske GM, Murphy MC, Schweitzer KJ, Parisi JE, Jack CR, Jr, Dickson DW. A quantitative postmortem MRI design sensitive to white matter hyperintensity differences and their relationship with underlying pathology. J Neuropathol Exp Neurol. 2012;71:1113&#x2013;1122. doi: 10.1097/NEN.0b013e318277387e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318277387e</ArticleId><ArticleId IdType="pmc">PMC3511604</ArticleId><ArticleId IdType="pubmed">23147507</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554. doi: 10.1212/WNL.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Rourke JG, Bogdanik L, Muhammad A, Gendron TF, Kim KJ, Austin A, Cady J, Liu EY, Zarrow J, Grant S, Ho R, Bell S, Carmona S, Simpkinson M, Lall D, Wu K, Daughrity L, Dickson DW, Harms MB, Petrucelli L, Lee EB, Lutz CM, Baloh RH. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron. 2015;88:892&#x2013;901. doi: 10.1016/j.neuron.2015.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J, Weiss A, Wightman N, Salameh J, Kim J, Sun H, Boylan KB, Dickson D, Kennedy Z, Lin Z, Zhang YJ, Daughrity L, Jung C, Gao FB, Sapp PC, Horvitz HR, Bosco DA, Brown SP, de Jong P, Petrucelli L, Mueller C, Brown RH., Jr Human C9ORF72 Hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 2015;88:902&#x2013;909. doi: 10.1016/j.neuron.2015.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D, Ohkubo T, Schloffman CL, Maldonado M, Baughn M, Rodriguez MJ, Pizzo D, Cleveland D, Ravits J. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135:459&#x2013;474. doi: 10.1007/s00401-017-1793-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1793-8</ArticleId><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N, Bieniek KF, Zhang YJ, Ross K, Gendron TF, Murray ME, Rademakers R, Petrucelli L, Dickson DW. Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol Commun. 2018;6:63. doi: 10.1186/s40478-018-0564-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0564-7</ArticleId><ArticleId IdType="pmc">PMC6054740</ArticleId><ArticleId IdType="pubmed">30029693</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Shibagaki Y, Hattori S, Matsuoka M. The proline-arginine repeat protein linked to C9-ALS/FTD causes neuronal toxicity by inhibiting the DEAD-box RNA helicase-mediated ribosome biogenesis. Cell Death Dis. 2018;9:975. doi: 10.1038/s41419-018-1028-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-1028-5</ArticleId><ArticleId IdType="pmc">PMC6155127</ArticleId><ArticleId IdType="pubmed">30250194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabet R, Schaeffer L, Freyermuth F, Jambeau M, Workman M, Lee CZ, Lin CC, Jiang J, Jansen-West K, Abou-Hamdan H, Desaubry L, Gendron T, Petrucelli L, Martin F, Lagier-Tourenne C. CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nat Commun. 2018;9:152. doi: 10.1038/s41467-017-02643-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02643-5</ArticleId><ArticleId IdType="pmc">PMC5764992</ArticleId><ArticleId IdType="pubmed">29323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z, Wang H, Xia Q, Li K, Li K, Jiang X, Xu G, Wang G, Ying Z. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum Mol Genet. 2015;24:2426&#x2013;2441. doi: 10.1093/hmg/ddv005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv005</ArticleId><ArticleId IdType="pubmed">25575510</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd TW, Petrucelli L. Insights into the pathogenic mechanisms of chromosome 9 open reading frame 72 (C9orf72) repeat expansions. J Neurochem. 2016;138(Suppl 1):145&#x2013;162. doi: 10.1111/jnc.13623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13623</ArticleId><ArticleId IdType="pubmed">27016280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, Pasinelli P, Ichida JK, Trotti D. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225. doi: 10.1016/j.neuron.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Abdallah A, Li Z, Lu Y, Almeida S, Gao FB. FTD/ALS-associated poly(GR) protein impairs the notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathol. 2015;130:525&#x2013;535. doi: 10.1007/s00401-015-1448-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1448-6</ArticleId><ArticleId IdType="pmc">PMC4575383</ArticleId><ArticleId IdType="pubmed">26031661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, Taylor JP, Gitler AD, Rothstein JD, Lloyd TE. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173(958&#x2013;971):e917. doi: 10.1016/j.cell.2018.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, Gupta S, Thomas MA, Hong I, Chiu SL, Huganir RL, Ostrow LW, Matunis MJ, Wang J, Sattler R, Lloyd TE, Rothstein JD. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Ebbert MTW, O'Raw AD, Yue M, Jansen-West K, Zhang X, Prudencio M, Chew J, Cook CN, Daughrity LM, Tong J, Song Y, Pickles SR, Castanedes-Casey M, Kurti A, Rademakers R, Oskarsson B, Dickson DW, Hu W, Gitler AD, Fryer JD, Petrucelli L. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat Med. 2018;24:1136&#x2013;1142. doi: 10.1038/s41591-018-0071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0071-1</ArticleId><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M, Lin WL, Garrett A, Stankowski JN, Daughrity L, Tong J, Perkerson EA, Yue M, Chew J, Castanedes-Casey M, Kurti A, Wang ZS, Liesinger AM, Baker JD, Jiang J, Lagier-Tourenne C, Edbauer D, Cleveland DW, Rademakers R, Boylan KB, Bu G, Link CD, Dickey CA, Rothstein JD, Dickson DW, Fryer JD, Petrucelli L. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci. 2016;19:668&#x2013;677. doi: 10.1038/nn.4272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4272</ArticleId><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bieniek KF, Lin WL, Sasaguri H, Caulfield T, Hubbard J, Daughrity L, Chew J, Belzil VV, Prudencio M, Stankowski JN, Castanedes-Casey M, Whitelaw E, Ash PE, DeTure M, Rademakers R, Boylan KB, Dickson DW, Petrucelli L. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505&#x2013;524. doi: 10.1007/s00401-014-1336-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1336-5</ArticleId><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973&#x2013;985. doi: 10.1038/sj.gt.3300938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3300938</ArticleId><ArticleId IdType="pubmed">10455399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, Ostrow LW, Rothstein JD, Troncoso JC, Ranum LP. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110:E4968&#x2013;E4977. doi: 10.1073/pnas.1315438110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30770411</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>216</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>555</EndPage><MedlinePgn>539-555</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20182184</ELocationID><Abstract><AbstractText>It has been challenging to produce ex vivo models of the inclusion pathologies that are hallmark pathologies of many neurodegenerative diseases. Using three-dimensional mouse brain slice cultures (BSCs), we have developed a paradigm that rapidly and robustly recapitulates mature neurofibrillary inclusion and Lewy body formation found in Alzheimer's and Parkinson's disease, respectively. This was achieved by transducing the BSCs with recombinant adeno-associated viruses (rAAVs) that express &#x3b1;-synuclein or variants of tau. Notably, the tauopathy BSC model enables screening of small molecule therapeutics and tracking of neurodegeneration. More generally, the rAAV BSC "toolkit" enables efficient transduction and transgene expression from neurons, microglia, astrocytes, and oligodendrocytes, alone or in combination, with transgene expression lasting for many months. These rAAV-based BSC models provide a cost-effective and facile alternative to in vivo studies, and in the future can become a widely adopted methodology to explore physiological and pathological mechanisms related to brain function and dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2019 Croft et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Croft</LastName><ForeName>Cara L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0001-7969-5084</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Pedro E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceballos-Diaz</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strang</LastName><ForeName>Kevin H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woody</LastName><ForeName>Brittany M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0003-4348-3316</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wen-Lang</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deture</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Lebr&#xf3;n</LastName><ForeName>Edgardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarty</LastName><ForeName>Paramita</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6226-3776</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levites</LastName><ForeName>Yona</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>Benoit I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0003-1867-7071</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD020026</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055798</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074041" MajorTopicYN="N">Microorganisms, Genetically-Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30770411</ArticleId><ArticleId IdType="pmc">PMC6400529</ArticleId><ArticleId IdType="doi">10.1084/jem.20182184</ArticleId><ArticleId IdType="pii">jem.20182184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., et al. . 2002. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22:9340&#x2013;9351. 10.1523/JNEUROSCI.22-21-09340.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-21-09340.2002</ArticleId><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., et al. . 2006. Phosphorylation of Ser-129 is the dominant pathological modification of &#x3b1;-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281:29739&#x2013;29752. 10.1074/jbc.M600933200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600933200</ArticleId><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C., Acker C.M., Kress Y., Hof P.R., Duff K., and Davies P.. 2005. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 25:5446&#x2013;5454. 10.1523/JNEUROSCI.4637-04.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4637-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack J.C., Schneider A., Mandelkow E.M., and Hyman B.T.. 2002. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 103:26&#x2013;35. 10.1007/s004010100423</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010100423</ArticleId><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr B.A. 1995. Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes. J. Neurosci. Res. 42:294&#x2013;305. 10.1002/jnr.490420303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490420303</ArticleId><ArticleId IdType="pubmed">8583497</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach R.L., Bathgate S.L., and Cotman C.W.. 1982. Identification of cell types in rat hippocampal slices maintained in organotypic cultures. Brain Res. 255:3&#x2013;20. 10.1016/0165-3806(82)90071-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-3806(82)90071-2</ArticleId><ArticleId IdType="pubmed">7034866</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R., Gergou A., Wacker I., Fath T., and Hutter H.. 2009. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer&#x2019;s disease-like modified tau. Neurobiol. Aging. 30:22&#x2013;33. 10.1016/j.neurobiolaging.2007.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.05.011</ArticleId><ArticleId IdType="pubmed">17590239</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion J.-P., Tremp G., and Octave J.-N.. 1999. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer&#x2019;s disease. Am. J. Pathol. 154:255&#x2013;270. 10.1016/S0002-9440(10)65272-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65272-8</ArticleId><ArticleId IdType="pmc">PMC1853433</ArticleId><ArticleId IdType="pubmed">9916940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L., Troquier L., Burnouf S., Belarbi K., Van der Jeugd A., Ahmed T., Fernandez-Gomez F., Caillierez R., Grosjean M.E., Begard S., et al. . 2010. From tau phosphorylation to tau aggregation: what about neuronal death? Biochem. Soc. Trans. 38:967&#x2013;972. 10.1042/BST0380967</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0380967</ArticleId><ArticleId IdType="pubmed">20658986</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiani O., Murrell J.R., Giaccone G., Hasegawa M., Ghigo G., Tabaton M., Morbin M., Primavera A., Carella F., Solaro C., et al. . 1999. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J. Neuropathol. Exp. Neurol. 58:667&#x2013;677. 10.1097/00005072-199906000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199906000-00011</ArticleId><ArticleId IdType="pubmed">10374757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceballos-Diaz C., Rosario A.M., Park H.-J., Chakrabarty P., Sacino A., Cruz P.E., Siemienski Z., Lara N., Moran C., Ravelo N., et al. . 2015. Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice. Mol. Neurodegener. 10:25 10.1186/s13024-015-0026-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0026-7</ArticleId><ArticleId IdType="pmc">PMC4495639</ArticleId><ArticleId IdType="pubmed">26152284</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P., Ceballos-Diaz C., Beccard A., Dickson D., Golde T.E., and Das P.. 2010. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in APP transgenic mice. J. Immunol. 184:5333&#x2013;5343. 10.4049/jimmunol.0903382</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903382</ArticleId><ArticleId IdType="pmc">PMC3798002</ArticleId><ArticleId IdType="pubmed">20368278</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.H., Kim Y.H., Hebisch M., Sliwinski C., Lee S., D&#x2019;Avanzo C., Chen H., Hooli B., Asselin C., Muffat J., et al. . 2014. A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature. 515:274&#x2013;278. 10.1038/nature13800</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13800</ArticleId><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft C.L., Kurbatskaya K., Hanger D.P., and Noble W.. 2017a Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer&#x2019;s disease. Sci. Rep. 7:7434 10.1038/s41598-017-07906-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07906-1</ArticleId><ArticleId IdType="pmc">PMC5547074</ArticleId><ArticleId IdType="pubmed">28785087</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft C.L., Wade M.A., Kurbatskaya K., Mastrandreas P., Hughes M.M., Phillips E.C., Pooler A.M., Perkinton M.S., Hanger D.P., and Noble W.. 2017b Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures. Cell Death Dis. 8:e2671 10.1038/cddis.2017.97</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.97</ArticleId><ArticleId IdType="pmc">PMC5386587</ArticleId><ArticleId IdType="pubmed">28300838</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther R.A. 1991. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc. Natl. Acad. Sci. USA. 88:2288&#x2013;2292. 10.1073/pnas.88.6.2288</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.6.2288</ArticleId><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker J.M., Kr&#xfc;ger L., Sydow A., Dennissen F.J.A., Siskova Z., Mandelkow E., and Mandelkow E.M.. 2016. The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity. EMBO Rep. 17:552&#x2013;569. 10.15252/embr.201541439</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201541439</ArticleId><ArticleId IdType="pmc">PMC4818782</ArticleId><ArticleId IdType="pubmed">26931569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B., Bourdenx M., Gorry P., Przedborski S., Vila M., Hunot S., Singleton A., Olanow C.W., Merchant K.M., Bezard E., et al. . 2015. Targeting &#x3b1;-synuclein for treatment of Parkinson&#x2019;s disease: mechanistic and therapeutic considerations. Lancet Neurol. 14:855&#x2013;866. 10.1016/S1474-4422(15)00006-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00006-X</ArticleId><ArticleId IdType="pmc">PMC5217462</ArticleId><ArticleId IdType="pubmed">26050140</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simoni A., Griesinger C.B., and Edwards F.A.. 2003. Development of rat CA1 neurones in acute versus organotypic slices: role of experience in synaptic morphology and activity. J. Physiol. 550:135&#x2013;147. 10.1113/jphysiol.2003.039099</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2003.039099</ArticleId><ArticleId IdType="pmc">PMC2343027</ArticleId><ArticleId IdType="pubmed">12879864</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K., Noble W., Gaynor K., and Matsuoka Y.. 2002. Organotypic slice cultures from transgenic mice as disease model systems. J. Mol. Neurosci. 19:317&#x2013;320. 10.1385/JMN:19:3:317</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:19:3:317</ArticleId><ArticleId IdType="pubmed">12540058</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman M.S., Trojanowski J.Q., and Lee V.M.Y.. 2004. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10:1055&#x2013;1063. 10.1038/nm1113</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1113</ArticleId><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., and Iwatsubo T.. 2002. &#x3b1;-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4:160&#x2013;164. 10.1038/ncb748</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb748</ArticleId><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgievska B., Sandin J., Doherty J., M&#xf6;rtberg A., Neelissen J., Andersson A., Gruber S., Nilsson Y., Sch&#xf6;tt P., Arvidsson P.I., et al. . 2013. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J. Neurochem. 125:446&#x2013;456. 10.1111/jnc.12203</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12203</ArticleId><ArticleId IdType="pubmed">23410232</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson B.I., Jakes R., Goedert M., Duda J.E., Leight S., Trojanowski J.Q., and Lee V.M.. 2000. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson&#x2019;s disease. J. Neurosci. Res. 59:528&#x2013;533. 10.1002/(SICI)1097-4547(20000215)59:4&lt;528::AID-JNR8&gt;3.0.CO;2-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(20000215)59:4&lt;528::AID-JNR8&gt;3.0.CO;2-0</ArticleId><ArticleId IdType="pubmed">10679792</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R., and Vanmechelen E.. 1995. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 189:167&#x2013;169. 10.1016/0304-3940(95)11484-E</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(95)11484-E</ArticleId><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R., and Spillantini M.G.. 2017. The Synucleinopathies: Twenty Years On. J. Parkinsons Dis. 7(s1):S51&#x2013;S69. 10.3233/JPD-179005</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-179005</ArticleId><ArticleId IdType="pmc">PMC5345650</ArticleId><ArticleId IdType="pubmed">28282814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogolla N., Galimberti I., DePaola V., and Caroni P.. 2006. Staining protocol for organotypic hippocampal slice cultures. Nat. Protoc. 1:2452&#x2013;2456. 10.1038/nprot.2006.180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.180</ArticleId><ArticleId IdType="pubmed">17406491</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T.E. 2014. Open questions for Alzheimer&#x2019;s disease immunotherapy. Alzheimers Res. Ther. 6:3 10.1186/alzrt233</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt233</ArticleId><ArticleId IdType="pmc">PMC4056616</ArticleId><ArticleId IdType="pubmed">24393284</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T.E., Borchelt D.R., Giasson B.I., and Lewis J.. 2013a Thinking laterally about neurodegenerative proteinopathies. J. Clin. Invest. 123:1847&#x2013;1855. 10.1172/JCI66029</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66029</ArticleId><ArticleId IdType="pmc">PMC3635732</ArticleId><ArticleId IdType="pubmed">23635781</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T.E., Lewis J., and McFarland N.R.. 2013b Anti-tau antibodies: hitting the target. Neuron. 80:254&#x2013;256. 10.1016/j.neuron.2013.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.009</ArticleId><ArticleId IdType="pubmed">24139027</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., and Hyman B.T.. 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann. Neurol. 41:17&#x2013;24. 10.1002/ana.410410106</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410106</ArticleId><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J., Probst A., Spillantini M.G., Sch&#xe4;fer T., Jakes R., B&#xfc;rki K., and Goedert M.. 1995. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14:1304&#x2013;1313. 10.1002/j.1460-2075.1995.tb07116.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1995.tb07116.x</ArticleId><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I., Iqbal K., Quinlan M., Tung Y.C., Zaidi M.S., and Wisniewski H.M.. 1986. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261:6084&#x2013;6089.</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S.K., Younkin S., et al. Alzheimer Genetic Analysis Group . 2013. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368:117&#x2013;127. 10.1056/NEJMoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Noble W., and Hanger D.P.. 2017. Roles of tau protein in health and disease. Acta Neuropathol. 133:665&#x2013;704. 10.1007/s00401-017-1707-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1707-9</ArticleId><ArticleId IdType="pmc">PMC5390006</ArticleId><ArticleId IdType="pubmed">28386764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger D.P., and Wray S.. 2010. Tau cleavage and tau aggregation in neurodegenerative disease. Biochem. Soc. Trans. 38:1016&#x2013;1020. 10.1042/BST0381016</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0381016</ArticleId><ArticleId IdType="pubmed">20658996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger D.P., Hughes K., Woodgett J.R., Brion J.-P., and Anderton B.H.. 1992. Glycogen synthase kinase-3 induces Alzheimer&#x2019;s disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147:58&#x2013;62. 10.1016/0304-3940(92)90774-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(92)90774-2</ArticleId><ArticleId IdType="pubmed">1336152</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., Carrillo M.C., Hendrix J.A., Bain L.J., Catafau A.M., Gault L.M., Goedert M., Mandelkow E., Mandelkow E.-M., Miller D.S., et al. . 2016. Tau: From research to clinical development. Alzheimers Dement. 12:1033&#x2013;1039. 10.1016/j.jalz.2016.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.018</ArticleId><ArticleId IdType="pubmed">27154059</ArticleId></ArticleIdList></Reference><Reference><Citation>Humpel C. 2015. Organotypic brain slice cultures: A review. Neuroscience. 305:86&#x2013;98. 10.1016/j.neuroscience.2015.07.086</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.07.086</ArticleId><ArticleId IdType="pmc">PMC4699268</ArticleId><ArticleId IdType="pubmed">26254240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., et al. . 1998. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:702&#x2013;705. 10.1038/31508</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson G.R., Wiedau-Pazos M., Sang T.-K., Wagle N., Brown C.A., Massachi S., and Geschwind D.H.. 2002. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 34:509&#x2013;519. 10.1016/S0896-6273(02)00706-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00706-7</ArticleId><ArticleId IdType="pubmed">12062036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., and Zheng H.. 2017. Practical considerations for choosing a mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 12:89 10.1186/s13024-017-0231-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0231-7</ArticleId><ArticleId IdType="pmc">PMC5741956</ArticleId><ArticleId IdType="pubmed">29273078</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha G.A., Lane E., Vincent I., Otvos L. Jr., Hoffmann R., and Davies P.. 1997. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer&#x2019;s disease. J. Neurochem. 69:2087&#x2013;2095. 10.1046/j.1471-4159.1997.69052087.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69052087.x</ArticleId><ArticleId IdType="pubmed">9349554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S., Aliberti J., Graemmel P., Sunshine M.J., Kreutzberg G.W., Sher A., and Littman D.R.. 2000. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20:4106&#x2013;4114. 10.1128/MCB.20.11.4106-4114.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.20.11.4106-4114.2000</ArticleId><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna M.R., Kovalevich J., Lee V.M.Y., Trojanowski J.Q., and Brunden K.R.. 2016. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement. 12:1051&#x2013;1065. 10.1016/j.jalz.2016.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.006</ArticleId><ArticleId IdType="pmc">PMC5116305</ArticleId><ArticleId IdType="pubmed">27751442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W.S., K&#xe5;gedal K., and Halliday G.M.. 2014. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res. Ther. 6:73 10.1186/s13195-014-0073-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0073-2</ArticleId><ArticleId IdType="pmc">PMC4288216</ArticleId><ArticleId IdType="pubmed">25580161</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R.L., Dayton R.D., Lin W.-L., and Dickson D.W.. 2005. Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. Neurobiol. Dis. 20:64&#x2013;73. 10.1016/j.nbd.2005.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.02.001</ArticleId><ArticleId IdType="pmc">PMC2975329</ArticleId><ArticleId IdType="pubmed">16137567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer B.C., Burgess J.K., Chen J.H., Thomas J.H., and Schellenberg G.D.. 2006. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum. Mol. Genet. 15:1483&#x2013;1496. 10.1093/hmg/ddl067</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl067</ArticleId><ArticleId IdType="pubmed">16600994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H., Dickson D.W., Davies P., and Yen S.H.. 1987. Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc. Natl. Acad. Sci. USA. 84:3410&#x2013;3414. 10.1073/pnas.84.10.3410</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.84.10.3410</ArticleId><ArticleId IdType="pmc">PMC304880</ArticleId><ArticleId IdType="pubmed">2437579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla K.V., Wegmann S., Kopeikina K.J., Hawkes J., Rudinskiy N., Andermann M.L., Spires-Jones T.L., Bacskai B.J., and Hyman B.T.. 2014. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. USA. 111:510&#x2013;514. 10.1073/pnas.1318807111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318807111</ArticleId><ArticleId IdType="pmc">PMC3890777</ArticleId><ArticleId IdType="pubmed">24368848</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy K., Yilmaz Z., and Brion J.P.. 2007. Increased level of active GSK-3&#x3b2; in Alzheimer&#x2019;s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol. 33:43&#x2013;55. 10.1111/j.1365-2990.2006.00795.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2006.00795.x</ArticleId><ArticleId IdType="pubmed">17239007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., et al. . 2000. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:402&#x2013;405. 10.1038/78078</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A., Ceballos-Diaz C., DiNunno N., Levites Y., Cruz P.E., Lewis J., Golde T.E., and Chakrabarty P.. 2015. IFN-&#x3b3; promotes &#x3c4; phosphorylation without affecting mature tangles. FASEB J. 29:4384&#x2013;4398. 10.1096/fj.15-275834</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.15-275834</ArticleId><ArticleId IdType="pmc">PMC6137542</ArticleId><ArticleId IdType="pubmed">26156074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W.-L., Lewis J., Yen S.-H., Hutton M., and Dickson D.W.. 2003. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J. Neurocytol. 32:1091&#x2013;1105. 10.1023/B:NEUR.0000021904.61387.95</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:NEUR.0000021904.61387.95</ArticleId><ArticleId IdType="pubmed">15044841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.-T., Chen C.-C., Huang C.-C., Nishimori K., and Hsu K.-S.. 2017. Oxytocin stimulates hippocampal neurogenesis via oxytocin receptor expressed in CA3 pyramidal neurons. Nat. Commun. 8:537 10.1038/s41467-017-00675-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00675-5</ArticleId><ArticleId IdType="pmc">PMC5599651</ArticleId><ArticleId IdType="pubmed">28912554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lossi L., Alasia S., Salio C., and Merighi A.. 2009. Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS. Prog. Neurobiol. 88:221&#x2013;245. 10.1016/j.pneurobio.2009.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2009.01.002</ArticleId><ArticleId IdType="pubmed">19552996</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S., Djukic B., Taneja P., Yu G.Q., Lo I., Davis A., Craft R., Guo W., Wang X., Kim D., et al. . 2016. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 17:530&#x2013;551. 10.15252/embr.201541438</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201541438</ArticleId><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Messing L., Decker J.M., Joseph M., Mandelkow E., and Mandelkow E.-M.. 2013. Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors. Neurobiol. Aging. 34:1343&#x2013;1354. 10.1016/j.neurobiolaging.2012.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.024</ArticleId><ArticleId IdType="pmc">PMC4984976</ArticleId><ArticleId IdType="pubmed">23158765</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., and Dickson D.W.. 2011. Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10:785&#x2013;796. 10.1016/S1474-4422(11)70156-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70156-9</ArticleId><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray M.E., Kouri N., Lin W.-L., Jack C.R. Jr., Dickson D.W., and Vemuri P.. 2014. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res. Ther. 6:1 10.1186/alzrt231</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt231</ArticleId><ArticleId IdType="pmc">PMC3978456</ArticleId><ArticleId IdType="pubmed">24382028</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W., Hanger D.P., and Gallo J.M.. 2010. Transgenic mouse models of tauopathy in drug discovery. CNS Neurol. Disord. Drug Targets. 9:403&#x2013;428. 10.2174/187152710791556131</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710791556131</ArticleId><ArticleId IdType="pubmed">20522014</ArticleId></ArticleIdList></Reference><Reference><Citation>Pir G.J., Choudhary B., Mandelkow E., and Mandelkow E.-M.. 2016. Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans Tauopathy model. Mol. Neurodegener. 11:33 10.1186/s13024-016-0096-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0096-1</ArticleId><ArticleId IdType="pmc">PMC4847334</ArticleId><ArticleId IdType="pubmed">27118310</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W., Seppi K., Tanner C.M., Halliday G.M., Brundin P., Volkmann J., Schrag A.-E., and Lang A.E.. 2017. Parkinson disease. Nat. Rev. Dis. Primers. 3:17013 10.1038/nrdp.2017.13</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.13</ArticleId><ArticleId IdType="pubmed">28332488</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Cruts M., and van Broeckhoven C.. 2004. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum. Mutat. 24:277&#x2013;295. 10.1002/humu.20086</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20086</ArticleId><ArticleId IdType="pubmed">15365985</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosario A.M., Cruz P.E., Ceballos-Diaz C., Strickland M.R., Siemienski Z., Pardo M., Schob K.-L., Li A., Aslanidi G.V., Srivastava A., et al. . 2016. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol. Ther. Methods Clin. Dev. 3:16026 10.1038/mtm.2016.26</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2016.26</ArticleId><ArticleId IdType="pmc">PMC4909093</ArticleId><ArticleId IdType="pubmed">27308302</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso S.M., van Herpen E., Deelen W., Kamphorst W., Severijnen L.-A., Willemsen R., Ravid R., Niermeijer M.F., Dooijes D., Smith M.J., et al. . 2002. A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick&#x2019;s disease. Ann. Neurol. 51:373&#x2013;376. 10.1002/ana.10140</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10140</ArticleId><ArticleId IdType="pubmed">11891833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino A.N., Thomas M.A., Ceballos-Diaz C., Cruz P.E., Rosario A.M., Lewis J., Giasson B.I., and Golde T.E.. 2013. Conformational templating of &#x3b1;-synuclein aggregates in neuronal-glial cultures. Mol. Neurodegener. 8:17 10.1186/1750-1326-8-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-17</ArticleId><ArticleId IdType="pmc">PMC3671973</ArticleId><ArticleId IdType="pubmed">23714769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R., van der Lee S.J., Naj A.C., Bellenguez C., Badarinarayan N., Jakobsdottir J., Kunkle B.W., Boland A., Raybould R., Bis J.C., et al. GERAD/PERADES, CHARGE, ADGC, EADI . 2017. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 49:1373&#x2013;1384. 10.1038/ng.3916</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M.. 1998. &#x3b1;-Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x2019;s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA. 95:6469&#x2013;6473. 10.1073/pnas.95.11.6469</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6469</ArticleId><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T., Preza E., Mahoney C.J., Set&#xf3;-Salvia N., Ryan N.S., Morris H.R., Arber C., Devine M.J., Houlden H., Warner T.T., et al. . 2015. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Hum. Mol. Genet. 24:5260&#x2013;5269. 10.1093/hmg/ddv246</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv246</ArticleId><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Stansley B., Post J., and Hensley K.. 2012. A comparative review of cell culture systems for the study of microglial biology in Alzheimer&#x2019;s disease. J. Neuroinflammation. 9:115 10.1186/1742-2094-9-115</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-115</ArticleId><ArticleId IdType="pmc">PMC3407712</ArticleId><ArticleId IdType="pubmed">22651808</ArticleId></ArticleIdList></Reference><Reference><Citation>Strang K.H., Goodwin M.S., Riffe C., Moore B.D., Chakrabarty P., Levites Y., Golde T.E., and Giasson B.I.. 2017. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. Acta Neuropathol. Commun. 5:58 10.1186/s40478-017-0458-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0458-0</ArticleId><ArticleId IdType="pmc">PMC5537986</ArticleId><ArticleId IdType="pubmed">28760159</ArticleId></ArticleIdList></Reference><Reference><Citation>Strang K.H., Croft C.L., Sorrentino Z.A., Chakrabarty P., Golde T.E., and Giasson B.I.. 2018. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. J. Biol. Chem. 293:2408&#x2013;2421. 10.1074/jbc.M117.815357</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.815357</ArticleId><ArticleId IdType="pmc">PMC5818185</ArticleId><ArticleId IdType="pubmed">29259137</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundstrom L., Morrison B. III, Bradley M., and Pringle A.. 2005. Organotypic cultures as tools for functional screening in the CNS. Drug Discov. Today. 10:993&#x2013;1000. 10.1016/S1359-6446(05)03502-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(05)03502-6</ArticleId><ArticleId IdType="pubmed">16023058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A., Hochgr&#xe4;fe K., K&#xf6;nen S., Cadinu D., Matenia D., Petrova O., Joseph M., Dennissen F.J., and Mandelkow E.-M.. 2016. Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD. Acta Neuropathol. Commun. 4:17 10.1186/s40478-016-0281-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0281-z</ArticleId><ArticleId IdType="pmc">PMC4766625</ArticleId><ArticleId IdType="pubmed">26916334</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejera D., and Heneka M.T.. 2016. Microglia in Alzheimer&#x2019;s disease: the good, the bad and the ugly. Curr. Alzheimer Res. 13:370&#x2013;380. 10.2174/1567205013666151116125012</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666151116125012</ArticleId><ArticleId IdType="pubmed">26567746</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D., Muyllaert D., Dewachter I., Borghgraef P., Croes S., Devijver H., and Van Leuven F.. 2008. Amyloid activates GSK-3&#x3b2; to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172:786&#x2013;798. 10.2353/ajpath.2008.070904</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.070904</ArticleId><ArticleId IdType="pmc">PMC2258274</ArticleId><ArticleId IdType="pubmed">18258852</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchihara T., Nakamura A., Yamazaki M., and Mori O.. 2001. Evolution from pretangle neurons to neurofibrillary tangles monitored by thiazin red combined with Gallyas method and double immunofluorescence. Acta Neuropathol. 101:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11515780</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeeck C., Deng Q., Dejesus-Hernandez M., Taylor G., Ceballos-Diaz C., Kocerha J., Golde T., Das P., Rademakers R., Dickson D.W., and Kukar T.. 2012. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Mol. Neurodegener. 7:53 10.1186/1750-1326-7-53</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-53</ArticleId><ArticleId IdType="pmc">PMC3519790</ArticleId><ArticleId IdType="pubmed">23046583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., and Mandelkow E.. 2016. Tau in physiology and pathology. Nat. Rev. Neurosci. 17:5&#x2013;21. 10.1038/nrn.2015.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2015.1</ArticleId><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman A.L., Patel S., Kazmi S.A., Oehler A., Freyman Y., Espiritu L., Cotter R., Castaneda J.A., Olson S.H., and Prusiner S.B.. 2017. Kinetics of human mutant tau prion formation in the brains of 2 transgenic mouse lines. JAMA Neurol. 74:1464&#x2013;1472. 10.1001/jamaneurol.2017.2822</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2822</ArticleId><ArticleId IdType="pmc">PMC5822201</ArticleId><ArticleId IdType="pubmed">29059326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30760929</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>566</Volume><Issue>7744</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution.</ArticleTitle><Pagination><StartPage>388</StartPage><EndPage>392</EndPage><MedlinePgn>388-392</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-0924-x</ELocationID><Abstract><AbstractText>Microglia have critical roles not only in neural development and homeostasis, but also in neurodegenerative and neuroinflammatory diseases of the central nervous system<sup>1-4</sup>. These highly diverse and specialized functions may be executed by subsets of microglia that already exist in situ, or by specific subsets of microglia that develop from a homogeneous pool of cells on demand. However, little is known about the presence of spatially and temporally restricted subclasses of microglia in the central nervous system during development or disease. Here we combine massively parallel single-cell analysis, single-molecule fluorescence in situ hybridization, advanced immunohistochemistry and computational modelling to comprehensively characterize subclasses of microglia in multiple regions of the central nervous system during development and disease. Single-cell analysis of tissues of the central nervous system during homeostasis in mice revealed specific time- and region-dependent subtypes of microglia. Demyelinating and neurodegenerative diseases evoked context-dependent subtypes of microglia with distinct molecular hallmarks and diverse cellular kinetics. Corresponding clusters of microglia were also identified in healthy human brains, and the brains of patients with multiple sclerosis. Our data provide insights into the endogenous immune system of the central nervous system during development, homeostasis and disease, and may also provide new targets for the treatment of neurodegenerative and neuroinflammatory pathologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masuda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankowski</LastName><ForeName>Roman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staszewski</LastName><ForeName>Ori</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;ttcher</LastName><ForeName>Chotima</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagar</LastName><AffiliationInfo><Affiliation>Max Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheiwe</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinic for Neurosurgery, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nessler</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunz</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Loo</LastName><ForeName>Geert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>VIB Center for Inflammation Research, Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coenen</LastName><ForeName>Volker Arnd</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Stereotactic and Functional Neurosurgery, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinacher</LastName><ForeName>Peter Christoph</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Stereotactic and Functional Neurosurgery, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sure</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University Hospital Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xfc;n</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Immunobiology and Epigenetics (MPI-IE), Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK DRI, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadelmann</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany. marco.prinz@uniklinik-freiburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany. marco.prinz@uniklinik-freiburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for NeuroModulation, Faculty of Medicine, University of Freiburg, Frieburg, Germany. marco.prinz@uniklinik-freiburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_16031</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2019 Apr;568(7751):E4. doi: 10.1038/s41586-019-1045-2.</RefSource><PMID Version="1">30918409</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Neurosci. 2019 Jul;42(7):440-443. doi: 10.1016/j.tins.2019.03.010.</RefSource><PMID Version="1">31005331</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002469" MajorTopicYN="N">Cell Separation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003711" MajorTopicYN="N">Demyelinating Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="Y">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062211" MajorTopicYN="Y">Spatio-Temporal Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30760929</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-0924-x</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-0924-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30760633</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study.</ArticleTitle><Pagination><StartPage>e1256</StartPage><EndPage>e1267</EndPage><MedlinePgn>e1256-e1267</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000007094</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To examine the association between systemic inflammation measured during midlife and 20-year cognitive decline.</AbstractText><AbstractText Label="METHODS">Within the Atherosclerosis Risk in Communities cohort study, inflammatory biomarkers were measured during middle adulthood. We created an inflammation composite score using 4 blood biomarkers measured at visit 1 (fibrinogen, white blood cell count, von Willebrand factor, and factor VIII); we measured C-reactive protein (CRP) at visit 2. Cognition was assessed over 3 visits spanning 20 years using measures of memory, executive function, and language.</AbstractText><AbstractText Label="RESULTS">A total of 12,336 participants (baseline age 56.8 [5.7], 21% black, 56% women) were included. After adjusting for demographic variables, vascular risk factors, and comorbidities, each standard deviation (SD) increase in midlife inflammation composite score was associated with an additional 20-year decline of -0.035 SD (95% confidence interval: -0.062 to -0.007) on the cognitive composite score. We found a similar association between each SD increase in midlife CRP level and additional 20-year cognitive decline (-0.038 SD, 95% confidence interval: -0.057 to -0.019). Participants with a midlife inflammation composite score in the top quartile had a 7.8% steeper cognitive decline, compared to participants in the lowest quartile; CRP in the top quartile was associated with an 11.6% steeper cognitive decline. In cognitive domain-specific analyses, elevated midlife inflammatory markers were most consistently associated with declines in memory. Results were similar after adjusting for attrition using inverse probability weighting.</AbstractText><AbstractText Label="CONCLUSIONS">Our findings highlight what may be an early pathogenic role for systemic inflammation as a driver of cognitive decline in the decades leading up to older adulthood.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Keenan A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-5989-</Identifier><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson. Kwalke26@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Aozhou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Alden L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvin</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windham</LastName><ForeName>B Gwen</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (K.A.W., R.F.G.) and Epidemiology (R.F.G., A.W., A.L.G., E.S.), Johns Hopkins University, Baltimore, MD; Department of Neurology (D.S.K.), Mayo Clinic, Rochester, MN; Department of Medicine (T.H.M., B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700002C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DK106414</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL070825</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700003I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK089174</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG050699</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700005C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700003C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG052573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700002I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201700005I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-27-8</RegistryNumber><NameOfSubstance UI="D005169">Factor VIII</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-32-5</RegistryNumber><NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005169" MajorTopicYN="N">Factor VIII</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30760633</ArticleId><ArticleId IdType="pmc">PMC6511107</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007094</ArticleId><ArticleId IdType="pii">WNL.0000000000007094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res Ther 2015;7:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369837</ArticleId><ArticleId IdType="pubmed">25802557</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh-Manoux A, Dugravot A, Brunner E, et al. . Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology 2014;83:486&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4141998</ArticleId><ArticleId IdType="pubmed">24991031</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Kanaya A, Lindquist K, et al. . The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pubmed">15536110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialystok E, Craik FIM. Lifespan Cognition: Mechanisms of Change. Oxford, UK: Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Salthouse TA. Continuity of cognitive change across adulthood. Psychon Bull Rev 2016;23:932&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740316</ArticleId><ArticleId IdType="pubmed">26238759</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma VR, Varma S, An Y, et al. . Alpha-2 macroglobulin in Alzheimer&#x2019;s disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry 2017;22:13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726508</ArticleId><ArticleId IdType="pubmed">27872486</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt MF, Freeman KB, Windham BG, et al. . Associations between serum inflammatory markers and hippocampal volume in a community sample. J Am Geriatr Soc 2016;64:1823&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026883</ArticleId><ArticleId IdType="pubmed">27549073</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KA, Power MC, Hoogeveen RC, et al. . Midlife systemic inflammation, late-life white matter integrity, and cerebral small vessel disease. Stroke 2017;48:3196&#x2013;3202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705320</ArticleId><ArticleId IdType="pubmed">29101255</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KA, Hoogeveen RC, Folsom AR, et al. . Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC Study. Neurology 2017;89:2262&#x2013;2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705246</ArticleId><ArticleId IdType="pubmed">29093073</ArticleId></ArticleIdList></Reference><Reference><Citation>The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study&#x2014;I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">2526384</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KA, Walston J, Gottesman RF, Kucharska-Newton A, Palta P, Windham BG. Midlife systemic inflammation is associated with frailty in later life: the ARIC Study. J Gerontol A Biol Sci Med Sci Epub 2018 Mar 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376088</ArticleId><ArticleId IdType="pubmed">29534173</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrinello CM, Grams ME, Couper D, et al. . Recalibration of blood analytes over 25 years in the Atherosclerosis Risk in Communities Study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem 2015;61:938&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782184</ArticleId><ArticleId IdType="pubmed">25952043</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider ALC, Sharrett AR, Gottesman RF, et al. . Normative data for 8 neuropsychological tests in older blacks and whites from the Atherosclerosis Risk in Communities (ARIC) Study. Alzheimer Dis Assoc Disord 2015;29:32&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206681</ArticleId><ArticleId IdType="pubmed">24759546</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">6851096</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379&#x2013;1388.</Citation><ArticleIdList><ArticleId IdType="pubmed">7074948</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud DS, Lu J, Peacock-Villada AY, et al. . Periodontal disease assessed using clinical dental measurements and cancer risk in the ARIC Study. J Natl Cancer Inst 2018;110:843-854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093423</ArticleId><ArticleId IdType="pubmed">29342298</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. Continuity of cognitive change across adulthood. Psychon Bull Rev 2016;23:932&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740316</ArticleId><ArticleId IdType="pubmed">26238759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings AM, Sharrett AR, Schneider ALC, et al. . Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 2014;161:785&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432464</ArticleId><ArticleId IdType="pubmed">25437406</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Rawlings A, Sharrett AR, et al. . Association of midlife lipids with 20-year cognitive change: a cohort study. Alzheimers Dement 2017;14:167&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803364</ArticleId><ArticleId IdType="pubmed">28916238</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Albert M, et al. . Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities neurocognitive study. JAMA Neurol 2014;71:1218&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226067</ArticleId><ArticleId IdType="pubmed">25090106</ArticleId></ArticleIdList></Reference><Reference><Citation>Metti AL, Yaffe K, Boudreau RM, et al. . Trajectories of inflammatory markers and cognitive decline over 10 years. Neurobiol Aging 2014;35:2785&#x2013;2790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252870</ArticleId><ArticleId IdType="pubmed">24997674</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002;59:371&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">12177370</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurin D, David Curb J, Masaki KH, White LR, Launer LJ. Midlife C-reactive protein and risk of cognitive decline: a 31-year follow-up. Neurobiol Aging 2009;30:1724&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477790</ArticleId><ArticleId IdType="pubmed">18316138</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210786</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. . Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickens AM, Tovar-y-Romo LB, Yoo SW, et al. . Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. Sci Signal 2017;10:eaai7696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5590230</ArticleId><ArticleId IdType="pubmed">28377412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against &#x3b2;-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009;65:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">19194878</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KJ, El Khoury J, Medeiros LA, et al. . A CD36-initiated signaling cascade mediates inflammatory effects of &#x3b2;-amyloid. J Biol Chem 2002;277:47373&#x2013;47379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12239221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavan SS, Huerta PT, Robbiati S, et al. . HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med 2012;18:930&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3459473</ArticleId><ArticleId IdType="pubmed">22634723</ArticleId></ArticleIdList></Reference><Reference><Citation>Carret-Rebillat AS, Pace C, Gourmaud S, et al. . Neuroinflammation and A&#x3b2; accumulation linked to systemic inflammation are decreased by genetic PKR down-regulation. Sci Rep 2015;5:8489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4330547</ArticleId><ArticleId IdType="pubmed">25687824</ArticleId></ArticleIdList></Reference><Reference><Citation>Thayer JF, Sternberg EM. Neural aspects of immunomodulation: focus on the vagus nerve. Brain Behav Immun 2010;24:1223&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949498</ArticleId><ArticleId IdType="pubmed">20674737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30820047</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing.</ArticleTitle><Pagination><StartPage>414</StartPage><EndPage>430</EndPage><MedlinePgn>414-430</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-019-0358-2</ELocationID><Abstract><AbstractText>Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially driven by genetics. To identify LOAD risk loci, we performed a large genome-wide association meta-analysis of clinically diagnosed LOAD (94,437 individuals). We confirm 20 previous LOAD risk loci and identify five new genome-wide loci (IQCK, ACE, ADAM10, ADAMTS1, and WWOX), two of which (ADAM10, ACE) were identified in a recent genome-wide association (GWAS)-by-familial-proxy of Alzheimer's or dementia. Fine-mapping of the human leukocyte antigen (HLA) region confirms the neurological and immune-mediated disease haplotype HLA-DR15 as a risk factor for LOAD. Pathway analysis implicates immunity, lipid metabolism, tau binding proteins, and amyloid precursor protein (APP) metabolism, showing that genetic variants affecting APP and A&#x3b2; processing are associated not only with early-onset autosomal dominant Alzheimer's disease but also with LOAD. Analyses of risk genes and pathways show enrichment for rare variants (P&#x2009;=&#x2009;1.32&#x2009;&#xd7;&#x2009;10<sup>-7</sup>), indicating that additional rare variants remain to be identified. We also identify important genetic correlations between LOAD and traits such as family history of dementia and education.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-9515-5157</Identifier><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA. bkunkle@miami.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damotte</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology/Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vronskaya</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-1606-8643</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amlie-Wolf</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2073-1519</Identifier><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellenguez</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1240-7874</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frizatti</LastName><ForeName>Aura</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chouraki</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0283-2332</Identifier><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badarinarayan</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakobsdottir</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Grau</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olaso</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raybould</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuning</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7358-7055</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Taniesha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UMR 894, Center for Psychiatry and Neuroscience, Inserm, Universit&#xe9; Paris Descartes, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomics, Life &amp; Brain Center, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Genetics, University Hospital and Department of Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merce</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garnier</LastName><ForeName>Jean-Guillaume</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Biotechnology, Dublin City University, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>Annette L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moutet</LastName><ForeName>Marie-Laure</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerrish</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Albert V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacq</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denning</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jian</LastName><ForeName>Xueqiu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Zompo</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seung-Hoan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateo</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Service and CIBERNED, 'Marqu&#xe9;s de Valdecilla' University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Joseph T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Hieab H</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0003-3687-2508</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malamon</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Garcia</LastName><ForeName>Florentino</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Yogen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-8509-148X</Identifier><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dombroski</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naranjo</LastName><ForeName>Maria Candida Deniz</ForeName><Initials>MCD</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniilidou</LastName><ForeName>Makrina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiriksdottir</LastName><ForeName>Gudny</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Shubhabrata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Normandie University, UNIROUEN, Inserm U1245, and Rouen University Hospital, Department of Neurology, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uphill</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aspelund</LastName><ForeName>Thor</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7998-5433</Identifier><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Public Health, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garzia</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Centro Dino Ferrari, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofer</LastName><ForeName>Edith</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Division of Neurogeriatrics, Department of Neurology, Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butkiewicz</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Computational Biology, Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fin</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Centro Dino Ferrari, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnowski</LastName><ForeName>Chloe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Will S</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0002-9729-6519</Identifier><AffiliationInfo><Affiliation>Institute for Computational Biology, Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meslage</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yuenjoo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Computational Biology, Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0001-6857-0286</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Memory Clinic, Hospital Network Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sordon</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Saarland, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voijnovic</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Perrie M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurology, University Hospital and University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayhaus</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Saarland, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0003-0273-7965</Identifier><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials><Identifier Source="ORCID">0000-0002-2228-2964</Identifier><AffiliationInfo><Affiliation>Laboratory for Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Memory Clinic, Hospital Network Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Saarland, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Himali</LastName><ForeName>Jayanadra J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-1391-9481</Identifier><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squassina</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7415-7607</Identifier><AffiliationInfo><Affiliation>Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Annette M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Martin Luther University Halle-Wittenberg, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orellana</LastName><ForeName>Adelina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Rodriguez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Service and CIBERNED, 'Marqu&#xe9;s de Valdecilla' University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munoz-Fernadez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sussams</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Honghuang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3043-3942</Identifier><AffiliationInfo><Affiliation>Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fairchild</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Office of Strategy and Measurement, University of North Texas Health Science Center, Fort Worth, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benito</LastName><ForeName>Yolanda A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hospital Universitario Doctor Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karamuji&#x107;-&#x10c;omi&#x107;</LastName><ForeName>Hata</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thonberg</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Theme Aging, Unit for Hereditary Dementias, Karolinska University Hospital-Solna, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Alzheimer Research Center, Division of Neurogeriatrics, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roshchupkin</LastName><ForeName>Gennady</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3403-2313</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giedraitis</LastName><ForeName>Vilmantas</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-3423-2021</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawalia</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2331-2448</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilander</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moebus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brundin</LastName><ForeName>RoseMarie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turton</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-3658-1375</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Mindy J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Concari</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Section of Neuroscience, DIMEC-University of Parma, Parma, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FERB-Alzheimer Center, Gazzaniga (Bergamo), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helisalmi</LastName><ForeName>Seppo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Elderly and Psychiatric Disorders Department, Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koivisto</LastName><ForeName>Anne Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Aoibhinn</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mercer's Institute for Research on Aging, St. James's Hospital and Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. James's Hospital and Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarraga</LastName><ForeName>Llu&#xed;s</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haapasalo</LastName><ForeName>Annakaisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mercer's Institute for Research on Aging, St. James's Hospital and Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. James's Hospital and Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Geriatrics, Gerontology and Neurology, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solfrizzi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Interdisciplinary Department of Medicine, Geriatric Medicine and Memory Unity, University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0206-5337</Identifier><AffiliationInfo><Affiliation>Mercer's Institute for Research on Aging, St. James's Hospital and Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. James's Hospital and Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longstreth</LastName><ForeName>W T</ForeName><Initials>WT</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisardi</LastName><ForeName>Vincenza</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Center for Aging Brain, University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez-Fairen</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; per la Recerca Biom&#xe8;dica i Social M&#xfa;tua Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivadeneira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9435-9441</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus University Medical Center, Rotterdamt, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Netherlands Consortium on Health Aging and National Genomics Initiative, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>CHU Lille, Memory Center of Lille (Centre M&#xe9;moire de Ressources et de Recherche), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; per la Recerca Biom&#xe8;dica i Social M&#xfa;tua Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salani</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical and Behavioral Neurology, Experimental Neuropsychobiology Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciaramella</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Behavioral Neurology, Experimental Neuropsychobiology Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boerwinkle</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Public Health, Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Arizona, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fievet</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Jerome I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine, Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisch</LastName><ForeName>Joan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanon</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>University Paris Descartes, EA 4468, AP-HP, Geriatrics Department, H&#xf4;pital Broca, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cupidi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andre Uitterlinden</LastName><ForeName>A G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus University Medical Center, Rotterdamt, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Netherlands Consortium on Health Aging and National Genomics Initiative, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royall</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Medicine, Family &amp; Community Medicine, South Texas Veterans Health Administration Geriatric Research Education &amp; Clinical Center (GRECC), UT Health Science Center at San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dufouil</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm 1219, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Bordeaux University Hospital / CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maletta</LastName><ForeName>Raffaele Giovanni</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rojas</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR 7225, Sorbonne Universit&#xe9;s, UPMC Universit&#xe9; Paris 06, UMRS 1127, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AP-HP, Department of Genetics, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchetti</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George-Hyslop</LastName><ForeName>Peter St</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Inserm U1061 Neuropsychiatry, La Colombi&#xe8;re Hospital, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montpellier University, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2072-8010</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>VA Puget Sound Health Care System/&gt;GRECC, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institut de la M&#xe9;moire et de la Maladie d'Alzheimer and Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut des Neurosciences Translationnelles de Paris, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, CNRS, UMR-S975, Institut du Cerveau et de la Moelle Epini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Pharmacology &amp; Neuroscience, Texas Tech University Health Science Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avramidou</LastName><ForeName>Despoina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center (GRECC), VA Ann Arbor Healthcare System (VAAAHS), Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Michigan Alzheimer Disease Center, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratiglioni</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Germanou</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer's Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koutroumani</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Center for Aging Brain, University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkatzima</LastName><ForeName>Olymbia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center (GRECC), University of Wisconsin, Madison, WI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin, Madison, WI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitehead</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0001-5040-1679</Identifier><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caffarra</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>AXA Research Fund &amp; Sorbonne University Chair, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne University, GRC n&#xb0; 21, Alzheimer Precision Medicine (APM), AP-HP, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain &amp; Spine Institute, Inserm U 1127, CNRS UMR 7225, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Memory and Alzheimer's Disease, Department of Neurology, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintela</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Grupo de Medicina Xenomica, Universidade de Santiago de Compostela, Centro Nacional de Genotipado, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carracedo</LastName><ForeName>&#xc1;ngel</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Grupo de Medicina Xenomica, Universidade de Santiago de Compostela, Centro Nacional de Genotipado, Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0001-5002-5263</Identifier><AffiliationInfo><Affiliation>Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9880-9788</Identifier><AffiliationInfo><Affiliation>CHU Lille, Memory Center of Lille (Centre M&#xe9;moire de Ressources et de Recherche), Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barral</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Janet A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-4425-4726</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2059-024X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Puget Sound Health Care System/&gt;GRECC, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0002-7274-7299</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-4258-250X</Identifier><AffiliationInfo><Affiliation>Swedish Medical Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-3408-7787</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JSK</Initials><AffiliationInfo><Affiliation>Departments of Biology, Brigham Young University, Provo, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>University of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancuso</LastName><ForeName>Michelangelo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2738-8562</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, Neurological Institute, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonuccelli</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, Neurological Institute, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuillin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1567-2240</Identifier><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Chris S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin, Madison, WI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bass</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Fred Hutchinson Cancer Research Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL, Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Mental Health &amp; Behavioral Science Service, Bruce W. Carter VA Medical Center, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Mariet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2850-9936</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masullo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Catholic University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crocco</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Davis, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bisceglio</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcolm</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer's Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riemenschneider</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Saarland, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fardo</LastName><ForeName>David W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0002-7207-4696</Identifier><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, Department of Biostatistics, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heun</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;lsch</LastName><ForeName>Heike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leber</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer's Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuser</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charit&#xe9; University Medicine, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giegling</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Martin Luther University Halle-Wittenberg, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Alzheimer's Disease Center, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xfc;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Neurogenetics Program, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Genetics, Department of Medicine and Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feulner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Saarland, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0002-6802-1102</Identifier><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drichel</LastName><ForeName>Dmitriy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cologne Center for Genomics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cushion</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Medical Genetics), University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meggy</LastName><ForeName>Alun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, College of Public Health, Department of Epidemiology, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menzies</LastName><ForeName>Georgina E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">0000-0002-6600-6507</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonenko</LastName><ForeName>Ganna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Real</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Unidad Cl&#xed;nica de Enfermedades Infecciosas y Microbiolog&#xed;a, Hospital Universitario de Valme, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grozeva</LastName><ForeName>Detelina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Swedish Medical Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Functional Genomics Center Zurich, ETH/University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health &amp;Science University, Portland, OR, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Portland Veterans Affairs Medical Center, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Boston University School of Medicine, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Inserm U558, University of Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neuropsychology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardy</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;ckel</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1561-6054</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klopp</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Neuherberg, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-9268-810X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>H-Erich</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Helmholtz Center Munich, Institute of Epidemiology, Neuherberg, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig-Maximilians University Chair of Epidemiology, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Biobank Munich and KORA Biobank, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8217-2396</Identifier><AffiliationInfo><Affiliation>Human Genetics, Schools of Life Sciences and Medicine, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Kristelle</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine-Pulmonary, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medway</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomics, Life &amp; Brain Center, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooper</LastName><ForeName>Nigel M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-5811-3484</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniele</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Catholic University of Sacred Hearth, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>School of Nursing Northwest Research Group on Aging, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayer</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Primary Care and Public Health, Cardiff University, University Hospital of Wales, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0002-6581-1213</Identifier><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallacher</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2394-5299</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Boston University School of Medicine, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Bussche</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel-Heller</LastName><ForeName>Steffi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience&#xf3;, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience&#xf3;, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Goettingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IBiMED, Medical Sciences Department, University of Aveiro, Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Bryant</LastName><ForeName>Sid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olichney</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Davis, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory-Hospital, University of Central Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulson</LastName><ForeName>Henry L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Michigan Alzheimer Disease Center, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>William R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials><Identifier Source="ORCID">0000-0003-0625-3968</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro di Ricerca, Trasferimento e Alta Formazione DENOTHE, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchinelli</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7648-5126</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Behavioral Neurology, Experimental Neuropsychobiology Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boss&#xf9;</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical and Behavioral Neurology, Experimental Neuropsychobiology Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orfei</LastName><ForeName>Maria Donata</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Center, New York University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9802-8241</Identifier><AffiliationInfo><Affiliation>Oxford Healthy Aging Project, Clinical Trial Service Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>A David</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Oxford Project to Investigate Memory and Ageing, University of Oxford, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine at the University of Southern California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warden</LastName><ForeName>Donald</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Oxford Project to Investigate Memory and Ageing, University of Oxford, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><Identifier Source="ORCID">0000-0002-1810-9763</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcock</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Oxford Project to Investigate Memory and Ageing, University of Oxford, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruni</LastName><ForeName>Amalia Cecilia</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regional Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben-Shlomo</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sager</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-1376-8532</Identifier><AffiliationInfo><Affiliation>Indiana Alzheimer's Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7493-8777</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; per la Recerca Biom&#xe8;dica i Social M&#xfa;tua Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuccaro</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lori S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slifer</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>University of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Eldik</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, Department of Neuroscience, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Pathology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhelmsen</LastName><ForeName>Kirk C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0002-7679-6282</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pathology, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saba</LastName><ForeName>Yasaman</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gerontology and Geriatrics Research Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Geriatric Care, Orthogeriatrics and Rehabilitation, Galliera Hospital, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullido</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-6477-1117</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IdiPAZ, Instituto de Investigaci&#xf3;n Sanitaria la Paz, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Biologia Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charit&#xe9; University Medicine, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosco</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Instituto di Ricovero e Cura a Carattere Scientifico, Associazione Oasi Maria Santissima Srl, Troina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coto</LastName><ForeName>Eliecer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory-Hospital, University of Central Asturias, Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccardi</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Phil L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lleo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Autonomous University Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Somerset Partnership NHS Trust, Somerset, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9251-070X</Identifier><AffiliationInfo><Affiliation>The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0276-2899</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Theme Aging, Unit for Hereditary Dementias, Karolinska University Hospital-Solna, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Alzheimer Research Center, Division of Neurogeriatrics, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gwilliam</LastName><ForeName>Rhian</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornage</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brown Foundation Institute of Molecular Medicine, University of Texas Health Sciences Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Juan</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurology Service and CIBERNED, 'Marqu&#xe9;s de Valdecilla' University Hospital (University of Cantabria and IDIVAL), Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kehoe</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>University of Bristol Medical School, Learning &amp; Research level 2, Southmead Hospital, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Najaf</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilifur</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5254-7655</Identifier><AffiliationInfo><Affiliation>Inserm U1061 Neuropsychiatry, La Colombi&#xe8;re Hospital, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montpellier University, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debette</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Inserm U1127, CNRS UMR 7225, Sorbonne Universit&#xe9;s, UPMC Universit&#xe9; Paris 06, UMRS 1127, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AP-HP, Department of Genetics, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Bristol Medical School, Learning &amp; Research level 2, Southmead Hospital, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Memory Research and Resources Center, CMRR de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcoran</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Radiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Gael</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Normandie University, UNIROUEN, Inserm U1245, and Rouen University Hospital, Department of Neurology, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Normandie University, UNIROUEN, Inserm U1245, and Rouen University Hospital, Department of Neurology, Department of Genetics and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research Rouvray Psychiatric Hospital, Sotteville-l&#xe8;s-Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tschanz</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, Children's Hospital of Philadelphia, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Autonomous University Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munger</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Utah State University, Logan, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Reinhold</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Division of Neurogeriatrics, Department of Neurology, Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0183-7665</Identifier><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C O'Donovan</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7073-2379</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3007-4612</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institute for Computational Biology, Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Centre National de Recherche en G&#xe9;nomique Humaine, Institut de Biologie Fran&#xe7;ois Jacob, CEA, Universit&#xe9; Paris-Saclay, and LabEx GENMED, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-4798-0862</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escott-Price</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1784-5483</Identifier><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Services, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kaiser Permanente, Washington Health Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4991-763X</Identifier><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agustin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic of Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades-Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Cardiff, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Phillippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9088-234X</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0829-7817</Identifier><AffiliationInfo><Affiliation>Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France. jean-charles.lambert@pasteur-lille.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur de Lille, Lille, France. jean-charles.lambert@pasteur-lille.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France. jean-charles.lambert@pasteur-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-7283-8804</Identifier><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA. mpericak@miami.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer Disease Genetics Consortium (ADGC),</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>European Alzheimer&#x2019;s Disease Initiative (EADI),</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE),</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium (GERAD/PERADES),</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0500289</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900688</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/9</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600237</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K013041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG054060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900421</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL120393</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160657</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>203249/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N012453/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_00024/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 HL120393</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG055620</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG017266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_14095</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501517/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L021803/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M024784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG061796</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG041232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG044271</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M009076/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0801418</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SHAW/NOV14/985-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_18025</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG018454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G9810900</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Genet. 2019 Sep;51(9):1423-1424. doi: 10.1038/s41588-019-0495-7.</RefSource><PMID Version="1">31417202</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cardiovasc Res. 2019 Sep 1;115(11):e102-e104. doi: 10.1093/cvr/cvz196.</RefSource><PMID Version="1">31436832</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. D. Blacker is a consultant for Biogen, Inc. R.C.P. is a consultant for
Roche, Inc.; Merck, Inc.; Genentech, Inc.; Biogen, Inc.; GE Healthcare; and
Eisai, Inc. A.R.W. is a former employee and stockholder of Pfizer, Inc., and a
current employee of the Perelman School of Medicine at the University of
Pennsylvania Orphan Disease Center in partnership with the Loulou. A.M.G. is a
member of the scientific advisory board for Denali Therapeutics. N.E.-T. is a
consultant for Cytox. J.Hardy holds a collaborative grant with Cytox cofunded by
the Department of Business (Biz). F.J. acts as a consultant for Novartis, Eli
Lilly, Nutricia, MSD, Roche and Piramal. Neither J.M. nor his family owns stock
or has equity interest (outside of mutual funds or other externally directed
accounts) in any pharmaceutical or biotechnology company. J.M. is currently
participating in clinical trials of antidementia drugs from Eli Lilly and
Company, Biogen and Janssen. J.M. serves as a consultant for Lilly USA. He
receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded
by NIH grant nos. P50AG005681, P01AG003991, P01AG026276 and UF01AG032438.
C.Cruchaga receives research support from Biogen, EISAI, Alector and Parabon.
The funders of the study had no role in the collection, analysis or
interpretation of data; in the writing of the report; or in the decision to
submit the paper for publication. C.Cruchaga is a member of the advisory board
of ADx Healthcare. M.R.F. receives grant/research support from AbbVie, Accera,
ADCS Posiphen, Biogen, Eisai, Eli Lilly, Genentech, Novartis and Suven Life
Sciences, Ltd. He is a consultant/advisory board/DSMB board member for Accera,
Avanir, AZTherapies, Cognition Therapeutics, Cortexyme, Eli Lilly &amp; Company,
Longeveron, Medavante, Merck and Co. Inc., Otsuka Pharmaceutical, Proclara
(formerly Neurophage Pharmaceuticals), Neurotrope Biosciences, Takeda, vTv
Therapeutics and Zhejian Hisun Pharmaceuticals. He has a transgenic mouse model
patent that is licensed to Elan. R.A.S. receives consulting fees as a member of
the Alzheimer&#x2019;s Disease Advisory Board, Biogen; and as member of the
Executive Committee for AZD3293 Alzheimer&#x2019;s Disease Studies, Eli Lilly.
R.B.L. receives consulting fees from Merch, Inc. E.M.R. receives grant funding
from several NIH grant and research contracts with Genentech/Roche, Novartis/
Amgen and Avid/Lilly. He is a compensated scientific advisor to Alkahest,
Alzheon, Aural Analytics, Denali, Takeda and Zinfandel. He is an advisor to
Roche and Roche Diagnostics, which reimburse his expenses only. T.G.B. has
research support/contracts from the National Institutes of Health, State of
Arizona, Michael J Fox Foundation, Avid Radiopharmaceuticals, Navida
Biopharmaceuticals and Aprinoia Therapeutics. He is an advisory board member
with Vivid Genomics and has consultancy work with Roche Diagnostics. A.G.S.
conducts multiple industry-funded clinical trials, but all funds go to her
academic institution. They have current (within last 12 months) research
contracts with Eli Lilly, Novartis, Roche, Janssen, AbbVie, Biogen, NeuroEM,
Suven and Merck. She does not receive personal compensations from these
organizations. G.D.S. is a consultant for Biogen, Inc. J.M.B. is participating
in clinical trials of antidementia drugs for Eli Lilly, Toyama Chemical Company,
Merck, Biogen, AbbVie, vTv Therapeutics, Janssen and Roche. He has received
research grants from Eli Lilly, Avid Radiopharmaceuticals and Astra Zeneca. He
is a consultant for Stage 2 Innovations. L.F. is a consultant for Allergan, Eli
Lilly, Avraham Pharmaceuticals, Axon Neuroscience, Axovant, Biogen, Boehringer
Ingelheim, Eisai, Functional Neuromodulation, Lundbeck, MerckSharpe &amp; Dohme,
Novartis, Pfizer, Pharnext, Roche and Schwabe Pharma. M.B has consulted as an
advisory board member for Araclon, Grifols, Lilly, Nutricia, Roche and Servier.
She received fees for lectures and funds for research from Araclon, Grifols,
Nutricia, Roche and Servier. She has not received personal compensations from
these organizations. A.Ruiz has consulted for Grifols and Landsteiner Genmed. He
received fees for lectures or funds for research and/or reimbursement of
expenses for congresses attendance from Araclon and Grifols. He has not received
personal compensations from these organizations. O.P. acts as a consultant for
Roche and Biogen, Inc. He is currently participating in clinical trials of
antidementia drugs from Novartis, Genentech, Roche and Pharmatrophix. B.T.H. is
a consultant for Aztherapy, Biogen, Calico, Ceregene, Genentech, Lilly,
Neurophage, Novartis and Takeda, and receives research support from Abbvie,
Amgen, Deanli, Fidelity Biosciences, General Electric, Lilly, Merck, Sangamo and
Spark therapeutics. BTH owns Novartis stock. H.Hampel serves as Senior Associate
Editor for the Journal Alzheimer&#x2019;s &amp; Dementia; he received lecture
fees from Biogen and Roche, research grants from Pfizer, Avid and MSD AVENIR
(paid to the institution), travel funding from Functional Neuromodulation,
Axovant, Eli Lilly and company, Takeda and Zinfandel, GE Healthcare and Oryzon
Genomics, consultancy fees from Jung Diagnostics, Cytox Ltd., Axovant, Anavex,
Takeda and Zinfandel, GE Healthcare, Oryzon Genomics and Functional
Neuromodulation, and participated in scientific advisory boards of Functional
Neuromodulation, Axovant, Eli Lilly and company, Cytox Ltd., GE Healthcare,
Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostica. Harald Hampel is a
co-inventor on numerous patents relating to biomarker measurement but has
received no royalties from these patents. A.A.-C. has consultancies for GSK,
Cytokinetics, Biogen Idec, Treeway Inc, Chronos Therapeutics, OrionPharma and
Mitsubishi-Tanabe Pharma, and was Chief Investigator for commercial clinical
trials run by OrionPharma and Cytokinetics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30820047</ArticleId><ArticleId IdType="mid">NIHMS1021255</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pii">10.1038/s41588-019-0358-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambert JC et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PM et al. Assessment of the genetic variance of late-onset Alzheimer&#x2019;s disease. Neurobiol. Aging 41, 1&#x2013;8 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948179</ArticleId><ArticleId IdType="pubmed">27036079</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63, 168&#x2013;174 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet 43, 436&#x2013;441 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832&#x2013;1840 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat. Genet 43, 429&#x2013;435 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R et al. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol 67, 1473&#x2013;1484 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat. Genet 41, 1088&#x2013;1093 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat. Genet 41, 1094&#x2013;1099 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J et al. LD Hub: A centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. Bioinformatics 33, 051094 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5542030</ArticleId><ArticleId IdType="pubmed">27663502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet 47, 291&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims RC et al. Novel rare coding variants in PLCG2, ABI3 and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet 49, 1373&#x2013;1387 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ et al. Case-control association mapping by proxy using family history of disease. Nat. Genet 49, 325&#x2013;331 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS et al. Polygenic overlap between c-reactive protein, plasma lipids, and Alzheimer&#x2019;s disease. Circulation 131, 2061&#x2013;2069 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677995</ArticleId><ArticleId IdType="pubmed">25862742</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun GR et al. Transethnic genome-wide scan identifies novel Alzheimer&#x2019;s disease loci. Alzheimers Dement 13, 727&#x2013;738 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496797</ArticleId><ArticleId IdType="pubmed">28183528</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R ADAM10 prodomain mutations cause late-onset Alzheimer&#x2019;s disease: not just the latest FAD. Neuron 80, 250&#x2013;253 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090694</ArticleId><ArticleId IdType="pubmed">24139026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M et al. Potential late-onset Alzheimer&#x2019;s disease-associated mutations in the ADAM10 gene attenuate alpha-secretase activity. Hum. Mol. Genet 18, 3987&#x2013;3996 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748890</ArticleId><ArticleId IdType="pubmed">19608551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe PG et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat. Genet 21, 71&#x2013;72 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9916793</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y et al. Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community. Am. J. Hum. Genet 78, 871&#x2013;877 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474030</ArticleId><ArticleId IdType="pubmed">16642441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer&#x2019;s disease. Am. J. Epidemiol 162, 305&#x2013;317 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16033878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X-B et al. Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis. PLoS ONE 9, e111406 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216072</ArticleId><ArticleId IdType="pubmed">25360660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai G et al. Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer disease. Neurobiol. Aging 33, 416&#x2013;417.e3 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084881</ArticleId><ArticleId IdType="pubmed">20381196</ArticleId></ArticleIdList></Reference><Reference><Citation>Belbin O et al. A multi-center study of ACE and the risk of late-onset Alzheimer&#x2019;s disease. J. Alzheimers. Dis 24, 587&#x2013;597 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655234</ArticleId><ArticleId IdType="pubmed">21297258</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE et al. GWAS on family history of Alzheimeras disease. Transl. Psychiatry 8, 99 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet 44, 369&#x2013;375 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593158</ArticleId><ArticleId IdType="pubmed">22426310</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J-Y &amp; Chang N-S WWOX dysfunction induces sequential aggregation of TRAPPC6A&#x394;, TIAF1, tau and amyloid &#x3b2;, and causes apoptosis. Cell Death Discov 1, 15003 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981022</ArticleId><ArticleId IdType="pubmed">27551439</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze CI et al. Down-regulation of WW domain-containing oxidoreductase induces tau phosphorylation in vitro: a potential role in Alzheimer&#x2019;s disease. J. Biol. Chem 279, 30498&#x2013;30506 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15126504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Z et al. AlzBase: an integrative database for gene dysregulation in Alzheimer&#x2019;s disease. Mol. Neurobiol 53, 310&#x2013;319 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25432889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M et al. A transcriptomic atlas of aged human microglia. Nat. Commun 9, 539 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet 7, 180&#x2013;184 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM &amp; Holtzman DM The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron 63, 287&#x2013;303 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer&#x2019;s disease. Nat. Genet 47, 445&#x2013;447 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasquez JB, Fardo DW &amp; Estus S ABCA7 expression is associated with Alzheimer&#x2019;s disease polymorphism and disease status. Neurosci. Lett 556, 58&#x2013;62 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863933</ArticleId><ArticleId IdType="pubmed">24141082</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roeck A et al. An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer&#x2019;s disease. Acta Neuropathol 135, 827&#x2013;837 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5954066</ArticleId><ArticleId IdType="pubmed">29589097</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roeck A et al. Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer&#x2019;s disease. Acta Neuropathol 134, 475&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563332</ArticleId><ArticleId IdType="pubmed">28447221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol. Psychiatry 18, 1225&#x2013;1234 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807661</ArticleId><ArticleId IdType="pubmed">23399914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet 39, 168&#x2013;177 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN et al. Coding mutations in SORL 1 and Alzheimer disease. Ann. Neurol 77, 215&#x2013;227 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh J et al. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron 80, 385&#x2013;401 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105199</ArticleId><ArticleId IdType="pubmed">24055016</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nat. Neurosci 20, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol. Psychiatry 17, 223&#x2013;233 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265835</ArticleId><ArticleId IdType="pubmed">21403675</ArticleId></ArticleIdList></Reference><Reference><Citation>Flister MJ et al. Identifying multiple causative genes at a single GWAS locus. Genome Res 23, 1996&#x2013;2002 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3847770</ArticleId><ArticleId IdType="pubmed">24006081</ArticleId></ArticleIdList></Reference><Reference><Citation>Farh KK-H et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337&#x2013;343 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336207</ArticleId><ArticleId IdType="pubmed">25363779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis JC et al. Whole exome sequencing study identifies novel rare and common Alzheimer&#x2019;s-associated variants involved in immune response and transcriptional regulation. Mol. Psychiatry 10.1038/s41380-018-0112-7 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0112-7</ArticleId><ArticleId IdType="pmc">PMC6375806</ArticleId><ArticleId IdType="pubmed">30108311</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN et al. Coding mutations in SORL1 and Alzheimer disease. Ann. Neurol 77, 215&#x2013;227 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J et al. A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer&#x2019;s disease. Acta Neuropathol 132, 213&#x2013;224 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947104</ArticleId><ArticleId IdType="pubmed">27026413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C et al. Contribution to Alzheimer&#x2019;s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol. Aging 59, 220.e1&#x2013;220.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28789839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Targeted sequencing of ABCA7 identifies splicing, stop-gain and intronic risk variants for Alzheimer disease. Neurosci. Lett 649, 124&#x2013;129 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28400126</ArticleId></ArticleIdList></Reference><Reference><Citation>May P et al. Rare ABCA7 variants in 2 German families with Alzheimer disease. Neurol. Genet 4, e224 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863691</ArticleId><ArticleId IdType="pubmed">29577078</ArticleId></ArticleIdList></Reference><Reference><Citation>Guennec K. Le et al. ABCA7 rare variants and Alzheimer disease risk. Neurology 86, 1&#x2013;4 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898320</ArticleId><ArticleId IdType="pubmed">27037229</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle AP et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22, 1790&#x2013;1797 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431494</ArticleId><ArticleId IdType="pubmed">22955989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD &amp; Kellis M HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40, D930&#x2013;D934 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245002</ArticleId><ArticleId IdType="pubmed">22064851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbino DR, Wilder SP, Johnson N, Juettemann T &amp; Flicek PR The Ensembl Regulatory Build. Genome. Biol 16, 56 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407537</ArticleId><ArticleId IdType="pubmed">25887522</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D et al. GWAS4D: multidimensional analysis of context-specific regulatory variant for human complex diseases and traits. Nucleic Acids Res 46, W114&#x2013;W120 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030885</ArticleId><ArticleId IdType="pubmed">29771388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature 518, 365&#x2013;369 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T &amp; Posthuma D MAGMA: Generalized Gene-Set Analysis of GWAS Data. PLoS Comput. Biol 11, 1&#x2013;19 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L alpha-Synuclein in Parkinson&#x2019;s disease. Cold Spring Harb. Perspect. Med 2, 1&#x2013;23 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281589</ArticleId><ArticleId IdType="pubmed">22355802</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A et al. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol 99, 296&#x2013;304 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10663973</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Pottier C, Nicolas G, Le Guennec K &amp; Rovelet-Lecrux A Alzheimer disease: modeling an A&#x3b2;-centered biological network. Mol. Psychiatry 7, 861&#x2013;871 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27021818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC &amp; Sheng M TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91, 328&#x2013;340 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche LG et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat. Genet 48, 134&#x2013;143 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4745342</ArticleId><ArticleId IdType="pubmed">26691988</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G &amp; Sisodia S Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med 2, a006270 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med 6, 243ra86 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Postina R et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest 113, 1456&#x2013;1464 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406531</ArticleId><ArticleId IdType="pubmed">15146243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinney A et al. Genetic variation at the CELF1 (CUGBP, elav-like family member 1 gene) locus is genome-wide associated with Alzheimer&#x2019;s disease and obesity. Am. J. Med. Genet. B 165B, 283&#x2013;293 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24788522</ArticleId></ArticleIdList></Reference><Reference><Citation>Speliotes EK et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet 42, 937&#x2013;948 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014648</ArticleId><ArticleId IdType="pubmed">20935630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurabayashi N, Nguyen MD &amp; Sanada K The G protein-coupled receptor GPRC5B contributes to neurogenesis in the developing mouse neocortex. Development 140, 4335&#x2013;4346 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24089469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cool BH et al. A flanking gene problem leads to the discovery of a Gprc5b splice variant predominantly expressed in C57BL/6J mouse brain and in maturing neurons. PLoS ONE 5, e10351 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859937</ArticleId><ArticleId IdType="pubmed">20436672</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y-J, Sano T, Nabetani T, Asano Y &amp; Hirabayashi Y GPRC5B activates obesity-associated inflammatory signaling in adipocytes. Sci. Signal 5, ra85&#x2013;ra85 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23169819</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat K et al. The 19S proteasome ATPase Sug1 plays a critical role in regulating MHC class II transcription. Mol. Immunol 45, 2214&#x2013;2224 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18215421</ArticleId></ArticleIdList></Reference><Reference><Citation>Inostroza-Nieves Y, Venkatraman P &amp; Zavala-Ruiz Z Role of Sug1, a 19S proteasome ATPase, in the transcription of MHC I and the atypical MHC II molecules, HLA-DM and HLA-DO. Immunol. Lett 147, 67&#x2013;74 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654650</ArticleId><ArticleId IdType="pubmed">22771340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Duramad O, Qin XF &amp; Su B MEKK3 is essential for lipopolysaccharide-induced interleukin-6 and granulocyte-macrophage colony-stimulating factor production in macrophages. Immunology 120, 242&#x2013;250 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265862</ArticleId><ArticleId IdType="pubmed">17116170</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki K et al. Two mechanistically and temporally distinct NF-&#x3ba;B activation pathways in IL-1 signaling. Sci. Signal 2, 1&#x2013;12 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19843958</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA et al. Association between angiotensin-converting enzyme and Alzheimer disease. New Engl. J. Med 57, 210&#x2013;214 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10681079</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners JS et al. Angiotensin-converting enzyme levels and activity in Alzheimer&#x2019;s disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am. J. Transl. Res 1, 163&#x2013;177 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776311</ArticleId><ArticleId IdType="pubmed">19956428</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochemsen HM et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer&#x2019;s disease. Alzheimers Res. Ther 6, 1&#x2013;10 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075229</ArticleId><ArticleId IdType="pubmed">24987467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JSK et al. Genome-wide association study of CSFl Levels of 59 Alzheimer&#x2019;s disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet 10, e1004758 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207667</ArticleId><ArticleId IdType="pubmed">25340798</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranello RJ et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer&#x2019;s disease. Curr. Alzheimers Res 12, 32&#x2013;46 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820400</ArticleId><ArticleId IdType="pubmed">25523424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe PG The coming of age of the angiotensin hypothesis in Alzheimer&#x2019;s disease: progress toward disease prevention and treatment? J. Alzheimers. Dis 62, 1443&#x2013;1466 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870007</ArticleId><ArticleId IdType="pubmed">29562545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe PG et al. The rationale and design of the reducing pathology in Alzheimer&#x2019;s disease through Angiotensin TaRgeting (RADAR) Trial. J. Alzheimers. Dis 61, 803&#x2013;814 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29226862</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel RF, Pollak A &amp; Lubec G Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer&#x2019;s and Pick&#x2019;s disease. Brain. Res. Mol. Brain. Res 133, 1&#x2013;5 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15661359</ArticleId></ArticleIdList></Reference><Reference><Citation>Suttkus A et al. Aggrecan, link protein and tenascin-R are essential components of the perineuronal net to protect neurons against iron-induced oxidative stress. Cell Death Dis 5, e1119 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973247</ArticleId><ArticleId IdType="pubmed">24625978</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;gh MJ et al. Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun 2, 76 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149201</ArticleId><ArticleId IdType="pubmed">24974208</ArticleId></ArticleIdList></Reference><Reference><Citation>Morawski M, Filippov M, Tzinia A, Tsilibary E &amp; Vargova L ECM in brain aging and dementia. Prog. Brain. Res 214, 207&#x2013;227 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25410360</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer&#x2019;s disease. Curr. Gerontol. Geriatr. Res 2012, 170276 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3290800</ArticleId><ArticleId IdType="pubmed">22454637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K et al. A genome-wide association study on obesity and obesity-related traits. PLoS ONE 6, 3&#x2013;8 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084240</ArticleId><ArticleId IdType="pubmed">21552555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang K et al. Interferon-&#x3b3; represses M2 gene expression in human macrophages by disassembling enhancers bound by the transcription factor MAF. Immunity 47, 235&#x2013;250.e4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568089</ArticleId><ArticleId IdType="pubmed">28813657</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Liu J, Song L &amp; Ma X The protooncogene c-Maf Is an essential transcription factor for IL-10 gene expression in macrophages. J. Immunol 174, 3484&#x2013;3492 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955976</ArticleId><ArticleId IdType="pubmed">15749884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC et al. WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am. J. Hum. Genet 83, 180&#x2013;192 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495060</ArticleId><ArticleId IdType="pubmed">18674750</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez ME et al. WWOX gene is associated with HDL cholesterol and triglyceride levels. BMC. Med. Genet 11, 148 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967537</ArticleId><ArticleId IdType="pubmed">20942981</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HT et al. WW domain-containing oxidoreductase in neuronal injury and neurological diseases. Oncotarget 5, 11792&#x2013;11799 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322972</ArticleId><ArticleId IdType="pubmed">25537520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH et al. Zfra restores memory deficits in Alzheimer&#x2019;s disease triple-transgenic mice by blocking aggregation of TRAPPC6A&#x394;, SH3GLB2, tau, and amyloid &#x3b2;, and inflammatory NF-&#x3ba;B activation. Alzheimers Dement. Transl. Res. Clin. Interv 3, 189&#x2013;204 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651433</ArticleId><ArticleId IdType="pubmed">29067327</ArticleId></ArticleIdList></Reference><Reference><Citation>Dourlen P et al. Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Mol. Psychiatry 22, 874&#x2013;883 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444024</ArticleId><ArticleId IdType="pubmed">27113998</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuis J et al. Genome-wide, high-content siRNA screening identifies the Alzheimer&#x2019;s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathol 133, 955&#x2013;966 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427165</ArticleId><ArticleId IdType="pubmed">27933404</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM et al. Functional screening in Drosophila identifies Alzheimer&#x2019;s disease susceptibility genes and implicates tau-mediated mechanisms. Hum. Mol. Genet 23, 870&#x2013;877 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900103</ArticleId><ArticleId IdType="pubmed">24067533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z et al. Central role for PICALM in amyloid-&#x3b2; blood-brain barrier transcytosis and clearance. Nat. Neurosci 18, 978&#x2013;987 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482781</ArticleId><ArticleId IdType="pubmed">26005850</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguet F et al. Genetic effects on gene expression across human tissues. Nature 550, 204&#x2013;213 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776756</ArticleId><ArticleId IdType="pubmed">29022597</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA et al. Transcriptional landscape of the prenatal human brain. Nature 508, 199&#x2013;206 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105188</ArticleId><ArticleId IdType="pubmed">24695229</ArticleId></ArticleIdList></Reference><Reference><Citation>Knickmeyer RC &amp; Ross ME Imaging and rare APOE alleles. Neurology 87, 558&#x2013;559 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27412139</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G et al. A common brain network links development, aging, and vulnerability to disease. Proc. Natl Acad. Sci. USA 111, 17648&#x2013;17653 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267352</ArticleId><ArticleId IdType="pubmed">25422429</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele NZ et al. Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: a case-control study. PLoS Med 14, 1&#x2013;25 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5369701</ArticleId><ArticleId IdType="pubmed">28350795</ArticleId></ArticleIdList></Reference><Reference><Citation>Fekih Mrissa N et al. Association of HLA-DR-DQ polymorphisms with diabetes in Tunisian patients. Transfus. Apher. Sci 49, 200&#x2013;204 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23402837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliese A et al. HLA-DRB1 15:01-DQA1 01:02-DQB1 06:02 haplotype protects autoantibody-positive relatives from type 1 diabetes throughout the stages of disease progression. Diabetes 65, 1109&#x2013;1119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806662</ArticleId><ArticleId IdType="pubmed">26822082</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsopoulos Na et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet 9, e1003926 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836799</ArticleId><ArticleId IdType="pubmed">24278027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, Williamson D &amp; Ashley-Koch A HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol 165, 1097&#x2013;1109 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17329717</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnes JH et al. Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci. Transl. Med 9, 1&#x2013;14 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563969</ArticleId><ArticleId IdType="pubmed">28490672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wissemann WT et al. Association of Parkinson disease with structural and regulatory variants in the HLA region. Am. J. Hum. Genet 93, 984&#x2013;993 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824116</ArticleId><ArticleId IdType="pubmed">24183452</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra MK, Damotte V &amp; Hollenbach JA The immunogenetics of neurological disease. Immunology 153, 399&#x2013;414 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5838423</ArticleId><ArticleId IdType="pubmed">29159928</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ZS Thyroid function and the risk of Alzheimer disease: the Framingham study. Arch. Intern. Med 168, 1514 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694610</ArticleId><ArticleId IdType="pubmed">18663163</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendrou CA, Petersen J, Rossjohn J &amp; Fugger L HLA variation and disease. Nat. Rev. Immunol 18, 325&#x2013;339 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29292391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet 47, 1236&#x2013;1241 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet. Neurol 11, 1006&#x2013;1012 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadar D et al. Individual and area-based socioeconomic factors associated with dementia incidence in England: evidencefrom a 12-year follow-up in the English longitudinal study of ageing. JAMA Psychiatry 75, 723&#x2013;732 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6145673</ArticleId><ArticleId IdType="pubmed">29799983</ArticleId></ArticleIdList></Reference><Reference><Citation>Marden JR, Tchetgen Tchetgen EJ, Kawachi I &amp; Glymour MM Contribution of socioeconomic status at 3 life-course periods to late-life memory function and decline: early and late predictors of dementia risk. Am. J. Epidemiol 186, 805&#x2013;814 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5859987</ArticleId><ArticleId IdType="pubmed">28541410</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard SDSD et al. Associations between potentially modifiable risk factors and Alzheimer disease: a Mendelian randomization study. PLoS Med 12, e1001841 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469461</ArticleId><ArticleId IdType="pubmed">26079503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat. Commun 9, 224 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5768719</ArticleId><ArticleId IdType="pubmed">29335400</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgart M et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 11, 1&#x2013;9 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26045020</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson SC, Traylor M, Burgess S &amp; Markus HS Genetically-predicted adult height and Alzheimer&#x2019;s disease. J. Alzheimers. Dis 60, 691&#x2013;698 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6037293</ArticleId><ArticleId IdType="pubmed">28869480</ArticleId></ArticleIdList></Reference><Reference><Citation>Helzner EP et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch. Neurol 66, 343&#x2013;348 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105324</ArticleId><ArticleId IdType="pubmed">19273753</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch. Neurol 67, 1491&#x2013;1497 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065942</ArticleId><ArticleId IdType="pubmed">21149810</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S et al. Genetically predicted body mass index and Alzheimer&#x2019;s disease-related phenotypes in three large samples: Mendelian randomization analyses. Alzheimers Dement 11, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676945</ArticleId><ArticleId IdType="pubmed">26079416</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z et al. Late-life blood pressure association with cerebrovascular and Alzheimer disease pathology. Neurology 91, e517&#x2013;e525 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105052</ArticleId><ArticleId IdType="pubmed">29997190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku&#x17a;ma E et al. Which risk factors causally influence dementia? A systematic review of mendelian randomization studies. J. Alzheimers. Dis 36, 215&#x2013;221 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004893</ArticleId><ArticleId IdType="pubmed">29865062</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer&#x2019;s disease spectrum. Brain 138, 1370&#x2013;1381 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MRMR et al. Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci. Transl. Med 8, 338ra66 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomes Project, C.. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56&#x2013;65 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie BN, Donnelly P &amp; Marchini J A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5, e1000529 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689936</ArticleId><ArticleId IdType="pubmed">19543373</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaneau O, Marchini J &amp; Zagury JF A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179&#x2013;181 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22138821</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Willer CJ, Ding J, Scheet P &amp; Abecasis GR MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes.. Genet. Epidemiol 34, 816&#x2013;834 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175618</ArticleId><ArticleId IdType="pubmed">21058334</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Fuchsberger C, Stephens M, Marchini J &amp; Abecasis GR Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet 44, 955&#x2013;959 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696580</ArticleId><ArticleId IdType="pubmed">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Marchini J &amp; Stephens M Genotype imputation with thousands of genomes. G3 1, 457&#x2013;470 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276165</ArticleId><ArticleId IdType="pubmed">22384356</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet 38, 904&#x2013;909 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C et al. Recommended joint and meta-analysis strategies for case-control association testing of single low-count variants. Genet. Epidemiol 37, 539&#x2013;550 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049324</ArticleId><ArticleId IdType="pubmed">23788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M-HH &amp; Yang Q GWAF: an R package for genome-wide association analyses with family data. Bioinformatics 26, 580&#x2013;581 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852219</ArticleId><ArticleId IdType="pubmed">20040588</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y &amp; Abecasis GR METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190&#x2013;2191 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulchenko YS, Ripke S, Isaacs A &amp; van Duijn CM GenABEL: an R library for genome-wide association analysis. Bioinformatics 23, 1294&#x2013;1296 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17384015</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C et al. UK Biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12, 1&#x2013;10 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry A et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol 186, 1026&#x2013;1034 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860371</ArticleId><ArticleId IdType="pubmed">28641372</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson N, Price AL &amp; Reich D Population structure and eigenanalysis. PLoS Genet 2, e190 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1713260</ArticleId><ArticleId IdType="pubmed">17194218</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiela MJ &amp; Chanock SJ LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555&#x2013;3557 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626747</ArticleId><ArticleId IdType="pubmed">26139635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X et al. Synthesis of 53 tissue and cell line expression QTL datasets reveals master eQTLs. BMC Genomics 15, 532 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102726</ArticleId><ArticleId IdType="pubmed">24973796</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruitt KD, Tatusova T, Brown GR &amp; Maglott DR NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res 40, D130&#x2013;D135 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245008</ArticleId><ArticleId IdType="pubmed">22121212</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrow J et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 22, 1760&#x2013;1774 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431492</ArticleId><ArticleId IdType="pubmed">22955987</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold M, Raffler J, Pfeufer a, Suhre K &amp; Kastenmuller G. SNiPA: an interactive, genetic variant-centered annotation browser. Bioinformatics 31, 1334&#x2013;1336 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393511</ArticleId><ArticleId IdType="pubmed">25431330</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W et al. The Ensembl variant effect predictor. Genome Biol 17, 122 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Cargill M et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet 22, 231&#x2013;238 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10391209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng PC &amp; Henikoff S SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31, 3812&#x2013;3814 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC168916</ArticleId><ArticleId IdType="pubmed">12824425</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei IA et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248&#x2013;249 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet 46, 310&#x2013;315 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Perez A &amp; Lopez-Bigas N Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am. J. Hum. Genet 88, 440&#x2013;449 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071923</ArticleId><ArticleId IdType="pubmed">21457909</ArticleId></ArticleIdList></Reference><Reference><Citation>Samocha KE et al. Regional missense constraint improves variant deleteriousness prediction Preprint at 10.1101/148353 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/148353</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionita-Laza I, McCallum K, Xu B &amp; Buxbaum JD A spectral approach integrating functional genomic annotations for coding and noncoding variants. Nat. Genet 48, 214&#x2013;220 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731313</ArticleId><ArticleId IdType="pubmed">26727659</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo G &amp; Burge CB Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol 11, 377&#x2013;394 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15285897</ArticleId></ArticleIdList></Reference><Reference><Citation>Amlie-Wolf A et al. INFERNO&#x2014;INFERring the molecular mechanisms of NOncoding genetic variants. Nucleic Acids Res 46, 8740&#x2013;8753 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158604</ArticleId><ArticleId IdType="pubmed">30113658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD &amp; Kellis M HaploRegv4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res 44, D877&#x2013;D881 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702929</ArticleId><ArticleId IdType="pubmed">26657631</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;riault P, ElAli A &amp; Rivest S The dynamics of monocytes and microglia in Alzheimer&#x2019;s disease. Alzheimers Res. Ther 7, 41 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397873</ArticleId><ArticleId IdType="pubmed">25878730</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344, 519&#x2013;523 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi T et al. Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. Nat. Commun 9, 2282 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5995828</ArticleId><ArticleId IdType="pubmed">29891976</ArticleId></ArticleIdList></Reference><Reference><Citation>Schramm K et al. Mapping the genetic architecture of gene regulation in whole blood. PLoS ONE 9, e93844 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989189</ArticleId><ArticleId IdType="pubmed">24740359</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet 48, 481&#x2013;489 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra H-J et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet 45, 1238&#x2013;1243 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991562</ArticleId><ArticleId IdType="pubmed">24013639</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet 25, 25&#x2013;29 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake JA et al. Gene ontology consortium: going forward. Nucleic Acids Res 43, D1049&#x2013;D1056 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383973</ArticleId><ArticleId IdType="pubmed">25428369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Sato Y, Kawashima M, Furumichi M &amp; Tanabe M KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res 44, D457&#x2013;D462 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702792</ArticleId><ArticleId IdType="pubmed">26476454</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata H et al. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 27, 29&#x2013;34 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC148090</ArticleId><ArticleId IdType="pubmed">9847135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabregat A et al. The reactome pathway knowledgebase. Nucleic Acids Res 44, D481&#x2013;D487 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702931</ArticleId><ArticleId IdType="pubmed">26656494</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft D et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 39, D691&#x2013;D697 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013646</ArticleId><ArticleId IdType="pubmed">21067998</ArticleId></ArticleIdList></Reference><Reference><Citation>Eppig JT, Blake Ja, Bult CJ, Kadin Ja &amp; Richardson JE. The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res 43, D726&#x2013;D736 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384027</ArticleId><ArticleId IdType="pubmed">25348401</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Dushlaine C et al. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci 18, 199&#x2013;209 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4378867</ArticleId><ArticleId IdType="pubmed">25599223</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D et al. STRINGv10: protein&#x2013;protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, D447&#x2013;D452 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383874</ArticleId><ArticleId IdType="pubmed">25352553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletscher-Frankild S, Pallej&#xe0; A, Tsafou K, Binder JX &amp; Jensen LJ DISEASES: text mining and data integration of disease-gene associations. Methods 74, 83&#x2013;89 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25484339</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos A et al. Comprehensive comparison of large-scale tissue expression datasets. PeerJ 3, e1054 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493645</ArticleId><ArticleId IdType="pubmed">26157623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann A et al. Massive mining of publicly available RNA-seq data from human and mouse. Nat. Commun 9, 1366 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893633</ArticleId><ArticleId IdType="pubmed">29636450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90&#x2013;W97 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Taskesen E, Van Bochoven A &amp; Posthuma D Functional mapping and annotation of genetic associations with FUMA. Nat. Commun 8, 1826 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705698</ArticleId><ArticleId IdType="pubmed">29184056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X et al. HIBAG&#x2014;HLA genotype imputation with attribute bagging. Pharmacogenomics. J 14, 192&#x2013;200 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772955</ArticleId><ArticleId IdType="pubmed">23712092</ArticleId></ArticleIdList></Reference><Reference><Citation>R v.3.4.3 (R Development Core Team, 2017). 185.</Citation></Reference><Reference><Citation>haplo.stats v.1.7.9 (2018).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30830941</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study.</ArticleTitle><Pagination><StartPage>e0213321</StartPage><MedlinePgn>e0213321</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0213321</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0213321</ELocationID><Abstract><AbstractText Label="BACKGROUND">Fibroblast growth factor 23 is an emerging vascular biomarker, recently associated with cerebral small vessel disease and poor cognition in patients on dialysis. It also interacts with klotho, an anti-aging and cognition enhancing protein.</AbstractText><AbstractText Label="OBJECTIVE">To determine if circulating Fibroblast growth factor 23 (FGF23) is associated with new-onset cognitive outcomes in a community-based cohort of cognitively healthy adults with long-term follow-up.</AbstractText><AbstractText Label="METHODS">We measured serum FGF23 levels in 1537 [53% women, mean age 68.7 (SD 5.7)] dementia-free Framingham Offspring participants at their 7th quadrennial examination (1998-2001), and followed these participants for the development of clinical all-cause dementia and Alzheimer's disease (AD). Secondary outcomes included MRI-based structural brain measures, and neurocognitive test performance at exam 7.</AbstractText><AbstractText Label="RESULTS">During a median (Q1, Q3) 12-year (7.0, 13.3) follow up, 122 (7.9%) participants developed dementia, of whom 91 (5.9%) had AD. Proportional-hazards regression analysis, adjusted for age, sex, education, systolic blood pressure, antihypertensive medication, prevalent cardiovascular disease, diabetes mellitus, smoking status and apoE &#x3b5;4 carrier status, revealed that higher serum FGF23 levels were associated with an increased risk of incident dementia and AD (Hazard ratio [HR] per 1 standard deviation increment in inverse transformed FGF23 level 1.25, 95% CI 1.02-1.53, and 1.32, 95% CI 1.04-1.69, respectively). There was no significant interaction according to presence/absence of significant renal impairment (eGFR &lt;30 versus &#x2265;30ml/min) and risk of dementia (based on 1537; p = 0.97).</AbstractText><AbstractText Label="CONCLUSIONS">Higher circulating FGF23 is associated with an increased risk of dementia, suggesting that FGF23-related biological pathways may play a role in the development of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Emer R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-3589-2964</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Brigham &amp; Women's Hospital, Boston, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Himali</LastName><ForeName>Jayandra J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University School of Public Health, Boston, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Sciences Branch, National Heart, Lung and Blood Institutes of Health, Bethesda, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conner</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University School of Public Health, Boston, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pase</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Carmela R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courchesne</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satizabal</LastName><ForeName>Claudia L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-1115-4430</Identifier><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasan</LastName><ForeName>Ramachandran S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University School of Public Health, Boston, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UH3 NS100605</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201500001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH2 NS100605</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL070100</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL060040</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC025195</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717427">FGF23 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>62031-54-3</RegistryNumber><NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>7Q7P4S7RRE</RegistryNumber><NameOfSubstance UI="D000089703">Fibroblast Growth Factor-23</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089703" MajorTopicYN="N">Fibroblast Growth Factor-23</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30830941</ArticleId><ArticleId IdType="pmc">PMC6398923</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0213321</ArticleId><ArticleId IdType="pii">PONE-D-18-35509</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's &amp; dementia: the journal of the Alzheimer's Association. 2013;9(1):63&#x2013;75 e2. Epub 2013/01/12. 10.1016/j.jalz.2012.11.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.007</ArticleId><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochemical and biophysical research communications. 2004;314(2):409&#x2013;14. Epub 2004/01/22. .</Citation><ArticleIdList><ArticleId IdType="pubmed">14733920</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, et al. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology. 2014;82(19):1700&#x2013;6. Epub 2014/04/08. 10.1212/WNL.0000000000000410</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000410</ArticleId><ArticleId IdType="pmc">PMC4032206</ArticleId><ArticleId IdType="pubmed">24706015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CB, Shah NH, Mendez AJ, DeRosa JT, Yoshita M, Elkind MS, et al. Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. Stroke. 2016;47(4):923&#x2013;8. Epub 2016/03/10. 10.1161/STROKEAHA.115.012379</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.115.012379</ArticleId><ArticleId IdType="pmc">PMC4811730</ArticleId><ArticleId IdType="pubmed">26956260</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew DA, Tighiouart H, Scott TM, Lou KV, Fan L, Shaffi K, et al. FGF-23 and cognitive performance in hemodialysis patients. Hemodialysis international International Symposium on Home Hemodialysis. 2014;18(1):78&#x2013;86. Epub 2013/10/30. 10.1111/hdi.12100</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hdi.12100</ArticleId><ArticleId IdType="pmc">PMC4443906</ArticleId><ArticleId IdType="pubmed">24164913</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The framingham offspring study. Design and preliminary data. Preventive Medicine. 1975;4(4):518&#x2013;25. 10.1016/0091-7435(75)90037-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0091-7435(75)90037-7</ArticleId><ArticleId IdType="pubmed">1208363</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf P, Beiser A, Au R, McNulty K, White R, et al. Lifetime risk of dementia and Alzheimer's disease The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49(6):1498&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">9409336</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;44. Epub 1984/07/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath ER, Beiser AS, DeCarli C, Plourde KL, Vasan RS, Greenberg SM, et al. Blood pressure from mid- to late life and risk of incident dementia. Neurology. 2017;89(24):2447&#x2013;54. Epub 2017/11/10. 10.1212/WNL.0000000000004741</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004741</ArticleId><ArticleId IdType="pmc">PMC5729797</ArticleId><ArticleId IdType="pubmed">29117954</ArticleId></ArticleIdList></Reference><Reference><Citation>Au R, Seshadri S, Wolf PA, Elias M, Elias P, Sullivan L, et al. New norms for a new generation: cognitive performance in the framingham offspring cohort. Experimental aging research. 2004;30(4):333&#x2013;58. Epub 2004/09/17. 10.1080/03610730490484380 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610730490484380</ArticleId><ArticleId IdType="pubmed">15371099</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Miller B, Swan G, Reed T, Wolf P, Garner J, et al. Predictors of brain morphology for the men of the NHLBI twin study. Stroke. 1999;30(3):529&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">10066847</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf P, Beiser A, Elias M, Au R, Kase C, et al. Stroke risk profile, brain volume, and cognitive function The Framingham Offspring Study. Neurology. 2004;63(9):1591&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534241</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Maisog J, Murphy DG, Teichberg D, Rapoport SI, Horwitz B. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. Journal of computer assisted tomography. 1992;16(2):274&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">1545026</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiology of Aging. 2005;26(4):491&#x2013;510. 10.1016/j.neurobiolaging.2004.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.05.004</ArticleId><ArticleId IdType="pubmed">15653178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29&#x2013;36. Epub 1982/04/01. 10.1148/radiology.143.1.7063747 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.143.1.7063747</ArticleId><ArticleId IdType="pubmed">7063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157&#x2013;72; discussion 207&#x2013;12. Epub 2007/06/15. 10.1002/sim.2929 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2929</ArticleId><ArticleId IdType="pubmed">17569110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr KF, McClelland RL, Brown ER, Lumley T. Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol. 2011;174(3):364&#x2013;74. Epub 2011/06/16. 10.1093/aje/kwr086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwr086</ArticleId><ArticleId IdType="pmc">PMC3202159</ArticleId><ArticleId IdType="pubmed">21673124</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D'Agostino RB Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11&#x2013;21. Epub 2011/01/05. 10.1002/sim.4085</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4085</ArticleId><ArticleId IdType="pmc">PMC3341973</ArticleId><ArticleId IdType="pubmed">21204120</ArticleId></ArticleIdList></Reference><Reference><Citation>Haring R, Enserro D, Xanthakis V, Mitchell GF, Benjamin EJ, Hamburg NM, et al. Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study. Journal of the American Heart Association. 2016;5(7). Epub 2016/07/08. 10.1161/jaha.116.003486</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/jaha.116.003486</ArticleId><ArticleId IdType="pmc">PMC5015386</ArticleId><ArticleId IdType="pubmed">27385427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207(2):546&#x2013;51. Epub 2009/06/16. 10.1016/j.atherosclerosis.2009.05.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2009.05.013</ArticleId><ArticleId IdType="pubmed">19524924</ArticleId></ArticleIdList></Reference><Reference><Citation>Toffanello ED, Coin A, Perissinotto E, Zambon S, Sarti S, Veronese N, et al. Vitamin D deficiency predicts cognitive decline in older men and women: The Pro.V.A. Study. Neurology. 2014;83(24):2292&#x2013;8. Epub 2014/11/08. 10.1212/WNL.0000000000001080 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001080</ArticleId><ArticleId IdType="pubmed">25378671</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Quarles LD. How fibroblast growth factor 23 works. Journal of the American Society of Nephrology: JASN. 2007;18(6):1637&#x2013;47. Epub 2007/05/15. 10.1681/ASN.2007010068 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2007010068</ArticleId><ArticleId IdType="pubmed">17494882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensel N, Schon A, Konen T, Lubben V, Forthmann B, Baron O, et al. Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density. Journal of neurochemistry. 2016;137(5):756&#x2013;69. Epub 2016/02/21. 10.1111/jnc.13585 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13585</ArticleId><ArticleId IdType="pubmed">26896818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. The Journal of biological chemistry. 2006;281(10):6120&#x2013;3. Epub 2006/01/27. 10.1074/jbc.C500457200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C500457200</ArticleId><ArticleId IdType="pmc">PMC2637204</ArticleId><ArticleId IdType="pubmed">16436388</ArticleId></ArticleIdList></Reference><Reference><Citation>Cararo-Lopes MM, Mazucanti CHY, Scavone C, Kawamoto EM, Berwick DC. The relevance of alpha-KLOTHO to the central nervous system: Some key questions. Ageing Res Rev. 2017;36:137&#x2013;48. Epub 2017/03/23. 10.1016/j.arr.2017.03.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2017.03.003</ArticleId><ArticleId IdType="pubmed">28323064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeldich E, Chen CD, Colvin TA, Bove-Fenderson EA, Liang J, Tucker Zhou TB, et al. The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. The Journal of biological chemistry. 2014;289(35):24700&#x2013;15. Epub 2014/07/20. 10.1074/jbc.M114.567321</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.567321</ArticleId><ArticleId IdType="pmc">PMC4148892</ArticleId><ArticleId IdType="pubmed">25037225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, et al. Life extension factor klotho enhances cognition. Cell reports. 2014;7(4):1065&#x2013;76. Epub 2014/05/13. 10.1016/j.celrep.2014.03.076</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.076</ArticleId><ArticleId IdType="pmc">PMC4176932</ArticleId><ArticleId IdType="pubmed">24813892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the hormone Klotho. Science (New York, NY). 2005;309(5742):1829&#x2013;33. Epub 2005/08/27. 10.1126/science.1112766</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1112766</ArticleId><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Shardell M, Semba RD, Rosano C, Kalyani RR, Bandinelli S, Chia CW, et al. Plasma Klotho and Cognitive Decline in Older Adults: Findings From the InCHIANTI Study. The journals of gerontology Series A, Biological sciences and medical sciences. 2016;71(5):677&#x2013;82. Epub 2015/08/25. 10.1093/gerona/glv140</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glv140</ArticleId><ArticleId IdType="pmc">PMC5007737</ArticleId><ArticleId IdType="pubmed">26297657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45&#x2013;51. Epub 1997/11/18. 10.1038/36285 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/36285</ArticleId><ArticleId IdType="pubmed">9363890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annual review of physiology. 2013;75:503&#x2013;33. Epub 2013/02/13. 10.1146/annurev-physiol-030212-183727</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-030212-183727</ArticleId><ArticleId IdType="pmc">PMC3770142</ArticleId><ArticleId IdType="pubmed">23398153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30814321</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>13</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>26</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.</ArticleTitle><Pagination><StartPage>e1435</StartPage><EndPage>e1446</EndPage><MedlinePgn>e1435-e1446</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000007174</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk.</AbstractText><AbstractText Label="METHODS">The Heart Outcomes Prevention Evaluation-3 (HOPE-3) study was a double-blind, randomized, placebo-controlled clinical trial using a 2 &#xd7; 2 factorial design. Participants without known cardiovascular disease or need for treatment were randomized to candesartan (16 mg) plus hydrochlorothiazide (12.5 mg) or placebo and to rosuvastatin (10 mg) or placebo. Participants who were &#x2265;70 years of age completed the Digit Symbol Substitution Test (DSST), the modified Montreal Cognitive Assessment, and the Trail Making Test Part B at baseline and study end.</AbstractText><AbstractText Label="RESULTS">Cognitive assessments were completed by 2,361 participants from 228 centers in 21 countries. Compared with placebo, candesartan/hydrochlorothiazide reduced systolic blood pressure by 6.0 mm Hg, and rosuvastatin reduced low-density lipoprotein cholesterol by 24.8 mg/dL. Participants were followed up for 5.7 years (median), and 1,626 completed both baseline and study-end assessments. Mean participant age was 74 years (SD &#xb1;3.5 years); 59% were women; 45% had hypertension; and 24% had &#x2265;12 years of education. The mean difference in change in DSST scores was -0.91 (95% confidence interval [CI] -2.25 to 0.42) for candesartan/hydrochlorothiazide compared with placebo, -0.54 (95% CI -1.88 to 0.80) for rosuvastatin compared with placebo, and -1.43 (95% CI -3.37 to 0.50) for combination therapy vs double placebo. No significant differences were found for other measures.</AbstractText><AbstractText Label="CONCLUSIONS">Long-term blood pressure lowering with candesartan plus hydrochlorothiazide, rosuvastatin, or their combination did not significantly affect cognitive decline in older people.</AbstractText><AbstractText Label="CLINICALTRIALSGOV IDENTIFIER">NCT00468923.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class II evidence that for older people, candesartan plus hydrochlorothiazide, rosuvastatin, or their combination does not significantly affect cognitive decline.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Jackie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6292-4207</Identifier><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa. boschj@mcmaster.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Balakumar</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonn</LastName><ForeName>Eva Marie</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Mikul</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagenais</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Basil S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avezum</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Claes</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keltai</LastName><ForeName>Matyas</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toff</LastName><ForeName>William D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dans</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leiter</LastName><ForeName>Lawrence A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sliwa</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shun Fu</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pogue</LastName><ForeName>Janice M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Salim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Qu&#xe9;bec (G.D.), Universit&#xe9; Laval, Qu&#xe9;bec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), S&#xe3;o Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HOPE-3 Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00468923</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0J48LPH2TH</RegistryNumber><NameOfSubstance UI="D006852">Hydrochlorothiazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>83MVU38M7Q</RegistryNumber><NameOfSubstance UI="D000068718">Rosuvastatin Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>S8Q36MD2XX</RegistryNumber><NameOfSubstance UI="C081643">candesartan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2019 Mar 26;92(13):593-594. doi: 10.1212/WNL.0000000000007175.</RefSource><PMID Version="1">30814323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006852" MajorTopicYN="N">Hydrochlorothiazide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000960" MajorTopicYN="N">Hypolipidemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068718" MajorTopicYN="N">Rosuvastatin Calcium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Alzogaray</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aparici</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bevacqua</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labarta</LastName><ForeName>M Bustamante</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustos</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caccavo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Candiello</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carignano</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carro</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cartasegna</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casali</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassettari</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Centeno</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuello</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuneo</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cusimano</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damonte</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Landaluc</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Martino</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forti</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galello</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duran</LastName><ForeName>R Garcia</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrido</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giachello</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilamajo</LastName><ForeName>O Gomez</ForeName><Initials>OG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerlloy</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerrero</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hominal</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hrabar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imposti</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanchiotti</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laugle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liniado</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litvak</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longhi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luciardi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackinnon</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manzano</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marino</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merlo</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milesi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulazzi</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nemi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orio</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelagagge</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raimondi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodino</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sago</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sala</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schygiel</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sernia</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sokn</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soso</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trivi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vico</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villamil</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogel</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaidman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abhayaratna</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canalese</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krum</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brasil</LastName><ForeName>C K O L</ForeName><Initials>CKOL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>C B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>A R</ForeName><Initials>AR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Ayoub</LastName><ForeName>J C A</ForeName><Initials>JCA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergoli</LastName><ForeName>L C C</ForeName><Initials>LCC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacher</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodanese</LastName><ForeName>L C</ForeName><Initials>LC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Braga</LastName><ForeName>J C F</ForeName><Initials>JCF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costa</LastName><ForeName>O M C</ForeName><Initials>OMC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costa</LastName><ForeName>M K M</ForeName><Initials>MKM</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Faria</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Monaco</LastName><ForeName>M I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Restelatto</LastName><ForeName>L Fabian</ForeName><Initials>LF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filho</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franco</LastName><ForeName>R J S</ForeName><Initials>RJS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furtado</LastName><ForeName>M V</ForeName><Initials>MV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leaes</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leaes</LastName><ForeName>Paulo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maia</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Investigator><Investigator ValidYN="Y"><LastName>MarinNeto</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattar</LastName><ForeName>E T B</ForeName><Initials>ETB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melo</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mothe</LastName><ForeName>F S</ForeName><Initials>FS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliveira</LastName><ForeName>G B F</ForeName><Initials>GBF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelloso</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polanczyk</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosa</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sales</LastName><ForeName>S O C</ForeName><Initials>SOC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraiva</LastName><ForeName>J F K</ForeName><Initials>JFK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silva</LastName><ForeName>V S</ForeName><Initials>VS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sousa</LastName><ForeName>A C S</ForeName><Initials>ACS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valle</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiehe</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abramson</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anand</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aw</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baxter</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berlingieri</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cha</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaulk</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chetty</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dagenais</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dattani</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delage</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dion</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dominguez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glendinning</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gosselin</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenspoon</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ly</LastName><ForeName>Q Hung</ForeName><Initials>QH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juneau</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keegan</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelly</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kilby</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavoi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leiter</LastName><ForeName>L A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lonn</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magloire</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mercante</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miscescu</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moran</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nawaz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nigam</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pang</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papp</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poirier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabasa-Lhoret</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizvi</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saulnier</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohal</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tobe</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walsh</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weeks</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yellin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zuliani</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bai</LastName><ForeName>X J</ForeName><Initials>XJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dong</LastName><ForeName>L G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duan</LastName><ForeName>Y W</ForeName><Initials>YW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feng</LastName><ForeName>J Z</ForeName><Initials>JZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fu</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gao</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gao</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ge</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ge</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hua</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>X L</ForeName><Initials>XL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>X L</ForeName><Initials>XL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Z D</ForeName><Initials>ZD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Y J</ForeName><Initials>YJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>F Y</ForeName><Initials>FY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>L H</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>F H</ForeName><Initials>FH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lv</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ma</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ma</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Man</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tan</LastName><ForeName>Hui Qiong</ForeName><Initials>HQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shi</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sun</LastName><ForeName>X D</ForeName><Initials>XD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>S Y</ForeName><Initials>SY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Y Q</ForeName><Initials>YQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wei</LastName><ForeName>Y J</ForeName><Initials>YJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>X C</ForeName><Initials>XC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>L T</ForeName><Initials>LT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>H Y</ForeName><Initials>HY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Accini</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arcos</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aroca</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casanova</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celemin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coronel</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotes</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cure</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diego-Olite</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escobar</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueredo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grisales</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molina de Salazar</LastName><ForeName>D I</ForeName><Initials>DI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castellanos</LastName><ForeName>B Nino</ForeName><Initials>BN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Posada</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quintero</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiros</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sotomayor</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suarez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urina</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adamkova</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cifkova</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferkl</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galovcova</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jozifova</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linhart</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linhart</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moravcikova</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nussbaumerova</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plachy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosolova</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seifert</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soucek</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte Vera</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espinel</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez-Jaramillo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDermont</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Penaherrera</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plascencia</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pow-Chon-Long</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tettamanti</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bajnok</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baranyi</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartfai</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bod</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodis</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Czuriga</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huber</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mezosi</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poor</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Somos</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarjanyi</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tatrai</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomcsanyi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vertes</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zsary</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>D K</ForeName><Initials>DK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>K G</ForeName><Initials>KG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aman</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayyar</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balaji</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bantwal</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bosco</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chidambaram</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dabra</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniel</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deshpande</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devendra</LastName><ForeName>H R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghoshroy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gnanasekaran</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutti</LastName><ForeName>M Z</ForeName><Initials>MZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joshi</LastName><ForeName>G S</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joshi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalantri</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapoor</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khedar</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manjunath</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohan</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murthy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nambiar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narendra</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>S K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qureshi</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajasekaran</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rangadham</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ranka</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sathyanarayan</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selvam</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sethuraman</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shunmugvavelu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidhu</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srinivas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srinivas</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srinivasulu</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Umarani</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varghese</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varma</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yelvatkar</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biton</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldhaber</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ivri</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shapiro</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shveydel</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shveydel</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsalihin</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinker</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yosefy</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choe</LastName><ForeName>K H</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kil Kim</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ambigga</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aris</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghapar</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krishnan</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahadasa</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maizatullifah</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazapuspavina</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohd Shah</LastName><ForeName>A Shah</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yusoff</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonarius</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Jong</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeRuiter</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVos</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dirkse</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drenth</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferguson</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jansen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mevissen</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rol</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schilder</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spelt</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>VanLeeuwen</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abola</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Co</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loyola</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mercado</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morales</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padua</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palileo</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patanao</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogelio</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roxas</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sulit</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang-Manga</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tumanan-Mendoza</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boytsov</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chukaeva</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karpov</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kisliak</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kobalava</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ledyacva</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopatin</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nedogoda</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solovieva</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsoma</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyurina</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hranai</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badat</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sliwa</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerntholtz</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Khalili</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlberg</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dotevall</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nilsson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olsson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosengren</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soderberg</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Artomov</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babanina</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bagriy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danyliuk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doretska</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorovska</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dovgan</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dzyak</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glushko</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorbas</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ilashchuk</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karapetyan</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karavanska</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khimion</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khorsun</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kononenko</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuryata</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kvasha</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazareva</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loktyev</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lysenko</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miroshnchenko</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyschenko</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parkhomenko</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petryk</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pivovarova</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rakytskay</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sapozhnychenko</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smymova</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soya</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tashchuk</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turubarova-Leunova</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasilyeva</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velichko</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yagensky</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>ZhurbaK Khunti</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loke</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toff</LastName><ForeName>W D</ForeName><Initials>WD</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30814321</ArticleId><ArticleId IdType="pmc">PMC6453765</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007174</ArticleId><ArticleId IdType="pii">WNL.0000000000007174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO Fact Sheet on Dementia. Geneva: World Health Organization; 2016.</Citation></Reference><Reference><Citation>World Health Organization. Dementia Cases Set to Triple by 2050 but Still Largely Ignored.Geneva: World Health Organization; 2016.</Citation></Reference><Reference><Citation>Lee Y JHK, Lee KJ, Han G, Kim JL. Association of cognitive status with functional limitation and disability in older adults. Aging Clin Exp Res 2005;17:20&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15847118</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuck AE, Walthert JM, Nikolaus T, B&#xfc;la CJ, Hohmann C, Beck JC. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Social Sci Med 1999;48:445&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, et al. . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672&#x2013;2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouch L, Cestac P, Hanon O, et al. . Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs 2015;29:113&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">25700645</ArticleId></ArticleIdList></Reference><Reference><Citation>Langa KM, Larson EB, Crimmins EM, et al. . A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med 2016:E1&#x2013;E8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5195883</ArticleId><ArticleId IdType="pubmed">27893041</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology 2003;61:1667&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pubmed">14694027</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 2003;60:223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">12580707</ArticleId></ArticleIdList></Reference><Reference><Citation>Gifford KA, Badaracco M, Liu D, et al. . Blood pressure and cognition among older adults: a meta-analysis. Arch Clin Neuropsychol 2013;28:649&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807830</ArticleId><ArticleId IdType="pubmed">23838685</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Albert M, et al. . Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurol 2014;71:1218&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226067</ArticleId><ArticleId IdType="pubmed">25090106</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014;12:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3998050</ArticleId><ArticleId IdType="pubmed">24655568</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Expands Advice on Statin Risk. 2015. Available at: fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm. Accessed September 19, 2016.</Citation></Reference><Reference><Citation>Ott BR, Daiello LA, Dahabreh IJ, et al. . Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 2015;30:348&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351273</ArticleId><ArticleId IdType="pubmed">25575908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Krishnamoorthy P, Ranjan P, et al. . Statins and cognitive function: an updated review. Curr Cardiol Rep 2015;17:4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25618304</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier JM, Massicotte A. Statins and their effect on cognition: let's clear up the confusion. Can Pharm J (Ott) 2015;148:150&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4483758</ArticleId><ArticleId IdType="pubmed">26150888</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins R, Reith C, Emberson J, et al. . Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016:1&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27616593</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Bosch J, Dagenais G, et al. . Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pubmed">27040132</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf S, Lonn E, Pais P, et al. . Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pubmed">27039945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonn EM, Bosch J, Lopez-Jaramillo P, et al. . Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2009&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">27041480</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Langa KM. The rising tide of dementia worldwide. Lancet 2008;372:430&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667232</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AB, Glynn NW, Taylor CA, et al. . Health and function of participants in the Long Life Family Study: a comparison with other cohorts. Aging 2011;3:63&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047140</ArticleId><ArticleId IdType="pubmed">21258136</ArticleId></ArticleIdList></Reference><Reference><Citation>Cukierman-Yaffe T, Bosch J, Diaz R, et al. . Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol 2014;7:562&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">24898834</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Miller ME, Williamson JD, et al. . Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011;10:969&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3333485</ArticleId><ArticleId IdType="pubmed">21958949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale Revised Manual. New York: Psychological Corp; 1981.</Citation></Reference><Reference><Citation>Brumback T, Cao D, King A. Effects of alcohol on psychomotor performance and perceived impairment in heavy binge social drinkers. Drug Alcohol Depend 2007;91:10&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764986</ArticleId><ArticleId IdType="pubmed">17560739</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, Amieva H, Dartigues J-F, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol 2007;165:344&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2244646</ArticleId><ArticleId IdType="pubmed">17105962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski V, Iadecola C, Petersen RC, et al. . National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220&#x2013;2241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917086</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan R. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271&#x2013;276.</Citation></Reference><Reference><Citation>Ashendorf L, Jefferson AL, O'Connor MK, Chaisson C, Green RC, Stern RA. Trail making test errors in normal aging, mild cognitive impairment, and dementia. Arch Clin Neuropsychol 2008;23:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693196</ArticleId><ArticleId IdType="pubmed">18178372</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol Group's International Task Force on Self-Reported Health. Measuring Self-Reported Population Health: An International Perspective Based on EQ-5D. 2004. Available at: https://euroqol.org/wp-content/uploads/2016/10/Measuring_Self-Reported_Population_Health_-_An_International_Perspective_based_on_EQ-5D.pdf. Accessed February 16, 2019.</Citation></Reference><Reference><Citation>Graham JW. Missing data analysis: making it work in the real world. Annu Rev Psychol 2009;60:549&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">18652544</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Weuve J, Sharrett AR, Blacker D, Gottesman RF. Statins, cognition, and dementia-systematic review and methodological commentary. Nat Rev Neurol 2015;11:220&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4458855</ArticleId><ArticleId IdType="pubmed">25799928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kherada N, Heimowitz T, Rosendorff C. Antihypertensive therapies and cognitive function: a review. Curr Hypertens Rep 2015;17:79.</Citation><ArticleIdList><ArticleId IdType="pubmed">26298567</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009:CD004034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163274</ArticleId><ArticleId IdType="pubmed">19821318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M, Iwanami J, Horiuchi M. Roles of brain angiotensin II in cognitive function and dementia. Int J Hypertens 2012;2012:169649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529904</ArticleId><ArticleId IdType="pubmed">23304450</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013;31:1073&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">23552124</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio C, Anderson C, Chapman N, et al. . Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742805</ArticleId></ArticleIdList></Reference><Reference><Citation>Forette F, Seux ML, Staessen JA, et al. . The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046&#x2013;2052.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374512</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce LA, McClure LA, Anderson DC, et al. . Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol 2014;13:1177&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284947</ArticleId><ArticleId IdType="pubmed">25453457</ArticleId></ArticleIdList></Reference><Reference><Citation>Diener HC, Sacco RL, Yusuf S, et al. . Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772657</ArticleId><ArticleId IdType="pubmed">18757238</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Supiano MA, Applegate WB, et al. . Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged &gt;/=75 years: a randomized clinical trial. JAMA 2016;315:2673&#x2013;2682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4988796</ArticleId><ArticleId IdType="pubmed">27195814</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner DE, Gaussoin SA, Nord J, et al. . Cognitive function and kidney disease: baseline data from the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis 2017;70:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5572661</ArticleId><ArticleId IdType="pubmed">28606731</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30858603</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>524</StartPage><EndPage>528</EndPage><MedlinePgn>524-528</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0352-0</ELocationID><Abstract><AbstractText>In vivo gene editing in post-mitotic neurons of the adult brain may be a useful strategy for treating neurological diseases. Here, we develop CRISPR-Cas9 nanocomplexes and show they were effective in the adult mouse brain, with minimal off-target effects. Using this system to target Bace1 suppressed amyloid beta (A&#x3b2;)-associated pathologies and cognitive deficits in two mouse models of Alzheimer's disease. These results broaden the potential application of CRISPR-Cas9 systems to neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hanseul</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Jungju</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shim</LastName><ForeName>Gayong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Byounggook</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yujung</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Siyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Soonbong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hongwon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Jeain</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hwan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Junsang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Junyeop</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Won</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Nanobiomedical Science, Dankook University, Cheonan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Minhyung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lengner</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, School of Veterinary Medicine and Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Yu-Kyoung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jongpil</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3876-6020</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering (BK21 plus), Dongguk University, Seoul, Republic of Korea. jpkim153@dongguk.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Stem Cells &amp; Cell Reprogramming, Department of Chemistry, Dongguk University, Seoul, Republic of Korea. jpkim153@dongguk.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 May;15(5):247. doi: 10.1038/s41582-019-0172-6.</RefSource><PMID Version="1">30894699</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="Y">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30858603</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0352-0</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0352-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe, D. J. Science 298, 789&#x2013;791 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1074069</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies, W. H. Alzheimers Dement. 11, 727&#x2013;729 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.06.1883</ArticleId></ArticleIdList></Reference><Reference><Citation>Small, D. H., Mok, S. S. &amp; Bornstein, J. C. Nat. Rev. Neurosci. 2, 595&#x2013;598 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35086072</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto, H., Cheung, B. S., Hyman, B. T. &amp; Irizarry, M. C. Arch. Neurol. 59, 1381&#x2013;1389 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.9.1381</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo, A., Frosch, M. P., Masliah, E. &amp; Hyman, B. T. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, L. B. et al. Nat. Med. 9, 3&#x2013;4 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0103-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds, S. L. et al. Hum. Mol. Genet. 10, 1317&#x2013;1324 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/10.12.1317</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R. et al. Curr. Alzheimer Res. 9, 606&#x2013;615 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512799361691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, E. L., Biscaro, B., Piazza, F. &amp; Tesco, G. J. Biol. Chem. 287, 42867&#x2013;42880 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.407072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, H. et al. Nat. Biotechnol. 34, 328&#x2013;333 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3471</ArticleId></ArticleIdList></Reference><Reference><Citation>Long, C. et al. Science 351, 400&#x2013;403 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5725</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, H. et al. Nat. Biotechnol. 32, 551&#x2013;553 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabebordbar, M. et al. Science 351, 407&#x2013;411 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, C. E. et al. Science 351, 403&#x2013;407 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad5143</ArticleId></ArticleIdList></Reference><Reference><Citation>Doran, A. G. et al. Genome Biol. 17, 167 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-1024-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley, H. et al. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, H. et al. Nature 548, 413&#x2013;419 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23305</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito, T. et al. Nat. Neurosci. 17, 661&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, D. et al. Nat. Methods 12, 237&#x2013;243 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, E. et al. Nat. Commun. 8, 14500 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. Y. et al. Nat. Commun. 6, 8997 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9997</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiech, L. et al. Nat. Biotechnol. 33, 102&#x2013;106 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Y. et al. Nat. Biotechnol. 34, 334&#x2013;338 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3469</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30860560</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>321</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of Midlife Diet With Subsequent Risk for Dementia.</ArticleTitle><Pagination><StartPage>957</StartPage><EndPage>968</EndPage><MedlinePgn>957-968</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.1432</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Observational studies suggest that diet is linked to cognitive health. However, the duration of follow-up in many studies is not sufficient to take into account the long preclinical phase of dementia, and the evidence from interventional studies is not conclusive.</AbstractText><AbstractText Label="OBJECTIVE">To examine whether midlife diet is associated with subsequent risk for dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Population-based cohort study established in 1985-1988 that had dietary intake assessed in 1991-1993, 1997-1999, and 2002-2004 and follow-up for incident dementia until March 31, 2017.</AbstractText><AbstractText Label="EXPOSURES">Food frequency questionnaire to derive the Alternate Healthy Eating Index (AHEI), an 11-component diet quality score (score range, 0-110), with higher scores indicating a healthier diet.</AbstractText><AbstractText Label="MAIN OUTCOME AND MEASURES">Incident dementia ascertained through linkage to electronic health records.</AbstractText><AbstractText Label="RESULTS">Among 8225 participants without dementia in 1991-1993 (mean age, 50.2 years [SD, 6.1 years]; 5686 [69.1%] were men), a total of 344 cases of incident dementia were recorded during a median follow-up of 24.8 years (interquartile range, 24.2-25.1 years). No significant difference in the incidence rate for dementia was observed in tertiles of AHEI exposure during 1991-1993, 1997-1999 (median follow-up, 19.1 years), and 2002-2004 (median follow-up, 13.5 years). Compared with an incidence rate for dementia of 1.76 (95% CI, 1.47-2.12) per 1000 person-years in the worst tertile of AHEI (lowest tertile of diet quality) in 1991-1993, the absolute rate difference for the intermediate tertile was 0.03 (95% CI, -0.43 to 0.49) per 1000 person-years and for the best tertile was 0.04 (95% CI, -0.42 to 0.51) per 1000 person-years. Compared with the worst AHEI tertile in 1997-1999 (incidence rate for dementia, 2.06 [95% CI, 1.62 to 2.61] per 1000 person-years), the absolute rate difference for the intermediate AHEI tertile was 0.14 (95% CI, -0.58 to 0.86) per 1000 person-years and for the best AHEI tertile was 0.14 (95% CI, -0.58 to 0.85) per 1000 person-years. Compared with the worst AHEI tertile in 2002-2004 (incidence rate for dementia, 3.12 [95% CI, 2.49 to 3.92] per 1000 person-years), the absolute rate difference for the intermediate AHEI tertile was -0.61 (95% CI, -1.56 to 0.33) per 1000 person-years and for the best AHEI tertile was -0.73 (95% CI, -1.67 to 0.22) per 1000 person-years. In the multivariable analysis, the adjusted hazard ratios (HRs) for dementia per 1-SD (10-point) AHEI increment were not significant as assessed in 1991-1993 (adjusted HR, 0.97 [95% CI, 0.87 to 1.08]), in 1997-1999 (adjusted HR, 0.97 [95% CI, 0.83 to 1.12]), or in 2002-2004 (adjusted HR, 0.87 [95% CI, 0.75 to 1.00]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this long-term prospective cohort study, diet quality assessed during midlife was not significantly associated with subsequent risk for dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akbaraly</LastName><ForeName>Tasnime N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Montpellier, Inserm, U1198, Ecole Pratique des Hautes Etudes, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Autism Resources Centre, University Research and Hospital Center of Montpellier, Inserm, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh-Manoux</LastName><ForeName>Archana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; Paris Descartes, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugravot</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm, U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; Paris Descartes, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivim&#xe4;ki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabia</LastName><ForeName>S&#xe9;verine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, England.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm, U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; Paris Descartes, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG056477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RG/16/11/32334</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="Y">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004034" MajorTopicYN="N">Diet Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072001" MajorTopicYN="N">Diet, Healthy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002149" MajorTopicYN="N">Energy Intake</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015438" MajorTopicYN="N">Health Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Sabia reported receiving grants from ERC Horizon 2020 outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30860560</ArticleId><ArticleId IdType="mid">EMS82158</ArticleId><ArticleId IdType="pmc">PMC6436698</ArticleId><ArticleId IdType="doi">10.1001/jama.2019.1432</ArticleId><ArticleId IdType="pii">2727449</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Livingston G, Sommerlad A, Orgeta V, et al. . Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31363-6</ArticleId><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Amouyel P, Andrieu S, et al. . Defeating Alzheimer&#x2019;s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455-532. doi:10.1016/S1474-4422(16)00062-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00062-4</ArticleId><ArticleId IdType="pubmed">26987701</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci. 2008;9(7):568-578. doi:10.1038/nrn2421</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2421</ArticleId><ArticleId IdType="pmc">PMC2805706</ArticleId><ArticleId IdType="pubmed">18568016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin Lipidol. 2002;13(1):3-9. doi:10.1097/00041433-200202000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00041433-200202000-00002</ArticleId><ArticleId IdType="pubmed">11790957</ArticleId></ArticleIdList></Reference><Reference><Citation>All&#xe8;s B, Samieri C, F&#xe9;art C, Jutand MA, Laurin D, Barberger-Gateau P. Dietary patterns: a novel approach to examine the link between nutrition and cognitive function in older individuals. Nutr Res Rev. 2012;25(2):207-222. doi:10.1017/S0954422412000133</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0954422412000133</ArticleId><ArticleId IdType="pubmed">22874455</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Rest O, Berendsen AA, Haveman-Nies A, de Groot LC. Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr. 2015;6(2):154-168. doi:10.3945/an.114.007617</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.114.007617</ArticleId><ArticleId IdType="pmc">PMC4352174</ArticleId><ArticleId IdType="pubmed">25770254</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbaraly T, Sexton C, Zsoldos E, et al. . Association of long-term diet quality with hippocampal volume: longitudinal cohort study. Am J Med. 2018;131(11):1372-1381.e4. doi:10.1016/j.amjmed.2018.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.07.001</ArticleId><ArticleId IdType="pmc">PMC6237674</ArticleId><ArticleId IdType="pubmed">30056104</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciano M, Corley J, Cox SR, et al. . Mediterranean-type diet and brain structural change from 73 to 76 years in a Scottish cohort. Neurology. 2017;88(5):449-455. doi:10.1212/WNL.0000000000003559</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003559</ArticleId><ArticleId IdType="pmc">PMC5278943</ArticleId><ArticleId IdType="pubmed">28053008</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Tan L, Wang HF, et al. . Dietary patterns and risk of dementia: a systematic review and meta-analysis of cohort studies. Mol Neurobiol. 2016;53(9):6144-6154. doi:10.1007/s12035-015-9516-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9516-4</ArticleId><ArticleId IdType="pubmed">26553347</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrieu S, Guyonnet S, Coley N, et al. ; MAPT Study Group . Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377-389. doi:10.1016/S1474-4422(17)30040-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30040-6</ArticleId><ArticleId IdType="pubmed">28359749</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight A, Bryan J, Wilson C, Hodgson JM, Davis CR, Murphy KJ. The Mediterranean diet and cognitive function among healthy older adults in a 6-month randomised controlled trial: the MedLey study. Nutrients. 2016;8(9):E579. doi:10.3390/nu8090579</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu8090579</ArticleId><ArticleId IdType="pmc">PMC5037563</ArticleId><ArticleId IdType="pubmed">27657119</ArticleId></ArticleIdList></Reference><Reference><Citation>Marseglia A, Xu W, Fratiglioni L, et al. . Effect of the NU-AGE diet on cognitive functioning in older adults: a randomized controlled trial. Front Physiol. 2018;9:349. doi:10.3389/fphys.2018.00349</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00349</ArticleId><ArticleId IdType="pmc">PMC5893841</ArticleId><ArticleId IdType="pubmed">29670545</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen H, Solomon A, Visser PJ, et al. ; LipiDiDiet Clinical Study Group . 24-month intervention with a specific multinutrient in people with prodromal Alzheimer&#x2019;s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(12):965-975. doi:10.1016/S1474-4422(17)30332-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30332-0</ArticleId><ArticleId IdType="pmc">PMC5697936</ArticleId><ArticleId IdType="pubmed">29097166</ArticleId></ArticleIdList></Reference><Reference><Citation>Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. . Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern Med. 2015;175(7):1094-1103. doi:10.1001/jamainternmed.2015.1668</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2015.1668</ArticleId><ArticleId IdType="pubmed">25961184</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmot M, Brunner E. Cohort profile: the Whitehall II study. Int J Epidemiol. 2005;34(2):251-256. doi:10.1093/ije/dyh372</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyh372</ArticleId><ArticleId IdType="pubmed">15576467</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner E, Stallone D, Juneja M, Bingham S, Marmot M. Dietary assessment in Whitehall II: comparison of 7 d diet diary and food-frequency questionnaire and validity against biomarkers. Br J Nutr. 2001;86(3):405-414. doi:10.1079/BJN2001414</Citation><ArticleIdList><ArticleId IdType="doi">10.1079/BJN2001414</ArticleId><ArticleId IdType="pubmed">11570993</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett WC, Sampson L, Stampfer MJ, et al. . Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122(1):51-65. doi:10.1093/oxfordjournals.aje.a114086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a114086</ArticleId><ArticleId IdType="pubmed">4014201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bingham SA, Gill C, Welch A, et al. . Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. Int J Epidemiol. 1997;26(suppl 1):S137-S151. doi:10.1093/ije/26.suppl_1.S137</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/26.suppl_1.S137</ArticleId><ArticleId IdType="pubmed">9126542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiuve SE, Fung TT, Rimm EB, et al. . Alternative dietary indices both strongly predict risk of chronic disease. J Nutr. 2012;142(6):1009-1018. doi:10.3945/jn.111.157222</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.111.157222</ArticleId><ArticleId IdType="pmc">PMC3738221</ArticleId><ArticleId IdType="pubmed">22513989</ArticleId></ArticleIdList></Reference><Reference><Citation>Commission on the Future of Health and Social Care in England  The UK private health market: 2014. 
https://www.kingsfund.org.uk/sites/default/files/media/commission-appendix-uk-private-health-market.pdf. Accessed February 8, 2019.</Citation></Reference><Reference><Citation>Sommerlad A, Perera G, Singh-Manoux A, Lewis G, Stewart R, Livingston G. Accuracy of general hospital dementia diagnoses in England: sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. Alzheimers Dement. 2018;14(7):933-943. doi:10.1016/j.jalz.2018.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.012</ArticleId><ArticleId IdType="pmc">PMC6057268</ArticleId><ArticleId IdType="pubmed">29703698</ArticleId></ArticleIdList></Reference><Reference><Citation>Heim AW. AH 4 Group Test of General Intelligence ASE. Windsor, England: NFER-Nelson Publishing Co LTD; 1970.</Citation></Reference><Reference><Citation>Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5(2):135-140. doi:10.1016/0028-3932(67)90015-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0028-3932(67)90015-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis of age-related cognitive decline. Neurology. 2010;75(12):1070-1078. doi:10.1212/WNL.0b013e3181f39adc</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f39adc</ArticleId><ArticleId IdType="pmc">PMC2942064</ArticleId><ArticleId IdType="pubmed">20844243</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice G, Laird N, Ware J. Applied Longitudinal Analysis. Hoboken, NJ: Wiley; 2004.</Citation></Reference><Reference><Citation>Solfrizzi V, Custodero C, Lozupone M, et al. . Relationships of dietary patterns, foods, and micro- and macronutrients with Alzheimer&#x2019;s disease and late-life cognitive disorders: a systematic review. J Alzheimers Dis. 2017;59(3):815-849. doi:10.3233/JAD-170248</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170248</ArticleId><ArticleId IdType="pubmed">28697569</ArticleId></ArticleIdList></Reference><Reference><Citation>Haring B, Wu C, Mossavar-Rahmani Y, et al. . No association between dietary patterns and risk for cognitive decline in older women with 9-year follow-up: data from the Women&#x2019;s Health Initiative memory study. J Acad Nutr Diet. 2016;116(6):921-930.e1. doi:10.1016/j.jand.2015.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jand.2015.12.017</ArticleId><ArticleId IdType="pmc">PMC4884559</ArticleId><ArticleId IdType="pubmed">27050728</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson E, Karlstr&#xf6;m B, Kilander L, Byberg L, Cederholm T, Sj&#xf6;gren P. Dietary patterns and cognitive dysfunction in a 12-year follow-up study of 70 year old men. J Alzheimers Dis. 2015;43(1):109-119. doi:10.3233/JAD-140867</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140867</ArticleId><ArticleId IdType="pubmed">25062901</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatenstein B, Ferland G, Belleville S, et al. . Diet quality and cognition among older adults from the NuAge study. Exp Gerontol. 2012;47(5):353-360. doi:10.1016/j.exger.2012.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2012.02.002</ArticleId><ArticleId IdType="pubmed">22386581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardman RJ, Kennedy G, Macpherson H, Scholey AB, Pipingas A. Adherence to a Mediterranean-style diet and effects on cognition in adults: a qualitative evaluation and systematic review of longitudinal and prospective trials. Front Nutr. 2016;3:22. doi:10.3389/fnut.2016.00022</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2016.00022</ArticleId><ArticleId IdType="pmc">PMC4956662</ArticleId><ArticleId IdType="pubmed">27500135</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N. Mediterranean diet, stroke, cognitive impairment, and depression: a meta-analysis. Ann Neurol. 2013;74(4):580-591. doi:10.1002/ana.23944</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23944</ArticleId><ArticleId IdType="pubmed">23720230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Sun D. Adherence to Mediterranean diet and risk of developing cognitive disorders: an updated systematic review and meta-analysis of prospective cohort studies. Sci Rep. 2017;7:41317. doi:10.1038/srep41317</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41317</ArticleId><ArticleId IdType="pmc">PMC5256032</ArticleId><ArticleId IdType="pubmed">28112268</ArticleId></ArticleIdList></Reference><Reference><Citation>Baquero M, Mart&#xed;n N. Depressive symptoms in neurodegenerative diseases. World J Clin Cases. 2015;3(8):682-693. doi:10.12998/wjcc.v3.i8.682</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v3.i8.682</ArticleId><ArticleId IdType="pmc">PMC4539408</ArticleId><ArticleId IdType="pubmed">26301229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner M, Dartigues JF, Samieri C, Proust-Lima C. Modeling risk-factor trajectories when measurement tools change sequentially during follow-up in cohort studies: application to dietary habits in prodromal dementia. Am J Epidemiol. 2018;187(4):845-854. doi:10.1093/aje/kwx293</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwx293</ArticleId><ArticleId IdType="pubmed">29020158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesse-Guyot E, Andreeva VA, Lassale C, et al. ; SU.VI.MAX 2 Research Group . Mediterranean diet and cognitive function: a French study. Am J Clin Nutr. 2013;97(2):369-376. doi:10.3945/ajcn.112.047993</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.112.047993</ArticleId><ArticleId IdType="pubmed">23283500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wengreen H, Munger RG, Cutler A, et al. . Prospective study of Dietary Approaches to Stop Hypertension- and Mediterranean-style dietary patterns and age-related cognitive change: the Cache County Study on memory, health and aging. Am J Clin Nutr. 2013;98(5):1263-1271. doi:10.3945/ajcn.112.051276</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.112.051276</ArticleId><ArticleId IdType="pmc">PMC3798079</ArticleId><ArticleId IdType="pubmed">24047922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozawa M, Ninomiya T, Ohara T, et al. . Dietary patterns and risk of dementia in an elderly Japanese population: the Hisayama study. Am J Clin Nutr. 2013;97(5):1076-1082. doi:10.3945/ajcn.112.045575</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.112.045575</ArticleId><ArticleId IdType="pubmed">23553168</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30879788</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>177</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>04</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition.</ArticleTitle><Pagination><StartPage>256</StartPage><EndPage>271.e22</EndPage><MedlinePgn>256-271.e22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2019.02.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(19)30163-1</ELocationID><Abstract><AbstractText>We previously reported that inducing gamma oscillations with a non-invasive light flicker (gamma entrainment using sensory stimulus or GENUS) impacted pathology in the visual cortex of Alzheimer's disease mouse models. Here, we designed auditory tone stimulation that drove gamma frequency neural activity in auditory cortex (AC) and hippocampal CA1. Seven days of auditory GENUS improved spatial and recognition memory and reduced amyloid in AC and hippocampus of 5XFAD mice. Changes in activation responses were evident in microglia, astrocytes, and vasculature. Auditory GENUS also reduced phosphorylated tau in the P301S tauopathy model. Furthermore, combined auditory and visual GENUS, but not either alone, produced microglial-clustering responses, and decreased amyloid in medial prefrontal cortex. Whole brain analysis using SHIELD revealed widespread reduction of amyloid plaques throughout neocortex after multi-sensory GENUS. Thus, GENUS can be achieved through multiple sensory modalities with wide-ranging effects across multiple brain areas to improve cognitive function.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martorell</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulson</LastName><ForeName>Abigail L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA 30332, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suk</LastName><ForeName>Ho-Jun</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; MIT Media Lab, Departments of Biological Engineering and Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Harvard-MIT Health Sciences and Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdurrob</LastName><ForeName>Fatema</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drummond</LastName><ForeName>Gabrielle T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Webster</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jennie Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>David Nam-Woo</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kritskiy</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Scarlett J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangena</LastName><ForeName>Vamsi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Harvard-MIT Health Sciences and Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Stephanie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA 30332, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Emery N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Institute for Medical Engineering and Science, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA; Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kwanghun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Chemical Engineering, MIT, Cambridge, MA, USA; Institute for Medical Engineering and Science, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyden</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; MIT Media Lab, Departments of Biological Engineering and Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Annabelle C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA 30332, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02139, USA. Electronic address: lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007484</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS090473</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY023173</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007480</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047661</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS109226</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 OD003646</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH117072</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104948</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 ES027992</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2019 May;20(5):249. doi: 10.1038/s41583-019-0167-8.</RefSource><PMID Version="1">30940918</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2019 May;25(5):710. doi: 10.1038/s41591-019-0454-y.</RefSource><PMID Version="1">31068706</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001307" MajorTopicYN="N">Auditory Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065818" MajorTopicYN="N">Gamma Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">acoustic stimulation</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">gamma rhythms</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">photic stimulation</Keyword><Keyword MajorTopicYN="N">vasculature</Keyword></KeywordList><CoiStatement>Conflict of Interest. L.-H.T. and E.S.B are co-Scientific Founders and serve on the scientific advisory board of Cognito Therapeutics and A.C.S. owns shares of Cognito Therapeutics Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30879788</ArticleId><ArticleId IdType="mid">NIHMS1538841</ArticleId><ArticleId IdType="pmc">PMC6774262</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.02.014</ArticleId><ArticleId IdType="pii">S0092-8674(19)30163-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen NJ, and Barres BA (2005). Signaling between glia and neurons: focus on synaptic plasticity. Curr Opin Neurobiol 15, 542&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16144764</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronov D, Nevers R, and Tank DW (2017). Mapping of a non-spatial dimension by the hippocampal-entorhinal circuit. Nature 543, 719&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5492514</ArticleId><ArticleId IdType="pubmed">28358077</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, and Newman EA (2010). Glial and neuronal control of brain blood flow. Nature 468, 232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206737</ArticleId><ArticleId IdType="pubmed">21068832</ArticleId></ArticleIdList></Reference><Reference><Citation>Berens P (2009). CircStat: A MATLAB Toolbox for Circular Statistics. Journal of Statistical Software Vol 31, 1&#x2013;21.</Citation></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, and Holtzman DM (2011). Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci 14, 750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter RG, Penney J, and Tsai LH (2016). The road to restoring neural circuits for the treatment of Alzheimer&#x2019;s disease. Nature 539, 187&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830780</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardin JA, Carl&#xe9;n M, Meletis K, Knoblich U, Zhang F, Deisseroth K, Tsai LH, and Moore CI (2009). Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459, 663&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655711</ArticleId><ArticleId IdType="pubmed">19396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung JE, Magland JF, Barnett AH, Tolosa VM, Tooker AC, Lee KY, Shah KG, Felix SH, Frank LM, and Greengard LF (2017). A Fully Automated Approach to Spike Sorting. Neuron 95, 1381&#x2013;1394.e1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743236</ArticleId><ArticleId IdType="pubmed">28910621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Allen NJ, and Eroglu C (2015). Astrocytes Control Synapse Formation, Function, and Elimination. Cold Spring Harb Perspect Biol 7, a020370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527946</ArticleId><ArticleId IdType="pubmed">25663667</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, and Holtzman DM (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Csicsvari J, Hirase H, Czurk&#xf3; A, Mamiya A, and Buzs&#xe1;ki G (1999). Oscillatory coupling of hippocampal pyramidal cells and interneurons in the behaving Rat. J Neurosci 19, 274&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782375</ArticleId><ArticleId IdType="pubmed">9870957</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosa JA, and Iddings JA (2013). Astrocyte regulation of cerebral vascular tone. Am J Physiol Heart Circ Physiol 305, H609&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3761330</ArticleId><ArticleId IdType="pubmed">23792684</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries P (2009). Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annu Rev Neurosci 32, 209&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">19400723</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie AK, Jones EA, Lin YH, Karlsson MP, Kay K, Yoon SY, Tong LM, Nova P, Carr JS, Frank LM, et al. (2016). Apolipoprotein E4 Causes Age-Dependent Disruption of Slow Gamma Oscillations during Hippocampal Sharp-Wave Ripples. Neuron 90, 740&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097044</ArticleId><ArticleId IdType="pubmed">27161522</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, and Higgins GA (1992). Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science 256, 184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, and Latz E (2014). Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14, 463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, and Diamond MI (2014). Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 111, E4376&#x2013;4385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, et al. (2016). Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540, 230&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="pubmed">27929004</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, et al. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci Transl Med 4, 147ra111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Holtzman DM, and Bu G (2013). Neuronal clearance of amyloid-&#x3b2; by endocytic receptor LRP1. J Neurosci 33, 19276&#x2013;19283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850043</ArticleId><ArticleId IdType="pubmed">24305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, &#xc4;hrlund-Richter S, Wang X, Deisseroth K, and Carl&#xe9;n M (2016). Prefrontal Parvalbumin Neurons in Control of Attention. Cell 164, 208&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715187</ArticleId><ArticleId IdType="pubmed">26771492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Cho JH, Murray E, Bakh N, Choi H, Ohn K, Ruelas L, Hubbert A, McCue M, Vassallo SL, et al. (2015). Stochastic electrotransport selectively enhances the transport of highly electromobile molecules. Proc Natl Acad Sci U S A 112, E6274&#x2013;6283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655572</ArticleId><ArticleId IdType="pubmed">26578787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisler K, Nelson AR, Montagne A, and Zlokovic BV (2017). Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci 18, 419&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759779</ArticleId><ArticleId IdType="pubmed">28515434</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard P, and Freret T (2013). Object recognition test in mice. Nat Protoc 8, 2531&#x2013;2537.</Citation><ArticleIdList><ArticleId IdType="pubmed">24263092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Liang L, and Wang X (2001). Neural representations of temporally asymmetric stimuli in the auditory cortex of awake primates. J Neurophysiol 85, 2364&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pubmed">11387383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Tai X, Su L, Shi L, Wang E, and Qin L (2013). The neuronal responses to repetitive acoustic pulses in different fields of the auditory cortex of awake rats. PLoS One 8, e64288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655960</ArticleId><ArticleId IdType="pubmed">23696877</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, and Tsai LH (2017). Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep 21, 366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mears RP, Klein AC, and Cromwell HC (2006). Auditory inhibitory gating in medial prefrontal cortex: Single unit and local field potential analysis. Neuroscience 141, 47&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675142</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CL, and Freedman R (1995). The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli. Neuroscience 69, 371&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">8552235</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11, 47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, and Wyss-Coray T (2014). Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem Pharmacol 88, 594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al.(2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron 55, 697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YG, Sohn CH, Chen R, McCue M, Yun DH, Drummond GT, Ku T, Evans NB, Oak HC, Trieu W, et al. (2018). Protection of tissue physicochemical properties using polyfunctional crosslinkers. Nat Biotechnol</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579717</ArticleId><ArticleId IdType="pubmed">30556815</ArticleId></ArticleIdList></Reference><Reference><Citation>Rager G, and Singer W (1998). The response of cat visual cortex to flicker stimuli of variable frequency. Eur J Neurosci 10, 1856&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, and Cardona AE (2010). The myeloid cells of the central nervous system parenchyma. Nature 468, 253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">21068834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez JJ, Olabarria M, Chvatal A, and Verkhratsky A (2009). Astroglia in dementia and Alzheimer&#x2019;s disease. Cell Death Differ 16, 378&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">19057621</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo K, and Glass CK (2011). Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 11, 775&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">22025055</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, and Greicius MD (2009). Neurodegenerative diseases target large-scale human brain networks. Neuron 62, 42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, and Haass C (1996). The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci 777, 57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, Zhang F, Yizhar O, and Deisseroth K (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969859</ArticleId><ArticleId IdType="pubmed">19396159</ArticleId></ArticleIdList></Reference><Reference><Citation>Spellman T, Rigotti M, Ahmari SE, Fusi S, Gogos JA, and Gordon JA (2015). Hippocampal-prefrontal input supports spatial encoding in working memory. Nature 522, 309&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505751</ArticleId><ArticleId IdType="pubmed">26053122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, et al. (2010). Functional alterations in memory networks in early Alzheimer&#x2019;s disease. Neuromolecular Med 12, 27&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036844</ArticleId><ArticleId IdType="pubmed">20069392</ArticleId></ArticleIdList></Reference><Reference><Citation>Storck SE, Meister S, Nahrath J, Mei&#xdf;ner JN, Schubert N, Di Spiezio A, Baches S, Vandenbroucke RE, Bouter Y, Prikulis I, et al. (2016). Endothelial LRP1 transports amyloid-&#x3b2;(1&#x2013;42) across the blood-brain barrier. J Clin Invest 126, 123&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4701557</ArticleId><ArticleId IdType="pubmed">26619118</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, et al. (2012). Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorhees CV, and Williams MT (2006). Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1, 848&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895266</ArticleId><ArticleId IdType="pubmed">17406317</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, and Lue LF (2015). Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res Ther 7, 56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4543480</ArticleId><ArticleId IdType="pubmed">26286145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf SA, Boddeke HW, and Kettenmann H (2017). Microglia in Physiology and Disease. Annu Rev Physiol 79, 619&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959620</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto J, Suh J, Takeuchi D, and Tonegawa S (2014). Successful execution of working memory linked to synchronized high-frequency gamma oscillations. Cell 157, 845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">24768692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, and Lu T (2009). Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 284, 4755&#x2013;4759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643502</ArticleId><ArticleId IdType="pubmed">18957434</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, and Lee VM (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">30867273</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>16</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle><i>KLOTHO</i> heterozygosity attenuates <i>APOE4</i>-related amyloid burden in preclinical AD.</ArticleTitle><Pagination><StartPage>e1878</StartPage><EndPage>e1889</EndPage><MedlinePgn>e1878-e1889</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000007323</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether the <i>KLOTHO</i> gene variant KL-VS attenuates <i>APOE4-</i>associated &#x3b2;-amyloid (A&#x3b2;) accumulation in a late-middle-aged cohort enriched with Alzheimer disease (AD) risk factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three hundred nine late-middle-aged adults from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center were genotyped to determine KL-VS and <i>APOE4</i> status and underwent CSF sampling (n = 238) and/or <sup>11</sup>C-Pittsburgh compound B (PiB)-PET imaging (n = 183). Covariate-adjusted regression analyses were used to investigate whether <i>APOE4</i> exerted expected effects on A&#x3b2; burden. Follow-up regression analyses stratified by KL-VS genotype (i.e., noncarrier vs heterozygous; there were no homozygous individuals) evaluated whether the influence of <i>APOE4</i> on A&#x3b2; was different among KL-VS heterozygotes compared to noncarriers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS"><i>APOE4</i> carriers exhibited greater A&#x3b2; burden than <i>APOE4</i>-negative participants. This effect was stronger in CSF (<i>t</i> = -5.12, <i>p</i> &lt; 0.001) compared with PiB-PET (<i>t</i> = 3.93, <i>p</i> &lt; 0.001). In the stratified analyses, this <i>APOE4</i> effect on A&#x3b2; load was recapitulated among KL-VS noncarriers (CSF: <i>t</i> = -5.09, <i>p</i> &lt; 0.001; PiB-PET: <i>t</i> = 3.77, <i>p</i> &lt; 0 .001). In contrast, among KL-VS heterozygotes, <i>APOE4</i>-positive individuals did not exhibit higher A&#x3b2; burden than <i>APOE4</i>-negative individuals (CSF: <i>t</i> = -1.03, <i>p</i> = 0.308; PiB-PET: t = 0.92, <i>p</i> = 0.363). These differential <i>APOE4</i> effects remained after KL-VS heterozygotes and noncarriers were matched on age and sex.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In a cohort of at-risk late-middle-aged adults, KL-VS heterozygosity was associated with an abatement of <i>APOE4-</i>associated A&#x3b2; aggregation, suggesting KL-VS heterozygosity confers protections against <i>APOE4-</i>linked pathways to disease onset in AD.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Claire M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6217-5434</Identifier><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8460-4415</Identifier><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-0056-8662</Identifier><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darst</LastName><ForeName>Burcu F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Derek</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2554-5499</Identifier><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betthauser</LastName><ForeName>Tobey</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8856-1352</Identifier><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Catherine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendlin</LastName><ForeName>Barbara B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Bruce P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sager</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelman</LastName><ForeName>Corinne D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christian</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0001-7504-4372</Identifier><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okonkwo</LastName><ForeName>Ozioma C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>From the Geriatric Research Education and Clinical Center (C.L.G., C.M.C., S.A., S.C.J., O.C.O.), William S. Middleton Memorial VA Hospital; Wisconsin Alzheimer's Disease Research Center (C.M.E., J.M.O., Y.M., C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., B.T.C., S.C.J., O.C.O.); Departments of Population Health Sciences (B.F.D., C.D.E.), Neurology (C.L.G., B.P.H.), Radiology (M.A.S.), Medical Physics (T.B., B.T.C.), and Biostatistics &amp; Medical Informatics (D.N.), University of Wisconsin School of Medicine and Public Health, Madison; Division of Biology and Biomedical Sciences (S.A.S.), Washington University in St. Louis, MO; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (C.L.G., H.Z.), University College London, Queen Square; UK Dementia Research Institute (H.Z.), London; Wisconsin Alzheimer's Institute (C.M.C., B.B.B., S.A., B.P.H., M.A.S., C.D.E., S.C.J., O.C.O.), Madison; and Department of Neurology and Weill Institute for Neurosciences (D.B.D.), University of California, San Francisco. ozioma@medicine.wisc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG037639</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 CX000555</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007359</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090256</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092918</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054047</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062285</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2019 Apr 16;92(16):751. doi: 10.1212/WNL.0000000000007302.</RefSource><PMID Version="1">30867268</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014922" MajorTopicYN="N" Type="Geographic">Wisconsin</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30867273</ArticleId><ArticleId IdType="pmc">PMC6550504</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007323</ArticleId><ArticleId IdType="pii">WNL.0000000000007323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996;47:387&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">8712790</ArticleId></ArticleIdList></Reference><Reference><Citation>Brousseau T, Legrain S, Berr C, Gourlet V, Vidal O, Amouyel P. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994;44:342&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">8309588</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski T, Sulkava R, Haltia M, et al. . Apolipoprotein E, dementia, and cortical deposition of &#x3b2;-amyloid protein. N Engl J Med 1995;333:1242&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino S, Scarmeas N, Helzner E, et al. . APOE &#x3b5;4 allele predicts faster cognitive decline in mild Alzheimer's disease. Neurology 2008;70:1842&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676693</ArticleId><ArticleId IdType="pubmed">18401023</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Mintun MA, Xiong C, et al. . Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 2011;70:857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243969</ArticleId><ArticleId IdType="pubmed">22162065</ArticleId></ArticleIdList></Reference><Reference><Citation>Darst BF, Koscik RL, Racine AM, et al. . Pathway-specific polygenic risk scores as predictors of amyloid-beta deposition and cognitive function in a sample at increased risk for Alzheimer's disease. J Alzheimers Dis 2017;55:473&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123972</ArticleId><ArticleId IdType="pubmed">27662287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Lowe V, Przybelski SA, et al. . APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 2012;78:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280056</ArticleId><ArticleId IdType="pubmed">22189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Graff-Radford NR, Reiman EM, et al. . Preclinical memory decline in cognitively normal apolipoprotein E-&#x3b5;4 homozygotes. Neurology 1999;53:201.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer S, Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol 2009;5:343&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118550</ArticleId><ArticleId IdType="pubmed">19327032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe2;teau MT, Araiz C, Descamps S, Galas S. Klotho interferes with a novel FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress resistance in Caenorhabditis elegans. Aging 2010;2:567&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2984606</ArticleId><ArticleId IdType="pubmed">20844315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Yamamoto M, Clark JD, et al. . Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Yokoyama JS, Zhu L, et al. . Life extension factor klotho enhances cognition. Cell Rep 2014;7:1065&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176932</ArticleId><ArticleId IdType="pubmed">24813892</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Zhu L, Sanchez PE, et al. . Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J Neurosci 2015;35:2358&#x2013;2371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323521</ArticleId><ArticleId IdType="pubmed">25673831</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon J, Moreno AJ, Garay BI, et al. . Peripheral elevation of a Klotho fragment enhances brain function and resilience in young, aging, and alpha-synuclein transgenic mice. Cell Rep 2017;20:1360&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816951</ArticleId><ArticleId IdType="pubmed">28793260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Kuro-o M. The Klotho gene family and the endocrine fibroblast growth factors. Curr Opin Nephrol Hypertens 2008;17:368&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">18660672</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Krebsova A, Macek M, et al. . Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 2002;99:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117395</ArticleId><ArticleId IdType="pubmed">11792841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Sturm VE, Bonham LW, et al. . Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann Clin Transl Neurol 2015;2:215&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369272</ArticleId><ArticleId IdType="pubmed">25815349</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 2005;96:412&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">15677572</ArticleId></ArticleIdList></Reference><Reference><Citation>Invidia L, Salvioli S, Altilia S, et al. . The frequency of Klotho KL-VS polymorphism in a large Italian population, from young subjects to centenarians, suggests the presence of specific time windows for its effect. Biogerontology 2010;11:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19421891</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries CF, Staff RT, Harris SE, et al. . Klotho, APOEepsilon4, cognitive ability, brain size, atrophy, and survival: a study in the Aberdeen Birth Cohort of 1936. Neurobiol Aging 2017;55:91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28431289</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Marx G, Brown JA, et al. . Systemic klotho is associated with KLOTHO variation and predicts intrinsic cortical connectivity in healthy human aging. Brain Imaging Behav 2017;11:391&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382127</ArticleId><ArticleId IdType="pubmed">27714549</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Koscik RL, Jonaitis EM, et al. . The Wisconsin Registry for Alzheimer's Prevention: a review of findings and current directions. Alzheimers Dement (Amst) 2018;10:130&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5755749</ArticleId><ArticleId IdType="pubmed">29322089</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Schultz SA, Oh JM, et al. . Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 2014;83:1753&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239838</ArticleId><ArticleId IdType="pubmed">25298312</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida RP, Schultz SA, Austin BP, et al. . Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease. JAMA Neurol 2015;72:699&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639566</ArticleId><ArticleId IdType="pubmed">25893879</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. . Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014;71:1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Floberg JM, Mistretta CA, Weichert JP, Hall LT, Holden JE, Christian BT. Improved kinetic analysis of dynamic PET data with optimized HYPR-LR. Med Phys 2012;39:3319&#x2013;3331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371076</ArticleId><ArticleId IdType="pubmed">22755714</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. . Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosario BL, Weissfeld LA, Laymon CM, et al. . Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage 2011;55:933&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057323</ArticleId><ArticleId IdType="pubmed">21195782</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LR, Racine AM, Koscik RL, et al. . Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement 2016;12:805&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947439</ArticleId><ArticleId IdType="pubmed">26806386</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens G, Winkler TW, Gorski M, Leitzmann MF, Heid IM. To stratify or not to stratify: power considerations for population-based genome-wide association studies of quantitative traits. Genet Epidemiol 2011;35:867&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">22125224</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm S. A simple sequential rejective multiple test procedure. Scand J Stat 1979;6:65&#x2013;70.</Citation></Reference><Reference><Citation>Saunders AM, Schmader K, Breitner JC, et al. . Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993;342:710&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103823</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. . Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">1625800</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, et al. . Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without beta-amyloid. Neurobiol Aging 2016;37:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4716785</ArticleId><ArticleId IdType="pubmed">26481403</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. . Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013;74:826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Donohue M, et al. . Alzheimer's disease neuroimaging I: independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain 2015;138:772&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339769</ArticleId><ArticleId IdType="pubmed">25541191</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz SA, Boots EA, Almeida RP, et al. . Cardiorespiratory fitness attenuates the influence of amyloid on cognition. J Int Neuropsychol Soc 2015;21:841&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4716656</ArticleId><ArticleId IdType="pubmed">26581795</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Whiteman MC, Pattie A, et al. . Cognitive change and the APOE epsilon 4 allele. Nature 2002;418:932.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198535</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida OP, Morar B, Hankey GJ, et al. . Longevity Klotho gene polymorphism and the risk of dementia in older men. Maturitas 2017;101:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28539162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengel-From J, Soerensen M, Nygaard M, McGue M, Christensen K, Christiansen L. Genetic variants in KLOTHO associate with cognitive function in the oldest old group. J Gerontol A Biol Sci Med Sci 2016;71:1151&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978356</ArticleId><ArticleId IdType="pubmed">26405063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Verghese PB, Chakraborty C, et al. . Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci USA 2016;113:10186&#x2013;10191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018780</ArticleId><ArticleId IdType="pubmed">27559087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YA, Zhou B, Wernig M, Sudhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Abeta secretion. Cell 2017;168:427&#x2013;441.e421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30882841</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology.</ArticleTitle><Pagination><StartPage>710</StartPage><EndPage>717</EndPage><MedlinePgn>710-717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.0250</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The association between the microtubule-associated protein tau (MAPT) H1 haplotype and the risk of progressive supranuclear palsy (PSP) has been well documented. However, the specific H1 subhaplotypes that drive the association have not been evaluated in large studies, nor have they been studied in relation to neuropathologic severity of disease.</AbstractText><AbstractText Label="OBJECTIVE">To comprehensively evaluate the associations of MAPT haplotypes with the risk of PSP and the severity of tau pathology using a large series of neuropathologically confirmed PSP cases.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A case-control study was used to investigate the associations between MAPT haplotypes and the risk of PSP, and a case series was conducted for examination of associations of MAPT haplotypes with the severity of tau pathology. All 802 neuropathologically confirmed PSP cases were obtained from a neurodegenerative disorders brain bank between January 1, 1998, and December 31, 2013, and 1312 clinical controls were obtained from the neurology department of the Mayo Clinic. Statistical analysis was performed from February 17 to December 12, 2018.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Presence of PSP in case-control analysis and semiquantitative tau pathology scores for neurofibrillary tangles, neuropil threads, tufted astrocytes, and oligodendroglial coiled bodies in PSP cases.</AbstractText><AbstractText Label="RESULTS">For 802 patients with PSP (376 women and 426 men), the median age at death was 75 years (range, 52-98 years). For 1312 controls (701 women and 611 men), the median age at blood collection was 69 years (range, 45-92 years). After adjustment for multiple testing, known associations with risk of PSP were observed for the H2 and H1c haplotypes. Novel associations with PSP were observed for 3 H1 subhaplotypes, including H1d (odds ratio, 1.86; 95% CI, 1.43-2.42; P&#x2009;=&#x2009;2&#x2009;&#xd7;&#x2009;10-6), H1g (odds ratio, 3.64; 95% CI, 2.04-6.50; P&#x2009;=&#x2009;2&#x2009;&#xd7;&#x2009;10-6), and H1o (odds ratio, 2.60; 95% CI, 1.63-4.16; P&#x2009;=&#x2009;2&#x2009;&#xd7;&#x2009;10-5). Although not significant after multiple testing adjustment, 3 of these PSP risk haplotypes (H2, H1c, and H1d) were also nominally associated with measures of severity of tau pathology in PSP cases. Nominally significant associations with severity of tau pathology were also noted for the H1e and H1q haplotypes.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study has identified novel associations with risk of PSP for 3 MAPT H1 subhaplotypes. In addition, potential weaker associations between several haplotypes (including several PSP risk haplotypes) and severity of tau pathology were observed. These findings expand the current understanding of the role of MAPT haplotypic variation in susceptibility to and neuropathologic severity of PSP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heckman</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Rebecca R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labb&#xe9;</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Alexandra I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koga</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gerpen</LastName><ForeName>Jay A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitti</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genomics, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097261</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100693</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Petersen reported receiving personal fees from Hoffman&#x2013;La Roche Inc, Merck Inc, Genentech Inc, Biogen Inc, GE Healthcare, and Eisai Inc outside the submitted work. Dr Boeve reported receiving grants from the National Institutes of Health during the conduct of the study; and receiving grants from Axovant and Biogen and personal fees from Tau Consortium outside the submitted work. Dr Wszolek reported receiving grants from Mayo Clinic Center for Regenerative Medicine, Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation, and the James C. and Sarah K. Kennedy Fund for Neurodegenerative Disease Research at Mayo Clinic in Florida), and The Sol Goldman Charitable Trust during the conduct of the study and receiving grants from the National Institutes of Health/National Institute on Aging (primary), National Institutes of Health/National Institute of Neurological Disorders and Stroke (secondary; 1U01AG045390-01A1), and National Institutes of Health/National Institute of Neurological Disorders and Stroke (P50 NS072187) outside the submitted work. Dr Ross reported receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30882841</ArticleId><ArticleId IdType="pmc">PMC6563568</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.0250</ArticleId><ArticleId IdType="pii">2728174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>H&#xf6;glinger GU, Respondek G, Stamelou M, et al. ; Movement Disorder Society-endorsed PSP Study Group . Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26987</ArticleId><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23(4):394-400. doi:10.1097/WCO.0b013e32833be924</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e32833be924</ArticleId><ArticleId IdType="pubmed">20610990</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord. 2003;18(9):1018-1026. doi:10.1002/mds.10488</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.10488</ArticleId><ArticleId IdType="pubmed">14502669</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, H&#xf6;glinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16(7):552-563. doi:10.1016/S1474-4422(17)30157-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30157-6</ArticleId><ArticleId IdType="pmc">PMC5802400</ArticleId><ArticleId IdType="pubmed">28653647</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz SW, Bras J. Genetics underlying atypical parkinsonism and related neurodegenerative disorders. Int J Mol Sci. 2015;16(10):24629-24655. doi:10.3390/ijms161024629</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms161024629</ArticleId><ArticleId IdType="pmc">PMC4632769</ArticleId><ArticleId IdType="pubmed">26501269</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, Helgason A, Thorleifsson G, et al. . A common inversion under selection in Europeans. Nat Genet. 2005;37(2):129-137. doi:10.1038/ng1508</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1508</ArticleId><ArticleId IdType="pubmed">15654335</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad C, Andreadis A, Trojanowski JQ, et al. . Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997;41(2):277-281. doi:10.1002/ana.410410222</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410222</ArticleId><ArticleId IdType="pubmed">9029080</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Litvan I, Houlden H, et al. . Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999;8(4):711-715. doi:10.1093/hmg/8.4.711</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.4.711</ArticleId><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Ezquerra M, Perez JC, et al. . Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. Ann Neurol. 2004;56(2):249-258. doi:10.1002/ana.20178</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20178</ArticleId><ArticleId IdType="pubmed">15293277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Melquist S, Cruts M, et al. . High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet. 2005;14(21):3281-3292. doi:10.1093/hmg/ddi361</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi361</ArticleId><ArticleId IdType="pubmed">16195395</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, Myers AJ, Abou-Sleiman P, et al. . Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42(11):837-846. doi:10.1136/jmg.2005.031377</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2005.031377</ArticleId><ArticleId IdType="pmc">PMC1735957</ArticleId><ArticleId IdType="pubmed">15792962</ArticleId></ArticleIdList></Reference><Reference><Citation>Melquist S, Craig DW, Huentelman MJ, et al. . Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet. 2007;80(4):769-778. doi:10.1086/513320</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/513320</ArticleId><ArticleId IdType="pmc">PMC1852701</ArticleId><ArticleId IdType="pubmed">17357082</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Melhem NM, Dickson DW, et al. ; PSP Genetics Study Group . Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699-705. doi:10.1038/ng.859</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.859</ArticleId><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Labb&#xe9; C, Heckman MG, Lorenzo-Betancor O, et al. . MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimers Dement. 2016;12(12):1297-1304. doi:10.1016/j.jalz.2016.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.05.002</ArticleId><ArticleId IdType="pmc">PMC5143206</ArticleId><ArticleId IdType="pubmed">27287057</ArticleId></ArticleIdList></Reference><Reference><Citation>Set&#xf3;-Salvia N, Clarim&#xf3;n J, Pagonabarraga J, et al. . Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol. 2011;68(3):359-364. doi:10.1001/archneurol.2011.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.17</ArticleId><ArticleId IdType="pubmed">21403021</ArticleId></ArticleIdList></Reference><Reference><Citation>Labb&#xe9; C, Heckman MG, Lorenzo-Betancor O, et al. . MAPT haplotype diversity in multiple system atrophy. Parkinsonism Relat Disord. 2016;30:40-45. doi:10.1016/j.parkreldis.2016.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2016.06.010</ArticleId><ArticleId IdType="pmc">PMC5007155</ArticleId><ArticleId IdType="pubmed">27374978</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Baker M, Hutton M. Tau genotype: no effect on onset, symptom severity, or survival in progressive supranuclear palsy. Neurology. 2001;57(1):138-140. doi:10.1212/WNL.57.1.138</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.1.138</ArticleId><ArticleId IdType="pubmed">11445645</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba Y, Putzke JD, Tsuboi Y, et al. . Effect of MAPT and APOE on prognosis of progressive supranuclear palsy. Neurosci Lett. 2006;405(1-2):116-119. doi:10.1016/j.neulet.2006.06.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.06.032</ArticleId><ArticleId IdType="pubmed">16839689</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Vidal-Taboada JM, Ezquerra M, et al. ; Iberian Atypical Parkinsonism Study Group Researchers . 5&#x2032;-Upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiol Dis. 2009;33(2):164-170. doi:10.1016/j.nbd.2008.09.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.09.027</ArticleId><ArticleId IdType="pubmed">19022385</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Burgess JD, Ballard T, et al. . Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathol. 2016;132(2):197-211. doi:10.1007/s00401-016-1576-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1576-7</ArticleId><ArticleId IdType="pmc">PMC4947429</ArticleId><ArticleId IdType="pubmed">27115769</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstenecker A, Roberson ED, Schellenberg GD, et al. . Genetic influences on cognition in progressive supranuclear palsy. Mov Disord. 2017;32(12):1764-1771. doi:10.1002/mds.27196</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27196</ArticleId><ArticleId IdType="pmc">PMC5818145</ArticleId><ArticleId IdType="pubmed">29076559</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauw JJ, Daniel SE, Dickson D, et al. . Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44(11):2015-2019. doi:10.1212/WNL.44.11.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.11.2015</ArticleId><ArticleId IdType="pubmed">7969952</ArticleId></ArticleIdList></Reference><Reference><Citation>Labb&#xe9; C, Soto-Ortolaza AI, Rayaprolu S, et al. . Investigating the role of FUS exonic variants in essential tremor. Parkinsonism Relat Disord. 2013;19(8):755-757. doi:10.1016/j.parkreldis.2013.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2013.03.005</ArticleId><ArticleId IdType="pmc">PMC3691340</ArticleId><ArticleId IdType="pubmed">23601511</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Kachadoorian M, Quicksall Z, et al. . Association of MAPT haplotypes with Alzheimer&#x2019;s disease risk and MAPT brain gene expression levels. Alzheimers Res Ther. 2014;6(4):39. doi:10.1186/alzrt268</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt268</ArticleId><ArticleId IdType="pmc">PMC4198935</ArticleId><ArticleId IdType="pubmed">25324900</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Hauw J-J, Agid Y, Litvan I Progressive supranuclear palsy and corticobasal degeneration. In: Dickson DW, Weller RO, eds. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2011.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800. doi:10.1212/WNL.58.12.1791</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, et al. . Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer&#x2019;s disease spectrum. Brain. 2015;138(pt 5):1370-1381. doi:10.1093/brain/awv050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv050</ArticleId><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70(2):425-434. doi:10.1086/338688</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338688</ArticleId><ArticleId IdType="pmc">PMC384917</ArticleId><ArticleId IdType="pubmed">11791212</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Kaleem M, Marlowe L, et al. . The H1c haplotype at the MAPT locus is associated with Alzheimer&#x2019;s disease. Hum Mol Genet. 2005;14(16):2399-2404. doi:10.1093/hmg/ddi241</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi241</ArticleId><ArticleId IdType="pubmed">16000317</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Pittman AM, Zhao AS, et al. . The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007;25(3):561-570. doi:10.1016/j.nbd.2006.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.10.018</ArticleId><ArticleId IdType="pubmed">17174556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandrovcova J, Pittman AM, Malzer E, et al. . Association of MAPT haplotype-tagging SNPs with sporadic Parkinson&#x2019;s disease. Neurobiol Aging. 2009;30(9):1477-1482. doi:10.1016/j.neurobiolaging.2007.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.11.019</ArticleId><ArticleId IdType="pubmed">18162161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30894745</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>568</Volume><Issue>7752</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules.</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>423</EndPage><MedlinePgn>420-423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1026-5</ELocationID><Abstract><AbstractText>Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy that is associated with repetitive head impacts or exposure to blast waves. First described as punch-drunk syndrome and dementia pugilistica in retired boxers<sup>1-3</sup>, CTE has since been identified in former participants of other contact sports, ex-military personnel and after physical abuse<sup>4-7</sup>. No disease-modifying therapies currently exist, and diagnosis requires an autopsy. CTE is defined by an abundance of hyperphosphorylated tau protein in neurons, astrocytes and cell processes around blood vessels<sup>8,9</sup>. This, together with the accumulation of tau inclusions in cortical layers II and III, distinguishes CTE from Alzheimer's disease and other tauopathies<sup>10,11</sup>. However, the morphologies of tau filaments in CTE and the mechanisms by which brain trauma can lead to their formation are unknown. Here we determine the structures of tau filaments from the brains of three individuals with CTE at resolutions down to 2.3&#xa0;&#xc5;, using cryo-electron microscopy. We show that filament structures are identical in the three cases but are distinct from those of Alzheimer's and Pick's diseases, and from those formed in vitro<sup>12-15</sup>. Similar to Alzheimer's disease<sup>12,14,16-18</sup>, all six brain tau isoforms assemble into filaments in CTE, and residues K274-R379 of three-repeat tau and S305-R379 of four-repeat tau form the ordered core of two identical C-shaped protofilaments. However, a different conformation of the &#x3b2;-helix region creates a hydrophobic cavity that is absent in tau filaments from the brains of patients with Alzheimer's disease. This cavity encloses an additional density that is not connected to tau, which suggests that the incorporation of cofactors may have a role in tau aggregation in CTE. Moreover, filaments in CTE have distinct protofilament interfaces to those of Alzheimer's disease. Our structures provide a unifying neuropathological criterion for CTE, and support the hypothesis that the formation and propagation of distinct conformers of assembled tau underlie different neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zivanov</LastName><ForeName>Jasenko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowther</LastName><ForeName>R Anthony</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105192716</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17136</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072973</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N027892/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS110437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Jun;15(6):308-309. doi: 10.1038/s41582-019-0185-1.</RefSource><PMID Version="1">30988502</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070627" MajorTopicYN="Y">Chronic Traumatic Encephalopathy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057927" MajorTopicYN="Y">Hydrophobic and Hydrophilic Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30894745</ArticleId><ArticleId IdType="mid">NIHMS1522205</ArticleId><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1026-5</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1026-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martland HS Punch drunk. J. Am. Med. Assoc. 19, 1103&#x2013;1107 (1928).</Citation></Reference><Reference><Citation>Millspaugh JA Dementia pugilistica. US Nav Med. Bull. 35, 297&#x2013;303 (1937).</Citation></Reference><Reference><Citation>Corsellis JA, Bruton CJ &amp; Freeman-Browne D The aftermath of boxing. Psychol. Med. 3, 270&#x2013;303 (1973).</Citation><ArticleIdList><ArticleId IdType="pubmed">4729191</ArticleId></ArticleIdList></Reference><Reference><Citation>Omalu BI et al. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 57, 128&#x2013;134 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15987548</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Daneshvar DH, Alvarez VE &amp; Stein TD The neuropathology of sport. Acta Neuropathol. 127, 29&#x2013;51 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255282</ArticleId><ArticleId IdType="pubmed">24366527</ArticleId></ArticleIdList></Reference><Reference><Citation>Omalu B et al. Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. Neurosurg. Focus 31, E3 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22044102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Knabe R, Bovier P &amp; Bouras C Neuropathological observations in a case of autism presenting with self-injury behavior. Acta Neuropathol. 82, 321&#x2013;326 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759563</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes JF, Vowles GH, Nicoll JA &amp; Revesz T Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol. 98, 171&#x2013;178 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10442557</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 131, 75&#x2013;86 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR et al. Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer&#x2019;s disease cases. Acta Neuropathol. 85, 23&#x2013;30 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1285493</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T, Ikeda S, Yanagisawa N, Ihara Y &amp; Glenner GG Re-examination of ex-boxers&#x2019; brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. Acta Neuropathol. 82, 280&#x2013;285 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759560</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 136, 699&#x2013;708 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W et al. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer&#x2019;s and Pick&#x2019;s diseases. eLife 8:e43584 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375701</ArticleId><ArticleId IdType="pubmed">30720432</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Zhukareva V, Newell KL, Lee VM &amp; Trojanowski JQ Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer&#x2019;s disease. Acta Neuropathol. 101, 518&#x2013;524 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11484824</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ &amp; Crowther RA Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8, 159&#x2013;168 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulot SF, Hughes K, Woodgett JR, Anderton BH &amp; Hanger DP PHF-tau from Alzheimer&#x2019;s brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Lett. 349, 359&#x2013;364 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8050597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. USA 85, 4884&#x2013;4888 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280541</ArticleId><ArticleId IdType="pubmed">2455299</ArticleId></ArticleIdList></Reference><Reference><Citation>He S &amp; Scheres SHW Helical reconstruction in RELION. J. Struct. Biol. 198, 163&#x2013;176 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlomagno Y et al. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function. J. Biol. Chem. 292, 15277&#x2013;15286 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602388</ArticleId><ArticleId IdType="pubmed">28760828</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550&#x2013;553 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez M, Valpuesta JM, Medina M, Montejo de Garcini E &amp; Avila J Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J. Neurochem. 67, 1183&#x2013;1190 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8752125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM &amp; Mandelkow E RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 399, 344&#x2013;349 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DM &amp; Binder LI Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer&#x2019;s disease. Am. J. Pathol. 150, 2181&#x2013;2195 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858305</ArticleId><ArticleId IdType="pubmed">9176408</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL et al. Tau prions from Alzheimer&#x2019;s disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proc. Natl. Acad. Sci. USA 113, E8187&#x2013;E8196 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167200</ArticleId><ArticleId IdType="pubmed">27911827</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S, Bridges LR &amp; Case CP Neurofibrillary tangles in Niemann-Pick disease type C. Brain 118 119&#x2013;129 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7894998</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K et al. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 89, 227&#x2013;238 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7754743</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B et al. Cryo-EM of full-length alpha-synuclein reveals fibril polymorphs with a common structural kernel. Nat. Commun 9, 3609 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127345</ArticleId><ArticleId IdType="pubmed">30190461</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadanza MG et al. The structure of a beta2-microglobulin fibril suggests a molecular basis for its amyloid polymorphism. Nat. Commun 9, 4517 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6207761</ArticleId><ArticleId IdType="pubmed">30375379</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y et al. Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy. Cell Res. 28, 897&#x2013;903 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123497</ArticleId><ArticleId IdType="pubmed">30065316</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero-Ferreira R et al. Cryo-EM structure of alpha-synuclein fibrils. eLife 7, e36402 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092118</ArticleId><ArticleId IdType="pubmed">29969391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H &amp; Hu HY Sequestration of cellular interacting partners by protein aggregates: implication in a loss-of-function pathology. FEBS J. 283, 3705&#x2013;3717 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27016044</ArticleId></ArticleIdList></Reference><Reference><Citation>Donat CK, Scott G, Gentleman SM &amp; Sastre M Microglial activation in traumatic brain injury. Front. Aging Neurosci. 9, 208 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5487478</ArticleId><ArticleId IdType="pubmed">28701948</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfinger MH et al. The aftermath of boxing revisited: identifying chronic traumatic encephalopathy pathology in the original Corsellis boxer series. Acta Neuropathol. 136, 973&#x2013;974 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280830</ArticleId><ArticleId IdType="pubmed">30377771</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujols J et al. Small molecule inhibits alpha-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc. Natl. Acad. Sci. USA 115, 10481&#x2013;10486 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187188</ArticleId><ArticleId IdType="pubmed">30249646</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DA &amp; Newell KL Case records of the Massachusetts General Hospital. Case 12-1999. N. Engl. J. Med. 340, 1269&#x2013;1277 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10210712</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68, 709&#x2013;735 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945234</ArticleId><ArticleId IdType="pubmed">19535999</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J. Neuropathol. Exp. Neurol. 69, 918&#x2013;929 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokjohn TA et al. Neurochemical profile of dementia pugilistica. J. Neurotr. 30, 981&#x2013;997 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684215</ArticleId><ArticleId IdType="pubmed">23268705</ArticleId></ArticleIdList></Reference><Reference><Citation>King A et al. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer&#x2019;s disease. Neuropathology 30, 408&#x2013;419 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20102526</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt S, Kwee LC, Allen KD &amp; Oddone EZ Association of ALS with head injury, cigarette smoking and APOE genotypes. J. Neurol. Sci. 291, 22&#x2013;29 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840700</ArticleId><ArticleId IdType="pubmed">20129626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111&#x2013;113 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43&#x2013;64 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD et al. Variation in TMEM106B in chronic traumatic encephalopathy. Acta Neuropathol. Commun. 6, 115 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215686</ArticleId><ArticleId IdType="pubmed">30390709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiung GY, Fok A, Feldman HH, Rademakers R &amp; Mackenzie IR rs5848 polymorphism and serum progranulin level. J. Neurol. Sci. 300, 28&#x2013;32 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085023</ArticleId><ArticleId IdType="pubmed">21047645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SQ et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Meth. 14, 331&#x2013;332 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24&#x2013;35 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG &amp; Cowtan K Features and development of Coot. Acta Crystallogr. D 66, 486&#x2013;501 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Murshudov GN, Vagin AA &amp; Dodson EJ Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240&#x2013;255 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12&#x2013;21 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan A et al. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer&#x2019;s disease brain. Acta Neuropathol. Commun. 1, 54 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893535</ArticleId><ArticleId IdType="pubmed">24252707</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D &amp; Crowther RA Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3, 519&#x2013;526 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131, 267&#x2013;280 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain 131, 72&#x2013;89 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K et al. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol. 110, 298&#x2013;305 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15981014</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallyas F Silver staining of Alzheimer&#x2019;s neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 19, 1&#x2013;8 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">4107507</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Ohm T &amp; Bohl J Silver impregnation of Alzheimer&#x2019;s neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. Stain Technol. 63, 197&#x2013;200 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2464205</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow JL et al. Whole-exome sequencing in familial Parkinson disease. JAMA Neurol. 73, 68&#x2013;75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4946647</ArticleId><ArticleId IdType="pubmed">26595808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M &amp; Hakonarson H ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucl. Ac. Res. 38, e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30911133</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>554</StartPage><EndPage>560</EndPage><MedlinePgn>554-560</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-019-0375-9</ELocationID><Abstract><AbstractText>The hippocampus is one of the most affected areas in Alzheimer's disease (AD)<sup>1</sup>. Moreover, this structure hosts one of the most unique phenomena of the adult mammalian brain, namely, the addition of new neurons throughout life<sup>2</sup>. This process, called adult hippocampal neurogenesis (AHN), confers an unparalleled degree of plasticity to the entire hippocampal circuitry<sup>3,4</sup>. Nonetheless, direct evidence of AHN in humans has remained elusive. Thus, determining whether new neurons are continuously incorporated into the human dentate gyrus (DG) during physiological and pathological aging is a crucial question with outstanding therapeutic potential. By combining human brain samples obtained under tightly controlled conditions and state-of-the-art tissue processing methods, we identified thousands of immature neurons in the DG of neurologically healthy human subjects up to the ninth decade of life. These neurons exhibited variable degrees of maturation along differentiation stages of AHN. In sharp contrast, the number and maturation of these neurons progressively declined as AD advanced. These results demonstrate the persistence of AHN during both physiological and pathological aging in humans and provide evidence for impaired neurogenesis as a potentially relevant mechanism underlying memory deficits in AD that might be amenable to novel therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Moreno-Jim&#xe9;nez</LastName><ForeName>Elena P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular 'Severo Ochoa', CBMSO, CSIC-UAM, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Flor-Garc&#xed;a</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular 'Severo Ochoa', CBMSO, CSIC-UAM, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Terreros-Roncal</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular 'Severo Ochoa', CBMSO, CSIC-UAM, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;bano</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuropathology Department, CIEN Foundation, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cafini</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallas-Bazarra</LastName><ForeName>Noem&#xed;</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0175-5080</Identifier><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular 'Severo Ochoa', CBMSO, CSIC-UAM, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular 'Severo Ochoa', CBMSO, CSIC-UAM, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorens-Mart&#xed;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9129-5198</Identifier><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular 'Severo Ochoa', CBMSO, CSIC-UAM, Madrid, Spain. m.llorens@csic.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain. m.llorens@csic.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain. m.llorens@csic.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089622">Doublecortin Domain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2019 Apr;25(4):542-543. doi: 10.1038/s41591-019-0408-4.</RefSource><PMID Version="1">30911138</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 May;15(5):245. doi: 10.1038/s41582-019-0182-4.</RefSource><PMID Version="1">30953034</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>ACS Chem Neurosci. 2019 May 15;10(5):2091-2093. doi: 10.1021/acschemneuro.9b00196.</RefSource><PMID Version="1">31007011</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2019 Jul 3;25(1):7-8. doi: 10.1016/j.stem.2019.06.001.</RefSource><PMID Version="1">31271749</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscientist. 2019 Aug;25(4):285. doi: 10.1177/1073858419859505.</RefSource><PMID Version="1">31514645</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000089622" MajorTopicYN="N">Doublecortin Domain Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30911133</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0375-9</ArticleId><ArticleId IdType="pii">10.1038/s41591-019-0375-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak, H. &amp; Braak, E. Morphology of Alzheimer disease. Fortschr. Med. 108, 621&#x2013;624 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2289729</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman, J. Autoradiographic investigation of cell proliferation in the brains of rats and cats. Anat. Rec. 145, 573&#x2013;591 (1963).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.1091450409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay, A. et al. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature 472, 466&#x2013;470 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09817</ArticleId></ArticleIdList></Reference><Reference><Citation>Anacker, C. et al. Hippocampal neurogenesis confers stress resilience by inhibiting the ventral dentate gyrus. Nature 559, 98&#x2013;102 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0262-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson, P. S. et al. Neurogenesis in the adult human hippocampus. Nat. Med. 4, 1313&#x2013;1317 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3305</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding, K. L. et al. Dynamics of hippocampal neurogenesis in adult humans. Cell 153, 1219&#x2013;1227 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini, M. et al. Human hippocampal neurogenesis persists throughout aging. Cell Stem Cell 22, 589&#x2013;599 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.03.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoth, R. et al. Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS ONE 5, e8809 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrells, S. F. et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature 555, 377&#x2013;381 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25975</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani, S. et al. Hippocampal radial glial subtypes and their neurogenic potential in human fetuses and healthy and Alzheimer&#x2019;s disease adults. Cereb. Cortex 28, 2458&#x2013;2478 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhy096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann, G. et al. Human adult neurogenesis: evidence and remaining questions. Cell Stem Cell 23, 25&#x2013;30 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2018.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann, G., Jessberger, S., Steiner, B. &amp; Kronenberg, G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 27, 447&#x2013;452 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2004.05.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Plumpe, T. et al. Variability of doublecortin-associated dendrite maturation in adult hippocampal neurogenesis is independent of the regulation of precursor cell proliferation. BMC Neurosci. 7, 77 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-7-77</ArticleId></ArticleIdList></Reference><Reference><Citation>Karalay, O. et al. Prospero-related homeobox 1 gene (Prox1) is regulated by canonical Wnt signaling and has a stage-specific role in adult hippocampal neurogenesis. Proc. Natl Acad. Sci. USA 108, 5807&#x2013;5812 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1013456108</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt, M. D. et al. Transient calretinin expression defines early postmitotic step of neuronal differentiation in adult hippocampal neurogenesis of mice. Mol. Cell. Neurosci. 24, 603&#x2013;613 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1044-7431(03)00207-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, C., Teng, E. M., Summers, R. G. Jr, Ming, G. L. &amp; Gage, F. H. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J. Neurosci. 26, 3&#x2013;11 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3648-05.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler, S. J., Williams, N. I., Stanton, G. B., Cameron, J. L. &amp; Greenough, W. T. Maturation time of new granule cells in the dentate gyrus of adult macaque monkeys exceeds six months. Proc. Natl Acad. Sci. USA 108, 10326&#x2013;10331 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017099108</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Martin, M. et al. GSK-3&#x3b2; overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Mol. Psychiatry 18, 451&#x2013;460 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov, O., Mattson, M. P., Peterson, D. A., Pimplikar, S. W. &amp; van Praag, H. When neurogenesis encounters aging and disease. Trends Neurosci. 33, 569&#x2013;579 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2010.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. &amp; Braak, E. Staging of Alzheimer&#x2019;s disease&#x2013;related neurofibrillary changes. Neurobiol. Aging 16, 271&#x2013;278 (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra, A. et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 7, 483&#x2013;495 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2010.08.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin-Burgin, A., Mongiat, L. A., Pardi, M. B. &amp; Schinder, A. F. Unique processing during a period of high excitation/inhibition balance in adult-born neurons. Science 335, 1238&#x2013;1242 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1214956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischofberger, J. Young and excitable: new neurons in memory networks. Nat. Neurosci. 10, 273&#x2013;275 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn0307-273</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesnes, K. A., Annas, P., Basun, H., Edgar, C. &amp; Blennow, K. Performance on a pattern separation task by Alzheimer&#x2019;s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E4 in status and cerebrospinal fluid amyloid-&#x3b2;42 levels. Alzheimers Res. Ther. 6, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt250</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka, M. T. et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 14, 388&#x2013;405 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai, J., Majtanik, M. &amp; Paxinos, G. Atlas of the Human Brain (Academic Press, 2008).</Citation></Reference><Reference><Citation>Martinez-Martin, P. &amp; Avila, J. Alzheimer Center Reina Sofia Foundation: fighting the disease and providing overall solutions. J. Alzheimers Dis. 21, 337&#x2013;348 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-101149</ArticleId></ArticleIdList></Reference><Reference><Citation>International Society for Biological and Environmental Repositories. 2012 best practices for repositories collection, storage, retrieval, and distribution of biological materials for research. Biopreserv. Biobank 10, 79&#x2013;161 (2012).</Citation></Reference><Reference><Citation>Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. &amp; Del Tredici, K. Staging of Alzheimer disease&#x2013;associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389&#x2013;404 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolos, M. et al. Absence of CX3CR1 impairs the internalization of tau by microglia. Mol. Neurodegener. 12, 59 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0200-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Martin, M. et al. Tau isoform with three microtubule binding domains is a marker of new axons generated from the subgranular zone in the hippocampal dentate gyrus: implications for Alzheimer&#x2019;s disease. J. Alzheimers Dis. 29, 921&#x2013;930 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-112057</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Martin, M. et al. Peripherally triggered and GSK-3&#x3b2;-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. Transl. Psychiatry 4, e463 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2014.92</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Fraile, A., Van Hecke, N., Gu&#xe9;rin, C. J. &amp; D&#x2019;Herde, K. Applications of immunocytochemistry. InTechOpen 1, 320 (2012).</Citation></Reference><Reference><Citation>Llorens-Martin, M., Torres-Aleman, I. &amp; Trejo, J. L. Pronounced individual variation in the response to the stimulatory action of exercise on immature hippocampal neurons. Hippocampus 16, 480&#x2013;490 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30911003</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.</ArticleTitle><Pagination><StartPage>1365</StartPage><MedlinePgn>1365</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1365</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-09118-9</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial surface receptor genetically linked to the risk for Alzheimer's disease (AD). A proteolytic product, soluble TREM2 (sTREM2), is abundant in the cerebrospinal fluid and its levels positively correlate with neuronal injury markers. To gain insights into the pathological roles of sTREM2, we studied sTREM2 in the brain of 5xFAD mice, a model of AD, by direct stereotaxic injection of recombinant sTREM2 protein or by adeno-associated virus (AAV)-mediated expression. We found that sTREM2 reduces amyloid plaque load and rescues functional deficits of spatial memory and long-term potentiation. Importantly, sTREM2 enhances microglial proliferation, migration, clustering in the vicinity of amyloid plaques and the uptake and degradation of A&#x3b2;. Depletion of microglia abolishes the neuroprotective effects of sTREM2. Our study demonstrates a protective role of sTREM2 against amyloid pathology and related toxicity and suggests that increasing sTREM2 can be explored for AD therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuo</LastName><ForeName>Rengong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Traditional Chinese Medicine, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shenzhen Research Institute of Xiamen University, Shenzhen, 518063, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ruizhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Daxin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Can</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marten</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinohara</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Traditional Chinese Medicine, School of Medicine, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Initiative, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA. bu.guojun@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao-Fen</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, 361102, China. chenxf@xmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shenzhen Research Institute of Xiamen University, Shenzhen, 518063, China. chenxf@xmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37AG027924</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056114</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG056114</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG035355</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056130</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG056130</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Commun. 2019 Jul 2;10(1):2923. doi: 10.1038/s41467-019-10950-2.</RefSource><PMID Version="1">31266955</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013238" MajorTopicYN="N">Stereotaxic Techniques</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30911003</ArticleId><ArticleId IdType="pmc">PMC6433910</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-09118-9</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-09118-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heneka MT, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405. doi: 10.1016/S1474-4422(15)70016-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci. Transl. Med. 2011;3:77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185. doi: 10.1126/science.1566067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SS, Jo SA. Mechanisms of amyloid-beta peptide clearance: potential therapeutic targets for Alzheimer&#x2019;s disease. Biomol.Ther. 2012;20:245&#x2013;255. doi: 10.4062/biomolther.2012.20.3.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2012.20.3.245</ArticleId><ArticleId IdType="pmc">PMC3794520</ArticleId><ArticleId IdType="pubmed">24130920</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 2010;117:949&#x2013;960. doi: 10.1007/s00702-010-0433-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-010-0433-4</ArticleId><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 1987;79:195&#x2013;200. doi: 10.1016/0304-3940(87)90696-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(87)90696-3</ArticleId><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter LS, Barron E, Chui HC. Morphologic association between microglia and senile plaque amyloid in Alzheimer&#x2019;s disease. Neurosci. Lett. 1990;119:32&#x2013;36. doi: 10.1016/0304-3940(90)90748-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(90)90748-X</ArticleId><ArticleId IdType="pubmed">2097581</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, et al. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol. 1999;154:1673&#x2013;1684. doi: 10.1016/S0002-9440(10)65423-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65423-5</ArticleId><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat. Commun. 2015;6:6176. doi: 10.1038/ncomms7176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7176</ArticleId><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724&#x2013;739. doi: 10.1016/j.neuron.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, et al. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am. J. Human Genet. 2008;83:623&#x2013;632. doi: 10.1016/j.ajhg.2008.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.10.008</ArticleId><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. New Engl. J. Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:429&#x2013;435. doi: 10.1038/ng.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, et al. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Human Mol. Genet. 2014;23:5838&#x2013;5846. doi: 10.1093/hmg/ddu277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu277</ArticleId><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. New Engl. J. Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 2017;49:1373&#x2013;1384. doi: 10.1038/ng.3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM. Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 2017;12:43. doi: 10.1186/s13024-017-0184-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0184-x</ArticleId><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid CD, et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J. Neurochem. 2002;83:1309&#x2013;1320. doi: 10.1046/j.1471-4159.2002.01243.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01243.x</ArticleId><ArticleId IdType="pmc">PMC2637869</ArticleId><ArticleId IdType="pubmed">12472885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, von Saucken VE, Landreth GE. TREM2 in neurodegenerative diseases. Mol. Neurodegener. 2017;12:56. doi: 10.1186/s13024-017-0197-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0197-5</ArticleId><ArticleId IdType="pmc">PMC5541421</ArticleId><ArticleId IdType="pubmed">28768545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YM, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071. doi: 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2) J. Biol. Chem. 2015;290:26043&#x2013;26050. doi: 10.1074/jbc.M115.679043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.679043</ArticleId><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J. Biol. Chem. 2015;290:26033&#x2013;26042. doi: 10.1074/jbc.M115.677286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.677286</ArticleId><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328&#x2013;340. doi: 10.1016/j.neuron.2016.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.06.015</ArticleId><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron. 2018;97:1023&#x2013;1031 e1027. doi: 10.1016/j.neuron.2018.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.01.031</ArticleId><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2) Mol. Neurodegener. 2018;13:15. doi: 10.1186/s13024-018-0247-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0247-7</ArticleId><ArticleId IdType="pmc">PMC5870375</ArticleId><ArticleId IdType="pubmed">29587871</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2018;13:66. doi: 10.1186/s13024-018-0298-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0298-9</ArticleId><ArticleId IdType="pmc">PMC6302500</ArticleId><ArticleId IdType="pubmed">30572908</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipello F, et al. The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. Immunity. 2018;48:979&#x2013;991 e978. doi: 10.1016/j.immuni.2018.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.04.016</ArticleId><ArticleId IdType="pubmed">29752066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, et al. TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell. 2017;170:649&#x2013;663 e613. doi: 10.1016/j.cell.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, et al. TREM2 promotes microglial survival by activating Wnt/beta-catenin pathway. J. Neurosci. 2017;37:1772&#x2013;1784. doi: 10.1523/JNEUROSCI.2459-16.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2459-16.2017</ArticleId><ArticleId IdType="pmc">PMC5320608</ArticleId><ArticleId IdType="pubmed">28077724</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. DAP12 stabilizes the C-terminal fragment of the triggering receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-inflammatory response. J. Biol. Chem. 2015;290:15866&#x2013;15877. doi: 10.1074/jbc.M115.645986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.645986</ArticleId><ArticleId IdType="pmc">PMC4505493</ArticleId><ArticleId IdType="pubmed">25957402</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2&#x2009;+&#x2009;inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med. 2015;212:287&#x2013;295. doi: 10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s Disease. J. Neurosci. 2017;37:637&#x2013;647. doi: 10.1523/JNEUROSCI.2110-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2110-16.2016</ArticleId><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerbach D, et al. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Neurosci. Lett. 2017;660:109&#x2013;114. doi: 10.1016/j.neulet.2017.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.09.034</ArticleId><ArticleId IdType="pubmed">28923481</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, et al. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. Embo Mol. Med. 2017;9:1356&#x2013;1365. doi: 10.15252/emmm.201707672.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707672</ArticleId><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton P, et al. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer&#x2019;s disease-associated H157Y variant. Embo Mol. Med. 2017;9:1366&#x2013;1378. doi: 10.15252/emmm.201707673.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707673</ArticleId><ArticleId IdType="pmc">PMC5623839</ArticleId><ArticleId IdType="pubmed">28855301</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. Embo Mol. Med. 2016;8:466&#x2013;476. doi: 10.15252/emmm.201506123.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201506123</ArticleId><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave A, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2016;11:3. doi: 10.1186/s13024-016-0071-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0071-x</ArticleId><ArticleId IdType="pmc">PMC4709982</ArticleId><ArticleId IdType="pubmed">26754172</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer&#x2019;s disease occur after amyloid deposition and neuronal injury. Sci. Transl. Med. 2016;8:369ra178. doi: 10.1126/scitranslmed.aag1767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aag1767</ArticleId><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925&#x2013;933. doi: 10.1007/s00401-016-1533-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1533-5</ArticleId><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med. 2018;215:745&#x2013;760. doi: 10.1084/jem.20171529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171529</ArticleId><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J. Exp. Med. 2017;214:597&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339672</ArticleId><ArticleId IdType="pubmed">28209725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer&#x2019;s disease. J. Cell Biol. 2018;217:459&#x2013;472. doi: 10.1083/jcb.201709069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201709069</ArticleId><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Ohsawa K, Kanazawa H, Kohsaka S, Imai Y. Iba1 is an actin-cross-linking protein in macrophages/microglia. Biochem. Biophys. Res. Commun. 2001;286:292&#x2013;297. doi: 10.1006/bbrc.2001.5388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2001.5388</ArticleId><ArticleId IdType="pubmed">11500035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J. Histochem. Cytochem. 2007;55:687&#x2013;700. doi: 10.1369/jhc.6A7156.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/jhc.6A7156.2007</ArticleId><ArticleId IdType="pubmed">17341475</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397. doi: 10.1016/j.neuron.2014.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, et al. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain. 2016;139:1265&#x2013;1281. doi: 10.1093/brain/aww016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosario AM, et al. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol. Ther. Methods Clin. Dev. 2016;3:16026. doi: 10.1038/mtm.2016.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2016.26</ArticleId><ArticleId IdType="pmc">PMC4909093</ArticleId><ArticleId IdType="pubmed">27308302</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, et al. Amyloid-beta42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J. Neurosci. Methods. 2011;196:51&#x2013;59. doi: 10.1016/j.jneumeth.2010.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2010.12.025</ArticleId><ArticleId IdType="pmc">PMC3049315</ArticleId><ArticleId IdType="pubmed">21219931</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Guo Z, Gearing M, Chen G. Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer&#x2019;s disease model. Nat. Commun. 2014;5:4159. doi: 10.1038/ncomms5159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5159</ArticleId><ArticleId IdType="pmc">PMC4159602</ArticleId><ArticleId IdType="pubmed">24923909</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease. Nat. Neurosci. 2005;8:977&#x2013;979. doi: 10.1038/nn0805-977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn0805-977</ArticleId><ArticleId IdType="pubmed">16047022</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15:84&#x2013;87. doi: 10.1111/j.1750-3639.2005.tb00104.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2005.tb00104.x</ArticleId><ArticleId IdType="pmc">PMC8095797</ArticleId><ArticleId IdType="pubmed">15779241</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz TM, Town T. Microglia in Alzheimer&#x2019;s disease: it&#x2019;s all about context. Int. J. Alzheimer&#x2019;s Dis. 2012;2012:314185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388286</ArticleId><ArticleId IdType="pubmed">22779026</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer&#x2019;s disease. Nat. Immunol. 2015;16:229&#x2013;236. doi: 10.1038/ni.3102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3102</ArticleId><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 2014;9:20. doi: 10.1186/1750-1326-9-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, et al. Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer&#x2019;s disease models. Neuron. 2018;97:1032&#x2013;1048 e1035. doi: 10.1016/j.neuron.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.002</ArticleId><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290 e1217. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581 e569. doi: 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;1609. doi: 10.1016/j.cell.2013.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.11.030</ArticleId><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci. 2005;25:3219&#x2013;3228. doi: 10.1523/JNEUROSCI.4486-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4486-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725093</ArticleId><ArticleId IdType="pubmed">15788779</ArticleId></ArticleIdList></Reference><Reference><Citation>Viviani B, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J. Neurosci. 2003;23:8692&#x2013;8700. doi: 10.1523/JNEUROSCI.23-25-08692.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-25-08692.2003</ArticleId><ArticleId IdType="pmc">PMC6740426</ArticleId><ArticleId IdType="pubmed">14507968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J. Neurosci. 2008;28:5189&#x2013;5194. doi: 10.1523/JNEUROSCI.3338-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3338-07.2008</ArticleId><ArticleId IdType="pmc">PMC2408767</ArticleId><ArticleId IdType="pubmed">18480275</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer&#x2019;s disease. Sci. Transl. Med. 2016;8:332ra344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512541</ArticleId><ArticleId IdType="pubmed">27030596</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 1998;4:447&#x2013;451. doi: 10.1038/nm0498-447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0498-447</ArticleId><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678. doi: 10.1038/nature11729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, et al. VPS35 haploinsufficiency increases Alzheimer&#x2019;s disease neuropathology. J. Cell Biol. 2011;195:765&#x2013;779. doi: 10.1083/jcb.201105109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201105109</ArticleId><ArticleId IdType="pmc">PMC3257571</ArticleId><ArticleId IdType="pubmed">22105352</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, Neugebauer V. mGluR1, but not mGluR5, activates feed-forward inhibition in the medial prefrontal cortex to impair decision making. J. Neurophysiol. 2011;106:960&#x2013;973. doi: 10.1152/jn.00762.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00762.2010</ArticleId><ArticleId IdType="pmc">PMC3154822</ArticleId><ArticleId IdType="pubmed">21613584</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30923235</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>17</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Reproductive period and risk of dementia in a diverse cohort of health care members.</ArticleTitle><Pagination><StartPage>e2005</StartPage><EndPage>e2014</EndPage><MedlinePgn>e2005-e2014</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000007326</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Women have &gt;50% greater lifetime risk of dementia than men but the role of female-specific endocrine milieu is not well-understood. This study evaluates associations between indicators of estrogen exposure from women's reproductive period and dementia risk in a large diverse population.</AbstractText><AbstractText Label="METHODS">We evaluated 15,754 female members (29.9% nonwhite) of Kaiser Permanente with clinical examinations and health survey data from 1964 to 1973 and were members as of January 1, 1996. In midlife (mean age 51.1 years), women reported age at menarche and menopause and hysterectomy status. Reproductive span was calculated as menopause age minus menarche age. Dementia diagnoses were abstracted from January 1, 1996 to September 30, 2017 medical records (mean age at start of dementia follow-up 76.5 years). Cox proportional hazard models evaluated associations between aspects of reproductive span and dementia risk adjusting for demographics and life course health indicators.</AbstractText><AbstractText Label="RESULTS">Forty-two percent of women developed dementia. Compared to menarche at age 13.0 (mean menarche age), menarche at &#x2265;16 was associated with 23% greater dementia risk (adjusted hazard ratio [HR] 1.23; 95% confidence interval [CI] 1.01-1.50) adjusting for demographics and life course health indicators. Natural menopause at age &lt;47.4 (mean menopause age) was associated with 19% elevated dementia risk (HR 1.19; 95% CI 1.07-1.31). Reproductive spans &lt;34.4 years (mean duration) were associated with 20% elevated dementia risk (HR 1.20; 95% CI 1.08-1.32). Hysterectomies were associated with 8% elevated dementia risk (HR 1.08; 95% CI 1.01-1.16).</AbstractText><AbstractText Label="CONCLUSION">In this large prospective cohort study, endocrine events signaling less estradiol exposure (i.e., later age at menarche, younger age at menopause, shorter reproductive span, and hysterectomies) were associated with elevated risk of dementia.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gilsanz</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From Kaiser Permanente Division of Research (P.G., C.L., C.P.Q., R.A.W.), Oakland; Departments of Neurology (M.M.C., C.H.K.), Epidemiology (M.M.C.), and Neurobiology and Behavior (C.H.K.), University of California, Irvine; Department of Public Health Sciences (R.A.W.), University of California, Davis; and Department of Epidemiology and Biostatistics (R.A.W.), University of California, San Francisco. Paola.Gilsanz@kp.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Kaiser Permanente Division of Research (P.G., C.L., C.P.Q., R.A.W.), Oakland; Departments of Neurology (M.M.C., C.H.K.), Epidemiology (M.M.C.), and Neurobiology and Behavior (C.H.K.), University of California, Irvine; Department of Public Health Sciences (R.A.W.), University of California, Davis; and Department of Epidemiology and Biostatistics (R.A.W.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrada</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>From Kaiser Permanente Division of Research (P.G., C.L., C.P.Q., R.A.W.), Oakland; Departments of Neurology (M.M.C., C.H.K.), Epidemiology (M.M.C.), and Neurobiology and Behavior (C.H.K.), University of California, Irvine; Department of Public Health Sciences (R.A.W.), University of California, Davis; and Department of Epidemiology and Biostatistics (R.A.W.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>From Kaiser Permanente Division of Research (P.G., C.L., C.P.Q., R.A.W.), Oakland; Departments of Neurology (M.M.C., C.H.K.), Epidemiology (M.M.C.), and Neurobiology and Behavior (C.H.K.), University of California, Irvine; Department of Public Health Sciences (R.A.W.), University of California, Davis; and Department of Epidemiology and Biostatistics (R.A.W.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quesenberry</LastName><ForeName>Charles P</ForeName><Initials>CP</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From Kaiser Permanente Division of Research (P.G., C.L., C.P.Q., R.A.W.), Oakland; Departments of Neurology (M.M.C., C.H.K.), Epidemiology (M.M.C.), and Neurobiology and Behavior (C.H.K.), University of California, Irvine; Department of Public Health Sciences (R.A.W.), University of California, Davis; and Department of Epidemiology and Biostatistics (R.A.W.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitmer</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From Kaiser Permanente Division of Research (P.G., C.L., C.P.Q., R.A.W.), Oakland; Departments of Neurology (M.M.C., C.H.K.), Epidemiology (M.M.C.), and Neurobiology and Behavior (C.H.K.), University of California, Irvine; Department of Public Health Sciences (R.A.W.), University of California, Davis; and Department of Epidemiology and Biostatistics (R.A.W.), University of California, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG052132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG049663</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008572" MajorTopicYN="N">Menarche</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008593" MajorTopicYN="N">Menopause</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012098" MajorTopicYN="N">Reproduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016387" MajorTopicYN="N">Women's Health</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30923235</ArticleId><ArticleId IdType="pmc">PMC6511081</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007326</ArticleId><ArticleId IdType="pii">WNL.0000000000007326</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chene G, Beiser A, Au R, et al. . Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement 2015;11:310&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4092061</ArticleId><ArticleId IdType="pubmed">24418058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 2009;30:239&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728624</ArticleId><ArticleId IdType="pubmed">19427328</ArticleId></ArticleIdList></Reference><Reference><Citation>Azcoitia I, Arevalo MA, De Nicola AF, Garcia-Segura LM. Neuroprotective actions of estradiol revisited. Trends Endocrinol Metab 2011;22:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">21889354</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakis MK, Kalogirou EI, Diamantaras AA, et al. . Age at menopause and duration of reproductive period in association with dementia and cognitive function: a systematic review and meta-analysis. Psychoneuroendocrinology 2016;73:224&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">27543884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong X, Zhang X, Li H. A case-control study of endogenous estrogen and risk of Alzheimer's disease [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2001;22:379&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">11769698</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings MI, Ruitenberg A, Witteman JC, et al. . Reproductive period and risk of dementia in postmenopausal women. JAMA 2001;285:1475&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255424</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince MJ, Acosta D, Guerra M, et al. . Reproductive period, endogenous estrogen exposure and dementia incidence among women in Latin America and China: a 10/66 population-based cohort study. PLoS One 2018;13:e0192889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831083</ArticleId><ArticleId IdType="pubmed">29489847</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox M, Berzuini C, Knapp LA. Cumulative estrogen exposure, number of menstrual cycles, and Alzheimer's risk in a cohort of British women. Psychoneuroendocrinology 2013;38:2973&#x2013;2982.</Citation><ArticleIdList><ArticleId IdType="pubmed">24064221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon NP. Similarity of the Kaiser Permanente Senior Member Population in Northern California to the Non-Kaiser Permanente Covered and General Population of Seniors in Northern California: Statistics from the 2009 California Health Interview Survey. Oakland: Kaiser Permanente Northern California Division of Research; 2012.</Citation></Reference><Reference><Citation>Collen MF. Multiphasic Health Testing Services. New York: John Wiley; 1978.</Citation></Reference><Reference><Citation>Friedman GD, Seltzer CC, Siegelaub AB, Feldman R, Collen MF. Smoking among white, black, and yellow men and women: Kaiser-Permanente multiphasic health examination data, 1964&#x2013;1968. Am J Epidemiol 1972;96:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">5039726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement 2016;12:216&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="pubmed">26874595</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008;71:1057&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367704</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilsanz P, Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Association between birth in a high stroke mortality state, race, and risk of dementia. JAMA Neurol 2017;74:1056&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5691590</ArticleId><ArticleId IdType="pubmed">28759663</ArticleId></ArticleIdList></Reference><Reference><Citation>Katon WJ, Lin EH, Williams LH, et al. . Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study. J Gen Intern Med 2010;25:423&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855007</ArticleId><ArticleId IdType="pubmed">20108126</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am 2011;38:425&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285482</ArticleId><ArticleId IdType="pubmed">21961711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove R, Secor E, Chibnik LB, et al. . Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014;82:222&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902759</ArticleId><ArticleId IdType="pubmed">24336141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasgon NL, Magnusson C, Johansson AL, Pedersen NL, Elman S, Gatz M. Endogenous and exogenous hormone exposure and risk of cognitive impairment in Swedish twins: a preliminary study. Psychoneuroendocrinology 2005;30:558&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808925</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Grossardt BR, Shuster LT, Stewart EA. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neurodegener Dis 2012;10:175&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3702015</ArticleId><ArticleId IdType="pubmed">22269187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Bower JH, Maraganore DM, et al. . Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761551</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Grossardt BR, Maraganore DM. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008;5:257&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768565</ArticleId><ArticleId IdType="pubmed">18322406</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson VW. Aging, estrogens, and episodic memory in women. Cogn Behav Neurol 2009;22:205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791907</ArticleId><ArticleId IdType="pubmed">19996872</ArticleId></ArticleIdList></Reference><Reference><Citation>WR A, QC P, Jufen Z, Kristine Y. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011;69:163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058824</ArticleId><ArticleId IdType="pubmed">21280086</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA, Group MS. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739309</ArticleId><ArticleId IdType="pubmed">15608005</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, Breitner JC, Whitmer RA, et al. . Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012;79:1846&#x2013;1852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525314</ArticleId><ArticleId IdType="pubmed">23100399</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M. Progesterone-induced neuroprotection. Endocrine 2006;29:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">16785602</ArticleId></ArticleIdList></Reference><Reference><Citation>Slanger T, Mutschelknauss E, Kropp S, Braendle W, Flesch-Janys D, Chang-Claude J. Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy. Ann Epidemiol 2007;17:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord C, Duchesne A, Pruessner JC, Lupien SJ. Measuring indices of lifelong estrogen exposure: self-report reliability. Climacteric 2009;12:387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">19142763</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 2001;54:902&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas R, Azevedo A, Barros H. Self-reported data on reproductive variables were reliable among postmenopausal women. J Clin Epidemiol 2008;61:945&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">18468857</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokras R, Hufnagel VG. Hysterectomy in the United States, 1965&#x2013;84. Am J Public Health 1988;78:852&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1350353</ArticleId><ArticleId IdType="pubmed">3381968</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30918111</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>485</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>27</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaat3005</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aat3005</ELocationID><Abstract><AbstractText>Tau inclusions are a shared feature of many neurodegenerative diseases, among them frontotemporal dementia caused by tau mutations. Treatment approaches for these conditions include targeting posttranslational modifications of tau proteins, maintaining a steady-state amount of tau, and preventing its tendency to aggregate. We discovered a new regulatory pathway for tau degradation that operates through the farnesylated protein, Rhes, a GTPase in the Ras family. Here, we show that treatment with the farnesyltransferase inhibitor lonafarnib reduced Rhes and decreased brain atrophy, tau inclusions, tau sumoylation, and tau ubiquitination in the rTg4510 mouse model of tauopathy. In addition, lonafarnib treatment attenuated behavioral abnormalities in rTg4510 mice and reduced microgliosis in mouse brain. Direct reduction of Rhes in the rTg4510 mouse by siRNA reproduced the results observed with lonafarnib treatment. The mechanism of lonafarnib action mediated by Rhes to reduce tau pathology was shown to operate through activation of lysosomes. We finally showed in mouse brain and in human induced pluripotent stem cell-derived neurons a normal developmental increase in Rhes that was initially suppressed by tau mutations. The known safety of lonafarnib revealed in human clinical trials for cancer suggests that this drug could be repurposed for treating tauopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Israel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0776-317X</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Jennifer N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Surya A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-0119-6730</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Chemical Neurobiology Lab, and Center for Genomic Medicine, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giroux</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4800-592X</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6854-5547</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boctor</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibih</LastName><ForeName>Youssef E</ForeName><Initials>YE</Initials><Identifier Source="ORCID">0000-0002-0839-5428</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Storm</LastName><ForeName>Nadia J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology and Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology and Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaushik</LastName><ForeName>Susmita</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6096-5387</Identifier><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology and Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zekanowski</LastName><ForeName>Cezary</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego St., 02-106 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Alexander A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-1831-0886</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinman</LastName><ForeName>Cassidy R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerovac</LastName><ForeName>Vesna</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5002-1251</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Elmer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Honjun</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8873-293X</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-7872-168X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Chemical Neurobiology Lab, and Center for Genomic Medicine, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Steven K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuervo</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology and Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0003-3224-5179</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA. kenneth.kosik@lifesci.ucsb.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054008</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG021904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG046374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056058</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054108</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG031782</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.5.1.29</RegistryNumber><NameOfSubstance UI="D051231">Farnesyltranstransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C488189">Rasd2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>IOW153004F</RegistryNumber><NameOfSubstance UI="C115354">lonafarnib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051231" MajorTopicYN="N">Farnesyltranstransferase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057170" MajorTopicYN="N">Translational Research, Biomedical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><u><b>Competing financial interests:</b></u> K.S.K. consults for ADRx (Thousand Oaks, CA, U.S.A.), A.M.C. is cofounder of Selphagy (Boston, MA, U.S.A.)</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30918111</ArticleId><ArticleId IdType="mid">NIHMS1671313</ArticleId><ArticleId IdType="pmc">PMC7961212</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aat3005</ArticleId><ArticleId IdType="pii">11/485/eaat3005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Onyike CU, Diehl-Schmid J, The epidemiology of frontotemporal dementia., Int. Rev. Psychiatry Abingdon Engl 25, 130&#x2013;137 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932112</ArticleId><ArticleId IdType="pubmed">23611343</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Ittner A, Ittner LM, Tau-targeted treatment strategies in Alzheimer&#x2019;s disease., Br. J. Pharmacol 165, 1246&#x2013;1259 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372713</ArticleId><ArticleId IdType="pubmed">22044248</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA, Kordasiewicz HB, Swayze EE, Bennett CF, Diamond MI, Miller TM, Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy., Sci. Transl. Med 9, eaag0481 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead E, Kestoras D, Gibson Y, Hamilton L, Goodson R, Jones S, Eversden S, Davies P, O&#x2019;Neill M, Hutton M, Szekeres P, Wolak J, Halting of Caspase Activity Protects Tau from MC1-Conformational Change and Aggregation, J. Alzheimers Dis. JAD 54, 1521&#x2013;1538 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088409</ArticleId><ArticleId IdType="pubmed">27589517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgr&#xe4;fe K, Sydow A, Matenia D, Cadinu D, K&#xf6;nen S, Petrova O, Pickhardt M, Goll P, Morellini F, Mandelkow E, Mandelkow E-M, Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau., Acta Neuropathol. Commun 3, 25 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425867</ArticleId><ArticleId IdType="pubmed">25958115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Hernandez I, Rei D, Mair W, Laha JK, Cornwell ME, Cuny GD, Tsai L-H, Steen JAJ, Kosik KS, Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models., J. Biol. Chem 288, 22042&#x2013;22056 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724657</ArticleId><ArticleId IdType="pubmed">23737518</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S-W, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA, Sohn PD, Schilling B, Cong X, Ellerby L, Gibson BW, Johnson J, Krogan N, Shamloo M, Gestwicki J, Masliah E, Verdin E, Gan L, Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits., Nat. Med 21, 1154&#x2013;1162 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero B, Wang Y, Diaz A, Tasset I, Juste YR, Stiller B, Mandelkow E-M, Mandelkow E, Cuervo AM, Interplay of pathogenic forms of human tau with different autophagic pathways, Aging Cell 17 (2018), doi:10.1111/acel.12692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12692</ArticleId><ArticleId IdType="pmc">PMC5770880</ArticleId><ArticleId IdType="pubmed">29024336</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, The role of autophagy in neurodegenerative disease, Nat. Med 19, 983&#x2013;997 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Srinivasan K, Friedman BA, Suto E, Modrusan Z, Lee WP, Kaminker JS, Hansen DV, Sheng M, Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation, J. Exp. Med 214, 2611&#x2013;2628 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584112</ArticleId><ArticleId IdType="pubmed">28778989</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MP, Boutin M, Tse TE, Lu H, Haley ED, Ouyang X, Zhang J, Auray-Blais C, Shacka JJ, The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson&#x2019;s disease brain in association with the pathologic accumulation of alpha-synuclein, Neurobiol. Dis 110, 68&#x2013;81 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747987</ArticleId><ArticleId IdType="pubmed">29196214</ArticleId></ArticleIdList></Reference><Reference><Citation>Colicelli J, Human RAS superfamily proteins and related GTPases, Sci. STKE Signal Transduct. Knowl. Environ 2004, RE13 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828947</ArticleId><ArticleId IdType="pubmed">15367757</ArticleId></ArticleIdList></Reference><Reference><Citation>Spano D, Branchi I, Rosica A, Pirro MT, Riccio A, Mithbaokar P, Affuso A, Arra C, Campolongo P, Terracciano D, Macchia V, Bernal J, Alleva E, Di Lauro R, Rhes is involved in striatal function., Mol. Cell. Biol 24, 5788&#x2013;5796 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC480889</ArticleId><ArticleId IdType="pubmed">15199135</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitucci D, Di Giorgio A, Napolitano F, Pelosi B, Blasi G, Errico F, Attrotto MT, Gelao B, Fazio L, Taurisano P, Di Maio A, Marsili V, Pasqualetti M, Bertolino A, Usiello A, Rasd2 Modulates Prefronto-Striatal Phenotypes in Humans and &#x201c;Schizophrenia-Like Behaviors&#x201d; in Mice., Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol 41, 916&#x2013;927 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707838</ArticleId><ArticleId IdType="pubmed">26228524</ArticleId></ArticleIdList></Reference><Reference><Citation>Mealer RG, Murray AJ, Shahani N, Subramaniam S, Snyder SH, Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy., J. Biol. Chem 289, 3547&#x2013;3554 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916556</ArticleId><ArticleId IdType="pubmed">24324270</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam S, Sixt KM, Barrow R, Snyder SH, Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity, Science 324, 1327&#x2013;1330 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745286</ArticleId><ArticleId IdType="pubmed">19498170</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Song E, Cheng C, Lee M-H, Yeung S-CJ, Farnesyltransferase inhibitors-induced autophagy: alternative mechanisms?, Autophagy 5, 129&#x2013;131 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19066466</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon LB, Massaro J, D&#x2019;Agostino RB, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW, Progeria Clinical Trials Collaborative, Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome., Circulation 130, 27&#x2013;34 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4082404</ArticleId><ArticleId IdType="pubmed">24795390</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE, Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 25, 3137&#x2013;3143 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17634493</ArticleId></ArticleIdList></Reference><Reference><Citation>Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WKA, Gilbert MR, Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma., Cancer 119, 2747&#x2013;2753 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001735</ArticleId><ArticleId IdType="pubmed">23633392</ArticleId></ArticleIdList></Reference><Reference><Citation>Desjardins A, Reardon DA, Peters KB, Threatt S, Coan AD, Herndon JE, Friedman AH, Friedman HS, Vredenburgh JJ, A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma., J. Neurooncol 105, 601&#x2013;606 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21735117</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH, Tau suppression in a neurodegenerative mouse model improves memory function., Science 309, 476&#x2013;481 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA, Pathological tau disrupts ongoing network activity, Neuron 85, 959&#x2013;966 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Crimins JL, Rocher AB, Luebke JI, Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy, Acta Neuropathol. (Berl.) 124, 777&#x2013;795 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509230</ArticleId><ArticleId IdType="pubmed">22976049</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Taylor SA, Marrinan CH, Hsieh Y, Bishop WR, Kirschmeier P, Long BJ, Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models, Int. J. Cancer 125, 2711&#x2013;2720 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19530253</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RMJ, Digging and marble burying in mice: simple methods for in vivo identification of biological impacts., Nat. Protoc 1, 122&#x2013;124 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406223</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RMJ, Assessing nest building in mice., Nat. Protoc 1, 1117&#x2013;1119 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel D, Dorith Shafry D, Gordon LB, Djabali K, Intermittent treatment with Farnesyltransferase inhibitor and Sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts, Oncotarget (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630293</ArticleId><ArticleId IdType="pubmed">29029393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtkowiak JW, Sane KM, Kleinman M, Sloane BF, Reiners JJ, Mattingly RR, Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin., J. Pharmacol. Exp. Ther 337, 65&#x2013;74 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063739</ArticleId><ArticleId IdType="pubmed">21228063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S, Noda T, Yoshimori T, Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3., Autophagy 3, 452&#x2013;460 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17534139</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga H, Martinez-Vicente M, Macian F, Verkhusha VV, Cuervo AM, A photoconvertible fluorescent reporter to track chaperone-mediated autophagy., Nat. Commun 2, 386 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529934</ArticleId><ArticleId IdType="pubmed">21750540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, Follenzi A, Potolicchio I, Nieves E, Cuervo AM, Santambrogio L, Microautophagy of cytosolic proteins by late endosomes., Dev. Cell 20, 131&#x2013;139 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025279</ArticleId><ArticleId IdType="pubmed">21238931</ArticleId></ArticleIdList></Reference><Reference><Citation>Greussing R, Unterluggauer H, Koziel R, Maier AB, Jansen-D&#xfc;rr P, Monitoring of ubiquitin-proteasome activity in living cells using a Degron (dgn)-destabilized green fluorescent protein (GFP)-based reporter protein., J. Vis. Exp. JoVE, e3327&#x2013;e3327 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3520582</ArticleId><ArticleId IdType="pubmed">23169445</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H-B, Xia Y-Y, Shu X-J, Liu Z-C, Feng Y, Liu X-H, Yu G, Yin G, Xiong Y-S, Zeng K, Jiang J, Ye K, Wang X-C, Wang J-Z, SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination, Proc. Natl. Acad. Sci. U. S. A 111, 16586&#x2013;16591 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246270</ArticleId><ArticleId IdType="pubmed">25378699</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam S, Mealer RG, Sixt KM, Barrow RK, Usiello A, Snyder SH, Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9., J. Biol. Chem 285, 20428&#x2013;20432 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898300</ArticleId><ArticleId IdType="pubmed">20424159</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M, CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation., Hum. Mol. Genet 13, 703&#x2013;714 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargiu P, De Abajo R, Garcia-Ranea JA, Valencia A, Santisteban P, Crespo P, Bernal J, The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors., Oncogene 23, 559&#x2013;568 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14724584</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M, Tau pathology and neurodegeneration., Lancet Neurol 12, 609&#x2013;622 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A, Lapointe NE, Zielke K, Berdynski M, Guzman E, Barczak A, M. Chodakowska-\.Zebrowska, Barcikowska M, Feinstein S, Zekanowski C, A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function., PloS One 8, e76409 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785453</ArticleId><ArticleId IdType="pubmed">24086739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P, Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17., Nature 393, 702&#x2013;705 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Smith MJ, Goedert M, Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly., FEBS Lett 437, 207&#x2013;210 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9824291</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung G-YR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R, Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS., Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Wong WH, A bootstrap-based non-parametric ANOVA method with applications to factorial microarray data, Stat. Sin 21, 495 (2011).</Citation></Reference><Reference><Citation>Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M, Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy., Brain J. Neurol 135, 2169&#x2013;2177 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381726</ArticleId><ArticleId IdType="pubmed">22689910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez A, Lee SE, Wojta K, Ramos EM, Klein E, Chen J, Boxer AL, Gorno-Tempini ML, Geschwind DH, Schlotawa L, Ogryzko NV, Bigio EH, Rogalski E, Weintraub S, Mesulam MM, Tauopathy Genetics Consortium A. Fleming, Coppola G, Miller BL, Rubinsztein DC, A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction., Brain J. Neurol 140, 1128&#x2013;1146 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382950</ArticleId><ArticleId IdType="pubmed">28334843</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS, The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule., J. Neurosci. Off. J. Soc. Neurosci 29, 2151&#x2013;2161 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768429</ArticleId><ArticleId IdType="pubmed">19228967</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitoh H, Hinchey J, Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3., J. Biol. Chem 275, 6252&#x2013;6258 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10692421</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Miyake S, Wakita H, McMullen DC, Azuma Y, Auh S, Hallenbeck JM, Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells., J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab 27, 950&#x2013;962 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396349</ArticleId><ArticleId IdType="pubmed">16955077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurepa J, Walker JM, Smalle J, Gosink MM, Davis SJ, Durham TL, Sung D-Y, Vierstra RD, The small ubiquitin-like modifier (SUMO) protein modification system in Arabidopsis. Accumulation of SUMO1 and &#x2212;2 conjugates is increased by stress., J. Biol. Chem 278, 6862&#x2013;6872 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12482876</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang J, Wang Y, Kim H-S, Lalli MA, Kosik KS, Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells, Stem Cells Dayt. Ohio 32, 2616&#x2013;2625 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165656</ArticleId><ArticleId IdType="pubmed">24895273</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto RI, Cuervo AM, Proteostasis and the aging proteome in health and disease, J. Gerontol. A. Biol. Sci. Med. Sci 69 Suppl 1, S33&#x2013;38 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022129</ArticleId><ArticleId IdType="pubmed">24833584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Tecedor L, Chen YH, Monteys AM, Sowada MJ, Thompson LM, Davidson BL, Reinstating aberrant mTORC1 activity in Huntington&#x2019;s disease mice improves disease phenotypes., Neuron 85, 303&#x2013;315 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355620</ArticleId><ArticleId IdType="pubmed">25556834</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA, Selective deficits in the expression of striatal-enriched mRNAs in Huntington&#x2019;s disease., J. Neurochem 96, 743&#x2013;757 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16405510</ArticleId></ArticleIdList></Reference><Reference><Citation>Seredenina T, Gokce O, Luthi-Carter R, Decreased striatal RGS2 expression is neuroprotective in Huntington&#x2019;s disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation., PloS One 6, e22231 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136499</ArticleId><ArticleId IdType="pubmed">21779398</ArticleId></ArticleIdList></Reference><Reference><Citation>Prahlad V, Morimoto RI, Integrating the stress response: lessons for neurodegenerative diseases from C. elegans, Trends Cell Biol 19, 52&#x2013;61 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4843516</ArticleId><ArticleId IdType="pubmed">19112021</ArticleId></ArticleIdList></Reference><Reference><Citation>Voisine C, Pedersen JS, Morimoto RI, Chaperone networks: tipping the balance in protein folding diseases, Neurobiol. Dis 40, 12&#x2013;20 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3429345</ArticleId><ArticleId IdType="pubmed">20472062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL, TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions., Genome Biol 14, R36 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053844</ArticleId><ArticleId IdType="pubmed">23618408</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup, The Sequence Alignment/Map format and SAMtools., Bioinforma. Oxf. Engl 25, 2078&#x2013;2079 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruitt KD, Harrow J, Harte RA, Wallin C, Diekhans M, Maglott DR, Searle S, Farrell CM, Loveland JE, Ruef BJ, Hart E, Suner M-M, Landrum MJ, Aken B, Ayling S, Baertsch R, Fernandez-Banet J, Cherry JL, Curwen V, Dicuccio M, Kellis M, Lee J, Lin MF, Schuster M, Shkeda A, Amid C, Brown G, Dukhanina O, Frankish A, Hart J, Maidak BL, Mudge J, Murphy MR, Murphy T, Rajan J, Rajput B, Riddick LD, Snow C, Steward C, Webb D, Weber JA, Wilming L, Wu W, Birney E, Haussler D, Hubbard T, Ostell J, Durbin R, Lipman D, The consensus coding sequence (CCDS) project: Identifying a common protein-coding gene set for the human and mouse genomes., Genome Res 19, 1316&#x2013;1323 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704439</ArticleId><ArticleId IdType="pubmed">19498102</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data., Bioinforma. Oxf. Engl 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Chen Y, Smyth GK, Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation., Nucleic Acids Res 40, 4288&#x2013;4297 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378882</ArticleId><ArticleId IdType="pubmed">22287627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK, limma powers differential expression analyses for RNA-sequencing and microarray studies., Nucleic Acids Res 43, e47&#x2013;e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna G, Kjellstrom S, Verardo MR, Lewis GP, Byun J, Sieving PA, Fisher SK, The effects of transient retinal detachment on cavity size and glial and neural remodeling in a mouse model of X-linked retinoschisis, Invest. Ophthalmol. Vis. Sci 50, 3977&#x2013;3984 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735860</ArticleId><ArticleId IdType="pubmed">19387072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvilekval K, Fedorov D, Obara B, Singh A, Manjunath BS, Bisque: a platform for bioimage analysis and management., Bioinforma. Oxf. Engl 26, 544&#x2013;552 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20031971</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A, Fiji: an open-source platform for biological-image analysis., Nat. Methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Arganda-Carreras I, Kaynig V, Rueden C, Eliceiri KW, Schindelin J, Cardona A, Seung HS, Trainable Weka Segmentation: a machine learning tool for microscopy pixel classification., Bioinforma. Oxf. Engl (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28369169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik S, Cuervo AM, Methods to monitor chaperone-mediated autophagy., Methods Enzymol 452, 297&#x2013;324 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300957</ArticleId><ArticleId IdType="pubmed">19200890</ArticleId></ArticleIdList></Reference><Reference><Citation>Auteri JS, Okada A, Bochaki V, Dice JF, Regulation of intracellular protein degradation in IMR-90 human diploid fibroblasts., J. Cell. Physiol 115, 167&#x2013;174 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6341382</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano F, Booth Warren E, Migliarini S, Punzo D, Errico F, Li Q, Thiolat M-L, Vescovi AL, Calabresi P, Bezard E, Morelli M, Konradi C, Pasqualetti M, Usiello A, Decreased Rhes mRNA levels in the brain of patients with Parkinson&#x2019;s disease and MPTP-treated macaques, PloS One 12, e0181677 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526584</ArticleId><ArticleId IdType="pubmed">28742811</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30936558</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Senolytic therapy alleviates A&#x3b2;-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model.</ArticleTitle><Pagination><StartPage>719</StartPage><EndPage>728</EndPage><MedlinePgn>719-728</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0372-9</ELocationID><Abstract><AbstractText>Neuritic plaques, a pathological hallmark in Alzheimer's disease (AD) brains, comprise extracellular aggregates of amyloid-beta (A&#x3b2;) peptide and degenerating neurites that accumulate autolysosomes. We found that, in the brains of patients with AD and in AD mouse models, A&#x3b2; plaque-associated Olig2- and NG2-expressing oligodendrocyte progenitor cells (OPCs), but not astrocytes, microglia, or oligodendrocytes, exhibit a senescence-like phenotype characterized by the upregulation of p21/CDKN1A, p16/INK4/CDKN2A proteins, and senescence-associated &#x3b2;-galactosidase activity. Molecular interrogation of the A&#x3b2; plaque environment revealed elevated levels of transcripts encoding proteins involved in OPC function, replicative senescence, and inflammation. Direct exposure of cultured OPCs to aggregating A&#x3b2; triggered cell senescence. Senolytic treatment of AD mice selectively removed senescent cells from the plaque environment, reduced neuroinflammation, lessened A&#x3b2; load, and ameliorated cognitive deficits. Our findings suggest a role for A&#x3b2;-induced OPC cell senescence in neuroinflammation and cognitive deficits in AD, and a potential therapeutic benefit of senolytic treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Peisu</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2719-4143</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA. zhangpei@mail.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishimoto</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grammatikakis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottimukkala</LastName><ForeName>Kamalvishnu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Investigation, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutler</LastName><ForeName>Roy G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shiliang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Electron Microscopy Core, National Institute on Drug Abuse Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelmohsen</LastName><ForeName>Kotb</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohr</LastName><ForeName>Vilhelm A</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0003-4823-6429</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Gerontology, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misra Sen</LastName><ForeName>Jyoti</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Investigation, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Program, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorospe</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattson</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-9816-4155</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD, USA. mark.mattson@nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. mark.mattson@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9IKM0I5T1E</RegistryNumber><NameOfSubstance UI="D011794">Quercetin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RBZ1571X5H</RegistryNumber><NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2019 May;22(5):683-684. doi: 10.1038/s41593-019-0395-2.</RefSource><PMID Version="1">31024116</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016922" MajorTopicYN="Y">Cellular Senescence</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073637" MajorTopicYN="N">Oligodendrocyte Precursor Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011794" MajorTopicYN="N">Quercetin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30936558</ArticleId><ArticleId IdType="mid">NIHMS1031989</ArticleId><ArticleId IdType="pmc">PMC6605052</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0372-9</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0372-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wyss-Coray T Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med 12, 1005&#x2013;1015 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA The role of autophagy in neurodegenerative disease. Nat. Med 19, 983&#x2013;997 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P et al. Alzheimer&#x2019;s disease. Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm TM, Jay TR &amp; Landreth GE The evolving biology of microglia in Alzheimer&#x2019;s disease. Neurotherapeutics 12, 81&#x2013;93 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322081</ArticleId><ArticleId IdType="pubmed">25404051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz-Esp&#xed;n D &amp; Serrano M Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol 15, 482&#x2013;496 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24954210</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodier F &amp; Campisi J Four faces of cellular senescence. J. Cell Biol. 192, 547&#x2013;556 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044123</ArticleId><ArticleId IdType="pubmed">21321098</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232&#x2013;236 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468323</ArticleId><ArticleId IdType="pubmed">22048312</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ et al. Naturally occurringp16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184&#x2013;189 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845101</ArticleId><ArticleId IdType="pubmed">26840489</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs BG et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472&#x2013;477 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112585</ArticleId><ArticleId IdType="pubmed">27789842</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nawt. Med 24, 1246&#x2013;1256 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6082705</ArticleId><ArticleId IdType="pubmed">29988130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussian TJ et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578&#x2013;582 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="pubmed">30232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Musi N et al. Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell 17, e12840 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260915</ArticleId><ArticleId IdType="pubmed">30126037</ArticleId></ArticleIdList></Reference><Reference><Citation>Geha S et al. NG2+/Olig2+ cells are the major cycle-related cell population of the adult human normal brain. Brain Pathol. 20, 399&#x2013;411 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094800</ArticleId><ArticleId IdType="pubmed">19486010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SH, Fukaya M, Yang JK, Rothstein JD &amp; Bergles DE NG2+CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron 68, 668&#x2013;681 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989827</ArticleId><ArticleId IdType="pubmed">21092857</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemente D, Ortega MC, Melero-Jerez C &amp; de Castro F The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases. Front. Cell. Neurosci 7, 268 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868919</ArticleId><ArticleId IdType="pubmed">24391545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings AR &amp; Carroll WM Oligodendrocyte lineage cells in chronic demyelination of multiple sclerosis optic nerve. Brain Pathol. 25, 517&#x2013;530 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028859</ArticleId><ArticleId IdType="pubmed">25175564</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimri GP et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363&#x2013;9367 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40985</ArticleId><ArticleId IdType="pubmed">7568133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz DJ, Decary S, Hong Y &amp; Erusalimsky JD Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Sci. 113, 3613&#x2013;3622 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11017877</ArticleId></ArticleIdList></Reference><Reference><Citation>Debacq-Chainiaux F, Erusalimsky JD, Campisi J &amp; Toussaint O Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc 4, 1798&#x2013;1806 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20010931</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939&#x2013;945 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Piechota M et al. Is senescence-associated &#x3b2;-galactosidase a marker of neuronal senescence? Oncotarget 7, 81099&#x2013;81109 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5348379</ArticleId><ArticleId IdType="pubmed">27768595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan X et al. Myelin basic protein associates with A&#x3b2;PP, A&#x3b2;1&#x2013;42, and amyloid plaques in cortex of Alzheimer&#x2019;s disease brain. J. Alzheimers Dis 44, 1213&#x2013;1229 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4422390</ArticleId><ArticleId IdType="pubmed">25697841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P et al. Generation and characterization of spiking and nonspiking oligodendroglial progenitor cells from embryonic stem cells. Stem Cells 31, 2620&#x2013;2631 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923867</ArticleId><ArticleId IdType="pubmed">23940003</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer DH et al. Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2. Nat Rev. Neurosci 13, 819&#x2013;831 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733228</ArticleId><ArticleId IdType="pubmed">23165259</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A &amp; Grutzendler J Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun 6, 6176 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer&#x2019;s disease amyloid plaques. Proc. Natl Acad. Sci. USA 112, E3699&#x2013;E3708 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507205</ArticleId><ArticleId IdType="pubmed">26124111</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrachina M, Maes T, Buesa C &amp; Ferrer I Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer&#x2019;s disease. Neuropathol. Appl. Neurobiol 32, 505&#x2013;516 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16972884</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol 64, 113&#x2013;122 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y et al. The Achilles&#x2019; heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644&#x2013;658 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531078</ArticleId><ArticleId IdType="pubmed">25754370</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr JN et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat. Med 23, 1072&#x2013;1079 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657592</ArticleId><ArticleId IdType="pubmed">28825716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat R et al. Astrocyte senescence as a component of Alzheimer&#x2019;s disease. PLoS One 7, e45069 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3440417</ArticleId><ArticleId IdType="pubmed">22984612</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M &amp; Mackenzie IR Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol 8, 423&#x2013;434 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBrasseur NK, Tchkonia T &amp; Kirkland JL Cellular senescence and the biology of aging, disease, and frailty. Nestle Nutr. Inst. Workshop Ser 83, 11&#x2013;18 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780350</ArticleId><ArticleId IdType="pubmed">26485647</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ &amp; Petersen RC Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J. Clin. Invest 128, 1208&#x2013;1216 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873891</ArticleId><ArticleId IdType="pubmed">29457783</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann B &amp; Kazanis I Oligodendrocyte progenitor cells: the ever mitotic cells of the CNS. Front. Biosci. (Schol. Ed.) 8, 29&#x2013;43 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26709894</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Chopp M &amp; Zhang ZG Oligodendrogenesis after cerebral ischemia. Front Cell. Neurosci 7, 201 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810592</ArticleId><ArticleId IdType="pubmed">24194700</ArticleId></ArticleIdList></Reference><Reference><Citation>Antel JP et al. Immunology of oligodendrocyte precursor cells in vivo and in vitro.J. Neuroimmunol 10.1016/j.jneuroim.2018.03.006 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2018.03.006</ArticleId><ArticleId IdType="pubmed">29566973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinta SJ et al. Cellular senescence is induced by the environmental neurotoxin paraquat and contributes to neuropathology linked to Parkinson&#x2019;s disease. Cell Rep. 22, 930&#x2013;940 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806534</ArticleId><ArticleId IdType="pubmed">29386135</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP Pathways towards and away from Alzheimer&#x2019;s disease. Nature 430, 631&#x2013;639 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW &amp; Stevens B Microglia emerge as central players in brain disease. Nat. Med 23, 1018&#x2013;1027 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LL et al. Pharmacokinetic comparison between quercetin and quercetin 3-O-&#x3b2;-glucuronide in rats by UHPLC-MS/MS. Sci. Rep 6, 35460 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075792</ArticleId><ArticleId IdType="pubmed">27775094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S et al. Dopaminergic and glutamatergic microdomains in a subset of rodent mesoaccumbens axons. Nat. Neurosci 18, 386&#x2013;392 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340758</ArticleId><ArticleId IdType="pubmed">25664911</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P et al. Novel RNA- and FMRP-binding protein TRF2-S regulates axonal mRNA transport and presynaptic plasticity. Nat. Commun 6, 8888 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673492</ArticleId><ArticleId IdType="pubmed">26586091</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB Jr., Dahlgren KN, Krafft GA &amp; LaDu MJ In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis./. Biol. Chem 278, 11612&#x2013;11622 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Faucher P, Mons N, Micheau J, Louis C &amp; Beracochea DJ Hippocampal injections of oligomeric amyloid &#x3b2;-peptide (1&#x2013;42) induce selective working memory deficits and long-lasting alterations of ERK signaling pathway. Front. Aging Neurosci 7, 245 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707555</ArticleId><ArticleId IdType="pubmed">26793098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashiwaya Y et al. A ketone ester diet exhibits anxiolytic and cognition- sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer&#x2019;s disease. Neurobiol. Aging 34, 1530&#x2013;1539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619192</ArticleId><ArticleId IdType="pubmed">23276384</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykora P et al. DNA polymerase &#x3b2; deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes. Nucleic Acids Res. 43, 943&#x2013;959 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333403</ArticleId><ArticleId IdType="pubmed">25552414</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30944478</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>568</Volume><Issue>7751</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>CD22 blockade restores homeostatic microglial phagocytosis in ageing brains.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>192</EndPage><MedlinePgn>187-192</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1088-4</ELocationID><Abstract><AbstractText>Microglia maintain homeostasis in the central nervous system through phagocytic clearance of protein aggregates and cellular debris. This function deteriorates during ageing and neurodegenerative disease, concomitant with cognitive decline. However, the mechanisms of impaired microglial homeostatic function and the cognitive effects of restoring this function remain unknown. We combined CRISPR-Cas9 knockout screens with RNA&#xa0;sequencing analysis to discover age-related genetic modifiers of microglial phagocytosis. These screens identified CD22, a canonical B&#xa0;cell receptor, as a negative regulator of phagocytosis that is upregulated on aged microglia. CD22 mediates the anti-phagocytic effect of &#x3b1;2,6-linked sialic acid, and inhibition of CD22 promotes the clearance of myelin debris, amyloid-&#x3b2; oligomers and &#x3b1;-synuclein fibrils in vivo. Long-term central nervous system delivery of an antibody that blocks CD22 function reprograms microglia towards a homeostatic transcriptional state and improves cognitive function in aged mice. These findings elucidate a mechanism of age-related microglial impairment and a strategy to restore homeostasis in the ageing brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pluvinage</LastName><ForeName>John V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stem Cell Biology and Regenerative Medicine Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haney</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Benjamin A H</ForeName><Initials>BAH</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iram</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Liana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lulin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Davis P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgens</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuken</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Madeleine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Biomedical Informatics Research, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khatri</LastName><ForeName>Purvesh</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Biomedical Informatics Research, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertozzi</LastName><ForeName>Carolyn R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassik</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Administration Palo Alto Healthcare System, Palo Alto, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM059907</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007365</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD020141</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG000044</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG060638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM120007</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AG053015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA227942</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497867">CD22 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051918">Sialic Acid Binding Ig-like Lectin 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.-</RegistryNumber><NameOfSubstance UI="D000076987">CRISPR-Associated Protein 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>GZP2782OP0</RegistryNumber><NameOfSubstance UI="D019158">N-Acetylneuraminic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Front Immunol. 2019 Jun 06;10:1301. doi: 10.3389/fimmu.2019.01301.</RefSource><PMID Version="1">31244847</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076987" MajorTopicYN="N">CRISPR-Associated Protein 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019158" MajorTopicYN="N">N-Acetylneuraminic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051918" MajorTopicYN="N">Sialic Acid Binding Ig-like Lectin 2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30944478</ArticleId><ArticleId IdType="mid">NIHMS1523028</ArticleId><ArticleId IdType="pmc">PMC6574119</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1088-4</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1088-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>F&#xfc;ger P et al. Microglia turnover with aging and in an Alzheimer&#x2019;s model via long-term in vivo single-cell imaging. Nat. Neurosci. 20, 1371&#x2013;1376 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28846081</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe9;u P et al. The lifespan and turnover of microglia in the human brain. Cell Reports 20, 779&#x2013;784 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5540680</ArticleId><ArticleId IdType="pubmed">28746864</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, &amp; Helmchen F Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Arandjelovic S, and Ravichandran KS Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol. 16, 907&#x2013;917 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826466</ArticleId><ArticleId IdType="pubmed">26287597</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456&#x2013;1458 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 165, 921&#x2013;935 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 19, 995&#x2013;998 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Amit I, &amp; Schwartz M Microglial immune checkpoint mechanisms. Nat. Neurosci. 21, 779&#x2013;786 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29735982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl JK et al. Homeostatic and injury-induced microglia behavior in the aging brain. Aging Cell 13, 60&#x2013;69 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326865</ArticleId><ArticleId IdType="pubmed">23953759</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan DW &amp; Peters A Neuroglial cells in the cerebral cortex of rats from young adulthood to old age: an electron microscope study. J Neurocytol. 3, 405&#x2013;429 (1974).</Citation><ArticleIdList><ArticleId IdType="pubmed">4373545</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M-&#xc8;, Zettel ML, Ison JR, Allen PD, &amp; Majewska AK Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices. Glia 60, 541&#x2013;558 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276747</ArticleId><ArticleId IdType="pubmed">22223464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Gottfried-Blackmore AC, McEwen BS, &amp; Bulloch K Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 55, 412&#x2013;424 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17203473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, &amp; Khoury, El J Microglial dysfunction and defective amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 28, 8354&#x2013;8360 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16, 1896&#x2013;1905 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci 19, 504&#x2013;516 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgens DW et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat. Commun. 8, 1&#x2013;8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5424143</ArticleId><ArticleId IdType="pubmed">28474669</ArticleId></ArticleIdList></Reference><Reference><Citation>Haney MS et al. Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens. Nat. Genet. 50, 1716&#x2013;1727 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6719718</ArticleId><ArticleId IdType="pubmed">30397336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, Bennett FC, &amp; Bennett ML Isolation and Culture of Microglia. Current Protocols in Immunology 339, e70&#x2013;21 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510657</ArticleId><ArticleId IdType="pubmed">30414379</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ et al. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron 94, 759&#x2013;773 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131&#x2013;143 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgens DW, Deans RM, Li A, &amp; Bassik MC Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nat. Biotechnol. 34, 634&#x2013;636 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900911</ArticleId><ArticleId IdType="pubmed">27159373</ArticleId></ArticleIdList></Reference><Reference><Citation>Macauley MS, Crocker PR, &amp; Paulson JC Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653&#x2013;666 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191907</ArticleId><ArticleId IdType="pubmed">25234143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitschke L, Carsetti R, Ocker B, K&#xf6;hler G &amp; Lamers MC CD22 is a negative regulator of B-cell receptor signalling. Curr. Biol. 7, 133&#x2013;143 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9016707</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y-Q, Sun L, &amp; Li J Macropinocytosis-dependent endocytosis of Japanese flounder IgM+ B cells and its regulation by CD22. Fish and Shellfish Immunology 84, 138&#x2013;147 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30266605</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnartz-Gerlach B, Kopatz J, &amp; Neumann H Siglec functions of microglia. Glycobiology 24, 794&#x2013;799 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24833613</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, et al. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631&#x2013;643 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML et al. (2016). New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci USA 113, E1738&#x2013;E1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA et al. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex. J Neurosci. 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller J et al. CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc. Natl. Acad. Sci. U.S.A. 110, 12402&#x2013;12407 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725054</ArticleId><ArticleId IdType="pubmed">23836650</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudak JE, Canham SM, &amp; Bertozzi CR Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat. Chem. Biol. 10, 69&#x2013;75 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893890</ArticleId><ArticleId IdType="pubmed">24292068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ere&#xf1;o-Orbea J et al. Molecular basis of human CD22 function and therapeutic targeting. Nature Communications 8, 764 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624926</ArticleId><ArticleId IdType="pubmed">28970495</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, &amp; LaDu MJ Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046&#x2013;32053 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, and Amit I Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell 173, 1073&#x2013;1081 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A et al. Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner. Nature Communications 8, 717 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5620041</ArticleId><ArticleId IdType="pubmed">28959042</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer&#x2019;s Disease Model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciniak E et al. The Chemokine MIP-1alpha/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci Rep 5, 15862 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625372</ArticleId><ArticleId IdType="pubmed">26511387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole AJ, Saffen DW, Baraban JM &amp; Worley PF Rapid increase of an immediate early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation. Nature 340, 474&#x2013;476 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2547165</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M, McFadden G &amp; Greenberg ME Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron 4, 571&#x2013;582 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2157471</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159, 1327&#x2013;1340 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364385</ArticleId><ArticleId IdType="pubmed">25480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312&#x2013;1326 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett FC et al. A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98, 1170&#x2013;1183.e8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023731</ArticleId><ArticleId IdType="pubmed">29861285</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q et al. Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron 101, 207&#x2013;223 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress BT et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 76, 845&#x2013;861 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245362</ArticleId><ArticleId IdType="pubmed">25204284</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM et al. CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 16, 848&#x2013;850 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui SS et al. The Alzheimer&#x2019;s disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool. J. Biol. Chem. 292, 15312&#x2013;15320 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602391</ArticleId><ArticleId IdType="pubmed">28747436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 6, 243ra86 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-L et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nat. Neurosci. 20, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Reports 22, 832&#x2013;847 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M et al. A single cell-based atlas of human microglial states reveals associations with neurological disorders and histopathological features of the aging brain. bioRxiv 343780 (2018).</Citation></Reference><Reference><Citation>Zhang Y, Sloan SA, et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nature Genetics 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Funikov SY et al. FUS(1&#x2013;359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy. Neurogenetics 19, 189&#x2013;204 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29982879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cougnoux A et al. Microglia activation in Niemann&#x2013;Pick disease, type C1 is amendable to therapeutic intervention. Hum. Mol. Genet. 27, 2076&#x2013;2089 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985727</ArticleId><ArticleId IdType="pubmed">29617956</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao H, Woods EC, Vukojicic P, &amp; Bertozzi CR Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Natl Acad Sci USA 113, 10304&#x2013;10309 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027407</ArticleId><ArticleId IdType="pubmed">27551071</ArticleId></ArticleIdList></Reference><Reference><Citation>Larocca JN &amp; Norton WT Isolation of myelin. Curr. Protoc. Cell Biol. Chapter 3, 25 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18228513</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jungbauer L, Yu C, &amp; LaDu MJ Preparing Synthetic A&#x3b2; in Different Aggregation States In Biological Microarrays, Khademhosseini A, Suh K-Y, and Zourob M, eds. (Totowa, NJ: Humana Press; ), pp. 13&#x2013;32 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Polinski NK et al. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson&#x2019;s Disease in Rodents. Journal of Parkinson&#x2019;s disease 8, 303&#x2013;322 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004926</ArticleId><ArticleId IdType="pubmed">29400668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Bauer B, Abner EL, Ashkenazy-Frolinger T, &amp; Hartz AMS A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice. PLoS ONE 11, e0147733&#x2013;23 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4726499</ArticleId><ArticleId IdType="pubmed">26808326</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature 544, 488&#x2013;492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586222</ArticleId><ArticleId IdType="pubmed">28424512</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30936556</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Molecularly defined cortical astroglia subpopulation modulates neurons via secretion of Norrin.</ArticleTitle><Pagination><StartPage>741</StartPage><EndPage>752</EndPage><MedlinePgn>741-752</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0366-7</ELocationID><Abstract><AbstractText>Despite expanding knowledge regarding the role of astroglia in regulating neuronal function, little is known about regional or functional subgroups of brain astroglia and how they may interact with neurons. We use an astroglia-specific promoter fragment in transgenic mice to identify an anatomically defined subset of adult gray matter astroglia. Using transcriptomic and histological analyses, we generate a combinatorial profile for the in vivo identification and characterization of this astroglia subpopulation. These astroglia are enriched in mouse cortical layer V; express distinct molecular markers, including Norrin and leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6), with corresponding layer-specific neuronal ligands; are found in the human cortex; and modulate neuronal activity. Astrocytic Norrin appears to regulate dendrites and spines; its loss, as occurring in Norrie disease, contributes to cortical dendritic spine loss. These studies provide evidence that human and rodent astroglia subtypes are regionally and functionally distinct, can regulate local neuronal dendrite and synaptic spine development, and contribute to disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Sean J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular &amp; Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philips</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Namho</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dastgheyb</LastName><ForeName>Raha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Richard T. Johnson Division of Neuroimmunology and Neurological Infections, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhuoxun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Yi-Chun</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daigle</LastName><ForeName>J Gavin</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Datta</LastName><ForeName>Malika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidensky</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Jacqueline T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular &amp; Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Ethan G</ForeName><Initials>EG</Initials><Identifier Source="ORCID">0000-0003-3243-7429</Identifier><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0003-0162-2218</Identifier><AffiliationInfo><Affiliation>Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattler</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomer</LastName><ForeName>Raju</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suk</LastName><ForeName>Jung Soo</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>The Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Biomedical Engineering, Environmental and Health Sciences, Oncology, Neurosurgery, and Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergles</LastName><ForeName>Dwight E</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000-0002-7133-7378</Identifier><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haughey</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Richard T. Johnson Division of Neuroimmunology and Neurological Infections, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikov</LastName><ForeName>Mikhail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanes</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Biomedical Engineering, Environmental and Health Sciences, Oncology, Neurosurgery, and Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-2001-8470</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jrothstein@jhmi.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jrothstein@jhmi.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular &amp; Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jrothstein@jhmi.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jrothstein@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS113565</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062171</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD016374</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA041208</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036465</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH083728</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008752</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092067</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005136">Eye Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C548022">Lgr6 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489916">Ndph protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005136" MajorTopicYN="N">Eye Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Financial Interests. A patent has been filed on the use of norrin (S.J.M. and J.D.R). The reminaing authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30936556</ArticleId><ArticleId IdType="mid">NIHMS1521956</ArticleId><ArticleId IdType="pmc">PMC6551209</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0366-7</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0366-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang Y &amp; Barres BA Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr Opin Neurobiol 20, 588&#x2013;594 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20655735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18, 327&#x2013;338 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Molofsky AV, et al. Astrocyte-encoded positional cues maintain sensorimotor circuit integrity. Nature 509, 189&#x2013;194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057936</ArticleId><ArticleId IdType="pubmed">24776795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai HH, et al. Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science 337, 358&#x2013;362 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4059181</ArticleId><ArticleId IdType="pubmed">22745251</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberheim NA, Goldman SA &amp; Nedergaard M Heterogeneity of astrocytic form and function. Methods Mol Biol 814, 23&#x2013;45 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506190</ArticleId><ArticleId IdType="pubmed">22144298</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaboub LS &amp; Deneen B Developmental origins of astrocyte heterogeneity: the final frontier of CNS development. Developmental neuroscience 34, 379&#x2013;388 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576470</ArticleId><ArticleId IdType="pubmed">23147551</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SJ Astrocyte Heterogeneity in the Adult Central Nervous System. Frontiers in Cellular Neuroscience 12 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262303</ArticleId><ArticleId IdType="pubmed">30524236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A, et al. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347, 1138&#x2013;1142 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25700174</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Van Kammen M, Levey AI, Martin LJ and Kuncl RW Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38, 73&#x2013;84 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, et al. Glutamate transporter subtypes: role in excitotoxicity and amyotrophic lateral sclerosis. Ann.Neurol 36, 282 (1994).</Citation></Reference><Reference><Citation>Rothstein JD, Van Kammen M, Levey AI, Martin LJ &amp; Kuncl RW Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol 38, 73&#x2013;84 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan MR, et al. Variations in Promoter Activity Reveal a Differential Expression and Physiology of Glutamate Transporters by Glia in the Developing and Mature CNS. J. Neurosci 27, 6607&#x2013;6619 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672708</ArticleId><ArticleId IdType="pubmed">17581948</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699&#x2013;1702 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9180080</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashimori H, et al. Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse. Hum Mol Genet 22, 2041&#x2013;2054 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633372</ArticleId><ArticleId IdType="pubmed">23396537</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson RA, et al. Neuronal Regulation of Glutamate Transporter Subtype Expression in Astrocytes. J. Neurosci 17, 932&#x2013;940 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573161</ArticleId><ArticleId IdType="pubmed">8994048</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis BL, Hirsch ML, Porter SN, Samulski RJ &amp; Porteus MH Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther 20, 35&#x2013;42 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4957644</ArticleId><ArticleId IdType="pubmed">22257934</ArticleId></ArticleIdList></Reference><Reference><Citation>Parr-Brownlie LC, et al. Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms. Front Mol Neurosci 8, 14 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434958</ArticleId><ArticleId IdType="pubmed">26041987</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo LC Purification of astrocytes from transgenic rodents by fluorescence-activated cell sorting. Cold Spring Harb. Protoc 2013, 551&#x2013;560 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23734019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy JD, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28, 264&#x2013;278 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieweg K, Schaller H &amp; Pfrieger FW Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem 109, 125&#x2013;134 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19166509</ArticleId></ArticleIdList></Reference><Reference><Citation>Snippert HJ, et al. Lgr6 marks stem cells in the hair follicle that generate all cell lineages of the skin. Science 327, 1385&#x2013;1389 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20223988</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, et al. hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury. Nat. Commun 4, 2196 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903179</ArticleId><ArticleId IdType="pubmed">23880652</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsumi K, et al. Olig2-Lineage Astrocytes: A Distinct Subtype of Astrocytes That Differs from GFAP Astrocytes. Front Neuroanat 12, 8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819569</ArticleId><ArticleId IdType="pubmed">29497365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrvatin S, et al. Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex. Nat Neurosci 21, 120&#x2013;129 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742025</ArticleId><ArticleId IdType="pubmed">29230054</ArticleId></ArticleIdList></Reference><Reference><Citation>Quake SR, Wyss-Coray T &amp; Darmanis S Transcriptomic characterization of 20 organs and tissues from mouse at single cell resolution creates a Tabula Muris. Nature (2018).</Citation></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, et al. LGR4 and its ligands, R-spondin 1 and R-spondin 3, regulate food intake in the hypothalamus of male rats. Endocrinology 155, 429&#x2013;440 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891940</ArticleId><ArticleId IdType="pubmed">24280058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Smallwood P &amp; Nathans J Expression of the Norrie disease gene (Ndp) in developing and adult mouse eye, ear, and brain. Gene Expr Patterns 11, 151&#x2013;155 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061303</ArticleId><ArticleId IdType="pubmed">21055480</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunger BM, The TER different functions of Norrin. Retinal Degenerative Diseases 723, 679&#x2013;683 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22183393</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz R, Hackl S, Seibuchner T, Tamm ER &amp; Ohlmann A Norrin mediates neuroprotective effects on retinal ganglion cells via activation of the Wnt/beta-catenin signaling pathway and the induction of neuroprotective growth factors in Muller cells. J Neurosci 30, 5998&#x2013;6010 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632606</ArticleId><ArticleId IdType="pubmed">20427659</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C, et al. Multi-functional norrin is a ligand for the LGR4 receptor. J Cell Sci 126, 2060&#x2013;2068 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3666258</ArticleId><ArticleId IdType="pubmed">23444378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott S, Patel RJ, Appukuttan B, Wang X &amp; Stout JT A novel mutation in the Norrie disease gene. Journal of American Association for Pediatric Ophthalmology and Strabismus 4, 125&#x2013;126 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10773814</ArticleId></ArticleIdList></Reference><Reference><Citation>M, W. Norrie&#x2019;s disease. Birth defects orginal article series 7, 117&#x2013;124 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">5006136</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong X, et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington&#x2019;s disease model mice. Nat. Neurosci 17, 694&#x2013;703 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064471</ArticleId><ArticleId IdType="pubmed">24686787</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao XH &amp; Nguyen H Epidermal expression of Lgr6 is dependent on nerve endings and Schwann cells. Exp Dermatol 23, 195&#x2013;198 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089962</ArticleId><ArticleId IdType="pubmed">24499442</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 61, 880&#x2013;894 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743171</ArticleId><ArticleId IdType="pubmed">19323997</ArticleId></ArticleIdList></Reference><Reference><Citation>Swann JW, A.-N.S. Spine Loss and Other Dendritic Abnormalities in Epilepsy. Hippocampus 10, 617&#x2013;625 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11075833</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty MJ, Noakes PG &amp; Bellingham MC Motor cortex layer V pyramidal neurons exhibit dendritic regression, spine loss, and increased synaptic excitation in the presymptomatic hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Neurosci 35, 643&#x2013;647 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605367</ArticleId><ArticleId IdType="pubmed">25589758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala JC, S.J., Harris KM Dendritic Spine Pathology: Cause or Consequence of Neurological Disorders? Brain Research Reviews 39, 29&#x2013;54 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12086707</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, et al. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and dysfunction. Neurobiol Aging 35, 2746&#x2013;2760 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Suarez E, Liu TF, Kopelevich A &amp; Allen NJ Astrocyte-Secreted Chordin-like 1 Drives Synapse Maturation and Limits Plasticity by Increasing Synaptic GluA2 AMPA Receptors. Neuron 100, 1116&#x2013;1132 e1113 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382071</ArticleId><ArticleId IdType="pubmed">30344043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanjakornsiripan D, et al. Layer-specific morphological and molecular differences in neocortical astrocytes and their dependence on neuronal layers. Nat Commun 9, 1623 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5915416</ArticleId><ArticleId IdType="pubmed">29691400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30952794</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>18</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.</ArticleTitle><Pagination><StartPage>e2070</StartPage><EndPage>e2080</EndPage><MedlinePgn>e2070-e2080</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000007232</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk.</AbstractText><AbstractText Label="METHODS">Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in &#x223c;50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS).</AbstractText><AbstractText Label="RESULTS">Naproxen-treated individuals showed a clear excess of adverse events. Among treatment groups combined, the APS increased by 0.102 points/year (SE 0.014; <i>p</i> &lt; 10<sup>-12</sup>), but rate of change showed little difference by treatment assignment (0.019 points/year). The treatment-related rate ratio of 1.16 (95% confidence interval 0.64-1.96) suggested that naproxen does not reduce the rate of APS progression by more than 36%. Secondary analyses revealed no notable treatment effects on individual CSF, cognitive, or neurosensory biomarker indicators of progressive presymptomatic AD.</AbstractText><AbstractText Label="CONCLUSIONS">In cognitively intact individuals at risk, sustained treatment with naproxen sodium 220 mg twice daily increases frequency of adverse health effects but does not reduce apparent progression of presymptomatic AD.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class I evidence that, for people who are cognitively intact, low-dose naproxen does not significantly reduce progression of a composite indicator of presymptomatic AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Pierre-Fran&#xe7;ois</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremblay-Mercier</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leoutsakos</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madjar</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafaille-Magnan</LastName><ForeName>Marie-Elyse</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savard</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9116-1376</Identifier><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Judes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etienne</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montr&#xe9;al, Canada; and John Hopkins University (J.L.), Baltimore, MD. john.breitner@mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PREVENT-AD Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>57Y76R9ATQ</RegistryNumber><NameOfSubstance UI="D009288">Naproxen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2019 Apr 30;92(18):829-830. doi: 10.1212/WNL.0000000000007233.</RefSource><PMID Version="1">30952790</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2019 Apr 30;92(18):e2181-e2184. doi: 10.1212/WNL.0000000000007418.</RefSource><PMID Version="1">31036584</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neurology. 2019 Aug 20;93(8):371. doi: 10.1212/WNL.0000000000007919.</RefSource><PMID Version="1">31427496</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2020 Mar 31;94(13):593-594. doi: 10.1212/WNL.0000000000009184.</RefSource><PMID Version="1">32229635</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2020 Mar 31;94(13):594. doi: 10.1212/WNL.0000000000009185.</RefSource><PMID Version="1">32229636</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009288" MajorTopicYN="N">Naproxen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30952794</ArticleId><ArticleId IdType="pmc">PMC6512884</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007232</ArticleId><ArticleId IdType="pii">WNL.0000000000007232</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR Jr., Knopman DS, Jagust WJ, et al. . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoutsakos JM, Gross AL, Jones RN, Albert MS, Breitner JCS. &#x201c;Alzheimer's Progression Score&#x201d;: development of a biomarker summary outcome for AD prevention trials. J Prev Alz Dis 2016;3:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639716</ArticleId><ArticleId IdType="pubmed">29034223</ArticleId></ArticleIdList></Reference><Reference><Citation>in t' Veld BA, Ruitenberg A, Hofman A, et al. . Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794217</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Haneuse SJ, Walker R, et al. . Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009;72:1899&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690966</ArticleId><ArticleId IdType="pubmed">19386997</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Davis KL, Berg JD, et al. . A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study. Neurology 2000;54:588&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680787</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Ferris SH, Kirby L, et al. . A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">15742005</ArticleId></ArticleIdList></Reference><Reference><Citation>Adapt Research Group, Lyketsos CG, Breitner JC, Green RC, et al. . Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007;68:1800&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460158</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM; PREVENT-AD Research G. Rationale and structure for a new center for studies on prevention of Alzheimer's disease (StoP-AD). J Prev Alz Dis 2016;3:236&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">29199324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, Bedirian V, et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845158</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Soldan A, Gottesman R, et al. . Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Curr Alzheimer Res 2014;11:773&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163954</ArticleId><ArticleId IdType="pubmed">25212916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajah MN, Languay R, Grady CL. Age-related changes in right middle frontal gyrus volume correlate with altered episodic retrieval activity. J Neurosci 2011;31:17941&#x2013;17954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634153</ArticleId><ArticleId IdType="pubmed">22159109</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984;32:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">6463130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafaille-Magnan ME, Poirier J, Etienne P, et al. . Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology 2017;89:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574678</ArticleId><ArticleId IdType="pubmed">28659431</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijdenbos AP, Forghani R, Evans AC. Automatic &#x201c;pipeline&#x201d; analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging 2002;21:1280&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12585710</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubert-Broche B, Fonov VS, Garcia-Lorenzo D, et al. . A new method for structural volume analysis of longitudinal brain MRI data and its application in studying the growth trajectories of anatomical brain structures in childhood. Neuroimage 2013;82:393&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">23719155</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Alsop DC, Song HK, et al. . Arterial transit time imaging with flow encoding arterial spin tagging (FEAST). Magn Reson Med 2003;50:599&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939768</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Mungas DM, Leoutsakos JS, Albert MS, Jones RN. Alzheimer's disease severity, objectively determined and measured. Alzheimers Dement 2016;4:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078784</ArticleId><ArticleId IdType="pubmed">27830173</ArticleId></ArticleIdList></Reference><Reference><Citation>Muth&#xe9;n LK, Muth&#xe9;n BO. Mplus user's guide: Statistical analysis with latent variables: User's guide. Los Angeles: Muth&#xe9;n &amp; Muth&#xe9;n; 2004.</Citation></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. . Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Ann Neurol 1993;33:258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">8498809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer's Disease [online]. Available at: clinicaltrials.gov/show/NCT02565511. Accessed May 2018.</Citation></Reference><Reference><Citation>Villeneuve S, Vogel JW, Gonneaud J, et al. . Proximity to parental symptom onset and amyloid-beta burden in sporadic Alzheimer disease. JAMA Neurol 2018;75:608&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885216</ArticleId><ArticleId IdType="pubmed">29482212</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Vachon-Presseau E, Pichet Binette A, et al. . Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease. Brain 2018;141:1871&#x2013;1883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972641</ArticleId><ArticleId IdType="pubmed">29688388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedynak BM, Lang A, Liu B, et al. . A computational neurodegenerative disease progression score: method and results with the Alzheimer's Disease Neuroimaging Initiative cohort. Neuroimage 2012;63:1478&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472161</ArticleId><ArticleId IdType="pubmed">22885136</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, van Belle G, Chen K, et al. . Combining multiple markers to improve the longitudinal rate of progression-application to clinical trials on the early stage of Alzheimer's disease. Stat Biopharm Res 2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868484</ArticleId><ArticleId IdType="pubmed">24363827</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical trial of solanezumab for older individuals who may be at risk for memory loss [online]. Available at: clinicaltrials.gov/show/NCT02008357. Accessed May 2018.</Citation></Reference><Reference><Citation>Budur K, Welsh-Bohmer K, Burns D, et al. . A pharmacogenetics-supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease using low-dose pioglitazone: an update on the TOMORROW study. Alzheimers Dement 2014;10:P809&#x2013;P810.</Citation></Reference><Reference><Citation>Langman MJ, Weil J, Wainwright P, et al. . Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909103</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirmohamed M, James S, Meakin S, et al. . Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC443443</ArticleId><ArticleId IdType="pubmed">15231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473048</ArticleId><ArticleId IdType="pubmed">16740558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden KM, Zandi PP, Khachaturian AS, et al. . Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology 2007;69:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">17636065</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schafer KA, Grundman M, et al. . Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819&#x2013;2826.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783912</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Baker LD, Montine TJ, et al. . Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011;7:402&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149804</ArticleId><ArticleId IdType="pubmed">21784351</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, ADAPT Research Team. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry 2012;27:364&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208130</ArticleId><ArticleId IdType="pubmed">21560159</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30962628</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Working memory revived in older adults by synchronizing rhythmic brain circuits.</ArticleTitle><Pagination><StartPage>820</StartPage><EndPage>827</EndPage><MedlinePgn>820-827</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0371-x</ELocationID><Abstract><AbstractText>Understanding normal brain aging and developing methods to maintain or improve cognition in older adults are major goals of fundamental and translational neuroscience. Here we show a core feature of cognitive decline-working-memory deficits-emerges from disconnected local and long-range circuits instantiated by theta-gamma phase-amplitude coupling in temporal cortex and theta phase synchronization across frontotemporal cortex. We developed a noninvasive stimulation procedure for modulating long-range theta interactions in adults aged 60-76 years. After 25&#x2009;min of stimulation, frequency-tuned to individual brain network dynamics, we observed a preferential increase in neural synchronization patterns and the return of sender-receiver relationships of information flow within and between frontotemporal regions. The end result was rapid improvement in working-memory performance that outlasted a 50&#x2009;min post-stimulation period. The results provide insight into the physiological foundations of age-related cognitive impairment and contribute to groundwork for future non-pharmacological interventions targeting aspects of cognitive decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinhart</LastName><ForeName>Robert M G</ForeName><Initials>RMG</Initials><Identifier Source="ORCID">0000-0003-2156-4633</Identifier><AffiliationInfo><Affiliation>Department of Psychological &amp; Brain Sciences, Center for Systems Neuroscience, Cognitive Neuroimaging Center, Center for Research in Sensory Communication &amp; Emerging Neural Technology, Boston University, Boston, MA, USA. rmgr@bu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychological &amp; Brain Sciences, Center for Systems Neuroscience, Cognitive Neuroimaging Center, Center for Research in Sensory Communication &amp; Emerging Neural Technology, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH114877</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2019 May;22(5):686-688. doi: 10.1038/s41593-019-0386-3.</RefSource><PMID Version="1">30962629</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Hum Behav. 2019 Jun;3(6):547. doi: 10.1038/s41562-019-0608-4.</RefSource><PMID Version="1">31048745</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066492" MajorTopicYN="Y">Cognitive Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003344" MajorTopicYN="Y">Cortical Synchronization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065818" MajorTopicYN="Y">Gamma Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013826" MajorTopicYN="Y">Theta Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065908" MajorTopicYN="N">Transcranial Direct Current Stimulation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30962628</ArticleId><ArticleId IdType="mid">NIHMS1522405</ArticleId><ArticleId IdType="pmc">PMC6486414</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0371-x</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0371-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bishop NA, Lu T &amp; Yankner BA Neural mechanisms of ageing and cognitive decline. Nature 464, 529&#x2013;535 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927852</ArticleId><ArticleId IdType="pubmed">20336135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Weuve J, Scherr PA &amp; Evans DA Alzheimer disease in the United States (2010&#x2013;2050) estimated using the 2010 Census. Neurology 80, 1778&#x2013;1783 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayutin AM Global demographic shifts create challenges and opportunities. PREA Quart, 46&#x2013;53 (2007).</Citation></Reference><Reference><Citation>Park DC &amp; Reuter-Lorenz PA The adaptive brain: aging and neurocognitive scaffolding. Nature Reviews Neuroscience 60, 173&#x2013;196 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359129</ArticleId><ArticleId IdType="pubmed">19035823</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady C Trends in neurocognitive aging. Nature Reviews Neuroscience 13, 491&#x2013;505 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800175</ArticleId><ArticleId IdType="pubmed">22714020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T &amp; Gabrieli JD Insights into the ageing mind: a view from cognitive neuroscience. Nature Reviews Neuroscience 5, 87&#x2013;96 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14735112</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasi D &amp; Volkow ND Aging and functional brain networks. Molecular Psychiatry 17, 549&#x2013;558 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193908</ArticleId><ArticleId IdType="pubmed">21727896</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, et al. Disruption of large-scale brain systems in advanced aging. Neuron 56, 924&#x2013;935 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SW, et al. Assessing the effects of age on long white matter tracts using diffusion tensor tractography. NeuroImage 46, 530&#x2013;541 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775533</ArticleId><ArticleId IdType="pubmed">19385018</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan M, et al. Evidence for cortical &#x201c;disconnection&#x201d; as a mechanism of age-related cognitive decline. Neurology 57, 632&#x2013;638 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11524471</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel M, Donner TH &amp; Engel AK Spectral fingerprints of large-scale neuronal interactions. Nature Reviews Neuroscience 13, 121&#x2013;134 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22233726</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux F &amp; Uhlhaas PJ Working memory and neural oscillations: alpha-gamma versus theta-gamma codes for distinct WM information? Trends in Cognitive Sciences 18, 16&#x2013;25 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24268290</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfrich RF &amp; Knight RT Oscillatory dynamics of prefrontal cognitive control. Trends in Cognitive Sciences 20, 916&#x2013;930 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127407</ArticleId><ArticleId IdType="pubmed">27743685</ArticleId></ArticleIdList></Reference><Reference><Citation>Fell J &amp; Axmacher N The role of phase synchronization in memory processes. Nature Reviews Neuroscience 12, 105&#x2013;118 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21248789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarnthein J, Petsche H, Rappelsberger P, Shaw G &amp; von Stein A Synchronization between prefrontal and posterior association cortex during human working memory. Proceedings of the National Academy of Sciences of the USA 95, 7092&#x2013;7096 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22750</ArticleId><ArticleId IdType="pubmed">9618544</ArticleId></ArticleIdList></Reference><Reference><Citation>Axmacher N, et al. Cross-frequency coupling supports multi-item working memory in the human hippocampus. Proceedings of the National Academy of Sciences 107, 3228&#x2013;3233 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840289</ArticleId><ArticleId IdType="pubmed">20133762</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries P Rhythms for cognition: communication through coherence. Neuron 88, 220&#x2013;235 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605134</ArticleId><ArticleId IdType="pubmed">26447583</ArticleId></ArticleIdList></Reference><Reference><Citation>Daume J, Gruber T, Engel AK &amp; Friese U Phase-amplitude coupling and long-range phase synchronization reveal frontotemporal interactions during visual working memory. Journal of Neuroscience 37, 313&#x2013;322 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596581</ArticleId><ArticleId IdType="pubmed">28077711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreenivasan KK, Curtis CE &amp; D&#x2019;Esposito M Revisiting the role of persistent neural activity during working memory. Trends in Cognitive Sciences 18, 82&#x2013;89 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964018</ArticleId><ArticleId IdType="pubmed">24439529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara AH &amp; Wallis JD Executive control processes underlying multiitem working memory. Nature Neuroscience 17, 876&#x2013;883 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039364</ArticleId><ArticleId IdType="pubmed">24747574</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart RMG Disruption and rescue of interareal theta phase coupling and adaptive behavior. Proceedings of the National Academy of Sciences, USA 114, 11542&#x2013;11547 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664527</ArticleId><ArticleId IdType="pubmed">29073084</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfrich RF, et al. Selective modulation of interhemispheric functional connectivity by HD-tACS shapes perception. Public Library of Sciences Biology 12, e1002031 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4280108</ArticleId><ArticleId IdType="pubmed">25549264</ArticleId></ArticleIdList></Reference><Reference><Citation>Polan&#xed;a R, Nitsche MA, Korman C, Batsikadze G &amp; Paulus W The importance of timing in segregated theta phase-coupling for cognitive performance. Current Biology 14, 1314&#x2013;1318 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22683259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinski N, Cooper NR, Sauseng P &amp; Romei V The speed of parietal theta frequency drives visuospatial working memory capacity. Public LIbrary of Sciences Biology 16, e2005348 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5868840</ArticleId><ArticleId IdType="pubmed">29538384</ArticleId></ArticleIdList></Reference><Reference><Citation>Alekseichuk I, Turi Z, Amador de Lara G, Antal A &amp; Paulus W Spatial working memory in humans depends on theta and high gamma synchronization in the prefrontal cortex. Current Biology 26, 1513&#x2013;1521 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27238283</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA The aging of working memory. Neuropsychology 8, 535&#x2013;543 (1994).</Citation></Reference><Reference><Citation>Voytek B, et al. Age-related changes in 1/f neural electrophysiological noise. Journal of Neuroscience 35, 13257&#x2013;13265 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4579381</ArticleId><ArticleId IdType="pubmed">26400953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole SR &amp; Voytek B Brain oscillations and the importance of waveform shape. Trends in Cognitive Sciences 21, 137&#x2013;149 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28063662</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffer-Teixeira R &amp; Tort AB On cross-frequency phase-phase coupling between theta and gamma oscillations in the hippocampus. Elife 5, 423&#x2013;435 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5199196</ArticleId><ArticleId IdType="pubmed">27925581</ArticleId></ArticleIdList></Reference><Reference><Citation>Daume J, Graetz S, Gruber T, Engel AK &amp; Friese U Cognitive control during audiovisual working memory engages frontotemporal theta band interactions. Scientific Reports 7, 12585 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626716</ArticleId><ArticleId IdType="pubmed">28974716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath C &amp; D&#x2019;Esposito M Medial temporal lobe activity associated with active maintenance of novel information. Neuron 31, 865&#x2013;873 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11567623</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols EA, Kao YC, Verfaellie M &amp; Gabrieli JD Hippocampus, working memory and long-term memory for faces: evidence from fMRI and global amnesia for involvement of the medial temporal lobes. Hippocampus 16, 604&#x2013;616 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1699801</ArticleId><ArticleId IdType="pubmed">16770797</ArticleId></ArticleIdList></Reference><Reference><Citation>Axmacher N, et al. Sustained neural activity patterns during working memory in the human medial temporal lobe. Journal of Neuroscience 27, 7807&#x2013;7816 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672876</ArticleId><ArticleId IdType="pubmed">17634374</ArticleId></ArticleIdList></Reference><Reference><Citation>Axmacher N, Schmitz DP, Wagner T, Elger CE &amp; Fell J Interactions between medial temporal lobe, prefrontal cortex, and inferior temporal regions during visual working memory: a combined intracranial EEG and functional magnetic resonance imaging study. Journal of Neuroscience 28, 7304&#x2013;7312 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670397</ArticleId><ArticleId IdType="pubmed">18632934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lueschow A, Miller EK &amp; Desimone R Inferior temporal mechanisms for invariant object recognition. Cerebral Cortex 5, 523&#x2013;531 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7833653</ArticleId></ArticleIdList></Reference><Reference><Citation>Woloszyn L &amp; Sheinberg DL Neural dynamics in inferior temporal cortex during a visual working memory task. Journal of Neuroscience 29, 5494&#x2013;5507 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688665</ArticleId><ArticleId IdType="pubmed">19403817</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell HW, et al. Material-specific lateralization of memory encoding in the medial temporal lobe: blocked versus event-related design. Neuroimage 27, 231&#x2013;239 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15927485</ArticleId></ArticleIdList></Reference><Reference><Citation>Henson R A mini-review of fMRI studies of human medial temporal lobe activity associated with recognition memory. Quarterly Journal of Experimental Psychology 58, 340&#x2013;360 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16194973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MM, Sellers KK &amp; Frohlich F Transcranial alternating current stimulation modulates large-scale cortical network activity by network resonance. Journal of Neuroscience 33, 11262&#x2013;11275 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618612</ArticleId><ArticleId IdType="pubmed">23825429</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann CS, Rach S, Neuling T &amp; Str&#xfc;ber D Transcranial alternating current stimulation: a review of the underlying mechanisms and modulation of cognitive processes. Frontiers in Human Neuroscience 7 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682121</ArticleId><ArticleId IdType="pubmed">23785325</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossen A, Gross J &amp; Thut G Alpha power increase after transcranial alternating current stimulation at alpha frequency (&#x3b1;-tACS) reflects plastic changes rather than entrainment. Brain Stimulation 8, 499&#x2013;508 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4464304</ArticleId><ArticleId IdType="pubmed">25648377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaehle T, Rach S &amp; Herrmann CS Transcranial alternating current stimulation enhances individual alpha activity in human EEG. Public Library of Sciences ONE 5, e13766 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967471</ArticleId><ArticleId IdType="pubmed">21072168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann TO &amp; Born J Phase-amplitude coupling: A general mechanism for memory processing and synaptic plasticity? Neuron 97, 10&#x2013;13 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29301097</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregoriou GG, Gotts SJ, Zhou H &amp; Desimone R High-frequency, long-range coupling between prefrontal and visual cortex during attention. Science 324, 1207&#x2013;1210 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849291</ArticleId><ArticleId IdType="pubmed">19478185</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XJ Neurophysiological and computational principles of cortical rhythms in cognition. Physiological Reviews 90, 1195&#x2013;1268 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923921</ArticleId><ArticleId IdType="pubmed">20664082</ArticleId></ArticleIdList></Reference><Reference><Citation>Violante IR, et al. Externally induced frontoparietal synchronization modulates network dynamics and enhances working memory performance. Elife 6, e22001 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349849</ArticleId><ArticleId IdType="pubmed">28288700</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein SE &amp; McHugh PR &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189&#x2013;198 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA &amp; Brown GK Manual for the beck depression inventory (The Psychological Association, San Antonio, TX, 1996).</Citation></Reference><Reference><Citation>Sabia S, et al. Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study. Archives in General Psychiatry 69, 627&#x2013;635 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675806</ArticleId><ArticleId IdType="pubmed">22309970</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundey J, Amu R, Batsikadze G, Paulus W &amp; Nitsche MA Diverging effects of nicotine on motor learning performance: improvement in deprived smokers and attenuation in non-smokers. Addictive Behaviors 74, 90&#x2013;97 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28600927</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundey J, et al. Double dissociation of working memory and attentional processes in smokers and non-smokers with and without nicotine. Psychopharmacology 232, 2491&#x2013;2501 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25721074</ArticleId></ArticleIdList></Reference><Reference><Citation>Noury N, Hipp JF &amp; Siegel M Physiological processes non-linearly affect electrophysiological recordings during transcranial electric stimulation. Neuroimage 140, 99&#x2013;109 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27039705</ArticleId></ArticleIdList></Reference><Reference><Citation>Noury N &amp; Siegel M Analyzing EEG and MEG signals recorded during tES, a reply. Neuroimage 167, 53&#x2013;61 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29155079</ArticleId></ArticleIdList></Reference><Reference><Citation>Konkle T, Brady TF, Alvarez GA &amp; Oliva A Conceptual distinctiveness supports detailed visual long-term memory for real-world objects. Journal of Experimental Psychology: General 139, 558&#x2013;578 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398125</ArticleId><ArticleId IdType="pubmed">20677899</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady TF, Konkle T, Alvarez GA &amp; Oliva A Visual long-term memory has a massive storage capacity for object details. Proceedings of the National Academy of Sciences 105, 14325&#x2013;14329 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533687</ArticleId><ArticleId IdType="pubmed">18787113</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JY, Jhung K, Lee J &amp; S.K., A. Theta-gamma coupling during a working memory task as compared to a simple vigilance task. Neuroscience Letters 532, 39&#x2013;43 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23149131</ArticleId></ArticleIdList></Reference><Reference><Citation>Oostenveld R, Fries P, Maris E &amp; Schoffelen JM FieldTrip: Open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data. Computational Intelligence and Neuroscience 2011, 1&#x2013;9 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021840</ArticleId><ArticleId IdType="pubmed">21253357</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen J, Deng Y &amp; Reinhart RMG Brain-state determines learning improvements after transcranial alternating-current stimulation to fontal cortex. Brain Stimulation 11, 723&#x2013;726 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6019559</ArticleId><ArticleId IdType="pubmed">29482970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai R, Chaieb L, Antal A, Walsh V &amp; Paulus W Frequency-dependent electrical stimulation of the visual cortex. Current Biology 18, 1839&#x2013;1843 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19026538</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutter DJ &amp; Hortensius R Retinal origin of phosphenes to transcranial alternating current stimulation. Clinical Neurophysiology 121, 1080&#x2013;1084 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20188625</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus W On the difficulties of separating retinal from cortical origins of phosphenes when using transcranial alternating current stimulation (tACS). Clinical Neurophysiology 121, 987&#x2013;991 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20181514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachaux JP, Rodriguez E, Martinerie J &amp; Varela FJ Measuring phase synchrony in brain signals. Human Brain Mapping 8, 194&#x2013;208 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873296</ArticleId><ArticleId IdType="pubmed">10619414</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart RMG, Zhu J, Park S &amp; Woodman GF Medial-frontal stimulation enhances learning in schizophrenia by restoring prediction-error signaling. Journal of Neuroscience 35, 12232&#x2013;12240 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4556788</ArticleId><ArticleId IdType="pubmed">26338333</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart RMG &amp; Woodman GF Enhancing long-term memory with stimulation tunes visual attention in one trial. Proceedings of the National Academy of Sciences of the USA 112, 625&#x2013;630 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299199</ArticleId><ArticleId IdType="pubmed">25548192</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart RMG &amp; Woodman GF Causal control of medial-frontal cortex governs electrophysiological and behavioral indices of performance monitoring and learning. Journal of Neuroscience 34, 4214&#x2013;4227 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960465</ArticleId><ArticleId IdType="pubmed">24647942</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart RMG, Zhu J, Park S &amp; Woodman GF Synchronizing theta oscillations with direct-current stimulation strengthens adaptive control in the human brain. Proceedings of the National Academy of Sciences of the USA 112, 9448&#x2013;9453 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522782</ArticleId><ArticleId IdType="pubmed">26124116</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart RMG, Cosman JD, Fukuda K &amp; Woodman GF Using transcranial direct-current stimulation (tDCS) to understand cognitive processing. Attention, Perception &amp; Psychophysics 79, 3&#x2013;23 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539401</ArticleId><ArticleId IdType="pubmed">27804033</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart RMG, Xiao W, McClenahan L &amp; Woodman GF Electrical stimulation of visual cortex can immediately improve spatial vision. Current Biology 25, 1867&#x2013;1872 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961578</ArticleId><ArticleId IdType="pubmed">27374337</ArticleId></ArticleIdList></Reference><Reference><Citation>Poreisz C, Boros K, Antal A &amp; Paulus W Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Research Bulletin 72, 208&#x2013;214 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17452283</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandiga P, Hummel F &amp; Cohen L Transcranial DC stimulation (tDCS): A tool for double-blind sham-controlled clinical studies in brain stimulation. Clinical Neurophysiology 117, 845&#x2013;850 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16427357</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung TP, et al. Imaging brain dynamics using independent component analysis. The Proceedings of the Institution of Electrical and Electronic Engineers 89, 1107&#x2013;1122 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932458</ArticleId><ArticleId IdType="pubmed">20824156</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorme A &amp; Makeig S EEGLAB: An open source toolbox for analysis of singel-trial EEG dynamics including independent component analysis. Journal of Neuroscience Methods 134, 9&#x2013;21 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15102499</ArticleId></ArticleIdList></Reference><Reference><Citation>Berens P CircStat: a MATLAB toolbox for circular statistics. Journal of Statistical Software 31, 21 (2009).</Citation></Reference><Reference><Citation>van Driel J, Cox R &amp; Cohen MX Phase-clustering bias in phase&#x2013;amplitude cross-frequency coupling and its removal. Journal of Neuroscience Methods 254, 60&#x2013;72 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26231622</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veen B, van Drongelen W, Yuchtman M &amp; Suzuki A Localization of brain electrical activity via linearly constraint minimum variance spatial filtering. IEEE Translations on Biomedical Engineering 44, 867&#x2013;880 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9282479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipp JF, Engel AK &amp; Siegel M Oscillatory synchronization in large-scale cortical networks predicts perception. Neuron 69, 387&#x2013;396 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21262474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekihara K &amp; Nagarajan SS Adaptive spatial filters for electromagnetic brain imaging (Springer, 2008).</Citation></Reference><Reference><Citation>Darvas F, Pantazis D, Kucukaltun-Yildirim E &amp; Leahy RM Mapping human brain function with MEG and EEG: methods and validation. NeuroImage 23, S289&#x2013;S299 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15501098</ArticleId></ArticleIdList></Reference><Reference><Citation>Dannhauer M, Lanfer B, Wolters CH &amp; Kn&#xf6;sche TR Modeling of the human skull in EEG source analysis. Human Brain Mapping 32 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6869856</ArticleId><ArticleId IdType="pubmed">20690140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters CH, et al. Influence of tissue conductivity anisotropy on EEG/MEG field and return current computation in a realistic head model: a simulation and visualization study using high-resolution finite element modeling. NeuroImage 30, 813&#x2013;826 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16364662</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JH, Vorwerk J, Wolters CH &amp; Kn&#xf6;sche TR Influence of the head model on EEG and MEG source connectivity analyses. Neuroimage 110, 60&#x2013;77 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25638756</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchner H, et al. Inverse localization of electric dipole current sources in finite element models of the human head. Electroencephalography Clinical Neurophysiology 102, 267&#x2013;278 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9146486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters CH, Grasedyck L &amp; Hackbusch W Efficient computation of lead field bases and influence matrix for the FEM-based EEG and MEG inverse problem. Inverse Problems 20, 1099&#x2013;1116 (2004).</Citation></Reference><Reference><Citation>Lew S, Wolters CH, Dierkes T, R&#xf6;er C &amp; Macleod RS Accuracy and run-time comparison for different potential approaches and iterative solvers in finite element method based EEG source analysis. Applied Numerical Mathematics 59, 1970&#x2013;1988 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791331</ArticleId><ArticleId IdType="pubmed">20161462</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Okamoto M, Dan H, Jurcak V &amp; Dan I Spatial registration of multichannel multi-subject fNIRS data to MNI space without MRI. Neuroimage 27, 842&#x2013;851 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15979346</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15, 273&#x2013;289 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster JL, et al. Automated Talairach Atlas labels for functional brain mapping. Human Brain Mapping 10, 120&#x2013;131 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871915</ArticleId><ArticleId IdType="pubmed">10912591</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Bahramisharif A, van Gerven MA &amp; Jensen O Measuring directionality between neuronal oscillations of different frequencies. Neuroimage 118, 359&#x2013;367 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26025291</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross J, et al. Dynamic imaging of coherent sources: Studying neural interactions in the human brain. Proceedings of the National Academy of Sciences of the USA 98, 694&#x2013;699 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14650</ArticleId><ArticleId IdType="pubmed">11209067</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolte G, et al. Robustly estimating the flow direction of information in complex physical systems. Physical Review Letters 100, 234101 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18643502</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimesch W EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Research Reviews 29, 169&#x2013;195 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10209231</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimesch W Alpha-band oscillations, attention, and controlled access to stored information. Trends in Cognitive Sciences 16, 606&#x2013;617 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507158</ArticleId><ArticleId IdType="pubmed">23141428</ArticleId></ArticleIdList></Reference><Reference><Citation>Maris E &amp; Oostenveld R Nonparametric statistical testing of EEG- and MEG-data. Journal of Neuroscience Methods 164, 177&#x2013;190 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17517438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolte G, et al. Identifying true brain interaction from EEG data using the imaginary part of coherency. Clinical Neurophysiology 115, 2292&#x2013;2307 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15351371</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD A direct approach to false discovery rates. Journal of the Royal Statistical Society, Series B 64, 479&#x2013;498 (2002).</Citation></Reference><Reference><Citation>Gazzaley A, Cooney JW, Rissman J &amp; D&#x2019;Esposito M Top-down suppression deficit underlies working memory impairment in normal aging. Nature Neuroscience 8, 1298&#x2013;1300 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16158065</ArticleId></ArticleIdList></Reference><Reference><Citation>McNab F, et al. Age-related changes in working memory and the ability to ignore distraction. Proceedings of the National Academy of Sciences 112, 6515&#x2013;6518 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443336</ArticleId><ArticleId IdType="pubmed">25941369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadick JZ, Zanto TP &amp; Gazzaley A Structural and functional differences in medial prefrontal cortex underlie distractibility and suppression deficits in ageing. Nature Communications 5, 4223 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4088291</ArticleId><ArticleId IdType="pubmed">24979364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30970186</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>380</Volume><Issue>15</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>11</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1408</StartPage><EndPage>1420</EndPage><MedlinePgn>1408-1420</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1812840</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered &#x3b2;-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (A&#x3b2;). The drug did not prevent clinical progression in a trial involving patients with mild-to-moderate dementia due to Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a randomized, double-blind, placebo-controlled, 104-week trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had memory impairment and elevated brain amyloid levels but whose condition did not meet the case definition of dementia. The primary outcome was the change from baseline to week 104 in the score on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating worse cognition and daily function). Secondary outcomes included other assessments of cognition and daily function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The trial was terminated for futility after 1454 patients had been enrolled; 485 had been assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 484 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 485 to receive placebo. A total of 234 patients, 231 patients, and 239 patients per group, respectively, completed 104 weeks of the trial regimen. The estimated mean change from baseline to week 104 in the CDR-SB score was 1.65 in the 12-mg group, 2.02 in the 40-mg group, and 1.58 in the placebo group (P&#x2009;=&#x2009;0.67 for the comparison between the 12-mg group and the placebo group and P&#x2009;=&#x2009;0.01 for the comparison between the 40-mg group and the placebo group), suggesting a worse outcome in the higher-dose group than in the placebo group. The estimated rate of progression to dementia due to Alzheimer's disease was 24.5, 25.5, and 19.3 events per 100 patient-years in the 12-mg group, the 40-mg group, and the placebo group, respectively (hazard ratio for 40 mg vs. placebo, 1.38; 97.51% confidence interval, 1.07 to 1.79, not adjusted for multiple comparisons), favoring placebo. Adverse events were more common in the verubecestat groups than in the placebo group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Verubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those who received placebo. (Funded by Merck Sharp &amp; Dohme; ClinicalTrials.gov number, NCT01953601.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Egan</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kost</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Tiffini</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukai</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merce</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furtek</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harper Mozley</LastName><ForeName>Lyn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sur</LastName><ForeName>Cyrille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michelson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From Merck, Kenilworth, NJ (M.F.E., J.K., T.V., Y. Mukai, Y.Z., W.L., C.F., E.M., L.H.M., Y. Mo, C.S., D.M.); the University of Southern California, San Diego (P.S.A.); Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas (J.L.C.); Banner Alzheimer's Institute, Phoenix, AZ (P.N.T.); Gerontopole, INSERM Unit&#xe9; 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France (B.V.); Yale University School of Medicine, New Haven, CT (C.H.D.); and the Research Center and Memory Cl&#xed;nic, Fundaci&#xf3; Alzheimer Centre Educacional, Institut Catal&#xe0; de Neuroci&#xe8;nces Aplicades-Universitat Internacional de Catalunya, Barcelona, and the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M.B.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01953601</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM109025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003499">Cyclic S-Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013829">Thiadiazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>J1I0P6WT7T</RegistryNumber><NameOfSubstance UI="C000613570">verubecestat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2019 Apr 11;380(15):1476-1478. doi: 10.1056/NEJMe1903193.</RefSource><PMID Version="1">30970194</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2019 Apr 11;380(15):1483-1485. doi: 10.1056/NEJMc1813435.</RefSource><PMID Version="1">30970197</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurodegener Dis Manag. 2019 Aug;9(4):189-191. doi: 10.2217/nmt-2019-0013.</RefSource><PMID Version="1">31337272</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2019 Jul 25;381(4):388. doi: 10.1056/NEJMc1906679.</RefSource><PMID Version="1">31340105</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003499" MajorTopicYN="N">Cyclic S-Oxides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013829" MajorTopicYN="N">Thiadiazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30970186</ArticleId><ArticleId IdType="mid">NIHMS1046474</ArticleId><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1812840</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer&#x2019;s disease. Nat Rev Dis Primers 2015;1:15056.</Citation><ArticleIdList><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Vassar R. Targeting the &#x3b2; secretase BACE1 for Alzheimer&#x2019;s disease therapy. Lancet Neurol 2014;13:319&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JD, Li SW, Brunskill AP, et al. Discovery of the 3-imino-1,2,4-thiadiazi-nane 1,1-dioxide derivative verubecestat (MK-8931) &#x2014; a 0-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer&#x2019;s disease. J Med Chem 2016;59:10435&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">27933948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS &#x3b2;-amyloid in animal models and in Alzheimer&#x2019;s disease patients. Sci Transl Med 2016;8: 363ra150.</Citation><ArticleIdList><ArticleId IdType="pubmed">27807285</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med 2018;378:1691&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="pubmed">29719179</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R. Physiological functions of the &#x3b2;-site amyloid precursor protein cleaving enzyme 1 and 2. Front Mol Neurosci 2017; 10:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395628</ArticleId><ArticleId IdType="pubmed">28469554</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Zhang Y, Liang Z, et al. Cleavage of potassium channel Kv2.1 by BACE2 reduces neuronal apoptosis. Mol Psychiatry 2018;23:1542&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">29703946</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Webb RL, Laux AL, et al. BACE2 expression increases in human neurodegenerative disease. Am J Pathol 2012;180:337&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338345</ArticleId><ArticleId IdType="pubmed">22074738</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer&#x2019;s disease: implications for prevention trials. Neuron 2014;84:608&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285623</ArticleId><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer&#x2019;s disease: a new lexicon. Lancet Neurol 2010;9: 1118&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 1984; 34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnostic and statistical manual of mental disorders, 4 th ed., rev.: DSM-IV-TR Arlington, VA: American Psychiatric Association, 2000.</Citation></Reference><Reference><Citation>Randolph C. RBANS: repeatable battery for the assessment of neuropsychological status. San Antonio, TX: Psychological Corporation, 1998.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state:&#x201d; a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease. Alzheimer Dis Assoc Disord 1997; 11:Suppl 2:S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal &#x3b2;-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015;56:567&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313473</ArticleId><ArticleId IdType="pubmed">25745095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo Y, Stromswold J, Wilson K, et al. A multinational study distinguishing Alzheimer&#x2019;s and healthy patients using cerebrospinal fluid tau/A&#x3b2;42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimers Dement (Amst) 2017;6:201&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5357677</ArticleId><ArticleId IdType="pubmed">28349119</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med 2014;370:322&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med 2014;370:311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature 2016;537:50&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K, Peters F, Filser S, Herms J. Consequences of pharmacological BACE inhibition on synaptic structure and function. Biol Psychiatry 2018;84:478&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">29945719</ArticleId></ArticleIdList></Reference><Reference><Citation>Barao S, Moechars D, Lichtenthaler SF, De Strooper B. BACE1 physiological functions may limit its use as therapeutic target for Alzheimer&#x2019;s disease. Trends Neurosci 2016;39:158&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">26833257</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kuhn PH, Haass C, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 2014; 130:4&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume T, Filser S, Jaworska A, et al. BACE1 inhibitor MK-8931 alters formation but not stability of dendritic spines. Front Aging Neurosci 2018;10:229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070607</ArticleId><ArticleId IdType="pubmed">30093858</ArticleId></ArticleIdList></Reference><Reference><Citation>Filser S, Ovsepian SV, Masana M, et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry 2015;77:729&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">25599931</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30969506</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>380</Volume><Issue>18</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Tau Positron-Emission Tomography in Former National Football League Players.</ArticleTitle><Pagination><StartPage>1716</StartPage><EndPage>1725</EndPage><MedlinePgn>1716-1725</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1900757</ELocationID><Abstract><AbstractText Label="BACKGROUND">Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been associated with a history of repetitive head impacts. The neuropathological diagnosis is based on a specific pattern of tau deposition with minimal amyloid-beta deposition that differs from other disorders, including Alzheimer's disease. The feasibility of detecting tau and amyloid deposition in the brains of living persons at risk for CTE has not been well studied.</AbstractText><AbstractText Label="METHODS">We used flortaucipir positron-emission tomography (PET) and florbetapir PET to measure deposition of tau and amyloid-beta, respectively, in the brains of former National Football League (NFL) players with cognitive and neuropsychiatric symptoms and in asymptomatic men with no history of traumatic brain injury. Automated image-analysis algorithms were used to compare the regional tau standardized uptake value ratio (SUVR, the ratio of radioactivity in a cerebral region to that in the cerebellum as a reference) between the two groups and to explore the associations of SUVR with symptom severity and with years of football play in the former-player group.</AbstractText><AbstractText Label="RESULTS">A total of 26 former players and 31 controls were included in the analysis. The mean flortaucipir SUVR was higher among former players than among controls in three regions of the brain: bilateral superior frontal (1.09 vs. 0.98; adjusted mean difference, 0.13; 95% confidence interval [CI], 0.06 to 0.20; P&lt;0.001), bilateral medial temporal (1.23 vs. 1.12; adjusted mean difference, 0.13; 95% CI, 0.05 to 0.21; P&lt;0.001), and left parietal (1.12 vs. 1.01; adjusted mean difference, 0.12; 95% CI, 0.05 to 0.20; P&#x2009;=&#x2009;0.002). In exploratory analyses, the correlation coefficients in these three regions between the SUVRs and years of play were 0.58 (95% CI, 0.25 to 0.79), 0.45 (95% CI, 0.07 to 0.71), and 0.50 (95% CI, 0.14 to 0.74), respectively. There was no association between tau deposition and scores on cognitive and neuropsychiatric tests. Only one former player had levels of amyloid-beta deposition similar to those in persons with Alzheimer's disease.</AbstractText><AbstractText Label="CONCLUSIONS">A group of living former NFL players with cognitive and neuropsychiatric symptoms had higher tau levels measured by PET than controls in brain regions that are affected by CTE and did not have elevated amyloid-beta levels. Further studies are needed to determine whether elevated CTE-associated tau can be detected in individual persons. (Funded by Avid Radiopharmaceuticals and others.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navitsky</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodick</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alosco</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripodis</LastName><ForeName>Yorghos</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goradia</LastName><ForeName>Dhruman D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastroeni</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritts</LastName><ForeName>Nathan G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarnagin</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Suffix>Sr</Suffix><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shenton</LastName><ForeName>Martha E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From the Boston University School of Medicine (R.A.S., M.L.A., N.G.F., J.J.), Boston University School of Public Health (Y.T., B.M.), Brigham and Women's Hospital (M.E.S.), Harvard Medical School (M.E.S.), and the Veterans Affairs Boston Healthcare System (M.E.S.) - all in Boston; Mayo Clinic Arizona, Scottsdale (C.H.A., D.W.D.), Banner Alzheimer's Institute, Phoenix (K.C., J.L., D.D.G., E.M.R.), and Arizona State University, Tempe (D.M.) - all in Arizona; and Avid Radiopharmaceuticals, Philadelphia (M.N., M.D.D., M.A.M., M.J.P.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01NS078337</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS102399</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS078337</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078337</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS093334</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>W81XWH-13-2-0063</GrantID><Agency>U.S. Department of Defense</Agency><Country>International</Country></Grant><Grant><GrantID>U01 NS093334</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1UL1TR001430</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>W81XWH-13-2-0064</GrantID><Agency>U.S. Department of Defense</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2019 May 2;380(18):1771-1772. doi: 10.1056/NEJMe1903746.</RefSource><PMID Version="1">30969505</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001924" MajorTopicYN="N">Brain Concussion</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070627" MajorTopicYN="N">Chronic Traumatic Encephalopathy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005538" MajorTopicYN="N">Football</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30969506</ArticleId><ArticleId IdType="mid">NIHMS1529616</ArticleId><ArticleId IdType="pmc">PMC6636818</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1900757</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136:43&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA 2017; 318:360&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807097</ArticleId><ArticleId IdType="pubmed">28742910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Ross OA, Cormier KA, et al. Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol 2015;130: 877&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655127</ArticleId><ArticleId IdType="pubmed">26518018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, Morris HR, Neal JW, et al. Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathol 2017; 133:337&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325836</ArticleId><ArticleId IdType="pubmed">28205009</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cairns NJ, Dickson DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 2016;131:75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RA, Daneshvar DH, Baugh CM, et al. Clinical presentation of chronic traumatic encephalopathy. Neurology 2013; 81:1122&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795597</ArticleId><ArticleId IdType="pubmed">23966253</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenigro PH, Baugh CM, Daneshvar DH, et al. Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther 2014;6:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288217</ArticleId><ArticleId IdType="pubmed">25580160</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Mez J, Tripodis Y, et al. Age of first exposure to tackle football and chronic traumatic encephalopathy. Ann Neurol 2018;83:886&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367933</ArticleId><ArticleId IdType="pubmed">29710395</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 2018;14:399&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463489</ArticleId><ArticleId IdType="pubmed">29895964</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Dor&#xe9; V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-&#x3b2; proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 2018;14:225&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">29449700</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Meltzer AC, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol 2017;81:117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319193</ArticleId><ArticleId IdType="pubmed">27997036</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein DL, Pullman MY, Fernandez C, et al. Cerebral [18F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy. Transl Psychiatry 2016;6(9):e900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048212</ArticleId><ArticleId IdType="pubmed">27676441</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Tripodis Y, Fritts NG, et al. Cerebrospinal fluid tau, A&#x3b2;, and sTREM2 in former National Football League players: modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimers Dement 2018;14:1159&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6131058</ArticleId><ArticleId IdType="pubmed">30049650</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Tripodis Y, Jarnagin J, et al. Repetitive head impact exposure and laterlife plasma total tau in former National Football League players. Alzheimers Dement (Amst) 2016;7:33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5312499</ArticleId><ArticleId IdType="pubmed">28229128</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD Sr, Navitsky M, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 2017;140:748&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Jarnagin J, Tripodis Y, et al. Olfactory function and associated clinical correlates in former National Football League players. J Neurotrauma 2017;34: 772&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5314992</ArticleId><ArticleId IdType="pubmed">27430424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CM, Jacobs HIL, Marqui&#xe9; M, et al. 18F-flortaucipir binding in choroid plexus: related to race and hippocampus signal. J Alzheimers Dis 2018;62:1691&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5957532</ArticleId><ArticleId IdType="pubmed">29614677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyoo CH, Cho H, Choi JY, Ryu YH, Lee MS. Tau positron emission tomography imaging in degenerative parkinsonisms. J Mov Disord 2018;11:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790630</ArticleId><ArticleId IdType="pubmed">29381890</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips JS, Das SR, McMillan CT, et al. Tau PET imaging predicts cognition in atypical variants of Alzheimer&#x2019;s disease. Hum Brain Mapp 2018;39:691&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5764792</ArticleId><ArticleId IdType="pubmed">29105977</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonhaut DR, McMillan CT, Spina S, et al. 18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol 2017;82:622&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5665658</ArticleId><ArticleId IdType="pubmed">28980714</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol 2012;11:669&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenigro PH, Alosco ML, Martin BM, et al. Cumulative head impact exposure predicts later-life depression, apathy, executive dysfunction, and cognitive impairment in former high school and college football players. J Neurotrauma 2017; 34:328&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5220530</ArticleId><ArticleId IdType="pubmed">27029716</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Tripodis Y, Alvarez VE, et al. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun 2016;4:112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084333</ArticleId><ArticleId IdType="pubmed">27793189</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Wibom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol 2018. December 3 (Epub ahead of print).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439731</ArticleId><ArticleId IdType="pubmed">30508025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 2018;320: 1151&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 2019. March 20 (Epub ahead of print).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Laforce R Jr, Soucy JP, Sellami L, et al. Molecular imaging in dementia: past, present, and future. Alzheimers Dement 2018;14:1522&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">30028955</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30980041</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta.</ArticleTitle><Pagination><StartPage>2919</StartPage><EndPage>2931</EndPage><MedlinePgn>2919-2931</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-019-0410-8</ELocationID><Abstract><AbstractText>Familial Alzheimer's disease (fAD) mutations alter amyloid precursor protein (APP) cleavage by &#x3b3;-secretase, increasing the proportion of longer amyloidogenic amyloid-&#x3b2; (A&#x3b2;) peptides. Using five control induced pluripotent stem cell (iPSC) lines and seven iPSC lines generated from fAD patients, we investigated the effects of mutations on the A&#x3b2; secretome in human neurons generated in 2D and 3D. We also analysed matched CSF, post-mortem brain tissue, and iPSCs from the same participant with the APP V717I mutation. All fAD mutation lines demonstrated an increased A&#x3b2;42:40 ratio relative to controls, yet displayed varied signatures for A&#x3b2;43, A&#x3b2;38, and short A&#x3b2; fragments. We propose four qualitatively distinct mechanisms behind raised A&#x3b2;42:40. (1) APP V717I mutations alter &#x3b3;-secretase cleavage site preference. Whereas, distinct presenilin 1 (PSEN1) mutations lead to either (2) reduced &#x3b3;-secretase activity, (3) altered protein stability or (4) reduced PSEN1 maturation, all culminating in reduced &#x3b3;-secretase carboxypeptidase-like activity. These data support A&#x3b2; mechanistic tenets in a human physiological model and substantiate iPSC-neurons for modelling fAD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Arber</LastName><ForeName>Charles</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9743-8134</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Toombs</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovejoy</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paterson</LastName><ForeName>Ross W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willumsen</LastName><ForeName>Nanet</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkanatsiou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heslegrave</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-2059-024X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. henrik.zetterberg@clinchem.gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK. henrik.zetterberg@clinchem.gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. henrik.zetterberg@clinchem.gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden. henrik.zetterberg@clinchem.gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. selina.wray@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1307</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U12266B</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J004758/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900421</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M02492X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Jun;15(6):310. doi: 10.1038/s41582-019-0195-z.</RefSource><PMID Version="1">31036954</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30980041</ArticleId><ArticleId IdType="mid">EMS82268</ArticleId><ArticleId IdType="pmc">PMC7577860</ArticleId><ArticleId IdType="doi">10.1038/s41380-019-0410-8</ArticleId><ArticleId IdType="pii">10.1038/s41380-019-0410-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18:421&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer&#x2019;s disease. Annu Rev Neurosci. 2011;34:185&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174086</ArticleId><ArticleId IdType="pubmed">21456963</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez MA, Biette KM, Dolios G, Seth D, Wang R, Wolfe MS. Transmembrane substrate determinants for &#x3b3;-secretase processing of APP CTF&#x3b2;. Biochemistry. 2016;55:5675&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539764</ArticleId><ArticleId IdType="pubmed">27649271</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. Gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of -carboxyl terminal fragment. J Neurosci. 2009;29:13042&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura N, Takami M, Okochi M, Wada-Kakuda S, Fujiwara H, Tagami S, et al. &#x3b3;-Secretase associated with lipid rafts: multiple interactive pathways in the stepwise processing of &#x3b2;-carboxylterminal fragment. J Biol Chem. 2014;289:5109&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931069</ArticleId><ArticleId IdType="pubmed">24375443</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez MA, Klutkowski JA, Freret T, Wolfe MS. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid &#x3b2;-peptides (A&#x3b2;) by &#x3b3;-secretase to increase 42-to-40-residue A&#x3b2;. J Biol Chem. 2014;289:31043&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223309</ArticleId><ArticleId IdType="pubmed">25239621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of gamma-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human &#x3b3;-secretase underlie familial Alzheimer&#x2019;s disease. J Exp Med. 2015;212:2003&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4647268</ArticleId><ArticleId IdType="pubmed">26481686</ArticleId></ArticleIdList></Reference><Reference><Citation>Slemmon JR, Shapiro A, Mercken M, Streffer J, Romano G, Andreasen N, et al. Impact of cerebrospinal fluid matrix on the detection of Alzheimer&#x2019;s disease with Abeta42 and influence of disease on the total-Abeta42/Abeta40 ratio. J Neurochem. 2015;135:1049&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">26332787</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer&#x2019;s disease diagnosis: a consensus paper from the Alzheimer&#x2019;s Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22047631</ArticleId></ArticleIdList></Reference><Reference><Citation>Toombs J, Paterson RW, Schott JM, Zetterberg H. Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res Ther. 2014;6:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4059346</ArticleId><ArticleId IdType="pubmed">24472496</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF A&#x3b2;42/A&#x3b2;40 and A&#x3b2;42/A&#x3b2;38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774260</ArticleId><ArticleId IdType="pubmed">27042676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorey A, Perret-Liaudet A, Tholance Y, Fourier A, Quadrio I. Cerebrospinal fluid A&#x3b2;40 improves the interpretation of A&#x3b2;42 concentration for diagnosing Alzheimer&#x2019;s disease. Front Neurol. 2015;6:247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4661235</ArticleId><ArticleId IdType="pubmed">26640457</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426814</ArticleId><ArticleId IdType="pubmed">22951438</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C, Lovejoy C, Wray S. Stem cell models of Alzheimer&#x2019;s disease: progress and challenges. Alzheimers Res Ther. 2017;9:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470327</ArticleId><ArticleId IdType="pubmed">28610595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, et al. Modeling familial Alzheimer&#x2019;s disease with induced pluripotent stem cells. Hum Mol Genet. 2011;20:4530&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahairaki V, Ryu J, Peters A, Chang Q, Li T, Park TS, et al. Induced pluripotent stem cells from familial Alzheimer&#x2019;s disease patients differentiate into mature neurons with amyloidogenic properties. Stem Cells Dev. 2014;23:2996&#x2013;3010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267410</ArticleId><ArticleId IdType="pubmed">25027006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, et al. Characterization and molecular profiling of PSEN1 familial Alzheimer&#x2019;s disease iPSC-Derived neural progenitors. PLoS One. 2014;9:e84547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885572</ArticleId><ArticleId IdType="pubmed">24416243</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff G, Young JE, Martinez FJ, Buen F, Gore A, Kinaga J, et al. The presenilin-1 &#x394;E9 mutation results in reduced &#x3b3;-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep. 2013;5:974&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867011</ArticleId><ArticleId IdType="pubmed">24239350</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S, Evans LDB, Andersson T, Portelius E, Smith J, Dias TB, et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 2015;11:689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431668</ArticleId><ArticleId IdType="pubmed">25921538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochalek A, Mihalik B, Avci HX, Chandrasekaran A, T&#xe9;gl&#xe1;si A, Bock I, et al. Neurons derived from sporadic Alzheimer&#x2019;s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimers Res Ther. 2017;9:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5709977</ArticleId><ArticleId IdType="pubmed">29191219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc Natl Acad Sci USA. 2017;114:E476&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LNP, et al. The familial Alzheimer&#x2019;s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet. 2014;23:3523&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster MA, Knoblich J. Generation of cerebral organoids from human pluripotent stem. Nat Protoc. 2014;10:2329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160653</ArticleId><ArticleId IdType="pubmed">25188634</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja WK, Mungenast AE, Lin YT, Ko T, Abdurrob F, Seo J, et al. Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer&#x2019;s disease phenotypes. PLoS One. 2016;11:e0161969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5021368</ArticleId><ArticleId IdType="pubmed">27622770</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Lee HK, Moo L, Hanlon E, Stein T, Xia W. Common proteomic profiles of induced pluripotent stem cell-derived three-dimensional neurons and brain tissue from Alzheimer patients. J Proteom. 2018;182:21&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7457321</ArticleId><ArticleId IdType="pubmed">29709615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray S, Self M, Lewis PA, Taanman JW, Ryan NS, Mahoney CJ, et al. Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One. 2012;7:e43099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428297</ArticleId><ArticleId IdType="pubmed">22952635</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:409&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc. 2012;7:1836&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmann G, Zetterberg H, et al. Characterization of amyloid &#x3b2; peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain PL, Testa G. Taming human genetic variability: transcriptomic meta-analysis guides the experimental design and interpretation of iPSC-based disease modeling. Stem Cell Rep. 2017;8:1784&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470233</ArticleId><ArticleId IdType="pubmed">28591656</ArticleId></ArticleIdList></Reference><Reference><Citation>British Standards Institution. Accuracy (trueness and precision) of measurement methods and results. Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method [Internet]. Mol. Ecol. 1994 Available from: http://www.iso.org/iso/iso_catalogue/catalogue_tc/catalogue_detail.htm?csnumber=11833. Accessed 11 Feb. 2017.</Citation></Reference><Reference><Citation>Bergstrom P, Agholme L, Nazir FH, Satir TM, Toombs J, Wellington H, et al. Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. Sci Rep. 2016;6:29200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4935877</ArticleId><ArticleId IdType="pubmed">27383650</ArticleId></ArticleIdList></Reference><Reference><Citation>Veugelen S, Saito T, Saido TC, Ch&#xe1;vez-Guti&#xe9;rrez L, De Strooper B. Familial Alzheimer&#x2019;s disease mutations in presenilin generate amyloidogenic A&#x3b2; peptide seeds. Neuron. 2016;90:410&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27100199</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of A&#x3b2;43. Nat Neurosci. 2011;14:1023&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M, Munteanu B, Lismont S, Veugelen S, Horr&#xe9; K, Mercken M, et al. Alzheimer&#x2019;s-causing mutations shift A&#x3b2; length by destabilizing &#x3b3;-secretase-A&#x3b2;n interactions. Cell. 2017;170:443&#x2013;.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">28753424</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Han P, Miao H, Greengard P, Xu H. The transmembrane domain of the Alzheimer&#x2019;s &#x3b2;-secretase (BACE1) determines its late Golgi localization and access to &#x3b2;-amyloid precursor protein (APP) substrate. J Biol Chem. 2001;276:36788&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11466313</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi XP, Tugusheva K, Bruce JE, Lucka A, Wu GX, Chen-Dodson E, et al. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity. J Biol Chem. 2003;278:21286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665519</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer&#x2019;s amyloid beta peptide by endothelin- converting enzyme. J Biol Chem. 2001;276:24540&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337485</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel G, Gerber H, Koch P, Bruestle O, Fraering PC, Rajendran L. The Alzheimer&#x2019;s disease &#x3b3;-secretase generates higher 42:40 ratios for &#x3b2;-amyloid than for p3 peptides. Cell Rep. 2017;19:1967&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">28591569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanngren J, Lara P, &#xd6;jemalm K, Maioli S, Moradi N, Chen L, et al. Changed membrane integration and catalytic site conformation are two mechanisms behind the increased A&#x3b2;42/A&#x3b2;40 ratio by presenilin 1 familial Alzheimer-linked mutations. FEBS Open Bio. 2014;4:393&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050182</ArticleId><ArticleId IdType="pubmed">24918054</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand P, Nandel FS, Hansmann UHE. The Alzheimer beta-amyloid (Abeta(1-39)) dimer in an implicit solvent. J Chem Phys. 2008;129:195102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942451</ArticleId><ArticleId IdType="pubmed">19026087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloe AL, Orgel JPRO, Sachleben JR, et al. The Japanese mutant A&#x3b2; (&#x394;E22-A&#x3b2; 1-39) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding of wild-type A&#x3b2; 1-40 into atypical fibrils by &#x394;e22- A&#x3b2; 1-39. Biochemistry. 2011;50:2026&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631511</ArticleId><ArticleId IdType="pubmed">21291268</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi-Niidome S, Sasaki T, Osawa S, Sato T, Morishima K, Cai T, et al. Cooperative roles of hydrophilic loop 1 and the C-terminus of presenilin 1 in the substrate-gating mechanism of gamma-secretase. J Neurosci. 2015;35:2646&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605612</ArticleId><ArticleId IdType="pubmed">25673856</ArticleId></ArticleIdList></Reference><Reference><Citation>Somavarapu AK, Kepp KP. The dynamic mechanism of presenilin-function: sensitive gate dynamics and loop unplugging control protein access. Neurobiol Dis. 2016;89:147&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">26852951</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdile G, Gnjec A, Miklossy J, Fonte J, Veurink G, Bates K, et al. Protein markers for Alzheimer in the frontal cortex and cerebellum. Neurology. 2004;63:1385&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Cataldo AM, Kao BH, Rudnicki AG, Qin X, Yang JL, et al. Brain expression of presenilins in sporadic and early-onset, familial Alzheimer&#x2019;s disease. Mol Med. 2000;6:878&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949913</ArticleId><ArticleId IdType="pubmed">11126202</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, et al. Short A&#x3b2; peptides attenuate A&#x3b2;42 toxicity in vivo. J Exp Med. 2018;215:283&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748850</ArticleId><ArticleId IdType="pubmed">29208777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer&#x2019;s disease: a case series. Lancet Neurol. 2016;15:1326&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">27777022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30982609</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Bi-allelic CSF1R Mutations Cause Skeletal Dysplasia of Dysosteosclerosis-Pyle Disease Spectrum and Degenerative Encephalopathy with Brain Malformation.</ArticleTitle><Pagination><StartPage>925</StartPage><EndPage>935</EndPage><MedlinePgn>925-935</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2019.03.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(19)30100-4</ELocationID><Abstract><AbstractText>Colony stimulating factor 1 receptor (CSF1R) plays key roles in regulating development and function of the monocyte/macrophage lineage, including microglia and osteoclasts. Mono-allelic mutations of CSF1R are known to cause hereditary diffuse leukoencephalopathy with spheroids (HDLS), an adult-onset progressive neurodegenerative disorder. Here, we report seven affected individuals from three unrelated families who had bi-allelic CSF1R mutations. In addition to early-onset HDLS-like neurological disorders, they had brain malformations and skeletal dysplasia compatible to dysosteosclerosis (DOS) or Pyle disease. We identified five CSF1R mutations that were homozygous or compound heterozygous in these affected individuals. Two of them were deep intronic mutations resulting in abnormal inclusion of intron sequences in the mRNA. Compared with Csf1r-null mice, the skeletal and neural phenotypes of the affected individuals appeared milder and variable, suggesting that at least one of the mutations in each affected individual is hypomorphic. Our results characterized a unique human skeletal phenotype caused by CSF1R deficiency and implied that bi-allelic CSF1R mutations cause a spectrum of neurological and skeletal disorders, probably depending on the residual CSF1R function.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 American Society of Human Genetics. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo 108-8639, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertola</LastName><ForeName>D&#xe9;bora Romeo</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Unidade de Gen&#xe9;tica Cl&#xed;nica, Instituto da Crian&#xe7;a do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05403-000, Brazil; Instituto de Bioci&#xea;ncias da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05508-090, Brazil. Electronic address: debora.bertola@usp.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takanohashi</LastName><ForeName>Asako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Asuka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segawa</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokota</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishibashi</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishida</LastName><ForeName>Yoichiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Guilherme Lopes</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Unidade de Gen&#xe9;tica Cl&#xed;nica, Instituto da Crian&#xe7;a do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05403-000, Brazil; Instituto de Bioci&#xea;ncias da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05508-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Jos&#xe9; Francisco da Silva</ForeName><Initials>JFDS</Initials><AffiliationInfo><Affiliation>Unidade de Gen&#xe9;tica Cl&#xed;nica, Instituto da Crian&#xe7;a do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honjo</LastName><ForeName>Rachel Sayuri</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Unidade de Gen&#xe9;tica Cl&#xed;nica, Instituto da Crian&#xe7;a do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chong Ae</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Unidade de Gen&#xe9;tica Cl&#xed;nica, Instituto da Crian&#xe7;a do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musso</LastName><ForeName>Camila Manso</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Instituto de Bioci&#xea;ncias da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05508-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timmons</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzino</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taft</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lajoie</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Melanie A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute of Aging, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Carlos R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA, and Division of Genetics and Metabolism, Children's National Health System, Washington, DC 20010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo 108-8639, Japan; Department of Medical Genetics, Institute of Basic Medical Sciences, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100005, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, China-Japan Friendship Hospital, Beijing 100029, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbern</LastName><ForeName>James Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Center of Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simsek-Kiper</LastName><ForeName>Pelin O</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hacettepe University Medical Faculty, Ankara 06100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohashi</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Medical Genetics, Saitama Children's Medical Center, Saitama 330-8777, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robey</LastName><ForeName>Pamela G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Skeletal Biology Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyde</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biophysics, Oral Growth and Development, Dental Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Naomichi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyake</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spranger</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Central German Competence Center for Rare Diseases (MKSE), Magdeburg 39120, Germany; Greenwood Genetic Center, Greenwood, SC 29646, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiffmann</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Baylor Scott &amp; White Research Institute, Dallas, TX 75204, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderver</LastName><ForeName>Adeline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Intractable Disease Center, Saitama University Hospital, Moro 350-0495, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passos-Bueno</LastName><ForeName>Maria Rita Dos Santos</ForeName><Initials>MRDS</Initials><AffiliationInfo><Affiliation>Instituto de Bioci&#xea;ncias da Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo 05508-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Cas</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Translational Bioinformatics Group, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC 3052, Australia; Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Kinya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikegawa</LastName><ForeName>Shiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo 108-8639, Japan. Electronic address: sikegawa@ims.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 NS115052</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000622186">CSF1R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000604004">Csf1r protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016187">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C562973">Dysosteosclerosis</SupplMeshName><SupplMeshName Type="Disease" UI="C580150">Hereditary Diffuse Leukoencephalopathy with Spheroids</SupplMeshName><SupplMeshName Type="Disease" UI="C536252">Pyle disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="Y">abnormalities</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056784" MajorTopicYN="N">Leukoencephalopathies</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010009" MajorTopicYN="N">Osteochondrodysplasias</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010026" MajorTopicYN="N">Osteosclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016187" MajorTopicYN="N">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CSF1R</Keyword><Keyword MajorTopicYN="N">HDLS</Keyword><Keyword MajorTopicYN="N">Pyle disease</Keyword><Keyword MajorTopicYN="N">dysosteosclerosis</Keyword><Keyword MajorTopicYN="N">leukoencephalopathy</Keyword><Keyword MajorTopicYN="N">mutation</Keyword><Keyword MajorTopicYN="N">osteoclast</Keyword><Keyword MajorTopicYN="N">osteosclerosis</Keyword><Keyword MajorTopicYN="N">skeletal dysplasia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30982609</ArticleId><ArticleId IdType="pmc">PMC6507048</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2019.03.004</ArticleId><ArticleId IdType="pii">S0002-9297(19)30100-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stanley E.R., Berg K.L., Einstein D.B., Lee P.S., Pixley F.J., Wang Y., Yeung Y.G. Biology and action of colony--stimulating factor-1. Mol. Reprod. Dev. 1997;46:4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981357</ArticleId></ArticleIdList></Reference><Reference><Citation>Pixley F.J., Stanley E.R. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004;14:628&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519852</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh D., Dai X.M., Nandi S., Lightowler S., Trivett M., Chan C.K., Bertoncello I., Ramsay R.G., Stanley E.R. Colony stimulating factor-1 dependence of paneth cell development in the mouse small intestine. Gastroenterology. 2009;137:136&#x2013;144, 144.e1&#x2013;144.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706482</ArticleId><ArticleId IdType="pubmed">19303020</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke J., Iwata Y., Rabacal W.A., Basu R., Yeung Y.G., Humphreys B.D., Wada T., Schwarting A., Stanley E.R., Kelley V.R. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J.&#xa0;Clin. Invest. 2009;119:2330&#x2013;2342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719924</ArticleId><ArticleId IdType="pubmed">19587445</ArticleId></ArticleIdList></Reference><Reference><Citation>Arceci R.J., Pampfer S., Pollard J.W. Expression of CSF-1/c-fms and SF/c-kit mRNA during preimplantation mouse development. Dev. Biol. 1992;151:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1374350</ArticleId></ArticleIdList></Reference><Reference><Citation>Arceci R.J., Shanahan F., Stanley E.R., Pollard J.W. Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development. Proc. Natl. Acad. Sci. USA. 1989;86:8818&#x2013;8822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298381</ArticleId><ArticleId IdType="pubmed">2554332</ArticleId></ArticleIdList></Reference><Reference><Citation>Erblich B., Zhu L., Etgen A.M., Dobrenis K., Pollard J.W. Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS ONE. 2011;6:e26317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203114</ArticleId><ArticleId IdType="pubmed">22046273</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai X.M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., Sylvestre V., Stanley E.R. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002;99:111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11756160</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai X.-M., Zong X.-H., Akhter M.P., Stanley E.R. Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J.&#xa0;Bone Miner. Res. 2004;19:1441&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312244</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V., Gokhan S., Gulinello M., Branch C.A., Patil M., Basu R., Stoddart C., Mehler M.F., Stanley E.R. Phenotypic characterization of a Csf1r haploinsufficient mouse model of adult-onset leukodystrophy with axonal spheroids and pigmented glia (ALSP) Neurobiol. Dis. 2015;74:219&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323933</ArticleId><ArticleId IdType="pubmed">25497733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Baker M., Nicholson A.M., Rutherford N.J., Finch N., Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 2011;44:200&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267847</ArticleId><ArticleId IdType="pubmed">22197934</ArticleId></ArticleIdList></Reference><Reference><Citation>Monies D., Maddirevula S., Kurdi W., Alanazy M.H., Alkhalidi H., Al-Owain M., Sulaiman R.A., Faqeih E., Goljan E., Ibrahim N. Autozygosity reveals recessive mutations and novel mechanisms in dominant genes: implications in variant interpretation. Genet. Med. 2017;19:1144&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">28383543</ArticleId></ArticleIdList></Reference><Reference><Citation>Spranger J., Albrecht C., Rohwedder H.J., Wiedemann H.R. [Dysosteosclerosis--a special form of generalized osteosclerosis] Fortschr. Geb. Rontgenstr. Nuklearmed. 1968;109:504&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">5750745</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwin P. A case of unusual bone development. JBJS. 1931;13:874&#x2013;876.</Citation></Reference><Reference><Citation>Wang Z., Horemuzova E., Iida A., Guo L., Liu Y., Matsumoto N., Nishimura G., Nordgren A., Miyake N., Tham E. Axial spondylometaphyseal dysplasia is also caused by NEK1 mutations. J.&#xa0;Hum. Genet. 2017;62:503&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">28123176</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Elcioglu N.H., Karalar O.K., Topkar M.O., Wang Z., Sakamoto Y., Matsumoto N., Miyake N., Nishimura G., Ikegawa S. Dysosteosclerosis is also caused by TNFRSF11A mutation. J.&#xa0;Hum. Genet. 2018;63:769&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">29568001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Elcioglu N.H., Mizumoto S., Wang Z., Noyan B., Albayrak H.M., Yamada S., Matsumoto N., Miyake N., Nishimura G., Ikegawa S. Identification of biallelic EXTL3 mutations in a novel type of spondylo-epi-metaphyseal dysplasia. J.&#xa0;Hum. Genet. 2017;62:797&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5537416</ArticleId><ArticleId IdType="pubmed">28331220</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons C., Dyment D., Bent S.J., Crawford J., D&#x2019;Hooghe M., Kohlsch&#xfc;tter A., Venkateswaran S., Helman G., Poll-The B.T., Makowski C.C., Care4Rare Consortium A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy. Brain. 2017;140:3105&#x2013;3111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841038</ArticleId><ArticleId IdType="pubmed">29186371</ArticleId></ArticleIdList></Reference><Reference><Citation>Morandi A., Barbetti V., Riverso M., Dello Sbarba P., Rovida E. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. PLoS ONE. 2011;6:e27450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3212567</ArticleId><ArticleId IdType="pubmed">22096574</ArticleId></ArticleIdList></Reference><Reference><Citation>Himes S.R., Sester D.P., Ravasi T., Cronau S.L., Sasmono T., Hume D.A. The JNK are important for development and survival of macrophages. J.&#xa0;Immunol. 2006;176:2219&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">16455978</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne P.V., Guilbert L.J., Stanley E.R. Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues. J.&#xa0;Cell Biol. 1981;91:848&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112824</ArticleId><ArticleId IdType="pubmed">6276411</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung Y.-G., Stanley E.R. Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction. Mol. Cell. Proteomics. 2003;2:1143&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966146</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson C., Part K., K&#xfc;nnis-Beres K., Kaldm&#xe4;e M., Fernaeus S.Z., Land T. Pro-survival effects of JNK and p38 MAPK pathways in LPS-induced activation of BV-2 cells. Biochem. Biophys. Res. Commun. 2011;406:488&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">21338578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafe L., Cormier-Daire V., Hall C., Lachman R., Mortier G., Mundlos S., Nishimura G., Sangiorgi L., Savarirayan R., Sillence D. Nosology and classification of genetic skeletal disorders: 2015 revision. Am. J. Med. Genet. A. 2015;167A:2869&#x2013;2892.</Citation><ArticleIdList><ArticleId IdType="pubmed">26394607</ArticleId></ArticleIdList></Reference><Reference><Citation>Houston C.S., Gerrard J.W., Ives E.J. Dysosteosclerosis. AJR Am. J. Roentgenol. 1978;130:988&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">417609</ArticleId></ArticleIdList></Reference><Reference><Citation>Campeau P.M., Lu J.T., Sule G., Jiang M.M., Bae Y., Madan S., H&#xf6;gler W., Shaw N.J., Mumm S., Gibbs R.A. Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. Hum. Mol. Genet. 2012;21:4904&#x2013;4909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607481</ArticleId><ArticleId IdType="pubmed">22875837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiper P.O.S., Saito H., Gori F., Unger S., Hesse E., Yamana K., Kiviranta R., Solban N., Liu J., Brommage R. Cortical-bone fragility--insights from sFRP4 deficiency in Pyle&#x2019;s disease. N.&#xa0;Engl. J. Med. 2016;374:2553&#x2013;2562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070790</ArticleId><ArticleId IdType="pubmed">27355534</ArticleId></ArticleIdList></Reference><Reference><Citation>Haraguchi R., Kitazawa R., Mori K., Tachibana R., Kiyonari H., Imai Y., Abe T., Kitazawa S. sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss. Sci. Rep. 2016;6:25198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846872</ArticleId><ArticleId IdType="pubmed">27117872</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno T., Broderick D.F., Mezaki N., Isami A., Kaneda D., Tashiro Y., Tokutake T., Keegan B.M., Woodruff B.K., Miura T. Diagnostic value of brain calcifications in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. AJNR Am. J. Neuroradiol. 2017;38:77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233547</ArticleId><ArticleId IdType="pubmed">27633805</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J.L., Suh E., Wood E.M., Lee E.B., Coslett H.B., Raible K., Lee V.M., Trojanowski J.Q., Van Deerlin V.M. Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His. Acta Neuropathol. Commun. 2015;3:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491242</ArticleId><ArticleId IdType="pubmed">26141825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pridans C., Sauter K.A., Baer K., Kissel H., Hume D.A. CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function. Sci. Rep. 2013;3:3013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804858</ArticleId><ArticleId IdType="pubmed">24145216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannarile M.A., Weisser M., Jacob W., Jegg A.M., Ries C.H., R&#xfc;ttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J.&#xa0;Immunother. Cancer. 2017;5:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5514481</ArticleId><ArticleId IdType="pubmed">28716061</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A., Schetters S.T., Sri S., Askew K., Mancuso R., Vargas-Caballero M., Holscher C., Perry V.H., Gomez-Nicola D. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain. 2016;139:891&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichler F.S., Li J., Guo Y., Caruso P.A., Bjonnes A.C., Pan J., Booker J.K., Lane J.M., Tare A., Vlasac I. CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids. Brain. 2016;139:1666&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4892751</ArticleId><ArticleId IdType="pubmed">27190017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31001580</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Comparative analyses of plasma amyloid-&#x3b2; levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system.</ArticleTitle><Pagination><StartPage>eaav1388</StartPage><MedlinePgn>eaav1388</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eaav1388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.aav1388</ELocationID><Abstract><AbstractText>Detection of amyloid-&#x3b2; (A&#x3b2;) aggregates contributes to the diagnosis of Alzheimer disease (AD). Plasma A&#x3b2; is deemed a less invasive and more accessible hallmark of AD, as A&#x3b2; can penetrate blood-brain barriers. However, correlations between biofluidic A&#x3b2; concentrations and AD progression has been tenuous. Here, we introduce a diagnostic technique that compares the heterogeneous and the monomerized states of A&#x3b2; in plasma. We used a small molecule, EPPS [4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid], to dissociate aggregated A&#x3b2; into monomers to enhance quantification accuracy. Subsequently, A&#x3b2; levels of EPPS-treated plasma were compared to those of untreated samples to minimize inter- and intraindividual variations. The interdigitated microelectrode sensor system was used to measure plasma A&#x3b2; levels on a scale of 0.1 pg/ml. The implementation of this self-standard blood test resulted in substantial distinctions between patients with AD and individuals with normal cognition (NC), with selectivity and sensitivity over 90%.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>YoungSoo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5029-7082</Identifier><AffiliationInfo><Affiliation>Integrated Science and Engineering Division, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Yong Kyoung</ForeName><Initials>YK</Initials><Identifier Source="ORCID">0000-0001-9003-7912</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical Engineering, Kwangwoon University, 20 Kwangwoon-ro, Nowon-gu, Seoul 01897, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye Yun</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0003-3757-5652</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Jee Hoon</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-3243-0529</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinsik</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9121-7031</Identifier><AffiliationInfo><Affiliation>Department of Medical Biotechnology, Dongguk University, 30 Pildong-ro 1-gil, Jung-gu, Seoul 04620, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Seungyeop</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5839-1110</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, Yonsei University, 50 Yonsei-ro Seodaemun-gu, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Korea Institute of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jinny Claire</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-6869-6671</Identifier><AffiliationInfo><Affiliation>Integrated Science and Engineering Division, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Myung-Sic</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Dahye</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Dongsung</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5235-7114</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sejin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Korea Institute of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>HoChung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Science Institute, Korea Institute of Science and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyeonghwan</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1681-8574</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jeong Hoon</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-7344-6060</Identifier><AffiliationInfo><Affiliation>Department of Electrical Engineering, Kwangwoon University, 20 Kwangwoon-ro, Nowon-gu, Seoul 01897, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byun</LastName><ForeName>Byung Hyun</ForeName><Initials>BH</Initials><Identifier Source="ORCID">0000-0002-1146-1916</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Korea Institute of Radiological &amp; Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Su Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Neurology of Korea Cancer Center Hospital, Korea Institute of Radiological &amp; Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Jeong Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology of Korea Cancer Center Hospital, Korea Institute of Radiological &amp; Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyo Chul</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Division of RI-Convergence Research, Korea Institute of Radiological &amp; Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Won Woo</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Cantis, Sangnok-gu, Ansan-si, Gyeonggi-do 15588, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae-Seung</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Jae-Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-4318-495X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Sang Moo</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology of Korea Cancer Center Hospital, Korea Institute of Radiological &amp; Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Kyo Seon</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0003-3590-2074</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000607446">N(2-hydroxythyl)piperazine-N'-(3-propanesulfonic acid)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056656" MajorTopicYN="N">Lab-On-A-Chip Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008839" MajorTopicYN="N">Microelectrodes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31001580</ArticleId><ArticleId IdType="pmc">PMC6469948</ArticleId><ArticleId IdType="doi">10.1126/sciadv.aav1388</ArticleId><ArticleId IdType="pii">aav1388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yaffe K., Weston A., Graff-Radford N. R., Satterfield S., Simonsick E. M., Younkin S. G., Younkin L. H., Kuller L., Ayonayon H. N., Ding J., Harris T. B., Association of plasma &#x3b2;-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261&#x2013;266 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108075</ArticleId><ArticleId IdType="pubmed">21245181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R., Tang M.-X., Jacobs D. M., Manly J., Bell K., Merchant C., Small S. A., Stern Y., Wisniewski H. M., Mehta P. D., Plasma amyloid &#x3b2;-peptide 1&#x2013;42 and incipient Alzheimer&#x2019;s disease. Ann. Neurol. 46, 412&#x2013;416 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10482274</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glund K., Thelen K. M., Syversen S., Sj&#xf6;gren M., von Bergmann K., Wallin A., Vanmechelen E., Vanderstichele H., L&#xfc;tjohann D., Blennow K., The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer&#x2019;s disease. Dement. Geriatr. Cogn. Disord. 19, 256&#x2013;265 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15785028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P. D., Pirttila T., Patrick B. A., Barshatzky M., Mehta S. P., Amyloid &#x3b2; protein 1&#x2013;40 and 1&#x2013;42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 304, 102&#x2013;106 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11335065</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y., Shoji S., Amyloid &#x3b2; protein in plasma from patients with sporadic Alzheimer&#x2019;s disease. J. Neurol. Sci. 141, 65&#x2013;68 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8880695</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R., Wu Z., Zlokovic B. V., RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid &#x3b2;-peptide clearance through transport across the blood&#x2013;brain barrier. Stroke 35, 2628&#x2013;2631 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15459432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Peng M., Jia J., Plasma amyloid-&#x3b2; oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD. Curr. Alzheimer Res. 11, 325&#x2013;331 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24635842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. Y., Kim H. V., Jo S., Lee C. J., Choi S. Y., Kim D. J., Kim Y., EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-&#x3b2; oligomers and plaques. Nat. Commun. 6, 8997 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4686862</ArticleId><ArticleId IdType="pubmed">26646366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y., Schupf N., Cosentino S. A., Luchsinger J. A., Scarmeas N., Nutrient intake and plasma &#x3b2;-amyloid. Neurology 78, 1832&#x2013;1840 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369517</ArticleId><ArticleId IdType="pubmed">22551728</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown B. M., Peiffer J. J., Taddei K., Lui J. K., Laws S. M., Gupta V. B., Taddei T., Ward V. K., Rodrigues M. A., Burnham S., Rainey-Smith S. R., Villemagne V. L., Bush A., Ellis K. A., Masters C. L., Ames D., Macaulay S. L., Szoeke C., Rowe C. C., Martins R. N.; AIBL Research Group12 , Physical activity and amyloid-&#x3b2; plasma and brain levels: Results from the Australian imaging, biomarkers and lifestyle study of ageing. Mol. Psych. 18, 875&#x2013;881 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22889922</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F., Poljak A., Valenzuela M., Mayeux R., Smythe G. A., Sachdev P. S., Meta-analysis of plasma amyloid-&#x3b2; levels in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 26, 365&#x2013;375 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660871</ArticleId><ArticleId IdType="pubmed">21709378</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo Y. K., Kim J., Kim G., Kim Y. S., Kim H. Y., Lee S., Cho W. W., Kim S., Lee S.-M., Lee B. C., Lee J. H., Hwang K. S., A highly sensitive plasma-based amyloid-&#x3b2; detection system through medium-changing and noise cancellation system for early diagnosis of the Alzheimer&#x2019;s disease. Sci. Rep. 7, 8882 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567090</ArticleId><ArticleId IdType="pubmed">28827785</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanyon H. F., Viles J. H., Human serum albumin can regulate amyloid-&#x3b2; peptide fiber growth in the brain interstitium: Implications for Alzheimer disease. J. Biol. Chem. 287, 28163&#x2013;28168 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431649</ArticleId><ArticleId IdType="pubmed">22718756</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike K. E., Savage G., Villemagne V. L., Ng S., Moss S. A., Maruff P., Mathis C. A., Klunk W. E., Masters C. L., Rowe C. C., &#x3b2;-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer&#x2019;s disease. Brain 130, 2837&#x2013;2844 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel H., Gertz H. J., Dresel S., Peters O., Bartenstein P., Buerger K., Hiemeyer F., Wittemer-Rump S. M., Seibyl J., Reininger C., Sabri O.; Florbetaben Study Group , Cerebral amyloid-&#x3b2; PET with florbetaben (18F) in patients with Alzheimer&#x2019;s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol. 10, 424&#x2013;435 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21481640</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson K. A., Fox N. C., Sperling R. A., Klunk W. E., Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006213 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312396</ArticleId><ArticleId IdType="pubmed">22474610</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici G. D., Rosen H. J., Alkalay A., Kornak J., Furst A. J., Agarwal N., Mormino E. C., O&#x2019;Neil J. P., Janabi M., Karydas A., Growdon M. E., Jang J. Y., Huang E. J., DeArmond S. J., Trojanowski J. Q., Grinberg L. T., Gorno-Tempini M. L., Seeley W. W., Miller B. L., Jagust W. J., Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77, 2034&#x2013;2042 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236517</ArticleId><ArticleId IdType="pubmed">22131541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman F. H., van der Flier W. M., Schoonenboom N. S. M., van Elk E. J., Kok A., Rijmen F., Blankenstein M. A., Scheltens P., Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69, 1006&#x2013;1011 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17785669</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon M. J., Desanti S., Zinkowski R., Mehta P. D., Pratic&#xf2; D., Segal S. R., Rusinek H., Li J., Tsui W., Saint Louis L. A., Clark C. M., Tarshish C. Y., Li Y., Lair L., Javier E., Rich K. C., Lesbre P., Mosconi L., Reisberg B., Sadowski M., DeBernadis J. F., Kerkman D., Hampel H., Wahlund L.-O., Davies P., Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 27, 394&#x2013;401 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16125823</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., Vanderstichele H., Vanmechelen E., Blennow K., Cerebrospinal fluid &#x3b2;-amyloid (1&#x2013;42) in Alzheimer disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56, 673&#x2013;680 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Brys M., Pirraglia E., Rich K., Rolstad S., Mosconi L., Switalski R., Glodzik-Sobanskaa L., De Santi S., Zinkowski R., Mehta P. D., Pratico D., Saint Louis L. A., Wallin A., Blennow K., de Leon M. J., Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging 30, 682&#x2013;690 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774781</ArticleId><ArticleId IdType="pubmed">17889968</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K., Yabuki C., Seubert P., Schenk D., Hori Y., Ohtsuki S., Terasaki T., Hashimoto T., Iwatsubo T., A&#x3b2; immunotherapy: Intracerebral sequestration of A&#x3b2; by an anti-A&#x3b2; monoclonal antibody 266 with high affinity to soluble A&#x3b2;. J. Neurosci. 29, 11393&#x2013;11398 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665926</ArticleId><ArticleId IdType="pubmed">19741145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H., Tokuda T., Kasai T., Ishigami N., Hidaka H., Kondo M., Allsop D., Nakagawa M., High-molecular-weight &#x3b2;-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716&#x2013;2726 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20339023</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein H. J., Nebes R. D., Saxton J. A., Price J. C., Mathis C. A., Tsopelas N. D., Ziolko S. K., James J. A., Snitz B. E., Houck P. R., Bi W., Cohen A. D., Lopresti B. J., DeKosky S. T., Halligan E. M., Klun W. E., Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509&#x2013;1517 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolochevska O., Taglialatela G., Non-demented individuals with Alzheimer&#x2019;s disease neuropathology: Resistance to cognitive decline may reveal new treatment strategies. Curr. Pharm. Des. 22, 4063&#x2013;4068 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6007878</ArticleId><ArticleId IdType="pubmed">27189599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondello S., Buki A., Barzo P., Randall J., Provuncher G., Hanlon D., Wilson D., Kobeissy F., Jeromin A., CSF and plasma amyloid-&#x3b2; temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury. Sci. Rep. 4, 6446 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192636</ArticleId><ArticleId IdType="pubmed">25300247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L. F., Galasko D. R., Jutel M., Karydas A., Kaye J. A., Leszek J., Miller B. L., Minthon L., Quinn J. F., Rabinovici G. D., Robinson W. H., Sabbagh M. N., So Y. T., Sparks D. L., Tabaton M., Tinklenberg J., Yesavage J. A., Tibshirani R., Wyss-Coray T., Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signaling proteins. Nat. Med. 13, 1359&#x2013;1362 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin D. M., Kan C. W., Campbell T. G., Howes S. C., Fournier D. R., Song L., Piech T., Patel P. P., Chang L., Rivnak A. J., Ferrell E. P., Randall J. D., Provuncher G. K., Walt D. R., Duffy D. C., Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595&#x2013;599 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggink K. A., M&#xfc;ller M., Kuiperij H. B., Verbeek M. M., Methods for analysis of amyloid-&#x3b2; aggregates. J. Alzheimers Dis. 28, 735&#x2013;758 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22156047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindhagen-Persson M., Br&#xe4;nnstr&#xf6;m K., Vestling M., Steinitz M., Olofsson A., Amyloid-&#x3b2; oligomer specificity mediated by the IgM isotype &#x2013; implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLOS ONE 5, e13928 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978096</ArticleId><ArticleId IdType="pubmed">21085663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiike Y., Minai R., Matsuo Y., Chen Y.-R., Kimura T., Takashima A., Amyloid oligomer conformation in a group of natively folded proteins. PLOS ONE 3, e3235 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2528939</ArticleId><ArticleId IdType="pubmed">18800165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. Y., Kim Y., Han G., Kim D. J., Regulation of in vitro A&#x3b2;1-40 aggregation mediated by small molecules. J. Alzheimers Dis. 22, 73&#x2013;85 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20847447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. S., Moss J. A., Janda K. D., Biological tuning of synthetic tactics in solid-phase synthesis: Application to A&#x3b2;(1&#x2013;42). J. Org. Chem. 69, 7776&#x2013;7778 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15498016</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi F., Maiti P., Bitan G., Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides. J. Vis. Exp., 1071 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763294</ArticleId><ArticleId IdType="pubmed">19229175</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G., Drachman D., Folstein M. F., Katzman R., Price D., Stadlan E. M., Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh J. H., Qiu A., Seo S. W., Soon H. W., Kim J. H., Kim G. H., Kim M.-J., Lee J.-M., Na D. L., Volume reduction in subcortical regions according to severity of Alzheimer&#x2019;s disease. J. Neurol. 258, 1013&#x2013;1020 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21240517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn H.-J., Chin J., Park A., Lee B. H., Suh M. K., Seo S. W., Na D. L., Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): A useful tool for assessing and monitoring cognitive impairments in dementia patients. J. Korean Med. Sci. 25, 1071&#x2013;1076 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890886</ArticleId><ArticleId IdType="pubmed">20592901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Na D. L., Normative data on the Korean version of the Boston Naming Test. J. Clin. Exp. Neuropsychol. 21, 127&#x2013;133 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10421007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y. J., Kim C.-M., Jang E. H., Hwang J., Roh J. H., Lee J.-H., White matter changes may precede gray matter loss in elderly with subjective memory impairment. Dement. Geriatr. Cogn. Disord. 42, 227&#x2013;235 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27701163</ArticleId></ArticleIdList></Reference><Reference><Citation>Byun B. H., Kim B., Park S., Ko I., Lee K., Kim K., Kim Y., Lee J.-Y., Bu S., Kim J., Chi D., Ha J., Lim S., Head-to-head comparison of 11C-PiB and 18F-FC119S for A&#x3b2; imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer&#x2019;s disease patients. Medicine 96, e6441 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5371492</ArticleId><ArticleId IdType="pubmed">28328855</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson B. C., Bakkour A., Salat D. H., Feczko E., Pacheco J., Greve D. N., Grodstein F., Wright C. I., Blacker D., Rosas H. D., Sperling R. A., Atri A., Growdon J. H., Hyman B. T., Morris J. C., Fischl B., Buckner R. L., The cortical signature of Alzheimer&#x2019;s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 19, 497&#x2013;510 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings D., Seibyl J., Sabbagh M., Lai F., Hopkins W., Bullich S., Gimenez M., Reininger C., Putz B., Stephens A., Catafau A. M., Marek K., Age dependence of brain &#x3b2;-amyloid deposition in Down syndrome: An [18F]florbetaben PET study. Neurology 84, 500&#x2013;507 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25568295</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30982608</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy and Can Result in Congenital Absence of Microglia.</ArticleTitle><Pagination><StartPage>936</StartPage><EndPage>947</EndPage><MedlinePgn>936-947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2019.03.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(19)30106-5</ELocationID><Abstract><AbstractText>Microglia are CNS-resident macrophages that scavenge debris and regulate immune responses. Proliferation and development of macrophages, including microglia, requires Colony Stimulating Factor 1 Receptor (CSF1R), a gene previously associated with a dominant adult-onset neurological condition (adult-onset leukoencephalopathy with axonal spheroids and pigmented glia). Here, we report two unrelated individuals with homozygous CSF1R mutations whose presentation was distinct from ALSP. Post-mortem examination of an individual with a homozygous splice mutation (c.1754-1G&gt;C) demonstrated several structural brain anomalies, including agenesis of corpus callosum. Immunostaining demonstrated almost complete absence of microglia within this brain, suggesting that it developed in the absence of microglia. The second individual had a homozygous missense mutation (c.1929C&gt;A [p.His643Gln]) and presented with developmental delay and epilepsy in childhood. We analyzed a zebrafish model (csf1r<sup>DM</sup>) lacking Csf1r function and found that their brains also lacked microglia and had reduced levels of CUX1, a neuronal transcription factor. CUX1<sup>+</sup> neurons were also reduced in sections of homozygous CSF1R mutant human brain, identifying an evolutionarily conserved role for CSF1R signaling in production or maintenance of CUX1<sup>+</sup> neurons. Since a large fraction of CUX1<sup>+</sup> neurons project callosal axons, we speculate that microglia deficiency may contribute to agenesis of the corpus callosum via reduction in CUX1<sup>+</sup> neurons. Our results suggest that CSF1R is required for human brain development and establish the csf1r<sup>DM</sup> fish as a model for microgliopathies. In addition, our results exemplify an under-recognized form of phenotypic expansion, in which genes associated with well-recognized, dominant conditions produce different phenotypes when biallelically mutated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oosterhof</LastName><ForeName>Nynke</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Irene J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Genetic Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karimiani</LastName><ForeName>Ehsan Ghayoor</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuil</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA 98101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daza</LastName><ForeName>Ray</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Astle</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory and Pathology, Alaska Native Medical Center, Anchorage, AK 99508, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Linde</LastName><ForeName>Herma C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shivaram</LastName><ForeName>Giridhar M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Radiology, Seattle Children's Hospital, Seattle, WA 98105.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demmers</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Proteomics Center, Erasmus University Medical Center, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latimer</LastName><ForeName>Caitlin S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loter</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Laboratories, Seattle Children's Hospital, Seattle, WA 98105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maroofian</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK; Department of Neuromuscular Disorders and Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Ham</LastName><ForeName>Tjakko J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands. Electronic address: t.vanham@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hevner</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA; Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Genetic Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA; Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, WA 98101, USA. Electronic address: jtbenn@uw.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007454</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000622186">CSF1R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C080632">CUX1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016187">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C000655126">csf1ra protein, zebrafish</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C000655124">csf1rb protein, zebrafish</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000013" MajorTopicYN="N">Congenital Abnormalities</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056784" MajorTopicYN="N">Leukoencephalopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016187" MajorTopicYN="N">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029961" MajorTopicYN="N">Zebrafish Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CSF1R</Keyword><Keyword MajorTopicYN="N">CUX1</Keyword><Keyword MajorTopicYN="N">agenesis corpus callosum</Keyword><Keyword MajorTopicYN="N">axonal spheroids</Keyword><Keyword MajorTopicYN="N">leukoencephalopathy</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword><Keyword MajorTopicYN="N">osteopetrosis</Keyword><Keyword MajorTopicYN="N">recessive</Keyword><Keyword MajorTopicYN="N">zebrafish</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30982608</ArticleId><ArticleId IdType="pmc">PMC6506793</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2019.03.010</ArticleId><ArticleId IdType="pii">S0002-9297(19)30106-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cunningham C.L., Mart&#xed;nez-Cerde&#xf1;o V., Noctor S.C. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J.&#xa0;Neurosci. 2013;33:4216&#x2013;4233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711552</ArticleId><ArticleId IdType="pubmed">23467340</ArticleId></ArticleIdList></Reference><Reference><Citation>Erblich B., Zhu L., Etgen A.M., Dobrenis K., Pollard J.W. Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS ONE. 2011;6:e26317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203114</ArticleId><ArticleId IdType="pubmed">22046273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemeyer N., Hanft K.M., Akriditou M.A., Unger N., Park E.S., Stanley E.R., Staszewski O., Dimou L., Prinz M. Microglia contribute to normal myelinogenesis and to oligodendrocyte progenitor maintenance during adulthood. Acta Neuropathol. 2017;134:441&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951721</ArticleId><ArticleId IdType="pubmed">28685323</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., Giustetto M., Ferreira T.A., Guiducci E., Dumas L. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Squarzoni P., Oller G., Hoeffel G., Pont-Lezica L., Rostaing P., Low D., Bessis A., Ginhoux F., Garel S. Microglia modulate wiring of the embryonic forebrain. Cell Rep. 2014;8:1271&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">25159150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodarczyk A., Holtman I.R., Krueger M., Yogev N., Bruttger J., Khorooshi R., Benmamar-Badel A., de Boer-Bergsma J.J., Martin N.A., Karram K. A novel microglial subset plays a key role in myelinogenesis in developing brain. EMBO J. 2017;36:3292&#x2013;3308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686552</ArticleId><ArticleId IdType="pubmed">28963396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V., Stanley E.R. Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol. 2006;18:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbomel P., Thisse B., Thisse C. Zebrafish early macrophages colonize cephalic mesenchyme and developing brain, retina, and epidermis through a M-CSF receptor-dependent invasive process. Dev. Biol. 2001;238:274&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">11784010</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley E.R., Berg K.L., Einstein D.B., Lee P.S., Pixley F.J., Wang Y., Yeung Y.G. Biology and action of colony--stimulating factor-1. Mol. Reprod. Dev. 1997;46:4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981357</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba Y., Ghetti B., Baker M.C., Uitti R.J., Hutton M.L., Yamaguchi K., Bird T., Lin W., DeLucia M.W., Dickson D.W., Wszolek Z.K. Hereditary diffuse leukoencephalopathy with spheroids: clinical, pathologic and genetic studies of a new kindred. Acta Neuropathol. 2006;111:300&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">16523341</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno T., Tada M., Tada M., Nishizawa M., Ikeuchi T. [Hereditary diffuse leukoencephalopathy with spheroids (HDLS): a review of the literature on its clinical characteristics and mutations in the colony-stimulating factor-1 receptor gene] Brain Nerve. 2014;66:581&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">24807373</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson A.M., Baker M.C., Finch N.A., Rutherford N.J., Wider C., Graff-Radford N.R., Nelson P.T., Clark H.B., Wszolek Z.K., Dickson D.W. CSF1R mutations link POLD and HDLS as a single disease entity. Neurology. 2013;80:1033&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653204</ArticleId><ArticleId IdType="pubmed">23408870</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Baker M., Nicholson A.M., Rutherford N.J., Finch N., Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 2011;44:200&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267847</ArticleId><ArticleId IdType="pubmed">22197934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundal C., Baker M., Karrenbauer V., Gustavsen M., Bedri S., Glaser A., Myhr K.-M., Haugarvoll K., Zetterberg H., Harbo H. Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. Eur. J. Neurol. 2015;22:328&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289423</ArticleId><ArticleId IdType="pubmed">25311247</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C., Wszolek Z.K. Hereditary diffuse leukoencephalopathy with axonal spheroids: more than just a rare disease. Neurology. 2014;82:102&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">24336229</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Knaap M.S., Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134:351&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563342</ArticleId><ArticleId IdType="pubmed">28638987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchin M.M., Martin K.C., de Souza A.C., de Oliveira M.A., Rieder C.R. Nasu-Hakola disease and primary microglial dysfunction. Nat. Rev. Neurol. 2010;6 2, 523.</Citation><ArticleIdList><ArticleId IdType="pubmed">20836191</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M., Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 2014;15:300&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterhof N., Kuil L.E., van der Linde H.C., Burm S.M., Berdowski W., van Ijcken W.F.J., van Swieten J.C., Hol E.M., Verheijen M.H.G., van Ham T.J. Colony-Stimulating Factor 1 Receptor (CSF1R) regulates microglia density and distribution, but not microglia differentiation in&#xa0;vivo. Cell Rep. 2018;24:1203&#x2013;1217.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30067976</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Tornos F.M., Briz C.G., Weiss L.A., Sebasti&#xe1;n-Serrano A., Ares S., Navarrete M., Frangeul L., Galazo M., Jabaudon D., Esteban J.A., Nieto M. Cux1 enables interhemispheric connections of layer II/III neurons by regulating Kv1-dependent firing. Neuron. 2016;89:494&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">26804994</ArticleId></ArticleIdList></Reference><Reference><Citation>Makrythanasis P., Maroofian R., Stray-Pedersen A., Musaev D., Zaki M.S., Mahmoud I.G., Selim L., Elbadawy A., Jhangiani S.N., Coban Akdemir Z.H. Biallelic variants in KIF14 cause intellectual disability with microcephaly. Eur. J. Hum. Genet. 2018;26:330&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839044</ArticleId><ArticleId IdType="pubmed">29343805</ArticleId></ArticleIdList></Reference><Reference><Citation>Retterer K., Juusola J., Cho M.T., Vitazka P., Millan F., Gibellini F., Vertino-Bell A., Smaoui N., Neidich J., Monaghan K.G. Clinical application of whole-exome&#xa0;sequencing across clinical indications. Genet. Med. 2016;18:696&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">26633542</ArticleId></ArticleIdList></Reference><Reference><Citation>Parichy D.M., Ransom D.G., Paw B., Zon L.I., Johnson S.L. An orthologue of the kit-related gene fms is required for development of neural crest-derived xanthophores and a subpopulation of adult melanocytes in the zebrafish, Danio rerio. Development. 2000;127:3031&#x2013;3044.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862741</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Luo D., Lei Y., Hu W., Zhao H., Cheng C.H. A highly effective TALEN-mediated approach for targeted gene disruption in Xenopus tropicalis and zebrafish. Methods. 2014;69:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">24556556</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbomel P., Thisse B., Thisse C. Ontogeny and behaviour of early macrophages in the zebrafish embryo. Development. 1999;126:3735&#x2013;3745.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433904</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterhof N., Kuil L.E., van Ham T.J. Microglial activation by genetically targeted conditional neuronal&#xa0;ablation in the zebrafish. Methods Mol. Biol. 2017;1559:377&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">28063058</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ham T.J., Brady C.A., Kalicharan R.D., Oosterhof N., Kuipers J., Veenstra-Algra A., Sjollema K.A., Peterson R.T., Kampinga H.H., Giepmans B.N. Intravital correlated microscopy reveals differential macrophage and microglial dynamics during resolution of neuroinflammation. Dis. Model. Mech. 2014;7:857&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073275</ArticleId><ArticleId IdType="pubmed">24973753</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani S., Nardelli J., Verney C., Delezoide A.L., Guimiot F., Gressens P., Adle-Biassette H. Dynamic expression patterns of progenitor and pyramidal neuron layer markers in the developing human hippocampus. Cereb. Cortex. 2016;26:1255&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">25882041</ArticleId></ArticleIdList></Reference><Reference><Citation>Hevner R.F., Daza R.A., Englund C., Kohtz J., Fink A. Postnatal shifts of interneuron position in the neocortex of normal and reeler mice: evidence for inward radial migration. Neuroscience. 2004;124:605&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980731</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber W., von Heydebreck A., S&#xfc;ltmann H., Poustka A., Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002;18(Suppl 1):S96&#x2013;S104.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Monies D., Maddirevula S., Kurdi W., Alanazy M.H., Alkhalidi H., Al-Owain M., Sulaiman R.A., Faqeih E., Goljan E., Ibrahim N. Autozygosity reveals recessive mutations and novel mechanisms in dominant genes: implications in variant interpretation. Genet. Med. 2017;19:1144&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">28383543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees J.H., Vaughan R.W., Kondeatis E., Hughes R.A. HLA-class II alleles in Guillain-Barr&#xe9; syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J.&#xa0;Neuroimmunol. 1995;62:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499492</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., ACMG Laboratory Quality Assurance Committee Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Meireles A.M., Shiau C.E., Guenther C.A., Sidik H., Kingsley D.M., Talbot W.S. The phosphate exporter xpr1b is required for differentiation of tissue-resident macrophages. Cell Rep. 2014;8:1659&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177277</ArticleId><ArticleId IdType="pubmed">25220463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi S., Gokhan S., Dai X.M., Wei S., Enikolopov G., Lin H., Mehler M.F., Stanley E.R. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev. Biol. 2012;367:100&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388946</ArticleId><ArticleId IdType="pubmed">22542597</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J., Elwood F., Britschgi M., Villeda S., Zhang H., Ding Z., Zhu L., Alabsi H., Getachew R., Narasimhan R. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J.&#xa0;Exp. Med. 2013;210:157&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549715</ArticleId><ArticleId IdType="pubmed">23296467</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V., Stanley E.R. Regulation of embryonic and postnatal development by the CSF-1 receptor. Curr. Top. Dev. Biol. 2017;123:229&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479137</ArticleId><ArticleId IdType="pubmed">28236968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett F.C., Bennett M.L., Yaqoob F., Mulinyawe S.B., Grant G.A., Hayden Gephart M., Plowey E.D., Barres B.A. A combination of ontogeny and CNS environment establishes microglial identity. Neuron. 2018;98:1170&#x2013;1183.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023731</ArticleId><ArticleId IdType="pubmed">29861285</ArticleId></ArticleIdList></Reference><Reference><Citation>Pridans C., Sauter K.A., Baer K., Kissel H., Hume D.A. CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function. Sci. Rep. 2013;3:3013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804858</ArticleId><ArticleId IdType="pubmed">24145216</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams S.J., Kirk A., Auer R.N. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): Integrating the literature on hereditary diffuse leukoencephalopathy with spheroids (HDLS) and pigmentary orthochromatic leukodystrophy (POLD) J.&#xa0;Clin. Neurosci. 2018;48:42&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">29122458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann S., Murrell J., Harms L., Miller K., Meisel A., Brosch T., Scheel M., Ghetti B., Goebel H.H., Stenzel W. Enlarging the nosological spectrum of hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) Brain Pathol. 2014;24:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029294</ArticleId><ArticleId IdType="pubmed">24428556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchin M.M., Lima J.E., Natel J., Sakamoto A.C. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2006;66:615&#x2013;616. author reply 615&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505336</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouery E., Delague V., Bergougnoux A., Koussa S., Serre J.L., M&#xe9;garban&#xe9; A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum. Mutat. 2008;29:E194&#x2013;E204.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546367</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J., Kestil&#xe4; M., Wu J., Salminen A., B&#xf6;hling T., Ruotsalainen V., Hakola P., Bakker A.B., Phillips J.H., Pekkarinen P. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet. 2000;25:357&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiialainen A., Hovanes K., Paloneva J., Kopra O., Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol. Dis. 2005;18:314&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15686960</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K., Turnbull I.R., Poliani P.L., Vermi W., Cerutti E., Aoshi T., Tassi I., Takai T., Stanley S.L., Miller M. Macrophage colony stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and &#x3b2;-catenin. Nat. Immunol. 2009;999:734&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004764</ArticleId><ArticleId IdType="pubmed">19503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J., Mandelin J., Kiialainen A., Bohling T., Prudlo J., Hakola P., Haltia M., Konttinen Y.T., Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J.&#xa0;Exp. Med. 2003;198:669&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194176</ArticleId><ArticleId IdType="pubmed">12925681</ArticleId></ArticleIdList></Reference><Reference><Citation>Codjia P., Ayrignac X., Mochel F., Mouzat K., Carra-Dalliere C., Castelnovo G., Ellie E., Etcharry-Bouyx F., Verny C., Belliard S. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: An MRI study of 16 French cases. AJNR Am. J. Neuroradiol. 2018;39:1657&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7655300</ArticleId><ArticleId IdType="pubmed">30115677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado E., Jansen M.H., Anink J., De Filippis L., Vescovi A.L., Watts C., Aronica E., Hol E.M., Kuijpers T.W. Chronic exposure of astrocytes to interferon-&#x3b1; reveals molecular changes related to Aicardi-Goutieres syndrome. Brain. 2013;136:245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">23365100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer K., Kratz C.P., Vasen H.F., Caron O., Colas C., Entz-Werle N., Gerdes A.M., Goldberg Y., Ilencikova D., Muleris M., EU-Consortium Care for CMMRD (C4CMMRD) Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium &#x2018;care for CMMRD&#x2019; (C4CMMRD) J.&#xa0;Med. Genet. 2014;51:355&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">24737826</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31009046</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.</ArticleTitle><Pagination><StartPage>1723</StartPage><EndPage>1735</EndPage><MedlinePgn>1723-1735</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awz090</ELocationID><Abstract><AbstractText>The advent of tau-targeted PET tracers such as flortaucipir (18F) (flortaucipir, also known as 18F-AV-1451 or 18F-T807) have made it possible to investigate the sequence of development of tau in relationship to age, amyloid-&#x3b2;, and to the development of cognitive impairment due to Alzheimer's disease. Here we report a multicentre longitudinal evaluation of the relationships between baseline tau, tau change and cognitive change, using flortaucipir PET imaging. A total of 202 participants 50 years old or older, including 57 cognitively normal subjects, 97 clinically defined mild cognitive impairment and 48 possible or probable Alzheimer's disease dementia patients, received flortaucipir PET scans of 20 min in duration beginning 80 min after intravenous administration of 370 MBq flortaucipir (18F). On separate days, subjects also received florbetapir amyloid PET imaging, and underwent a neuropsychological test battery. Follow-up flortaucipir scans and neuropsychological battery assessments were also performed at 9 and 18 months. Fifty-five amyloid-&#x3b2;+ and 90 amyloid-&#x3b2;- subjects completed the baseline and 18-month study visits and had valid quantifiable flortaucipir scans at both time points. There was a statistically significant increase in the global estimate of cortical tau burden as measured by standardized uptake value ratio (SUVr) from baseline to 18 months in amyloid-&#x3b2;+ but not amyloid-&#x3b2;- subjects (least squared mean change in flortaucipir SUVr : 0.0524 &#xb1; 0.0085, P &lt; 0.0001 and 0.0007 &#xb1; 0.0024 P = 0.7850, respectively), and a significant association between magnitude of SUVr increase and baseline tau burden. Voxel-wise evaluations further suggested that the regional pattern of change in flortaucipir PET SUVr over the 18-month study period (i.e. which regions exhibited the greatest change) also varied as a function of baseline global estimate of tau burden. In subjects with lower global SUVr, temporal lobe regions showed the greatest flortaucipir retention, whereas in subjects with higher baseline SUVr, parietal and frontal regions were increasingly affected. Finally, baseline flortaucipir and change in flortaucipir SUVr were both significantly (P &lt; 0.0001) associated with changes in cognitive performance. Taken together, these results provide a preliminary characterization of the longitudinal spread of tau in Alzheimer's disease and suggest that the amount and location of tau may have implications both for the spread of tau and the cognitive deterioration that may occur over an 18-month period.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navitsky</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galante</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Butler Hospital, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Duke University Health System, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southekal</LastName><ForeName>Sudeepti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Anupa K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGeehan</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Nathaniel C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truocchio</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Abhinay D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbinin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teske</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis IN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="Y">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18F-AV-1451</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">flortaucipir</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31009046</ArticleId><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="doi">10.1093/brain/awz090</ArticleId><ArticleId IdType="pii">5476105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert M. S., DeKosky S. T., Dickson D., Dubois B, Feldman HF, Fox NC et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging and Alzheimer&#x2019;s Association workgroup. Alzheimer&#x2019;s Dement, 2011; 7: 270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters C et al. . Cognitive impairment and decline in cognitively normal older adults with high amyloid-&#x3b2;: A meta analysis. Alzheimer&#x2019;s Dement 2017; 6: 108&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315443</ArticleId><ArticleId IdType="pubmed">28239636</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer&#x2019;s disease pathology and cerebral infarctions. Neurology 2005; 64: 834&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW Jr, Miller P, Storandt M, Rubin EH, Morris JC et al. . Clinicopathologic studies in cognitively healthy aging and Alzheimer disease. Arch Neurol 1998; 55: 326&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE et al. . In vivo characterization and quantification of neurofibrillary tau PET radioligand MK-6240 in humans from Alzheimer&#x2019;s disease dementia to young controls. J Nucl Med 2019; 60: 93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354223</ArticleId><ArticleId IdType="pubmed">29777006</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras C, Hof PR, Giannakopoulos Pl, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cerebral Cortex 1994; 4: 138&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">8038565</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J et al. . Tau and A&#x3b2; imaging, CSR measures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med 2016; 8: 338ra66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C et al. . Early Clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 2014; 38: 171&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948934</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS et al. . In vivo cortical spreading patter of tau and amyloid in the Alzheimer&#x2019;s disease spectrum. Ann Neurol 2016a; 80: 247&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lyoo CH et al. . Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 2016b; 87: 375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">27358341</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Lee SH, Lee JH, Choi YC, Ryu YH et al. . Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2017; 53: 103&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">28254589</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al. . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al. . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128: 755&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer&#x2019;s disease. Neurobiol Aging 1996; 17: 921&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363804</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN et al. . Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurology 2015; 72: 287&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25622185</ArticleId></ArticleIdList></Reference><Reference><Citation>De Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ et al. . Propogation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 2012; 73: 685&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Declercq L, Rombouts F, Koole M, Fierens K, Mari&#xeb;n J, Langlois X et al. . Preclinical evaluation of 18F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017; 58: 975&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">28232614</ArticleId></ArticleIdList></Reference><Reference><Citation>Devous MD Sr, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Siderowf A et al. . Test-retest reproducibility for the tau PET imaging agent flortaucipir F18. J Nucl Med 2018; 59: 937&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">29284675</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman PEM, Davis MD et al. . Florbetapir F 18 amyloid PET and longitudinal cognitive decline: a prospective 36-month multicenter study. Mol Psychiatry 2014; 19: 1044&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195975</ArticleId><ArticleId IdType="pubmed">24614494</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. FreeSurfer. Neuroimage 2012; 62: 774&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL et al. . Unbiased average age-appropriate atlases for pediatric studies. NeuroImage 2011; 54: 313&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962759</ArticleId><ArticleId IdType="pubmed">20656036</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, Penny WD, editors. Statistical Parametric Mapping: The Analysis of Functional Brain Images. London: Academic Press; 2007.</Citation></Reference><Reference><Citation>Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N et al. . Tau positron emission tomographic imaging in the lewy body diseases. JAMA Neurol. 2016; 73: 1334&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287290</ArticleId><ArticleId IdType="pubmed">27654968</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammes J, Bischof GN, Giehl K, Faber J, Drzezga A, Klockgether T et al. . Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord 2017; 32: 170&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">27476874</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N et al. . 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med 2016; 57: 208&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">26541774</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C et al. . Preclinical Characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med 2016; 57: 1599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">27230925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998; 57: 1168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al. . National Institute on Aging Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement 2012; 8: 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al. . Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ et al. . Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based longitudinal cohort study. Lancet Neurol 2016; 15: 56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784263</ArticleId><ArticleId IdType="pubmed">26597325</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P et al. . Longitudinal tau PET in aging and Alzheimer&#x2019;s disease. Brain 2018; 141: 1517&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson K.A., Sperling R.A., Gidicsin C., Carmasin J., Maye J.Colemanet al. . Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer&#x2019;s disease dementia, mild cognitive impairment, and normal aging. Alzheimer&#x2019;s Dement 2013; 9: S72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800236</ArticleId><ArticleId IdType="pubmed">23375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016; 79: 110&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N et al. . [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016; 132: 931&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5107140</ArticleId><ArticleId IdType="pubmed">27645292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Lowe VJ, Boeve BF, Senjem ML, Tosakulwong N, Lesnick TG et al. . AV-1451 tau and &#x3b2;-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 2017; 81: 58&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299616</ArticleId><ArticleId IdType="pubmed">27863444</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ et al. . Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003; 62: 1087&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu J, Witter MP, Small SA, Clelland C et al. . Trans-synaptic spread of tau pathology in vivo. PLoS One 2012; 7: e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S et al. . Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer&#x2019;s Disease Patients Measured Using [18F] THK-5351. PLoS One 2016; 11: e0158460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927104</ArticleId><ArticleId IdType="pubmed">27355840</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J et al. . Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. Medicine 2014; 93: e150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4602781</ArticleId><ArticleId IdType="pubmed">25501055</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Meltzer AC, Chong MST, Andrea NV, Ant&#xf3;n-Fern&#xe1;ndez A et al. . Pathologic correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol 2017; 81: 117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319193</ArticleId><ArticleId IdType="pubmed">27997036</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J et al. . Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G.M., Knopman D.S., Chertkow H., Hyman BT, Jack CR, Kawas CH et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement 2011; 7: 263&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan C. T., Irwin D. J., Nasrallah I., Phillips J. S., Spindler M., Rascovsky K. et al. . Multimodal evaluation demonstrates in vivo18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016; 132: 935&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5154298</ArticleId><ArticleId IdType="pubmed">27815633</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton LE, Grinberg LT, Miller B, Kawas C, Yaffe K. Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology 2011; 77: 1737&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208952</ArticleId><ArticleId IdType="pubmed">22031532</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A two-process model for neuropathology of Alzheimer&#x2019;s disease. Neurobiology of Aging 2014; 35: 301&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977862</ArticleId><ArticleId IdType="pubmed">24080173</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS et al. . Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol 2007; 66: 1136&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropath Exp Neurol 2009; 68: 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692822</ArticleId><ArticleId IdType="pubmed">19104448</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P et al. . Non-invasive assessment of Alzheimer&#x2019;s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014; 137: 1762&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain 2016; 139: 1551&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. . &#x3b2;-amyloid imaging and memory in non-demeted individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain 2007; 130: 2837&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Arora AK, Devine M, Lu M, Galante N, Siderowf A et al. . Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. E J Nuc Med 2017a; 44: 825&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">28064343</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW et al. . Relationships between flortaucipir (18F-AV-1451) positron emission tomography tau binding and amyloid burden clinical diagnosis, age and cognition. Brain 2017b; 140: 748&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382945</ArticleId><ArticleId IdType="pubmed">28077397</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M et al. . Effectiveness of florbetapir PET imaging in changing patient management. Dement Geriatr Cogn Disord 2017c; 44: 129&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806476</ArticleId><ArticleId IdType="pubmed">28787712</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Meurol 1999; 45: 358&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 2006; 66: 49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401845</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y et al. . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer&#x2019;s disease: phase 3 study. Alzheimers Dement 2015; 11: 964&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824567</ArticleId></ArticleIdList></Reference><Reference><Citation>Shcherbinin S, Schwarz AJ, Joshi AJ, Navitsky M, Flitter M, Shankle WR et al. . Kinetics of the tau PET tracer [18F]-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimer&#x2019;s disease. J Nuc Med 2016; 10: 1535&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27151986</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonhaut DR, McMillan CT, Spina S, Dickerson BC, Siderowf S, Devous MD Sr et al. . 18 F-flortaucipir tau positron emmission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol 2017; 82: 622&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5665658</ArticleId><ArticleId IdType="pubmed">28980714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, O&#x2019;Neil JP, Janabi M, Ossenkoppele R et al. . PET imaging of Tau deposition in the aging human brain. Neuron 2016; 89: 971&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Ossenkoppele R, Strandberg O, Palmqvist S, J&#xf6;gi J et al. Swedish BioFINDER study. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer&#x2019;s disease. Brain 2017; 140: 2286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29050382</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M et al. . Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 2016; 139: 1539&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The molecular pathology of Alzheimer&#x2019;s disease. Neuron 1991; 6: 487&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H. et al. . Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer&#x2019;s disease patients. Alzheimer&#x2019;s Dement 2016; 12: 110&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26238576</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Puschmann A, Sch&#xf6;ll M, Ohlsson T, van Swieten J, Honer M et al. . 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016; 139: 2372&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995360</ArticleId><ArticleId IdType="pubmed">27357347</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegener 2017; 12: 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319037</ArticleId><ArticleId IdType="pubmed">28219440</ArticleId></ArticleIdList></Reference><Reference><Citation>Southekal S, Devous MD Sr., Kennedy I, Navitsky M, Lu M et al. . Flortaucipir F 18 quantitation using a parametric estimate of reference signal intensity (PERSI). J Nucl Med 2018; 59: 944&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191858</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">5505685</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Dore V, Bourgeat P, Burnham SC, Laws S, Salvado O et al. . A&#x3b2;-amyloid and tau imaging in dementia. Semin Nucl Med 2017; 47: 75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">27987560</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Comley R, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S et al. . First in-human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948. J Nucl Med 2018; 59: 1869&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278896</ArticleId><ArticleId IdType="pubmed">29728519</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9062334</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D et al. . [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer&#x2019;s disease. Alzheimers Dement 2013; 9: 666&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31009033</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Cortical &#x3b2;-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease.</ArticleTitle><Pagination><StartPage>818</StartPage><EndPage>826</EndPage><MedlinePgn>818-826</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.0834</ELocationID><Abstract><AbstractText Label="IMPORTANCE">&#x3b2;-Amyloid deposits are a pathologic hallmark of Alzheimer disease (AD). However, the extent to which cortical &#x3b2;-amyloid protein in the absence of insoluble deposits is associated with classic features of AD appear to be unknown.</AbstractText><AbstractText Label="OBJECTIVE">To examine the associations of cortical &#x3b2;-amyloid protein in the absence of insoluble deposits with cognitive decline, neurofibrillary tangles, other age-associated neuropathologic conditions, and APOE.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This analysis combines data from 2 community-based clinicopathologic cohort studies of aging. The Religious Orders Study started in 1994, and the Rush Memory and Aging Project started in 1997. Both studies are ongoing. Participants without known dementia were enrolled and agreed to annual clinical evaluations and brain donation after death. Primary analyses focused on individuals without &#x3b2;-amyloid deposits. Data analyses occurred in mid-September 2018.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">&#x3b2;-Amyloid protein abundance was measured by targeted proteomics using selected reaction monitoring. &#x3b2;-Amyloid deposits were detected using immunohistochemistry. Other neuropathologic indices were quantified via uniform structured evaluation. Linear mixed models were used to examine the association of &#x3b2;-amyloid protein with cognitive decline. Regression models examined the protein associations with neuropathologic outcomes and the APOE genotype.</AbstractText><AbstractText Label="RESULTS">By mid-September 2018, 3575 older persons were enrolled, and 1559 had died and undergone brain autopsy. Proteomic data were collected in 1208 individuals, and 5 with missing cognitive scores were excluded. Of the remaining 1203, primary analyses focused on 148 individuals (12.3%) without &#x3b2;-amyloid deposits. In this group, the mean (SD) age at death was 87.0 (7.0) years, and 84 individuals (56.8%) were women. In the absence of &#x3b2;-amyloid deposits, we did not observe an association of &#x3b2;-amyloid protein with decline in episodic memory, but the protein was associated with faster rates of decline in processing speed (mean [SE] change, -0.014 [0.005]; P&#x2009;=&#x2009;.008) and visuospatial abilities (mean [SE] change, -0.013 [0.005]; P&#x2009;=&#x2009;.006). We did not observe protein association with paired helical filament tau tangle density. The protein was associated with amyloid angiopathy (odds ratio, 1.38 [95% CI, 1.15-1.67]; P&#x2009;&lt;&#x2009;.001) but no other brain pathology. The associations with cognitive decline were unchanged after controlling for amyloid angiopathy. Neither APOE &#x3b5;4 nor a polygenic Alzheimer risk score was associated with &#x3b2;-amyloid protein.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Cortical &#x3b2;-amyloid protein was associated with faster cognitive decline in the absence of &#x3b2;-amyloid deposits, which supports the role of cortical soluble &#x3b2;-amyloid as a neurotoxic agent in aging. The lack of protein association with paired helical filament tau tangles, episodic memory decline, or strong genetic drivers of deposited &#x3b2;-amyloid suggests an underlying neuropathologic change that may differ from that of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petyuk</LastName><ForeName>Vladislav A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Pacific Northwest National Laboratory, Richland, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasaki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiteri</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066492" MajorTopicYN="N">Cognitive Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012598" MajorTopicYN="N">Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Yu and Bennett report grants from the National Institute on Aging during the conduct of the study. Dr Schneider reports personal fees from AVID radiopharmaceuticals, Eli Lilly, Genetech, and Grifols, outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31009033</ArticleId><ArticleId IdType="pmc">PMC6583061</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.0834</ArticleId><ArticleId IdType="pii">2731441</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, et al. . Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(20):9649-9653. doi:10.1073/pnas.90.20.9649</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.20.9649</ArticleId><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Blazey TM, Holtzman DM, et al. . Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &#x3b5;4 genotype. Brain. 2018;141(6):1828-1839. doi:10.1093/brain/awy103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy103</ArticleId><ArticleId IdType="pmc">PMC5972633</ArticleId><ArticleId IdType="pubmed">29672664</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. . Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825. doi:10.1073/pnas.0900345106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900345106</ArticleId><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, Ibrahim-Verbaas CA, Harold D, et al. ; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452-1458. doi:10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Chen K, Keenan BT, et al. . Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol. 2013;70(9):1150-1157. doi:10.1001/jamaneurol.2013.2815</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.2815</ArticleId><ArticleId IdType="pmc">PMC3773291</ArticleId><ArticleId IdType="pubmed">23836404</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10(9):e1004606. doi:10.1371/journal.pgen.1004606</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004606</ArticleId><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, et al. . Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med. 2016;8(338):338ra66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Guo JL, McBride JD, et al. . Amyloid-&#x3b2; plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med. 2018;24(1):29-38. doi:10.1038/nm.4443</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4443</ArticleId><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378-384. doi:10.1001/archneur.61.3.378</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.3.378</ArticleId><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91(9):e859-e866. doi:10.1212/WNL.0000000000006075</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006075</ArticleId><ArticleId IdType="pmc">PMC6133625</ArticleId><ArticleId IdType="pubmed">30068637</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek-Ahmadi M, Perez SE, Chen K, Mufson EJ. Neuritic and diffuse plaque associations with memory in non-cognitively impaired elderly. J Alzheimers Dis. 2016;53(4):1641-1652. doi:10.3233/JAD-160365</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160365</ArticleId><ArticleId IdType="pmc">PMC6314669</ArticleId><ArticleId IdType="pubmed">27540968</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Wilson RS, Schneider JA, Bennett DA. Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci. 2013;5:50. doi:10.3389/fnagi.2013.00050</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2013.00050</ArticleId><ArticleId IdType="pmc">PMC3766823</ArticleId><ArticleId IdType="pubmed">24058343</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Coleman RE, et al. ; AV45-A11 Study Group . Amyloid-&#x3b2; assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79(16):1636-1644. doi:10.1212/WNL.0b013e3182661f74</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182661f74</ArticleId><ArticleId IdType="pmc">PMC3468774</ArticleId><ArticleId IdType="pubmed">22786606</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, et al. . Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74(10):807-815. doi:10.1212/WNL.0b013e3181d3e3e9</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181d3e3e9</ArticleId><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310-1323. doi:10.1093/brain/awn320</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn320</ArticleId><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden EY, Teplow DB. Amyloid &#x3b2;-protein oligomers and Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5(6):60. doi:10.1186/alzrt226</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt226</ArticleId><ArticleId IdType="pmc">PMC3978746</ArticleId><ArticleId IdType="pubmed">24289820</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. doi:10.15252/emmm.201606210</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, et al. . Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300(5618):486-489. doi:10.1126/science.1079469</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cline EN, Bicca MA, Viola KL, Klein WL. The amyloid-&#x3b2; oligomer hypothesis: beginning of the third decade. J Alzheimers Dis. 2018;64(s1):S567-S610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004937</ArticleId><ArticleId IdType="pubmed">29843241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, et al. . Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol. 1999;155(3):853-862. doi:10.1016/S0002-9440(10)65184-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65184-X</ArticleId><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, et al. . Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol. 1999;46(6):860-866. doi:10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M</ArticleId><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, Savva GM, Brayne C, et al. ; Medical Research Council Cognitive Function and Ageing Study . The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133(pt 5):1328-1341. doi:10.1093/brain/awq065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq065</ArticleId><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasaki S, Gaiteri C, Mostafavi S, De Jager PL, Bennett DA. The molecular and neuropathological consequences of genetic risk for Alzheimer&#x2019;s dementia. Front Neurosci. 2018;12(699):699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187226</ArticleId><ArticleId IdType="pubmed">30349450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64(s1):S161-S189. doi:10.3233/JAD-179939</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834-841. doi:10.1212/01.WNL.0000152982.47274.9E</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000152982.47274.9E</ArticleId><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Aggarwal NT, Barnes LL, Mendes de Leon CF, Hebert LE, Evans DA. Cognitive decline in incident Alzheimer disease in a community population. Neurology. 2010;74(12):951-955. doi:10.1212/WNL.0b013e3181d64786</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181d64786</ArticleId><ArticleId IdType="pmc">PMC2848102</ArticleId><ArticleId IdType="pubmed">20308679</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Petyuk VA, Gaiteri C, et al. . Targeted brain proteomics uncover multiple pathways to Alzheimer&#x2019;s dementia. Ann Neurol. 2018;84(1):78-88. doi:10.1002/ana.25266</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25266</ArticleId><ArticleId IdType="pmc">PMC6119500</ArticleId><ArticleId IdType="pubmed">29908079</ArticleId></ArticleIdList></Reference><Reference><Citation>Petyuk VA, Qian WJ, Smith RD, Smith DJ. Mapping protein abundance patterns in the brain using voxelation combined with liquid chromatography and mass spectrometry. Methods. 2010;50(2):77-84. doi:10.1016/j.ymeth.2009.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2009.07.009</ArticleId><ArticleId IdType="pmc">PMC2818068</ArticleId><ArticleId IdType="pubmed">19654045</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreev VP, Petyuk VA, Brewer HM, et al. . Label-free quantitative LC-MS proteomics of Alzheimer&#x2019;s disease and normally aged human brains. J Proteome Res. 2012;11(6):3053-3067. doi:10.1021/pr3001546</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr3001546</ArticleId><ArticleId IdType="pmc">PMC3445701</ArticleId><ArticleId IdType="pubmed">22559202</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean B, Tomazela DM, Shulman N, et al. . Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966-968. doi:10.1093/bioinformatics/btq054</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq054</ArticleId><ArticleId IdType="pmc">PMC2844992</ArticleId><ArticleId IdType="pubmed">20147306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185. doi:10.1126/science.1566067</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356. doi:10.1126/science.1072994</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers&#x2014;a decade of discovery. J Neurochem. 2007;101(5):1172-1184. doi:10.1111/j.1471-4159.2006.04426.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04426.x</ArticleId><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; SE, Sherman MA, Grant M, et al. . Brain amyloid-&#x3b2; oligomers in ageing and Alzheimer&#x2019;s disease. Brain. 2013;136(pt 5):1383-1398. doi:10.1093/brain/awt062</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt062</ArticleId><ArticleId IdType="pmc">PMC3634198</ArticleId><ArticleId IdType="pubmed">23576130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer&#x2019;s disease from normal and pathologic aging. Exp Neurol. 1999;158(2):328-337. doi:10.1006/exnr.1999.7085</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1999.7085</ArticleId><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without &#x3b2;-amyloid. Neurobiol Aging. 2016;37:19-25. doi:10.1016/j.neurobiolaging.2015.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.09.011</ArticleId><ArticleId IdType="pmc">PMC4716785</ArticleId><ArticleId IdType="pubmed">26481403</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Wu D, Lambert MP, et al. . Alzheimer&#x2019;s disease-type neuronal tau hyperphosphorylation induced by A &#x3b2; oligomers. Neurobiol Aging. 2008;29(9):1334-1347. doi:10.1016/j.neurobiolaging.2007.02.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.029</ArticleId><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108(14):5819-5824. doi:10.1073/pnas.1017033108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017033108</ArticleId><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM. Soluble A&#x3b2; promotes wild-type tau pathology in vivo. J Neurosci. 2012;32(48):17345-17350. doi:10.1523/JNEUROSCI.0172-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0172-12.2012</ArticleId><ArticleId IdType="pmc">PMC3586232</ArticleId><ArticleId IdType="pubmed">23197725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG. Soluble amyloid-&#x3b2; oligomers as synaptotoxins leading to cognitive impairment in Alzheimer&#x2019;s disease. Front Cell Neurosci. 2015;9:191. doi:10.3389/fncel.2015.00191</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00191</ArticleId><ArticleId IdType="pmc">PMC4443025</ArticleId><ArticleId IdType="pubmed">26074767</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, et al. . Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837-842. doi:10.1038/nm1782</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31009028</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.</ArticleTitle><Pagination><StartPage>791</StartPage><EndPage>799</EndPage><MedlinePgn>791-799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.0765</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking.</AbstractText><AbstractText Label="OBJECTIVE">To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This North American cohort study used data from 1583 individuals in the multicenter Alzheimer's Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018.</AbstractText><AbstractText Label="EXPOSURES">Clinical diagnosis, A&#x3b2; and tau cerebrospinal fluid (CSF) biomarkers, imaging measures (magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography), and tests on cognitive scores.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was the association between baseline exposures (diagnosis, CSF biomarkers, imaging measures, and cognition) and longitudinal plasma NfL levels, analyzed by an ultrasensitive assay. The secondary outcomes were the associations between a multimodal classification scheme with A&#x3b2;, tau, and neurodegeneration (ie, the ATN system) and plasma NfL levels and between longitudinal changes in plasma NfL levels and changes in the other measures.</AbstractText><AbstractText Label="RESULTS">Of the included 1583 participants, 716 (45.2%) were women, and the mean (SD) age was 72.9 (7.1) years; 401 had no cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P&#x2009;&lt;&#x2009;.001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. A longitudinal increase in NfL level correlated with baseline CSF biomarkers (low A&#x3b2;42 [P&#x2009;=&#x2009;.001], high total tau [P&#x2009;=&#x2009;.02], and high phosphorylated tau levels [P&#x2009;=&#x2009;.02]), magnetic resonance imaging measures (small hippocampal volumes [P&#x2009;&lt;&#x2009;.001], thin regional cortices [P&#x2009;=&#x2009;.009], and large ventricular volumes [P&#x2009;=&#x2009;.002]), low fluorodeoxyglucose-positron emission tomography uptake (P&#x2009;=&#x2009;.01), and poor cognitive performance (P&#x2009;&lt;&#x2009;.001) for a global cognitive score. With use of the ATN system, increased baseline NfL levels were seen in A-T+N+ (P&#x2009;&lt;&#x2009;.001), A+T-N+ (P&#x2009;&lt;&#x2009;.001), and A+T+N+ (P&#x2009;&lt;&#x2009;.001), and increased rates of NfL levels were seen in A-T+N- (P&#x2009;=&#x2009;.009), A-T+N+ (P&#x2009;=&#x2009;.02), A+T-N+ (P&#x2009;=&#x2009;.04), and A+T+N+ (P&#x2009;=&#x2009;.002). Faster increase in NfL levels correlated with faster increase in CSF biomarkers of neuronal injury, faster rates of atrophy and hypometabolism, and faster worsening in global cognition (all P&#x2009;&lt;&#x2009;.05 in patients with mild cognitive impairment; associations differed slightly in cognitively unimpaired controls and patients with AD dementia).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2019 Jul 1;76(7):872. doi: 10.1001/jamaneurol.2019.1649.</RefSource><PMID Version="1">31180462</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscientist. 2019 Oct;25(5):385. doi: 10.1177/1073858419868688.</RefSource><PMID Version="1">31554494</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Mattsson reported being a consultant for the Alzheimer&#x2019;s Disease Neuroimaging Initiative and being a Wallenberg Molecular Medicine Fellow. Dr Zetterberg reported serving on the advisory boards for Roche Diagnostics, Wave, Samumed, and CogRx and being a Wallenberg Academy Fellow. Drs Zetterberg and Blennow reported being cofounders of Brain Biomarker Solutions in Gothenburg AB, a Gothenburg University Ventures-based platform company at the University of Gothenburg. Dr Blennow reported serving as a consultant or on advisory boards for Alzheon, Eli Lilly and Company, Novartis, and Roche Diagnostics and holding a Torsten S&#xf6;derberg Professorship in Medicine. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31009028</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pii">2731440</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P, Blennow K, Breteler MM, et al. . Alzheimer&#x2019;s disease. Lancet. 2016;388(10043):505-517. doi:10.1016/S0140-6736(15)01124-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01124-1</ArticleId><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Barnes J, Bernstein MA, et al. . Magnetic resonance imaging in Alzheimer&#x2019;s Disease Neuroimaging Initiative 2. Alzheimers Dement. 2015;11(7):740-756. doi:10.1016/j.jalz.2015.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.002</ArticleId><ArticleId IdType="pmc">PMC4523217</ArticleId><ArticleId IdType="pubmed">26194310</ArticleId></ArticleIdList></Reference><Reference><Citation>Laforce R Jr, Soucy J-P, Sellami L, et al. . Molecular imaging in dementia: past, present, and future. Alzheimers Dement. 2018;14(11):1522-1552. doi:10.1016/j.jalz.2018.06.2855</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.06.2855</ArticleId><ArticleId IdType="pubmed">30028955</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H. The past and the future of Alzheimer&#x2019;s disease fluid biomarkers. J Alzheimers Dis. 2018;62(3):1125-1140. doi:10.3233/JAD-170773</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170773</ArticleId><ArticleId IdType="pmc">PMC5869995</ArticleId><ArticleId IdType="pubmed">29562534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, O&#x2019;Bryant SE, Molinuevo JL, et al. . Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14(11):639-652. doi:10.1038/s41582-018-0079-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0079-7</ArticleId><ArticleId IdType="pmc">PMC6211654</ArticleId><ArticleId IdType="pubmed">30297701</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135-140. doi:10.1016/j.ebiom.2015.11.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.11.036</ArticleId><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557-566. doi:10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Disease Neuroimaging Initiative 
http://adni.loni.usc.edu. Accessed October 8, 2018.</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. . Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209. doi:10.1212/WNL.0b013e3181cb3e25</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181cb3e25</ArticleId><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34(7):939-944. doi:10.1212/WNL.34.7.939</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Zetterberg H, Teunissen CE, et al. . Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of &#x3b2;-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517-526. doi:10.1016/j.jalz.2015.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.09.009</ArticleId><ArticleId IdType="pubmed">26555316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. ; Swedish BioFINDER study group; Alzheimer&#x2019;s Disease Neuroimaging Initiative . CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-&#x3b2; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470-1481. doi:10.1016/j.jalz.2018.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bernstein MA, Fox NC, et al. . The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685-691. doi:10.1002/jmri.21049</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.21049</ArticleId><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015;138(pt 12):3747-3759. doi:10.1093/brain/awv283</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv283</ArticleId><ArticleId IdType="pmc">PMC4655341</ArticleId><ArticleId IdType="pubmed">26428666</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging. 2009;21:239-251. doi:10.1007/978-3-642-02498-6_20</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-02498-6_20</ArticleId><ArticleId IdType="pmc">PMC2864489</ArticleId><ArticleId IdType="pubmed">19694267</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578-586. doi:10.1002/ana.23650</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Andreasson U, Liman V, et al. . Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017;24(11):1326-e77. doi:10.1111/ene.13389</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13389</ArticleId><ArticleId IdType="pubmed">28816001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Woollacott IOC, Dick KM, et al. . Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329-1336. doi:10.1212/WNL.0000000000003154</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003154</ArticleId><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchis GM, Katan M, Barro C, et al. . Serum neurofilament light chain in patients with acute cerebrovascular events. Eur J Neurol. 2018;25(3):562-568. doi:10.1111/ene.13554</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13554</ArticleId><ArticleId IdType="pubmed">29281157</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G, Barro C, Benkert P, et al. ; Swiss Multiple Sclerosis Cohort Study Group . Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857-870. doi:10.1002/ana.24954</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24954</ArticleId><ArticleId IdType="pmc">PMC5519945</ArticleId><ArticleId IdType="pubmed">28512753</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Gren M, Liman V, et al. . Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016;6:36791. doi:10.1038/srep36791</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36791</ArticleId><ArticleId IdType="pmc">PMC5098187</ArticleId><ArticleId IdType="pubmed">27819296</ArticleId></ArticleIdList></Reference><Reference><Citation>Moseby-Knappe M, Mattsson N, Nielsen N, et al. . Serum neurofilament light chain for prognosis of outcome after cardiac arrest. JAMA Neurol. 2019;76(1):64-71. doi:10.1001/jamaneurol.2018.3223</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.3223</ArticleId><ArticleId IdType="pmc">PMC6440255</ArticleId><ArticleId IdType="pubmed">30383090</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Sch&#xf6;ll M, Strandberg O, et al. . 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol Med. 2017;9(9):1212-1223. doi:10.15252/emmm.201707809</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707809</ArticleId><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31041379</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2374-7943</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>ACS central science</Title><ISOAbbreviation>ACS Cent Sci</ISOAbbreviation></Journal><ArticleTitle>Discovery of Volatile Biomarkers of Parkinson's Disease from Sebum.</ArticleTitle><Pagination><StartPage>599</StartPage><EndPage>606</EndPage><MedlinePgn>599-606</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acscentsci.8b00879</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is a progressive, neurodegenerative disease that presents with significant motor symptoms, for which there is no diagnostic chemical&#xa0;test. We have serendipitously identified a hyperosmic individual, a "Super Smeller" who can detect PD by odor alone, and our early pilot studies have indicated that the odor was present in the sebum from the skin of PD subjects. Here, we have employed an unbiased approach to investigate the volatile metabolites of sebum samples obtained noninvasively from the upper back of 64 participants in total (21 controls and 43 PD subjects). Our results, validated by an independent cohort&#xa0;(<i>n</i>=31), identified a distinct volatiles-associated signature of PD, including altered levels of perillic aldehyde and eicosane, the smell of which was then described as being highly similar to the scent of PD by our "Super Smeller".</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trivedi</LastName><ForeName>Drupad K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinclair</LastName><ForeName>Eleanor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Crown Street, Liverpool, U.K., L69 7ZB.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Depanjan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walton-Doyle</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liscio</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Anatune, 4 Wellbrook Way, Girton, Cambridge, U.K., CB3 0NA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banks</LastName><ForeName>Phine</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Anatune, 4 Wellbrook Way, Girton, Cambridge, U.K., CB3 0NA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milne</LastName><ForeName>Joy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverdale</LastName><ForeName>Monty</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Salford Royal Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, U.K., M6 8HD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunath</LastName><ForeName>Tilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Stem Cell Research, School of Biological Sciences, The University of Edinburgh, Edinburgh, U.K., EH16 4UU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodacre</LastName><ForeName>Royston</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Crown Street, Liverpool, U.K., L69 7ZB.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barran</LastName><ForeName>Perdita</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester, Princess Street, Manchester, U.K., M1 7DN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K-1504</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Cent Sci</MedlineTA><NlmUniqueID>101660035</NlmUniqueID><ISSNLinking>2374-7943</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31041379</ArticleId><ArticleId IdType="pmc">PMC6487537</ArticleId><ArticleId IdType="doi">10.1021/acscentsci.8b00879</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shirasu M.; Touhara K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. J. Biochem. 2011, 150 (3), 257&#x2013;266. 10.1093/jb/mvr090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvr090</ArticleId><ArticleId IdType="pubmed">21771869</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Y.; Le W. Recent advances and perspectives of metabolomics-based investigations in Parkinson&#x2019;s disease. Mol. Neurodegener. 2019, 14 (1), 3.10.1186/s13024-018-0304-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0304-2</ArticleId><ArticleId IdType="pmc">PMC6330496</ArticleId><ArticleId IdType="pubmed">30634989</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan J. Joy of super smeller: sebum clues for PD diagnostics. Lancet Neurol. 2016, 15, 138&#x2013;139. 10.1016/S1474-4422(15)00396-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00396-8</ArticleId><ArticleId IdType="pubmed">28463120</ArticleId></ArticleIdList></Reference><Reference><Citation>Krestin D. The Seborrhoeic Facies as a Manifestation of Post-Encephalitic Parkinsonism and Allied Disorders. QJM 1927, os-21 (81), 177&#x2013;186. 10.1093/qjmed/os-21.81.177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/os-21.81.177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravn J&#xf8;rgensen A.-H.; Thyssen J. P.; Egeberg A. Skin disorders in Parkinson&#x2019;s disease: potential biomarkers and risk factors. Clin., Cosmet. Invest. Dermatol. 2017, 10, 87&#x2013;92. 10.2147/CCID.S130319.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CCID.S130319</ArticleId><ArticleId IdType="pmc">PMC5352163</ArticleId><ArticleId IdType="pubmed">28331352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zange L.; Noack C.; Hahn K.; Stenzel W.; Lipp A. Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson&#x2019;s disease from multiple system atrophy. Brain 2015, 138 (Pt 8), 2310&#x2013;2321. 10.1093/brain/awv138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv138</ArticleId><ArticleId IdType="pubmed">26017579</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadio V.; Incensi A.; Leta V.; Giannoccaro M. P.; Scaglione C.; Martinelli P.; Capellari S.; Avoni P.; Baruzzi A.; Liguori R. Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 2014, 82 (15), 1362&#x2013;9. 10.1212/WNL.0000000000000316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000316</ArticleId><ArticleId IdType="pubmed">24634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmann-Weiler, A. P. a. W. F. a. J. W. a. C. A. a. H. W. a. R. K. a. J. B. a. C. T. a. C. A. M. a. G.;Pizzini A.; Filipiak W.; Wille J.; Ager C.; Wiesenhofer H.; Kubinec R.; Bla&#x161;ko J.; Tschurtschenthaler C.; Mayhew C. A.; Weiss G.; Bellmann-Weiler R. Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease. Journal of Breath Research 2018, 12, 036002.10.1088/1752-7163/aaa4c5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1752-7163/aaa4c5</ArticleId><ArticleId IdType="pubmed">29295966</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.-E.; Lee D.-S.; Ban S.-W.; Oh J.; Jung M. Y.; Kim S.-H.; Park S.; Persaud K.; Jheon S. Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system. Sens. Actuators, B 2018, 255, 800&#x2013;807. 10.1016/j.snb.2017.08.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.snb.2017.08.057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawal O.; Muhamadali H.; Ahmed W. M.; White I. R.; Nijsen T. M. E. E.; Goodacre R.; Fowler S. J. consortium, o. b. o. t. B., Headspace volatile organic compounds from bacteria implicated in ventilator-associated pneumonia analysed by TD-GC/MS. Journal of Breath Research 2018, 12, 026002.10.1088/1752-7163/aa8efc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1752-7163/aa8efc</ArticleId><ArticleId IdType="pubmed">28947683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rattray N. J. W.; Hamrang Z.; Trivedi D. K.; Goodacre R.; Fowler S. J. Taking your breath away: metabolomics breathes life in to personalized medicine. Trends Biotechnol. 2014, 32 (10), 538&#x2013;548. 10.1016/j.tibtech.2014.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2014.08.003</ArticleId><ArticleId IdType="pubmed">25179940</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J.; Deng L.; Zhou Y.; Yao S.; Zeng K. Analysis of changes in volatile constituents and expression of genes involved in terpenoid metabolism in oleocellosis peel. Food Chem. 2018, 243, 269&#x2013;276. 10.1016/j.foodchem.2017.09.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2017.09.142</ArticleId><ArticleId IdType="pubmed">29146338</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatzias I. S.; Karabagias I. K.; Kontakos S. P.; Kontominas M. G.; Badeka A. V. Characterization and differentiation of sheep&#x2019;s milk from Greek breeds based on physicochemical parameters, fatty acid composition and volatile profile. J. Sci. Food Agric. 2018, 98, 3935.10.1002/jsfa.8914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jsfa.8914</ArticleId><ArticleId IdType="pubmed">29377136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhardt N.; Birkenmeier M.; Schwolow S.; Rohn S.; Weller P. Volatile-Compound Fingerprinting by Headspace-Gas-Chromatography Ion-Mobility Spectrometry (HS-GC-IMS) as a Benchtop Alternative to 1H NMR Profiling for Assessment of the Authenticity of Honey. Anal. Chem. 2018, 90, 1777&#x2013;1785. 10.1021/acs.analchem.7b03748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.7b03748</ArticleId><ArticleId IdType="pubmed">29298045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosier E.; Cuypers E.; Dekens M.; Verplaetse R.; Develter W.; Van de Voorde W.; Maes D.; Tytgat J. Development and validation of a new TD-GC/MS method and its applicability in the search for human and animal decomposition products. Anal. Bioanal. Chem. 2014, 406, 3611&#x2013;3619. 10.1007/s00216-014-7741-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-014-7741-8</ArticleId><ArticleId IdType="pmc">PMC4026628</ArticleId><ArticleId IdType="pubmed">24633514</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrington J. S.; Myers C. Electronic cigarette solutions and resultant aerosol profiles. Journal of chromatography. A 2015, 1418, 192&#x2013;199. 10.1016/j.chroma.2015.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2015.09.034</ArticleId><ArticleId IdType="pubmed">26422308</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodacre R.; Broadhurst D.; Smilde A. K.; Kristal B. S.; Baker J. D.; Beger R.; Bessant C.; Connor S.; Capuani G.; Craig A.; Ebbels T.; Kell D. B.; Manetti C.; Newton J.; Paternostro G.; Somorjai R.; Sj&#xf6;str&#xf6;m M.; Trygg J.; Wulfert F. Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics 2007, 3 (3), 231&#x2013;241. 10.1007/s11306-007-0081-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-007-0081-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo-Almenara X.; Brezmes J.; Vinaixa M.; Samino S.; Ramirez N.; Ramon-Krauel M.; Lerin C.; D&#xed;az M.; Ib&#xe1;&#xf1;ez L.; Correig X.; Perera-Lluna A.; Yanes O. eRah: A Computational Tool Integrating Spectral Deconvolution and Alignment with Quantification and Identification of Metabolites in GC/MS-Based Metabolomics. Anal. Chem. 2016, 88 (19), 9821&#x2013;9829. 10.1021/acs.analchem.6b02927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.6b02927</ArticleId><ArticleId IdType="pubmed">27584001</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.; Muhamadali H.; Sayqal A.; Dixon N.; Goodacre R. Partial Least Squares with Structured Output for Modelling the Metabolomics Data Obtained from Complex Experimental Designs: A Study into the Y-Block Coding. Metabolites 2016, 6 (4), 38.10.3390/metabo6040038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo6040038</ArticleId><ArticleId IdType="pmc">PMC5192444</ArticleId><ArticleId IdType="pubmed">27801817</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.; Goodacre R. On Splitting Training and Validation Set: A Comparative Study of Cross-Validation, Bootstrap and Systematic Sampling for Estimating the Generalization Performance of Supervised Learning. Journal of Analysis and Testing 2018, 2 (3), 249&#x2013;262. 10.1007/s41664-018-0068-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41664-018-0068-2</ArticleId><ArticleId IdType="pmc">PMC6373628</ArticleId><ArticleId IdType="pubmed">30842888</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X.; Turck N.; Hainard A.; Tiberti N.; Lisacek F.; Sanchez J.-C.; M&#xfc;ller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf. 2011, 12 (1), 77.10.1186/1471-2105-12-77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-77</ArticleId><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-C.; Lin C.-J. LIBSVM: A library for support vector machines. ACM Trans. Intell. Syst. Technol. 2011, 2 (3), 1&#x2013;27. 10.1145/1961189.1961199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/1961189.1961199</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner F.-M.; Cove&#xf1;as R. Classical Neurotransmitters and Neuropeptides involved in Parkinson&#x2019;s disease: Focus on anti-Parkinsonian Drugs. Curr. Drug Ther. 2015, 10 (2), 66&#x2013;81. 10.2174/157488551002151222154335.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157488551002151222154335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahsan T.; Chen J.; Zhao X.; Irfan M.; Wu Y. Extraction and identification of bioactive compounds (eicosane and dibutyl phthalate) produced by Streptomyces strain KX852460 for the biological control of Rhizoctonia solani AG-3 strain KX852461 to control target spot disease in tobacco leaf. AMB Express 2017, 7, 54.10.1186/s13568-017-0351-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13568-017-0351-z</ArticleId><ArticleId IdType="pmc">PMC5334330</ArticleId><ArticleId IdType="pubmed">28255861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikoff W. R.; Anfora A. T.; Liu J.; Schultz P. G.; Lesley S. A.; Peters E. C.; Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (10), 3698&#x2013;3703. 10.1073/pnas.0812874106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812874106</ArticleId><ArticleId IdType="pmc">PMC2656143</ArticleId><ArticleId IdType="pubmed">19234110</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner C. E.; Smith S.; de Lacy Costello B. d. L.; White P.; Spencer R.; Probert C. S. J.; Ratcliffe N. M. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J. 2007, 21 (8), 1675&#x2013;1688. 10.1096/fj.06-6927com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-6927com</ArticleId><ArticleId IdType="pubmed">17314143</ArticleId></ArticleIdList></Reference><Reference><Citation>Soini H. A.; Klouckova I.; Wiesler D.; Oberzaucher E.; Grammer K.; Dixon S. J.; Xu Y.; Brereton R. G.; Penn D. J.; Novotny M. V. Analysis of Volatile Organic Compounds in Human Saliva by a Static Sorptive Extraction Method and Gas Chromatography-Mass Spectrometry. J. Chem. Ecol. 2010, 36 (9), 1035&#x2013;1042. 10.1007/s10886-010-9846-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10886-010-9846-7</ArticleId><ArticleId IdType="pubmed">20809147</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lacy Costello B.; Amann A.; Al-Kateb H.; Flynn C.; Filipiak W.; Khalid T.; Osborne D.; Ratcliffe N. M. A review of the volatiles from the healthy human body. J. Breath Res. 2014, 8 (1), 01400110.1088/1752-7155/8/1/014001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1752-7155/8/1/014001</ArticleId><ArticleId IdType="pubmed">24421258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann G. F.; Meier-Augenstein W.; St&#xf6;ckler S.; Surtees R.; Rating D.; Nyhan W. L. Physiology and pathophysiology of organic acids in cerebrospinal fluid. J. Inherited Metab. Dis. 1993, 16 (4), 648&#x2013;669. 10.1007/BF00711898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00711898</ArticleId><ArticleId IdType="pubmed">8412012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanhineva K.; Brunius C.; Andersson A.; Marklund M.; Juvonen R.; Keski-Rahkonen P.; Auriola S.; Landberg R. Discovery of urinary biomarkers of whole grain rye intake in free-living subjects using nontargeted LC-MS metabolite profiling. Mol. Nutr. Food Res. 2015, 59 (11), 2315&#x2013;2325. 10.1002/mnfr.201500423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201500423</ArticleId><ArticleId IdType="pubmed">26264776</ArticleId></ArticleIdList></Reference><Reference><Citation>Duranton F.; Cohen G.; De Smet R.; Rodriguez M.; Jankowski J.; Vanholder R.; Argiles A. European Uremic Toxin Work, G., Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 2012, 23 (7), 1258&#x2013;1270. 10.1681/ASN.2011121175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2011121175</ArticleId><ArticleId IdType="pmc">PMC3380651</ArticleId><ArticleId IdType="pubmed">22626821</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon E.; Clubb C.; Pittman S.; Ammann L.; Rasheed Z.; Kazmi N.; Keshavarzian A.; Gillevet P.; Rangwala H.; Couch R. D. Solid-phase microextraction and the human fecal VOC metabolome. PLoS One 2011, 6 (4), e18471&#x2013;e18471. 10.1371/journal.pone.0018471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018471</ArticleId><ArticleId IdType="pmc">PMC3072975</ArticleId><ArticleId IdType="pubmed">21494609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31034041</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Attitudes Toward Physician-Assisted Death From Individuals Who Learn They Have an Alzheimer Disease Biomarker.</ArticleTitle><Pagination><StartPage>864</StartPage><EndPage>866</EndPage><MedlinePgn>864-866</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.0797</ELocationID><Abstract><AbstractText>This study presents data regarding attitudes towards physician-assisted suicide from a survey of cognitively normal individuals enrolled in a clinical trial that required them to learn whether they have elevated amyloid-&#x3b2;.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Largent</LastName><ForeName>Emily A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terrasse</LastName><ForeName>M&#xe9;lanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Sociology, Princeton University, Princeton, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harkins</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisti</LastName><ForeName>Dominic A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001293" MajorTopicYN="Y">Attitude to Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004608" MajorTopicYN="N">Eligibility Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017236" MajorTopicYN="N">Suicide, Assisted</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Largent reported grants from National Institute on Aging and grants from the Alzheimer&#x2019;s Association during the conduct of the study. Dr Karlawish reported grants from Lilly Inc during the conduct of the study and grants from Novartis outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31034041</ArticleId><ArticleId IdType="pmc">PMC6583872</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.0797</ArticleId><ArticleId IdType="pii">2731580</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuznia R. In Oregon, pushing to give patients with degenerative diseases the right to die. Washington Post March 11, 2018. https://www.washingtonpost.com/national/in-oregon-pushing-to-give-patients-with-degenerative-diseases-the-right-to-die/2018/03/11/3b6a2362-230e-11e8-94da-ebf9d112159c_story.html. Accessed January 31, 2019.</Citation></Reference><Reference><Citation>Menzel PT, Steinbock B. Advance directives, dementia, and physician-assisted death. J Law Med Ethics. 2013;41(2):484-500. doi:10.1111/jlme.12057</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jlme.12057</ArticleId><ArticleId IdType="pubmed">23802899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547. doi:10.1212/WNL.0000000000002923</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozersky J, Sankar P, Harkins K, Hachey S, Karlawish J. Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults. JAMA Neurol. 2018;75(1):44-50. doi:10.1001/jamaneurol.2017.2954</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2954</ArticleId><ArticleId IdType="pmc">PMC5833492</ArticleId><ArticleId IdType="pubmed">29059270</ArticleId></ArticleIdList></Reference><Reference><Citation>Draper B, Peisah C, Snowdon J, Brodaty H. Early dementia diagnosis and the risk of suicide and euthanasia. Alzheimers Dement. 2010;6(1):75-82. doi:10.1016/j.jalz.2009.04.1229</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2009.04.1229</ArticleId><ArticleId IdType="pubmed">20129322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31039256</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.</ArticleTitle><Pagination><StartPage>1503</StartPage><EndPage>1527</EndPage><MedlinePgn>1503-1527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awz099</ELocationID><Abstract><AbstractText>We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer's-type dementia in retrospective autopsy studies. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology based on its epidemiology (LATE generally affects older subjects), and relatively restricted neuroanatomical distribution of TDP-43 proteinopathy. In community-based autopsy cohorts, &#x223c;25% of brains had sufficient burden of LATE-NC to be associated with discernible cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, often including amyloid-&#x3b2; plaques and tauopathy. Given that the 'oldest-old' are at greatest risk for LATE-NC, and subjects of advanced age constitute a rapidly growing demographic group in many countries, LATE has an expanding but under-recognized impact on public health. For these reasons, a working group was convened to develop diagnostic criteria for LATE, aiming both to stimulate research and to promote awareness of this pathway to dementia. We report consensus-based recommendations including guidelines for diagnosis and staging of LATE-NC. For routine autopsy workup of LATE-NC, an anatomically-based preliminary staging scheme is proposed with TDP-43 immunohistochemistry on tissue from three brain areas, reflecting a hierarchical pattern of brain involvement: amygdala, hippocampus, and middle frontal gyrus. LATE-NC appears to affect the medial temporal lobe structures preferentially, but other areas also are impacted. Neuroimaging studies demonstrated that subjects with LATE-NC also had atrophy in the medial temporal lobes, frontal cortex, and other brain regions. Genetic studies have thus far indicated five genes with risk alleles for LATE-NC: GRN, TMEM106B, ABCC9, KCNMB2, and APOE. The discovery of these genetic risk variants indicate that LATE shares pathogenetic mechanisms with both frontotemporal lobar degeneration and Alzheimer's disease, but also suggests disease-specific underlying mechanisms. Large gaps remain in our understanding of LATE. For advances in prevention, diagnosis, and treatment, there is an urgent need for research focused on LATE, including in vitro and animal models. An obstacle to clinical progress is lack of diagnostic tools, such as biofluid or neuroimaging biomarkers, for ante-mortem detection of LATE. Development of a disease biomarker would augment observational studies seeking to further define the risk factors, natural history, and clinical features of LATE, as well as eventual subject recruitment for targeted therapies in clinical trials.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyle</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Illinois Institute of Technology, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alafuzoff</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyle-Gilchrist</LastName><ForeName>Ian T S</ForeName><Initials>ITS</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fardo</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The University of Sydney Brain and Mind Centre and Central Clinical School Faculty of Medicine and Health, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hokkanen</LastName><ForeName>Suvi R K</ForeName><Initials>SRK</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsumata</LastName><ForeName>Yuriko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Institute of Neurology Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makkinejad</LastName><ForeName>Nazanin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Illinois Institute of Technology, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nag</LastName><ForeName>Sukriti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Harvard University, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG057707</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057191</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1100540</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061111</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG072122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG053983</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097261</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094003</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057187</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Jul;15(7):367. doi: 10.1038/s41582-019-0207-z.</RefSource><PMID Version="1">31110344</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Brain. 2019 Jul 1;142(7):e37. doi: 10.1093/brain/awz163.</RefSource><PMID Version="1">31147685</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2019 Aug 1;142(8):e42. doi: 10.1093/brain/awz184.</RefSource><PMID Version="1">31243434</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2019 Sep 1;142(9):e47. doi: 10.1093/brain/awz224.</RefSource><PMID Version="1">31359030</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2020 Mar 1;143(3):e20. doi: 10.1093/brain/awaa013.</RefSource><PMID Version="1">32016361</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2020 Mar 1;143(3):e21. doi: 10.1093/brain/awaa014.</RefSource><PMID Version="1">32016396</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">SNAP</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31039256</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pii">5481202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abner EL, Kryscio RJ, Schmitt FA, Fardo DW, Moga DC, Ighodaro ET et al. . Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann Neurol 2017; 81: 549&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5401633</ArticleId><ArticleId IdType="pubmed">28224671</ArticleId></ArticleIdList></Reference><Reference><Citation>Abner EL, Kryscio RJ, Schmitt FA, Santacruz KS, Jicha GA, Lin Y et al. . &#x201c;End-Stage&#x201d; neurofibrillary tangle pathology in preclinical Alzheimer&#x2019;s disease: fact or fiction? J Alzheimers Dis 2011; 25: 445&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171001</ArticleId><ArticleId IdType="pubmed">21471646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007; 4: 7&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805428</ArticleId><ArticleId IdType="pubmed">17291356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajilore O, Lamar M, Medina J, Watari K, Elderkin-Thompson V, Kumar A. Disassociation of verbal learning and hippocampal volume in type 2 diabetes and major depression. Int J Geriatr Psychiatry 2015; 30: 393&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264998</ArticleId><ArticleId IdType="pubmed">24920010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ala TA, Beh GO, Frey WH 2nd. Pure hippocampal sclerosis: a rare cause of dementia mimicking Alzheimer&#x2019;s disease. Neurology 2000; 54: 843&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10690974</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I et al. . Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009; 117: 635&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330340</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Pikkarainen M, Neumann M, Arzberger T, Al-Sarraj S, Bodi I et al. . Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. J Neural Transm (Vienna) 2015; 122: 957&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">25239189</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW. Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol (Berl) 2007a; 113: 245&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794627</ArticleId><ArticleId IdType="pubmed">17195931</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Dickson DW. Neuropathology of hippocampal sclerosis. Handb Clin Neurol 2008; 89: 569&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631779</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R et al. . TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol 2007b; 61: 435&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R et al. . Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP type A. Acta Neuropathol 2015; 129: 53&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282950</ArticleId><ArticleId IdType="pubmed">25367383</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Nonoka T, Kametani F, Yamashita M, Hosokawa M et al. . Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology 2010; 30: 170&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102522</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K et al. . Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol 2009; 117: 125&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol 2013; 126: 51&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691299</ArticleId><ArticleId IdType="pubmed">23604587</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA. Hippocampal sclerosis in Alzheimer disease and other dementias. Neurology 2006; 66: 775.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachstetter AD, Van Eldik LJ, Schmitt FA, Neltner JH, Ighodaro ET, Webster SJ et al. . Disease-related microglia heterogeneity in the hippocampus of Alzheimer&#x2019;s disease, dementia with Lewy bodies, and hippocampal sclerosis of aging. Acta Neuropathol Commun 2015; 3: 32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4489160</ArticleId><ArticleId IdType="pubmed">26001591</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C et al. . Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D et al. . Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002; 16: 203&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12468894</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkhof F, Polvikoski TM, van Straaten EC, Kalaria RN, Sulkava R, Aronen HJ et al. . The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007; 69: 1521&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923614</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ et al. . Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet 2014; 10: e1004606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC et al. . Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Kukull WA, Teylan MA, Bigio EH, Cairns NJ, Kofler JK et al. . The revised national Alzheimer&#x2019;s coordinating center&#x2019;s neuropathology form-available data and new analyses. J Neuropathol Exp Neurol 2018; 77: 717&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6044344</ArticleId><ArticleId IdType="pubmed">29945202</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Baker M, Dickson DW, Parisi JE, Giannini C, Josephs KA et al. . Frontotemporal dementia and parkinsonism associated with the IVS1+1G-&gt;A mutation in progranulin: a clinicopathologic study. Brain 2006; 129: 3103&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030535</ArticleId></ArticleIdList></Reference><Reference><Citation>Botha H, Mantyh WG, Murray ME, Knopman DS, Przybelski SA, Wiste HJ et al. . FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain 2018; 141: 1201&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889045</ArticleId><ArticleId IdType="pubmed">29538658</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA et al. . Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol 2013; 74: 478&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845973</ArticleId><ArticleId IdType="pubmed">23798485</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yang J, Yu L, Leurgans SE, Capuano AW, Schneider JA et al. . Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain 2017; 140: 804&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837473</ArticleId><ArticleId IdType="pubmed">28082297</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA et al. . Attributable risk of Alzheimer&#x2019;s dementia due to age-related neuropathologies. Ann Neurol 2019; 85: 114&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10128614</ArticleId><ArticleId IdType="pubmed">30421454</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33: 403&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307060</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Anterior cingulate cortex TDP-43 pathology in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2018; 77: 74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">29186496</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ludolph AC, Neumann M, Ravits J, Del Tredici K. Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal alpha-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol 2017; 133: 79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209403</ArticleId><ArticleId IdType="pubmed">27757524</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Muller CM, Rub U, Ackermann H, Bratzke H, de Vos RA et al. . Pathology associated with sporadic Parkinson&#x2019;s disease&#x2014;where does it end? J Neural Transm Suppl 2006: 89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17017514</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70: 960&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C. Research and Alzheimer&#x2019;s disease: an epidemiological perspective. Psychol Med 1993; 23: 287&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">8332643</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, Richardson K, Matthews FE, Fleming J, Hunter S, Xuereb JH et al. . Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75 s cohort (CC75C) study. J Alzheimers Dis 2009; 18: 645&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Monsell SE, Schmitt FA, Kukull WA, Nelson PT. Hippocampal sclerosis of aging is a key Alzheimer&#x2019;s disease mimic: clinical-pathologic correlations and comparisons with both alzheimer&#x2019;s disease and non-tauopathic frontotemporal lobar degeneration. J Alzheimers Dis 2014; 39: 691&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946156</ArticleId><ArticleId IdType="pubmed">24270205</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M et al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985; 122: 904&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">4050778</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Bourgeat P, Dore V, Savage G, Brown B, Laws S et al. . Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol 2016; 15: 1044&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ et al. . Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 2007a; 114: 5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ et al. . TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 2007b; 171: 227&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R et al. . Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 2015; 84: 508&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336071</ArticleId><ArticleId IdType="pubmed">25568301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L et al. . TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 2012; 32: 11213&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Mez J, Crary JF, Tripodis Y, Alvarez VE, Mahar I et al. . Variation in TMEM106B in chronic traumatic encephalopathy. Acta Neuropathol Commun 2018; 6: 115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215686</ArticleId><ArticleId IdType="pubmed">30390709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y, Fardo DW, Nelson PT. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Lab Invest 2019. doi: 10.1038/s41374-019-0196-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609463</ArticleId><ArticleId IdType="pubmed">30742063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ et al. . Cognitive impact of subcortical vascular and Alzheimer&#x2019;s disease pathology. Ann Neurol 2006; 60: 677&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851933</ArticleId><ArticleId IdType="pubmed">17192928</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Lee VM, Trojanowski JQ. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med 2011; 17: 659&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrada MM, Berlau DJ, Kawas CH. A population-based clinicopathological study in the oldest-old: the 90+ study. Curr Alzheimer Res 2012; 9: 709&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409303</ArticleId><ArticleId IdType="pubmed">22471863</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle-Gilchrist IT, Dick KM, Patterson K, Vazquez Rodriquez P, Wehmann E, Wilcox A et al. . Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 2016; 86: 1736&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854589</ArticleId><ArticleId IdType="pubmed">27037234</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al. . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128: 755&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D et al. . Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442: 920&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal HA, Dickson D, Davies P, Masur D, Grober E, Lipton RB. The relative frequency of &#x201c;dementia of unknown etiology&#x201d; increases with age and is nearly 50% in nonagenarians. Arch Neurol 2000; 57: 713&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815138</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal HA, Dickson DW, Sliwinski MJ, Lipton RB, Grober E, Marks-Nelson H et al. . Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 1993; 34: 566&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">8215244</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Aisen PS, DuBois B, Frolich L, Jack CR Jr, Jones RW et al. . Drug development in Alzheimer&#x2019;s disease: the path to 2025. Alzheimers Res Ther 2016; 8: 39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028936</ArticleId><ArticleId IdType="pubmed">27646601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Schulz PE, Takei H, Rivera AL, Jackson RE et al. . Hippocampal sclerosis in older patients: practical examples and guidance with a focus on cerebral age-related TDP-43 with sclerosis. Arch Pathol Lab Med 2017; 141: 1113&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5922266</ArticleId><ArticleId IdType="pubmed">28467211</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Takei H, Van Eldik LJ, Schmitt FA, Jicha GA, Powell SZ et al. . Hippocampal sclerosis but not normal aging or alzheimer disease is associated with TDP-43 pathology in the basal forebrain of aged persons. J Neuropathol Exp Neurol 2016; 75: 397&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009476</ArticleId><ArticleId IdType="pubmed">26971127</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallaire-Theroux C, Callahan BL, Potvin O, Saikali S, Duchesne S. Radiological-pathological correlation in Alzheimer&#x2019;s disease: Systematic review of antemortem magnetic resonance imaging findings. J Alzheimers Dis 2017; 57: 575&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">28282807</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S et al. . TDP-43 pathological changes in early onset familial and sporadic Alzheimer&#x2019;s disease, late onset Alzheimer&#x2019;s disease and Down&#x2019;s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011; 122: 703&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">21968532</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SA, Gan KA, Dowell JA, Cairns NJ, Gitcho MA. TDP-43 expression influences amyloidbeta plaque deposition and tau aggregation. Neurobiol Dis 2017; 103: 154&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5544914</ArticleId><ArticleId IdType="pubmed">28416393</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawe RJ, Bennett DA, Schneider JA, Arfanakis K. Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. PLoS ONE 2011; 6: e26286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197137</ArticleId><ArticleId IdType="pubmed">22043314</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawe RJ, Bennett DA, Schneider JA, Leurgans SE, Kotrotsou A, Boyle PA et al. . Ex vivo T2 relaxation: associations with age-related neuropathology and cognition. Neurobiol Aging 2014; 35: 1549&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989898</ArticleId><ArticleId IdType="pubmed">24582637</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Baker M, Rademakers R. Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener Dis 2010; 7: 170&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859236</ArticleId><ArticleId IdType="pubmed">20197700</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, Grober E et al. . Hippocampal sclerosis: a common pathological feature of dementia in very old (&gt; or =80 years of age) humans. Acta Neuropathol 1994; 88: 212&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">7810292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Rademakers R, Nicholson AM, Schneider JA, Yu L, Bennett DA. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 2015; 85: 1354&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990310</ArticleId><ArticleId IdType="pubmed">26459943</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutra JR, Cortes EP, Vonsattel JP. Update on hippocampal sclerosis. Curr Neurol Neurosci Rep 2015; 15: 67.</Citation><ArticleIdList><ArticleId IdType="pubmed">26299276</ArticleId></ArticleIdList></Reference><Reference><Citation>Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol 2016; 75: 316&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793886</ArticleId><ArticleId IdType="pubmed">26979082</ArticleId></ArticleIdList></Reference><Reference><Citation>Erten-Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB, Kramer P et al. . Neuropathologic basis of age-associated brain atrophy. JAMA neurology 2013; 70: 616&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898525</ArticleId><ArticleId IdType="pubmed">23552688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardo DW, Katsumata Y, Kauwe JS, Deming Y, Harari O, Cruchaga C et al. . CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN. Exp Gerontol 2017; 90: 83&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389672</ArticleId><ArticleId IdType="pubmed">28189700</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM, Yu L, Buchman AS, Schneider JA, De Jager PL, Bennett DA. Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. Neurology 2016; 87: 489&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970661</ArticleId><ArticleId IdType="pubmed">27371493</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M, Tan R, Halliday GM, Kril JJ. Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathol Commun 2015; 3: 47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517552</ArticleId><ArticleId IdType="pubmed">26216351</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujishiro H, Uchikado H, Arai T, Hasegawa M, Akiyama H, Yokota O et al. . Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 2009; 117: 151&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19039597</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC et al. . TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 2014; 127: 407&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner RC, Valcour V, Yaffe K. Dementia in the oldest old: a multi-factorial and growing public health issue. Alzheimers Res Ther 2013; 5: 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706944</ArticleId><ArticleId IdType="pubmed">23809176</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, Kwong LK et al. . Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol 2010; 67: 1238&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050578</ArticleId><ArticleId IdType="pubmed">20937952</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Bouras C, Hof PR. Clinicopathologic correlates in the oldest-old: commentary on &#x201c;No disease in the brain of a 115-year-old woman&#x201d;. Neurobiol Aging 2008; 29: 1137&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911139</ArticleId><ArticleId IdType="pubmed">18534719</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold G, Bouras C, Kovari E, Canuto A, Glaria BG, Malky A et al. . Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol (Berl) 2000; 99: 579&#x2013;82; discussion 83&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC et al. . Longitudinal beta-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol 2016; 73: 1192&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237381</ArticleId><ArticleId IdType="pubmed">27548756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulisano W, Maugeri D, Baltrons MA, Fa M, Amato A, Palmeri A et al. . Role of amyloid-beta and tau proteins in Alzheimer&#x2019;s disease: confuting the amyloid cascade. J Alzheimers Dis 2018; 64: S611&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371153</ArticleId><ArticleId IdType="pubmed">29865055</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Shorter J. Biology and pathobiology of TDP-43 and emergent therapeutic strategies. Cold Spring Harb Perspect Med 2017; 7. doi: 10.1101/cshperspect.a024554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580514</ArticleId><ArticleId IdType="pubmed">27920024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall A, Pekkala T, Polvikoski T, van Gils M, Kivipelto M, Lotjonen J et al. . Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study. Alzheimers Res Ther 2019; 11: 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343349</ArticleId><ArticleId IdType="pubmed">30670070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanko V, Apple AC, Alpert KI, Warren KN, Schneider JA, Arfanakis K et al. . In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies. Neurobiol Aging 2019; 74: 171&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331233</ArticleId><ArticleId IdType="pubmed">30453234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y et al. . Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008; 64: 60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Nonaka T, Tsuji H, Tamaoka A, Yamashita M, Kametani F et al. . Molecular dissection of TDP-43 proteinopathies. J Mol Neurosci 2011; 45: 480&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21678031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanpaa KJ, Bigio EH, Cairns NJ, Womack KB, Weintraub S, Morris JC et al. . TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol 2008; 67: 271&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635119</ArticleId><ArticleId IdType="pubmed">18379440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanpaa KJ, Raisanen JM, Herndon E, Burns DK, Foong C, Habib AA et al. . Hippocampal sclerosis in dementia, epilepsy, and ischemic injury: differential vulnerability of hippocampal subfields. J Neuropath Exp Neurol 2014; 73: 136&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076969</ArticleId><ArticleId IdType="pubmed">24423638</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K et al. . Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res 2007; 1184: 284&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokkanen SRK, Hunter S, Polvikoski TM, Keage HAD, Minett T, Matthews FE et al. . Hippocampal sclerosis, hippocampal neuron loss patterns and TDP-43 in the aged population. Brain Pathol 2018; 28: 548&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099461</ArticleId><ArticleId IdType="pubmed">28833898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao SJ, Karajannis MA, Diolaiti D, Mansukhani MM, Bender JG, Kung AL et al. . A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Cold Spring Harb Mol Case Stud 2017; 3: a001396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334470</ArticleId><ArticleId IdType="pubmed">28299358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen RC et al. . Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 2008; 116: 215&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404722</ArticleId><ArticleId IdType="pubmed">18592255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter S, Smailagic N, Brayne C. Abeta and the dementia syndrome: simple versus complex perspectives. Eur J Clin Invest 2018; 48: e13025.</Citation><ArticleIdList><ArticleId IdType="pubmed">30246866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ighodaro ET, Jicha GA, Schmitt FA, Neltner JH, Abner EL, Kryscio RJ et al. . Hippocampal sclerosis of aging can be segmental: two cases and review of the literature. J Neuropathol Exp Neurol 2015; 74: 642&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539239</ArticleId><ArticleId IdType="pubmed">26083567</ArticleId></ArticleIdList></Reference><Reference><Citation>Imhof A, Kovari E, von Gunten A, Gold G, Rivara CB, Herrmann FR et al. . Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? J Neurol Sci 2007; 257: 72&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303173</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, McMillan CT, Xie SX, Rascovsky K, Van Deerlin VM, Coslett HB et al. . Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. Brain 2018; 141: 288&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837322</ArticleId><ArticleId IdType="pubmed">29228211</ArticleId></ArticleIdList></Reference><Reference><Citation>Isnard J, Bourdillon P. Morphological imaging of the hippocampus in epilepsy. Rev Neurol (Paris) 2015; 171: 298&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">25744767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittermann T, Wittfeld K, Nauck M, Bulow R, Hosten N, Volzke H et al. . High thyrotropin is associated with reduced hippocampal volume in a population-based study from Germany. Thyroid 2018; 28: 1434&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">30259797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al. . NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 2018; 14: 535&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O&#x2019;Brien PC et al. . Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58: 750&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Chetelat G, Dickson D, Fagan AM, Frisoni GB et al. . Suspected non-Alzheimer disease pathophysiology&#x2014;concept and controversy. Nat Rev Neurol 2016; 12: 117&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784257</ArticleId><ArticleId IdType="pubmed">26782335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V et al. . An operational approach to National Institute on Aging-Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71: 765&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V et al. . Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50&#x2013;95 years: a cross-sectional study. Lancet Neurol 2017; 16: 435&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516534</ArticleId><ArticleId IdType="pubmed">28456479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW et al. . Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008; 63: 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2624571</ArticleId><ArticleId IdType="pubmed">18157909</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain 2016; 139: 2983&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K. Pure hippocampal sclerosis: a rare cause of dementia mimicking Alzheimer&#x2019;s disease. Neurology 2000; 55: 739&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10980757</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci 2007; 257: 80&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17324442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm (Vienna) 2015; 122: 505&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25091618</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS et al. . Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 2007; 66: 142&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17278999</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Dickson DW. TDP-43 in the olfactory bulb in Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol 2016; 42: 390&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5154242</ArticleId><ArticleId IdType="pubmed">26810591</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L et al. . Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer&#x2019;s disease: a longitudinal retrospective study. Lancet Neurol 2017a; 16: 917&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646369</ArticleId><ArticleId IdType="pubmed">28919059</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB et al. . Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol 2019; 137: 227&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358471</ArticleId><ArticleId IdType="pubmed">30604226</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Whitwell JL, Knopman DS, Machulda MM et al. . Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol 2017b; 133: 705&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091858</ArticleId><ArticleId IdType="pubmed">28160067</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR et al. . Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta Neuropathol 2014a; 127: 441&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L et al. . Updated TDP-43 in Alzheimer&#x2019;s disease staging scheme. Acta Neuropathol 2016; 131: 571&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M et al. . Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008; 70: 1850&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779031</ArticleId><ArticleId IdType="pubmed">18401022</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM et al. . TAR DNA-binding protein 43 and pathological subtype of Alzheimer&#x2019;s disease impact clinical features. Ann Neurol 2015; 78: 697&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623932</ArticleId><ArticleId IdType="pubmed">26224156</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM et al. . TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol 2014b; 127: 811&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung Y, Dickson DW, Murray ME, Whitwell JL, Knopman DS, Boeve BF et al. . TDP-43 in Alzheimer&#x2019;s disease is not associated with clinical FTLD or Parkinsonism. J Neurol 2014; 261: 1344&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4101047</ArticleId><ArticleId IdType="pubmed">24760339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 2009; 29: 566&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19422539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 2017; 134: 171&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y, Fardo DW, Kukull WA, Nelson PT. Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer&#x2019;s disease and cerebrovascular disease pathologies. Acta Neuropathol Commun 2018; 6: 142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6299605</ArticleId><ArticleId IdType="pubmed">30567576</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y, Nelson PT, Ellingson SR, Fardo DW. Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging 2017; 53: 193.e17&#x2013;193.e25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385271</ArticleId><ArticleId IdType="pubmed">28131462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur B, Himali JJ, Seshadri S, Beiser AS, Au R, McKee AC et al. . Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimer Dis Assoc Disord 2014; 28: 219&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139422</ArticleId><ArticleId IdType="pubmed">24614264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH, Corrada MM. Alzheimer&#x2019;s and dementia in the oldest-old: a century of challenges. Curr Alzheimer Res 2006; 3: 411&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373256</ArticleId><ArticleId IdType="pubmed">17168640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke YD, van Hummel A, Stevens CH, Gladbach A, Ippati S, Bi M et al. . Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol 2015; 130: 661&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437864</ArticleId></ArticleIdList></Reference><Reference><Citation>Keage HA, Hunter S, Matthews FE, Ince PG, Hodges J, Hokkanen SR et al. . TDP-43 pathology in the population: prevalence and associations with dementia and age. J Alzheimers Dis 2014; 42: 641&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">25170584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kero M, Raunio A, Polvikoski T, Tienari PJ, Paetau A, Myllykangas L. Hippocampal sclerosis in the oldest old: a Finnish population-based study. J Alzheimers Dis 2018; 63: 263&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5900558</ArticleId><ArticleId IdType="pubmed">29614661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Finger E, Murrell J, Chertkow H, Ang LC, Baker M et al. . Progressive supranuclear palsy in a family with TDP-43 pathology. Neurocase 2015; 21: 178&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4116482</ArticleId><ArticleId IdType="pubmed">24479957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimbrel NA, Garrett ME, Dennis MFVa Mid-Atlantic Mental Illness Research, Education, and Clinical Center WorkgroupHauser MA et al. . A genome-wide association study of suicide attempts and suicidal ideation in U.S. military veterans. Psychiatry Res 2018; 269: 64&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6207450</ArticleId><ArticleId IdType="pubmed">30145303</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT et al. . Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron 2017; 95: 281&#x2013;96.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Roberts RO. Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci 2011; 45: 330&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208074</ArticleId><ArticleId IdType="pubmed">21584654</ArticleId></ArticleIdList></Reference><Reference><Citation>Korczyn AD. Mixed dementia&#x2014;the most common cause of dementia. Ann N Y Acad Sci 2002; 977: 129&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortvelyessy P, Heinze HJ, Prudlo J, Bittner D. CSF biomarkers of neurodegeneration in progressive non-fluent aphasia and other forms of frontotemporal dementia: clues for pathomechanisms? Front Neurol 2018; 9: 504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036143</ArticleId><ArticleId IdType="pubmed">30013506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotrotsou A, Schneider JA, Bennett DA, Leurgans SE, Dawe RJ, Boyle PA et al. . Neuropathologic correlates of regional brain volumes in a community cohort of older adults. Neurobiol Aging 2015; 36: 2798&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562889</ArticleId><ArticleId IdType="pubmed">26195068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C et al. . Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol 2013; 126: 365&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kravitz E, Schmeidler J, Beeri MS. Cognitive decline and dementia in the oldest-old. Rambam Maimonides Med J 2012; 3: e0026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678827</ArticleId><ArticleId IdType="pubmed">23908850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuslansky G, Verghese J, Dickson D, Katz M, Busche H, Lipton RB. Hippocampal sclerosis: cognitive consequences and contribution to dementia. Neurology 2004; 62: A128&#x2013;9.</Citation></Reference><Reference><Citation>Laferriere F, Maniecka Z, Perez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock EM et al. . TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci 2019; 22: 65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Keene CD, Flanagan ME, Hemmy LS, Lim KO, White LR et al. . Resistance to Alzheimer disease neuropathologic changes and apparent cognitive resilience in the Nun and Honolulu-Asia aging studies. J Neuropathol Exp Neurol 2017; 76: 458&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6334750</ArticleId><ArticleId IdType="pubmed">28499012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ, Neumann M. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol 2008; 115: 305&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18087705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK et al. . Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 2017; 134: 65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB, Agustin CM, Tsuang D, Peskind ER, Edland SD, Nochlin D et al. . Clinical and neuropathological characteristics of hippocampal sclerosis: a community-based study. Arch Neurol 2002; 59: 1099&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">12117357</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB, Lipton AM. Clinical aspects of hippocampal sclerosis. Handb Clin Neurol 2008; 89: 565&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Castanedes-Casey M, Dickson DW. Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. J Neuropathol Exp Neurol 2009; 68: 1167&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783428</ArticleId><ArticleId IdType="pubmed">19816201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol 2008; 116: 205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, Morris HR, Neal JW, Lees AJ, Hardy J, Holton JL et al. . Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathol 2017; 133: 337&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325836</ArticleId><ArticleId IdType="pubmed">28205009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Dickson DW. Hippocampal sclerosis dementia: expanding the phenotypes of frontotemporal dementias? Neurology 2004; 63: 414&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Rosso AL, Stutzbach LD, Neumann M, Lee VM, Trojanowski JQ. Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. Arch Neurol 2009; 66: 1483&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864642</ArticleId><ArticleId IdType="pubmed">20008652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ et al. . Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol 2017; 134: 79&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28466142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al. . A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkinejad N, Schneider JA, Yu J, Leurgans SE, Kotrotsou A, Evia AM et al. . Associations of amygdala volume and shape with transactive response DNA-binding protein 43 (TDP-43) pathology in a community cohort of older adults. Neurobiol Aging 2019; 77: 104&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486844</ArticleId><ArticleId IdType="pubmed">30784812</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek-Ahmadi M, Kahlon V, Adler CH, Obradov A, Thind K, Shill HA et al. . Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort. Clin Exp Med Sci 2013; 1: 317&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196704</ArticleId><ArticleId IdType="pubmed">25324686</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol 2017; 27: 472&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029292</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki Y, Mori F, Seino Y, Tanji K, Yoshizawa T, Kijima H et al. . Colocalization of Bunina bodies and TDP-43 inclusions in a case of sporadic amyotrophic lateral sclerosis with Lewy body-like hyaline inclusions. Neuropathology 2018; 38: 521&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29938835</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM et al. . TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry 2013; 84: 956&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840954</ArticleId><ArticleId IdType="pubmed">23543794</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al. . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol 2012; 123: 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GP, Clark IA, Vissel B. Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer&#x2019;s disease. Acta Neuropathol 2018; 136: 663&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208728</ArticleId><ArticleId IdType="pubmed">30349969</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Bieniek KF, Banks Greenberg M, DeJesus-Hernandez M, Rutherford NJ, van Blitterswijk M et al. . Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathol 2013; 126: 545&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926101</ArticleId><ArticleId IdType="pubmed">23922030</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross OA et al. . Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 2014; 128: 411&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer&#x2019;s disease. Acta Neuropathol Commun 2018; 6: 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928580</ArticleId><ArticleId IdType="pubmed">29716643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA et al. . Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol 2015; 77: 942&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447563</ArticleId><ArticleId IdType="pubmed">25707479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA. TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology 2017; 88: 653&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317379</ArticleId><ArticleId IdType="pubmed">28087828</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE et al. . Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007; 114: 221&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, Sidhu M, Gaus SE, Hwang JL, Li L, Park Y et al. . Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol 2019; 137: 27&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C, Di Lorenzo Alho AT, Bazan Conceicao Amaral C, Leite REP, Nitrini R, Jacob-Filho W et al. . Prevalence of transactive response DNA-binding protein 43 (TDP-43) proteinopathy in cognitively normal older adults: systematic review and meta-analysis. Neuropathol Appl Neurobiol 2018; 44: 286&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902737</ArticleId><ArticleId IdType="pubmed">28793370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C, Suemoto CK, Rodriguez RD, Alho AT, Leite RP, Farfel JM et al. . Higher prevalence of TDP-43 proteinopathy in cognitively normal asians: a clinicopathological study on a multiethnic sample. Brain Pathol 2016; 26: 177&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751066</ArticleId><ArticleId IdType="pubmed">26260327</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Patel E, Anderson S, Wilcock DM, Kryscio RJ et al. . The amygdala as a locus of pathologic misfolding in neurodegenerative diseases. J Neuropathol Exp Neurol 2018; 77: 2&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901077</ArticleId><ArticleId IdType="pubmed">29186501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD et al. . Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 2010; 20: 66&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864342</ArticleId><ArticleId IdType="pubmed">19021630</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009; 68: 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692822</ArticleId><ArticleId IdType="pubmed">19104448</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Estus S, Abner EL, Parikh I, Malik M, Neltner JH et al. . ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 2014; 127: 825&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113197</ArticleId><ArticleId IdType="pubmed">24770881</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Gal Z, Wang WX, Niedowicz DM, Artiushin SC, Wycoff S et al. . TDP-43 proteinopathy in aging: associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. Neurobiol Dis 2019; 125: 67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6696921</ArticleId><ArticleId IdType="pubmed">30682540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA et al. . Alzheimer&#x2019;s disease is not &#x201c;brain aging&#x201d;: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 2011a; 121: 571&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179861</ArticleId><ArticleId IdType="pubmed">21516511</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Wang WX, Ighodaro E, Artiushin S, Nichols CG et al. . ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target. Ageing Res Rev 2015a; 24: 111&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4661124</ArticleId><ArticleId IdType="pubmed">26226329</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Katsumata Y, Nho K, Artiushin SC, Jicha GA, Wang WX et al. . Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging. Acta Neuropathol 2016a; 132: 841&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5154615</ArticleId><ArticleId IdType="pubmed">27815632</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E et al. . Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 2011b; 134: 1506&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097889</ArticleId><ArticleId IdType="pubmed">21596774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Smith CD, Abner EL, Wilfred BJ, Wang WX, Neltner JH et al. . Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol 2013; 126: 161&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889169</ArticleId><ArticleId IdType="pubmed">23864344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, Schmitt FA et al. . &#x201c;New Old Pathologies&#x201d;: AD, PART, and Cerebral Age-Related TDP-43 with Sclerosis (CARTS). J Neuropathol Exp Neurol 2016b; 75: 482&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6366658</ArticleId><ArticleId IdType="pubmed">27209644</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Wang WX, Partch AB, Monsell SE, Valladares O, Ellingson SR et al. . Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol 2015b; 74: 75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270894</ArticleId><ArticleId IdType="pubmed">25470345</ArticleId></ArticleIdList></Reference><Reference><Citation>Neltner JH, Abner EL, Baker S, Schmitt FA, Kryscio RJ, Jicha GA et al. . Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain 2014; 137: 255&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891448</ArticleId><ArticleId IdType="pubmed">24271328</ArticleId></ArticleIdList></Reference><Reference><Citation>Neltner JH, Abner EL, Jicha GA, Schmitt FA, Patel E, Poon LW et al. . Brain pathologies in extreme old age. Neurobiol Aging 2016; 37: 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4688098</ArticleId><ArticleId IdType="pubmed">26597697</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IRA. Review: Neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol Appl Neurobiol 2019; 45: 19&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30357887</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357: 169&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">11213093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K, Saykin AJAlzheimer&#x2019;s Disease Neuroimaging InitiativeNelson PT. Hippocampal sclerosis of aging, a common Alzheimer&#x2019;s disease &#x2018;mimic&#x2019;: risk genotypes are associated with brain atrophy outside the temporal lobe. J Alzheimers Dis 2016; 52: 373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978172</ArticleId><ArticleId IdType="pubmed">27003218</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Rademakers R. What we know about TMEM106B in neurodegeneration. Acta Neuropathol 2016; 132: 639&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074873</ArticleId><ArticleId IdType="pubmed">27543298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Chalmers ZR, Azada MC, Ross JS, Stephens PJ, Ali SM et al. . Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer 2015; 88: 352&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25851827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 1995; 69: 3584&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA. Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol 2018; 136: 887&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279593</ArticleId><ArticleId IdType="pubmed">30334074</ArticleId></ArticleIdList></Reference><Reference><Citation>Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-Radford NR. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis Assoc Disord 2011; 25: 364&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107353</ArticleId><ArticleId IdType="pubmed">21346515</ArticleId></ArticleIdList></Reference><Reference><Citation>Paushter DH, Du H, Feng T, Hu F. The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol 2018; 136: 1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117207</ArticleId><ArticleId IdType="pubmed">29744576</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelletier A, Bernard C, Dilharreguy B, Helmer C, Le Goff M, Chanraud S et al. . Patterns of brain atrophy associated with episodic memory and semantic fluency decline in aging. Aging (Albany NY) 2017; 9: 741&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391228</ArticleId><ArticleId IdType="pubmed">28278492</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins GD, McAuley DF, Davies S, Gao F. Discrepancies between clinical and postmortem diagnoses in critically ill patients: an observational study. Crit Care 2003; 7: R129&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC374369</ArticleId><ArticleId IdType="pubmed">14624686</ArticleId></ArticleIdList></Reference><Reference><Citation>Popkirov S, Ismail FS, Gronheit W, Kapauer M, Wellmer J, Bien CG. Progressive hippocampal sclerosis after viral encephalitis: potential role of NMDA receptor antibodies. Seizure 2017; 51: 6&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28750305</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta M. Dictionary of Epidemiology. 6th edn. New York: Oxford University Press; 2014.</Citation></Reference><Reference><Citation>Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ et al. . Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun 2018; 9: 4220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Zhou X, Perkerson RB 3rd, Baker M, Jenkins GD, Serie DJ et al. . Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 2018; 17: 548&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237181</ArticleId><ArticleId IdType="pubmed">29724592</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Mormino E, Soldan A, James BD, Yu L, Armstrong NM et al. . Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol 2018; 84: 10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119518</ArticleId><ArticleId IdType="pubmed">29944741</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, Taylor KI, Tolnay M. Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 2007; 114: 335&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17639426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ et al. . Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 2008; 17: 3631&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581433</ArticleId><ArticleId IdType="pubmed">18723524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 2014; 6: 82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239398</ArticleId><ArticleId IdType="pubmed">25419243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A et al. . TAR-DNA binding protein-43 and alterations in the hippocampus. J Neural Transm 2011; 118: 683&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21210283</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauramaa T, Pikkarainen M, Englund E, Ince PG, Jellinger K, Paetau A et al. . Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study. J Neuropathol Exp Neurol 2013; 72: 452&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23656988</ArticleId></ArticleIdList></Reference><Reference><Citation>Register OotF. Early Alzheimer&#x2019;s Disease: Developing Drugs for Treatment; Draft Guidance for Industry. In: USDoHaH S, Administration FaD CC, (CBER) CfBEaR, editors. Silver Spring, MD: Office of the Federal Register, National Archives and Records Administration; 2018. p. 7060&#x2013;1.</Citation></Reference><Reference><Citation>Ren Y, van Blitterswijk M, Allen M, Carrasquillo MM, Reddy JS, Wang X et al. . TMEM106B haplotypes have distinct gene expression patterns in aged brain. Mol Neurodegener 2018; 13: 35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029036</ArticleId><ArticleId IdType="pubmed">29970152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst 2017; 4: 404&#x2013;15.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson AC, Davidson YS, Horan MA, Pendleton N, Mann DMA. Pathological correlates of cognitive impairment in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. J Alzheimers Dis 2018a; 64: 483&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">29865073</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Corrada MM, Kovacs GG, Dominique M, Caswell C, Xie SX et al. . Non-Alzheimer&#x2019;s contributions to dementia and cognitive resilience in The 90+ Study. Acta Neuropathol 2018b; 136: 377&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6534149</ArticleId><ArticleId IdType="pubmed">29916037</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Stieber A, Umoh M, Kwong LK, Van Deerlin VM et al. . TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol 2013; 125: 121&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536927</ArticleId><ArticleId IdType="pubmed">23124365</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C et al. . Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 2018c; 141: 2181&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Molina-Porcel L, Corrada MM, Raible K, Lee EB, Lee VM et al. . Perforant path synaptic loss correlates with cognitive impairment and Alzheimer&#x2019;s disease in the oldest-old. Brain 2014; 137: 2578&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132652</ArticleId><ArticleId IdType="pubmed">25012223</ArticleId></ArticleIdList></Reference><Reference><Citation>Roostaei T, Nazeri A, Felsky D, De Jager PL, Schneider JA, Pollock BG et al. . Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer&#x2019;s disease. Mol Psychiatry 2016; 22: 287&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042808</ArticleId><ArticleId IdType="pubmed">27021820</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth M, Tomlinson BE, Blessed G. Correlation between scores for dementia and counts of &#x2018;senile plaques&#x2019; in cerebral grey matter of elderly subjects. Nature 1966; 209: 109&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">5927229</ArticleId></ArticleIdList></Reference><Reference><Citation>Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. Histopathology 2005; 47: 551&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16324191</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo A, Bejanin A, Murray ME, Tosakulwong N, Weigand SD, Serie AM et al. . TDP-43 and Alzheimer&#x2019;s disease pathologic subtype in non-amnestic Alzheimer&#x2019;s disease dementia. J Alzheimers Dis 2018; 64: 1227&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6258191</ArticleId><ArticleId IdType="pubmed">30010126</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH et al. . Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology 1993; 43: 1467&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH et al. . Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 9649&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Dugan P, Perucca P, Costello D, Choi H, Bazil C et al. . The phenotype of bilateral hippocampal sclerosis and its management in &#x201c;real life&#x201d; clinical settings. Epilepsia 2018; 59: 1410&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29901232</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennik S, Schweizer TA, Fischer CE, Munoz DG. Risk factors and pathological substrates associated with agitation/aggression in Alzheimer&#x2019;s disease: a preliminary study using NACC data. J Alzheimers Dis 2017; 55: 1519&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5607738</ArticleId><ArticleId IdType="pubmed">27911311</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M et al. . The antibody aducanumab reduces Abeta plaques in Alzheimer&#x2019;s disease. Nature 2016; 537: 50&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojania KG, Burton EC, McDonald KM, Goldman L. Changes in rates of autopsy-detected diagnostic errors over time: a systematic review. JAMA 2003; 289: 2849&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783916</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith VD, Bachstetter AD, Ighodaro E, Roberts K, Abner EL, Fardo DW et al. . Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol 2017; 28: 264&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5591757</ArticleId><ArticleId IdType="pubmed">28281308</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer W. Erkrankung des Ammon&#x2019;s horn als aetiologis ches moment der epilepsien. Arch Psychiatr Nurs 1880; 10: 631&#x2013;75.</Citation></Reference><Reference><Citation>Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 2017; 134: 187&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508034</ArticleId><ArticleId IdType="pubmed">28401333</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Barschke P, Otto M. Biomarkers for diseases with TDP-43 pathology. Mol Cell Neurosci 2018. pii: S1044-7431(18)30310-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30399416</ArticleId></ArticleIdList></Reference><Reference><Citation>Suemoto CK, Ferretti-Rebustini RE, Rodriguez RD, Leite RE, Soterio L, Brucki SM et al. . Neuropathological diagnoses and clinical correlates in older adults in Brazil: a cross-sectional study. PLoS Med 2017; 14: e1002267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5369698</ArticleId><ArticleId IdType="pubmed">28350821</ArticleId></ArticleIdList></Reference><Reference><Citation>Takao M, Hirose N, Arai Y, Mihara B, Mimura M. Neuropathology of supercentenarians&#x2014;four autopsy case studies. Acta Neuropathol Commun 2016; 4: 97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010697</ArticleId><ArticleId IdType="pubmed">27590044</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: experimental models and reality. Acta Neuropathol 2017a; 133: 177&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C et al. . TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain 2015; 138: 3110&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Yang Y, Halliday GM. Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. Neuropathol Appl Neurobiol 2017b. doi: 10.1111/nan.12455.</Citation><ArticleIdList><ArticleId IdType="pubmed">29215728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanskanen M, Makela M, Notkola IL, Myllykangas L, Rastas S, Oinas M et al. . Population-based analysis of pathological correlates of dementia in the oldest old. Ann Clin Transl Neurol 2017; 4: 154&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338150</ArticleId><ArticleId IdType="pubmed">28275649</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K et al. . Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000; 59: 733&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952063</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom M. Hippocampal sclerosis: progress since Sommer. Brain Pathol 2009; 19: 565&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094764</ArticleId><ArticleId IdType="pubmed">18761661</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom M, Eriksson S, Martinian L, Caboclo LO, McEvoy AW, Duncan JS et al. . Temporal lobe sclerosis associated with hippocampal sclerosis in temporal lobe epilepsy: neuropathological features. J Neuropathol Exp Neurol 2009; 68: 928&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723771</ArticleId><ArticleId IdType="pubmed">19606061</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom M, Sisodiya S. Epilepsy. In: Love S, Perry A, Ironside JW, Budka H, editors. Greenfield&#x2019;s Neuropathology. New York: CRC Press; 2015. p. 683&#x2013;739.</Citation></Reference><Reference><Citation>Tremblay C, St-Amour I, Schneider J, Bennett DA, Calon F. Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 2011; 70: 788&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197017</ArticleId><ArticleId IdType="pubmed">21865887</ArticleId></ArticleIdList></Reference><Reference><Citation>Trieu T, Sajjadi SA, Kawas CH, Nelson PT, Corrada MM. Risk factors of hippocampal sclerosis in the oldest old: the 90+ study. Neurology 2018; 91: e1788&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251605</ArticleId><ArticleId IdType="pubmed">30315072</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. &#x201c;Fatal attractions&#x201d; of proteins. A comprehensive hypothetical mechanism underlying Alzheimer&#x2019;s disease and other neurodegenerative disorders. Ann N Y Acad Sci 2000; 924: 62&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193803</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Kawas CH, Chang CK, Folstein MF, Hedreen JC. Lack of association of the apoE4 allele with hippocampal sclerosis dementia. Neurosci Lett 1996; 204: 138&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8929997</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M et al. . Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 2012; 135: 3380&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A et al. . Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun 2015; 3: 35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473839</ArticleId><ArticleId IdType="pubmed">26091809</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M et al. . Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 2008; 67: 555&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR et al. . Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010; 42: 234&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassilaki M, Aakre JA, Kremers WK, Mielke MM, Geda YE, Alhurani RE et al. . The Association of Multimorbidity with Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. J Gerontol A Biol Sci Med Sci 2018. doi: 10.1093/gerona/gly149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6521911</ArticleId><ArticleId IdType="pubmed">30124772</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A et al. . Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 2016; 139: 3202&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayi AV, Kofler J, Demichele-Sweet MA, Murray PS, Lopez OL, Sweet RA. TAR DNA-binding protein 43 pathology in Alzheimer&#x2019;s disease with psychosis. Int Psychogeriatr 2014; 26: 987&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157359</ArticleId><ArticleId IdType="pubmed">24588894</ArticleId></ArticleIdList></Reference><Reference><Citation>Velakoulis D, Walterfang M, Mocellin R, Pantelis C, Dean B, McLean C. Abnormal hippocampal distribution of TDP-43 in patients with-late onset psychosis. Aust N Z J Psychiatry 2009; 43: 739&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">19629795</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Del Tredici K, Braak H, Ludolph A. The multisystem degeneration amyotrophic lateral sclerosis&#x2014;neuropathological staging and clinical translation. Arch Ital Biol 2017; 155: 118&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29405032</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ et al. . Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000; 59: 931&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089571</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA et al. . Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM et al. . Association of Apolipoprotein E epsilon4 with Transactive Response DNA-Binding Protein 43. JAMA Neurol 2018; 75: 1347&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248121</ArticleId><ArticleId IdType="pubmed">30422173</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW et al. . Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci 2002; 977: 9&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480729</ArticleId></ArticleIdList></Reference><Reference><Citation>White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA et al. . Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology 2016; 86: 1000&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4799714</ArticleId><ArticleId IdType="pubmed">26888993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Yang J, Yu L, Leurgans SE, Capuano AW, Schneider JA et al. . Postmortem neurodegenerative markers and trajectories of decline in cognitive systems. Neurology 2019; 92: e831&#x2013;e840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396970</ArticleId><ArticleId IdType="pubmed">30674595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN et al. . Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging 2015; 36: 3152&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641774</ArticleId><ArticleId IdType="pubmed">26422359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisse LEM, Das SR, Davatzikos C, Dickerson BC, Xie SX, Yushkevich PA et al. . Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration. Neuroimage Clin 2018; 18: 407&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816023</ArticleId><ArticleId IdType="pubmed">29487798</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA et al. . Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study. Lancet Neurol 2018; 17: 773&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154505</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, Arai T et al. . Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol 2010; 120: 55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901929</ArticleId><ArticleId IdType="pubmed">20512649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 2015; 84: 927&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351662</ArticleId><ArticleId IdType="pubmed">25653292</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M, Guo L, Li N, Henzel KS, Gu H, Ran X et al. . Overexpression of Kcnmb2 in dorsal CA1 of offspring mice rescues hippocampal dysfunction caused by a methyl donor-rich paternal diet. Front Cell Neurosci 2018; 12: 360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206260</ArticleId><ArticleId IdType="pubmed">30405352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008; 70: 1042&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18362284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei MM, Song M, Wilson RJ, Cox N, Colom LV, Knaus HG et al. . Endocytic trafficking signals in KCNMB2 regulate surface expression of a large conductance voltage and Ca(2+)-activated K+ channel. Neuroscience 2007; 147: 80&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17521822</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Sitzer TE, Chui HC. Understanding hippocampal sclerosis in the elderly: epidemiology, characterization, and diagnostic issues. Curr Neurol Neurosci Rep 2008; 8: 363&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18713571</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L et al. . Correlates of hippocampal neuron number in Alzheimer&#x2019;s disease and ischemic vascular dementia. Ann Neurol 2005; 57: 896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851673</ArticleId><ArticleId IdType="pubmed">15929035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Wang L, Chui HC, Weiner MW, Csernansky JG. MRI shows more severe hippocampal atrophy and shape deformation in hippocampal sclerosis than in Alzheimer&#x2019;s disease. Int J Alzheimers Dis 2011; 2011: 483972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087502</ArticleId><ArticleId IdType="pubmed">21547227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Weiner MW, Ellis WG, Chui HC. Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav 2012; 2: 435&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3432966</ArticleId><ArticleId IdType="pubmed">22950047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc 2002; 50: 1431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 2016; 91: 1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27387643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Sun B, Wang X, Lu H, Shao F, Rozemuller AJM et al. . Phosphorylated TDP-43 staging of primary age-related tauopathy. Neurosci Bull 2019; 35: 183&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426920</ArticleId><ArticleId IdType="pubmed">30382507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Brady OA, Murphy KA, Hu F. Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. Acta Neuropathol Commun 2017; 5: 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5270347</ArticleId><ArticleId IdType="pubmed">28126008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31042697</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>570</Volume><Issue>7761</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Single-cell transcriptomic analysis of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>332</StartPage><EndPage>337</EndPage><MedlinePgn>332-337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1195-2</ELocationID><Abstract><AbstractText>Alzheimer's disease is a pervasive neurodegenerative disorder, the molecular complexity of which remains poorly understood. Here, we analysed 80,660 single-nucleus transcriptomes from the prefrontal cortex of 48 individuals with varying degrees of Alzheimer's disease pathology. Across six major brain cell types, we identified transcriptionally distinct subpopulations, including those associated with pathology and characterized by regulators of myelination, inflammation, and neuron survival. The strongest disease-associated changes appeared early in pathological progression and were highly cell-type specific, whereas genes upregulated at late stages were common across cell types and primarily involved in the global stress response. Notably, we found that female cells were overrepresented in disease-associated subpopulations, and that transcriptional responses were substantially different between sexes in several cell types, including oligodendrocytes. Overall, myelination-related processes were recurrently perturbed in multiple cell types, suggesting that myelination has a key role in Alzheimer's disease pathophysiology. Our single-cell transcriptomic resource provides a blueprint for interrogating the molecular and cellular basis of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mathys</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Davila-Velderrain</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Zhuyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jennie Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Madhvi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdurrob</LastName><ForeName>Fatema</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xueqiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martorell</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Third Rock Ventures, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hafler</LastName><ForeName>Brian P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA. manoli@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA. manoli@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA. lhtsai@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA. lhtsai@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA. lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054321</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110453</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062335</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH109978</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH119509</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058002</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG008155</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 EY026652</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2019 Jul;571(7763):E1. doi: 10.1038/s41586-019-1329-6.</RefSource><PMID Version="1">31209304</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Immunity. 2019 Jun 18;50(6):1349-1351. doi: 10.1016/j.immuni.2019.05.016.</RefSource><PMID Version="1">31216459</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="Y">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31042697</ArticleId><ArticleId IdType="mid">NIHMS1049060</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1195-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masters CL et al. Alzheimer&#x2019;s disease. Nat Rev Dis Primers 1, 15056 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J &amp; Selkoe DJ The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B &amp; Karran E The Cellular Phase of Alzheimer&#x2019;s Disease. Cell 164, 603&#x2013;615 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter RG, Penney J &amp; Tsai L-H The road to restoring neural circuits for the treatment of Alzheimer&#x2019;s disease. Nature 539, 187&#x2013;196 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27830780</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 14, 388&#x2013;405 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop NA, Lu T &amp; Yankner BA Neural mechanisms of ageing and cognitive decline. Nature 464, 529&#x2013;535 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927852</ArticleId><ArticleId IdType="pubmed">20336135</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimenova AA, Raj T &amp; Goate AM Untangling Genetic Risk for Alzheimer&#x2019;s Disease. Biological Psychiatry 83, 300&#x2013;310 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699970</ArticleId><ArticleId IdType="pubmed">28666525</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher DW, Bennett DA &amp; Dong H Sexual dimorphism in predisposition to Alzheimer&#x2019;s disease. Neurobiol. Aging (2018). 10.1016/j.neurobiolaging.2018.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.04.004</ArticleId><ArticleId IdType="pmc">PMC6368179</ArticleId><ArticleId IdType="pubmed">29754747</ArticleId></ArticleIdList></Reference><Reference><Citation>Nativio R et al. Dysregulation of the epigenetic landscape of normal aging in Alzheimer&#x2019;s disease. Nat. Neurosci 21, 497&#x2013;505 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6124498</ArticleId><ArticleId IdType="pubmed">29507413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossers K et al. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer&#x2019;s disease. Brain 133, 3699&#x2013;3723 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20889584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Woltjer RL, Goodenbour JM, Horvath S &amp; Geschwind DH Genes and pathways underlying regional and cell type changes in Alzheimer&#x2019;s disease. Genome Med. 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature 518, 365&#x2013;369 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955&#x2013;958 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352, 1586&#x2013;1590 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong S et al. A single-cell RNA-seq survey of the developmental landscape of the human prefrontal cortex. Nature 555, 524&#x2013;528 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29539641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol 36, 70&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Macosko EZ et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell 161, 1202&#x2013;1214 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4481139</ArticleId><ArticleId IdType="pubmed">26000488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Religious Orders Study and Rush Memory and Aging Project. J. Alzheimers. Dis 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z et al. Comprehensive transcriptome analysis of neocortical layers in humans, chimpanzees and macaques. Nat. Neurosci 20, 886&#x2013;895 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28414332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-T et al. APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron 98, 1294 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048952</ArticleId><ArticleId IdType="pubmed">29953873</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 21, 366&#x2013;380 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Enright F &amp; Andrews J Lingo-1: a novel target in therapy for Alzheimer&#x2019;s disease? Neural Regeneration Res. 11, 88 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774240</ArticleId><ArticleId IdType="pubmed">26981092</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi S et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci 8, 745&#x2013;751 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15895088</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C et al. Erbin is required for myelination in regenerated axons after injury. J. Neurosci 32, 15169&#x2013;15180 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617562</ArticleId><ArticleId IdType="pubmed">23100438</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott R et al. Loss of Cntnap2 Causes Axonal Excitability Deficits, Developmental Delay in Cortical Myelination, and Abnormal Stereotyped Motor Behavior. Cereb. Cortex (2017). 10.1093/cercor/bhx341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx341</ArticleId><ArticleId IdType="pubmed">29300891</ArticleId></ArticleIdList></Reference><Reference><Citation>Poplawski GHD et al. Adult rat myelin enhances axonal outgrowth from neural stem cells. Sci. Transl. Med 10, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377986</ArticleId><ArticleId IdType="pubmed">29794059</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazaei MR et al. Bex1 is involved in the regeneration of axons after injury. J. Neurochem 115, 910&#x2013;920 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382973</ArticleId><ArticleId IdType="pubmed">20731761</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiradake E et al. Structural basis for cell surface patterning through NetrinG-NGL interactions. EMBO J. 30, 4479&#x2013;4488 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230378</ArticleId><ArticleId IdType="pubmed">21946559</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC &amp; Goate AM Alzheimer&#x2019;s Disease: The Challenge of the Second Century. Sci. Transl. Med 3, 77sr1&#x2013;77sr1 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade WA et al. Early endosome localization and activity of RasGEF1b, a toll-like receptor-inducible Ras guanine-nucleotide exchange factor. Genes Immun. 11, 447&#x2013;457 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20090772</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch WE, Morimoto RI, Dillin A &amp; Kelly JW Adapting proteostasis for disease intervention. Science 319, 916&#x2013;919 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbadia J &amp; Morimoto RI The Biology of Proteostasis in Aging and Disease. Annu. Rev. Biochem 84, 435&#x2013;464 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539002</ArticleId><ArticleId IdType="pubmed">25784053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohonen T The self-organizing map. Proc. IEEE 78, 1464&#x2013;1480 (1990).</Citation></Reference><Reference><Citation>Karch CM &amp; Goate AM Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43&#x2013;51 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies G et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat. Commun 9, 2098 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5974083</ArticleId><ArticleId IdType="pubmed">29844566</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel VD, Guillaume J-L, Lambiotte R &amp; Lefebvre E Fast unfolding of communities in large networks. J. Stat. Mech: Theory Exp 2008, P10008 (2008).</Citation></Reference><Reference><Citation>Ousman SS et al. Protective and therapeutic role for aB-crystallin in autoimmune demyelination. Nature 448, 474&#x2013;479 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17568699</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y-J et al. Clusterin enhances proliferation of primary astrocytes through extracellular signal-regulated kinase activation. Neuroreport 17, 1871&#x2013;1875 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17179861</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M et al. A transcriptomic atlas of aged human microglia. Nat. Commun 9, 539 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Caso F et al. White Matter Degeneration in Atypical Alzheimer Disease. Radiology 277, 162&#x2013;172 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26018810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P et al. A transcriptional signature of Alzheimer&#x2019;s disease is associated with a metastable subproteome at risk for aggregation. Proceedings of the National Academy of Sciences 113, 4753&#x2013;4758 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4855616</ArticleId><ArticleId IdType="pubmed">27071083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Natural history of mild cognitive impairment in older persons. Neurology 59, 198&#x2013;205 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology 60, 246&#x2013;252 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL &amp; Arnold SE Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol 61, 378&#x2013;384 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837&#x2013;1844 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Decision Rules Guiding the Clinical Diagnosis of Alzheimer&#x2019;s Disease in Two Community-Based Cohort Studies Compared to Standard Practice in a Clinic-Based Cohort Study. Neuroepidemiology 27, 169&#x2013;176 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiech L et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol 33, 102&#x2013;106 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492112</ArticleId><ArticleId IdType="pubmed">25326897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Angerer P &amp; Theis FJ SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications 10, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde R &amp; Vilo J GOsummaries: an R Package for Visual Functional Annotation of Experimental Data. F1000Res. 4, 574 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743157</ArticleId><ArticleId IdType="pubmed">26913188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wehrens R &amp; Buydens LMC Self- and Super-organizing Maps inR: ThekohonenPackage. J. Stat. Softw 21, (2007).</Citation></Reference><Reference><Citation>Friston KJ et al. Spatial registration and normalization of images. Hum. Brain Mapp. 3, 165&#x2013;189 (1995).</Citation></Reference><Reference><Citation>Griffanti L et al. BIANCA (Brain Intensity AbNormality Classification Algorithm): A new tool for automated segmentation of white matter hyperintensities. Neuroimage 141, 191&#x2013;205 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035138</ArticleId><ArticleId IdType="pubmed">27402600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31076275</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection.</ArticleTitle><Pagination><StartPage>929</StartPage><EndPage>943.e8</EndPage><MedlinePgn>929-943.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.04.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)30346-0</ELocationID><Abstract><AbstractText>Neuronal and synaptic loss is characteristic in many neurodegenerative diseases, such as frontotemporal dementia and Alzheimer's disease. Recently, we showed that inducing gamma oscillations with visual stimulation (gamma entrainment using sensory stimuli, or GENUS) reduced amyloid plaques and phosphorylated tau in multiple mouse models. Whether GENUS can affect neurodegeneration or cognitive performance remains unknown. Here, we demonstrate that GENUS can entrain gamma oscillations in the visual cortex, hippocampus, and prefrontal cortex in Tau P301S and CK-p25 mouse models of neurodegeneration. Tau P301S and CK-p25 mice subjected to chronic, daily GENUS from the early stages of neurodegeneration showed a preservation of neuronal and synaptic density across multiple brain areas and modified cognitive performance. Our transcriptomic and phosphoproteomic data suggest that chronic GENUS shifts neurons to a less degenerative state, improving synaptic function, enhancing neuroprotective factors, and reducing DNA damage in neurons while also reducing inflammatory response in microglia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adaikkan</LastName><ForeName>Chinnakkaruppan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Laboratory for Circuit and Behavioral Physiology, RIKEN Center for Brain Science, Wako-shi, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marco</LastName><ForeName>Asaf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pao</LastName><ForeName>Ping-Chieh</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathys</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>David Nam-Woo</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jennie Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suk</LastName><ForeName>Ho-Jun</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; MIT Media Lab, Departments of Biological Engineering and Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Harvard-MIT Health Sciences and Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyden</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; MIT Media Lab, Departments of Biological Engineering and Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Laboratory for Circuit and Behavioral Physiology, RIKEN Center for Brain Science, Wako-shi, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02139, USA. Electronic address: lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG047661</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054321</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2019 Jun 5;102(5):901-902. doi: 10.1016/j.neuron.2019.05.020.</RefSource><PMID Version="1">31170394</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065818" MajorTopicYN="N">Gamma Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065853" MajorTopicYN="N">Spatial Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="N">Visual Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>DECLARATION OF INTEREST. L.-H.T. and E.S.B are scientific co-founders and serve on the scientific advisory board of Cognito Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31076275</ArticleId><ArticleId IdType="mid">NIHMS1528873</ArticleId><ArticleId IdType="pmc">PMC6697125</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.04.011</ArticleId><ArticleId IdType="pii">S0896-6273(19)30346-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Airavaara M, Shen H, Kuo C, Per&#xe4;nen J, Saarma M, Hoffer B, and Wang Y (2009). Mesencephalic astrocyte&#x1e6;derived neurotrophic factor reduces ischemic brain injury and promotes behavioral recovery in rats. J. Comp. Neurol 515, 116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723810</ArticleId><ArticleId IdType="pubmed">19399876</ArticleId></ArticleIdList></Reference><Reference><Citation>Armbruster M, Messa M, Ferguson SM, De Camilli P, and Ryan TA (2013). Dynamin phosphorylation controls optimization of endocytosis for brief action potential bursts. Elife 2, e00845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728620</ArticleId><ArticleId IdType="pubmed">23908769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachstetter AD, Ighodaro ET, Hassoun Y, Aldeiri D, Neltner JH, Patel E, Abner EL, and Nelson PT (2017). Rod-shaped microglia morphology is associated with aging in 2 human autopsy series. Neurobiol. Aging 52, 98&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5359029</ArticleId><ArticleId IdType="pubmed">28131016</ArticleId></ArticleIdList></Reference><Reference><Citation>Balschun D, Moechars D, Callaerts-Vegh Z, Vermaercke B, Van Acker N, Andries L, and D&#x2019;hooge R (2009). Vesicular glutamate transporter VGLUT1 has a role in hippocampal long-term potentiation and spatial reversal learning. Cerebral Cortex 20, 684&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">19574394</ArticleId></ArticleIdList></Reference><Reference><Citation>Benveniste EN, Nguyen VT, Wesemann DR. (2004) Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav Immun 18(1):7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">14651941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee J, and Holtzman DM (2011). Neuronal activity regulates the regional vulnerability to amyloid-[beta] deposition. Nat. Neurosci 14, 750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Kurth D, Phinney AL, Long JM, Hengemihle J, Mouton PR, Ingram DK, Jucker M. (1998) Hippocampal neuron and synaptophysin-positive bouton number in aging C57BL/6 mice. Neurobiol Aging 19(6):599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">10192220</ArticleId></ArticleIdList></Reference><Reference><Citation>Canter RG, Penney J, and Tsai L (2016). The road to restoring neural circuits for the treatment of Alzheimer&#x2019;s disease. Nature 539, 187&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830780</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardin JA, Carl&#xe9;n M, Meletis K, Knoblich U, Zhang F, Deisseroth K, Tsai L, and Moore CI (2009). Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459, 663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655711</ArticleId><ArticleId IdType="pubmed">19396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho KK, Hoch R, Lee AT, Patel T, Rubenstein JL, and Sohal VS (2015). Gamma rhythms link prefrontal interneuron dysfunction with cognitive inflexibility in Dlx5/6 /&#x2212; mice. Neuron 85, 1332&#x2013;1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503262</ArticleId><ArticleId IdType="pubmed">25754826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48(6):913&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. (2008). Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58(1):42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng H, Goldman JA, Shih H, and Tsai L (2003). Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton EL, Sue N, Smillie KJ, O&#x2019;Leary T, Bache N, Cheung G, Cole AR, Wyllie DJ, Sutherland C, Robinson PJ, Cousin MA. (201) Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles. Nat Neurosci 13(7):845&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894011</ArticleId><ArticleId IdType="pubmed">20526333</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, Huntley MA, De Mazi&#xe8;re A, Meilandt WJ, Wu T, Srinivasan K, Jiang Z, Gandham V, Friedman BA, Ngu H, Foreman O, et al., (2018). Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. Neuron 100(6):1322&#x2013;1336.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbin MM, Madabhushi R, Pan L, Chen Y, Kim D, Gao J, Ahanonu B, Pao P, Qiu Y, and Zhao Y (2013). SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat. Neurosci 16, 1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758134</ArticleId><ArticleId IdType="pubmed">23852118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, and Tsai L (2005). Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48, 825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey A, Listovsky T, Guilbaud G, Sarkies P, Sale JE. (2014). Histone H3.3 is required to maintain replication fork progression after UV damage. Curr Biol 24(18):2195&#x2013;2201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4175177</ArticleId><ArticleId IdType="pubmed">25201682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie AK, Jones EA, Lin Y, Karlsson MP, Kay K, Yoon SY, Tong LM, Nova P, Carr JS, and Frank LM (2016). Apolipoprotein E4 causes age-dependent disruption of slow gamma oscillations during hippocampal sharp-wave ripples. Neuron 90, 740&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097044</ArticleId><ArticleId IdType="pubmed">27161522</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH, Kellis M. (2015). Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature 518(7539):365&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillon J, Attal Y, Colliot O, La Corte V, Dubois B, Schwartz D, Chavez M, and Fallani FDV (2017). Loss of brain inter-frequency hubs in Alzheimer&#x2019;s disease. Scientific reports 7, 10879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589939</ArticleId><ArticleId IdType="pubmed">28883408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellman M, Arumae U, Yu LY, Lindholm P, Peranen J, Saarma M, and Permi P (2011). Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J. Biol. Chem 286, 2675&#x2013;2680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024763</ArticleId><ArticleId IdType="pubmed">21047780</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, and Ransohoff RM (2015). Neuroinflammation in Alzheimer&#x2019;s disease. The Lancet Neurology 14, 388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann CS (2001). Human EEG responses to 1&#x2013;100 Hz flicker: resonance phenomena in visual cortex and their potential correlation to cognitive phenomena. Experimental brain research 137, 346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11355381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, et al. (2016). Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540, 230&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="pubmed">27929004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M, Gonzalez B, Castellano B, and Zimmer J (1994). Microglial and astroglial reactions to anterograde axonal degeneration: a histochemical and immunocytochemical study of the adult rat fascia dentata after entorhinal perforant path lesions. Experimental brain research 98, 245&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8050511</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen MB, Finsen BR, Jensen MB, Castellano B, Diemer NH, and Zimmer J (1993). Microglial and astroglial reactions to ischemic and kainic acid-induced lesions of the adult rat hippocampus. Exp. Neurol 120, 70&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">7682970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastanenka KV, Hou SS, Shakerdge N, Logan R, Feng D, Wegmann S, Chopra V, Hawkes JM, Chen X, and Bacskai BJ (2017). Optogenetic Restoration of Disrupted Slow Oscillations Halts Amyloid Deposition and Restores Calcium Homeostasis in an Animal Model of Alzheimer&#x2019;s Disease. PloS one 12, e0170275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5257003</ArticleId><ArticleId IdType="pubmed">28114405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Frank CL, Dobbin MM, Tsunemoto RK, Tu W, Peng PL, Guan JS, Lee BH, Moy LY, Giusti P, Broodie N, Mazitschek R, Delalle I, Haggarty SJ, Neve RL, Lu Y, Tsai LH.. (2008). Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 60, 803&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912147</ArticleId><ArticleId IdType="pubmed">19081376</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, and Jelic V (2005). Decreased EEG synchronization in Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol. Aging 26, 165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582746</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Losa M, Tracy TE, Ma K, Verret L, Clemente-Perez A, Khan AS, Cobos I, Ho K, Gan L, and Mucke L (2018). Nav1. 1-Overexpressing Interneuron Transplants Restore Brain Rhythms and Cognition in a Mouse Model of Alzheimer&#x2019;s Disease. Neuron 98, 75&#x2013;89. e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886814</ArticleId><ArticleId IdType="pubmed">29551491</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorell AJ, Paulson AL, Suk HJ, Abdurrob F, Drummond G, Guan W, Young JZ, Kim DN, Kritskiy O, Barker SJ, et al., (2019). Multi-sensory Gamma Stimulation Ameliorates Alzheimer&#x2019;s-Associated Pathology and Improves Cognition. Advanced online publication: Cell 10.1016/j.cell.2019.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.02.014</ArticleId><ArticleId IdType="pmc">PMC6774262</ArticleId><ArticleId IdType="pubmed">30879788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, and Tsai L (2017). Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell reports 21, 366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki M, Ellis-Davies GC, Nemoto T, Miyashita Y, Iino M, Kasai H. (2001). Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat Neurosci 4(11):1086&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229049</ArticleId><ArticleId IdType="pubmed">11687814</ArticleId></ArticleIdList></Reference><Reference><Citation>Maze I, Wenderski W, Noh K, Bagot RC, Tzavaras N, Purushothaman I, Els&#xe4;sser SJ, Guo Y, Ionete C, and Hurd YL (2015). Critical role of histone turnover in neuronal transcription and plasticity. Neuron 87, 77&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491146</ArticleId><ArticleId IdType="pubmed">26139371</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton SJ, and McHugh TJ (2016). Silencing CA3 disrupts temporal coding in the CA1 ensemble. Nat. Neurosci 19, 945.</Citation><ArticleIdList><ArticleId IdType="pubmed">27239937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, and Helmchen F (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A, Cheng J, Gao F, Lin Y, Gjoneska E, Ko T, Minhas P, Zamudio AV, Meng J, and Zhang F (2016). Histone deacetylase 3 associates with MeCP2 to regulate FOXO and social behavior. Nat. Neurosci 19, 1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5083138</ArticleId><ArticleId IdType="pubmed">27428650</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al., (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, and Mucke L (2016). Network abnormalities and interneuron dysfunction in Alzheimer disease. Nature Reviews Neuroscience 17, 777&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor MA, Artieda J, Arbizu J, Valencia M, and Masdeu JC (2003). Human cerebral activation during steady-state visual-evoked responses. J. Neurosci 23, 11621&#x2013;11627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740964</ArticleId><ArticleId IdType="pubmed">14684864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rager G, and Singer W (1998). The response of cat visual cortex to flicker stimuli of variable frequency. Eur. J. Neurosci 10, 1856&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribary U, Ioannides AA, Singh KD, Hasson R, Bolton JP, Lado F, Mogilner A, and Llinas R (1991). Magnetic field tomography of coherent thalamocortical 40-Hz oscillations in humans. Proc. Natl. Acad. Sci. U. S. A 88, 11037&#x2013;11041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53068</ArticleId><ArticleId IdType="pubmed">1763020</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, et al., (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549(7673):523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, Stevens B, Lemere CA. (2017) Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med 9(392).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer AC, Martorell AJ, Douglas JM, Abdurrob F, Attokaren MK, Tipton J, Mathys H, Adaikkan C, and Tsai L (2018). Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load. Nature protocols 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">30072722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, Zhang F, Yizhar O, and Deisseroth K (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969859</ArticleId><ArticleId IdType="pubmed">19396159</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MR, Blurton-Jones M, West BL, and Green KN (2016). Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-&#x3b2; pathology. Brain 139, 1265&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam C, De Haan W, Daffertshofer A, Jones B, Manshanden I, van Cappellen van Walsum, Anne-Marie, Montez T, Verbunt J, De Munck J, and Van Dijk B (2008). Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer&#x2019;s disease. Brain 132, 213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18952674</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, van Walsum, Anne Marie van Cappellen, Pijnenburg YA, Berendse HW, de Munck JC, Scheltens P, and van Dijk BW (2002). Generalized synchronization of MEG recordings in Alzheimer&#x2019;s disease: evidence for involvement of the gamma band. Journal of Clinical Neurophysiology 19, 562&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">12488788</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK. (2010). Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer&#x2019;s disease transgenic mice. J Neurosci 30(43):14299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972675</ArticleId><ArticleId IdType="pubmed">20980585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, and Mullan MJ (2002). Role of CD40 ligand in amyloidosis in transgenic Alzheimer&#x2019;s mice. Nat. Neurosci 5, 1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor SE, Morganti-Kossmann C, Lifshitz J, and Ziebell JM (2014). Rod microglia: a morphological definition. PloS one 9, e97096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022629</ArticleId><ArticleId IdType="pubmed">24830807</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, and Pachter L (2012). Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature protocols 7, 562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334321</ArticleId><ArticleId IdType="pubmed">22383036</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, and Mody I (2012). Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinck M, Oostenveld R, Van Wingerden M, Battaglia F, and Pennartz CM (2011). An improved index of phase-synchronization for electrophysiological data in the presence of volume-conduction, noise and sample-size bias. Neuroimage 55, 1548&#x2013;1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">21276857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, Tan MS, Yu JT, and Tan L (2015). Role of pro-inflammatory cytokines released from microglia in Alzheimer&#x2019;s disease. Ann. Transl. Med 3, 136&#x2013;5839.2015.03.49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486922</ArticleId><ArticleId IdType="pubmed">26207229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, Sanders DW, Cook C, Fu H, and Boonen RA (2016). Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci 19, 1085&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgrafe K, Mandelkow EM, and Holtzman DM (2014). Neuronal activity regulates extracellular tau in vivo. J. Exp. Med 211, 387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Tanei ZI, Hashimoto T, Wakabayashi T, Okuno H, Naka Y, Yizhar O,Fenno LE, Fukayama M, Bito H, et al., (2015). Chronic optogenetic activation augments a&#x3b2; pathology in a mouse model of Alzheimer disease. Cell Rep 11(6):859&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">25937280</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang S, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, and Lee VM (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31086314</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo.</ArticleTitle><Pagination><StartPage>851</StartPage><EndPage>862</EndPage><MedlinePgn>851-862</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0397-0</ELocationID><Abstract><AbstractText>The GGGGCC repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). However, it is not known which dysregulated molecular pathways are primarily responsible for disease initiation or progression. We established an inducible mouse model of poly(GR) toxicity in which (GR)<sub>80</sub> gradually accumulates in cortical excitatory neurons. Low-level poly(GR) expression induced FTD/ALS-associated synaptic dysfunction and behavioral abnormalities, as well as age-dependent neuronal cell loss, microgliosis and DNA damage, probably caused in part by early defects in mitochondrial function. Poly(GR) bound preferentially to the mitochondrial complex V component ATP5A1 and enhanced its ubiquitination and degradation, consistent with reduced ATP5A1 protein level in both (GR)<sub>80</sub> mouse neurons and patient brains. Moreover, inducing ectopic Atp5a1 expression in poly(GR)-expressing neurons or reducing poly(GR) level in adult mice after disease onset rescued poly(GR)-induced neurotoxicity. Thus, poly(GR)-induced mitochondrial defects are a major driver of disease initiation in C9ORF72-related ALS/FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>So Yoen</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lopez-Gonzalez</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Krishnan</LastName><ForeName>Gopinath</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Hannah L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Alissa Nana</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0003-3474-8044</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Wei-Dong</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fen-Biao</ForeName><Initials>FB</Initials><Identifier Source="ORCID">0000-0001-8873-5404</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA. fen-biao.gao@umassmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS101986</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS093097</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS057553</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101986</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.14</RegistryNumber><NameOfSubstance UI="C000630910">ATP5A1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.14</RegistryNumber><NameOfSubstance UI="C000628214">ATP5F1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.3.-</RegistryNumber><NameOfSubstance UI="D025261">Mitochondrial Proton-Translocating ATPases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025261" MajorTopicYN="N">Mitochondrial Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31086314</ArticleId><ArticleId IdType="mid">NIHMS1054313</ArticleId><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0397-0</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0397-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Olney NT, Spina S. &amp; Miller BL Frontotemporal dementia. Neurol. Clin 35, 339&#x2013;374 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5472209</ArticleId><ArticleId IdType="pubmed">28410663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 3, 17085 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Almeida S. &amp; Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. EMBO J 36, 2931&#x2013;2950 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641681</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K. et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T. et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol 126, 859&#x2013;879 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson YS et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun 2, 70 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229740</ArticleId><ArticleId IdType="pubmed">24950788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol 130, 845&#x2013;861 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH et al. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol 130, 537&#x2013;555 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139, 3202&#x2013;3216 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S. et al. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol 135, 459&#x2013;474 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N. et al. Poly-GR dipeptide repeat polymers correlate with neurodegeneration and clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol. Commun 6, 63 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6054740</ArticleId><ArticleId IdType="pubmed">30029693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JD &amp; Ranum LP New developments in RAN translation: insights from multiple diseases. Curr. Opin. Genet. Dev 44, 125&#x2013;134 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951168</ArticleId><ArticleId IdType="pubmed">28365506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Richter JD &amp; Cleveland DW Rethinking unconventional translation in neurodegeneration. Cell 171, 994&#x2013;1000 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728172</ArticleId><ArticleId IdType="pubmed">29149615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S. et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192&#x2013;1194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X. et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84, 1213&#x2013;1225 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D. et al. FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathol 130, 525&#x2013;535 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575383</ArticleId><ArticleId IdType="pubmed">26031661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I. et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139&#x2013;1145 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z. et al. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum. Mol. Genet 24, 2426&#x2013;2441 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25575510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R. et al. Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron 92, 383&#x2013;391 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Konopka A, Soo KY, Ito D. &amp; Atkin JD The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet 26, 2882&#x2013;2896 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc. Natl Acad. Sci. USA 114, E1111&#x2013;E1117 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascon E. et al. Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia. Nat. Med 20, 1444&#x2013;1451 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257887</ArticleId><ArticleId IdType="pubmed">25401692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D. et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med 5, 208ra149 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J. et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151&#x2013;1154 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Moy SS et al. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 3, 287&#x2013;302 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15344922</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes CE &amp; Grafman J. The role of the human prefrontal cortex in social cognition and moral judgment. Annu. Rev. Neurosci 33, 299&#x2013;324 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20350167</ArticleId></ArticleIdList></Reference><Reference><Citation>Madabhushi R, Pan L. &amp; Tsai LH DNA damage and its links to neurodegeneration. Neuron 83, 266&#x2013;282 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564444</ArticleId><ArticleId IdType="pubmed">25033177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med 24, 1136&#x2013;1142 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavie J. et al. Ubiquitin-dependent degradation of mitochondrial proteins regulates energy metabolism. Cell Rep 23, 2852&#x2013;2863 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29874573</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz A, Kevei E. &amp; Hoppe T. Double-edged alliance: mitochondrial surveillance by the UPS and autophagy. Curr. Opin. Cell Biol 37, 18&#x2013;27 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26343990</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Okamoto K, Hayashi Y. &amp; Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119, 873&#x2013;887 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15607982</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak D. et al. The role of mitochondrially derived ATP in synaptic vesicle recycling. J. Biol. Chem 290, 22325&#x2013;22336 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4566209</ArticleId><ArticleId IdType="pubmed">26126824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi-Fakhari D. et al. Impaired mitochondrial dynamics and mitophagy in neuronal models of tuberous sclerosis complex. Cell Rep 17, 1053&#x2013;1070 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078873</ArticleId><ArticleId IdType="pubmed">27760312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Dissing-Olesen L. &amp; Stevens B. New insights on the role of microglia in synaptic pruning in health and disease. Curr. Opin. Neurobiol 36, 128&#x2013;134 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479435</ArticleId><ArticleId IdType="pubmed">26745839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH et al. Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathol 134, 241&#x2013;254 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508040</ArticleId><ArticleId IdType="pubmed">28409281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci 19, 668&#x2013;677 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31086348</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1.</ArticleTitle><Pagination><StartPage>988</StartPage><EndPage>1000</EndPage><MedlinePgn>988-1000</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-019-0440-4</ELocationID><Abstract><AbstractText>An aged circulatory environment can activate microglia, reduce neural precursor cell activity and impair cognition in mice. We hypothesized that brain endothelial cells (BECs) mediate at least some of these effects. We observe that BECs in the aged mouse hippocampus express an inflammatory transcriptional profile with focal upregulation of vascular cell adhesion molecule 1 (VCAM1), a protein that facilitates vascular-immune cell interactions. Concomitantly, levels of the shed, soluble form of VCAM1 are prominently increased in the plasma of aged humans and mice, and their plasma is sufficient to increase VCAM1 expression in cultured BECs and the hippocampi of young mice. Systemic administration of anti-VCAM1 antibody or genetic ablation of Vcam1 in BECs counteracts the detrimental effects of plasma from aged individuals on young brains and reverses aging aspects, including microglial reactivity and cognitive deficits, in the brains of aged mice. Together, these findings establish brain endothelial VCAM1 at the blood-brain barrier as a possible target to treat age-related neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yousef</LastName><ForeName>Hanadie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czupalla</LastName><ForeName>Cathrin J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palo Alto Veterans Institute for Research, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Davis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Michelle B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Departments of Bioengineering and Applied Physics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Ashley N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zera</LastName><ForeName>Kristy A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zandstra</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berber</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehallier</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathur</LastName><ForeName>Vidhu</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Ramesh V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Liana N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Bioengineering and Applied Physics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadeiba</LastName><ForeName>Husein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palo Alto Veterans Institute for Research, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkel</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rbelin</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Pneumology, Department of Oncology, Hematology and Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwaninger</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4510-9718</Identifier><AffiliationInfo><Affiliation>Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lubeck, Lubeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckwalter</LastName><ForeName>Marion S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-2807-2447</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quake</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Departments of Bioengineering and Applied Physics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butcher</LastName><ForeName>Eugene C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palo Alto Veterans Institute for Research, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palo Alto Veterans Institute for Research, Palo Alto, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AI047822</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI109452</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG051330</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AG053015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001085</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM037734</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM120007</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019010">Vascular Cell Adhesion Molecule-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Immunol. 2019 Jul;19(7):415. doi: 10.1038/s41577-019-0183-y.</RefSource><PMID Version="1">31127247</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2019 Jul;20(7):378-379. doi: 10.1038/s41583-019-0190-9.</RefSource><PMID Version="1">31138911</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019010" MajorTopicYN="N">Vascular Cell Adhesion Molecule-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31086348</ArticleId><ArticleId IdType="mid">NIHMS1523758</ArticleId><ArticleId IdType="pmc">PMC6642642</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0440-4</ArticleId><ArticleId IdType="pii">10.1038/s41591-019-0440-4</ArticleId></ArticleIdList><ReferenceList><Title>References (Main Text)</Title><Reference><Citation>Wyss-Coray T Ageing, neurodegeneration and brain rejuvenation. Nature 539, 180&#x2013;186 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5172605</ArticleId><ArticleId IdType="pubmed">27830812</ArticleId></ArticleIdList></Reference><Reference><Citation>Harry GJ Microglia during development and aging. Pharmacol Ther 139, 313&#x2013;326 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3737416</ArticleId><ArticleId IdType="pubmed">23644076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI &amp; Wyss-Coray T Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem. Pharmacol 88, 594&#x2013;604 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 19, 995&#x2013;998 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming GL &amp; Song H Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions. Neuron 70, 687&#x2013;702 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106107</ArticleId><ArticleId IdType="pubmed">21609825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O &amp; Marr RA Neurogenesis and Alzheimer&#x2019;s disease: At the crossroads. Exp. Neurol 223, 267&#x2013;281 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864344</ArticleId><ArticleId IdType="pubmed">19699201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S et al. Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signaling proteins. Nat. Med 13, 1359&#x2013;62 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda S et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90&#x2013;94 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Britschgi M et al. Modeling of pathological traits in Alzheimer&#x2019;s disease based on systemic extracellular signaling proteome. Mol. Cell. Proteomics 10, M111.008862 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205866</ArticleId><ArticleId IdType="pubmed">21742799</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 20, 659&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature 544, 488&#x2013;492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586222</ArticleId><ArticleId IdType="pubmed">28424512</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsimpardi L et al. Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors. Science 344, 630&#x2013;634 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123747</ArticleId><ArticleId IdType="pubmed">24797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebo J et al. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nat. Commun 7, 13363 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5121415</ArticleId><ArticleId IdType="pubmed">27874859</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B &amp; Liebner S Novel insights into the development and maintenance of the blood-brain barrier. Cell Tissue Res 355, 687&#x2013;99 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972432</ArticleId><ArticleId IdType="pubmed">24590145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabene PF et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med 14, 1377&#x2013;83 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710311</ArticleId><ArticleId IdType="pubmed">19029985</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivash L &amp; OBrien TJ Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases? J. Nucl. Med 57, 165&#x2013;168 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26697963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gragnano F, Sperlongano S, Golia E, Natale F, Bianchi R, Crisci M, Fimiani F, Pariggiano I, Diana V, Carbone A, Cesaro A, Concilio C, Limongelli G, Russo M, and The PC Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm 2017, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467347</ArticleId><ArticleId IdType="pubmed">28634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi B, Angiari S, Zenaro E, Budui SL &amp; Constantin G Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J. Leukoc. Biol 89, 539&#x2013;56 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21169520</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin C et al. &#x3b1;4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80, 413&#x2013;422 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7532110</ArticleId></ArticleIdList></Reference><Reference><Citation>Garton KJ et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J. Biol. Chem 278, 37459&#x2013;64 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12878595</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J et al. Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood 128, 104 LP&#x2013;109 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937354</ArticleId><ArticleId IdType="pubmed">27207787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M et al. Transcriptional programs of lymphoid tissue capillary and high endothelium reveal control mechanisms for lymphocyte homing. Nat Immunol 15, 982&#x2013;995 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222088</ArticleId><ArticleId IdType="pubmed">25173345</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M Signaling required for blood vessel maintenance: Molecular basis and pathological manifestations. Int. J. Vasc. Med 2012, (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236483</ArticleId><ArticleId IdType="pubmed">22187650</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R et al. The mouse blood-brain barrier transcriptome: A new resource for understanding the development and function of brain endothelial cells. PLoS One 5, e13741 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966423</ArticleId><ArticleId IdType="pubmed">21060791</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald JA, Murugesan N &amp; Pachter JS Endothelial cell heterogeneity of blood-brain barrier gene expression along the cerebral microvasculature. J. Neurosci. Res 88, 1457&#x2013;1474 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20025060</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J et al. Vascular Endothelial Growth Factor Receptor 3 Controls Neural Stem Cell Activation in Mice and Humans. Cell Rep 10, 1158&#x2013;1172 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685253</ArticleId><ArticleId IdType="pubmed">25704818</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine RH et al. Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis. Genes Dev 25, 831&#x2013;844 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078708</ArticleId><ArticleId IdType="pubmed">21498572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa Y, Hosokawa I, Ozaki K, Nakae H &amp; Matsuo T Cytokines differentially regulate ICAM-1 and VCAM-1 expression on human gingival fibroblasts. Clin. Exp. Immunol 144, 494&#x2013;502 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941975</ArticleId><ArticleId IdType="pubmed">16734619</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J et al. Regulation of Endothelial Cell Adhesion Molecule Expression by Mast Cells, Macrophages, and Neutrophils. PLoS One 6, e14525 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021513</ArticleId><ArticleId IdType="pubmed">21264293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruunsgaard H, Pedersen M &amp; Pedersen BK Aging and proinflammatory cytokines. Curr Opin Hematol 131, (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11303144</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BB et al. Consequences Of Natural Perturbations In The Human Plasma Proteome. bioRxiv (2017).</Citation></Reference><Reference><Citation>Shultz LD, Ishikawa F &amp; Greiner DL Humanized mice in translational biomedical research. Nat Rev Immunol 7, 118&#x2013;130 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17259968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridder D a et al. TAK1 in brain endothelial cells mediates fever and lethargy. J. Exp. Med 208, 2615&#x2013;23 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244031</ArticleId><ArticleId IdType="pubmed">22143887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokovay E et al. VCAM1 is essential to maintain the structure of the SVZ niche and acts as an environmental sensor to regulate SVZ lineage progression. Cell Stem Cell 11, 220&#x2013;30 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22862947</ArticleId></ArticleIdList></Reference><Reference><Citation>Elices MJ et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site. Cell 60, 577&#x2013;584 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">1689216</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DH et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N. Engl. J. Med 354, 899&#x2013;910 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16510744</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin JE et al. Airway recruitment of leukocytes in mice is dependent on alpha4-integrins and vascular cell adhesion molecule-1. Am. J. Physiol. Cell. Mol. Physiol 272, L219&#x2013;L229 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9124372</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, Zhao Z &amp; Zlokovic BV Alzheimer&#x2019;s disease: A matter of blood&#x2013;brain barrier dysfunction? J. Exp. Med 214, 3151 LP&#x2013;3169 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679168</ArticleId><ArticleId IdType="pubmed">29061693</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeier B, Daneman R &amp; Ransohoff RM Development, maintenance and disruption of the blood-brain barrier. Nat. Med 19, 1584&#x2013;96 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4080800</ArticleId><ArticleId IdType="pubmed">24309662</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RJR et al. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc. Res 67, 39&#x2013;49 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15949468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchalla AE et al. Elevated Soluble Vascular Cell Adhesion Molecule-1 Is Associated With Cerebrovascular Resistance and Cognitive Function. Journals Gerontol. Ser. A 72, 560&#x2013;566 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5861880</ArticleId><ArticleId IdType="pubmed">27317684</ArticleId></ArticleIdList></Reference><Reference><Citation>Merat S, Fruebis J, Sutphin M, Silvestre M &amp; Reaven PD Effect of aging on aortic expression of the vascular cell adhesion molecule-1 and atherosclerosis in murine models of atherosclerosis. journals Gerontol 55, B85&#x2013;B94 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10737683</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter V et al. Circulating vascular cell adhesion molecules VCAM-1, ICAM-1, and E-selectin in dependence on aging. Gerontology 49, 293&#x2013;300 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12920349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballantyne CM &amp; Entman ML Soluble Adhesion Molecules and the Search for Biomarkers for Atherosclerosis. Circulation 106, 766&#x2013;767 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12176941</ArticleId></ArticleIdList></Reference><Reference><Citation>Okugawa Y et al. Soluble VCAM-1 and its relation to disease progression in colorectal carcinoma. Exp. Ther. Med 1, 463&#x2013;469 (2010).</Citation></Reference><Reference><Citation>Schlesinger M &amp; Bendas G Vascular cell adhesion molecule-1 (VCAM-1)&#x2014;An increasing insight into its role in tumorigenicity and metastasis. International Journal of Cancer 1, 2504&#x2013;2514 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">24771582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Mielke MM &amp; Hampel H Blood-based Biomarkers of Microvascular Pathology in Alzheimer&#x2019;s disease. Exp. Gerontol 45, 75 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815204</ArticleId><ArticleId IdType="pubmed">19782124</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda M, Tsukada N, Miyagi K &amp; Yanagisawa N Increased levels of soluble vascular cell adhesion molecule-1 ( VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J. Neuroimmunol 59, 35&#x2013;40 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7541057</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahy M et al. Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun. Ageing 12, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362825</ArticleId><ArticleId IdType="pubmed">25784952</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook-Mills JM, Marchese ME &amp; Abdala-Valencia H Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid. Redox Signal. 15, 1607&#x2013;38 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151426</ArticleId><ArticleId IdType="pubmed">21050132</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestweber D How leukocytes cross the vascular endothelium. Nat. Rev. Immunol 15, 692&#x2013;704 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26471775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritzel RM et al. Age-Associated Resident Memory CD8 T Cells in the Central Nervous System Are Primed To Potentiate Inflammation after Ischemic Brain Injury. J. Immunol 196, 3318 LP&#x2013;3330 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868658</ArticleId><ArticleId IdType="pubmed">26962232</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef H et al. Systemic attenuation of the TGF-&#x3b2; pathway by a single drug simultaneously rejuvenates hippocampal neurogenesis and myogenesis in the same old mammal. Oncotarget 6, 11959&#x2013;11978 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494916</ArticleId><ArticleId IdType="pubmed">26003168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X-L et al. Persistent Expression of VCAM1 in Radial Glial Cells Is Required for the Embryonic Origin of Postnatal Neural Stem Cells. Neuron 95, 309&#x2013;325 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28728023</ArticleId></ArticleIdList></Reference><Reference><Citation>Erd&#x151; F, Denes L &amp; de Lange E Age-associated physiological and pathological changes at the blood-brain barrier: A review. J. Cereb. Blood Flow Metab. 37, 4&#x2013;24 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363756</ArticleId><ArticleId IdType="pubmed">27837191</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A et al. Blood-Brain barrier breakdown in the aging human hippocampus. Neuron 85, 296&#x2013;302 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N et al. Lack of Widespread BBB Disruption in Alzheimer&#x2019;s Disease Models: Focus on Therapeutic Antibodies. Neuron 88, 289&#x2013;297 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26494278</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffen BJ, Breier G, Butcher EC, Schulz M &amp; Engelhardt B ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. Am. J. Pathol 148, 1819&#x2013;1838 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861637</ArticleId><ArticleId IdType="pubmed">8669469</ArticleId></ArticleIdList></Reference><Reference><Citation>Vukovic J, Colditz MJ, Blackmore DG, Ruitenberg MJ &amp; Bartlett PF Microglia modulate hippocampal neural precursor activity in response to exercise and aging. J Neurosci 32, 6435&#x2013;6443 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621117</ArticleId><ArticleId IdType="pubmed">22573666</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>REFERENCES (Methods-only)</Title><Reference><Citation>Trapnell C et al. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat. Biotechnol 31, 46&#x2013;53 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869392</ArticleId><ArticleId IdType="pubmed">23222703</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B, Vajkoczy P &amp; Weller RO The movers and shapers in immune privilege of the CNS. Nat. Immunol 18, 123&#x2013;131 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092374</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery. Nat. Rev. Drug Discov 15, 275&#x2013;292 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26794270</ArticleId></ArticleIdList></Reference><Reference><Citation>Muggeo VMR Estimating regression models with unknown break-points. Stat. Med 22, 3055&#x2013;71 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12973787</ArticleId></ArticleIdList></Reference><Reference><Citation>Muggeo VMR segmented: An R package to Fit Regression Models with Broken-Line Relationships. R News 8, 20&#x2013;25 (2008).</Citation></Reference><Reference><Citation>Yousef H, Czupalla CJ, Lee D, Butcher EC &amp; Wyss-Coray T Papain-based Single Cell Isolation of Primary Murine Brain Endothelial Cells Using Flow Cytometry. Bio-protocol 8, e3091 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482965</ArticleId><ArticleId IdType="pubmed">31032379</ArticleId></ArticleIdList></Reference><Reference><Citation>Xaio H, Banks WA, Niehoff ML &amp; Morley JE Effect of LPS on the permeability of the blood&#x2013;brain barrier to insulin. Brain Res 896, 36&#x2013;42 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11277970</ArticleId></ArticleIdList></Reference><Reference><Citation>Picelli S et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc 9, 171 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24385147</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmanis S et al. A survey of human brain transcriptome diversity at the single cell level. Proc. Natl. Acad. Sci 112, 7285&#x2013;7290 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466750</ArticleId><ArticleId IdType="pubmed">26060301</ArticleId></ArticleIdList></Reference><Reference><Citation>Montesano R et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62, 435&#x2013;445 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2379237</ArticleId></ArticleIdList></Reference><Reference><Citation>Czupalla CJ, Liebner S &amp; Devraj K In Vitro Models of the Blood&#x2013;Brain Barrier BT - Cerebral Angiogenesis: Methods and Protocols. in (ed. Milner R) 415&#x2013;437 (Springer; New York, 2014). doi:10.1007/978-1-4939-0320-7_34</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-0320-7_34</ArticleId><ArticleId IdType="pubmed">24510883</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabria AR, Weidenfeller C, Jones AR, de Vries HE &amp; Shusta EV Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. J. Neurochem 97, 922&#x2013;33 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16573646</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J et al. Glia-dependent TGF-&#x3b2; signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest 117, 3306&#x2013;3315 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040317</ArticleId><ArticleId IdType="pubmed">17965773</ArticleId></ArticleIdList></Reference><Reference><Citation>Czupalla CJ, Yousef H, Wyss-Coray T &amp; Butcher EC Collagenase-based Single Cell Isolation of Primary Murine Brain Endothelial Cells Using Flow Cytometry. Bio-protocol 8, e3092 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6326170</ArticleId><ArticleId IdType="pubmed">30637296</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J et al. Long-term cognitive impairments and pathological alterations in a mouse model of repetitive mild traumatic brain injury. Front. Neurol 5, 12 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912443</ArticleId><ArticleId IdType="pubmed">24550885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann A et al. High and Low Molecular Weight Fluorescein Isothiocyanate (FITC)-Dextrans to Assess Blood-Brain Barrier Disruption: Technical Considerations. Transl. Stroke Res 2, 106&#x2013;111 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037479</ArticleId><ArticleId IdType="pubmed">21423333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kijanka G, Prokopowicz M, Schellekens H &amp; Brinks V Influence of aggregation and route of injection on the biodistribution of mouse serum albumin. PLoS One 9, (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898957</ArticleId><ArticleId IdType="pubmed">24465523</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meer P &amp; Raber J Mouse behavioural analysis in systems biology. Biochem. J. 389, 593 LP&#x2013;610 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180709</ArticleId><ArticleId IdType="pubmed">16035954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Bauer B, Abner EL, Ashkenazy-Frolinger T &amp; Hartz AMS A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice. PLoS One 11, e0147733 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4726499</ArticleId><ArticleId IdType="pubmed">26808326</ArticleId></ArticleIdList></Reference><Reference><Citation>Leger M et al. Object recognition test in mice. Nat. Protoc 8, 2531 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24263092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31110321</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Toxic expanded GGGGCC repeat transcription is mediated by the PAF1 complex in C9orf72-associated FTD.</ArticleTitle><Pagination><StartPage>863</StartPage><EndPage>874</EndPage><MedlinePgn>863-874</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0396-1</ELocationID><Abstract><AbstractText>An expanded GGGGCC hexanucleotide of more than 30 repeats (termed (G4C2)<sub>30+</sub>) within C9orf72 is the most prominent mutation in familial frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS) (termed C9<sup>+</sup>). Through an unbiased large-scale screen of (G4C2)<sub>49</sub>-expressing Drosophila we identify the CDC73/PAF1 complex (PAF1C), a transcriptional regulator of RNA polymerase II, as a suppressor of G4C2-associated toxicity when knocked-down. Depletion of PAF1C reduces RNA and GR dipeptide production from (G4C2)<sub>30+</sub> transgenes. Notably, in Drosophila, the PAF1C components Paf1 and Leo1 appear to be selective for the transcription of long, toxic repeat expansions, but not shorter, nontoxic expansions. In yeast, PAF1C components regulate the expression of both sense and antisense repeats. PAF1C is upregulated following (G4C2)<sub>30+</sub> expression in flies and mice. In humans, PAF1 is also upregulated in C9<sup>+</sup>-derived cells, and its heterodimer partner, LEO1, binds C9<sup>+</sup> repeat chromatin. In C9<sup>+</sup> FTD, PAF1 and LEO1 are upregulated and their expression positively correlates with the expression of repeat-containing C9orf72 transcripts. These data indicate that PAF1C activity is an important factor for transcription of the long, toxic repeat in C9<sup>+</sup> FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Lindsey D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudencio</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4894-4858</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-4557-8343</Identifier><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Ramirez</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0001-9619-1689</Identifier><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Ananth R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Matthews</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yongqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berson</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0001-8603-1526</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonini</LastName><ForeName>Nancy M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0003-0226-5291</Identifier><AffiliationInfo><Affiliation>Neuroscience Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. nbonini@sas.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA. nbonini@sas.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS009727</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078283</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097275</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007517</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM084947</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506154">LEO1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501972">PAF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2023 Mar;26(3):528. doi: 10.1038/s41593-023-01274-y.</RefSource><PMID Version="1">36810653</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. The authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31110321</ArticleId><ArticleId IdType="mid">NIHMS1525541</ArticleId><ArticleId IdType="pmc">PMC6535128</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0396-1</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0396-1</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES (main text)</Title><Reference><Citation>DeJesus-Hernandez M et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M et al. Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol. Aging 35, 2421.e13&#x2013;2421.e17 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105839</ArticleId><ArticleId IdType="pubmed">24866401</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol. (Berl.) 127, 397&#x2013;406 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944829</ArticleId><ArticleId IdType="pubmed">24385136</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R &amp; Isaacs AM C9orf72 -mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol 14, 544 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuva-Aydemir Y, Almeida S &amp; Gao F-B Insights into C9ORF72-Related ALS/FTD from Drosophila and iPSC Models. Trends Neurosci (2018). doi:10.1016/j.tins.2018.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2018.04.002</ArticleId><ArticleId IdType="pmc">PMC6015541</ArticleId><ArticleId IdType="pubmed">29729808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatovec S, Kovanda A &amp; Rogelj B Unconventional features of C9ORF72 expanded repeat in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neurobiol. Aging 35, 2421.e1&#x2013;2421.e12 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24836899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Nana AL, Yokoyama JS &amp; Seeley WW C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol. (Berl.) 137, 1&#x2013;26 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546170</ArticleId><ArticleId IdType="pubmed">30368547</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes D &amp; Lipps HJ G-quadruplexes and their regulatory roles in biology. Nucleic Acids Res 43, 8627&#x2013;8637 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605312</ArticleId><ArticleId IdType="pubmed">26350216</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R, Fratta P, Neidle S, Parkinson GN &amp; Isaacs AM G-quadruplexes: Emerging roles in neurodegenerative diseases and the non-coding transcriptome. FEBS Lett 589, 1653&#x2013;1668 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25979174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall AC, Ostrowski LA, Pietrobon V &amp; Mekhail K Repetitive DNA loci and their modulation by the non-canonical nucleic acid structures R-loops and G-quadruplexes. Nucleus 8, 162&#x2013;181 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5403138</ArticleId><ArticleId IdType="pubmed">28406751</ArticleId></ArticleIdList></Reference><Reference><Citation>Freudenreich CH R-loops: targets for nuclease cleavage and repeat instability. Curr. Genet 1&#x2013;6 (2018). doi:10.1007/s00294-018-0806-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00294-018-0806-z</ArticleId><ArticleId IdType="pmc">PMC6039234</ArticleId><ArticleId IdType="pubmed">29327083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer M &amp; Paeschke K G-quadruplex unwinding helicases and their function in vivo. Biochem. Soc. Trans 45, 1173&#x2013;1182 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28939694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rond&#xf3;n AG, Garc&#xed;a&#x2010;Rubio M, Gonz&#xe1;lez&#x2010;Barrera S &amp; Aguilera A Molecular evidence for a positive role of Spt4 in transcription elongation. EMBO J 22, 612&#x2013;620 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140732</ArticleId><ArticleId IdType="pubmed">12554661</ArticleId></ArticleIdList></Reference><Reference><Citation>Rond&#xf3;n AG, Gallardo M, Garc&#xed;a-Rubio M &amp; Aguilera A Molecular evidence indicating that the yeast PAF complex is required for transcription elongation. EMBO Rep 5, 47&#x2013;53 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1298956</ArticleId><ArticleId IdType="pubmed">14710186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Li T &amp; Price DH RNA Polymerase II Elongation Control. Annu. Rev. Biochem 81, 119&#x2013;143 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273853</ArticleId><ArticleId IdType="pubmed">22404626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y et al. DSIF, the Paf1 complex, and Tat-SF1 have nonredundant, cooperative roles in RNA polymerase II elongation. Genes Dev 23, 2765&#x2013;2777 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788331</ArticleId><ArticleId IdType="pubmed">19952111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartzog GA &amp; Fu J The Spt4-Spt5 complex: a multi-faceted regulator of transcription elongation. Biochim. Biophys. Acta 1829, 105 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545043</ArticleId><ArticleId IdType="pubmed">22982195</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaehning JA The Paf1 complex: Platform or player in RNA polymerase II transcription? Biochim. Biophys. Acta BBA - Gene Regul. Mech 1799, 379&#x2013;388 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862274</ArticleId><ArticleId IdType="pubmed">20060942</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Oss SB, Cucinotta CE &amp; Arndt KM Emerging Insights into the Roles of the Paf1 Complex in Gene Regulation. Trends Biochem. Sci 42, 788&#x2013;798 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658044</ArticleId><ArticleId IdType="pubmed">28870425</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-R et al. Spt4 Is Selectively Required for Transcription of Extended Trinucleotide Repeats. Cell 148, 690&#x2013;701 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22341442</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H-M et al. Effects on Murine Behavior and Lifespan of Selectively Decreasing Expression of Mutant Huntingtin Allele by Supt4h Knockdown. PLoS Genet 11, (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356588</ArticleId><ArticleId IdType="pubmed">25760041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science 353, 708&#x2013;712 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823025</ArticleId><ArticleId IdType="pubmed">27516603</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter SE, Washburn TM, Chang M &amp; Jaehning JA The Yeast Paf1-RNA Polymerase II Complex Is Required for Full Expression of a Subset of Cell Cycle-Regulated Genes. Eukaryot. Cell 1, 830&#x2013;842 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126743</ArticleId><ArticleId IdType="pubmed">12455700</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y et al. PAF Complex Plays Novel Subunit-Specific Roles in Alternative Cleavage and Polyadenylation. PLoS Genet 12, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713055</ArticleId><ArticleId IdType="pubmed">26765774</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl H, Howe FS, Furger A &amp; Mellor J Paf1 Has Distinct Roles in Transcription Elongation and Differential Transcript Fate. Mol. Cell 65, 685&#x2013;698.e8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316414</ArticleId><ArticleId IdType="pubmed">28190769</ArticleId></ArticleIdList></Reference><Reference><Citation>Moniaux N et al. The Human RNA Polymerase II-Associated Factor 1 (hPaf1): A New Regulator of Cell-Cycle Progression. PLoS ONE 4, (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740866</ArticleId><ArticleId IdType="pubmed">19771162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen CT, Langenbacher A, Hsieh M &amp; Chen J-N The Paf1 complex component Leo1 is essential for cardiac and neural crest development in zebrafish. Dev. Biol 341, 167&#x2013;175 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854236</ArticleId><ArticleId IdType="pubmed">20178782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P et al. Parafibromin, a Component of the Human PAF Complex, Regulates Growth Factors and Is Required for Embryonic Development and Survival in Adult Mice. Mol. Cell. Biol 28, 2930&#x2013;2940 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2293088</ArticleId><ArticleId IdType="pubmed">18212049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrampour S &amp; Thor S Ctr9, a Key Component of the Paf1 Complex, Affects Proliferation and Terminal Differentiation in the Developing Drosophila Nervous System. G3 GenesGenomesGenetics 6, 3229&#x2013;3239 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5068944</ArticleId><ArticleId IdType="pubmed">27520958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi D, Inaba M, Scoggin S &amp; Buszczak M Drosophila CG2469 Encodes a Homolog of Human CTR9 and Is Essential for Development. G3 GenesGenomesGenetics 6, 3849&#x2013;3857 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5144956</ArticleId><ArticleId IdType="pubmed">27678520</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan PPC, French L &amp; Pavlidis P Neuron-Enriched Gene Expression Patterns are Regionally Anti-Correlated with Oligodendrocyte-Enriched Patterns in the Adult Mouse and Human Brain. Front. Neurosci 7, (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578349</ArticleId><ArticleId IdType="pubmed">23440889</ArticleId></ArticleIdList></Reference><Reference><Citation>Soutourina J Transcription regulation by the Mediator complex. Nat. Rev. Mol. Cell Biol (2017). doi:10.1038/nrm.2017.115</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.115</ArticleId><ArticleId IdType="pubmed">29209056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192&#x2013;1194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung C-Y et al. Aberrant activation of non-coding RNA targets of transcriptional elongation complexes contributes to TDP-43 toxicity. Nat. Commun 9, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199344</ArticleId><ArticleId IdType="pubmed">30353006</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu X et al. Structural insights into Paf1 complex assembly and histone binding. Nucleic Acids Res 41, 10619&#x2013;10629 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905892</ArticleId><ArticleId IdType="pubmed">24038468</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y et al. Architecture of the RNA polymerase II-Paf1C-TFIIS transcription elongation complex. Nat. Commun 8, 15741 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467213</ArticleId><ArticleId IdType="pubmed">28585565</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Guermah M &amp; Roeder RG The Human PAF1 Complex Acts in Chromatin Transcription Elongation Both Independently and Cooperatively with SII/TFIIS. Cell 140, 491&#x2013;503 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853908</ArticleId><ArticleId IdType="pubmed">20178742</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M et al. RNA polymerase II&#x2013;associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science 350, 1383&#x2013;1386 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8729149</ArticleId><ArticleId IdType="pubmed">26659056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer A et al. Uniform transitions of the general RNA polymerase II transcription complex. Nat. Struct. Mol. Biol 17, 1272 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20818391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayekar MK, Gardner RG &amp; Arndt KM The Recruitment of the Saccharomyces cerevisiae Paf1 Complex to Active Genes Requires a Domain of Rtf1 That Directly Interacts with the Spt4-Spt5 Complex. Mol. Cell. Biol 33, 3259&#x2013;3273 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753903</ArticleId><ArticleId IdType="pubmed">23775116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q-F et al. Characterization of the Human Transcription Elongation Factor Rtf1: Evidence for Nonoverlapping Functions of Rtf1 and the Paf1 Complex. Mol. Cell. Biol 35, 3459&#x2013;3470 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573716</ArticleId><ArticleId IdType="pubmed">26217014</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H, Hu C, Gaur NA &amp; Hinnebusch AG Pol II CTD kinases Bur1 and Kin28 promote Spt5 CTR-independent recruitment of Paf1 complex. EMBO J 31, 3494&#x2013;3505 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419927</ArticleId><ArticleId IdType="pubmed">22796944</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermody JL &amp; Buratowski S Leo1 Subunit of the Yeast Paf1 Complex Binds RNA and Contributes to Complex Recruitment. J. Biol. Chem 285, 33671&#x2013;33679 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962465</ArticleId><ArticleId IdType="pubmed">20732871</ArticleId></ArticleIdList></Reference><Reference><Citation>Amrich CG et al. Cdc73 Subunit of Paf1 Complex Contains C-terminal Ras-like Domain That Promotes Association of Paf1 Complex with Chromatin. J. Biol. Chem 287, 10863&#x2013;10875 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322841</ArticleId><ArticleId IdType="pubmed">22318720</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y et al. Paf1 and Ctr9 subcomplex formation is essential for Paf1 complex assembly and functional regulation. Nat. Commun 9, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6143631</ArticleId><ArticleId IdType="pubmed">30228257</ArticleId></ArticleIdList></Reference><Reference><Citation>Omer T et al. Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. Amyotroph. Lateral Scler. Front. Degener 18, 611&#x2013;623 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28562080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;necker S et al. Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients &#x2013; An Atlas-Based Volumetric MRI Study. Front. Aging Neurosci 10, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863593</ArticleId><ArticleId IdType="pubmed">29599716</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach JM et al. PAF1 complex component Leo1 helps recruit Drosophila Myc to promoters. Proc. Natl. Acad. Sci 114, E9224&#x2013;E9232 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5676885</ArticleId><ArticleId IdType="pubmed">29078288</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan TF et al. Disease Model Discovery from 3,328 Gene Knockouts by The International Mouse Phenotyping Consortium. Nat. Genet 49, 1231&#x2013;1238 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546242</ArticleId><ArticleId IdType="pubmed">28650483</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>REFERENCES (methods)</Title><Reference><Citation>Chew J et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol. Neurodegener 14, 9 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L &amp; Bonini NM Protein interacting with C kinase (PICK1) is a suppressor of spinocerebellar ataxia 3-associated neurodegeneration in Drosophila. Hum. Mol. Genet 21, 76 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235011</ArticleId><ArticleId IdType="pubmed">21949352</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguete AS et al. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. eLife 4,</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordes DA et al. Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathol. Commun 6, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6031111</ArticleId><ArticleId IdType="pubmed">29973287</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z et al. A fly model for the CCUG-repeat expansion of myotonic dystrophy type 2 reveals a novel interaction with MBNL1. Hum. Mol. Genet 24, 954&#x2013;962 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6281364</ArticleId><ArticleId IdType="pubmed">25305073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni J-Q et al. A genome-scale shRNA resource for transgenic RNAi in Drosophila. Nat. Methods 8, 405 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489273</ArticleId><ArticleId IdType="pubmed">21460824</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins LA et al. The Transgenic RNAi Project at Harvard Medical School: Resources and Validation. Genetics 201, 843&#x2013;852 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649654</ArticleId><ArticleId IdType="pubmed">26320097</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietzl G et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448, 151 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17625558</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H-J et al. Therapeutic modulation of eIF2&#x3b1;-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet 46, 152&#x2013;160 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson A et al. TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. Curr. Biol 27, 3579&#x2013;3590.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5720388</ArticleId><ArticleId IdType="pubmed">29153328</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Lipson D, Yogev S &amp; Yakhini Z Discovering Motifs in Ranked Lists of DNA Sequences. PLoS Comput. Biol 3, (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829477</ArticleId><ArticleId IdType="pubmed">17381235</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Navon R, Steinfeld I, Lipson D &amp; Yakhini Z GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644678</ArticleId><ArticleId IdType="pubmed">19192299</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci 102, 15545&#x2013;15550 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Supek F, Bo&#x161;njak M, &#x160;kunca N &amp; &#x160;muc T REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms. PLOS ONE 6, e21800 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138752</ArticleId><ArticleId IdType="pubmed">21789182</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HYE, Trojanowski JQ, Lee VM-Y &amp; Bonini NM Chaperone Suppression of &#x3b1;-Synuclein Toxicity in a Drosophila Model for Parkinson&#x2019;s Disease. Science 295, 865&#x2013;868 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ et al. CRISPR&#x2013;Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat. Genet 1 (2018). doi:10.1038/s41588-018-0070-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0070-7</ArticleId><ArticleId IdType="pmc">PMC5893388</ArticleId><ArticleId IdType="pubmed">29507424</ArticleId></ArticleIdList></Reference><Reference><Citation>Adelman K et al. Drosophila Paf1 Modulates Chromatin Structure at Actively Transcribed Genes. Mol. Cell. Biol 26, 250&#x2013;260 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317635</ArticleId><ArticleId IdType="pubmed">16354696</ArticleId></ArticleIdList></Reference><Reference><Citation>Herr P et al. A genome-wide IR-induced RAD51 foci RNAi screen identifies CDC73 involved in chromatin remodeling for DNA repair. Cell Discov 1, 15034 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860774</ArticleId><ArticleId IdType="pubmed">27462432</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat. Neurosci 18, 1175&#x2013;1182 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Niblock M et al. Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. Acta Neuropathol. Commun 4, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766718</ArticleId><ArticleId IdType="pubmed">26916632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A et al. Modifiers of C9orf72 DPR toxicity implicate nucleocytoplasmic transport impairments in c9FTD/ALS. Nat. Neurosci 18, 1226&#x2013;1229 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai N &amp; Gitler AD Yeast screen for modifiers of C9orf72 poly(Glycine-Arginine) dipeptide repeat toxicity. FEMS Yeast Res doi:10.1093/femsyr/foy024</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsyr/foy024</ArticleId><ArticleId IdType="pmc">PMC5946852</ArticleId><ArticleId IdType="pubmed">29528392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TI, Johnstone SE &amp; Young RA Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc 1, 729&#x2013;748 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004291</ArticleId><ArticleId IdType="pubmed">17406303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N, Sun H-Y, Youn M-Y &amp; Yoo J-Y IL-1&#x3b2;&#x2013;specific recruitment of GCN5 histone acetyltransferase induces the release of PAF1 from chromatin for the de-repression of inflammatory response genes. Nucleic Acids Res 41, 4495&#x2013;4506 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632138</ArticleId><ArticleId IdType="pubmed">23502002</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M et al. Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Hum. Mol. Genet 26, 3421&#x2013;3431 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886204</ArticleId><ArticleId IdType="pubmed">28637276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31399126</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain.</ArticleTitle><Pagination><StartPage>71</StartPage><MedlinePgn>71</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">71</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13195-019-0524-x</ELocationID><Abstract><AbstractText Label="BACKGROUND">Alzheimer's disease (AD) is the most common form of dementia. This neurodegenerative disorder is associated with neuronal death and gliosis heavily impacting the cerebral cortex. AD has a substantial but heterogeneous genetic component, presenting both Mendelian and complex genetic architectures. Using bulk RNA-seq from the parietal lobes and deconvolution methods, we previously reported that brains exhibiting different AD genetic architecture exhibit different cellular proportions. Here, we sought to directly investigate AD brain changes in cell proportion and gene expression using single-cell resolution.</AbstractText><AbstractText Label="METHODS">We generated unsorted single-nuclei RNA sequencing data from brain tissue. We leveraged the tissue donated from a carrier of a Mendelian genetic mutation, PSEN1 p.A79V, and two family members who suffer from sporadic AD, but do not carry any autosomal mutations. We evaluated alternative alignment approaches to maximize the titer of reads, genes, and cells with high quality. In addition, we employed distinct clustering strategies to determine the best approach to identify cell clusters that reveal neuronal and glial cell types and avoid artifacts such as sample and batch effects. We propose an approach to cluster cells that reduces biases and enable further analyses.</AbstractText><AbstractText Label="RESULTS">We identified distinct types of neurons, both excitatory and inhibitory, and glial cells, including astrocytes, oligodendrocytes, and microglia, among others. In particular, we identified a reduced proportion of excitatory neurons in the Mendelian mutation carrier, but a similar distribution of inhibitory neurons. Furthermore, we investigated whether single-nuclei RNA-seq from the human brains recapitulate the expression profile of disease-associated microglia (DAM) discovered in mouse models. We also determined that when analyzing human single-nuclei data, it is critical to control for biases introduced by donor-specific expression profiles.</AbstractText><AbstractText Label="CONCLUSION">We propose a collection of best practices to generate a highly detailed molecular cell atlas of highly informative frozen tissue stored in brain banks. Importantly, we have developed a new web application to make this unique single-nuclei molecular atlas publicly available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del-Aguila</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zeran</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dube</LastName><ForeName>Umber</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihindukulasuriya</LastName><ForeName>Kathie A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budde</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Maria Victoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibanez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fengxian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmann</LastName><ForeName>Kristy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dougherty</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA. cruchagac@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA. cruchagac@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. cruchagac@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA. cruchagac@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA. cruchagac@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2635-6975</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 425 S. Euclid Ave, BJC Institute of Health, Office: 9607, St. Louis, MO, 63110, USA. harario@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA. harario@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. harario@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Department of Psychiatry, Washington University, St. Louis, MO, USA. harario@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA. harario@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG057777</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG057777</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001271" MajorTopicYN="N">Atlases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">PSEN1</Keyword><Keyword MajorTopicYN="N">Single-nuclei RNA-seq</Keyword><Keyword MajorTopicYN="N">Web-based brain molecular atlas</Keyword></KeywordList><CoiStatement>CC receives research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of ADx Healthcare, and Vivid Genomics. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Genentech, and Proclara. D.M.H. consults for AbbVie.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31399126</ArticleId><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="doi">10.1186/s13195-019-0524-x</ArticleId><ArticleId IdType="pii">10.1186/s13195-019-0524-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>LaFerla FM, Oddo S. Alzheimer&#x2019;s disease: A&#x3b2;, tau and synaptic dysfunction. Trends Mol Med. 2005;11(4):170&#x2013;176. doi: 10.1016/j.molmed.2005.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2005.02.009</ArticleId><ArticleId IdType="pubmed">15823755</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol. 2010;26:235&#x2013;260. doi: 10.1146/annurev-cellbio-100109-104117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100109-104117</ArticleId><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741&#x2013;766. doi: 10.1152/physrev.2001.81.2.741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2001.81.2.741</ArticleId><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Del-Aguila JL, Dube U, Budde J, Martinez R, Black K, et al. Genetic variants associated with Alzheimer&#x2019;s disease confer different cerebral cortex cell-type population structure. Genome Med. 2018;10(1):43. doi: 10.1186/s13073-018-0551-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-018-0551-4</ArticleId><ArticleId IdType="pmc">PMC5992755</ArticleId><ArticleId IdType="pubmed">29880032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, Ai R, Kaeser GE, Salathia NS, Yung YC, Liu R, et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016;352(6293):1586&#x2013;1590. doi: 10.1126/science.aaf1204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1204</ArticleId><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>10XGenomics. Genomics X: isolation of nuclei for single cell RNA sequencing.</Citation></Reference><Reference><Citation>Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14(10):979&#x2013;982. doi: 10.1038/nmeth.4402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4402</ArticleId><ArticleId IdType="pmc">PMC5764547</ArticleId><ArticleId IdType="pubmed">28825705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049. doi: 10.1038/ncomms14049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14049</ArticleId><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Grindberg RV, Yee-Greenbaum JL, McConnell MJ, Novotny M, O&#x2019;Shaughnessy AL, Lambert GM, et al. RNA-sequencing from single nuclei. Proc Natl Acad Sci U S A. 2013;110(49):19802&#x2013;19807. doi: 10.1073/pnas.1319700110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1319700110</ArticleId><ArticleId IdType="pmc">PMC3856806</ArticleId><ArticleId IdType="pubmed">24248345</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics Creating a Reference Package with cellranger mkref. https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/advanced/references#header. Accessed 10 July 2019</Citation></Reference><Reference><Citation>Saunders Arpiar, Macosko Evan Z., Wysoker Alec, Goldman Melissa, Krienen Fenna M., de Rivera Heather, Bien Elizabeth, Baum Matthew, Bortolin Laura, Wang Shuyu, Goeva Aleksandrina, Nemesh James, Kamitaki Nolan, Brumbaugh Sara, Kulp David, McCarroll Steven A. Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. Cell. 2018;174(4):1015-1030.e16. doi: 10.1016/j.cell.2018.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.07.028</ArticleId><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Benaglia T, Chauveau D, Hunter DR, Young DS. mixtools: An R package for analyzing mixture models. J Stat Softw. 2010;32(6). 10.18637/jss.v0.32.i06. https://www.jstatsoft.org/article/view/v032i06.</Citation></Reference><Reference><Citation>Xu C, Su Z. Identification of cell types from single-cell transcriptomes using a novel clustering method. Bioinformatics. 2015;31(12):1974&#x2013;1980. doi: 10.1093/bioinformatics/btv088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv088</ArticleId><ArticleId IdType="pmc">PMC6280782</ArticleId><ArticleId IdType="pubmed">25805722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Wu X, Jiang L, Zhang Y. Single-cell RNA-Seq reveals hypothalamic cell diversity. Cell Rep. 2017;18(13):3227&#x2013;3241. doi: 10.1016/j.celrep.2017.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.03.004</ArticleId><ArticleId IdType="pmc">PMC5782816</ArticleId><ArticleId IdType="pubmed">28355573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu P, Fabyanic E, Kwon DY, Tang S, Zhou Z, Wu H. Dissecting cell-type composition and activity-dependent transcriptional state in mammalian brains by massively parallel single-nucleus RNA-Seq. Mol Cell. 2017;68(5):1006&#x2013;1015. doi: 10.1016/j.molcel.2017.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.11.017</ArticleId><ArticleId IdType="pmc">PMC5743496</ArticleId><ArticleId IdType="pubmed">29220646</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasic B, Yao Z, Graybuck LT, Smith KA, Nguyen TN, Bertagnolli D, et al. Shared and distinct transcriptomic cell types across neocortical areas. Nature. 2018;563(7729):72&#x2013;78. doi: 10.1038/s41586-018-0654-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0654-5</ArticleId><ArticleId IdType="pmc">PMC6456269</ArticleId><ArticleId IdType="pubmed">30382198</ArticleId></ArticleIdList></Reference><Reference><Citation>ABCAM. Neural Lineage MArkers at a Glance. https://www.abcam.com/neuroscience/neural-markers-guide. Accessed 10 July 2019.</Citation></Reference><Reference><Citation>McKenzie AT, Wang M, Hauberg ME, Fullard JF, Kozlenkov A, Keenan A, et al. Brain cell type specific gene expression and co-expression network architectures. Sci Rep. 2018;8(1):8868. doi: 10.1038/s41598-018-27293-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-27293-5</ArticleId><ArticleId IdType="pmc">PMC5995803</ArticleId><ArticleId IdType="pubmed">29892006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice Heather C., de Malmazet Daniel, Schreurs An, Frere Samuel, Van Molle Inge, Volkov Alexander N., Creemers Eline, Vertkin Irena, Nys Julie, Ranaivoson Fanomezana M., Comoletti Davide, Savas Jeffrey N., Remaut Han, Balschun Detlef, Wierda Keimpe D., Slutsky Inna, Farrow Karl, De Strooper Bart, de Wit Joris. Secreted amyloid-&#x3b2; precursor protein functions as a GABABR1a ligand to modulate synaptic transmission. Science. 2019;363(6423):eaao4827. doi: 10.1126/science.aao4827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao4827</ArticleId><ArticleId IdType="pmc">PMC6366617</ArticleId><ArticleId IdType="pubmed">30630900</ArticleId></ArticleIdList></Reference><Reference><Citation>Li WV, Li JJ. An accurate and robust imputation method scImpute for single-cell RNA-seq data. Nat Commun. 2018;9(1):997. doi: 10.1038/s41467-018-03405-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03405-7</ArticleId><ArticleId IdType="pmc">PMC5843666</ArticleId><ArticleId IdType="pubmed">29520097</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon CE. The mathematical theory of communication. 1963. MD Comput. 1997;14(4):306&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9230594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Z, Ji H. TSCAN: pseudo-time reconstruction and evaluation in single-cell RNA-seq analysis. Nucleic Acids Res. 2016;44(13):e117. doi: 10.1093/nar/gkw430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw430</ArticleId><ArticleId IdType="pmc">PMC4994863</ArticleId><ArticleId IdType="pubmed">27179027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science. 2018;359(6376):693&#x2013;697. doi: 10.1126/science.aad6469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad6469</ArticleId><ArticleId IdType="pmc">PMC5898828</ArticleId><ArticleId IdType="pubmed">29439242</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe AE, Shin J, Collado-Torres L, Leek JT, Tao R, Li C, et al. Developmental regulation of human cortex transcription and its clinical relevance at single base resolution. Nat Neurosci. 2015;18(1):154&#x2013;161. doi: 10.1038/nn.3898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3898</ArticleId><ArticleId IdType="pmc">PMC4281298</ArticleId><ArticleId IdType="pubmed">25501035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley KW, Nakao-Inoue H, Molofsky AV, Oldham MC. Variation among intact tissue samples reveals the core transcriptional features of human CNS cell classes. Nat Neurosci. 2018;21(9):1171&#x2013;1184. doi: 10.1038/s41593-018-0216-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0216-z</ArticleId><ArticleId IdType="pmc">PMC6192711</ArticleId><ArticleId IdType="pubmed">30154505</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC, Konopka G, Iwamoto K, Langfelder P, Kato T, Horvath S, et al. Functional organization of the transcriptome in human brain. Nat Neurosci. 2008;11(11):1271&#x2013;1282. doi: 10.1038/nn.2207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2207</ArticleId><ArticleId IdType="pmc">PMC2756411</ArticleId><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference><Reference><Citation>Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474(7351):380&#x2013;384. doi: 10.1038/nature10110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10110</ArticleId><ArticleId IdType="pmc">PMC3607626</ArticleId><ArticleId IdType="pubmed">21614001</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Daifeng, Liu Shuang, Warrell Jonathan, Won Hyejung, Shi Xu, Navarro Fabio C. P., Clarke Declan, Gu Mengting, Emani Prashant, Yang Yucheng T., Xu Min, Gandal Michael J., Lou Shaoke, Zhang Jing, Park Jonathan J., Yan Chengfei, Rhie Suhn Kyong, Manakongtreecheep Kasidet, Zhou Holly, Nathan Aparna, Peters Mette, Mattei Eugenio, Fitzgerald Dominic, Brunetti Tonya, Moore Jill, Jiang Yan, Girdhar Kiran, Hoffman Gabriel E., Kalayci Selim, G&#xfc;m&#xfc;&#x15f; Zeynep H., Crawford Gregory E., Roussos Panos, Akbarian Schahram, Jaffe Andrew E., White Kevin P., Weng Zhiping, Sestan Nenad, Geschwind Daniel H., Knowles James A., Gerstein Mark B. Comprehensive functional genomic resource and integrative model for the human brain. Science. 2018;362(6420):eaat8464. doi: 10.1126/science.aat8464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat8464</ArticleId><ArticleId IdType="pmc">PMC6413328</ArticleId><ArticleId IdType="pubmed">30545857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruner E, Jacobs HI. Alzheimer&#x2019;s disease: the downside of a highly evolved parietal lobe? J Alzheimers Dis. 2013;35(2):227&#x2013;240. doi: 10.3233/JAD-122299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-122299</ArticleId><ArticleId IdType="pubmed">23435412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza R, Ciaramelli E, Olson IR, Moscovitch M. The parietal cortex and episodic memory: an attentional account. Nat Rev Neurosci. 2008;9(8):613&#x2013;625. doi: 10.1038/nrn2459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2459</ArticleId><ArticleId IdType="pmc">PMC2692883</ArticleId><ArticleId IdType="pubmed">18641668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HI, Van Boxtel MP, Jolles J, Verhey FR, Uylings HB. Parietal cortex matters in Alzheimer&#x2019;s disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev. 2012;36(1):297&#x2013;309. doi: 10.1016/j.neubiorev.2011.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2011.06.009</ArticleId><ArticleId IdType="pubmed">21741401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindeboom J, Weinstein H. Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer&#x2019;s disease, and vascular cognitive impairment. Eur J Pharmacol. 2004;490(1&#x2013;3):83&#x2013;86. doi: 10.1016/j.ejphar.2004.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2004.02.046</ArticleId><ArticleId IdType="pubmed">15094075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken TE, Hodge RD, Miller JA, Yao Z, Nguyen TN, Aevermann B, et al. Single-nucleus and single-cell transcriptomes compared in matched cortical cell types. PLoS One. 2018;13(12):e0209648. doi: 10.1371/journal.pone.0209648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0209648</ArticleId><ArticleId IdType="pmc">PMC6306246</ArticleId><ArticleId IdType="pubmed">30586455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, Chen S, Sos BC, Fan J, Kaeser GE, Yung YC, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat Biotechnol. 2018;36(1):70&#x2013;80. doi: 10.1038/nbt.4038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4038</ArticleId><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Chen L, Chen Z, Zhang W. RNA-seq based transcriptomic analysis of single bacterial cells. Integr Biol (Camb) 2015;7(11):1466&#x2013;1476. doi: 10.1039/C5IB00191A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5IB00191A</ArticleId><ArticleId IdType="pubmed">26331465</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411&#x2013;420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Herculano-Houzel S. The glia/neuron ratio: how it varies uniformly across brain structures and species and what that means for brain physiology and evolution. Glia. 2014;62(9):1377&#x2013;1391. doi: 10.1002/glia.22683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22683</ArticleId><ArticleId IdType="pubmed">24807023</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Rep. 2018;22(3):832&#x2013;847. doi: 10.1016/j.celrep.2017.12.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.066</ArticleId><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, Patrick E, Villani AC, Xu J, White CC, Ryan KJ, et al. A transcriptomic atlas of aged human microglia. Nat Commun. 2018;9(1):539. doi: 10.1038/s41467-018-02926-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31130513</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Human Hippocampal Neurogenesis Persists in Aged Adults and Alzheimer's Disease Patients.</ArticleTitle><Pagination><StartPage>974</StartPage><EndPage>982.e3</EndPage><MedlinePgn>974-982.e3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2019.05.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(19)30207-3</ELocationID><Abstract><AbstractText>Whether hippocampal neurogenesis persists throughout life in the human brain is not fully resolved. Here, we demonstrate that hippocampal neurogenesis is persistent through the tenth decade of life and is detectable in patients with mild cognitive impairments and Alzheimer's disease. In a cohort of 18 participants with a mean age of 90.6 years, Nestin<sup>+</sup>Sox2<sup>+</sup> neural progenitor cells (NPCs) and DCX<sup>+</sup> neuroblasts and immature neurons were detected, but their numbers greatly varied between participants. Nestin<sup>+</sup> cells localize in the anterior hippocampus, and NPCs, neuroblasts, and immature neurons are evenly distributed along the anterior to posterior axis. The number of DCX<sup>+</sup>PCNA<sup>+</sup> cells is reduced in mild cognitive impairments, and higher numbers of neuroblasts are associated with better cognitive status. The number of DCX<sup>+</sup>PCNA<sup>+</sup> cells correlates with functional interactions between presynaptic SNARE proteins. Our results suggest that hippocampal neurogenesis persists in the aged and diseased human brain and that it is possibly associated with cognition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tobin</LastName><ForeName>Matthew K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musaraca</LastName><ForeName>Kianna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Disouky</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shetti</LastName><ForeName>Aashutosh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bheri</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honer</LastName><ForeName>William G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Namhee</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawe</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Diagnostic Radiology, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Diagnostic Radiology, Rush University Medical Center, Chicago, IL, USA; Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarov</LastName><ForeName>Orly</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: olazarov@uic.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UH2 NS100599</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA060553</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062251</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 NS100599</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060238</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG033570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG061628</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000714328">DCX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089622">Doublecortin Domain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089662">Doublecortin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064231">Nestin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000629262">PCNA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018809">Proliferating Cell Nuclear Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527782">SOX2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055748">SOXB1 Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2019 Jul 3;25(1):7-8. doi: 10.1016/j.stem.2019.06.001.</RefSource><PMID Version="1">31271749</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089622" MajorTopicYN="N">Doublecortin Domain Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089662" MajorTopicYN="N">Doublecortin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018809" MajorTopicYN="N">Proliferating Cell Nuclear Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055748" MajorTopicYN="N">SOXB1 Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">adult neurogenesis</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">cognitive dysfunction</Keyword><Keyword MajorTopicYN="N">human neurogenesis</Keyword><Keyword MajorTopicYN="N">neural stem cells</Keyword><Keyword MajorTopicYN="N">neurogenesis in aging</Keyword></KeywordList><CoiStatement><b>Declaration of Interests:</b> The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31130513</ArticleId><ArticleId IdType="mid">NIHMS1529018</ArticleId><ArticleId IdType="pmc">PMC6608595</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2019.05.003</ArticleId><ArticleId IdType="pii">S1934-5909(19)30207-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizawa K, Ageyama N, Terao K, and Hisatsune T (2011). Primate-specific alterations in neural stem/progenitor cells in the aged hippocampus. Neurobiol Aging 32, 140&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">19201065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannerman DM, Grubb M, Deacon RM, Yee BK, Feldon J, and Rawlins JN (2003). Ventral hippocampal lesions affect anxiety but not spatial learning. Behav Brain Res 139, 197&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">12642189</ArticleId></ArticleIdList></Reference><Reference><Citation>Barakauskas VE, Beasley CL, Barr AM, Ypsilanti AR, Li HY, Thornton AE, Wong H, Rosokilja G, Mann JJ, Mancevski B, et al. (2010). A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. Neuropsychopharmacology 35, 1226&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055413</ArticleId><ArticleId IdType="pubmed">20072114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, and Schneider JA (2018). Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann O, Spalding KL, and Frisen J (2015). Adult Neurogenesis in Humans. Cold Spring Harb Perspect Biol 7, a018994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484963</ArticleId><ArticleId IdType="pubmed">26134318</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Fulmore CA, Tartt AN, Simeon LR, Pavlova I, Poposka V, Rosoklija GB, Stankov A, Arango V, Dwork AJ, et al. (2018). Human Hippocampal Neurogenesis Persists throughout Aging. Cell Stem Cell 22, 589&#x2013;599 e585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5957089</ArticleId><ArticleId IdType="pubmed">29625071</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, and Arango V (2009). Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 34, 2376&#x2013;2389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743790</ArticleId><ArticleId IdType="pubmed">19606083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bologna-Molina R, Mosqueda-Taylor A, Molina-Frechero N, Mori-Estevez AD, and Sanchez-Acuna G (2013). Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors. Med Oral Patol Oral Cir Bucal 18, e174&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613329</ArticleId><ArticleId IdType="pubmed">23229269</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Wilson RS, Schneider JA, and Bennett DA (2013). Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci 5, 50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766823</ArticleId><ArticleId IdType="pubmed">24058343</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawe RJ, Bennett DA, Schneider JA, and Arfanakis K (2011). Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. PLoS One 6, e26286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197137</ArticleId><ArticleId IdType="pubmed">22043314</ArticleId></ArticleIdList></Reference><Reference><Citation>Demars MP, Hollands C, Zhao Kda T, and Lazarov O (2013). Soluble amyloid precursor protein-alpha rescues age-linked decline in neural progenitor cell proliferation. Neurobiol Aging 34, 2431&#x2013;2440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706568</ArticleId><ArticleId IdType="pubmed">23683827</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, and Gage FH (1998). Neurogenesis in the adult human hippocampus. Nat Med 4, 1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, Possnert G, Druid H, and Frisen J (2014). Neurogenesis in the striatum of the adult human brain. Cell 156, 1072&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pubmed">24561062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanselow MS, and Dong HW (2010). Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65, 7&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822727</ArticleId><ArticleId IdType="pubmed">20152109</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamza TH, van Houwelingen HC, and Stijnen T (2008). The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 61, 41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083461</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke PG (1990). Hippocampal pathway to the amygdala and stress ulcer development. Brain Res Bull 25, 691&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">2289157</ArticleId></ArticleIdList></Reference><Reference><Citation>Honer WG, Barr AM, Sawada K, Thornton AE, Morris MC, Leurgans SE, Schneider JA, and Bennett DA (2012). Cognitive reserve, presynaptic proteins and dementia in the elderly. Transl Psychiatry 2, e114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365257</ArticleId><ArticleId IdType="pubmed">22832958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gage FH, Aigner L, Song H, Curtis MA, Thuret S, Kuhn HG, Jessberger S, Frankland PW, Cameron HA, et al. (2018). Human Adult Neurogenesis: Evidence and Remaining Questions. Cell Stem Cell 23, 25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035081</ArticleId><ArticleId IdType="pubmed">29681514</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, Horvat V, Volk B, and Kempermann G (2010). Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS One 5, e8809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813284</ArticleId><ArticleId IdType="pubmed">20126454</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuner B, Kozorovitskiy Y, Gross CG, and Gould E (2007). Diminished adult neurogenesis in the marmoset brain precedes old age. Proc Natl Acad Sci U S A 104, 17169&#x2013;17173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040400</ArticleId><ArticleId IdType="pubmed">17940008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis DA (2002). The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 26, 143&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790510</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Gould TD, Yuan P, Manji HK, and Chen G (2003). Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology 28, 1017&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637955</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jimenez EP, Flor-Garcia M, Terreros-Roncal J, Rabano A, Cafini F, Pallas-Bazarra N, Avila J, and Llorens-Martin M (2019). Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer&#x2019;s disease. Nat Med 25, 554&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser E, Moser MB, and Andersen P (1993). Spatial learning impairment parallels the magnitude of dorsal hippocampal lesions, but is hardly present following ventral lesions. J Neurosci 13, 3916&#x2013;3925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576447</ArticleId><ArticleId IdType="pubmed">8366351</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser MB, Moser EI, Forrest E, Andersen P, and Morris RG (1995). Spatial learning with a minislab in the dorsal hippocampus. Proc Natl Acad Sci U S A 92, 9697&#x2013;9701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40869</ArticleId><ArticleId IdType="pubmed">7568200</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruessner JC, Li LM, Serles W, Pruessner M, Collins DL, Kabani N, Lupien S, and Evans AC (2000). Volumetry of hippocampus and amygdala with high-resolution MRI and three-dimensional analysis software: minimizing the discrepancies between laboratories. Cereb Cortex 10, 433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Miguel A, Jones AA, Sawada K, Barr AM, Bayer TA, Falkai P, Leurgans SE, Schneider JA, Bennett DA, and Honer WG (2018). Frontotemporal dysregulation of the SNARE protein interactome is associated with faster cognitive decline in old age. Neurobiol Dis 114, 31&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6483375</ArticleId><ArticleId IdType="pubmed">29496544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Miguel A, Sawada K, Jones AA, Thornton AE, Barr AM, Leurgans SE, Schneider JA, Bennett DA, and Honer WG (2017). Presynaptic proteins complexin-I and complexin-II differentially influence cognitive function in early and late stages of Alzheimer&#x2019;s disease. Acta Neuropathol 133, 395&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6542594</ArticleId><ArticleId IdType="pubmed">27866231</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, and Bennett DA (2007). Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrells SF, Paredes MF, Cebrian-Silla A, Sandoval K, Qi D, Kelley KW, James D, Mayer S, Chang J, Auguste KI, et al. (2018). Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature 555, 377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179355</ArticleId><ArticleId IdType="pubmed">29513649</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, et al. (2013). Dynamics of hippocampal neurogenesis in adult humans. Cell 153, 1219&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson LW, and Cowan WM (1977). An autoradiographic study of the organization of the efferent connections of the hippocampal formation in the rat. J Comp Neurol 172, 49&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">65364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartt AN, Fulmore CA, Liu Y, Rosoklija GB, Dwork AJ, Arango V, Hen R, Mann JJ, and Boldrini M (2018). Considerations for Assessing the Extent of Hippocampal Neurogenesis in the Adult and Aging Human Brain. Cell Stem Cell 23, 782&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6830306</ArticleId><ArticleId IdType="pubmed">30526880</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W (2010). Conducting Meta-Analyses in R with the metafor Package. Journal of Statiscal Software 36, 48.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31131421</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>138</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.</ArticleTitle><Pagination><StartPage>237</StartPage><EndPage>250</EndPage><MedlinePgn>237-250</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-019-02026-8</ELocationID><Abstract><AbstractText>The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLC&#x3b3;2 pathway as drug-target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-1606-8643</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. s.j.vanderlee@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. s.j.vanderlee@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conway</LastName><ForeName>Olivia J</ForeName><Initials>OJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleineidam</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Akker</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pattern Recognition and Bioinformatics, Delft University of Technology, Delft, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Kristel R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stringa</LastName><ForeName>Najada</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Interdepartmental Program in Bioinformatics, University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zettergren</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andlauer</LastName><ForeName>Till F M</ForeName><Initials>TFM</Initials><Identifier Source="ORCID">0000-0002-2917-5889</Identifier><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Competence Network Multiple Sclerosis (KKNMS), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez-Fairen</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Movement Disorders and Memory Unit, Department of Neurology, University Hospital Mutua de Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundacio per la Recerca Biomedica I Social Mutua Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon-Sanchez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE)-T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygaard</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Danish Aging Research Center, Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blauwendraat</LastName><ForeName>Cornelis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, 20892-3707, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Jeanne E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengel-From</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Grau</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keogh</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>Ingmar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friese</LastName><ForeName>Manuel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>German Competence Network Multiple Sclerosis (KKNMS), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Neuroimmunologie und Multiple Sklerose (INIMS), Universit&#xe4;tsklinikum Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lage</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospital "Marques de Valdecilla", Santander, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Rojas</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel-Heller</LastName><ForeName>Steffi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Social Medicine, Occupational Health and Public Health (ISAP), University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ill&#xe1;n-Gala</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeune</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orellana</LastName><ForeName>Adelina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Then Bergh</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Competence Network Multiple Sclerosis (KKNMS), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulsman</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pattern Recognition and Bioinformatics, Delft University of Technology, Delft, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beker</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesi</LastName><ForeName>Niccolo</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1413-5091</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pattern Recognition and Bioinformatics, Delft University of Technology, Delft, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Newcastle Brain Tissue Resource, Edwardson Building, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Indakoetxea</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Hospital Universitario San Sebastian, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collij</LastName><ForeName>Lyduine E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Primary Medical Care, Center for Psychosocial Medicine, University Medical Center, Hamburg-Eppendorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morenas-Rodr&#xed;guez</LastName><ForeName>Estrella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ironside</LastName><ForeName>James W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH4 2XU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berckel</LastName><ForeName>Bart N M</ForeName><Initials>BNM</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiendl</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>German Competence Network Multiple Sclerosis (KKNMS), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Klinik f&#xfc;r Neurologie mit Institut f&#xfc;r Translationale Neurologie, University of M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strickland</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Movement Disorders and Memory Unit, Department of Neurology, University Hospital Mutua de Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundacio per la Recerca Biomedica I Social Mutua Terrassa, Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez Rodr&#xed;guez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospital "Marques de Valdecilla", Santander, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>EADB (Alzheimer Disease European DNA biobank)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>IPDGC (The International Parkinson Disease Genomics Consortium)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia)</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Netherlands Brain Bank (NBB)</CollectiveName></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Minnesota, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Minnesota, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferman</LastName><ForeName>Tanis J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gerpen</LastName><ForeName>Jay A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinders</LastName><ForeName>Marcel J T</ForeName><Initials>MJT</Initials><AffiliationInfo><Affiliation>Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitti</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xe1;rraga</LastName><ForeName>Llu&#xed;s</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols-Icardo</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawalia</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalmasso</LastName><ForeName>Maria Carolina</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3;n Instituto Leloir-IIBBA-CONICET, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zettl</LastName><ForeName>Uwe K</ForeName><Initials>UK</Initials><AffiliationInfo><Affiliation>German Competence Network Multiple Sclerosis (KKNMS), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Schoor</LastName><ForeName>Natasja M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekman</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Mariet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Munain</LastName><ForeName>Adolfo L&#xf3;pez</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitario San Sebastian, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pantelyat</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Minnesota, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemstra</LastName><ForeName>Afina W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande A L</ForeName><Initials>YAL</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1046-6408</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Neurology, Department of Neurodegenerative diseases, Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chinnery</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemmer</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Competence Network Multiple Sclerosis (KKNMS), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huisman</LastName><ForeName>Martijn A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Amsterdam UMC-Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Sociology, VU University, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Hospital Universitario San Sebastian, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nohr</LastName><ForeName>Ellen A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Research Unit of Gynecology and Obstetrics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Thorkild I A</ForeName><Initials>TIA</Initials><AffiliationInfo><Affiliation>Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, Section of Epidemiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Integrative Epidemiology Unit, Bristol University, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE)-T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Juan</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospital "Marques de Valdecilla", Santander, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posthuma</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer&#x2019;s Disease) Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Clarim&#xf3;n</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Kaare</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Danish Aging Research Center, Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nil&#xfc;fer</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Sonja W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD, 20892-3707, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agust&#xed;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Center and Memory Clinic, Fundaci&#xf3; ACE, Institut Catal&#xe0; de Neuroci&#xe8;ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slagboom</LastName><ForeName>Eline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dutch Society for Research on Ageing, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7688-3087</Identifier><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. h.holstege@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. h.holstege@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS078086</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097261</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_00015/9</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900580</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG061796</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG008761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UU_00015/8</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100693</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>212219/Z/18/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>13044</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100540</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG059891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EP-C-14-005</GrantID><Acronym>EPA</Acronym><Agency>EPA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA NS003154</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00015/7</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>WT 084762</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.3</RegistryNumber><NameOfSubstance UI="C000708928">PLCG2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.3</RegistryNumber><NameOfSubstance UI="D051966">Phospholipase C gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Aug;15(8):436. doi: 10.1038/s41582-019-0225-x.</RefSource><PMID Version="1">31201387</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Acta Neuropathol. 2020 May;139(5):959-962. doi: 10.1007/s00401-019-02107-8.</RefSource><PMID Version="1">31955222</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051966" MajorTopicYN="N">Phospholipase C gamma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Dementia with Lewy bodies</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Longevity</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">PLCG2</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Phospholipase C Gamma 2</Keyword><Keyword MajorTopicYN="N">Progressive supranuclear palsy</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Coppola</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varpetian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>A I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kukull</LastName><ForeName>W A</ForeName><Initials>WA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geschwind</LastName><ForeName>D H</ForeName><Initials>DH</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31131421</ArticleId><ArticleId IdType="pmc">PMC6660501</ArticleId><ArticleId IdType="doi">10.1007/s00401-019-02026-8</ArticleId><ArticleId IdType="pii">10.1007/s00401-019-02026-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s A. 2016 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2016;12:459&#x2013;509. doi: 10.1016/j.jalz.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.001</ArticleId><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging. 2014;35(934):e937-910. doi: 10.1016/j.neurobiolaging.2013.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.017</ArticleId><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Broce I, Karch CM, Wen N, Fan CC, Wang YP, Tan CH, et al. Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies. Plos Med. 2018 doi: 10.1371/journal.pmed.1002487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002487</ArticleId><ArticleId IdType="pmc">PMC5760014</ArticleId><ArticleId IdType="pubmed">29315334</ArticleId></ArticleIdList></Reference><Reference><Citation>Broer L, Buchman AS, Deelen J, Evans DS, Faul JD, Lunetta KL, et al. GWAS of longevity in CHARGE consortium confirms APOE and FOXO3 candidacy. J Gerontol A Biol Sci Med Sci. 2015;70:110&#x2013;118. doi: 10.1093/gerona/glu166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glu166</ArticleId><ArticleId IdType="pmc">PMC4296168</ArticleId><ArticleId IdType="pubmed">25199915</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae JJ, Park YH, Park C, Hwang IY, Hoffmann P, Kehrl JH, et al. Connecting two pathways through Ca2+ signaling: NLRP3 inflammasome activation induced by a hypermorphic PLCG2 mutation. Arthritis Rheumatol. 2015;67:563&#x2013;567. doi: 10.1002/art.38961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38961</ArticleId><ArticleId IdType="pmc">PMC4369162</ArticleId><ArticleId IdType="pubmed">25418813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JA, Wang Q, Davis-Turak J, Li Y, Karydas AM, Hsu SC, et al. A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. JAMA Neurol. 2015;72:414&#x2013;422. doi: 10.1001/jamaneurol.2014.4040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4040</ArticleId><ArticleId IdType="pmc">PMC4397175</ArticleId><ArticleId IdType="pubmed">25706306</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway OJ, Carrasquillo MM, Wang X, Bredenberg JM, Reddy JS, Strickland SL, et al. ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Mol Neurodegener. 2018;13:53. doi: 10.1186/s13024-018-0289-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0289-x</ArticleId><ArticleId IdType="pmc">PMC6190665</ArticleId><ArticleId IdType="pubmed">30326945</ArticleId></ArticleIdList></Reference><Reference><Citation>Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, et al. Successful replication of GWAS hits for multiple sclerosis in 10,000 germans using the exome array. Genet Epidemiol. 2015;39:601&#x2013;608. doi: 10.1002/gepi.21933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21933</ArticleId><ArticleId IdType="pubmed">26497834</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013. doi: 10.1172/JCI36663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI36663</ArticleId><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Deelen J, Beekman M, Uh HW, Broer L, Ayers KL, Tan Q, et al. Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90&#xa0;years of age. Hum Mol Genet. 2014;23:4420&#x2013;4432. doi: 10.1093/hmg/ddu139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu139</ArticleId><ArticleId IdType="pmc">PMC4103672</ArticleId><ArticleId IdType="pubmed">24688116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Wang Y, Vandrovcova J, Guelfi S, Witeolar A, Karch CM, et al. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J Neurol Neurosurg Psychiatry. 2017;88:152&#x2013;164. doi: 10.1136/jnnp-2016-314411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314411</ArticleId><ArticleId IdType="pmc">PMC5237405</ArticleId><ArticleId IdType="pubmed">27899424</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Rep. 2018;22:832&#x2013;847. doi: 10.1016/j.celrep.2017.12.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.066</ArticleId><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliano SA, Pouget JG, Hardy J, Knight J, Barnes MR, Ryten M, et al. Genomics implicates adaptive and innate immunity in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Ann Clin Transl Neur. 2016;3:924&#x2013;933. doi: 10.1002/acn3.369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.369</ArticleId><ArticleId IdType="pmc">PMC5224821</ArticleId><ArticleId IdType="pubmed">28097204</ArticleId></ArticleIdList></Reference><Reference><Citation>Garatachea N, Marin PJ, Santos-Lozano A, Sanchis-Gomar F, Emanuele E, Lucia A. The ApoE gene is related with exceptional longevity: a systematic review and meta-analysis. Rejuvenation Res. 2015;18:3&#x2013;13. doi: 10.1089/rej.2014.1605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2014.1605</ArticleId><ArticleId IdType="pubmed">25385258</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomes Project C. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74. doi: 10.1038/nature15393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15393</ArticleId><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdes LU, Jeune B, Ranberg KA, Nybo H, Vaupel JW. Estimation of apolipoprotein E genotype-specific relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: apolipoprotein E gene is a &#x201c;frailty gene,&#x201d; not a &#x201c;longevity gene&#x201d;. Genet Epidemiol. 2000;19:202&#x2013;210. doi: 10.1002/1098-2272(200010)19:3&lt;202::AID-GEPI2&gt;3.0.CO;2-Q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1098-2272(200010)19:3&lt;202::AID-GEPI2&gt;3.0.CO;2-Q</ArticleId><ArticleId IdType="pubmed">11015124</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918&#x2013;934. doi: 10.1016/j.cell.2010.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 2018;17:64&#x2013;74. doi: 10.1016/S1474-4422(17)30400-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30400-3</ArticleId><ArticleId IdType="pmc">PMC5805394</ArticleId><ArticleId IdType="pubmed">29263008</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41:1012&#x2013;1021. doi: 10.1016/j.tibs.2016.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2016.09.002</ArticleId><ArticleId IdType="pmc">PMC5123939</ArticleId><ArticleId IdType="pubmed">27669650</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14:406&#x2013;419. doi: 10.1016/S1474-4422(14)70305-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70305-9</ArticleId><ArticleId IdType="pubmed">25792099</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;1558. doi: 10.1002/sim.1186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, Schouten K, et al. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur J Epidemiol. 2018 doi: 10.1007/s10654-018-0451-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-018-0451-3</ArticleId><ArticleId IdType="pmc">PMC6290855</ArticleId><ArticleId IdType="pubmed">30362018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishioka YL, Gondo Y, Fuku N, Inagaki H, Masui Y, Takayama M. Effects of the APOE epsilon4 allele and education on cognitive function in Japanese centenarians. Age (Dordr) 2016;38:495&#x2013;503. doi: 10.1007/s11357-016-9944-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-016-9944-8</ArticleId><ArticleId IdType="pmc">PMC5266218</ArticleId><ArticleId IdType="pubmed">27558117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail K, Nussbaum L, Sebastiani P, Andersen S, Perls T, Barzilai N, et al. Compression of morbidity is observed across cohorts with exceptional longevity. J Am Geriatr Soc. 2016;64:1583&#x2013;1591. doi: 10.1111/jgs.14222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14222</ArticleId><ArticleId IdType="pmc">PMC4988893</ArticleId><ArticleId IdType="pubmed">27377170</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE. Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimers disease risk. Biorxiv. 2017;1:258533.</Citation></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia a meta-analysis. J Am Med Assoc. 2015;313:1924&#x2013;1938. doi: 10.1001/jama.2015.4668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi PK, Pirastu N, Kentistou KA, Fischer K, Hofer E, Schraut KE, et al. Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nat Commun. 2017;8:910. doi: 10.1038/s41467-017-00934-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00934-5</ArticleId><ArticleId IdType="pmc">PMC5715013</ArticleId><ArticleId IdType="pubmed">29030599</ArticleId></ArticleIdList></Reference><Reference><Citation>Keogh MJ, Wei W, Wilson I, Coxhead J, Ryan S, Rollinson S, et al. Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. Genome Res. 2017;27:165&#x2013;173. doi: 10.1101/gr.210609.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.210609.116</ArticleId><ArticleId IdType="pmc">PMC5204341</ArticleId><ArticleId IdType="pubmed">28003435</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Jun KS, Lee SB, Kang NG, Min DS, Kim YH, et al. Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature. 1997;389:290&#x2013;293. doi: 10.1038/38508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/38508</ArticleId><ArticleId IdType="pubmed">9305844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleineidam L, Chouraki V, Pr&#xf3;chnicki T, van der Lee S, Madrid-M&#xe1;rquez L, Wagner-Thelen H et al (2018) PLCG2 protective variant p.P522R modulates Tau pathology and disease progression in patients with mild cognitive impairment. Lancet. https://ssrn.com/abstract=3307649</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7244617</ArticleId><ArticleId IdType="pubmed">32166339</ArticleId></ArticleIdList></Reference><Reference><Citation>Koss H, Bunney TD, Behjati S, Katan M. Dysfunction of phospholipase Cgamma in immune disorders and cancer. Trends Biochem Sci. 2014;39:603&#x2013;611. doi: 10.1016/j.tibs.2014.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2014.09.004</ArticleId><ArticleId IdType="pubmed">25456276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291. doi: 10.1038/nature19057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19057</ArticleId><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Erlich Y, Pickrell JK. Case-control association mapping by proxy using family history of disease. Nat Genet. 2017;49:325&#x2013;331. doi: 10.1038/ng.3766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3766</ArticleId><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y, et al. Alzheimer&#x2019;s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res Ther. 2019;11:16. doi: 10.1186/s13195-019-0469-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0469-0</ArticleId><ArticleId IdType="pmc">PMC6359863</ArticleId><ArticleId IdType="pubmed">30711010</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on family history of Alzheimer&#x2019;s disease. Transl Psychiatry. 2018;8:99. doi: 10.1038/s41398-018-0150-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-018-0150-6</ArticleId><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48:1279&#x2013;1283. doi: 10.1038/ng.3643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3643</ArticleId><ArticleId IdType="pmc">PMC5388176</ArticleId><ArticleId IdType="pubmed">27548312</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaid AF, Joshi PK, Porcu E, Komljenovic A, Li H, Sorrentino V, et al. Bayesian association scan reveals loci associated with human lifespan and linked biomarkers. Nat Commun. 2017 doi: 10.1038/ncomms15842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15842</ArticleId><ArticleId IdType="pmc">PMC5537485</ArticleId><ArticleId IdType="pubmed">28748955</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA. Parkinson&#x2019;s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk. BioRxiv. 2018 doi: 10.1101/388165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/388165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med. 2012;366:330&#x2013;338. doi: 10.1056/NEJMoa1102140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1102140</ArticleId><ArticleId IdType="pmc">PMC3298368</ArticleId><ArticleId IdType="pubmed">22236196</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsopoulos NA. Genetics of multiple sclerosis: an overview and new directions. Cold Spring Harb Perspect Med. 2018;8:45. doi: 10.1101/cshperspect.a028951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028951</ArticleId><ArticleId IdType="pmc">PMC6027932</ArticleId><ArticleId IdType="pubmed">29440325</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson RL, van Rossum DB, Ford DL, Hurt KJ, Bae SS, Suh PG, et al. Phospholipase C-gamma is required for agonist-induced Ca2+&#x2009;entry. Cell. 2002;111:529&#x2013;541. doi: 10.1016/S0092-8674(02)01045-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)01045-0</ArticleId><ArticleId IdType="pubmed">12437926</ArticleId></ArticleIdList></Reference><Reference><Citation>Peuralinna T, Myllykangas L, Oinas M, Nalls MA, Keage HA, Isoviita VM, et al. Genome-wide association study of neocortical Lewy-related pathology. Ann Clin Transl Neurol. 2015;2:920&#x2013;931. doi: 10.1002/acn3.231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.231</ArticleId><ArticleId IdType="pmc">PMC4574809</ArticleId><ArticleId IdType="pubmed">26401513</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilling LC, Kuo CL, Sicinski K, Tamosauskaite J, Kuchel GA, Harries LW, et al. Human longevity: 25 genetic loci associated in 389,166 UK biobank participants. Aging (Albany NY) 2017;9:2504&#x2013;2520. doi: 10.18632/aging.101334.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101334</ArticleId><ArticleId IdType="pmc">PMC5764389</ArticleId><ArticleId IdType="pubmed">29227965</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem. 2001;70:281&#x2013;312. doi: 10.1146/annurev.biochem.70.1.281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.70.1.281</ArticleId><ArticleId IdType="pmc">PMC4781088</ArticleId><ArticleId IdType="pubmed">11395409</ArticleId></ArticleIdList></Reference><Reference><Citation>Schade A, Walliser C, Wist M, Haas J, Vatter P, Kraus JM, et al. Cool-temperature-mediated activation of phospholipase C-gamma2 in the human hereditary disease PLAID. Cell Signal. 2016;28:1237&#x2013;1251. doi: 10.1016/j.cellsig.2016.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2016.05.010</ArticleId><ArticleId IdType="pubmed">27196803</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. 2017;49:1373&#x2013;1384. doi: 10.1038/ng.3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209&#x2013;213. doi: 10.1038/ng1706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1706</ArticleId><ArticleId IdType="pubmed">16415888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. Plos Med. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018.</Citation></Reference><Reference><Citation>Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, et al. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer&#x2019;s disease. Eur J Hum Genet. 2018 doi: 10.1038/s41431-018-0273-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0273-5</ArticleId><ArticleId IdType="pmc">PMC6336855</ArticleId><ArticleId IdType="pubmed">30258121</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E&#x2014;a multifunctional protein with implications in various pathologies as a result of its structural features. Comput Struct Biotechnol J. 2017;15:359&#x2013;365. doi: 10.1016/j.csbj.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2017.05.003</ArticleId><ArticleId IdType="pmc">PMC5476973</ArticleId><ArticleId IdType="pubmed">28660014</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer&#x2019;s disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17:434&#x2013;444. doi: 10.1016/S1474-4422(18)30053-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30053-X</ArticleId><ArticleId IdType="pubmed">29555425</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton RL, Soto-Ortolaza AI, Murray ME, Lorenzo-Betancor O, Ogaki K, Heckman MG, et al. TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurol Genet. 2016;2:85. doi: 10.1212/nxg.0000000000000085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/nxg.0000000000000085</ArticleId><ArticleId IdType="pmc">PMC4946771</ArticleId><ArticleId IdType="pubmed">27458607</ArticleId></ArticleIdList></Reference><Reference><Citation>Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton&#x2019;s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286&#x2013;2294. doi: 10.1056/NEJMoa1400029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1400029</ArticleId><ArticleId IdType="pmc">PMC4144824</ArticleId><ArticleId IdType="pubmed">24869598</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Brayne C, Matthews FE, Medical Research Council Cognitive F, Ageing Study c Survival times in people with dementia: analysis from population based cohort study with 14&#xa0;year follow-up. BMJ. 2008;336:258&#x2013;262. doi: 10.1136/bmj.39433.616678.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39433.616678.25</ArticleId><ArticleId IdType="pmc">PMC2223023</ArticleId><ArticleId IdType="pubmed">18187696</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Constien R, Dear N, Katan M, Hanke P, Bunney TD, et al. Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+&#x2009;entry. Immunity. 2005;22:451&#x2013;465. doi: 10.1016/j.immuni.2005.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.01.016</ArticleId><ArticleId IdType="pubmed">15845450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet. 2012;91:713&#x2013;720. doi: 10.1016/j.ajhg.2012.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.08.006</ArticleId><ArticleId IdType="pmc">PMC3484656</ArticleId><ArticleId IdType="pubmed">23000145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou K, Shi L, Wang Y, Chen S, Zhang J. Recent Advances of the NLRP3 Inflammasome in Central Nervous System Disorders. J Immunol Res. 2016;2016:9238290. doi: 10.1155/2016/9238290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9238290</ArticleId><ArticleId IdType="pmc">PMC5019917</ArticleId><ArticleId IdType="pubmed">27652274</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31135820</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB.</ArticleTitle><Pagination><StartPage>809</StartPage><EndPage>817</EndPage><MedlinePgn>809-817</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.0648</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Early-onset Alzheimer disease (EOAD) is a rare form of Alzheimer disease (AD) with a large genetic basis that is only partially understood. In late-onset AD, elevated circulating cholesterol levels increase AD risk even after adjusting for the apolipoprotein E &#x3b5;4 (APOE E4) allele, a major genetic factor for AD and elevated cholesterol levels; however, the role of circulating cholesterol levels in EOAD is unclear.</AbstractText><AbstractText Label="OBJECTIVES">To investigate the association between circulating cholesterol levels and EOAD and to identify genetic variants underlying this possible association.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this case series, plasma cholesterol levels were directly measured in 267 samples from the AD research centers (ADRCs) of Emory University and University of California, San Francisco, collected from January 21, 2009, through August 21, 2014. The association between cholesterol and EOAD was examined using multiple linear regression. To determine the underlying genetic variants, APOB, APP, PSEN1, and PSEN2 were sequenced in samples from 2125 EOAD cases and controls recruited from 29 ADRCs from January 1, 1984, through December 31, 2015. Data were analyzed from November 23, 2016, through April 10, 2018.</AbstractText><AbstractText Label="EXPOSURES">Clinical diagnosis, age at clinical diagnosis, plasma cholesterol measures (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B), and genetic variants in APOE, APP, PSEN1, PSEN2, and APOB.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was the association between EOAD and plasma cholesterol measures. The secondary outcome was the association between EOAD and the burden of genetic variants in APOB.</AbstractText><AbstractText Label="RESULTS">Of the 2125 samples that underwent genetic sequencing, 1276 were from women (60.0%) and 654 (30.8%) were from patients with EOAD (mean [SD] ages, 55.6 [4.3] years for cases and 72.0 [9.6] years for controls). APOE E4 explained 10.1% of the variance of EOAD. After controlling for APOE E4, EOAD cases had higher levels of total cholesterol (mean difference [SE], 21.9 [5.2] mg/dL; P&#x2009;=&#x2009;2.9&#x2009;&#xd7;&#x2009;10-5), LDL-C (mean difference [SE], 22.0 [4.5] mg/dL; P&#x2009;=&#x2009;1.8&#x2009;&#xd7;&#x2009;10-6), and ApoB (mean difference [SE], 12.0 [2.4] mg/dL; P&#x2009;=&#x2009;2.0&#x2009;&#xd7;&#x2009;10-6) than controls in 267 frozen samples. Approximately 3% of EOAD cases carried known AD-causing mutations. Gene-based rare variant burden testing in 2066 samples showed that rare APOB coding variants were significantly more abundant in EOAD cases after adjusting for sex, APOE E4, genetic principal components, ADRC center, and batch (effect size, 0.20; P&#x2009;=&#x2009;4.20&#x2009;&#xd7;&#x2009;10-4).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Elevated LDL-C levels were associated with higher probability of having EOAD, and EOAD cases were enriched for rare coding variants in APOB, which codes for the major protein of LDL-C. Collectively, these novel findings highlight the important role of LDL-C in EOAD pathogenesis and suggest a direct link of APOB variants to AD risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Division of Neurology, Atlanta Veterans Affairs Medical Center, Decatur, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutler</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Aliza P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Division of Mental Health, Atlanta Veterans Affairs Medical Center, Decatur, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Ngoc-Anh</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Biomarker Core Laboratory, Atlanta Veterans Affairs Medical Center, Decatur, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IK2 BX001820</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056533</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG062633</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569471">APOB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053299">Apolipoprotein B-100</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2019 Jul 1;76(7):751-753. doi: 10.1001/jamaneurol.2019.0212.</RefSource><PMID Version="1">31135814</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053299" MajorTopicYN="N">Apolipoprotein B-100</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018389" MajorTopicYN="N">Codon, Nonsense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr T. Wingo reports receiving grants from the National Institutes of Health (NIH), the National Institute of Aging (NIA), and the Veterans Administration (VA) during conduct of the study. Dr Cutler reported receiving grants from the NIH during the conduct of the study. Dr A. Wingo reported receiving grants from the VA during conduct of the study. Dr Rabinovici reported receiving grants from Avid Radiopharmaceuticals, Eli Lilly, Piramal Imaging, and GE Healthcare and personal fees from Eisai, Axon Neuroscience, Merck, Genentech, and Roche outside the submitted work. Dr Miller reported receiving grants from the NIH, NIA, Quest Diagnostics Dementia Pathway Collaboration, Cornell University Subcontract, and the Bluefield Project to cure frontotemporal dementia during the conduct of the study. Dr Lah reported receiving grants from the NIH, Avanir Pharmaceuticals, Genentech, AbbVie, Novartis, Biogen, Lilly, Cognito Therapeutics, and Roche during the conduct of the study. Dr Levey reported serving as a webinar speaker for Future Health LLC, and receiving grants from the NIH, the NIA, AbbVie, Genentech, Cognito Therapeutics, Biogen, Merck, Esai, Novartis, and Takeda outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31135820</ArticleId><ArticleId IdType="pmc">PMC6547122</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.0648</ArticleId><ArticleId IdType="pii">2734865</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012;69(1):59-64. doi:10.1001/archneurol.2011.221</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.221</ArticleId><ArticleId IdType="pmc">PMC3332307</ArticleId><ArticleId IdType="pubmed">21911656</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer&#x2019;s disease revisited. Alzheimers Dement. 2016;12(6):733-748. doi:10.1016/j.jalz.2016.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.012</ArticleId><ArticleId IdType="pubmed">27016693</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Dumanchin C, Hannequin D, et al. . Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65(3):664-670. doi:10.1086/302553</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302553</ArticleId><ArticleId IdType="pmc">PMC1377972</ArticleId><ArticleId IdType="pubmed">10441572</ArticleId></ArticleIdList></Reference><Reference><Citation>van Duijn CM, de Knijff P, Cruts M, et al. . Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer&#x2019;s disease. Nat Genet. 1994;7(1):74-78. doi:10.1038/ng0594-74</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0594-74</ArticleId><ArticleId IdType="pubmed">8075646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasman DI, Par&#xe9; G, Mora S, et al. . Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009;5(11):e1000730. doi:10.1371/journal.pgen.1000730</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000730</ArticleId><ArticleId IdType="pmc">PMC2777390</ArticleId><ArticleId IdType="pubmed">19936222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer&#x2019;s disease: epidemiological evidence. Acta Neurol Scand Suppl. 2006;185:50-57. doi:10.1111/j.1600-0404.2006.00685.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2006.00685.x</ArticleId><ArticleId IdType="pubmed">16866911</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease, I: review of epidemiological and preclinical studies. Arch Neurol. 2011;68(10):1239-1244. doi:10.1001/archneurol.2011.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.203</ArticleId><ArticleId IdType="pmc">PMC3211071</ArticleId><ArticleId IdType="pubmed">21987540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, et al. . Apolipoprotein E &#x3b5;4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149-155. doi:10.7326/0003-4819-137-3-200208060-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-137-3-200208060-00006</ArticleId><ArticleId IdType="pubmed">12160362</ArticleId></ArticleIdList></Reference><Reference><Citation>Notkola IL, Sulkava R, Pekkanen J, et al. . Serum total cholesterol, apolipoprotein E &#x3b5;4 allele, and Alzheimer&#x2019;s disease. Neuroepidemiology. 1998;17(1):14-20. doi:10.1159/000026149</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000026149</ArticleId><ArticleId IdType="pubmed">9549720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmijn S, Foley D, White L, et al. . Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol. 2000;20(10):2255-2260. doi:10.1161/01.ATV.20.10.2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.20.10.2255</ArticleId><ArticleId IdType="pubmed">11031212</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-281. doi:10.1212/01.WNL.0000149519.47454.F2</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000149519.47454.F2</ArticleId><ArticleId IdType="pubmed">15668425</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer&#x2019;s disease: a case-control study. Neurology. 1995;45(6):1092-1096. doi:10.1212/WNL.45.6.1092</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.45.6.1092</ArticleId><ArticleId IdType="pubmed">7783869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10):1439-1443. doi:10.1001/archneur.57.10.1439</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.10.1439</ArticleId><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Larson EB, Sonnen JA, et al. . Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69(9):878-885. doi:10.1212/01.wnl.0000277657.95487.1c</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000277657.95487.1c</ArticleId><ArticleId IdType="pubmed">17724290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627-1631. doi:10.1016/S0140-6736(00)03155-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)03155-X</ArticleId><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008;5(4):416-421. doi:10.2174/156720508785132316</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720508785132316</ArticleId><ArticleId IdType="pubmed">18690839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71(5):344-350. doi:10.1212/01.wnl.0000319647.15752.7b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000319647.15752.7b</ArticleId><ArticleId IdType="pmc">PMC2676946</ArticleId><ArticleId IdType="pubmed">18663180</ArticleId></ArticleIdList></Reference><Reference><Citation>Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13-17. doi:10.1136/jnnp.2008.150433</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.150433</ArticleId><ArticleId IdType="pubmed">18931004</ArticleId></ArticleIdList></Reference><Reference><Citation>Peloso GM, Auer PL, Bis JC, et al. ; NHLBI GO Exome Sequencing Project . Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet. 2014;94(2):223-232. doi:10.1016/j.ajhg.2014.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2014.01.009</ArticleId><ArticleId IdType="pmc">PMC3928662</ArticleId><ArticleId IdType="pubmed">24507774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange LA, Willer CJ, Rich SS. Recent developments in genome and exome-wide analyses of plasma lipids. Curr Opin Lipidol. 2015;26(2):96-102. doi:10.1097/MOL.0000000000000159</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000159</ArticleId><ArticleId IdType="pubmed">25692345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange LA, Hu Y, Zhang H, et al. ; NHLBI Grand Opportunity Exome Sequencing Project . Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014;94(2):233-245. doi:10.1016/j.ajhg.2014.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2014.01.010</ArticleId><ArticleId IdType="pmc">PMC3928660</ArticleId><ArticleId IdType="pubmed">24507775</ArticleId></ArticleIdList></Reference><Reference><Citation>National Alzheimer&#x2019;s Coordinating Center  Description of NCAA database. https://www.alz.washington.edu/WEB/data_descript.html. Accessed April 10, 2018.</Citation></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, et al. ; NIA Alzheimer&#x2019;s Disease Centers . The National Alzheimer&#x2019;s Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord. 2007;21(3):249-258. doi:10.1097/WAD.0b013e318142774e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318142774e</ArticleId><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944. doi:10.1212/WNL.34.7.939</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo TS, Kotlar A, Cutler DJ. MPD: multiplex primer design for next-generation targeted sequencing. BMC Bioinformatics. 2017;18(1):14. doi:10.1186/s12859-016-1453-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-016-1453-3</ArticleId><ArticleId IdType="pmc">PMC5217220</ArticleId><ArticleId IdType="pubmed">28056760</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston HR, Chopra P, Wingo TS, et al. ; International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome . PEMapper and PECaller provide a simplified approach to whole-genome sequencing. Proc Natl Acad Sci U S A. 2017;114(10):E1923-E1932. doi:10.1073/pnas.1618065114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1618065114</ArticleId><ArticleId IdType="pmc">PMC5347547</ArticleId><ArticleId IdType="pubmed">28223510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotlar AV, Trevino CE, Zwick ME, Cutler DJ, Wingo TS Bystro: rapid online variant annotation and natural-language filtering at whole-genome scale. Genome Biol. 2018;19(1):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801807</ArticleId><ArticleId IdType="pubmed">29409527</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Kryukov GV, de Bakker PI, et al. . Pooled association tests for rare variants in exon-resequencing studies. Am J Hum Genet. 2010;86(6):832-838. doi:10.1016/j.ajhg.2010.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2010.04.005</ArticleId><ArticleId IdType="pmc">PMC3032073</ArticleId><ArticleId IdType="pubmed">20471002</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Liu D, Zhan X, Wing MK, Abecasis GR. RAREMETAL: fast and powerful meta-analysis for rare variants. Bioinformatics. 2014;30(19):2828-2829. doi:10.1093/bioinformatics/btu367</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu367</ArticleId><ArticleId IdType="pmc">PMC4173011</ArticleId><ArticleId IdType="pubmed">24894501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, Witten DM, Jain P, O&#x2019;Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-315. doi:10.1038/ng.2892</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2892</ArticleId><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski KJ, Minikel EV, et al. ; Exome Aggregation Consortium . Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285-291. doi:10.1038/nature19057</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19057</ArticleId><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Lee JM, Benson M, et al. . ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862-D868. doi:10.1093/nar/gkv1222</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1222</ArticleId><ArticleId IdType="pmc">PMC4702865</ArticleId><ArticleId IdType="pubmed">26582918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lye SH, Chahil JK, Bagali P, et al. . Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia. PLoS One. 2013;8(4):e60729. doi:10.1371/journal.pone.0060729</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060729</ArticleId><ArticleId IdType="pmc">PMC3620484</ArticleId><ArticleId IdType="pubmed">23593297</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis. 2017;56(1):215-228. doi:10.3233/JAD-160826</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160826</ArticleId><ArticleId IdType="pmc">PMC5240556</ArticleId><ArticleId IdType="pubmed">27911314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge PG, Hoyt KB, Boehme K, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Assessment of the genetic variance of late-onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2016;41:200.e13-200.e20. doi:10.1016/j.neurobiolaging.2016.02.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.02.024</ArticleId><ArticleId IdType="pmc">PMC4948179</ArticleId><ArticleId IdType="pubmed">27036079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium . Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):429-435. doi:10.1038/ng.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. ; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology . Meta-analysis of 74 046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452-1458. doi:10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436-441. doi:10.1038/ng.801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S, Stefansson H, Jonsson T, et al. ; DemGene . Loss-of-function variants in ABCA7 confer risk of Alzheimer&#x2019;s disease. Nat Genet. 2015;47(5):445-447. doi:10.1038/ng.3246</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3246</ArticleId><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereczki E, Bern&#xe1;t G, Csont T, Ferdinandy P, Scheich H, S&#xe1;ntha M. Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J Proteome Res. 2008;7(6):2246-2252. doi:10.1021/pr7006329</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr7006329</ArticleId><ArticleId IdType="pubmed">18473452</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;ffler T, Flunkert S, Havas D, et al. . Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiol Aging. 2013;34(10):2379-2388. doi:10.1016/j.neurobiolaging.2013.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.04.008</ArticleId><ArticleId IdType="pubmed">23643485</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Schellenberg GD; Alzheimer&#x2019;s Disease Genetics Consortium (ADGC) . Genomic variants, genes, and pathways of Alzheimer&#x2019;s disease: an overview. Am J Med Genet B Neuropsychiatr Genet. 2017;174(1):5-26. doi:10.1002/ajmg.b.32499</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.32499</ArticleId><ArticleId IdType="pmc">PMC6179157</ArticleId><ArticleId IdType="pubmed">27943641</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GD, Ebrahim S &#x201c;Mendelian randomization&#x201d;: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22. doi:10.1093/ije/dyg070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyg070</ArticleId><ArticleId IdType="pubmed">12689998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31133559</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>29</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Activity-Dependent Reconnection of Adult-Born Dentate Granule Cells in a Mouse Model of Frontotemporal Dementia.</ArticleTitle><Pagination><StartPage>5794</StartPage><EndPage>5815</EndPage><MedlinePgn>5794-5815</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2724-18.2019</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) is characterized by neuronal loss in the frontal and temporal lobes of the brain. Here, we provide the first evidence of striking morphological alterations in dentate granule cells (DGCs) of FTD patients and in a mouse model of the disease, Tau<sup>VLW</sup> mice. Taking advantage of the fact that the hippocampal dentate gyrus (DG) gives rise to newborn DGCs throughout the lifetime in rodents, we used RGB retroviruses to study the temporary course of these alterations in newborn DGCs of female Tau<sup>VLW</sup> mice. In addition, retroviruses that encode either PSD95:GFP or Syn:GFP revealed striking alterations in the afferent and efferent connectivity of newborn Tau<sup>VLW</sup> DGCs, and monosynaptic retrograde rabies virus tracing showed that these cells are disconnected from distal brain regions and local sources of excitatory innervation. However, the same cells exhibited a predominance of local inhibitory innervation. Accordingly, the expression of presynaptic and postsynaptic markers of inhibitory synapses was markedly increased in the DG of Tau<sup>VLW</sup> mice and FTD patients. Moreover, an increased number of neuropeptide Y-positive interneurons in the DG correlated with a reduced number of activated egr-1<sup>+</sup> DGCs in Tau<sup>VLW</sup> mice. Finally, we tested the therapeutic potential of environmental enrichment and chemoactivation to reverse these alterations in mice. Both strategies reversed the morphological alterations of newborn DGCs and partially restored their connectivity in a mouse model of the disease. Moreover, our data point to remarkable morphological similarities between the DGCs of Tau<sup>VLW</sup> mice and FTD patients.<b>SIGNIFICANCE STATEMENT</b> We show, for the first time to our knowledge, that the population of dentate granule cells is disconnected from other regions of the brain in the neurodegenerative disease frontotemporal dementia (FTD). These alterations were observed in FTD patients and in a mouse model of this disease. Moreover, we tested the therapeutic potential of two strategies, environmental enrichment and chemoactivation, to stimulate the activity of these neurons in mice. We found that some of the alterations were reversed by these therapeutic interventions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 the authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Terreros-Roncal</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular "Severo Ochoa", CBMSO, CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flor-Garc&#xed;a</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular "Severo Ochoa", CBMSO, CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Jim&#xe9;nez</LastName><ForeName>Elena P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular "Severo Ochoa", CBMSO, CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallas-Bazarra</LastName><ForeName>Noem&#xed;</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0175-5080</Identifier><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular "Severo Ochoa", CBMSO, CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;bano</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuropathology Department, CIEN Foundation, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sah</LastName><ForeName>Nirnath</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroplasticity and Behavior Unit, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Praag</LastName><ForeName>Henriette</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5727-434X</Identifier><AffiliationInfo><Affiliation>Neuroplasticity and Behavior Unit, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Science, Charles E. Schmidt College of Medicine, and Brain Institute, Florida Atlantic University, Jupiter, Florida 33458, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacomini</LastName><ForeName>Damiana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratorio de Plasticidad Neuronal, Fundaci&#xf3;n Instituto Leloir-Instituto de Investigaciones Bioqu&#xed;micas de Buenos Aires-Consejo Nacional de Investigaciones Cient&#xed;ficas y T&#xe9;cnicas (CONICET), C1405BWE Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schinder</LastName><ForeName>Alejandro F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0003-4863-8348</Identifier><AffiliationInfo><Affiliation>Laboratorio de Plasticidad Neuronal, Fundaci&#xf3;n Instituto Leloir-Instituto de Investigaciones Bioqu&#xed;micas de Buenos Aires-Consejo Nacional de Investigaciones Cient&#xed;ficas y T&#xe9;cnicas (CONICET), C1405BWE Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular "Severo Ochoa", CBMSO, CSIC-UAM, 28049 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorens-Mart&#xed;n</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9129-5198</Identifier><AffiliationInfo><Affiliation>Department of Molecular Neuropathology, Centro de Biolog&#xed;a Molecular "Severo Ochoa", CBMSO, CSIC-UAM, 28049 Madrid, Spain, m.llorens@csic.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Faculty of Sciences, Universidad Aut&#xf3;noma de Madrid, 28049 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>55007652</GrantID><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DREADD</Keyword><Keyword MajorTopicYN="N">RGB retrovirus</Keyword><Keyword MajorTopicYN="N">dentate granule cells (DGCs)</Keyword><Keyword MajorTopicYN="N">environmental enrichment</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia (FTD)</Keyword><Keyword MajorTopicYN="N">rabies virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31133559</ArticleId><ArticleId IdType="pmc">PMC6636081</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2724-18.2019</ArticleId><ArticleId IdType="pii">JNEUROSCI.2724-18.2019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA, Nonneman RJ, Hartmann J, Moy SS, Nicolelis MA, McNamara JO, Roth BL (2009) Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63:27&#x2013;39. 10.1016/j.neuron.2009.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.06.014</ArticleId><ArticleId IdType="pmc">PMC2751885</ArticleId><ArticleId IdType="pubmed">19607790</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22:9340&#x2013;9351. 10.1523/JNEUROSCI.22-21-09340.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-21-09340.2002</ArticleId><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279:34873&#x2013;34881. 10.1074/jbc.M405131200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M405131200</ArticleId><ArticleId IdType="pubmed">15190058</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman J, Das GD (1965) Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol 124:319&#x2013;335. 10.1002/cne.901240303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.901240303</ArticleId><ArticleId IdType="pubmed">5861717</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez DD, Giacomini D, Yang SM, Trinchero MF, Temprana SG, B&#xfc;ttner KA, Beltramone N, Schinder AF (2016) A disynaptic feedback network activated by experience promotes the integration of new granule cells. Science 354:459&#x2013;465. 10.1126/science.aaf2156</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf2156</ArticleId><ArticleId IdType="pubmed">27789840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandopadhyay R, Liu JY, Sisodiya SM, Thom M (2014) A comparative study of the dentate gyrus in hippocampal sclerosis in epilepsy and dementia. Neuropathol Appl Neurobiol 40:177&#x2013;190. 10.1111/nan.12087</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12087</ArticleId><ArticleId IdType="pmc">PMC4282449</ArticleId><ArticleId IdType="pubmed">24028428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KF, de Kort GJ, Steggerda S, Shigemoto R, Ribeiro-da-Silva A, Cuello AC (2003) Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci Lett 353:143&#x2013;147. 10.1016/j.neulet.2003.09.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.09.027</ArticleId><ArticleId IdType="pubmed">14664921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergami M, Masserdotti G, Temprana SG, Motori E, Eriksson TM, G&#xf6;bel J, Yang SM, Conzelmann KK, Schinder AF, G&#xf6;tz M, Berninger B (2015) A critical period for experience-dependent remodeling of adult-born neuron connectivity. Neuron 85:710&#x2013;717. 10.1016/j.neuron.2015.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.01.001</ArticleId><ArticleId IdType="pubmed">25661179</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD, Nochlin D, Poorkaj P, Cherrier M, Kaye J, Payami H, Peskind E, Lampe TH, Nemens E, Boyer PJ, Schellenberg GD (1999) A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 122:741&#x2013;756. 10.1093/brain/122.4.741</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/122.4.741</ArticleId><ArticleId IdType="pubmed">10219785</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco-Iba&#xf1;ez JM, Freund TF (1997) Distribution, ultrastructure, and connectivity of calretinin-immunoreactive mossy cells of the mouse dentate gyrus. Hippocampus 7, 307&#x2013;320. 10.1002/(sici)1098-1063(1997)7:3&lt;307::aid-hipo6&gt;3.0.co;2-h</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1098-1063(1997)7:3&lt;307::aid-hipo6&gt;3.0.co;2-h</ArticleId><ArticleId IdType="pubmed">9228528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s M, Pallas-Bazarra N, Terreros-Roncal J, Perea JR, Jurado-Arjona J, &#xc1;vila J, Llorens-Mart&#xed;n M (2017a) Soluble tau has devastating effects on the structural plasticity of hippocampal granule neurons. Translational Psychiatry 7:1267. 10.1038/s41398-017-0013-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-017-0013-6</ArticleId><ArticleId IdType="pmc">PMC5802513</ArticleId><ArticleId IdType="pubmed">29217824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s M, Llorens-Mart&#xed;n M, Perea JR, Jurado-Arjona J, R&#xe1;bano A, Hern&#xe1;ndez F, Avila J (2017b) Absence of CX3CR1 impairs the internalization of tau by microglia. Mol Neurodegener 12:59. 10.1186/s13024-017-0200-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0200-1</ArticleId><ArticleId IdType="pmc">PMC5558740</ArticleId><ArticleId IdType="pubmed">28810892</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16:271&#x2013;278; discussion 278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389&#x2013;404. 10.1007/s00401-006-0127-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, Cooper-Kuhn CM, Kempermann G, Van Praag H, Winkler J, Gage FH, Kuhn HG (2003) Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci 17:2042&#x2013;2046. 10.1046/j.1460-9568.2003.02647.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2003.02647.x</ArticleId><ArticleId IdType="pubmed">12786970</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Hamdane M, Delobel P, Sambo AV, B&#xe9;gard S, Ghestem A, Sergeant N, Delacourte A (2002) Tau story: from frontotemporal dementia to other tauopathies. J Soc Biol 196:103&#x2013;108. 10.1051/jbio/2002196010103</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/jbio/2002196010103</ArticleId><ArticleId IdType="pubmed">12134624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HT, Cortez S, Vonsattel JP, Stopa EG, Schelper RL (2004) Familial frontotemporal dementia: a report of three cases of severe cerebral atrophy with rare inclusions that are negative for tau and synuclein, but positive for ubiquitin. Acta Neuropathol 108:10&#x2013;16. 10.1007/s00401-004-0836-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-004-0836-0</ArticleId><ArticleId IdType="pubmed">15108011</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DH, Lee KH, Lee J (2016) Effect of exercise-induced neurogenesis on cognitive function deficit in a rat model of vascular dementia. Mol Med Rep 13:2981&#x2013;2990. 10.3892/mmr.2016.4891</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.4891</ArticleId><ArticleId IdType="pmc">PMC4805106</ArticleId><ArticleId IdType="pubmed">26934837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper PN, Jackson M, Lennox G, Lowe J, Mann DM (1995) Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia. Arch Neurol 52:1011&#x2013;1015. 10.1001/archneur.1995.00540340103019</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1995.00540340103019</ArticleId><ArticleId IdType="pubmed">7575218</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Bergami M, Ghanem A, Conzelmann KK, Lepier A, G&#xf6;tz M, Berninger B (2013) Retrograde monosynaptic tracing reveals the temporal evolution of inputs onto new neurons in the adult dentate gyrus and olfactory bulb. Proc Natl Acad Sci U S A 110:E1152&#x2013;1161. 10.1073/pnas.1218991110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218991110</ArticleId><ArticleId IdType="pmc">PMC3607028</ArticleId><ArticleId IdType="pubmed">23487772</ArticleId></ArticleIdList></Reference><Reference><Citation>Drakew A, Frotscher M, Heimrich B (1999) Blockade of neuronal activity alters spine maturation of dentate granule cells but not their dendritic arborization. Neuroscience 94:767&#x2013;774. 10.1016/S0306-4522(99)00378-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(99)00378-4</ArticleId><ArticleId IdType="pubmed">10579567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB (1986) A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Ann Neurol 20:616&#x2013;621. 10.1002/ana.410200510</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410200510</ArticleId><ArticleId IdType="pubmed">2878639</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel T, Go&#xf1;i-Oliver P, Gomez-Ramos P, Mor&#xe1;n MA, Lucas JJ, Avila J, Hern&#xe1;ndez F (2008) Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta. Neuroscience 157:772&#x2013;780. 10.1016/j.neuroscience.2008.09.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.09.047</ArticleId><ArticleId IdType="pubmed">18951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson PS, Perfilieva E, Bj&#xf6;rk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH (1998) Neurogenesis in the adult human hippocampus. Nat Med 4:1313&#x2013;1317. 10.1038/3305</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3305</ArticleId><ArticleId IdType="pubmed">9809557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I. (1999) Neurons and their dendrites in frontotemporal dementia. Dement Geriatr Cogn Disord 10:55&#x2013;60. 10.1159/000051214</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000051214</ArticleId><ArticleId IdType="pubmed">10436342</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ. (2013) The mouse brain in stereotaxic coordinates. San Diego: Academic.</Citation></Reference><Reference><Citation>Freund TF, Buzs&#xe1;ki G (1996) Interneurons of the hippocampus. Hippocampus 6:347&#x2013;470. 10.1002/(SICI)1098-1063(1996)6:4&lt;347::AID-HIPO1&gt;3.0.CO;2-I</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-1063(1996)6:4&lt;347::AID-HIPO1&gt;3.0.CO;2-I</ArticleId><ArticleId IdType="pubmed">8915675</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, D'Souza I, Crudder CH, Onodera H, Itoyama Y, Poorkaj P, Bird TD, Schellenberg GD (2000) Pro-apoptotic effects of tau mutations in chromosome 17 frontotemporal dementia and parkinsonism. Neuroreport 11:57&#x2013;60. 10.1097/00001756-200001170-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200001170-00011</ArticleId><ArticleId IdType="pubmed">10683829</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa K, Wang Y, Yao PJ, Fu W, Mattson MP, Itoyama Y, Onodera H, D'Souza I, Poorkaj PH, Bird TD, Schellenberg GD (2003) Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. J Neurochem 87:427&#x2013;436. 10.1046/j.1471-4159.2003.02020.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.02020.x</ArticleId><ArticleId IdType="pubmed">14511120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, Terni B, Spillantini MG (2007) Frontotemporal dementia with tau pathology. Neurodegener Dis 4:236&#x2013;253. 10.1159/000101848</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000101848</ArticleId><ArticleId IdType="pubmed">17596718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B, Murrell J, Spillantini MG (1999) Mutations in the tau gene cause frontotemporal dementia. Brain Res Bull 50:471&#x2013;472. 10.1016/S0361-9230(99)00139-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(99)00139-2</ArticleId><ArticleId IdType="pubmed">10643489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M (2015) Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 41:24&#x2013;46. 10.1111/nan.12213</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12213</ArticleId><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Crowther RA (1999) Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett 450:306&#x2013;311. 10.1016/S0014-5793(99)00508-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(99)00508-6</ArticleId><ArticleId IdType="pubmed">10359094</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Ghetti B, Spillantini MG (2000) Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). their relevance for understanding the neurogenerative process. Ann N Y Acad Sci 920:74&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193179</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Nicola D, Riecken K, Fehse B, Perry VH (2014) In-vivo RGB marking and multicolour single-cell tracking in the adult brain. Sci Rep 4:7520. 10.1038/srep07520</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07520</ArticleId><ArticleId IdType="pmc">PMC4273606</ArticleId><ArticleId IdType="pubmed">25531807</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276:529&#x2013;534. 10.1074/jbc.M006531200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M006531200</ArticleId><ArticleId IdType="pubmed">11013246</ArticleId></ArticleIdList></Reference><Reference><Citation>Govindpani K, Calvo-Flores Guzm&#xe1;n B, Vinnakota C, Waldvogel HJ, Faull RL, Kwakowsky A (2017) Towards a better understanding of GABAergic remodeling in Alzheimer's disease. Int J Mol Sci 18:E1813. 10.3390/ijms18081813</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18081813</ArticleId><ArticleId IdType="pmc">PMC5578199</ArticleId><ArticleId IdType="pubmed">28825683</ArticleId></ArticleIdList></Reference><Reference><Citation>International Society for Biological and Environmental Repositories (2012) 2012 best practices for repositories collection, storage, retrieval, and distribution of biological materials for research international society for biological and environmental repositories. Biopreserv Biobank 10:79&#x2013;161. 10.1089/bio.2012.1022</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/bio.2012.1022</ArticleId><ArticleId IdType="pubmed">24844904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, G&#xf6;tz J (2011) Amyloid-beta and tau&#x2013;a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12:65&#x2013;72. 10.1038/nrn2967</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2967</ArticleId><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142:387&#x2013;397. 10.1016/j.cell.2010.06.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Rockwood JM, Berenfeld B, Hutton M, Davies P (1999) Altered conformation of recombinant frontotemporal dementia-17 mutant tau proteins. Neurosci Lett 260:153&#x2013;156. 10.1016/S0304-3940(98)00980-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(98)00980-X</ArticleId><ArticleId IdType="pubmed">10076890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsch W, Lin CW, Lois C (2008) Sequential development of synapses in dendritic domains during adult neurogenesis. Proc Natl Acad Sci U S A 105:16803&#x2013;16808. 10.1073/pnas.0807970105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807970105</ArticleId><ArticleId IdType="pmc">PMC2567906</ArticleId><ArticleId IdType="pubmed">18922783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsch W, Sim S, Lois C (2010) Watching synaptogenesis in the adult brain. Annu Rev Neurosci 33:131&#x2013;149. 10.1146/annurev-neuro-060909-153252</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-060909-153252</ArticleId><ArticleId IdType="pubmed">20572770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kuhn HG, Gage FH (1997) More hippocampal neurons in adult mice living in an enriched environment. Nature 386:493&#x2013;495. 10.1038/386493a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/386493a0</ArticleId><ArticleId IdType="pubmed">9087407</ArticleId></ArticleIdList></Reference><Reference><Citation>Komuro Y, Xu G, Bhaskar K, Lamb BT (2015) Human tau expression reduces adult neurogenesis in a mouse model of tauopathy. Neurobiol Aging 36:2034&#x2013;2042. 10.1016/j.neurobiolaging.2015.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.03.002</ArticleId><ArticleId IdType="pmc">PMC4724414</ArticleId><ArticleId IdType="pubmed">25863528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozorovitskiy Y, Gould E (2004) Dominance hierarchy influences adult neurogenesis in the dentate gyrus. J Neurosci 24:6755&#x2013;6759. 10.1523/JNEUROSCI.0345-04.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0345-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729707</ArticleId><ArticleId IdType="pubmed">15282279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Cooper-Kuhn CM, Boekhoorn K, Lucassen PJ (2007) Changes in neurogenesis in dementia and alzheimer mouse models: are they functionally relevant? Eur Arch Psychiatry Clin Neurosci 257:281&#x2013;289. 10.1007/s00406-007-0732-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-007-0732-4</ArticleId><ArticleId IdType="pubmed">17639447</ArticleId></ArticleIdList></Reference><Reference><Citation>Laakso MP, Frisoni GB, K&#xf6;n&#xf6;nen M, Mikkonen M, Beltramello A, Geroldi C, Bianchetti A, Trabucchi M, Soininen H, Aronen HJ (2000) Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: a morphometric MRI study. Biol Psychiatry 47:1056&#x2013;1063. 10.1016/S0006-3223(99)00306-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3223(99)00306-6</ArticleId><ArticleId IdType="pubmed">10862805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Marr RA (2010) Neurogenesis and Alzheimer's disease: at the crossroads. Exp Neurol 223:267&#x2013;281. 10.1016/j.expneurol.2009.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.08.009</ArticleId><ArticleId IdType="pmc">PMC2864344</ArticleId><ArticleId IdType="pubmed">19699201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Marr RA (2013) Of mice and men: neurogenesis, cognition and Alzheimer's disease. Front Aging Neurosci 5:43. 10.3389/fnagi.2013.00043</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2013.00043</ArticleId><ArticleId IdType="pmc">PMC3753540</ArticleId><ArticleId IdType="pubmed">23986699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402&#x2013;405. 10.1038/78078</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Lv J, Wang J, Wan P, Li Y, Jiang H, Jin Q (2016) GABAB receptors in the hippocampal dentate gyrus are involved in spatial learning and memory impairment in a rat model of vascular dementia. Brain Res Bull 124:190&#x2013;197. 10.1016/j.brainresbull.2016.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.05.006</ArticleId><ArticleId IdType="pubmed">27181927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim F, Hern&#xe1;ndez F, Lucas JJ, G&#xf3;mez-Ramos P, Mor&#xe1;n MA, Avila J (2001) FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain. Mol Cell Neurosci 18:702&#x2013;714. 10.1006/mcne.2001.1051</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.2001.1051</ArticleId><ArticleId IdType="pubmed">11749044</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Mart&#xed;n M, Torres-Aleman I, Trejo JL (2006) Pronounced individual variation in the response to the stimulatory action of exercise on immature hippocampal neurons. Hippocampus 16:480&#x2013;490. 10.1002/hipo.20175</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20175</ArticleId><ArticleId IdType="pubmed">16596582</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Mart&#xed;n M, Torres-Alem&#xe1;n I, Trejo JL (2009) Mechanisms mediating brain plasticity: IGF1 and adult hippocampal neurogenesis. Neuroscientist 15:134&#x2013;148. 10.1177/1073858408331371</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858408331371</ArticleId><ArticleId IdType="pubmed">19307421</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Mart&#xed;n M, Tejeda GS, Trejo JL (2010) Differential regulation of the variations induced by environmental richness in adult neurogenesis as a function of time: a dual birthdating analysis. PLoS One 5:e12188. 10.1371/journal.pone.0012188</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012188</ArticleId><ArticleId IdType="pmc">PMC2922333</ArticleId><ArticleId IdType="pubmed">20808440</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Mart&#xed;n M, Hern&#xe1;ndez F, Avila J (2011) Expression of frontotemporal dementia with parkinsonism associated to chromosome 17 tau induces specific degeneration of the ventral dentate gyrus and depressive-like behavior in mice. Neuroscience 196:215&#x2013;227. 10.1016/j.neuroscience.2011.08.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.08.057</ArticleId><ArticleId IdType="pubmed">21907761</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Mart&#xed;n M, Fuster-Matanzo A, Teixeira CM, Jurado-Arjona J, Ulloa F, Defelipe J, R&#xe1;bano A, Hern&#xe1;ndez F, Soriano E, Avila J (2013) GSK-3beta overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Molecular Psychiatry 18:451&#x2013;460. 10.1038/mp.2013.4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.4</ArticleId><ArticleId IdType="pubmed">23399915</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Mart&#xed;n M, Jurado-Arjona J, Avila J, Hern&#xe1;ndez F (2015) Novel connection between newborn granule neurons and the hippocampal CA2 field. Exp Neurol 263:285&#x2013;292. 10.1016/j.expneurol.2014.10.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.10.021</ArticleId><ArticleId IdType="pubmed">25446721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugert S, Basak O, Knuckles P, Haussler U, Fabel K, G&#xf6;tz M, Haas CA, Kempermann G, Taylor V, Giachino C (2010) Quiescent and active hippocampal neural stem cells with distinct morphologies respond selectively to physiological and pathological stimuli and aging. Cell Stem Cell 6:445&#x2013;456. 10.1016/j.stem.2010.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2010.03.017</ArticleId><ArticleId IdType="pubmed">20452319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai JM, Paxinos G (2015) Atlas of the human brain, Ed 3 San Diego: Academic.</Citation></Reference><Reference><Citation>Mart&#xed;nez-Mart&#xed;n P, Avila J (2010) Alzheimer center reina sofia foundation: fighting the disease and providing overall solutions. J Alzheimers Dis 21:337&#x2013;348. 10.3233/JAD-2010-101149</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-101149</ArticleId><ArticleId IdType="pubmed">20693620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC (2013) Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiol Aging 34:2341&#x2013;2351. 10.1016/j.neurobiolaging.2013.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.04.010</ArticleId><ArticleId IdType="pubmed">23643146</ArticleId></ArticleIdList></Reference><Reference><Citation>Montejo de Garcini E, de la Luna S, Dominguez JE, Avila J (1994) Overexpression of tau protein in COS-1 cells results in the stabilization of centrosome-independent microtubules and extension of cytoplasmic processes. Mol Cell Biochem 130:187&#x2013;196. 10.1007/BF01457399</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01457399</ArticleId><ArticleId IdType="pubmed">8028597</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jim&#xe9;nez EP, Flor-Garc&#xed;a M, Terreros-Roncal J, R&#xe1;bano A, Cafini F, Pallas-Bazarra N, &#xc1;vila J, Llorens-Mart&#xed;n M (2019) Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease. Nat Med 25:554&#x2013;560. 10.1038/s41591-019-0375-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0375-9</ArticleId><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mountjoy CQ, Rossor MN, Iversen LL, Roth M (1984) Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain 107:507&#x2013;518. 10.1093/brain/107.2.507</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/107.2.507</ArticleId><ArticleId IdType="pubmed">6722514</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsen LH, Rae C, Ittner LM, G&#xf6;tz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation. J Cereb Blood Flow Metab 33:684&#x2013;691. 10.1038/jcbfm.2012.212</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2012.212</ArticleId><ArticleId IdType="pmc">PMC3652703</ArticleId><ArticleId IdType="pubmed">23340677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A, Ikemoto K, Satoh K, Yamamoto Y, Rand S, Brinkmann B, Nishi K (2000) The carbohydrate deposits detected by histochemical methods in the molecular layer of the dentate gyrus in the hippocampal formation of patients with schizophrenia, Down's syndrome and dementia, and aged person. Glycoconj J 17:815&#x2013;822. 10.1023/A:1010996911581</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1010996911581</ArticleId><ArticleId IdType="pubmed">11443283</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliva R. (2000) Genetics of frontotemporal dementia and alterations of the tau gene. Neurologia 15:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">10723173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallas-Bazarra N, Jurado-Arjona J, Navarrete M, Esteban JA, Hern&#xe1;ndez F, &#xc1;vila J, Llorens-Mart&#xed;n M (2016) Novel function of tau in regulating the effects of external stimuli on adult hippocampal neurogenesis. EMBO J 35:1417&#x2013;1436. 10.15252/embj.201593518</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201593518</ArticleId><ArticleId IdType="pmc">PMC4876034</ArticleId><ArticleId IdType="pubmed">27198172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallas-Bazarra N, Kastanauskaite A, Avila J, DeFelipe J, Llorens-Mart&#xed;n M (2017) GSK-3beta overexpression alters the dendritic spines of developmentally generated granule neurons in the mouse hippocampal dentate gyrus. Front Neuroanat 11:18. 10.3389/fnana.2017.00018</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2017.00018</ArticleId><ArticleId IdType="pmc">PMC5344922</ArticleId><ArticleId IdType="pubmed">28344548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL (2008) Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images. PLoS One 3:e1997. 10.1371/journal.pone.0001997</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001997</ArticleId><ArticleId IdType="pmc">PMC2292261</ArticleId><ArticleId IdType="pubmed">18431482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC. (2016) Tau toxicity feeds forward in frontotemporal dementia. Nat Med 22:24&#x2013;25. 10.1038/nm.4029</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4029</ArticleId><ArticleId IdType="pubmed">26735407</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah N, Peterson BD, Lubejko ST, Vivar C, van Praag H (2017) Running reorganizes the circuitry of one-week-old adult-born hippocampal neurons. Sci Rep 7:10903. 10.1038/s41598-017-11268-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-11268-z</ArticleId><ArticleId IdType="pmc">PMC5589841</ArticleId><ArticleId IdType="pubmed">28883658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay A, Hen R (2007) Adult hippocampal neurogenesis in depression. Nat Neurosci 10:1110&#x2013;1115. 10.1038/nn1969</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1969</ArticleId><ArticleId IdType="pubmed">17726477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay A, Scobie KN, Hill AS, O'Carroll CM, Kheirbek MA, Burghardt NS, Fenton AA, Dranovsky A, Hen R (2011) Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature 472:466&#x2013;470. 10.1038/nature09817</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09817</ArticleId><ArticleId IdType="pmc">PMC3084370</ArticleId><ArticleId IdType="pubmed">21460835</ArticleId></ArticleIdList></Reference><Reference><Citation>Schambach A, Mueller D, Galla M, Verstegen MM, Wagemaker G, Loew R, Baum C, Bohne J (2006) Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 13:1524&#x2013;1533. 10.1038/sj.gt.3302807</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3302807</ArticleId><ArticleId IdType="pubmed">16763662</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Belarbi K, Bretteville A, Ando K, Bu&#xe9;e L (2008) Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation. Genes Brain Behav 7:92&#x2013;100. 10.1111/j.1601-183X.2007.00377.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1601-183X.2007.00377.x</ArticleId><ArticleId IdType="pmc">PMC2239302</ArticleId><ArticleId IdType="pubmed">18184373</ArticleId></ArticleIdList></Reference><Reference><Citation>Senut MC, Roudier M, Davous P, Fallet-Bianco C, Lamour Y (1991) Senile dementia of the alzheimer type: is there a correlation between entorhinal cortex and dentate gyrus lesions? Acta Neuropathol 82:306&#x2013;315. 10.1007/BF00308817</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308817</ArticleId><ArticleId IdType="pubmed">1759562</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiarli AM, Jennings R, Shi J, Bailey K, Davidson Y, Tian J, Bigio EH, Ghetti B, Murrell JR, Delisle MB, Mirra S, Crain B, Zolo P, Arima K, Iseki E, Murayama S, Kretzschmar H, Neumann M, Lippa C, Halliday G, et al. (2006) Comparison of extent of tau pathology in patients with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with pick bodies and early onset Alzheimer's disease. Neuropathol Appl Neurobiol 32:374&#x2013;387. 10.1111/j.1365-2990.2006.00736.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2006.00736.x</ArticleId><ArticleId IdType="pubmed">16866983</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, Possnert G, Mash DC, Druid H, Fris&#xe9;n J (2013) Dynamics of hippocampal neurogenesis in adult humans. Cell 153:1219&#x2013;1227. 10.1016/j.cell.2013.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.002</ArticleId><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M (2000) Tau mutations in familial frontotemporal dementia. Brain 123:857&#x2013;859. 10.1093/brain/123.5.857</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.5.857</ArticleId><ArticleId IdType="pubmed">10775532</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M (2001) Tau gene mutations and tau pathology in frontotemporal dementia and parkinsonism linked to chromosome 17. Adv Exp Med Biol 487:21&#x2013;37. 10.1007/978-1-4615-1249-3_3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4615-1249-3_3</ArticleId><ArticleId IdType="pubmed">11403160</ArticleId></ArticleIdList></Reference><Reference><Citation>Temprana SG, Mongiat LA, Yang SM, Trinchero MF, Alvarez DD, Kropff E, Giacomini D, Beltramone N, Lanuza GM, Schinder AF (2015) Delayed coupling to feedback inhibition during a critical period for the integration of adult-born granule cells. Neuron 85:116&#x2013;130. 10.1016/j.neuron.2014.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.11.023</ArticleId><ArticleId IdType="pmc">PMC4329739</ArticleId><ArticleId IdType="pubmed">25533485</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni N, Laplagne DA, Zhao C, Lombardi G, Ribak CE, Gage FH, Schinder AF (2008) Neurons born in the adult dentate gyrus form functional synapses with target cells. Nat Neurosci 11:901&#x2013;907. 10.1038/nn.2156</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2156</ArticleId><ArticleId IdType="pmc">PMC2572641</ArticleId><ArticleId IdType="pubmed">18622400</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H. (2008) Neurogenesis and exercise: past and future directions. Neuromolecular Med 10:128&#x2013;140. 10.1007/s12017-008-8028-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-008-8028-z</ArticleId><ArticleId IdType="pubmed">18286389</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H. (2009) Exercise and the brain: something to chew on. Trends Neurosci 32:283&#x2013;290. 10.1016/j.tins.2008.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2008.12.007</ArticleId><ArticleId IdType="pmc">PMC2680508</ArticleId><ArticleId IdType="pubmed">19349082</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Kempermann G, Gage FH (2000) Neural consequences of environmental enrichment. Nat Rev Neurosci 1:191&#x2013;198. 10.1038/35044558</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35044558</ArticleId><ArticleId IdType="pubmed">11257907</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH (2002) Functional neurogenesis in the adult hippocampus. Nature 415:1030&#x2013;1034. 10.1038/4151030a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4151030a</ArticleId><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivar C, Potter MC, Choi J, Lee JY, Stringer TP, Callaway EM, Gage FH, Suh H, van Praag H (2012) Monosynaptic inputs to new neurons in the dentate gyrus. Nat Commun 3:1107. 10.1038/ncomms2101</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2101</ArticleId><ArticleId IdType="pmc">PMC4603575</ArticleId><ArticleId IdType="pubmed">23033083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickersham IR, Finke S, Conzelmann KK, Callaway EM (2007a) Retrograde neuronal tracing with a deletion-mutant rabies virus. Nat Methods 4:47&#x2013;49. 10.1038/nmeth999</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth999</ArticleId><ArticleId IdType="pmc">PMC2755236</ArticleId><ArticleId IdType="pubmed">17179932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickersham IR, Lyon DC, Barnard RJ, Mori T, Finke S, Conzelmann KK, Young JA, Callaway EM (2007b) Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron 53:639&#x2013;647. 10.1016/j.neuron.2007.01.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.033</ArticleId><ArticleId IdType="pmc">PMC2629495</ArticleId><ArticleId IdType="pubmed">17329205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Guo Z, Gearing M, Chen G (2014) Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model. Nat Commun 5:4159. 10.1038/ncomms5159</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5159</ArticleId><ArticleId IdType="pmc">PMC4159602</ArticleId><ArticleId IdType="pubmed">24923909</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337&#x2013;351. 10.1016/j.neuron.2007.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Teng EM, Summers RG Jr, Ming GL, Gage FH (2006) Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci 26:3&#x2013;11. 10.1523/JNEUROSCI.3648-05.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3648-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674324</ArticleId><ArticleId IdType="pubmed">16399667</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31122495</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.</ArticleTitle><Pagination><StartPage>549</StartPage><EndPage>558</EndPage><MedlinePgn>549-558</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(19)30139-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(19)30139-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Progressive supranuclear palsy is a rare neurodegenerative disease associated with dysfunctional tau protein. BIIB092 is a humanised monoclonal antibody that binds to N-terminal tau and is thus being assessed as a potential novel treatment for progressive supranuclear palsy. We aimed to investigate the safety and tolerability of BIIB092 in individuals with progressive supranuclear palsy.</AbstractText><AbstractText Label="METHODS">This 12-week, double-blind, randomised, placebo-controlled, multiple ascending dose, phase 1b trial was done at 13 outpatient sites in the USA. Participants aged 41-86 years with probable or possible progressive supranuclear palsy with a score of 20 or greater on the Mini-Mental State Examination (MMSE) were enrolled. Three BIIB092 dose escalation cohorts (150 mg, 700 mg, or 2100 mg; eight participants per cohort) were tested sequentially. For each dose cohort, the first two participants were randomly assigned by a computer-generated scheme to receive either BIIB092 or placebo intravenously every 4 weeks for 57 days. After 2 days, the six remaining participants in each cohort were randomly assigned (5:1) to receive BIIB092 or placebo for 57 days. An additional expansion panel of 24 patients was randomly assigned (3:1) to receive 2100 mg or placebo every 4 weeks for 57 days. All participants were followed up to day 85. The primary outcome was safety, which was analysed in the treated population (all enrolled participants who received at least one dose of the study drug). This trial is registered with ClinicalTrials.gov, NCT02460094.</AbstractText><AbstractText Label="FINDINGS">Between Oct 2, 2015, and Oct 19, 2016, 48 participants were enrolled and randomly assigned to the BIIB092 (n=36) and placebo (n=12) groups. No apparent demographic differences were observed between the two groups at baseline. All 48 participants completed the treatment phase of the study. Adverse events were generally mild to moderate in severity; the most common in the placebo and BIIB092 groups were falls (in two [17%] of 12 patients and in ten [28%] of 36 patients), urinary tract infections (in one [8%] of 12 and in six [17%] of 36), contusions (in one [8%] of 12 and in five [14%] of 36), and headaches (in none and in five [14%] of 36). Four serious adverse events resulting in admission to hospital were reported in three participants who received BIIB092 2100 mg: two severe adverse events of urinary tract infection, one severe adverse event of change in mental status, and one moderate adverse event of aspiration pneumonia. None was considered to be related to the study drug, all were resolved, and no deaths were reported.</AbstractText><AbstractText Label="INTERPRETATION">Repeated administration of the anti-tau monoclonal antibody BIIB092, at doses of up to 2100 mg, appears to be well tolerated in participants with progressive supranuclear palsy. Results of this phase 1b trial have informed the design of the ongoing phase 2 PASSPORT (NCT03068468) study to examine the efficacy and safety of BIIB092.</AbstractText><AbstractText Label="FUNDING">Bristol-Myers Squibb, Biogen.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Irfan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahlijanian</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global R&amp;D Partners, LLC, San Diego, CA, USA; University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golbe</LastName><ForeName>Lawrence I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuite</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McFarland</LastName><ForeName>Nikolaus R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Suilleabhain</LastName><ForeName>Padraig</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirucherai</LastName><ForeName>Giridhar S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bechtold</LastName><ForeName>Clifford</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordelon</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacson</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Boca Raton Institute for Neurodegenerative Disorders, Boca Raton, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zesiewicz</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muralidharan</LastName><ForeName>Kumar Kandadi</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Danielle L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Gorman</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haeberlein</LastName><ForeName>Samantha Budd</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dam</LastName><ForeName>Tien</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA. Electronic address: tien.dam@biogen.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02460094</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>09FZ7Q0PQZ</RegistryNumber><NameOfSubstance UI="C000707052">gosuranemab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2019 Jun;18(6):517-518. doi: 10.1016/S1474-4422(19)30161-9.</RefSource><PMID Version="1">31122487</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31122495</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(19)30139-5</ArticleId><ArticleId IdType="pii">S1474-4422(19)30139-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31150388</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7404</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>PLoS genetics</Title><ISOAbbreviation>PLoS Genet</ISOAbbreviation></Journal><ArticleTitle>Enhancing face validity of mouse models of Alzheimer's disease with natural genetic variation.</ArticleTitle><Pagination><StartPage>e1008155</StartPage><MedlinePgn>e1008155</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1008155</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgen.1008155</ELocationID><Abstract><AbstractText>Classical laboratory strains show limited genetic diversity and do not harness natural genetic variation. Mouse models relevant to Alzheimer's disease (AD) have largely been developed using these classical laboratory strains, such as C57BL/6J (B6), and this has likely contributed to the failure of translation of findings from mice to the clinic. Therefore, here we test the potential for natural genetic variation to enhance the translatability of AD mouse models. Two widely used AD-relevant transgenes, APPswe and PS1de9 (APP/PS1), were backcrossed from B6 to three wild-derived strains CAST/EiJ, WSB/EiJ, PWK/PhJ, representative of three Mus musculus subspecies. These new AD strains were characterized using metabolic, functional, neuropathological and transcriptional assays. Strain-, sex- and genotype-specific differences were observed in cognitive ability, neurodegeneration, plaque load, cerebrovascular health and cerebral amyloid angiopathy. Analyses of brain transcriptional data showed strain was the greatest driver of variation. We identified significant variation in myeloid cell numbers in wild type mice of different strains as well as significant differences in plaque-associated myeloid responses in APP/PS1 mice between the strains. Collectively, these data support the use of wild-derived strains to better model the complexity of human AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Onos</LastName><ForeName>Kristen D</ForeName><Initials>KD</Initials><Identifier Source="ORCID">0000-0001-6443-6557</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uyar</LastName><ForeName>Asli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keezer</LastName><ForeName>Kelly J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Harriet M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0001-7571-1868</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preuss</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acklin</LastName><ForeName>Casey J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0003-3493-1279</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Rourke</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchanan</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cossette</LastName><ForeName>Travis L</ForeName><Initials>TL</Initials><Identifier Source="ORCID">0000-0003-0398-5047</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sukoff Rizzo</LastName><ForeName>Stacey J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Ileana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Translational Sciences, Rowan University, Glassboro, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Gregory W</ForeName><Initials>GW</Initials><Identifier Source="ORCID">0000-0002-2834-8186</Identifier><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, Maine, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howell</LastName><ForeName>Gareth R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, Maine, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, Maine, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG067923</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055104</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD007065</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AG054345</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Genet</MedlineTA><NlmUniqueID>101239074</NlmUniqueID><ISSNLinking>1553-7390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000835" MajorTopicYN="N">Animals, Wild</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>NO authors have competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31150388</ArticleId><ArticleId IdType="pmc">PMC6576791</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1008155</ArticleId><ArticleId IdType="pii">PGENETICS-D-18-02083</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. Alzheimers Dement. 2017. 10.1016/j.jalz.2017.10.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.10.009</ArticleId><ArticleId IdType="pmc">PMC5803316</ArticleId><ArticleId IdType="pubmed">29233480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan He DG, Paul Kowal. An Aging World In: Bureau USC, editor. International Population Reports: U.S. Government Publishing Office; 2016.</Citation></Reference><Reference><Citation>International AsD. World Alzheimer Report 2018 The state of the art of dementia research: New frontiers. London: 2018.</Citation></Reference><Reference><Citation>Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin Transl Sci. 2018;11(2):147&#x2013;52. 10.1111/cts.12491</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12491</ArticleId><ArticleId IdType="pmc">PMC5866992</ArticleId><ArticleId IdType="pubmed">28767185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253&#x2013;60. Epub 2014/06/15. 10.1212/WNL.0000000000000596</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000596</ArticleId><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64(s1):S161&#x2013;S89. Epub 2018/06/06. 10.3233/JAD-179939 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on family history of Alzheimer's disease. Transl Psychiatry. 2018;8(1):99 10.1038/s41398-018-0150-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-018-0150-6</ArticleId><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, et al. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet. 2003;12(22):2949&#x2013;56. 10.1093/hmg/ddg322 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg322</ArticleId><ArticleId IdType="pubmed">14506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman D, Gao Y, Lamb BT. Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease. Neurobiol Aging. 2008;29(8):1190&#x2013;8. 10.1016/j.neurobiolaging.2007.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.017</ArticleId><ArticleId IdType="pmc">PMC3745768</ArticleId><ArticleId IdType="pubmed">17400334</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson HM, Onos KD, Pepper KW, Graham LC, Akeson EC, Byers C, et al. DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease. PLoS One. 2015;10(5):e0125897 10.1371/journal.pone.0125897</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0125897</ArticleId><ArticleId IdType="pmc">PMC4416920</ArticleId><ArticleId IdType="pubmed">25933409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittig LJ, Carbonetto P, Engel KA, Krauss KS, Barrios-Camacho CM, Palmer AA. Genetic Background Limits Generalizability of Genotype-Phenotype Relationships. Neuron. 2016;91(6):1253&#x2013;9. 10.1016/j.neuron.2016.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.08.013</ArticleId><ArticleId IdType="pmc">PMC5033712</ArticleId><ArticleId IdType="pubmed">27618673</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuner SM, Heuer SE, Huentelman MJ, O'Connell KMS, Kaczorowski CC. Harnessing Genetic Complexity to Enhance Translatability of Alzheimer's Disease Mouse Models: A Path toward Precision Medicine. Neuron. 2019;101(3):399&#x2013;+. 10.1016/j.neuron.2018.11.040 WOS:000457856700014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.11.040</ArticleId><ArticleId IdType="pmc">PMC6886697</ArticleId><ArticleId IdType="pubmed">30595332</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse HC, Cancer Research Institute., National Institute of Allergy and Infectious Diseases (U.S.). Origins of inbred mice: proceedings of a workshop, Bethesda, Maryland, February 14&#x2013;16, 1978. New York: Academic Press; 1978. xvi, 719 p. p.</Citation></Reference><Reference><Citation>Keane TM, Goodstadt L, Danecek P, White MA, Wong K, Yalcin B, et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature. 2011;477(7364):289&#x2013;94. 10.1038/nature10413</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10413</ArticleId><ArticleId IdType="pmc">PMC3276836</ArticleId><ArticleId IdType="pubmed">21921910</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver LM. Mouse genetics: concepts and applications. New York: Oxford University Press; 1995. xiii, 362 p. p.</Citation></Reference><Reference><Citation>Deschepper CF, Olson JL, Otis M, Gallo-Payet N. Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. J Appl Physiol (1985). 2004;97(1):369&#x2013;76. 10.1152/japplphysiol.00073.2004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00073.2004</ArticleId><ArticleId IdType="pubmed">15047670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KT, Karunakaran S, Ho MM, Clee SM. PWD/PhJ and WSB/EiJ mice are resistant to diet-induced obesity but have abnormal insulin secretion. Endocrinology. 2011;152(8):3005&#x2013;17. 10.1210/en.2011-0060 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2011-0060</ArticleId><ArticleId IdType="pubmed">21673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho MM, Hu X, Karunakaran S, Johnson JD, Clee SM. Altered pancreatic growth and insulin secretion in WSB/EiJ mice. PLoS One. 2014;9(2):e88352 10.1371/journal.pone.0088352</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0088352</ArticleId><ArticleId IdType="pmc">PMC3914989</ArticleId><ArticleId IdType="pubmed">24505481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreznar JH, Keller MP, Traeger LL, Rabaglia ME, Schueler KL, Stapleton DS, et al. Host Genotype and Gut Microbiome Modulate Insulin Secretion and Diet-Induced Metabolic Phenotypes. Cell Rep. 2017;18(7):1739&#x2013;50. 10.1016/j.celrep.2017.01.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.01.062</ArticleId><ArticleId IdType="pmc">PMC5325228</ArticleId><ArticleId IdType="pubmed">28199845</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell JH, Foster CM, Vishnivetskaya T, Campbell AG, Yang ZK, Wymore A, et al. Host genetic and environmental effects on mouse intestinal microbiota. ISME J. 2012;6(11):2033&#x2013;44. 10.1038/ismej.2012.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2012.54</ArticleId><ArticleId IdType="pmc">PMC3475380</ArticleId><ArticleId IdType="pubmed">22695862</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P, Striz M, Wisor JP, O'Hara BF. Behavioral and genetic dissection of a mouse model for advanced sleep phase syndrome. Sleep. 2011;34(1):39&#x2013;48. 10.1093/sleep/34.1.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/34.1.39</ArticleId><ArticleId IdType="pmc">PMC3001793</ArticleId><ArticleId IdType="pubmed">21203370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A. 2009;106(48):20324&#x2013;9. 10.1073/pnas.0911281106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911281106</ArticleId><ArticleId IdType="pmc">PMC2787156</ArticleId><ArticleId IdType="pubmed">19910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson HM, Soto I, Graham LC, Carter GW, Howell GR. Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease. BMC Genomics. 2013;14:831 10.1186/1471-2164-14-831</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-14-831</ArticleId><ArticleId IdType="pmc">PMC3907022</ArticleId><ArticleId IdType="pubmed">24274089</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, et al. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron. 2017;96(5):1024&#x2013;+. 10.1016/j.neuron.2017.11.013 WOS:000417336100011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.11.013</ArticleId><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers SP, Born HA, Das P, Jankowsky JL. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener. 2012;7:28 10.1186/1750-1326-7-28</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-28</ArticleId><ArticleId IdType="pmc">PMC3457908</ArticleId><ArticleId IdType="pubmed">22709352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlsten D, Metten P, Crabbe JC. A rating scale for wildness and ease of handling laboratory mice: results of 21 inbred strains tested in two laboratories. Genes Brain and Behavior. 2003;2(2):71&#x2013;9. 10.1034/j.1601-183X.2003.00012.x WOS:000182147800002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1601-183X.2003.00012.x</ArticleId><ArticleId IdType="pubmed">12884964</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip VM, Sokoloff G, Ackert-Bicknell CL, Striz M, Branstetter L, Beckmann MA, et al. Genetic analysis in the Collaborative Cross breeding population. Genome Research. 2011;21(8):1223&#x2013;38. 10.1101/gr.113886.110 WOS:000293335700003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.113886.110</ArticleId><ArticleId IdType="pmc">PMC3149490</ArticleId><ArticleId IdType="pubmed">21734011</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukoff Rizzo SJ, Anderson LC, Green TL, McGarr T, Wells G, Winter SS. Assessing Healthspan and Lifespan Measures in Aging Mice: Optimization of Testing Protocols, Replicability, and Rater Reliability. Curr Protoc Mouse Biol. 2018;8(2):e45 Epub 2018/06/21. 10.1002/cpmo.45 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpmo.45</ArticleId><ArticleId IdType="pubmed">29924918</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto I, Grabowska WA, Onos KD, Graham LC, Jackson HM, Simeone SN, et al. Meox2 haploinsufficiency increases neuronal cell loss in a mouse model of Alzheimer's disease. Neurobiol Aging. 2016;42:50&#x2013;60. 10.1016/j.neurobiolaging.2016.02.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.02.025</ArticleId><ArticleId IdType="pmc">PMC4878023</ArticleId><ArticleId IdType="pubmed">27143421</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham LC, Harder JM, Soto I, de Vries WN, John SWM, Howell GR. Chronic consumption of a western diet induces robust glial activation in aging mice and in a mouse model of Alzheimer's disease. Scientific reports. 2016;6:21568 Medline:26888450. 10.1038/srep21568</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep21568</ArticleId><ArticleId IdType="pmc">PMC4757836</ArticleId><ArticleId IdType="pubmed">26888450</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. The Lancet Neurology. 2016;15(9):934&#x2013;43. Medline:27312738. 10.1016/S1474-4422(16)30029-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30029-1</ArticleId><ArticleId IdType="pmc">PMC4969105</ArticleId><ArticleId IdType="pubmed">27312738</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott TM, Bhadelia RA, Qiu WQ, Folstein MF, Rosenberg IH. Small Vessel Cerebrovascular Pathology Identified by Magnetic Resonance Imaging Is Prevalent in Alzheimer's Disease and Mild Cognitive Impairment: A Potential Target for Intervention. Journal of Alzheimer's disease: JAD. 2018;65(1):293&#x2013;302. Medline:30040728. 10.3233/JAD-180366</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180366</ArticleId><ArticleId IdType="pubmed">30040728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Nicola D, Fransen NL, Suzzi S, Perry VH. Regulation of microglial proliferation during chronic neurodegeneration. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013;33(6):2481&#x2013;93. Medline:23392676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619184</ArticleId><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuger P, Hefendehl JK, Veeraraghavalu K, Wendeln A-C, Schlosser C, Obermuller U, et al. Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging. Nature neuroscience. 2017;20(10):1371&#x2013;6. Medline:28846081. 10.1038/nn.4631</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4631</ArticleId><ArticleId IdType="pubmed">28846081</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, Dumaine A, et al. Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens. Cell. 2016;167(3):657&#x2013;69 e21. 10.1016/j.cell.2016.09.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.09.025</ArticleId><ArticleId IdType="pubmed">27768889</ArticleId></ArticleIdList></Reference><Reference><Citation>As Association. 2017 Alzheimer's disease facts and figures. Alzheimer's &amp; Dementia. 2017;13(4):325&#x2013;73.</Citation></Reference><Reference><Citation>Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease. Neuropsychopharmacology. 2010;35(4):870&#x2013;80. 10.1038/npp.2009.197 WOS:000274424900004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2009.197</ArticleId><ArticleId IdType="pmc">PMC3055373</ArticleId><ArticleId IdType="pubmed">20010553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Kim HD, Maxwell JA, Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett. 2005;390(2):87&#x2013;92. Epub 2005/09/20. 10.1016/j.neulet.2005.08.028 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.08.028</ArticleId><ArticleId IdType="pubmed">16169151</ArticleId></ArticleIdList></Reference><Reference><Citation>Volianskis A, Kostner R, Molgaard M, Hass S, Jensen MS. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1deltaE9-deleted transgenic mice model of ss-amyloidosis. Neurobiol Aging. 2010;31(7):1173&#x2013;87. Epub 2008/09/16. 10.1016/j.neurobiolaging.2008.08.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.08.005</ArticleId><ArticleId IdType="pubmed">18790549</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem. 2004;279(17):17490&#x2013;9. 10.1074/jbc.M311300200 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311300200</ArticleId><ArticleId IdType="pubmed">14752113</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van den Haute C, et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol. 2000;157(4):1283&#x2013;98. 10.1016/S0002-9440(10)64644-5 WOS:000089761200026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64644-5</ArticleId><ArticleId IdType="pmc">PMC1850171</ArticleId><ArticleId IdType="pubmed">11021833</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein Transgenic mice. Journal of Neuroscience. 2003;23(21):7889&#x2013;96. WOS:000185001700021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740607</ArticleId><ArticleId IdType="pubmed">12944519</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, et al. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain. 2007;130:2310&#x2013;9. 10.1093/brain/awm156 WOS:000250039300009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm156</ArticleId><ArticleId IdType="pubmed">17638859</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC, Alzheimer's Disease Neuroimaging I. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun. 2016;7:11934 10.1038/ncomms11934</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11934</ArticleId><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Xiong DD, Holtzman DM. Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease. Exp Mol Med. 2015;47 ARTN e148 10.1038/emm.2014.121 WOS:000358592900005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2014.121</ArticleId><ArticleId IdType="pmc">PMC4351409</ArticleId><ArticleId IdType="pubmed">25766617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruthirakuhan M, Lanctot KL, Di Scipio M, Ahmed M, Herrmann N. Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review. Alzheimer's &amp; dementia: the journal of the Alzheimer's Association; 2018. Medline:29940162.</Citation><ArticleIdList><ArticleId IdType="pubmed">29940162</ArticleId></ArticleIdList></Reference><Reference><Citation>Abolins S, King EC, Lazarou L, Weldon L, Hughes L, Drescher P, et al. The comparative immunology of wild and laboratory mice, Mus musculus domesticus. Nat Commun. 2017;8:14811 10.1038/ncomms14811</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14811</ArticleId><ArticleId IdType="pmc">PMC5418598</ArticleId><ArticleId IdType="pubmed">28466840</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass DS, Riedel-Kruse IH. A Genetically Encoded Toolbox of Orthogonal Adhesins for Bacterial Self-Assembly. Biophys J. 2018;114(3):666a&#x2013;a. WOS:000430563300322.</Citation></Reference><Reference><Citation>Council NR. Mammalian models for research on aging: National Academies; 1981.</Citation></Reference><Reference><Citation>Rivera J, Tessarollo L. Genetic background and the dilemma of translating mouse studies to humans. Immunity. 2008;28(1):1&#x2013;4. 10.1016/j.immuni.2007.12.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.12.008</ArticleId><ArticleId IdType="pubmed">18199409</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RA. Not Your Father's, or Mother's, Rodent: Moving Beyond B6. Neuron. 2016;91(6):1185&#x2013;6. 10.1016/j.neuron.2016.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.009</ArticleId><ArticleId IdType="pmc">PMC5495110</ArticleId><ArticleId IdType="pubmed">27657444</ArticleId></ArticleIdList></Reference><Reference><Citation>Mang GM, Nicod J, Emmenegger Y, Donohue KD, O'Hara BF, Franken P. Evaluation of a piezoelectric system as an alternative to electroencephalogram/ electromyogram recordings in mouse sleep studies. Sleep. 2014;37(8):1383&#x2013;92. 10.5665/sleep.3936</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.3936</ArticleId><ArticleId IdType="pmc">PMC4096208</ArticleId><ArticleId IdType="pubmed">25083019</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaghouby F, Donohue KD, O'Hara BF, Sunderam S. Noninvasive dissection of mouse sleep using a piezoelectric motion sensor. J Neurosci Methods. 2016;259:90&#x2013;100. 10.1016/j.jneumeth.2015.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2015.11.004</ArticleId><ArticleId IdType="pmc">PMC4715949</ArticleId><ArticleId IdType="pubmed">26582569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudchenko PA. An overview of the tasks used to test working memory in rodents. Neurosci Biobehav Rev. 2004;28(7):699&#x2013;709. 10.1016/j.neubiorev.2004.09.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2004.09.002</ArticleId><ArticleId IdType="pubmed">15555679</ArticleId></ArticleIdList></Reference><Reference><Citation>Oades R, Taghzouti K, Simon H, Le Moal M. Dopamine-sensitive alternation and collateral behaviour in a Y-maze: effects of d-amphetamine and haloperidol. Psychopharmacology (Berl). 1985;85(1):123&#x2013;8. Epub 1985/01/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">3920694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114&#x2013;20. Epub 2014/04/04. 10.1093/bioinformatics/btu170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15&#x2013;21. Epub 2012/10/30. 10.1093/bioinformatics/bts635</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi KB, Vincent M.J., Churchill G.A. g2gtools: A Versatile Toolset for Custom Diploid Genome Creation and Coordinate Conversation. 2017. 10.5281/zenodo.292952</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.292952</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323 Epub 2011/08/06. 10.1186/1471-2105-12-323</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-323</ArticleId><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559 Epub 2008/12/31. 10.1186/1471-2105-9-559</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-559</ArticleId><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576&#x2013;89. Epub 2010/06/02. 10.1016/j.molcel.2010.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2010.05.004</ArticleId><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazer KA, Eskin E, Kang HM, Bogue MA, Hinds DA, Beilharz EJ, et al. A sequence-based variation map of 8.27 million SNPs in inbred mouse strains. Nature. 2007;448(7157):1050&#x2013;3. 10.1038/nature06067 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06067</ArticleId><ArticleId IdType="pubmed">17660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade CM, Kulbokas EJ 3rd, Kirby AW, Zody MC, Mullikin JC, Lander ES, et al. The mosaic structure of variation in the laboratory mouse genome. Nature. 2002;420(6915):574&#x2013;8. Epub 2002/12/06. 10.1038/nature01252 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01252</ArticleId><ArticleId IdType="pubmed">12466852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tournissac M, Vandal M, Francois A, Planel E, Calon F. Old age potentiates cold-induced tau phosphorylation: linking thermoregulatory deficit with Alzheimer's disease. Neurobiol Aging. 2017;50:25&#x2013;9. 10.1016/j.neurobiolaging.2016.09.024 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.09.024</ArticleId><ArticleId IdType="pubmed">27838492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology&#x2014;a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115&#x2013;9. 10.1038/nrneurol.2013.269</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.269</ArticleId><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends Neurosci. 2016;39(8):552&#x2013;66. 10.1016/j.tins.2016.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2016.05.002</ArticleId><ArticleId IdType="pmc">PMC4967375</ArticleId><ArticleId IdType="pubmed">27325209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DW, Lee CU, Lim HK. Role of Sleep Disturbance in the Trajectory of Alzheimer's Disease. Clin Psychopharmacol Neurosci. 2017;15(2):89&#x2013;99. 10.9758/cpn.2017.15.2.89</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2017.15.2.89</ArticleId><ArticleId IdType="pmc">PMC5426492</ArticleId><ArticleId IdType="pubmed">28449556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. Sleep. 2013;36(7):1027&#x2013;32. 10.5665/sleep.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.2802</ArticleId><ArticleId IdType="pmc">PMC3669060</ArticleId><ArticleId IdType="pubmed">23814339</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley JN. Unusual behavioral phenotypes of inbred mouse strains. Trends Neurosci. 1996;19(5):181&#x2013;2; discussion 8&#x2013;9. .</Citation><ArticleIdList><ArticleId IdType="pubmed">8723201</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nature Biotechnology. 2011;29(1):24&#x2013;6. 10.1038/nbt.1754 WOS:000286048900013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1754</ArticleId><ArticleId IdType="pmc">PMC3346182</ArticleId><ArticleId IdType="pubmed">21221095</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31157827</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study.</ArticleTitle><Pagination><StartPage>915</StartPage><EndPage>924</EndPage><MedlinePgn>915-924</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.1424</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Positron emission tomography (PET) imaging now allows in vivo visualization of both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-&#x3b2; (A&#x3b2;) plaques and tau neurofibrillary tangles. Observing their progressive accumulation in the brains of clinically normal older adults is critically important to understand the pathophysiologic cascade leading to AD and to inform the choice of outcome measures in prevention trials.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the associations among A&#x3b2;, tau, and cognition, measured during different observation periods for 7 years.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Prospective cohort study conducted between 2010 and 2017 at the Harvard Aging Brain Study, Boston, Massachusetts. The study enrolled 279 clinically normal participants. An additional 90 individuals were approached but declined the study or did not meet the inclusion criteria. In this report, we analyzed data from 60 participants who had multiple A&#x3b2; and tau PET observations available on October 31, 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">A median of 3 Pittsburgh compound B-PET (A&#x3b2;, 2010-2017) and 2 flortaucipir-PET (tau, 2013-2017) images were collected. We used initial PET and slope data, assessing the rates of change in A&#x3b2; and tau, to measure cognitive changes. Cognition was evaluated annually using the Preclinical Alzheimer Cognitive Composite (2010-2017). Annual consensus meetings evaluated progression to mild cognitive impairment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 60 participants, 35 were women (58%) and 25 were men (42%); median age at inclusion was 73 years (range, 65-85 years). Seventeen participants (28%) exhibited an initial high A&#x3b2; burden. An antecedent rise in A&#x3b2; was associated with subsequent changes in tau (1.07 flortaucipir standardized uptake value ratios [SUVr]/PiB-SUVr; 95% CI, 0.13-3.46; P&#x2009;=&#x2009;.02). Tau changes were associated with cognitive changes (-3.28 z scores/SUVR; 95% CI, -6.67 to -0.91; P&#x2009;=&#x2009;.001), covarying baseline A&#x3b2; and tau. Tau changes were greater in the participants who progressed to mild cognitive impairment (n&#x2009;=&#x2009;6) than in those who did not (n&#x2009;=&#x2009;11; 0.05 SUVr per year; 95% CI, 0.03-0.07; P&#x2009;=&#x2009;.001). A serial mediation model demonstrated that the association between initial A&#x3b2; and final cognition, measured 7 years later, was mediated by successive changes in A&#x3b2; and tau.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">We identified sequential changes in normal older adults, from A&#x3b2; to tau to cognition, after which the participants with high A&#x3b2; with greater tau increase met clinical criteria for mild cognitive impairment. These findings highlight the importance of repeated tau-PET observations to track disease progression and the importance of repeated amyloid-PET observations to detect the earliest AD pathologic changes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hanseeuw</LastName><ForeName>Bernard J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betensky</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Heidi I L</ForeName><Initials>HIL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosio</LastName><ForeName>Danielle M Orozco</ForeName><Initials>DMO</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Rachel F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Florey Institute, The University of Melbourne, Victoria, Australia; Melbourne School of Psychological Science, University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>Kathryn V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewachter</LastName><ForeName>Ilse</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Dementia Research Group, BioMedical Research Institute, Hasselt University, Hasselt, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanoiu</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huijbers</LastName><ForeName>Willem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cognitive Science and Artificial Intelligence, Tilburg University, Tilburg, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG051718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Aug;15(8):433. doi: 10.1038/s41582-019-0230-0.</RefSource><PMID Version="1">31217578</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2019 Aug 1;76(8):986. doi: 10.1001/jamaneurol.2019.2144.</RefSource><PMID Version="1">31403691</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Hanseeuw reported grants from the Belgian National Fund for Scientific Research and the Belgian Foundation for Alzheimer Research during the conduct of the study and personal fees from GE Healthcare outside the submitted work. Dr Jacobs reported funding from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant agreement (IF-2015-GF, 706714). Dr Becker reported grants from the National Institutes of Health during the conduct of the study. Dr Quiroz reported grants from the National Institutes of Health and the National Institute on Aging during the conduct of the study. Dr Hedden reported grants from the National Institutes of Health during the conduct of the study. Dr Rentz reported other support from Eli Lilly, Neurotrack, and Biogen outside the submitted work. Dr Sperling reported grants from Janssen during the conduct of the study and personal fees from AC Immune, Biogen, and Roche outside the submitted work. Dr Johnson reported grants from the National Institutes of Health; personal fees from Biogen, Lilly/Avid, Merck, Novartis, Takeda, Roche/Genentech, and Janssen; and grants from Alzheimer&#x2019;s Association and from Alzheimer&#x2019;s Drug Discovery Foundation during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31157827</ArticleId><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.1424</ArticleId><ArticleId IdType="pii">2735107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW Jr, Buckles VD, et al. . Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026-1036. doi:10.1016/j.neurobiolaging.2009.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.04.002</ArticleId><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. doi:10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. . [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452. doi:10.1212/01.wnl.0000228230.26044.a4</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000228230.26044.a4</ArticleId><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119. doi:10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. ; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group . Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367. doi:10.1016/S1474-4422(13)70044-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Fero A, Baker SL, et al. . Measurement of longitudinal &#x3b2;-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56(4):567-574. doi:10.2967/jnumed.114.148981</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.114.148981</ArticleId><ArticleId IdType="pmc">PMC5313473</ArticleId><ArticleId IdType="pubmed">25745095</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Schwarz CG, et al. . Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain. 2018;141(5):1517-1528. doi:10.1093/brain/awy059</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy059</ArticleId><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, La Joie R, Maass A, et al. . Longitudinal tau accumulation and atrophy in aging and Alzheimer&#x2019;s disease. Ann Neurol. 2019;85:229-240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Therneau TM, Wiste HJ, et al. . Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol. 2016;15(1):56-64. doi:10.1016/S1474-4422(15)00323-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00323-3</ArticleId><ArticleId IdType="pmc">PMC4784263</ArticleId><ArticleId IdType="pubmed">26597325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV, Rentz DM, et al. . Early and late change on the preclinical Alzheimer&#x2019;s cognitive composite in clinically normal older individuals with elevated amyloid &#x3b2;. Alzheimers Dement. 2017;13(9):1004-1012. doi:10.1016/j.jalz.2017.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.018</ArticleId><ArticleId IdType="pmc">PMC5573651</ArticleId><ArticleId IdType="pubmed">28253478</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305-2316. doi:10.1001/jama.2017.6669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.6669</ArticleId><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Benzinger TL, Su Y, et al. . Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between &#x3b2;-amyloid and tauopathy. JAMA Neurol. 2016;73(9):1070-1077. doi:10.1001/jamaneurol.2016.2078</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.2078</ArticleId><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="pubmed">27454922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(pt 5):1551-1567. doi:10.1093/brain/aww027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww027</ArticleId><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Schultz AP, et al. . Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81(4):583-596. doi:10.1002/ana.24910</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24910</ArticleId><ArticleId IdType="pmc">PMC5404378</ArticleId><ArticleId IdType="pubmed">28253546</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Lundt ES, Senjem ML, et al. . White matter reference region in PET studies of 11C-Pittsburgh compound b uptake: effects of age and amyloid-&#x3b2; deposition. J Nucl Med. 2018;59(10):1583-1589. doi:10.2967/jnumed.117.204271</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.117.204271</ArticleId><ArticleId IdType="pmc">PMC6167534</ArticleId><ArticleId IdType="pubmed">29674420</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Joshi AD, Sundell KL, et al. . Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimers Dement. 2017;13(10):1117-1124. doi:10.1016/j.jalz.2017.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.02.009</ArticleId><ArticleId IdType="pubmed">28365320</ArticleId></ArticleIdList></Reference><Reference><Citation>Southekal S, Devous MD Sr, Kennedy I, et al. . Flortaucipir F 18 quantitation using a Parametric Estimate of Reference Signal Intensity (PERSI). J Nucl Med. 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191858</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study . Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767. doi:10.1212/WNL.0000000000000431</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000431</ArticleId><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46. doi:10.1097/00001648-199001000-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001648-199001000-00010</ArticleId><ArticleId IdType="pubmed">2081237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacchetti P. Peer review of statistics in medical research: the other problem. BMJ. 2002;324(7348):1271-1273. doi:10.1136/bmj.324.7348.1271</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.324.7348.1271</ArticleId><ArticleId IdType="pmc">PMC1123222</ArticleId><ArticleId IdType="pubmed">12028986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes AF. Beyond baron and kenny: statistical mediation analysis in the new millennium. Commun Monogr. 2009;76(4):408-420. doi:10.1080/03637750903310360</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03637750903310360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Landau S, Aisen PS, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between tau deposition and antecedent amyloid-&#x3b2; accumulation rates in normal and early symptomatic individuals. Brain. 2017;140(5):1499-1512. doi:10.1093/brain/awx046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx046</ArticleId><ArticleId IdType="pubmed">28334939</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci. 2018;38(19):4482-4489. doi:10.1523/JNEUROSCI.0485-18.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0485-18.2018</ArticleId><ArticleId IdType="pmc">PMC5943976</ArticleId><ArticleId IdType="pubmed">29686045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Lee HS, et al. . Progressive tau accumulation in Alzheimer&#x2019;s disease: two-year follow-up study. J Nucl Med. 2019;jnumed.118.221697. doi:10.2967/jnumed.118.221697</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.221697</ArticleId><ArticleId IdType="pmc">PMC6836867</ArticleId><ArticleId IdType="pubmed">30926651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Anti-correlated cerebrospinal fluid biomarker trajectories in preclinical Alzheimer&#x2019;s disease. J Alzheimers Dis. 2016;51(4):1085-1097. doi:10.3233/JAD-150937</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150937</ArticleId><ArticleId IdType="pubmed">26967213</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Jasielec MS, Weng H, et al. . Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology. 2016;86(16):1499-1506. doi:10.1212/WNL.0000000000002593</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002593</ArticleId><ArticleId IdType="pmc">PMC4836885</ArticleId><ArticleId IdType="pubmed">27009258</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz AP, Chhatwal JP, Hedden T, et al. . Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals. J Neurosci. 2017;37(16):4323-4331. doi:10.1523/JNEUROSCI.3263-16.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3263-16.2017</ArticleId><ArticleId IdType="pmc">PMC5413178</ArticleId><ArticleId IdType="pubmed">28314821</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricker NH, Dodge HH, Dowling NM, Han SD, Erosheva EA, Jagust WJ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer&#x2019;s pathological cascade. Brain Imaging Behav. 2012;6(4):599-609. doi:10.1007/s11682-012-9171-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-012-9171-6</ArticleId><ArticleId IdType="pmc">PMC3656503</ArticleId><ArticleId IdType="pubmed">22614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Grothe MJ, Sabuncu M, et al. . Hierarchical organization of tau and amyloid deposits in the cerebral cortex. JAMA Neurol. 2017;74(7):813-820. doi:10.1001/jamaneurol.2017.0263</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0263</ArticleId><ArticleId IdType="pmc">PMC5710537</ArticleId><ArticleId IdType="pubmed">28558094</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Zhu Y, Moghekar A, et al. . Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain. 2018;141(3):877-887. doi:10.1093/brain/awx365</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx365</ArticleId><ArticleId IdType="pmc">PMC5837651</ArticleId><ArticleId IdType="pubmed">29365053</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LR, Berman SE, Norton D, et al. . Age-accelerated cognitive decline in asymptomatic adults with CSF &#x3b2;-amyloid. Neurology. 2018;90(15):e1306-e1315. doi:10.1212/WNL.0000000000005291</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005291</ArticleId><ArticleId IdType="pmc">PMC5894934</ArticleId><ArticleId IdType="pubmed">29523644</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Horng A, Jagust WJ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018;90(17):e1452-e1460. doi:10.1212/WNL.0000000000005354</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005354</ArticleId><ArticleId IdType="pmc">PMC5921038</ArticleId><ArticleId IdType="pubmed">29572282</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, et al. . Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer&#x2019;s disease spectrum. Brain. 2015;138(pt 5):1370-1381. doi:10.1093/brain/awv050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv050</ArticleId><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokouhi S, Campbell D, Brill AB, Gwirtsman HE; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Longitudinal positron emission tomography in preventive Alzheimer&#x2019;s disease drug trials, critical barriers from imaging science perspective. Brain Pathol. 2016;26(5):664-671. doi:10.1111/bpa.12399</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12399</ArticleId><ArticleId IdType="pmc">PMC5958602</ArticleId><ArticleId IdType="pubmed">27327527</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer&#x2019;s disease. Brain. 2015;138(pt 10):2814-2833. doi:10.1093/brain/awv236</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv236</ArticleId><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31160442</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>116</Volume><Issue>25</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Specific factors in blood from young but not old mice directly promote synapse formation and NMDA-receptor recruitment.</ArticleTitle><Pagination><StartPage>12524</StartPage><EndPage>12533</EndPage><MedlinePgn>12524-12533</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1902672116</ELocationID><Abstract><AbstractText>Aging drives a progressive decline in cognition and decreases synapse numbers and synaptic function in the brain, thereby increasing the risk for neurodegenerative disease. Pioneering studies showed that introduction of blood from young mice into aged mice reversed age-associated cognitive impairments and increased synaptic connectivity in brain, suggesting that young blood contains specific factors that remediate age-associated decreases in brain function. However, whether such factors in blood from young animals act directly on neurons to enhance synaptic connectivity, or whether they act by an indirect mechanism remains unknown. Moreover, which factors in young blood mediate cognitive improvements in old mice is incompletely understood. Here, we show that serum extracted from the blood of young but not old mice, when applied to neurons transdifferentiated from human embryonic stem cells, directly increased dendritic arborization, augmented synapse numbers, doubled dendritic spine-like structures, and elevated synaptic <i>N</i>-methyl-d-aspartate (NMDA) receptors, thereby increasing synaptic connectivity. Mass spectrometry revealed that thrombospondin-4 (THBS4) and SPARC-like protein 1 (SPARCL1) were enriched in serum from young mice. Strikingly, recombinant THBS4 and SPARCL1 both increased dendritic arborization and doubled synapse numbers in cultured neurons. In addition, SPARCL1 but not THBS4 tripled NMDA receptor-mediated synaptic responses. Thus, at least two proteins enriched in young blood, THBS4 and SPARCL1, directly act on neurons as synaptogenic factors. These proteins may represent rejuvenation factors that enhance synaptic connectivity by increasing dendritic arborization, synapse formation, and synaptic transmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Kathlyn J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305; tcs1@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH092931</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH052804</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MFE-141209</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C503127">Sparcl1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019699">Thrombospondins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101864">thrombospondin 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016326" MajorTopicYN="N">Extracellular Matrix Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019699" MajorTopicYN="N">Thrombospondins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NMDA receptors</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">synapse</Keyword><Keyword MajorTopicYN="N">synaptic transmission</Keyword><Keyword MajorTopicYN="N">synaptogenesis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31160442</ArticleId><ArticleId IdType="pmc">PMC6589664</ArticleId><ArticleId IdType="doi">10.1073/pnas.1902672116</ArticleId><ArticleId IdType="pii">1902672116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brody H., Organization of the cerebral cortex. III. A study of aging in the human cerebral cortex. J. Comp. Neurol. 102, 511&#x2013;516 (1955).</Citation><ArticleIdList><ArticleId IdType="pubmed">14381544</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke S. N., Barnes C. A., Neural plasticity in the ageing brain. Nat. Rev. Neurosci. 7, 30&#x2013;40 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16371948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein D. L., et al. , Changes in the structural complexity of the aged brain. Aging Cell 6, 275&#x2013;284 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441530</ArticleId><ArticleId IdType="pubmed">17465981</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada A., et al. , Apical vulnerability to dendritic retraction in prefrontal neurones of ageing SAMP10 mouse: A model of cerebral degeneration. Neuropathol. Appl. Neurobiol. 32, 1&#x2013;14 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16409548</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A., Sethares C., Moss M. B., The effects of aging on layer 1 in area 46 of prefrontal cortex in the rhesus monkey. Cereb. Cortex 8, 671&#x2013;684 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9863695</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A., Sethares C., Luebke J. I., Synapses are lost during aging in the primate prefrontal cortex. Neuroscience 152, 970&#x2013;981 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441531</ArticleId><ArticleId IdType="pubmed">18329176</ArticleId></ArticleIdList></Reference><Reference><Citation>de Brabander J. M., Kramers R. J., Uylings H. B., Layer-specific dendritic regression of pyramidal cells with ageing in the human prefrontal cortex. Eur. J. Neurosci. 10, 1261&#x2013;1269 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9749780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S., Akiguchi I., Kameyama M., Mizuno N., Age-related changes of pyramidal cell basal dendrites in layers III and V of human motor cortex: A quantitative Golgi study. Acta Neuropathol. 65, 281&#x2013;284 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3976364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs B., Driscoll L., Schall M., Life-span dendritic and spine changes in areas 10 and 18 of human cortex: A quantitative Golgi study. J. Comp. Neurol. 386, 661&#x2013;680 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9378859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs B., et al. , Regional dendritic and spine variation in human cerebral cortex: A quantitative golgi study. Cereb. Cortex 11, 558&#x2013;571 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11375917</ArticleId></ArticleIdList></Reference><Reference><Citation>Luebke J. I., Chang Y. M., Moore T. L., Rosene D. L., Normal aging results in decreased synaptic excitation and increased synaptic inhibition of layer 2/3 pyramidal cells in the monkey prefrontal cortex. Neuroscience 125, 277&#x2013;288 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15051166</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaley A. H., Siegel S. J., Kordower J. H., Mufson E. J., Morrison J. H., Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys. Proc. Natl. Acad. Sci. U.S.A. 93, 3121&#x2013;3125 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39772</ArticleId><ArticleId IdType="pubmed">8610179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof P. R., et al. , Age-related changes in GluR2 and NMDAR1 glutamate receptor subunit protein immunoreactivity in corticocortically projecting neurons in macaque and patas monkeys. Brain Res. 928, 175&#x2013;186 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11844485</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X., Wheatley E. G., Villeda S. A., Mechanisms of hippocampal aging and the potential for rejuvenation. Annu. Rev. Neurosci. 40, 251&#x2013;272 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28441118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S., Izzy S., Sen P., Morsett L., El Khoury J., Microglia in neurodegeneration. Nat. Neurosci. 21, 1359&#x2013;1369 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Labzin L. I., Heneka M. T., Latz E., Innate immunity and neurodegeneration. Annu. Rev. Med. 69, 437&#x2013;449 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29106805</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M. P., Magnus T., Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7, 278&#x2013;294 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Drapeau E., et al. , Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proc. Natl. Acad. Sci. U.S.A. 100, 14385&#x2013;14390 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283601</ArticleId><ArticleId IdType="pubmed">14614143</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H., Shubert T., Zhao C., Gage F. H., Exercise enhances learning and hippocampal neurogenesis in aged mice. J. Neurosci. 25, 8680&#x2013;8685 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith L. K., White C. W. 3rd, Villeda S. A., The systemic environment: At the interface of aging and adult neurogenesis. Cell Tissue Res. 371, 105&#x2013;113 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748432</ArticleId><ArticleId IdType="pubmed">29124393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T., Ageing, neurodegeneration and brain rejuvenation. Nature 539, 180&#x2013;186 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5172605</ArticleId><ArticleId IdType="pubmed">27830812</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda S. A., et al. , The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90&#x2013;94 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda S. A., et al. , Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 20, 659&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsimpardi L., et al. , Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 344, 630&#x2013;634 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123747</ArticleId><ArticleId IdType="pubmed">24797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha M., et al. , Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 344, 649&#x2013;652 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104429</ArticleId><ArticleId IdType="pubmed">24797481</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano J. M., et al. , Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature 544, 488&#x2013;492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586222</ArticleId><ArticleId IdType="pubmed">28424512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., et al. , Hypothalamic programming of systemic ageing involving IKK-&#x3b2;, NF-&#x3ba;B and GnRH. Nature 497, 211&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756938</ArticleId><ArticleId IdType="pubmed">23636330</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker R. G., et al. , Biochemistry and biology of GDF11 and myostatin: Similarities, differences, and questions for future investigation. Circ. Res. 118, 1125&#x2013;1141; discussion 1142 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818972</ArticleId><ArticleId IdType="pubmed">27034275</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer M. J., et al. , Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab. 23, 1207&#x2013;1215 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913514</ArticleId><ArticleId IdType="pubmed">27304512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., et al. , Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785&#x2013;798 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy-Ullrich J. E., Sage E. H., Revisiting the matricellular concept. Matrix Biol. 37, 1&#x2013;14 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4379989</ArticleId><ArticleId IdType="pubmed">25064829</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y. A., Zhou B., Wernig M., S&#xfc;dhof T. C., ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A&#x3b2; secretion. Cell 168, 427&#x2013;441.e21 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber S., Caroni P., Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth. J. Cell Biol. 131, 1083&#x2013;1094 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200004</ArticleId><ArticleId IdType="pubmed">7490284</ArticleId></ArticleIdList></Reference><Reference><Citation>Au E., et al. , SPARC from olfactory ensheathing cells stimulates Schwann cells to promote neurite outgrowth and enhances spinal cord repair. J. Neurosci. 27, 7208&#x2013;7221 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794587</ArticleId><ArticleId IdType="pubmed">17611274</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopherson K. S., et al. , Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120, 421&#x2013;433 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15707899</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle E. T., Zaucke F., Clegg D. O., Thrombospondin-4 and matrix three-dimensionality in axon outgrowth and adhesion in the developing retina. Exp. Eye Res. 84, 707&#x2013;717 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17320079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukdereli H., et al. , Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc. Natl. Acad. Sci. U.S.A. 108, E440&#x2013;E449 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156217</ArticleId><ArticleId IdType="pubmed">21788491</ArticleId></ArticleIdList></Reference><Reference><Citation>Eroglu C., et al. , Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 139, 380&#x2013;392 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791798</ArticleId><ArticleId IdType="pubmed">19818485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lana B., et al. , Thrombospondin-4 reduces binding affinity of [(3)H]-gabapentin to calcium-channel &#x3b1;2&#x3b4;-1-subunit but does not interact with &#x3b1;2&#x3b4;-1 on the cell-surface when co-expressed. Sci. Rep. 6, 24531 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830977</ArticleId><ArticleId IdType="pubmed">27076051</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Xiao N., Xia J., Thrombospondin 1 accelerates synaptogenesis in hippocampal neurons through neuroligin 1. Nat. Neurosci. 13, 22&#x2013;24 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19915562</ArticleId></ArticleIdList></Reference><Reference><Citation>Varoqueaux F., et al. , Neuroligins determine synapse maturation and function. Neuron 51, 741&#x2013;754 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16982420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., et al. , Conditional ablation of neuroligin-1 in CA1 pyramidal neurons blocks LTP by a cell-autonomous NMDA receptor-independent mechanism. Mol. Psychiatry 22, 375&#x2013;383 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5122464</ArticleId><ArticleId IdType="pubmed">27217145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler J., Hynes R. O., An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood 74, 2022&#x2013;2027 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2478219</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner E. J., et al. , Protective astrogenesis from the SVZ niche after injury is controlled by Notch modulator Thbs4. Nature 497, 369&#x2013;373 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667629</ArticleId><ArticleId IdType="pubmed">23615612</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S. K., et al. , Astrocytes assemble thalamocortical synapses by bridging NRX1&#x3b1; and NL1 via hevin. Cell 164, 183&#x2013;196 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715262</ArticleId><ArticleId IdType="pubmed">26771491</ArticleId></ArticleIdList></Reference><Reference><Citation>Elegheert J., et al. , Structural mechanism for modulation of synaptic neuroligin-neurexin signaling by MDGA proteins. Neuron 95, 896&#x2013;913.e10 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563082</ArticleId><ArticleId IdType="pubmed">28817804</ArticleId></ArticleIdList></Reference><Reference><Citation>Missler M., et al. , &#x3b1;-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. Nature 423, 939&#x2013;948 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12827191</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L. Y., Jiang M., Zhang B., Gokce O., S&#xfc;dhof T. C., Conditional deletion of all neurexins defines diversity of essential synaptic organizer functions for neurexins. Neuron 94, 611&#x2013;625.e4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501922</ArticleId><ArticleId IdType="pubmed">28472659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher D. F., Adams J. C., Adhesion-modulating/matricellular ECM protein families: A structural, functional and evolutionary appraisal. Matrix Biol. 31, 155&#x2013;161 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22265890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan M. M., et al. , Matricellular hevin regulates decorin production and collagen assembly. J. Biol. Chem. 281, 27621&#x2013;27632 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16844696</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan M. M., Puolakkainen P. A., Barker T. H., Funk S. E., Sage E. H., Altered tissue repair in hevin-null mice: Inhibition of fibroblast migration by a matricellular SPARC homolog. Wound Repair Regen. 16, 310&#x2013;319 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18318815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer-Ferrer M., Dityatev A., Shaping synapses by the neural extracellular matrix. Front. Neuroanat. 12, 40 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962695</ArticleId><ArticleId IdType="pubmed">29867379</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof T. C., Towards an understanding of synapse formation. Neuron 100, 276&#x2013;293 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226307</ArticleId><ArticleId IdType="pubmed">30359597</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuma P., Hubbard A. L., Transcytosis: Crossing cellular barriers. Physiol. Rev. 83, 871&#x2013;932 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12843411</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X., et al. , LRP-1-mediated intracellular antibody delivery to the Central Nervous System. Sci. Rep. 5, 11990 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507173</ArticleId><ArticleId IdType="pubmed">26189707</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailenko I., et al. , Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J. Biol. Chem. 272, 6784&#x2013;6791 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9045712</ArticleId></ArticleIdList></Reference><Reference><Citation>Patzke C., Acuna C., Giam L. R., Wernig M., S&#xfc;dhof T. C., Conditional deletion of L1CAM in human neurons impairs both axonal and dendritic arborization and action potential generation. J. Exp. Med. 213, 499&#x2013;515 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821644</ArticleId><ArticleId IdType="pubmed">27001749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwinter D. M., Lo K., Mafi P., Silverman M. A., Dynactin regulates bidirectional transport of dense-core vesicles in the axon and dendrites of cultured hippocampal neurons. Neuroscience 162, 1001&#x2013;1010 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19497353</ArticleId></ArticleIdList></Reference><Reference><Citation>Maximov A., Pang Z. P., Tervo D. G., S&#xfc;dhof T. C., Monitoring synaptic transmission in primary neuronal cultures using local extracellular stimulation. J. Neurosci. Methods 161, 75&#x2013;87 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17118459</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak C., et al. , Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1. Cell Stem Cell 17, 316&#x2013;328 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4560990</ArticleId><ArticleId IdType="pubmed">26279266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31164641</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2;-induced vulnerability propagates via the brain's default mode network.</ArticleTitle><Pagination><StartPage>2353</StartPage><MedlinePgn>2353</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2353</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-10217-w</ELocationID><Abstract><AbstractText>The link between brain amyloid-&#x3b2; (A&#x3b2;), metabolism, and dementia symptoms remains a pressing question in Alzheimer's disease. Here, using positron emission tomography ([<sup>18</sup>F]florbetapir tracer for A&#x3b2; and [<sup>18</sup>F]FDG tracer for glucose metabolism) with a novel analytical framework, we found that A&#x3b2; aggregation within the brain's default mode network leads to regional hypometabolism in distant but functionally connected brain regions. Moreover, we found that an interaction between this hypometabolism with overlapping A&#x3b2; aggregation is associated with subsequent cognitive decline. These results were also observed in transgenic A&#x3b2; rats that do not form neurofibrillary tangles, which support these findings as an independent mechanism of cognitive deterioration. These results suggest a model in which distant A&#x3b2; induces regional metabolic vulnerability, whereas the interaction between local A&#x3b2; with a vulnerable environment drives the clinical progression of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pascoal</LastName><ForeName>Tharick A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0001-9057-8014</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, H3A 2B4, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathotaarachchi</LastName><ForeName>Sulantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Min Su</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, H3A 2B4, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohaddes</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Ah Yeon</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Statistical Laboratory, University of Cambridge, CB3 0WB, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parent</LastName><ForeName>Maxime J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, H3A 2B4, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedet</LastName><ForeName>Andrea L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0001-8219-1741</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamoun</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Therriault</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Heungsun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychology, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuello</LastName><ForeName>A Claudio</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, McGill University, H3A 2T5, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misic</LastName><ForeName>Bratislav</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, H3A 2B4, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soucy</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, H3A 2B4, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aston</LastName><ForeName>John A D</ForeName><Initials>JAD</Initials><AffiliationInfo><Affiliation>Statistical Laboratory, University of Cambridge, CB3 0WB, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9116-1376</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, H3A 2B4, Montreal, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, McGill University, H3A 2T5, Montreal, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31164641</ArticleId><ArticleId IdType="pmc">PMC6547716</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-10217-w</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-10217-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Edison P, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;508. doi: 10.1212/01.wnl.0000244749.20056.d4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000244749.20056.d4</ArticleId><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain : a J. Neurol. 2006;129:2856&#x2013;2866. doi: 10.1093/brain/awl178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl178</ArticleId><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, et al. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology. 2014;82:1959&#x2013;1967. doi: 10.1212/WNL.0000000000000467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000467</ArticleId><ArticleId IdType="pmc">PMC4105262</ArticleId><ArticleId IdType="pubmed">24793183</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, et al. Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain : a J. Neurol. 2015;138:3734&#x2013;3746. doi: 10.1093/brain/awv278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv278</ArticleId><ArticleId IdType="pmc">PMC4806718</ArticleId><ArticleId IdType="pubmed">26419799</ArticleId></ArticleIdList></Reference><Reference><Citation>Furst AJ, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol. aging. 2012;33:215&#x2013;225. doi: 10.1016/j.neurobiolaging.2010.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.03.011</ArticleId><ArticleId IdType="pmc">PMC2920373</ArticleId><ArticleId IdType="pubmed">20417582</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. imaging. 2008;35:2169&#x2013;2181. doi: 10.1007/s00259-008-0833-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-008-0833-y</ArticleId><ArticleId IdType="pmc">PMC2693402</ArticleId><ArticleId IdType="pubmed">18566819</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster S, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol. Psychiatry. 2012;71:792&#x2013;797. doi: 10.1016/j.biopsych.2011.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2011.04.023</ArticleId><ArticleId IdType="pubmed">21679929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagasawa H, Kogure K, Fujiwara T, Itoh M, Ido T. Metabolic disturbances in exo-focal brain areas after cortical stroke studied by positron emission tomography. J. Neurol. Sci. 1994;123:147&#x2013;153. doi: 10.1016/0022-510X(94)90217-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90217-8</ArticleId><ArticleId IdType="pubmed">8064308</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Harrop R, McGeer P, Peppard R, McGeer E. Crossed cerebellar and uncrossed basal ganglia and thalarnic diaschisis in Alzheimer's disease. Neurology. 1989;39:541&#x2013;541. doi: 10.1212/WNL.39.4.541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.39.4.541</ArticleId><ArticleId IdType="pubmed">2784550</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro K, et al. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Brain : a J. Neurol. 1999;122:1519&#x2013;1531. doi: 10.1093/brain/122.8.1519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/122.8.1519</ArticleId><ArticleId IdType="pubmed">10430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. : Off. J. Soc. Neurosci. 2005;25:7709&#x2013;7717. doi: 10.1523/JNEUROSCI.2177-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi Lisa. Glucose metabolism in normal aging and Alzheimer&#x2019;s disease: methodological and physiological considerations for PET studies. Clinical and Translational Imaging. 2013;1(4):217&#x2013;233. doi: 10.1007/s40336-013-0026-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40336-013-0026-y</ArticleId><ArticleId IdType="pmc">PMC3881550</ArticleId><ArticleId IdType="pubmed">24409422</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012;72:578&#x2013;586. doi: 10.1002/ana.23650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188. doi: 10.1016/j.neuron.2009.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.07.003</ArticleId><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732&#x2013;1740. doi: 10.1212/01.wnl.0000435556.21319.e4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000435556.21319.e4</ArticleId><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 2017;8:1214. doi: 10.1038/s41467-017-01150-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01150-x</ArticleId><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379&#x2013;1385. doi: 10.1001/jamaneurol.2014.2031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2031</ArticleId><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, et al. Rat brains also have a default mode network. Proc. Natl. Acad. Sci. USA. 2012;109:3979&#x2013;3984. doi: 10.1073/pnas.1200506109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200506109</ArticleId><ArticleId IdType="pmc">PMC3309754</ArticleId><ArticleId IdType="pubmed">22355129</ArticleId></ArticleIdList></Reference><Reference><Citation>Do Carmo S, Cuello AC. Modeling Alzheimer's disease in transgenic rats. Mol. Neurodegener. 2013;8:37. doi: 10.1186/1750-1326-8-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-37</ArticleId><ArticleId IdType="pmc">PMC4231465</ArticleId><ArticleId IdType="pubmed">24161192</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52. doi: 10.1016/j.neuron.2009.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.03.024</ArticleId><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews&#x2010;Hanna JR, Schacter DL. The brain's default network. Ann. New Y. Acad. Sci. 2008;1124:1&#x2013;38. doi: 10.1196/annals.1440.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1440.011</ArticleId><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman JA, et al. Neural compensation in older people with brain amyloid-[beta] deposition. Nat. Neurosci. 2014;17:1316&#x2013;1318. doi: 10.1038/nn.3806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3806</ArticleId><ArticleId IdType="pmc">PMC4177011</ArticleId><ArticleId IdType="pubmed">25217827</ArticleId></ArticleIdList></Reference><Reference><Citation>Passow S, et al. Default&#x2010;mode network functional connectivity is closely related to metabolic activity. Hum. brain Mapp. 2015;36:2027&#x2013;2038. doi: 10.1002/hbm.22753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.22753</ArticleId><ArticleId IdType="pmc">PMC5006878</ArticleId><ArticleId IdType="pubmed">25644693</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl V, et al. Metabolic connectivity mapping reveals effective connectivity in the resting human brain. Proc. Natl. Acad. Sci. USA. 2016;113:428&#x2013;433. doi: 10.1073/pnas.1513752113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1513752113</ArticleId><ArticleId IdType="pmc">PMC4720331</ArticleId><ArticleId IdType="pubmed">26712010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DS, et al. Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur. J. Nucl. Med Mol. Imaging. 2008;35:1681&#x2013;1691. doi: 10.1007/s00259-008-0808-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-008-0808-z</ArticleId><ArticleId IdType="pubmed">18491089</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, et al. Brain networks associated with cognitive reserve in healthy young and old adults. Cereb. Cortex. 2005;15:394&#x2013;402. doi: 10.1093/cercor/bhh142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhh142</ArticleId><ArticleId IdType="pmc">PMC3025536</ArticleId><ArticleId IdType="pubmed">15749983</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 2016;17:251&#x2013;260. doi: 10.1038/nrn.2016.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.13</ArticleId><ArticleId IdType="pmc">PMC6701169</ArticleId><ArticleId IdType="pubmed">26988744</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 2006;7:278&#x2013;294. doi: 10.1038/nrn1886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1886</ArticleId><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson WS. Selective vulnerability to neurodegenerative disease: the curious case of Prion Protein. Dis. Models Mech. 2014;7:21&#x2013;29. doi: 10.1242/dmm.012146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.012146</ArticleId><ArticleId IdType="pmc">PMC3882045</ArticleId><ArticleId IdType="pubmed">24396151</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas JN, et al. The sorting receptor SorCS1 regulates trafficking of neurexin and AMPA receptors. Neuron. 2015;87:764&#x2013;780. doi: 10.1016/j.neuron.2015.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.08.007</ArticleId><ArticleId IdType="pmc">PMC4692362</ArticleId><ArticleId IdType="pubmed">26291160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne SE, et al. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain : a J. Neurol. 2013;136:1383&#x2013;1398. doi: 10.1093/brain/awt062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt062</ArticleId><ArticleId IdType="pmc">PMC3634198</ArticleId><ArticleId IdType="pubmed">23576130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain : a J. Neurol. 2013;136:2228&#x2013;2238. doi: 10.1093/brain/awt145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt145</ArticleId><ArticleId IdType="pmc">PMC3692038</ArticleId><ArticleId IdType="pubmed">23775979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal T A, Mathotaarachchi S, Mohades S, Benedet A L, Chung C-O, Shin M, Wang S, Beaudry T, Kang M S, Soucy J-P, Labbe A, Gauthier S, Rosa-Neto P. Amyloid-&#x3b2; and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer&#x2019;s disease. Molecular Psychiatry. 2016;22(2):306&#x2013;311. doi: 10.1038/mp.2016.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.37</ArticleId><ArticleId IdType="pmc">PMC5262471</ArticleId><ArticleId IdType="pubmed">27021814</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 1999;24:521&#x2013;529. doi: 10.1016/S0896-6273(00)81109-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81109-5</ArticleId><ArticleId IdType="pubmed">10595506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann. Neurol. 2015;77:338&#x2013;342. doi: 10.1002/ana.24321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24321</ArticleId><ArticleId IdType="pmc">PMC4382124</ArticleId><ArticleId IdType="pubmed">25448043</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Alzheimer's Disease Neuroimaging I, Apolipoprotein E. not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J. Neurosci. : Off. J. Soc. Neurosci. 2012;32:18227&#x2013;18233. doi: 10.1523/JNEUROSCI.3266-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3266-12.2012</ArticleId><ArticleId IdType="pmc">PMC3537830</ArticleId><ArticleId IdType="pubmed">23238736</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, et al. Positron emission tomography studies of normal aging: a replication of PET III and 18-FDG using PET VI and 11-CDG. Neurobiol. Aging. 1987;8:319&#x2013;323. doi: 10.1016/0197-4580(87)90070-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(87)90070-4</ArticleId><ArticleId IdType="pubmed">3498127</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer Eduardo R, Parent Maxime J, Souza D&#xe9;bora G, Leuzy Antoine, Lecrux Clotilde, Kim Hyoung-Ihl, Gauthier Serge, Pellerin Luc, Hamel Edith, Rosa-Neto Pedro. [18F]FDG PET signal is driven by astroglial glutamate transport. Nature Neuroscience. 2017;20(3):393&#x2013;395. doi: 10.1038/nn.4492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4492</ArticleId><ArticleId IdType="pmc">PMC5378483</ArticleId><ArticleId IdType="pubmed">28135241</ArticleId></ArticleIdList></Reference><Reference><Citation>Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat. Rev. Neurosci. 2005;6:626&#x2013;640. doi: 10.1038/nrn1722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1722</ArticleId><ArticleId IdType="pubmed">16025096</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal Tharick A., Mathotaarachchi Sulantha, Shin Monica, Benedet Andrea L., Mohades Sara, Wang Seqian, Beaudry Tom, Kang Min Su, Soucy Jean-Paul, Labbe Aurelie, Gauthier Serge, Rosa-Neto Pedro. Synergistic interaction between amyloid and tau predicts the progression&#xa0;to dementia. Alzheimer's &amp; Dementia. 2017;13(6):644&#x2013;653. doi: 10.1016/j.jalz.2016.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.11.005</ArticleId><ArticleId IdType="pubmed">28024995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, et al. Cerebrospinal fluid beta-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann. Neurol. 2014;76:223&#x2013;230. doi: 10.1002/ana.24186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24186</ArticleId><ArticleId IdType="pubmed">24852682</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson L. Brain maps: structure of the rat brain (2nd edn) Nature. 1992;363:347&#x2013;350.</Citation></Reference><Reference><Citation>Ashraf A, Fan Z, Brooks DJ, Edison P. Cortical hypermetabolism in MCI subjects: a compensatory mechanism? Eur. J. Nucl. Med. Mol. Imaging. 2015;42:447&#x2013;458. doi: 10.1007/s00259-014-2919-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-014-2919-z</ArticleId><ArticleId IdType="pubmed">25267349</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol. 2006;63:674&#x2013;681. doi: 10.1001/archneur.63.5.674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.5.674</ArticleId><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon WC, et al. J. Alzheimer's Dis.: JAD. 2010. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment; pp. 113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer ER, Parent MJ, Cuello AC, Gauthier S, Rosa-Neto P. MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. Trends Neurosci. 2014;37:629&#x2013;641. doi: 10.1016/j.tins.2014.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.07.002</ArticleId><ArticleId IdType="pubmed">25151336</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944. doi: 10.1212/WNL.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1992;1:345&#x2013;347. doi: 10.1038/ng0892-345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0892-345</ArticleId><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 1991;254:97&#x2013;99. doi: 10.1126/science.1925564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1925564</ArticleId><ArticleId IdType="pubmed">1925564</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 1984;11:47&#x2013;60. doi: 10.1016/0165-0270(84)90007-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(84)90007-4</ArticleId><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijdenbos AP, Forghani R, Evans AC. Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans. Med. Imaging. 2002;21:1280&#x2013;1291. doi: 10.1109/TMI.2002.806283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TMI.2002.806283</ArticleId><ArticleId IdType="pubmed">12585710</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas BA, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 2011;38:1104&#x2013;1119. doi: 10.1007/s00259-011-1745-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-1745-9</ArticleId><ArticleId IdType="pubmed">21336694</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, et al. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 2018;45:1021&#x2013;1030. doi: 10.1007/s00259-018-3933-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-3933-3</ArticleId><ArticleId IdType="pmc">PMC5915512</ArticleId><ArticleId IdType="pubmed">29396637</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppelt A, et al. FISP&#x2014;a new fast MRI sequence. Electromedica. 1986;54:15&#x2013;18.</Citation></Reference><Reference><Citation>Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage. 1997;6:279&#x2013;287. doi: 10.1006/nimg.1997.0303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.1997.0303</ArticleId><ArticleId IdType="pubmed">9417971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009;65:403&#x2013;413. doi: 10.1002/ana.21610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126:659&#x2013;670. doi: 10.1007/s00401-013-1151-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1151-4</ArticleId><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathotaarachchi S, et al. VoxelStats: A MATLAB package for multi-modal voxel-wise brain image analysis. Front Neuroinform. 2016;10:20. doi: 10.3389/fninf.2016.00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fninf.2016.00020</ArticleId><ArticleId IdType="pmc">PMC4908129</ArticleId><ArticleId IdType="pubmed">27378902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM) Philos Trans. R. Soc. Lond. B Biol. Sci. 2001;356:1293&#x2013;1322. doi: 10.1098/rstb.2001.0915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2001.0915</ArticleId><ArticleId IdType="pmc">PMC1088516</ArticleId><ArticleId IdType="pubmed">11545704</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo BT, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 2011;106:1125&#x2013;1165. doi: 10.1152/jn.00338.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00338.2011</ArticleId><ArticleId IdType="pmc">PMC3174820</ArticleId><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>MacCallum RC, Austin JT. Applications of structural equation modeling in psychological research. Annu Rev. Psychol. 2000;51:201&#x2013;226. doi: 10.1146/annurev.psych.51.1.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.psych.51.1.201</ArticleId><ArticleId IdType="pubmed">10751970</ArticleId></ArticleIdList></Reference><Reference><Citation>Schermelleh-Engel, K., Moosbrugger, H. &amp; M&#xfc;ller, H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. Methods of psychological research online8, 23&#x2013;74 (2003).</Citation></Reference><Reference><Citation>Kievit RA, et al. Distinct aspects of frontal lobe structure mediate age-related differences in fluid intelligence and multitasking. Nat. Commun. 2014;5:5658. doi: 10.1038/ncomms6658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6658</ArticleId><ArticleId IdType="pmc">PMC4284640</ArticleId><ArticleId IdType="pubmed">25519467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31171783</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice.</ArticleTitle><Pagination><StartPage>2479</StartPage><MedlinePgn>2479</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2479</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-10428-1</ELocationID><Abstract><AbstractText>The tauopathy-like phenotype observed in the rTg4510 mouse line, in which human tau<sub>P301L</sub> expression specifically within the forebrain can be temporally controlled, has largely been attributed to high overexpression of mutant human tau in the forebrain region. Unexpectedly, we found that in a different mouse line with a targeted-insertion of the same transgene driven by the same tetracycline-TransActivator (tTA) allele, but with even higher overexpression of tauP301L than rTg4510, atrophy and tau histopathology are delayed, and a different behavioral profile is observed. This suggests that it is not overexpression of mutant human tau alone that contributes to the phenotype in rTg4510 mice. Furthermore we show that the tauopathy-like phenotype seen in rTg4510 requires a ~70-copy tau-transgene insertion in a 244&#x2009;kb deletion in Fgf14, a ~7-copy tTA-transgene insertion in a 508&#x2009;kb deletion that disrupts another five genes, in addition to high transgene overexpression. We propose that these additional effects need to be accounted for in any studies using rTg4510.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gamache</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3750-147X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, N. Bud Grossman Center for Memory Research and Care, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzow</LastName><ForeName>Kellie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forster</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BLS Histology and IHC Laboratory, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemper</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, N. Bud Grossman Center for Memory Research and Care, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hlynialuk</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, N. Bud Grossman Center for Memory Research and Care, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furrow</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7339-2354</Identifier><AffiliationInfo><Affiliation>Veterinary Clinical Sciences (College of Veterinary Medicine), University of Minnesota, Minneapolis, MN, 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Neurology, N. Bud Grossman Center for Memory Research and Care, Minneapolis, MN, USA. hsiao005@umn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koob</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-7738-8232</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Minneapolis, MN, USA. koobx001@umn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 OD019912</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA077598</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Zen-15-320450</GrantID><Agency>Alzheimer's Association</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C112971">fibroblast growth factor 14</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>62031-54-3</RegistryNumber><NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="Y">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The University of Minnesota has certain ownership rights in the rTg4510 mouse and has received royalty income pursuant to a licensing agreement with the Mayo Medical Foundation, which holds the patent on rTg4510 mice; a portion of that royalty income has been distributed to K.A. No royalty income has been received by K.A. since May 2016. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31171783</ArticleId><ArticleId IdType="pmc">PMC6554306</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-10428-1</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-10428-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ramsden M, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J. Neurosci. 2005;25:10637&#x2013;10647. doi: 10.1523/JNEUROSCI.3279-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3279-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481. doi: 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 2001;276:529&#x2013;534. doi: 10.1074/jbc.M006531200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M006531200</ArticleId><ArticleId IdType="pubmed">11013246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000;25:402&#x2013;405. doi: 10.1038/78078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, et al. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683. doi: 10.1126/science.274.5293.1678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5293.1678</ArticleId><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081. doi: 10.1016/j.neuron.2010.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard C, Hochedlinger K, Plath K, Wutz A, Jaenisch R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis. 2006;44:23&#x2013;28. doi: 10.1002/gene.20180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gene.20180</ArticleId><ArticleId IdType="pubmed">16400644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo LM, et al. Regional differences in gene expression and promoter usage in aged human brains. Neurobiol. Aging. 2013;34:1825&#x2013;1836. doi: 10.1016/j.neurobiolaging.2013.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.01.005</ArticleId><ArticleId IdType="pubmed">23428183</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, et al. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 2016;17:530&#x2013;551. doi: 10.15252/embr.201541438.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201541438</ArticleId><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Shineman DW, et al. Accelerating drug discovery for Alzheimer&#x2019;s disease: best practices for preclinical animal studies. Alzheimers Res. Ther. 2011;3:28. doi: 10.1186/alzrt90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt90</ArticleId><ArticleId IdType="pmc">PMC3218805</ArticleId><ArticleId IdType="pubmed">21943025</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue F, et al. A comparative encyclopedia of DNA elements in the mouse genome. Nature. 2014;515:355&#x2013;364. doi: 10.1038/nature13992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13992</ArticleId><ArticleId IdType="pmc">PMC4266106</ArticleId><ArticleId IdType="pubmed">25409824</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith ED, et al. More than blood, a novel gene required for mammalian postimplantation development. Mol. Cell Biol. 2004;24:1168&#x2013;1173. doi: 10.1128/MCB.24.3.1168-1173.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.3.1168-1173.2004</ArticleId><ArticleId IdType="pmc">PMC321451</ArticleId><ArticleId IdType="pubmed">14729962</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HJ, et al. Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J. Neurosci. 2012;32:10574&#x2013;10586. doi: 10.1523/JNEUROSCI.0893-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0893-12.2012</ArticleId><ArticleId IdType="pmc">PMC3431916</ArticleId><ArticleId IdType="pubmed">22855807</ArticleId></ArticleIdList></Reference><Reference><Citation>Helboe L, Egebjerg J, Barkholt P, Volbracht C. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model. Brain Res. 2017;1665:22&#x2013;35. doi: 10.1016/j.brainres.2017.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2017.04.002</ArticleId><ArticleId IdType="pubmed">28411086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejar R, Yasuda R, Krugers H, Hood K, Mayford M. Transgenic calmodulin-dependent protein kinase II activation: dose-dependent effects on synaptic plasticity, learning, and memory. J. Neurosci. 2002;22:5719&#x2013;5726. doi: 10.1523/JNEUROSCI.22-13-05719.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-13-05719.2002</ArticleId><ArticleId IdType="pmc">PMC6758231</ArticleId><ArticleId IdType="pubmed">12097524</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Re,J, Wadsworth PA, Laezza F. Intracellular fibroblast growth factor 14: emerging risk factor for brain disorders. Front. Cell. Neurosci. 2017;11:103. doi: 10.3389/fncel.2017.00103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00103</ArticleId><ArticleId IdType="pmc">PMC5396478</ArticleId><ArticleId IdType="pubmed">28469558</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, McEwen DG, Ornitz DM. Subcellular and developmental expression of alternatively spliced forms of fibroblast growth factor 14. Mech. Dev. 2000;90:283&#x2013;287. doi: 10.1016/S0925-4773(99)00241-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4773(99)00241-5</ArticleId><ArticleId IdType="pubmed">10640713</ArticleId></ArticleIdList></Reference><Reference><Citation>Laezza F, et al. FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channels. Mol. Cell Neurosci. 2009;42:90&#x2013;101. doi: 10.1016/j.mcn.2009.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2009.05.007</ArticleId><ArticleId IdType="pmc">PMC2832592</ArticleId><ArticleId IdType="pubmed">19465131</ArticleId></ArticleIdList></Reference><Reference><Citation>Pablo JL, Wang C, Presby MM, Pitt GS. Polarized localization of voltage-gated Na+&#x2009;channels is regulated by concerted FGF13 and FGF14 action. Proc. Natl Acad. Sci. USA. 2016;113:E2665&#x2013;E2674. doi: 10.1073/pnas.1521194113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1521194113</ArticleId><ArticleId IdType="pmc">PMC4868475</ArticleId><ArticleId IdType="pubmed">27044086</ArticleId></ArticleIdList></Reference><Reference><Citation>Smallwood PM, et al. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc. Natl Acad. Sci. USA. 1996;93:9850&#x2013;9857. doi: 10.1073/pnas.93.18.9850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.18.9850</ArticleId><ArticleId IdType="pmc">PMC38518</ArticleId><ArticleId IdType="pubmed">8790420</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M, et al. Impaired hippocampal synaptic transmission and plasticity in mice lacking fibroblast growth factor 14. Mol. Cell Neurosci. 2007;34:366&#x2013;377. doi: 10.1016/j.mcn.2006.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2006.11.020</ArticleId><ArticleId IdType="pubmed">17208450</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshammari TK, et al. Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia. Transl. Psychiatry. 2016;6:e806. doi: 10.1038/tp.2016.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2016.66</ArticleId><ArticleId IdType="pmc">PMC5070049</ArticleId><ArticleId IdType="pubmed">27163207</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshammari MA, Alshammari TK, Nenov MN, Scala F, Laezza F. Fibroblast growth factor 14 modulates the neurogenesis of granule neurons in the adult dentate gyrus. Mol. Neurobiol. 2016;53:7254&#x2013;7270. doi: 10.1007/s12035-015-9568-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9568-5</ArticleId><ArticleId IdType="pmc">PMC4916041</ArticleId><ArticleId IdType="pubmed">26687232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou JY, et al. Fibroblast growth factor 14 is an intracellular modulator of voltage-gated sodium channels. J. Physiol. 2005;569:179&#x2013;193. doi: 10.1113/jphysiol.2005.097220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2005.097220</ArticleId><ArticleId IdType="pmc">PMC1464207</ArticleId><ArticleId IdType="pubmed">16166153</ArticleId></ArticleIdList></Reference><Reference><Citation>Misceo D, et al. SCA27 caused by a chromosome translocation: further delineation of the phenotype. Neurogenetics. 2009;10:371&#x2013;374. doi: 10.1007/s10048-009-0197-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-009-0197-x</ArticleId><ArticleId IdType="pubmed">19471976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, et al. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. Hum. Mol. Genet. 2015;24:6198&#x2013;6212. doi: 10.1093/hmg/ddv336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv336</ArticleId><ArticleId IdType="pmc">PMC4599677</ArticleId><ArticleId IdType="pubmed">26276810</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 2005;25:5446&#x2013;5454. doi: 10.1523/JNEUROSCI.4637-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4637-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, et al. Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat. Neurosci. 2014;17:661&#x2013;663. doi: 10.1038/nn.3697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3697</ArticleId><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, et al. APP mouse models for Alzheimer&#x2019;s disease preclinical studies. EMBO J. 2017;36:2473&#x2013;2487. doi: 10.15252/embj.201797397.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797397</ArticleId><ArticleId IdType="pmc">PMC5579350</ArticleId><ArticleId IdType="pubmed">28768718</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ. The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J. Neurosci. Methods. 2008;172:250&#x2013;254. doi: 10.1016/j.jneumeth.2008.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2008.05.003</ArticleId><ArticleId IdType="pmc">PMC2567873</ArticleId><ArticleId IdType="pubmed">18571732</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, et al. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 2009;23:2595&#x2013;2604. doi: 10.1096/fj.08-122424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-122424</ArticleId><ArticleId IdType="pmc">PMC2717763</ArticleId><ArticleId IdType="pubmed">19279139</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabir DV, et al. Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J. Neurosci. 2006;26:644&#x2013;654. doi: 10.1523/JNEUROSCI.3861-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3861-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674424</ArticleId><ArticleId IdType="pubmed">16407562</ArticleId></ArticleIdList></Reference><Reference><Citation>Afgan E, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res. 2016;44:W3&#x2013;W10. doi: 10.1093/nar/gkw343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw343</ArticleId><ArticleId IdType="pmc">PMC4987906</ArticleId><ArticleId IdType="pubmed">27137889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent WJ. BLAT--the BLAST-like alignment tool. Genome Res. 2002;12:656&#x2013;664. doi: 10.1101/gr.229202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.229202</ArticleId><ArticleId IdType="pmc">PMC187518</ArticleId><ArticleId IdType="pubmed">11932250</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9:357&#x2013;359. doi: 10.1038/nmeth.1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 2013;14:178&#x2013;192. doi: 10.1093/bib/bbs017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbs017</ArticleId><ArticleId IdType="pmc">PMC3603213</ArticleId><ArticleId IdType="pubmed">22517427</ArticleId></ArticleIdList></Reference><Reference><Citation>Westaway D, et al. Structure and polymorphism of the mouse prion protein gene. Proc. Natl Acad. Sci. USA. 1994;91:6418&#x2013;6422. doi: 10.1073/pnas.91.14.6418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.14.6418</ArticleId><ArticleId IdType="pmc">PMC44213</ArticleId><ArticleId IdType="pubmed">7912827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankevich A, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J. Comput. Biol. 2012;19:455&#x2013;477. doi: 10.1089/cmb.2012.0021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cmb.2012.0021</ArticleId><ArticleId IdType="pmc">PMC3342519</ArticleId><ArticleId IdType="pubmed">22506599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31180460</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype.</ArticleTitle><Pagination><StartPage>1099</StartPage><EndPage>1108</EndPage><MedlinePgn>1099-1108</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.1456</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Previous genome-wide association studies of common variants identified associations for Alzheimer disease (AD) loci evident only among individuals with particular APOE alleles.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify APOE genotype-dependent associations with infrequent and rare variants using whole-exome sequencing.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The discovery stage included 10&#x202f;441 non-Hispanic white participants in the Alzheimer Disease Sequencing Project. Replication was sought in 2 independent, whole-exome sequencing data sets (1766 patients with AD, 2906 without AD [controls]) and a chip-based genotype imputation data set (8728 patients with AD, 9808 controls). Bioinformatics and functional analyses were conducted using clinical, cognitive, neuropathologic, whole-exome sequencing, and gene expression data obtained from a longitudinal cohort sample including 402 patients with AD and 647 controls. Data were analyzed between March 2017 and September 2018.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Score, Firth, and sequence kernel association tests were used to test the association of AD risk with individual variants and genes in subgroups of APOE &#x3b5;4 carriers and noncarriers. Results with P&#x2009;&#x2264;&#x2009;1&#x2009;&#xd7;&#x2009;10-5 were further evaluated in the replication data sets and combined by meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 3145 patients with AD and 4213 controls lacking &#x3b5;4 (mean [SD] age, 83.4 [7.6] years; 4363 [59.3.%] women), novel genome-wide significant associations were obtained in the discovery sample with rs536940594 in AC099552 (odds ratio [OR], 88.0; 95% CI, 9.08-852.0; P&#x2009;=&#x2009;2.22&#x2009;&#xd7;&#x2009;10-7) and rs138412600 in GPAA1 (OR, 1.78; 95% CI, 1.44-2.2; meta-P&#x2009;=&#x2009;7.81&#x2009;&#xd7;&#x2009;10-8). GPAA1 was also associated with expression in the brain of GPAA1 (&#x3b2;&#x2009;=&#x2009;-0.08; P&#x2009;=&#x2009;.03) and its repressive transcription factor, FOXG1 (&#x3b2;&#x2009;=&#x2009;0.13; P&#x2009;=&#x2009;.003), and global cognition function (&#x3b2;&#x2009;=&#x2009;-0.53; P&#x2009;=&#x2009;.009). Significant gene-wide associations (threshold P&#x2009;&#x2264;&#x2009;6.35&#x2009;&#xd7;&#x2009;10-7) were observed for OR8G5 (P&#x2009;=&#x2009;4.67&#x2009;&#xd7;&#x2009;10-7), IGHV3-7 (P&#x2009;=&#x2009;9.75&#x2009;&#xd7;&#x2009;10-16), and SLC24A3 (P&#x2009;=&#x2009;2.67&#x2009;&#xd7;&#x2009;10-12) in 2377 patients with AD and 706 controls with &#x3b5;4 (mean [SD] age, 75.2 [9.6] years; 1668 [54.1%] women).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The study identified multiple possible novel associations for AD with individual and aggregated rare variants in groups of individuals with and without APOE &#x3b5;4 alleles that reinforce known and suggest additional pathways leading to AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Multiple Sclerosis Clinical Care and Research Center, Division of Neuroimmunology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jaeyoon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuning</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellenguez</LastName><ForeName>Celine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universite de Lille, INSERM UMR1167, Institute Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debette</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bordeaux Population Health Research Center, UMR1219, University Bordeaux, Inserm, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornage</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Public Health, University of Texas Health Science Center at Houston, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Ga&#xeb;l</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UNIROUEN, Inserm U1245, Normandie University, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Normandy Centre for Genomic and Personalized Medicine, Centre National de R&#xe9;f&#xe9;rence pour les Malades Alzheimer Jeunes, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational &amp; Computational Neuroimmunology, Multiple Sclerosis Clinical Care and Research Center, Division of Neuroimmunology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institute for Computational Biology, Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Universite de Lille, INSERM UMR1167, Institute Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Sequencing Project and Alzheimer&#x2019;s Disease Exome Sequencing&#x2013;France Project</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG047133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058654</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048927</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr DeStefano reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study that are not related to this study. Dr Haines reported receiving grants from the NIH during the conduct of the study. Dr Schellenberg reported receiving grants from National Institute on Aging (NIA) during the conduct of the study. Dr Farrer reported receiving grants from the NIH during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31180460</ArticleId><ArticleId IdType="pmc">PMC6563544</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.1456</ArticleId><ArticleId IdType="pii">2735123</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherva R, Farrer LA. Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer&#x2019;s disease. Curr Psychiatry Rep. 2011;13(2):138-146. doi:10.1007/s11920-011-0184-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-011-0184-4</ArticleId><ArticleId IdType="pmc">PMC3154249</ArticleId><ArticleId IdType="pubmed">21312009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. ; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452-1458. doi:10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Umar T, Hoda N. Alzheimer&#x2019;s disease: a systemic review of substantial therapeutic targets and the leading multi-functional molecules. Curr Top Med Chem. 2017;17(31):3370-3389. doi:10.2174/1568026618666180112161024</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026618666180112161024</ArticleId><ArticleId IdType="pubmed">29332579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruthirakuhan M, Lanct&#xf4;t KL, Di Scipio M, Ahmed M, Herrmann N. Biomarkers of agitation and aggression in Alzheimer&#x2019;s disease: A systematic review. Alzheimers Dement. 2018;14(10):1344-1376. doi:10.1016/j.jalz.2018.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.04.013</ArticleId><ArticleId IdType="pubmed">29940162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LC, Goh MQL, Koo EH. Transcriptional regulation of APP by apoE: to boldly go where no isoform has gone before: ApoE, APP transcription and AD&#x2014;hypothesised mechanisms and existing knowledge gaps. Bioessays. 2017;39(9). doi:10.1002/bies.201700062</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.201700062</ArticleId><ArticleId IdType="pmc">PMC5647194</ArticleId><ArticleId IdType="pubmed">28731260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al. ; IGAP Consortium . A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21(1):108-117. doi:10.1038/mp.2015.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.23</ArticleId><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun GR, Chung J, Mez J, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium . Transethnic genome-wide scan identifies novel Alzheimer&#x2019;s disease loci. Alzheimers Dement. 2017;13(7):727-738. doi:10.1016/j.jalz.2016.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.12.012</ArticleId><ArticleId IdType="pmc">PMC5496797</ArticleId><ArticleId IdType="pubmed">28183528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Chung J, Jun G, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium . Two novel loci, COBL and SLC10A2, for Alzheimer&#x2019;s disease in African Americans. Alzheimers Dement. 2017;13(2):119-129. doi:10.1016/j.jalz.2016.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.09.002</ArticleId><ArticleId IdType="pmc">PMC5318231</ArticleId><ArticleId IdType="pubmed">27770636</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, van der Lee SJ, Naj AC, et al. ; ARUK Consortium; GERAD/PERADES, CHARGE, ADGC, EADI . Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. 2017;49(9):1373-1384. doi:10.1038/ng.3916</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Bellenguez C, Wang LS, et al. ; United Kingdom Brain Expression Consortium; Cardiovascular Health Study (CHS) . Gene-wide analysis detects two new susceptibility genes for Alzheimer&#x2019;s disease. PLoS One. 2014;9(6):e94661. doi:10.1371/journal.pone.0094661</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094661</ArticleId><ArticleId IdType="pmc">PMC4055488</ArticleId><ArticleId IdType="pubmed">24922517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancour D, Naj A, Mayeux R, et al. . One for all and all for one: improving replication of genetic studies through network diffusion. PLoS Genet. 2018;14(4):e1007306. doi:10.1371/journal.pgen.1007306</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007306</ArticleId><ArticleId IdType="pmc">PMC5933817</ArticleId><ArticleId IdType="pubmed">29684019</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, et al. ; ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators . Genetic overlap between Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease at the MAPT locus. Mol Psychiatry. 2015;20(12):1588-1595. doi:10.1038/mp.2015.6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.6</ArticleId><ArticleId IdType="pmc">PMC4539304</ArticleId><ArticleId IdType="pubmed">25687773</ArticleId></ArticleIdList></Reference><Reference><Citation>Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013;9(1):25-34. doi:10.1038/nrneurol.2012.236</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.236</ArticleId><ArticleId IdType="pubmed">23183882</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis JC, Jian X, Kunkle BW, et al. ; Alzheimer&#x2019;s Disease Sequencing Project . Whole exome sequencing study identifies novel rare and common Alzheimer&#x2019;s-associated variants involved in immune response and transcriptional regulation. Mol Psychiatry. In press. doi:10.1038/s41380-018-0112-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0112-7</ArticleId><ArticleId IdType="pmc">PMC6375806</ArticleId><ArticleId IdType="pubmed">30108311</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Bis JC, Martin ER, et al. . The Alzheimer&#x2019;s Disease Sequencing Project: study design and sample selection. Neurol Genet. 2017;3(5):e194. doi:10.1212/NXG.0000000000000194</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000194</ArticleId><ArticleId IdType="pmc">PMC5646177</ArticleId><ArticleId IdType="pubmed">29184913</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, McCabe C, et al. . A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci Data. 2018;5:180142. doi:10.1038/sdata.2018.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.142</ArticleId><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Gaiteri C, Sullivan SE, et al. . A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat Neurosci. 2018;21(6):811-819. doi:10.1038/s41593-018-0154-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Tang ZZ. A general framework for detecting disease associations with rare variants in sequencing studies. Am J Hum Genet. 2011;89(3):354-367. doi:10.1016/j.ajhg.2011.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.07.015</ArticleId><ArticleId IdType="pmc">PMC3169821</ArticleId><ArticleId IdType="pubmed">21885029</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Statistical Genetics  EPACTS. https://genome.sph.umich.edu/wiki/EPACTS. Accessed September 15, 2015.</Citation></Reference><Reference><Citation>Ma C, Blackwell T, Boehnke M, Scott LJ; GoT2D investigators . Recommended joint and meta-analysis strategies for case-control association testing of single low-count variants. Genet Epidemiol. 2013;37(6):539-550. doi:10.1002/gepi.21742</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21742</ArticleId><ArticleId IdType="pmc">PMC4049324</ArticleId><ArticleId IdType="pubmed">23788246</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub 
https://github.com/rmkoesterer/uga. Accessed February 21, 2016.</Citation></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-2191. doi:10.1093/bioinformatics/btq340</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq340</ArticleId><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor. Bioinformatics. 2010;26(16):2069-2070. doi:10.1093/bioinformatics/btq330</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq330</ArticleId><ArticleId IdType="pmc">PMC2916720</ArticleId><ArticleId IdType="pubmed">20562413</ArticleId></ArticleIdList></Reference><Reference><Citation>Cingolani P, Platts A, Wang L, et al. . A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80-92. doi:10.4161/fly.19695</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/fly.19695</ArticleId><ArticleId IdType="pmc">PMC3679285</ArticleId><ArticleId IdType="pubmed">22728672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Wu MC, Lin X. Optimal tests for rare variant effects in sequencing association studies. Biostatistics. 2012;13(4):762-775. doi:10.1093/biostatistics/kxs014</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxs014</ArticleId><ArticleId IdType="pmc">PMC3440237</ArticleId><ArticleId IdType="pubmed">22699862</ArticleId></ArticleIdList></Reference><Reference><Citation>seqMeta: Meta-Analysis of Region-Based Tests of Rare DNA Variants. https://cran.r-project.org/web/packages/seqMeta/index.html. Accessed February 21, 2016.</Citation></Reference><Reference><Citation>Zerbino DR, Wilder SP, Johnson N, Juettemann T, Flicek PR. The ensembl regulatory build. Genome Biol. 2015;16:56. doi:10.1186/s13059-015-0621-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0621-5</ArticleId><ArticleId IdType="pmc">PMC4407537</ArticleId><ArticleId IdType="pubmed">25887522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ensambl. Gene regulation data in Ensembl. https://useast.ensembl.org/info/genome/funcgen/index.html. Accessed March 29, 2018.</Citation></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. ; Alzheimer Genetic Analysis Group . TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):117-127. doi:10.1056/NEJMoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. . Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):107-116. doi:10.1056/NEJMoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhaber B, Eisenhaber S, Kwang TY, Gr&#xfc;ber G, Eisenhaber F. Transamidase subunit GAA1/GPAA1 is a M28 family metallo-peptide-synthetase that catalyzes the peptide bond formation between the substrate protein&#x2019;s omega-site and the GPI lipid anchor&#x2019;s phosphoethanolamine. Cell Cycle. 2014;13(12):1912-1917. doi:10.4161/cc.28761</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.28761</ArticleId><ArticleId IdType="pmc">PMC4111754</ArticleId><ArticleId IdType="pubmed">24743167</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainauskas S, Maeda Y, Kurniawan H, Kinoshita T, Menon AK. Structural requirements for the recruitment of Gaa1 into a functional glycosylphosphatidylinositol transamidase complex. J Biol Chem. 2002;277(34):30535-30542. doi:10.1074/jbc.M205402200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205402200</ArticleId><ArticleId IdType="pubmed">12052837</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainauskas S, Menon AK. Endoplasmic reticulum localization of Gaa1 and PIG-T, subunits of the glycosylphosphatidylinositol transamidase complex. J Biol Chem. 2005;280(16):16402-16409. doi:10.1074/jbc.M414253200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M414253200</ArticleId><ArticleId IdType="pubmed">15713669</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy DB, Wiese S, Burfeind P, et al. . Human brain factor 1, a new member of the fork head gene family. Genomics. 1994;21(3):551-557. doi:10.1006/geno.1994.1313</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1994.1313</ArticleId><ArticleId IdType="pubmed">7959731</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitter D, Pringsheim M, Kaulisch M, et al. . FOXG1 syndrome: genotype-phenotype association in 83 patients with FOXG1 variants. Genet Med. 2018;20(1):98-108. doi:10.1038/gim.2017.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2017.75</ArticleId><ArticleId IdType="pubmed">28661489</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno K, Antunes-Martins A, Ris L, Peters M, Godaux E, Giese KP. Calcium/calmodulin kinase kinase beta has a male-specific role in memory formation. Neuroscience. 2007;145(2):393-402. doi:10.1016/j.neuroscience.2006.11.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.11.056</ArticleId><ArticleId IdType="pubmed">17207577</ArticleId></ArticleIdList></Reference><Reference><Citation>Shleper M, Kartvelishvily E, Wolosker H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J Neurosci. 2005;25(41):9413-9417. doi:10.1523/JNEUROSCI.3190-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3190-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725696</ArticleId><ArticleId IdType="pubmed">16221850</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelan RS, Parthasarathy LK, Parthasarathy RN. E2F1 regulation of the human myo-inositol 1-phosphate synthase (ISYNA1) gene promoter. Arch Biochem Biophys. 2004;431(1):95-106. doi:10.1016/j.abb.2004.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2004.08.002</ArticleId><ArticleId IdType="pubmed">15464731</ArticleId></ArticleIdList></Reference><Reference><Citation>Calsolaro V, Edison P. Alterations in glucose metabolism in Alzheimer&#x2019;s Disease. Recent Pat Endocr Metab Immune Drug Discov. 2016;10(1):31-39. doi:10.2174/1872214810666160615102809</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1872214810666160615102809</ArticleId><ArticleId IdType="pubmed">27306508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins R, Reiter D, Kapogiannis D. Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer&#x2019;s brain. Ann Clin Transl Neurol. 2018;5(3):262-272. doi:10.1002/acn3.530</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.530</ArticleId><ArticleId IdType="pmc">PMC5846391</ArticleId><ArticleId IdType="pubmed">29560372</ArticleId></ArticleIdList></Reference><Reference><Citation>Waragai M, Moriya M, Nojo T. Decreased N-acetyl aspartate/myo-inositol ratio in the posterior cingulate cortex shown by magnetic resonance spectroscopy may be one of the risk markers of preclinical alzheimer&#x2019;s disease: a 7-year follow-up study. J Alzheimers Dis. 2017;60(4):1411-1427. doi:10.3233/JAD-170450</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170450</ArticleId><ArticleId IdType="pmc">PMC5676849</ArticleId><ArticleId IdType="pubmed">28968236</ArticleId></ArticleIdList></Reference><Reference><Citation>Voevodskaya O, Sundgren PC, Strandberg O, et al. ; Swedish BioFINDER study group . Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology. 2016;86(19):1754-1761. doi:10.1212/WNL.0000000000002672</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002672</ArticleId><ArticleId IdType="pmc">PMC4862247</ArticleId><ArticleId IdType="pubmed">27164711</ArticleId></ArticleIdList></Reference><Reference><Citation>Pountney DL, Raftery MJ, Chegini F, Blumbergs PC, Gai WP. NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture. Acta Neuropathol. 2008;116(6):603-614. doi:10.1007/s00401-008-0437-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0437-4</ArticleId><ArticleId IdType="pubmed">18836734</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Luo F, Zhang Z, et al. . SNARE proteins synaptobrevin, SNAP-25, and syntaxin are involved in rapid and slow endocytosis at synapses. Cell Rep. 2013;3(5):1414-1421. doi:10.1016/j.celrep.2013.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.03.010</ArticleId><ArticleId IdType="pmc">PMC3672373</ArticleId><ArticleId IdType="pubmed">23643538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhu C, Beecham G, et al. ; Alzheimer&#x2019;s Disease Sequencing Project . A rare missense variant of CASP7 is associated with familial late-onset Alzheimer&#x2019;s disease. Alzheimers Dement. 2019;15(3):441-452. doi:10.1016/j.jalz.2018.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.10.005</ArticleId><ArticleId IdType="pmc">PMC6408965</ArticleId><ArticleId IdType="pubmed">30503768</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, Acero L, Williams AD, et al. . Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry. 2008;47(47):12254-12256. doi:10.1021/bi801767k</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi801767k</ArticleId><ArticleId IdType="pubmed">18956886</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31182869</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Central nervous system regeneration is driven by microglia necroptosis and repopulation.</ArticleTitle><Pagination><StartPage>1046</StartPage><EndPage>1052</EndPage><MedlinePgn>1046-1052</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0418-z</ELocationID><Abstract><AbstractText>Failed regeneration of CNS myelin contributes to clinical decline in neuroinflammatory and neurodegenerative diseases, for which there is an unmet therapeutic need. Here we reveal that efficient remyelination requires death of proinflammatory microglia followed by repopulation to a pro-regenerative state. We propose that impaired microglia death and/or repopulation may underpin dysregulated microglia activation in neurological diseases, and we reveal therapeutic targets to promote white matter regeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Amy F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Claire L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holloway</LastName><ForeName>Rebecca K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labrak</LastName><ForeName>Yasmine</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ireland</LastName><ForeName>Graeme</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carradori</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillenburg</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borger</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soong</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Jill C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Neurosciences Therapeutic Area Unit, GlaxoSmithKline R&amp;D Ltd, Stevenage, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Discovery Research MRL UK, Merck Sharp &amp; Dohme, The London Bioscience Innovation Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhlmann</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6329-382X</Identifier><AffiliationInfo><Affiliation>Medical Research Council Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollard</LastName><ForeName>Jeffrey W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-4579-0053</Identifier><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>des Rieux</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charit&#xe9; Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miron</LastName><ForeName>Veronique E</ForeName><Initials>VE</Initials><Identifier Source="ORCID">0000-0003-1738-0647</Identifier><AffiliationInfo><Affiliation>Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK. vmiron@ed.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CGA/18/20</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/P016022/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>101067</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N022556/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S035915/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_16031</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M020827/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1002033</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008244">Lysophosphatidylcholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577484">NES protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577485">Nes protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064231">Nestin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003711" MajorTopicYN="N">Demyelinating Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008244" MajorTopicYN="N">Lysophosphatidylcholines</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b>
 A.F.L.&#x2019;s salary and experiments for this study were co-funded by
GlaxoSmithKline. J.C.R. was a full time employee at GlaxoSmithKline at the time
of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31182869</ArticleId><ArticleId IdType="mid">EMS83278</ArticleId><ArticleId IdType="pmc">PMC6597360</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0418-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0418-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Franklin RJM, Ffrench-Constant C. Nat Rev Neurosci. 2017;18:753&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">29142295</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes A, et al. Neuron. 2014;81:1009&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron V, et al. Nature Neuroscience. 2013;16:1211&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977045</ArticleId><ArticleId IdType="pubmed">23872599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kigerl K, et al. J Neurosci. 2009;29:13435&#x2013;13444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788152</ArticleId><ArticleId IdType="pubmed">19864556</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodarczyk A, et al. EMBO J. 2017;36:3292&#x2013;3308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686552</ArticleId><ArticleId IdType="pubmed">28963396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemeyer N, et al. Acta Neuropathologica. 2017;134:441&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951721</ArticleId><ArticleId IdType="pubmed">28685323</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. Cell. 2017;169:1276&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. Immunity. 2017;47:566&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis N, Hill J, Juchem K, Stefanopoulos D, Modis L. Journal of Neuroimmunology. 2014;277:26&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">25270668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei F, et al. eLIFE. 2016</Citation></Reference><Reference><Citation>Ofengeim D, et al. Cell Reports. 2015;10:1836&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494996</ArticleId><ArticleId IdType="pubmed">25801023</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassamo A, et al. Nature Neuroscience. 2017</Citation></Reference><Reference><Citation>Bruttger J, et al. Immunity. 2015;43:92&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore M, et al. Neuron. 2014;82:380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, et al. Nat Neurosci. 2018</Citation></Reference><Reference><Citation>Hammond TR, et al. Immunity. 2018</Citation></Reference><Reference><Citation>Elmore MRP, et al. Aging Cell. 2018;17:e12832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260908</ArticleId><ArticleId IdType="pubmed">30276955</ArticleId></ArticleIdList></Reference><Reference><Citation>Krukowski K, et al. Sci Rep. 2018;8:7857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959907</ArticleId><ArticleId IdType="pubmed">29777152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice RA, et al. Glia. 2017;65:931&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395311</ArticleId><ArticleId IdType="pubmed">28251674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino SJ, et al. Nat Commun. 2018;9:4578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6212411</ArticleId><ArticleId IdType="pubmed">30385785</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31182505</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures.</ArticleTitle><Pagination><StartPage>e252</StartPage><EndPage>e260</EndPage><MedlinePgn>e252-e260</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000007767</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We aimed to (1) assess and compare baseline plasma and CSF neurofilament light (NfL) for cross-sectional and longitudinal associations with neuroimaging or cognition and (2) determine whether change in plasma NfL corresponded with change in these outcomes.</AbstractText><AbstractText Label="METHODS">Seventy-nine participants without dementia, median age 76 years, had plasma and CSF NfL, neuropsychological testing, and neuroimaging (MRI, amyloid PET, FDG-PET) at the same study visit, and a repeat visit (15 or 30 months later) with both plasma NfL and neuroimaging. Plasma NfL was measured on the Simoa-HD1 Platform and CSF NfL with an in-house ELISA. Linear mixed effects models were used to examine the associations between baseline plasma or CSF NfL and cognitive and neuroimaging outcomes adjusting for age, sex, and education. The relationship between change in plasma NfL and change in the outcomes was assessed using linear regression.</AbstractText><AbstractText Label="RESULTS">There were no cross-sectional associations between CSF or plasma NfL and any neuroimaging or cognitive measure. Longitudinally, higher baseline plasma NfL was associated with worsening in all neuroimaging measures, except amyloid PET, and global cognition. Higher baseline CSF NfL was associated with worsening in cortical thickness and diffusion MRI. The beta estimates for CSF NfL were similar to those for plasma NfL. Change in plasma NfL was associated with change in global cognition, attention, and amyloid PET.</AbstractText><AbstractText Label="CONCLUSION">Elevated baseline plasma NfL is a prognostic marker of cognitive decline and neuroimaging measures of neurodegeneration, and has similar effect sizes to baseline CSF NfL. Change in plasma NfL also tracked with short-term cognitive change.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK. mielke.michelle@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syrjanen</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>Ingmar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremers</LastName><ForeName>Walter K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford</ForeName><Initials>C</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Departments of Health Sciences Research (M.M. Mielke, J.A.S., W.K.K., R.C.P., S.K.), Neurology (M.M. Mielke, D.S.K., R.C.P.), Radiology (P.V., C.J.), and Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; Department of Psychiatry and Neurochemistry (K.B., H.Z., I.S., S.K.), Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Institute of Neurology (H.Z.), University College London, Queen Square; and UK Dementia Research Institute at UCL (H.Z.), London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097495</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG049704</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31182505</ArticleId><ArticleId IdType="pmc">PMC6656645</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007767</ArticleId><ArticleId IdType="pii">WNL.0000000000007767</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci USA 1987;84:3472&#x2013;3476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304893</ArticleId><ArticleId IdType="pubmed">3472217</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003;987:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14499942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017;74:557&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern S, Syrjanen JA, Blennow K, et al. . Association of cerebrospinal fluid neurofilament light protein with risk of mild cognitive impairment among individuals without cognitive impairment. JAMA Neurol Epub 2018 Nov 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439969</ArticleId><ArticleId IdType="pubmed">30419087</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherling CS, Hall T, Berisha F, et al. . Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020786</ArticleId><ArticleId IdType="pubmed">24242746</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15620855</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Gren M, Liman V, et al. . Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep 2016;6:36791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098187</ArticleId><ArticleId IdType="pubmed">27819296</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Karlsson JE, Sj&#xf6;gren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999;52:1090&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">10102440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000;54:1960&#x2013;1964.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822437</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. . The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>St Sauver JL, Grossardt BR, Yawn BP, et al. . Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol 2012;41:1614&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535751</ArticleId><ArticleId IdType="pubmed">23159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivnik RJ, Malec JF, Smith GE, et al. . Mayo's older Americans normative studies: updated AVLT norms for ages 56 to 97. Clin Neuropsychol 1992;6:83&#x2013;104.</Citation></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Gaetani L, H&#xf6;glund K, Parnetti L, et al. . A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther 2018;10:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389166</ArticleId><ArticleId IdType="pubmed">29370869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisslen M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NfL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 2016;3:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Lowe VJ, Senjem ML, et al. . 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Kemp BJ, Jack CR Jr, et al. . Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886669</ArticleId><ArticleId IdType="pubmed">19443597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement 2017;13:205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, et al. . Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage 2005;26:600&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739382</ArticleId><ArticleId IdType="pubmed">15907317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Przybelski SA, Graff-Radford J, et al. . Statins and brain health: Alzheimer's disease and cerebrovascular disease biomarkers in older adults. J Alzheimers Dis 2018;65:1345&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260813</ArticleId><ArticleId IdType="pubmed">30149450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubukata S, Ueda K, Sugihara G, et al. . Corpus callosum pathology as a potential surrogate marker of cognitive impairment in diffuse axonal injury. J Neuropsychiatry Clin Neurosci 2016;28:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">26569151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljungqvist J, Zetterberg H, Mitsis M, Blennow K, Skoglund T. Serum neurofilament light protein as a marker for diffuse axonal injury: results from a case series study. J Neurotrauma 2017;34:1124&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">27539721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Skillb&#xe4;ck T, Mattsson N, et al. . Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 2016;73:60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624219</ArticleId><ArticleId IdType="pubmed">26524180</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Westman E, Hansson O. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiol Aging 2017;58:14&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">28692877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31168563</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection.</ArticleTitle><Pagination><StartPage>1019</StartPage><EndPage>1027</EndPage><MedlinePgn>1019-1027</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.1368</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Epidemiologic evidence suggests that hepatitis C virus (HCV) could be a risk factor for Parkinson disease (PD), but treatment for HCV infection has never been considered in these studies; hence, the association between antiviral therapy and PD incidence has remained unclear. Understanding this association may help in developing strategies to reduce PD occurrence.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify the risk of PD development in patients with HCV infection receiving antiviral treatment and in patients not receiving this treatment.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This cohort study obtained claims data from the Taiwan National Health Insurance Research Database. Adult patients with a new HCV diagnosis with or without hepatitis per International Classification of Diseases, Ninth Revision, Clinical Modification codes and anti-PD medications from January 1, 2003, to December 31, 2013, were selected for inclusion. After excluding participants not eligible for analysis, the remaining patients (n&#x2009;=&#x2009;188&#x202f;152) were categorized into treated and untreated groups according to whether they received antiviral therapy. Propensity score matching was performed to balance the covariates across groups for comparison of main outcomes. This study was conducted from July 1, 2017, to December 31, 2017.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Development of PD was the main outcome. A Cox proportional hazards regression model was used to compare the risk of PD, and the hazard ratio (HR) was calculated at 1 year, 3 years, and 5 years after the index date and at the end of the cohort.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 188&#x202f;152 patients were included in the analysis. An equal number (n&#x2009;=&#x2009;39&#x202f;936) and comparable characteristics of participants were retained in the treated group (with 17&#x202f;970 female [45.0%] and a mean [SD] age of 52.8 [11.4] years) and untreated group (with 17&#x202f;725 female [44.4%] and a mean [SD] age of 52.5 [12.9] years) after matching. The incidence density of PD was 1.00 (95% CI, 0.85-1.15) in the treated group and 1.39 (95% CI, 1.21-1.57) per 1000 person-years in the untreated group. The advantage of antiviral therapy reached statistical significance at the 5-year follow-up (HR, 0.75; 95% CI, 0.59-0.96), and this advantage continued to increase until the end of follow-up (HR, 0.71; 95% CI, 0.58-0.87).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Evidence suggested that the PD incidence was lower in patients with chronic HCV infection who received interferon-based antiviral therapy; this finding may support the hypothesis that HCV could be a risk factor for PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wey-Yil</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Landseed International Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ming-Shyan</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Yi-Hsin</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Tu-Hsueh</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Sheng</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chang Gung Memorial Hospital, Chiayi, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Po-Yu</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yih-Ru</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chin-Song</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Landseed International Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rou-Shayn</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ying-Zu</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Research Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Neuroscience, National Central University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamaneurol.2019.1377</RefSource></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31168563</ArticleId><ArticleId IdType="pmc">PMC6551582</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.1368</ArticleId><ArticleId IdType="pii">2735574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Messina JP, Humphreys I, Flaxman A, et al. . Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi:10.1002/hep.27259</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27259</ArticleId><ArticleId IdType="pmc">PMC4303918</ArticleId><ArticleId IdType="pubmed">25069599</ArticleId></ArticleIdList></Reference><Reference><Citation>Negro F, Forton D, Crax&#xec; A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-1360. doi:10.1053/j.gastro.2015.08.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.08.035</ArticleId><ArticleId IdType="pubmed">26319013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10(3):415-423. doi:10.1007/s12072-015-9684-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-015-9684-3</ArticleId><ArticleId IdType="pmc">PMC4819925</ArticleId><ArticleId IdType="pubmed">26660706</ArticleId></ArticleIdList></Reference><Reference><Citation>Olubamwo OO, Aregbesola AO, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C and risk of coronary atherosclerosis: a systematic review. Public Health. 2016;138:12-25. doi:10.1016/j.puhe.2016.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2016.04.005</ArticleId><ArticleId IdType="pubmed">27207725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MS, Guo SE, Chen MY, et al. . The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. Am J Med Sci. 2014;347(6):478-484. doi:10.1097/MAJ.0b013e3182a5587d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAJ.0b013e3182a5587d</ArticleId><ArticleId IdType="pubmed">24335568</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakpoor J, Noyce A, Goldacre R, et al. . Viral hepatitis and Parkinson disease: a national record-linkage study. Neurology. 2017;88(17):1630-1633. doi:10.1212/WNL.0000000000003848</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003848</ArticleId><ArticleId IdType="pubmed">28356465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu WY, Kang KH, Chen SL, et al. . Hepatitis C virus infection: a risk factor for Parkinson&#x2019;s disease. J Viral Hepat. 2015;22(10):784-791. doi:10.1111/jvh.12392</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.12392</ArticleId><ArticleId IdType="pubmed">25608223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai HH, Liou HH, Muo CH, Lee CZ, Yen RF, Kao CH. Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study. Neurology. 2016;86(9):840-846. doi:10.1212/WNL.0000000000002307</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002307</ArticleId><ArticleId IdType="pubmed">26701382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JM, Jang ES, Ok K, et al. . Association between hepatitis C virus infection and Parkinson&#x2019;s disease. Mov Disord. 2016;31(10):1584-1585. doi:10.1002/mds.26755</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26755</ArticleId><ArticleId IdType="pubmed">27549922</ArticleId></ArticleIdList></Reference><Reference><Citation>Golabi P, Otgonsuren M, Sayiner M, Arsalla A, Gogoll T, Younossi ZM. The prevalence of Parkinson disease among patients with hepatitis C infection. Ann Hepatol. 2017;16(3):342-348. doi:10.5604/01.3001.0009.8588</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/01.3001.0009.8588</ArticleId><ArticleId IdType="pubmed">28425403</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahon P, Bourcier V, Layese R, et al. ; ANRS CO12 CirVir Group . Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142-156.e2. doi:10.1053/j.gastro.2016.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.09.009</ArticleId><ArticleId IdType="pubmed">27641509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu YC, Ho HJ, Huang YT, et al. . Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495-503. doi:10.1136/gutjnl-2014-308163</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-308163</ArticleId><ArticleId IdType="pubmed">25398770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MS, Chung CM, Lin WY, et al. . Antiviral therapy reduces risk of haemorrhagic stroke in patients with HCV infection: a nationwide cohort study. Antivir Ther. 2018;23(1):43-52. doi:10.3851/IMP3172</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP3172</ArticleId><ArticleId IdType="pubmed">28471350</ArticleId></ArticleIdList></Reference><Reference><Citation>Wangensteen KJ, Krawitt EL, Hamill RW, Boyd JT. Parkinsonism in patients with chronic hepatitis C treated with interferons: case reports and review of the literature. Clin Neuropharmacol. 2016;39(1):1-5. doi:10.1097/WNF.0000000000000120</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNF.0000000000000120</ArticleId><ArticleId IdType="pubmed">26757310</ArticleId></ArticleIdList></Reference><Reference><Citation>Wangensteen KJ, Krawitt EL, Hamill RW, Boyd JT. Hepatitis C virus infection: a risk factor for Parkinson&#x2019;s disease. J Viral Hepat. 2016;23(7):535. doi:10.1111/jvh.12517</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.12517</ArticleId><ArticleId IdType="pubmed">26913500</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd JT, Wangensteen KJ, Krawitt EL, Hamill RW, Kao CH, Tsai HH. Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study. Neurology. 2016;87(3):342. doi:10.1212/01.wnl.0000489939.73359.c3</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000489939.73359.c3</ArticleId><ArticleId IdType="pubmed">27432181</ArticleId></ArticleIdList></Reference><Reference><Citation>Abushouk AI, El-Husseny MWA, Magdy M, et al. . Evidence for association between hepatitis C virus and Parkinson&#x2019;s disease. Neurol Sci. 2017;38(11):1913-1920. doi:10.1007/s10072-017-3077-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3077-4</ArticleId><ArticleId IdType="pubmed">28780707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijarnpreecha K, Chesdachai S, Jaruvongvanich V, Ungprasert P. Hepatitis C virus infection and risk of Parkinson&#x2019;s disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(1):9-13. doi:10.1097/MEG.0000000000000991</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000991</ArticleId><ArticleId IdType="pubmed">29049127</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Insurance Administration, Ministry of Health and Welfare  2014-2015 National Health Insurance annual report. http://www.nhi.gov.tw/Resource/webdata/28140_1_National%20Health%20Insurance%20in%20Taiwan%202014-2015%20(bilingual).pdf. Accessed April 29, 2015.</Citation></Reference><Reference><Citation>Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24(3):336-345. doi:10.1111/j.1440-1746.2009.05789.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2009.05789.x</ArticleId><ArticleId IdType="pubmed">19335784</ArticleId></ArticleIdList></Reference><Reference><Citation>Omata M, Kanda T, Yu ML, et al. . APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6(2):409-435. doi:10.1007/s12072-012-9342-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-012-9342-y</ArticleId><ArticleId IdType="pubmed">26201405</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4(1):207-220. doi:10.2215/CJN.03710708</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03710708</ArticleId><ArticleId IdType="pubmed">19129320</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37(6):647-652. doi:10.1111/apt.12234</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12234</ArticleId><ArticleId IdType="pubmed">23384408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Schwarzschild MA. The epidemiology of Parkinson&#x2019;s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257-1272. doi:10.1016/S1474-4422(16)30230-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30230-7</ArticleId><ArticleId IdType="pubmed">27751556</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology. 2018;91(2):e139-e142. doi:10.1212/WNL.0000000000005771</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005771</ArticleId><ArticleId IdType="pubmed">29898968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin PY, Chang SN, Hsiao TH, Huang BT, Lin CH, Yang PC. Association between Parkinson disease and risk of cancer in Taiwan. JAMA Oncol. 2015;1(5):633-640. doi:10.1001/jamaoncol.2015.1752</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2015.1752</ArticleId><ArticleId IdType="pubmed">26181771</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KD, Yang CY, Lee MY, Ho SC, Liu CK, Shin SJ. Statin therapy prevents the onset of Parkinson disease in patients with diabetes. Ann Neurol. 2016;80(4):532-540. doi:10.1002/ana.24751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24751</ArticleId><ArticleId IdType="pubmed">27471847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CH, Lin JW, Liu YC, Chang CH, Wu RM. Risk of Parkinson&#x2019;s disease following anxiety disorders: a nationwide population-based cohort study. Eur J Neurol. 2015;22(9):1280-1287. doi:10.1111/ene.12740</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12740</ArticleId><ArticleId IdType="pubmed">26031920</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Aarsland D, Barone P, et al. . Identifying prodromal Parkinson&#x2019;s disease: pre-motor disorders in Parkinson&#x2019;s disease. Mov Disord. 2012;27(5):617-626. doi:10.1002/mds.24996</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.24996</ArticleId><ArticleId IdType="pubmed">22508280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YC, Lin CH, Wu RM, et al. . Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology. 2013;81(5):410-416. doi:10.1212/WNL.0b013e31829d873c</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31829d873c</ArticleId><ArticleId IdType="pubmed">23884037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Pieper CF, Ahmed A, Col&#xf3;n-Emeric CS. Use and interpretation of propensity scores in aging research: a guide for clinical researchers. J Am Geriatr Soc. 2016;64(10):2065-2073. doi:10.1111/jgs.14253</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14253</ArticleId><ArticleId IdType="pmc">PMC5072994</ArticleId><ArticleId IdType="pubmed">27550392</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172(9):1092-1097. doi:10.1093/aje/kwq224</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq224</ArticleId><ArticleId IdType="pmc">PMC2962254</ArticleId><ArticleId IdType="pubmed">20802241</ArticleId></ArticleIdList></Reference><Reference><Citation>De Virgilio A, Greco A, Fabbrini G, et al. . Parkinson&#x2019;s disease: autoimmunity and neuroinflammation. Autoimmun Rev. 2016;15(10):1005-1011. doi:10.1016/j.autrev.2016.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.07.022</ArticleId><ArticleId IdType="pubmed">27497913</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1316-1324. doi:10.1001/jamaneurol.2016.2742</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.2742</ArticleId><ArticleId IdType="pubmed">27668667</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampino R, Marrone A, Restivo L, et al. . Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5(10):528-540. doi:10.4254/wjh.v5.i10.528</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v5.i10.528</ArticleId><ArticleId IdType="pmc">PMC3812455</ArticleId><ArticleId IdType="pubmed">24179612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokemeyer M, Ding XQ, Goldbecker A, et al. . Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut. 2011;60(3):370-377. doi:10.1136/gut.2010.217976</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2010.217976</ArticleId><ArticleId IdType="pubmed">20926642</ArticleId></ArticleIdList></Reference><Reference><Citation>Forton DM, Hamilton G, Allsop JM, et al. . Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol. 2008;49(3):316-322. doi:10.1016/j.jhep.2008.03.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2008.03.022</ArticleId><ArticleId IdType="pubmed">18538439</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissenborn K, Ennen JC, Bokemeyer M, et al. . Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut. 2006;55(11):1624-1630. doi:10.1136/gut.2005.080267</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.080267</ArticleId><ArticleId IdType="pmc">PMC1860082</ArticleId><ArticleId IdType="pubmed">16682431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Serrano E, Rodr&#xed;guez-Ramos C, D&#xed;az F, Mart&#xed;n-Herrera L, Gir&#xf3;n-Gonz&#xe1;lez JA. Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat. 2006;13(4):230-234. doi:10.1111/j.1365-2893.2005.00679.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2893.2005.00679.x</ArticleId><ArticleId IdType="pubmed">16611188</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher NF, Wilson GK, Murray J, et al. . Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology. 2012;142(3):634-643.e6. doi:10.1053/j.gastro.2011.11.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.11.028</ArticleId><ArticleId IdType="pmc">PMC3801216</ArticleId><ArticleId IdType="pubmed">22138189</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat. 2012;19(5):301-306. doi:10.1111/j.1365-2893.2012.01591.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2893.2012.01591.x</ArticleId><ArticleId IdType="pubmed">22497808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman SL, Murray JM, Eng FJ, Walewski JL, Morgello S, Branch AD. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis. 2008;197(4):597-607. doi:10.1086/526519</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/526519</ArticleId><ArticleId IdType="pmc">PMC2736634</ArticleId><ArticleId IdType="pubmed">18275278</ArticleId></ArticleIdList></Reference><Reference><Citation>Radkowski M, Wilkinson J, Nowicki M, et al. . Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002;76(2):600-608. doi:10.1128/JVI.76.2.600-608.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.2.600-608.2002</ArticleId><ArticleId IdType="pmc">PMC136845</ArticleId><ArticleId IdType="pubmed">11752151</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas HE, Laskus T, Radkowski M, et al. . Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl. 2002;8(11):1014-1019. doi:10.1053/jlts.2002.36393</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jlts.2002.36393</ArticleId><ArticleId IdType="pubmed">12424714</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol. 1997;76(1-2):105-111. doi:10.1016/S0165-5728(97)00034-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(97)00034-9</ArticleId><ArticleId IdType="pubmed">9184639</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson&#x2019;s disease. Curr Opin Neurol. 2014;27(4):434-441. doi:10.1097/WCO.0000000000000112</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000112</ArticleId><ArticleId IdType="pmc">PMC4181670</ArticleId><ArticleId IdType="pubmed">24978368</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, Zhang J. Biochemical premotor biomarkers for Parkinson&#x2019;s disease. Mov Disord. 2012;27(5):644-650. doi:10.1002/mds.24956</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.24956</ArticleId><ArticleId IdType="pmc">PMC3428741</ArticleId><ArticleId IdType="pubmed">22508282</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichmann H. Premotor diagnosis of Parkinson&#x2019;s disease. Neurosci Bull. 2017;33(5):526-534. doi:10.1007/s12264-017-0159-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-017-0159-5</ArticleId><ArticleId IdType="pmc">PMC5636732</ArticleId><ArticleId IdType="pubmed">28776303</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo G, Lorenzini L, Zironi E, et al. . Brain distribution of ribavirin after intranasal administration. Antiviral Res. 2011;92(3):408-414. doi:10.1016/j.antiviral.2011.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.09.012</ArticleId><ArticleId IdType="pubmed">22001322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajihara M, Montagnese S, Khanna P, et al. . Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases. Eur J Gastroenterol Hepatol. 2010;22(5):628-631. doi:10.1097/MEG.0b013e32833383e3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0b013e32833383e3</ArticleId><ArticleId IdType="pubmed">20075741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67(5):600-606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917467</ArticleId><ArticleId IdType="pubmed">20437557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak B, Svanstr&#xf6;m H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson&#x2019;s disease. Am J Epidemiol. 2012;175(7):627-635. doi:10.1093/aje/kwr362</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwr362</ArticleId><ArticleId IdType="pubmed">22387374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS. Antihypertensive agents and risk of Parkinson&#x2019;s disease: a nationwide cohort study. PLoS One. 2014;9(6):e98961. doi:10.1371/journal.pone.0098961</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098961</ArticleId><ArticleId IdType="pmc">PMC4049613</ArticleId><ArticleId IdType="pubmed">24910980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31209175</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>32</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Sleep as a Potential Biomarker of Tau and &#x3b2;-Amyloid Burden in the Human Brain.</ArticleTitle><Pagination><StartPage>6315</StartPage><EndPage>6324</EndPage><MedlinePgn>6315-6324</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0503-19.2019</ELocationID><Abstract><AbstractText>Recent proposals suggest that sleep may be a factor associated with accumulation of two core pathological features of Alzheimer's disease (AD): tau and &#x3b2;-amyloid (A&#x3b2;). Here we combined PET measures of A&#x3b2; and tau, electroencephalogram sleep recordings, and retrospective sleep evaluations to investigate the potential utility of sleep measures in predicting <i>in vivo</i> AD pathology in male and female older adults. Regression analyses revealed that the severity of impaired slow oscillation-sleep spindle coupling predicted greater medial temporal lobe tau burden. A&#x3b2; burden was not associated with coupling impairment but instead predicted the diminished amplitude of &lt;1 Hz slow-wave-activity, results that were statistically dissociable from each other. Additionally, comparisons of AD pathology and retrospective, self-reported changes in sleep duration demonstrated that changes in sleep across the lifespan can predict late-life A&#x3b2; and tau burden. Thus, quantitative and qualitative features of human sleep represent potential noninvasive, cost-effective, and scalable biomarkers (current and future forecasting) of AD pathology, and carry both therapeutic and public health implications.<b>SIGNIFICANCE STATEMENT</b> Several studies have linked sleep disruption to the progression of Alzheimer's disease (AD). Tau and &#x3b2;-amyloid (A&#x3b2;), the primary pathological features of AD, are associated with both objective and subjective changes in sleep. However, it remains unknown whether late life tau and A&#x3b2; burden are associated with distinct impairments in sleep physiology or changes in sleep across the lifespan. Using polysomnography, retrospective questionnaires, and tau- and A&#x3b2;-specific PET, the present study reveals human sleep signatures that dissociably predict levels of brain tau and A&#x3b2; in older adults. These results suggest that a night of polysomnography may aid in evaluating tau and A&#x3b2; burden, and that treating sleep deficiencies within decade-specific time windows may serve in delaying AD progression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 the authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winer</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-4069-3158</Identifier><AffiliationInfo><Affiliation>Center for Human Sleep Science, Department of Psychology, University of California Berkeley, Berkeley, California 94720, mpwalker@berkeley.edu jwiner@berkeley.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mander</LastName><ForeName>Bryce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Center for Human Sleep Science, Department of Psychology, University of California Berkeley, Berkeley, California 94720.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, University of California Irvine, Orange, California 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helfrich</LastName><ForeName>Randolph F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maass</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California 94720.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Magdeburg 39120, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Theresa M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Suzanne L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0003-0209-3127</Identifier><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Robert T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4458-113X</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California 94720.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Center for Human Sleep Science, Department of Psychology, University of California Berkeley, Berkeley, California 94720, mpwalker@berkeley.edu jwiner@berkeley.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California 94720.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS021135</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG057107</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG063428</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 NS107609</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031164</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054106</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS021135</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054019</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000615233">Carbon-11</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>GZ5I74KB8G</RegistryNumber><NameOfSubstance UI="C000615276">Fluorine-18</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020919" MajorTopicYN="N">Sleep Disorders, Intrinsic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012894" MajorTopicYN="N">Sleep Stages</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">beta-amyloid</Keyword><Keyword MajorTopicYN="N">sleep</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31209175</ArticleId><ArticleId IdType="pmc">PMC6687908</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0503-19.2019</ArticleId><ArticleId IdType="pii">JNEUROSCI.0503-19.2019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams JN, Lockhart SN, Li L, Jagust WJ (2018) Relationships between tau and glucose metabolism reflect Alzheimer's disease pathology in cognitively normal older adults. Cereb Cortex 29:1997&#x2013;2009. 10.1093/cercor/bhy078</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhy078</ArticleId><ArticleId IdType="pmc">PMC6458898</ArticleId><ArticleId IdType="pubmed">29912295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahnaou A, Moechars D, Raeymaekers L, Biermans R, Manyakov NV, Bottelbergs A, Wintmolders C, Van Kolen K, Van De Casteele T, Kemp JA, Drinkenburg WH (2017) Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer's disease pathology. Sci Rep 7:14189. 10.1038/s41598-017-13839-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-13839-6</ArticleId><ArticleId IdType="pmc">PMC5660172</ArticleId><ArticleId IdType="pubmed">29079799</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631&#x2013;639. 10.1212/WNL.42.3.631</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.3.631</ArticleId><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Maass A, Jagust WJ (2017) Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data. Data Brief 15:648&#x2013;657. 10.1016/j.dib.2017.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dib.2017.10.024</ArticleId><ArticleId IdType="pmc">PMC5671473</ArticleId><ArticleId IdType="pubmed">29124088</ArticleId></ArticleIdList></Reference><Reference><Citation>Berens P. (2009) CircStat: a MATLAB toolbox for circular statistics. J Stat Softw 31:1&#x2013;21.</Citation></Reference><Reference><Citation>Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351&#x2013;357. 10.1016/S0197-4580(97)00056-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00056-0</ArticleId><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho DZ, St Louis EK, Knopman DS, Boeve BF, Lowe VJ, Roberts RO, Mielke MM, Przybelski SA, Machulda MM, Petersen RC, Jack CR Jr, Vemuri P (2018) Association of excessive daytime sleepiness with longitudinal &#x3b2;-amyloid accumulation in elderly persons without dementia. JAMA Neurol 75:672&#x2013;680. 10.1001/jamaneurol.2018.0049</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0049</ArticleId><ArticleId IdType="pmc">PMC5885188</ArticleId><ArticleId IdType="pubmed">29532057</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens Z, M&#xf6;lle M, Eross L, Barsi P, Hal&#xe1;sz P, Born J (2007) Temporal coupling of parahippocampal ripples, sleep spindles and slow oscillations in humans. Brain 130:2868&#x2013;2878. 10.1093/brain/awm146</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm146</ArticleId><ArticleId IdType="pubmed">17615093</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekelmann S, Born J (2010) The memory function of sleep. Nat Rev Neurosci 11:114&#x2013;126. 10.1038/nrn2762</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2762</ArticleId><ArticleId IdType="pubmed">20046194</ArticleId></ArticleIdList></Reference><Reference><Citation>Dvorak D, Fenton AA (2014) Toward a proper estimation of phase-amplitude coupling in neural oscillations. J Neurosci Methods 225:42&#x2013;56. 10.1016/j.jneumeth.2014.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2014.01.002</ArticleId><ArticleId IdType="pmc">PMC3955271</ArticleId><ArticleId IdType="pubmed">24447842</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR (1975) &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189&#x2013;198. 10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedenreich CM, Courneya KS, Bryant HE (1998) The Lifetime Total Physical Activity Questionnaire: development and reliability. Med Sci Sports Exerc 30:266&#x2013;274. 10.1097/00005768-199805001-01514</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005768-199805001-01514</ArticleId><ArticleId IdType="pubmed">9502356</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60:1495&#x2013;1500. 10.1212/01.WNL.0000063311.58879.01</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000063311.58879.01</ArticleId><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfrich RF, Mander BA, Jagust WJ, Knight RT, Walker MP (2018) Old brains come uncoupled in sleep: slow wave-spindle synchrony, brain atrophy, and forgetting. Neuron 97:221&#x2013;230.e4. 10.1016/j.neuron.2017.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.11.020</ArticleId><ArticleId IdType="pmc">PMC5754239</ArticleId><ArticleId IdType="pubmed">29249289</ArticleId></ArticleIdList></Reference><Reference><Citation>Hita-Ya&#xf1;ez E, Atienza M, Cantero JL (2013) Polysomnographic and subjective sleep markers of mild cognitive impairment. Sleep 36:1327&#x2013;1334. 10.5665/sleep.2956</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.2956</ArticleId><ArticleId IdType="pmc">PMC3738041</ArticleId><ArticleId IdType="pubmed">23997365</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Mahan TE, Robinson GO, Rocha A, Holtzman DM (2017) Altered sleep and EEG power in the P301S Tau transgenic mouse model. Ann Clin Transl Neurol 4:180&#x2013;190. 10.1002/acn3.390</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.390</ArticleId><ArticleId IdType="pmc">PMC5338139</ArticleId><ArticleId IdType="pubmed">28275652</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM (2019) The sleep&#x2013;wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363:880&#x2013;884. 10.1126/science.aav2546</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav2546</ArticleId><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="pubmed">30679382</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207&#x2013;216. 10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, Machulda MM, Mielke MM, Roberts RO, Vemuri P, Reyes DA, Petersen RC (2017) Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement 13:205&#x2013;216. 10.1016/j.jalz.2016.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R (2018) NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 14:535&#x2013;562. 10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. (2018) Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci 19:687&#x2013;700. 10.1038/s41583-018-0067-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0067-3</ArticleId><ArticleId IdType="pmc">PMC7032048</ArticleId><ArticleId IdType="pubmed">30266970</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, et al. (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79:110&#x2013;119. 10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, Morris JC, Holtzman DM (2013) Sleep quality and preclinical Alzheimer disease. JAMA Neurol 70:587&#x2013;593. 10.1001/jamaneurol.2013.2334</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.2334</ArticleId><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM (2009) Amyloid-&#x3b2; dynamics are regulated by orexin and the sleep&#x2013;wake cycle. Science 326:1005&#x2013;1007. 10.1126/science.1180962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1180962</ArticleId><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, Wilson RS, Jagust WJ (2012) Association of lifetime cognitive engagement and low &#x3b2;-amyloid deposition. Arch Neurol 69:623&#x2013;629. 10.1001/archneurol.2011.2748</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.2748</ArticleId><ArticleId IdType="pmc">PMC3747737</ArticleId><ArticleId IdType="pubmed">22271235</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834&#x2013;840. 10.1097/00004647-199609000-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004647-199609000-00008</ArticleId><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TL, Holtzman DM (2019) Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Sci Transl Med 11:eaau6550. 10.1126/scitranslmed.aau6550</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6550</ArticleId><ArticleId IdType="pmc">PMC6342564</ArticleId><ArticleId IdType="pubmed">30626715</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, Rabinovici GD, Jagust WJ (2017) Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage 157:448&#x2013;463. 10.1016/j.neuroimage.2017.05.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, Baker SL, Rabinovici GD, Jagust WJ (2018) Entorhinal tau pathology, episodic memory decline and neurodegeneration in aging. J Neurosci 38:530&#x2013;543. 10.1523/JNEUROSCI.2028-17.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2028-17.2017</ArticleId><ArticleId IdType="pmc">PMC5777108</ArticleId><ArticleId IdType="pubmed">29192126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP (2015) &#x3b2;-Amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci 18:1051&#x2013;1057. 10.1038/nn.4035</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4035</ArticleId><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="pubmed">26030850</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Winer JR, Jagust WJ, Walker MP (2016) Sleep: a novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer's disease? Trends Neurosci 39:552&#x2013;566. 10.1016/j.tins.2016.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2016.05.002</ArticleId><ArticleId IdType="pmc">PMC4967375</ArticleId><ArticleId IdType="pubmed">27325209</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA (2015) Pathological tau disrupts ongoing network activity. Neuron 85:959&#x2013;966. 10.1016/j.neuron.2015.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.01.025</ArticleId><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;lle M, Bergmann TO, Marshall L, Born J (2011) Fast and slow spindles during the sleep slow oscillation: disparate coalescence and engagement in memory processing. Sleep 34:1411&#x2013;1421. 10.5665/SLEEP.1290</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/SLEEP.1290</ArticleId><ArticleId IdType="pmc">PMC3174843</ArticleId><ArticleId IdType="pubmed">21966073</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M, Riedner BA, Huber R, Massimini M, Ferrarelli F, Tononi G (2009) Source modeling sleep slow waves. Proc Natl Acad Sci U S A 106:1608&#x2013;1613. 10.1073/pnas.0807933106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807933106</ArticleId><ArticleId IdType="pmc">PMC2635823</ArticleId><ArticleId IdType="pubmed">19164756</ArticleId></ArticleIdList></Reference><Reference><Citation>Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP (1999) Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 131:485&#x2013;491. 10.7326/0003-4819-131-7-199910050-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-131-7-199910050-00002</ArticleId><ArticleId IdType="pubmed">10507956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucci M, Mapelli D, Mondini S (2012) Cognitive Reserve Index questionnaire (CRIq): a new instrument for measuring cognitive reserve. Aging Clin Exp Res 24:218&#x2013;226. 10.3275/7800</Citation><ArticleIdList><ArticleId IdType="doi">10.3275/7800</ArticleId><ArticleId IdType="pubmed">21691143</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L (2016) Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci 17:777&#x2013;792. 10.1038/nrn.2016.141</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.141</ArticleId><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernet CR, Wilcox R, Rousselet GA (2012) Robust correlation analyses: false positive and power validation using a new open source Matlab toolbox. Front Psychol 3:606. 10.3389/fpsyg.2012.00606</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2012.00606</ArticleId><ArticleId IdType="pmc">PMC3541537</ArticleId><ArticleId IdType="pubmed">23335907</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ (2012) Subjective cognition and amyloid deposition imaging: a Pittsburgh compound B positron emission tomography study in normal elderly individuals. Arch Neurol 69:223&#x2013;229. 10.1001/archneurol.2011.666</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.666</ArticleId><ArticleId IdType="pmc">PMC4004919</ArticleId><ArticleId IdType="pubmed">22332189</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 25:1528&#x2013;1547. 10.1038/sj.jcbfm.9600146</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600146</ArticleId><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz PN, Vitaliano PP, Vitiello MV, Bokan J, Raskind M, Peskind E, Gerber C (1982) Sleep, EEG and mental function changes in senile dementia of the Alzheimer's type. Neurobiol Aging 3:361&#x2013;370. 10.1016/0197-4580(82)90024-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(82)90024-0</ArticleId><ArticleId IdType="pubmed">7170052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtschaffen A, Kales A (1968) A manual standardized terminology, techniques and scoring system for sleep stages of human subjects. Bethesda, MD: Department of Health.</Citation><ArticleIdList><ArticleId IdType="pubmed">11422885</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM (2012) Disruption of the sleep&#x2013;wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med 4:150ra122. 10.1126/scitranslmed.3004291</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004291</ArticleId><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC (1998) Correction for partial volume effects in PET: principle and validation. J Nucl Med 39:904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ME, Slanger T, Chang-Claude J, Wahrendorf J, Steindorf K (2006) Evaluation of a short retrospective questionnaire for physical activity in women. Eur J Epidemiol 21:575&#x2013;585. 10.1007/s10654-006-9042-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-006-9042-9</ArticleId><ArticleId IdType="pubmed">17004027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ (2016) PET imaging of tau deposition in the aging human brain. Neuron 89:971&#x2013;982. 10.1016/j.neuron.2016.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobell J, Block G, Koslowe P, Tobin J, Andres R (1989) Validation of a retrospective questionnaire assessing diet 10&#x2013;15 years ago. Am J Epidemiol 130:173&#x2013;187. 10.1093/oxfordjournals.aje.a115310</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a115310</ArticleId><ArticleId IdType="pubmed">2741904</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, Li QX, Collins SJ, Carlsson C, Asthana S, Masters CL, Johnson S, Morris JC, Albert M, Gross AL (2019) ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology 92:e1567&#x2013;e1579. 10.1212/WNL.0000000000007248</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007248</ArticleId><ArticleId IdType="pmc">PMC6448449</ArticleId><ArticleId IdType="pubmed">30842300</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Gamaldo AA, An Y, Wu MN, Simonsick EM, Bilgel M, Zhou Y, Wong DF, Ferrucci L, Resnick SM (2013) Self-reported sleep and beta-amyloid deposition in community-dwelling older adults. JAMA Neurol 70:1537&#x2013;1543. 10.1001/jamaneurol.2013.4258</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4258</ArticleId><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, An Y, Wu MN, Owusu JT, Simonsick EM, Bilgel M, Ferrucci L, Wong DF, Resnick SM (2018) Excessive daytime sleepiness and napping in cognitively normal adults: associations with subsequent amyloid deposition measured by PiB PET. Sleep 41:zsy152. 10.1093/sleep/zsy152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsy152</ArticleId><ArticleId IdType="pmc">PMC6289234</ArticleId><ArticleId IdType="pubmed">30257013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, Bendlin BB, Racine AM, Okonkwo OC, Christian BT, Koscik RL, Sager MA, Asthana S, Johnson SC, Benca RM (2015) Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging 36:2568&#x2013;2576. 10.1016/j.neurobiolaging.2015.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.05.004</ArticleId><ArticleId IdType="pmc">PMC4523445</ArticleId><ArticleId IdType="pubmed">26059712</ArticleId></ArticleIdList></Reference><Reference><Citation>Staresina BP, Bergmann TO, Bonnefond M, van der Meij R, Jensen O, Deuker L, Elger CE, Axmacher N, Fell J (2015) Hierarchical nesting of slow oscillations, spindles and ripples in the human hippocampus during sleep. Nat Neurosci 18:1679&#x2013;1686. 10.1038/nn.4119</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4119</ArticleId><ArticleId IdType="pmc">PMC4625581</ArticleId><ArticleId IdType="pubmed">26389842</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, La Joie R, Arthur-Bentil SK, Vogel JW, Marks SM, Lehmann M, Rosen HJ, Reed B, Olichney J, Boxer AL, Miller BL, Borys E, Jin LW, Huang EJ, Grinberg LT, et al. (2015) Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 138:2020&#x2013;2033. 10.1093/brain/awv112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv112</ArticleId><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Witton J, Staniaszek LE, Bartsch U, Randall AD, Jones MW, Brown JT (2016) Disrupted hippocampal sharp-wave ripple-associated spike dynamics in a transgenic mouse model of dementia. J Physiol 594:4615&#x2013;4630. 10.1113/jphysiol.2014.282889</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2014.282889</ArticleId><ArticleId IdType="pmc">PMC4983632</ArticleId><ArticleId IdType="pubmed">25480798</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Zhan G, Fenik P, Brandes M, Bell P, Francois N, Shulman K, Veasey S (2018) Chronic sleep disruption advances the temporal progression of tauopathy in P301S mutant mice. J Neurosci 38:10255&#x2013;10270. 10.1523/JNEUROSCI.0275-18.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0275-18.2018</ArticleId><ArticleId IdType="pmc">PMC6262148</ArticleId><ArticleId IdType="pubmed">30322903</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31221773</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>365</Volume><Issue>6450</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Amyloid &#x3b2; oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaav9518</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aav9518</ELocationID><Abstract><AbstractText>Cerebral blood flow is reduced early in the onset of Alzheimer's disease (AD). Because most of the vascular resistance within the brain is in capillaries, this could reflect dysfunction of contractile pericytes on capillary walls. We used live and rapidly fixed biopsied human tissue to establish disease relevance, and rodent experiments to define mechanism. We found that in humans with cognitive decline, amyloid &#x3b2; (A&#x3b2;) constricts brain capillaries at pericyte locations. This was caused by A&#x3b2; generating reactive oxygen species, which evoked the release of endothelin-1 (ET) that activated pericyte ET<sub>A</sub> receptors. Capillary, but not arteriole, constriction also occurred in vivo in a mouse model of AD. Thus, inhibiting the capillary constriction caused by A&#x3b2; could potentially reduce energy lack and neurodegeneration in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nortley</LastName><ForeName>Ross</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9967-4774</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korte</LastName><ForeName>Nils</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7893-8432</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izquierdo</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4372-348X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirunpattarasilp</LastName><ForeName>Chanawee</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1262-9466</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Anusha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3642-5049</Identifier><AffiliationInfo><Affiliation>Knight Cardiovascular Institute, Oregon Health &amp; Science University, Portland, OR 97239, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaunmuktane</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-7738-8881</Identifier><AffiliationInfo><Affiliation>Division of Neuropathology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyrargyri</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0571-4139</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khennouf</LastName><ForeName>Lila</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6078-7819</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madry</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0522-7197</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6483-7684</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard-Loendt</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6970-4992</Identifier><AffiliationInfo><Affiliation>Division of Neuropathology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Wenhui</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-9865-0375</Identifier><AffiliationInfo><Affiliation>Molecular Physiology, CIPMM, University of Saarland, D-66421 Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9659-9251</Identifier><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Centre for Brain Science, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0003-1970-6903</Identifier><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Centre for Brain Science, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9821-0342</Identifier><AffiliationInfo><Affiliation>Division of Neuropathology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sethi</LastName><ForeName>Huma</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurosurgery, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attwell</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3618-0843</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK. d.attwell@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>099222</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>203736</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>249670</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019332">Endothelin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044022">Receptor, Endothelin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2019 Jul 19;365(6450):223-224. doi: 10.1126/science.aay2720.</RefSource><PMID Version="1">31320524</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019332" MajorTopicYN="N">Endothelin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044022" MajorTopicYN="N">Receptor, Endothelin A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31221773</ArticleId><ArticleId IdType="mid">EMS83750</ArticleId><ArticleId IdType="pmc">PMC6658218</ArticleId><ArticleId IdType="doi">10.1126/science.aav9518</ArticleId><ArticleId IdType="pii">science.aav9518</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-P&#xe9;rez JM, Evans AC. Alzheimer&#x2019;s Disease Neuroimaging Initiative, Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Comm. 2016;7 11934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="pubmed">27327500</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer's disease. Acta Neuropathol. 2016;131:645&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835514</ArticleId><ArticleId IdType="pubmed">26711459</ArticleId></ArticleIdList></Reference><Reference><Citation>Asllani I, Habeck C, Scarmeas N, Borogovac A, Brown TR, Stern Y. Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab. 2008;28:725&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711077</ArticleId><ArticleId IdType="pubmed">17960142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, M&#xfc;ller-Hill B. The precursor of Alzheimer&#x2019;s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 1991;12:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The molecular pathology of Alzheimer&#x2019;s disease. Neuron. 1991;6:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Hashimura T, Miyakawa T. Observations of microvessels in the brain with Alzheimer&#x2019;s disease by the scanning electron microscope. Jap J Psychiatr Neurol. 1991;45:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">1800815</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res. 1993;15:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103579</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. &#x3b2;-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996;380:168&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600393</ArticleId></ArticleIdList></Reference><Reference><Citation>Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F, Mullan M. Soluble Alzheimer&#x2019;s &#x3b2;-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett. 1998;257:77&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9865931</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Molec Neurodegen. 2010;5:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873254</ArticleId><ArticleId IdType="pubmed">20388225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W. Hypoxia facilitates Alzheimer&#x2019;s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA. 2006;103:18727&#x2013;18732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693730</ArticleId><ArticleId IdType="pubmed">17121991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW. Hypoxia-inducible factor 1&#x3b1;(HIF-1&#x3b1;)-mediated hypoxia increases BACE1 expression and &#x3b2;-amyloid generation. J Biol Chem. 2007;282:10873&#x2013;10880.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303576</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. A&#x3b2;-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol. 2001;281:H2417&#x2013;2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709407</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould IG, Tsai P, Kleinfeld D, Linninger A. The capillary bed offers the largest hemodynamic resistance to the cortical blood supply. J Cereb Blood Flow Metab. 2017;37:52&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363755</ArticleId><ArticleId IdType="pubmed">27780904</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen RB, Egefjord L, Angleys H, Mouridsen K, Gejl M, M&#xf8;ller A, Brock B, Br&#xe6;ndgaard H, Gottrup H, Rungby J, Eskildsen SF, et al. Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease. Alz Dement. 2017;13:1143&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">28343848</ArticleId></ArticleIdList></Reference><Reference><Citation>Peppiatt CM, Howarth C, Mobbs PG, Attwell D. Bidirectional control of CNS capillary diameter by pericytes. Nature. 2006;443:700&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761848</ArticleId><ArticleId IdType="pubmed">17036005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, O&#x2019;Farrell FM, Buchan AM, Lauritzen M, Attwell D. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976267</ArticleId><ArticleId IdType="pubmed">24670647</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Mishra A, Hall CN, O&#x2019;Farrell FM, Dalkara T. What is a pericyte? J Cereb Blood Flow Metab. 2016;36:451&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759679</ArticleId><ArticleId IdType="pubmed">26661200</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Jim&#xe9;nez E, Angleys H, Rasmussen PM, West MJ, Catalini L, Iversen NK, Jensen MS, Frische S, &#xd8;stergaard L. Disturbances in the control of capillary flow in an aged APPswe/PS1&#x394;E9 model of Alzheimer's disease. Neurobiol Aging. 2017;62:82&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29131981</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small A&#x3b2; oligomers: the solution to an Alzheimer&#x2019;s disease conundrum? Trends Neurosci. 2001;24:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Lintner F, Jellinger KA. Amyloid &#x3b2; peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol. 2004;107:283&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">14986026</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon-Martinez L, Yilmaz-Ozcan S, Yemisci M, Schallek J, K&#x131;l&#x131;&#xe7; K, Can A, Di Polo A, Dalkara T. Capillary pericytes express &#x3b1;-smooth muscle actin, which requires prevention of filamentous-actin depolymerization for detection. Elife. 2018;7:e34861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5862523</ArticleId><ArticleId IdType="pubmed">29561727</ArticleId></ArticleIdList></Reference><Reference><Citation>Love S, Palmer J. Endothelin receptor antagonists: potential in Alzheimer's disease. Pharmacol Res. 2011;63:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193044</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999;2:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda J, Ago T, Nishimura A, Nakamura K, Matsuo R, Wakisaka Y, Kamouchi M, Kitazono T. Nox4 is a major source of superoxide production in human brain pericytes. J Vasc Res. 2014;51:429&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">25612841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, et al. An RNA-Seq transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A, Hochgerner H, L&#xf6;nnerberg P, Johnsson A, Memic F, van der Zwan J, H&#xe4;ring M, Braun E, Borm LE, La Manno G, Codeluppi S, et al. Molecular architecture of the mouse nervous system. Cell. 2018;174:999&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Grammas P. Endothelin-1 is elevated in Alzheimer's disease brain microvessels and is neuroprotective. J Alzheimers Dis. 2010;21:887&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">20634595</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer JC, Barker R, Kehoe PG, Love S. Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-&#x3b2;. J Alzheimers Dis. 2012;29:853&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">22330820</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, Mullan M. Vasoactive effects of A&#x3b2; in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res. 2003;25:642&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">14503019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton NB, Attwell D, Hall CN. Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front Neuroenergetics. 2010;2:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912025</ArticleId><ArticleId IdType="pubmed">20725515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianca VD, Dusi S, Bianchini E, Dal Pr&#xe0; I, Rossi F. &#x3b2;-amyloid activates the O2. forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol Chem. 1999;274:15493&#x2013;15499.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336441</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Uekawa K, Garcia-Bonilla L, Koizumi K, Murphy M, Pistik R, Younkin L, Younkin S, Zhou P, Carlson G, Anrather J, et al. Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer A&#x3b2; peptides. Circ Res. 2017;121:258&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522360</ArticleId><ArticleId IdType="pubmed">28515043</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;piranec K, Chen W, Werner F, Nikolaev VO, Naruke T, Koch F, Werner A, Eder-Negrin P, Di&#xe9;guez-Hurtado R, Adams RH, Baba HA, et al. Endothelial C-type natriuretic peptide acts on pericytes to regulate microcirculatory flow and blood pressure. Circulation. 2018;138:494&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626067</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, Lind M, Wagen AZ, Rembach A, Frugier T, Li QX, Ryan TM, McLean CA, Doecke JD, Rowe CC, Villemagne VL, et al. Biochemically-defined pools of amyloid-&#x3b2; in sporadic Alzheimer&#x2019;s disease: correlation with amyloid PET. Brain. 2017;140:1486&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pubmed">28383676</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz Hern&#xe1;ndez JC, Bracko O, Kersbergen CJ, Muse V, Haft-Javaherian M, Berg M, Park L, Vinarcsik LK, Ivasyk I, Rivera DA, Kang Y, et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models. Nat Neurosci. 2019;22:413&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508667</ArticleId><ArticleId IdType="pubmed">30742116</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Anrather J, Forster C, Kazama K, Carlson GA, Iadecola C. Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab. 2004;24:334&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">15091114</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet. 1997;6:1951&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A, O&#x2019;Farrell FM, Reynall C, Hamilton NB, Hall CN, Attwell D. Imaging pericytes and capillary diameter in brain slices and isolated retinae. Nat Protoc. 2014;9:323&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">24434801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Vaccination with soluble A&#x3b2; oligomers generates toxicity-neutralizing antibodies. J Neurochem. 2001;79:595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701763</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, Hartley DM, Lashuel HA. Preparation and characterization of toxic A&#x3b2; aggregates for structural and functional studies in Alzheimer&#x2019;s disease research. Nat Prot. 2010;5:1186&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pubmed">20539293</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Zhao N, Bai X, Karram K, Trotter J, Goebbels S, Scheller A, Kirchhoff F. Novel NG2-CreERT2 knock-in mice demonstrate heterogeneous differentiation potential of NG2 glia during development. Glia. 2014;62:896&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">24578301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L-J, Wu G, Akhavan Sharif MR, Baker A, Jia Y, Fahey FH, Luo HR, Feener EP, Clapham DE. The voltage-gated proton channel, Hv1, enhances brain damage from ischemic stroke. Nat Neurosci. 2012;15:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314139</ArticleId><ArticleId IdType="pubmed">22388960</ArticleId></ArticleIdList></Reference><Reference><Citation>Won SJ, Kim JE, Cittolin-Santos GF, Swanson RA. Assessment at the single-cell level identifies neuronal glutathione depletion as both a cause and effect of ischemia-reperfusion oxidative stress. J Neurosci. 2015;35:7143&#x2013;7152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4420782</ArticleId><ArticleId IdType="pubmed">25948264</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP, Levine H., III Alzheimer&#x2019;s disease and the &#x3b2;-amyloid peptide. J Alzheimer&#x2019;s Dis. 2010;19:311&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813509</ArticleId><ArticleId IdType="pubmed">20061647</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014;1:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Pries AR, Secomb TW, Gaehtgens P, Gross JF. Blood flow in microvascular networks. Experiments and simulation. Circ Res. 1990;67:826&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">2208609</ArticleId></ArticleIdList></Reference><Reference><Citation>Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Brit J Cancer. 1995;72:889&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034023</ArticleId><ArticleId IdType="pubmed">7547236</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzs&#xe1;ki G, Kaila K, Raichle M. Inhibition and brain work. Neuron. 2006;56:771&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2266612</ArticleId><ArticleId IdType="pubmed">18054855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31217332</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>34</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Deficits in Enrichment-Dependent Neurogenesis and Enhanced Anxiety Behaviors Mediated by Expression of Alzheimer's Disease-Linked Ps1 Variants Are Rescued by Microglial Depletion.</ArticleTitle><Pagination><StartPage>6766</StartPage><EndPage>6780</EndPage><MedlinePgn>6766-6780</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0884-19.2019</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive neurodegenerative disorder that presently affects an estimated 5.7 million Americans. Understanding the basis for this disease is key for the development of a future successful treatment. In this effort, we previously reported that mouse prion protein-promoter-driven, ubiquitous expression of familial AD (FAD)-linked human <i>PSEN1</i> variants in transgenic mice impairs environmental enrichment (EE)-induced proliferation and neurogenesis of adult hippocampal neural progenitor cells (AHNPCs) and in a non-cell autonomous manner. These findings were confirmed in <i>PS1<sup>M146V/+</sup></i> mice that harbor an FAD-linked mutation in the endogenous <i>PSEN1</i> gene. We now demonstrate that CSF1R antagonist-mediated microglial depletion in transgenic male mice expressing mutant presenilin 1 (PS1) or <i>PS1<sup>M146V/+</sup></i> "knock-in" mice leads to a complete rescue of deficits in proliferation, differentiation and survival of AHNPCs. Moreover, microglia depletion suppressed the heightened baseline anxiety behavior observed in transgenic mice expressing mutant PS1 and <i>PS1<sup>M146V/+</sup></i> mice to levels observed in mice expressing wild-type human PS1 or nontransgenic mice, respectively. These findings demonstrate that in mice expressing FAD-linked PS1, microglia play a critical role in the regulation of EE-dependent AHNPC proliferation and neurogenesis and the modulation of affective behaviors.<b>SIGNIFICANCE STATEMENT</b> Inheritance of mutations in genes encoding presenilin 1 (PS1) causes familial Alzheimer's disease (FAD). Mutant PS1 expression enhances the levels and assembly of toxic A&#x3b2;42 peptides and impairs the self-renewal and neuronal differentiation of adult hippocampal neural progenitor cells (AHNPCs) following environmental enrichment (EE) that is associated with heightened baseline anxiety. We now show that microglial depletion fully restores the EE-mediated impairments in AHNPC phenotypes and suppresses the heightened baseline anxiety observed in mice expressing FAD-linked PS1. Thus, we conclude that the memory deficits and anxiety-related behaviors in patients with PS1 mutations is a reflection not just of an increase in the levels of A&#x3b2;42 peptides, but to impairments in the self-renewal and neuronal differentiation of AHNPCs that modulate affective behaviors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 the authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ortega-Martinez</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurobiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palla</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>B.A. Neuroscience, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoqiong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Departments of Neurobiology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipman</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Statistics, The University of Chicago, Chicago, Illinois 60637.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Departments of Neurobiology, ssisodia@bsd.uchicago.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000633404">CSF1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009930">Organic Chemicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000630231">PLX5622</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>81627-83-0</RegistryNumber><NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="Y">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009930" MajorTopicYN="N">Organic Chemicals</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer</Keyword><Keyword MajorTopicYN="N">anxiety behaviors</Keyword><Keyword MajorTopicYN="N">environmental enrichment</Keyword><Keyword MajorTopicYN="N">hippocampal neurogenesis</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">presenilin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31217332</ArticleId><ArticleId IdType="pmc">PMC6703877</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0884-19.2019</ArticleId><ArticleId IdType="pii">JNEUROSCI.0884-19.2019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angoa-Perez M, Kane MJ, Briggs DI, Francescutti DM, Kuhn DM (2013) Marble burying and nestlet shredding as tests of repetitive, compulsive-like behaviors in mice. J Vis Exp 82:e50978. 10.3791/50978</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/50978</ArticleId><ArticleId IdType="pmc">PMC4108161</ArticleId><ArticleId IdType="pubmed">24429507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom GS. (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505&#x2013;508. 10.1001/jamaneurol.2013.5847</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5847</ArticleId><ArticleId IdType="pubmed">24493463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonds JA, Kuttner-Hirshler Y, Bartolotti N, Tobin MK, Pizzi M, Marr R, Lazarov O (2015) Presenilin-1 dependent neurogenesis regulates hippocampal learning and memory. PLoS One 10:e0131266. 10.1371/journal.pone.0131266</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0131266</ArticleId><ArticleId IdType="pmc">PMC4476567</ArticleId><ArticleId IdType="pubmed">26098332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourin M, Hasco&#xeb;t M (2003) The mouse light/dark box test. Eur J Pharmacol 463:55&#x2013;65. 10.1016/S0014-2999(03)01274-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(03)01274-3</ArticleId><ArticleId IdType="pubmed">12600702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z, Hussain MD, Yan LJ (2014) Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci 124:307&#x2013;321. 10.3109/00207454.2013.833510</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2013.833510</ArticleId><ArticleId IdType="pubmed">23930978</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS (2008) Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 59:568&#x2013;580. 10.1016/j.neuron.2008.07.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.07.033</ArticleId><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian KM, Song H, Ming GL (2014) Functions and dysfunctions of adult hippocampal neurogenesis. Annu Rev Neurosci 37:243&#x2013;262. 10.1146/annurev-neuro-071013-014134</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-071013-014134</ArticleId><ArticleId IdType="pmc">PMC5531058</ArticleId><ArticleId IdType="pubmed">24905596</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley JN. (1985) Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev 9:37&#x2013;44. 10.1016/0149-7634(85)90030-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0149-7634(85)90030-2</ArticleId><ArticleId IdType="pubmed">2858080</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher NN, Najafi AR, Kayala KM, Elmore MR, White TE, Medeiros R, West BL, Green KN (2015) Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J Neuroinflammation 12:139. 10.1186/s12974-015-0366-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0366-9</ArticleId><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. (2003) Aph-1, pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38:9&#x2013;12. 10.1016/S0896-6273(03)00205-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00205-8</ArticleId><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W, Aimone JB, Gage FH (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 11:339&#x2013;350. 10.1038/nrn2822</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2822</ArticleId><ArticleId IdType="pmc">PMC2886712</ArticleId><ArticleId IdType="pubmed">20354534</ArticleId></ArticleIdList></Reference><Reference><Citation>Dondu A, Sevincoka L, Akyol A, Tataroglu C (2015) Is obsessive-compulsive symptomatology a risk factor for Alzheimer-type dementia? Psychiatry Res 225:381&#x2013;386. 10.1016/j.psychres.2014.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2014.12.010</ArticleId><ArticleId IdType="pubmed">25576369</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan NJ, Locascio JJ, Marshall GA, Gatchel J, Hanseeuw BJ, Rentz DM, Johnson KA, Sperling RA; Harvard Aging Brain Study (2018) Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults. Am J Psychiatry 175:530&#x2013;537. 10.1176/appi.ajp.2017.17040442</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2017.17040442</ArticleId><ArticleId IdType="pmc">PMC5988933</ArticleId><ArticleId IdType="pubmed">29325447</ArticleId></ArticleIdList></Reference><Reference><Citation>Elder GA, Tezapsidis N, Carter J, Shioi J, Bouras C, Li HC, Johnston JM, Efthimiopoulos S, Friedrich VL Jr, Robakis NK (1996) Identification and neuron specific expression of the S182/presenilin I protein in human and rodent brains. J Neurosci Res 45:308&#x2013;320. 10.1002/(SICI)1097-4547(19960801)45:3&lt;308::AID-JNR13&gt;3.0.CO;2-#</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19960801)45:3&lt;308::AID-JNR13&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">8841992</ArticleId></ArticleIdList></Reference><Reference><Citation>Erblich B, Zhu L, Etgen AM, Dobrenis K, Pollard JW (2011) Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS One 6:e26317. 10.1371/journal.pone.0026317</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026317</ArticleId><ArticleId IdType="pmc">PMC3203114</ArticleId><ArticleId IdType="pubmed">22046273</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, Sopher B, Miller MW, Ware CB, Martin GM, Kim SH, Langdon RB, Sisodia SS, Tsien JZ (2001) Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 32:911&#x2013;926. 10.1016/S0896-6273(01)00523-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00523-2</ArticleId><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira MDC, Abreu MJ, Machado C, Santos B, Machado &#xc1;, Costa AS (2018) Neuropsychiatric profile in early versus late onset Alzheimer's disease. Am J Alzheimers Dis Other Demen 33:93&#x2013;99. 10.1177/1533317517744061</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317517744061</ArticleId><ArticleId IdType="pmc">PMC10852442</ArticleId><ArticleId IdType="pubmed">29210282</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadadhar A, Marr R, Lazarov O (2011) Presenilin-1 regulates neural progenitor cell differentiation in the adult brain. J Neurosci 31:2615&#x2013;2623. 10.1523/JNEUROSCI.4767-10.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4767-10.2011</ArticleId><ArticleId IdType="pmc">PMC3050597</ArticleId><ArticleId IdType="pubmed">21325529</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemma C, Bachstetter AD (2013) The role of microglia in adult hippocampal neurogenesis. Front Cell Neurosci 7:229. 10.3389/fncel.2013.00229</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00229</ArticleId><ArticleId IdType="pmc">PMC3837350</ArticleId><ArticleId IdType="pubmed">24319411</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP (1999) Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5:101&#x2013;106. 10.1038/4789</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4789</ArticleId><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AS, Sahay A, Hen R (2015) Increasing adult hippocampal neurogenesis is sufficient to reduce anxiety and depression-like behaviors. Neuropsychopharmacology 40:2368&#x2013;2378. 10.1038/npp.2015.85</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2015.85</ArticleId><ArticleId IdType="pmc">PMC4538351</ArticleId><ArticleId IdType="pubmed">25833129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KK, Adelstein RS, Kawamoto S (2009) Identification of neuronal nuclei (NeuN) as fox-3, a new member of the fox-1 gene family of splicing factors. J Biol Chem 284:31052&#x2013;31061. 10.1074/jbc.M109.052969</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.052969</ArticleId><ArticleId IdType="pmc">PMC2781505</ArticleId><ArticleId IdType="pubmed">19713214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, Levey AI (1997) Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci 17:1971&#x2013;1980. 10.1523/JNEUROSCI.17-06-01971.1997</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-06-01971.1997</ArticleId><ArticleId IdType="pmc">PMC6793763</ArticleId><ArticleId IdType="pubmed">9045726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L, Kim TW (2002) Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 277:6318&#x2013;6323. 10.1074/jbc.M110371200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110371200</ArticleId><ArticleId IdType="pubmed">11741961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS (1997) Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med 3:756&#x2013;760. 10.1038/nm0797-756</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0797-756</ArticleId><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens-Mart&#xed;n M, Jurado-Arjona J, Avila J, Hern&#xe1;ndez F (2015) Novel connection between newborn granule neurons and the hippocampal CA2 field. Exp Neurol 263:285&#x2013;292. 10.1016/j.expneurol.2014.10.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.10.021</ArticleId><ArticleId IdType="pubmed">25446721</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmberg-Aiello P, Ipponi A, Bartolini A, Schunack W (2002) Mouse light/dark box test reveals anxiogenic-like effects by activation of histamine H1 receptors. Pharmacol Biochem Behav 71:313&#x2013;318. 10.1016/S0091-3057(01)00691-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-3057(01)00691-8</ArticleId><ArticleId IdType="pubmed">11812538</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumori Y, Hong SM, Fan Y, Kayama T, Hsu CY, Weinstein PR, Liu J (2006) Enriched environment and spatial learning enhance hippocampal neurogenesis and salvages ischemic penumbra after focal cerebral ischemia. Neurobiol Dis 22:187&#x2013;198. 10.1016/j.nbd.2005.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.10.015</ArticleId><ArticleId IdType="pubmed">16361108</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, Ferrari D, Rossi F (1995) Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374:647&#x2013;650. 10.1038/374647a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/374647a0</ArticleId><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-David I, David DJ, Darcet F, Wu MV, Kerdine-R&#xf6;mer S, Gardier AM, Hen R (2014) Rapid anxiolytic effects of a 5-HT(4) receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology 39:1366&#x2013;1378. 10.1038/npp.2013.332</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2013.332</ArticleId><ArticleId IdType="pmc">PMC3988540</ArticleId><ArticleId IdType="pubmed">24287720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad H, Marchisella F, Ortega-Martinez S, Hollos P, Eerola K, Komulainen E, Kulesskaya N, Freemantle E, Fagerholm V, Savontous E, Rauvala H, Peterson BD, van Praag H, Coffey ET (2018) JNK1 controls adult hippocampal neurogenesis and imposes cell-autonomous control of anxiety behaviour from the neurogenic niche. Mol Psychiatry 23:487. 10.1038/mp.2017.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.21</ArticleId><ArticleId IdType="pmc">PMC5794892</ArticleId><ArticleId IdType="pubmed">28194007</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H, Kotter MR, Franklin RJ (2009) Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132:288&#x2013;295. 10.1093/brain/awn109</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn109</ArticleId><ArticleId IdType="pmc">PMC2640215</ArticleId><ArticleId IdType="pubmed">18567623</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyatsanza S, Shetty T, Gregory C, Lough S, Dawson K, Hodges JR (2003) A study of stereotypic behaviours in Alzheimer's disease and frontal and temporal variant frontotemporal dementia. J Neurol Neurosurg Psychiatry 74:1398&#x2013;1402. 10.1136/jnnp.74.10.1398</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.74.10.1398</ArticleId><ArticleId IdType="pmc">PMC1757381</ArticleId><ArticleId IdType="pubmed">14570833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Mart&#xed;nez S. (2015) A new perspective on the role of the CREB family of transcription factors in memory consolidation via adult hippocampal neurogenesis. Front Mol Neurosci 8:46. 10.3389/fnmol.2015.00046</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2015.00046</ArticleId><ArticleId IdType="pmc">PMC4549561</ArticleId><ArticleId IdType="pubmed">26379491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Mart&#xed;nez S, Trejo JL (2015) The postnatal origin of adult neural stem cells and the effects of glucocorticoids on their genesis. Behav Brain Res 279:166&#x2013;176. 10.1016/j.bbr.2014.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.11.013</ArticleId><ArticleId IdType="pubmed">25446750</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Player MR (2009) Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr Top Med Chem 9:599&#x2013;610. 10.2174/156802609789007327</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156802609789007327</ArticleId><ArticleId IdType="pubmed">19689368</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xfc;mpe T, Ehninger D, Steiner B, Klempin F, Jessberger S, Brandt M, R&#xf6;mer B, Rodriguez GR, Kronenberg G, Kempermann G (2006) Variability of doublecortin-associated dendrite maturation in adult hippocampal neurogenesis is independent of the regulation of precursor cell proliferation. BMC Neurosci 7:77. 10.1186/1471-2202-7-77</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-7-77</ArticleId><ArticleId IdType="pmc">PMC1657022</ArticleId><ArticleId IdType="pubmed">17105671</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 21:479&#x2013;505. 10.1146/annurev.neuro.21.1.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.21.1.479</ArticleId><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Quesseveur G, David DJ, Gaillard MC, Pla P, Wu MV, Nguyen HT, Nicolas V, Auregan G, David I, Dranovsky A, Hantraye P, Hen R, Gardier AM, D&#xe9;glon N, Guiard BP (2013) BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry 3:e253. 10.1038/tp.2013.30</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2013.30</ArticleId><ArticleId IdType="pmc">PMC3641417</ArticleId><ArticleId IdType="pubmed">23632457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran KS. (2003) &#x201c;Recruitment signals&#x201d; from apoptotic cells: invitation to a quiet meal. Cell 113:817&#x2013;820. 10.1016/S0092-8674(03)00471-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00471-9</ArticleId><ArticleId IdType="pubmed">12837239</ArticleId></ArticleIdList></Reference><Reference><Citation>Revest JM, Dupret D, Koehl M, Funk-Reiter C, Grosjean N, Piazza PV, Abrous DN (2009) Adult hippocampal neurogenesis is involved in anxiety-related behaviors. Mol Psychiatry 14:959&#x2013;967. 10.1038/mp.2009.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2009.15</ArticleId><ArticleId IdType="pubmed">19255582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet-Wadiche LS, Tsirka SE, Maletic-Savatic M (2010) Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 7:483&#x2013;495. 10.1016/j.stem.2010.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2010.08.014</ArticleId><ArticleId IdType="pmc">PMC4008496</ArticleId><ArticleId IdType="pubmed">20887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR. (1992) Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol Rev 99:195&#x2013;231. 10.1037/0033-295X.99.2.195</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0033-295X.99.2.195</ArticleId><ArticleId IdType="pubmed">1594723</ArticleId></ArticleIdList></Reference><Reference><Citation>Sztainberg Y, Chen A (2010) An environmental enrichment model for mice. Nat Protoc 5:1535&#x2013;1539. 10.1038/nprot.2010.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2010.114</ArticleId><ArticleId IdType="pubmed">20725068</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17:181&#x2013;190. 10.1016/S0896-6273(00)80291-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80291-3</ArticleId><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, Borchelt DR, Sisodia SS (1997) Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem 272:28415&#x2013;28422. 10.1074/jbc.272.45.28415</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.45.28415</ArticleId><ArticleId IdType="pubmed">9353300</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Lista V, L&#xf3;pez-Pousa S, Gim&#xe9;nez-Llort L (2015) Marble-burying is enhanced in 3xTg-AD mice, can be reversed by risperidone and it is modulable by handling. Behav Processes 116:69&#x2013;74. 10.1016/j.beproc.2015.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beproc.2015.05.001</ArticleId><ArticleId IdType="pubmed">25957954</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger MS, Schernthaner P, Marschallinger J, Mrowetz H, Aigner L (2018) Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. J Neuroinflammation 15:274. 10.1186/s12974-018-1304-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1304-4</ArticleId><ArticleId IdType="pmc">PMC6151006</ArticleId><ArticleId IdType="pubmed">30241479</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K, Sisodia SS (2013) Mutant presenilin 1 expression in excitatory neurons impairs enrichment-mediated phenotypes of adult hippocampal progenitor cells. Proc Natl Acad Sci U S A 110:9148&#x2013;9153. 10.1073/pnas.1302106110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1302106110</ArticleId><ArticleId IdType="pmc">PMC3670351</ArticleId><ArticleId IdType="pubmed">23674689</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K, Choi SH, Zhang X, Sisodia SS (2013) Endogenous expression of FAD-linked PS1 impairs proliferation, neuronal differentiation and survival of adult hippocampal progenitors. Mol Neurodegener 8:41. 10.1186/1750-1326-8-41</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-41</ArticleId><ArticleId IdType="pmc">PMC3853710</ArticleId><ArticleId IdType="pubmed">24138759</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz TM, Town T (2012) Microglia in Alzheimer's disease: it's all about context. Int J Alzheimers Dis 2012:314185. 10.1155/2012/314185</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/314185</ArticleId><ArticleId IdType="pmc">PMC3388286</ArticleId><ArticleId IdType="pubmed">22779026</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31233127</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related &#x3b2;-Amyloid Status.</ArticleTitle><Pagination><StartPage>1060</StartPage><EndPage>1069</EndPage><MedlinePgn>1060-1069</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.1632</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Accurate blood-based biomarkers for Alzheimer disease (AD) might improve the diagnostic accuracy in primary care, referrals to memory clinics, and screenings for AD trials.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the accuracy of plasma &#x3b2;-amyloid (A&#x3b2;) and tau measured using fully automated assays together with other blood-based biomarkers to detect cerebral A&#x3b2;.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Two prospective, cross-sectional, multicenter studies. Study participants were consecutively enrolled between July 6, 2009, and February 11, 2015 (cohort 1), and between January 29, 2000, and October 11, 2006 (cohort 2). Data were analyzed in 2018. The first cohort comprised 842 participants (513 cognitively unimpaired [CU], 265 with mild cognitive impairment [MCI], and 64 with AD dementia) from the Swedish BioFINDER study. The validation cohort comprised 237 participants (34 CU, 109 MCI, and 94 AD dementia) from a German biomarker study.</AbstractText><AbstractText Label="MAIN OUTCOME AND MEASURES" NlmCategory="METHODS">The cerebrospinal fluid (CSF) A&#x3b2;42/A&#x3b2;40 ratio was used as the reference standard for brain A&#x3b2; status. Plasma A&#x3b2;42, A&#x3b2;40 and tau were measured using Elecsys immunoassays (Roche Diagnostics) and examined as predictors of A&#x3b2; status in logistic regression models in cohort 1 and replicated in cohort 2. Plasma neurofilament light chain (NFL) and heavy chain (NFH) and APOE genotype were also examined in cohort 1.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean (SD) age of the 842 participants in cohort 1 was 72 (5.6) years, with a range of 59 to 88 years, and 446 (52.5%) were female. For the 237 in cohort 2, mean (SD) age was 66 (10) years with a range of 23 to 85 years, and 120 (50.6%) were female. In cohort 1, plasma A&#x3b2;42 and A&#x3b2;40 predicted A&#x3b2; status with an area under the receiver operating characteristic curve (AUC) of 0.80 (95% CI, 0.77-0.83). When adding APOE, the AUC increased significantly to 0.85 (95% CI, 0.82-0.88). Slight improvements were seen when adding plasma tau (AUC, 0.86; 95% CI, 0.83-0.88) or tau and NFL (AUC, 0.87; 95% CI, 0.84-0.89) to A&#x3b2;42, A&#x3b2;40 and APOE. The results were similar in CU and cognitively impaired participants, and in younger and older participants. Applying the plasma A&#x3b2;42 and A&#x3b2;40 model from cohort 1 in cohort 2 resulted in slightly higher AUC (0.86; 95% CI, 0.81-0.91), but plasma tau did not contribute. Using plasma A&#x3b2;42, A&#x3b2;40, and APOE in an AD trial screening scenario reduced positron emission tomography costs up to 30% to 50% depending on cutoff.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Plasma A&#x3b2;42 and A&#x3b2;40 measured using Elecsys immunoassays predict A&#x3b2; status in all stages of AD with similar accuracy in a validation cohort. Their accuracy can be further increased by analyzing APOE genotype. Potential future applications of these blood tests include prescreening of A&#x3b2; positivity in clinical AD trials to lower the costs and number of positron emission tomography scans or lumbar punctures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karl</LastName><ForeName>Johann</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zink</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Genentech, a Member of the Roche Group, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichenlaub</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamaneurol.2019.0845</RefSource></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Zetterberg reported serving on scientific advisory boards for Roche Diagnostics, Eli Lilly, and Wave, receiving travel support from Teva, and being a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr Karl reported having a patent pending regarding methods of identifying an individual as having or being at risk of developing a primary Alzheimer dementia based on marker molecules and related uses and being an employee of the Roche Group. Ms Zink reported being an employee of the Roche Group. Dr Bittner reported having a patent pending regarding blood-based biomarkers for Alzheimer disease and being an employee of the Roche Group. and Dr Eichenlaub reported being an employee of the Roche Group. Dr Blennow reported serving as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, and receiving institutional research support from Roche Diagnostics and Fujirebio Europe. Dr Hansson has acquired research support for his institution from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun, and in the past 2 years, he has received consultancy or speaker fees (paid to his institution) from Lilly, Roche, and Fujirebio. No other disclosures were reported. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31233127</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pii">2736342</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Carrillo MC, Dean RA, et al. . Revolutionizing Alzheimer&#x2019;s disease and clinical trials through biomarkers. Alzheimers Dement (Amst). 2015;1(4):412-419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879481</ArticleId><ArticleId IdType="pubmed">27239522</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Mattsson N, Sch&#xf6;ll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer&#x2019;s disease. Trends Pharmacol Sci. 2015;36(5):297-309. doi:10.1016/j.tips.2015.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2015.03.002</ArticleId><ArticleId IdType="pubmed">25840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association 2017 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2017;13 (4):325-273. doi:10.1016/j.jalz.2017.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3(3):186-191. doi:10.1016/j.jalz.2007.04.381</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.04.381</ArticleId><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan A, Heslegrave A, Zetterberg H, Schott JM. Blood biomarkers for Alzheimer&#x2019;s disease: much promise, cautious progress. Mol Diagn Ther. 2017;21(1):13-22. doi:10.1007/s40291-016-0241-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40291-016-0241-0</ArticleId><ArticleId IdType="pubmed">27738910</ArticleId></ArticleIdList></Reference><Reference><Citation>Voyle N, Baker D, Burnham SC, et al. ; AIBL research group . Blood protein markers of neocortical amyloid-&#x3b2; burden: a candidate study using SOMAscan technology. J Alzheimers Dis. 2015;46(4):947-961. doi:10.3233/JAD-150020</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150020</ArticleId><ArticleId IdType="pmc">PMC4923714</ArticleId><ArticleId IdType="pubmed">25881911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Goozee K, Sohrabi HR, et al. . Association of plasma neurofilament light chain with neocortical amyloid-&#x3b2; load and cognitive performance in cognitively normal elderly participants. J Alzheimers Dis. 2018;63(2):479-487. doi:10.3233/JAD-180025</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180025</ArticleId><ArticleId IdType="pubmed">29630554</ArticleId></ArticleIdList></Reference><Reference><Citation>Dage JL, Wennberg AMV, Airey DC, et al. . Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement. 2016;12(12):1226-1234. doi:10.1016/j.jalz.2016.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.06.001</ArticleId><ArticleId IdType="pmc">PMC5148697</ArticleId><ArticleId IdType="pubmed">27436677</ArticleId></ArticleIdList></Reference><Reference><Citation>Deters KD, Risacher SL, Kim S, et al. ; Alzheimer Disease Neuroimaging Initiative . Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer&#x2019;s disease. J Alzheimers Dis. 2017;58(4):1245-1254. doi:10.3233/JAD-161114</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161114</ArticleId><ArticleId IdType="pmc">PMC5523909</ArticleId><ArticleId IdType="pubmed">28550246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fandos N, P&#xe9;rez-Grijalba V, Pesini P, et al. ; AIBL Research Group . Plasma amyloid &#x3b2; 42/40 ratios as biomarkers for amyloid &#x3b2; cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179-187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602863</ArticleId><ArticleId IdType="pubmed">28948206</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Palmqvist S, et al. . Plasma &#x3b2;-amyloid in Alzheimer&#x2019;s disease and vascular disease. Sci Rep. 2016;6:26801. doi:10.1038/srep26801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26801</ArticleId><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Sabbagh MN, Chiu MJ, et al. . Plasma levels of A&#x3b2;42 and tau identified probable Alzheimer&#x2019;s dementia: findings in two cohorts. Front Aging Neurosci. 2017;9:226. doi:10.3389/fnagi.2017.00226</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00226</ArticleId><ArticleId IdType="pmc">PMC5522888</ArticleId><ArticleId IdType="pubmed">28790911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557-566. doi:10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Janelidze S, et al. ; ADNI Investigators . Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827-1835. doi:10.1212/WNL.0000000000003246</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003246</ArticleId><ArticleId IdType="pmc">PMC5089525</ArticleId><ArticleId IdType="pubmed">27694257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Zhang J, Ye F, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Plasma neurofilament light chain levels in Alzheimer&#x2019;s disease. Neurosci Lett. 2017;650:60-64. doi:10.1016/j.neulet.2017.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.04.027</ArticleId><ArticleId IdType="pubmed">28428015</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, et al. . CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684. doi:10.1016/S1474-4422(16)00070-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et al. . High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554(7691):249-254. doi:10.1038/nature25456</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, et al. . Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841-849. doi:10.1016/j.jalz.2017.06.2266</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, et al. ; Alzheimer&#x2019;s Association QC Program Work Group . CSF biomarker variability in the Alzheimer&#x2019;s Association quality control program [published correction appears in Alzheimers Dement. 2015;11(2):237]. Alzheimers Dement. 2013;9(3):251-261. doi:10.1016/j.jalz.2013.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.01.010</ArticleId><ArticleId IdType="pmc">PMC3707386</ArticleId><ArticleId IdType="pubmed">23622690</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Visser PJ, Verhey F, et al. . Variability of CSF Alzheimer&#x2019;s disease biomarkers: implications for clinical practice. PLoS One. 2014;9(6):e100784. doi:10.1371/journal.pone.0100784</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100784</ArticleId><ArticleId IdType="pmc">PMC4069102</ArticleId><ArticleId IdType="pubmed">24959687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Zetterberg H, Teunissen CE, et al. . Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of&#xa0;&#x3b2;-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517-526. doi:10.1016/j.jalz.2015.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.09.009</ArticleId><ArticleId IdType="pubmed">26555316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. ; Swedish BioFINDER study group; Alzheimer&#x2019;s Disease Neuroimaging Initiative . CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-&#x3b2; PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470-1481. doi:10.1016/j.jalz.2018.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Pannee J, Mikulskis A, et al. . Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492-1501. doi:10.1001/jamaneurol.2017.2814</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2814</ArticleId><ArticleId IdType="pmc">PMC5822196</ArticleId><ArticleId IdType="pubmed">29114726</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Palmqvist S, et al. . Increased amyloidogenic APP processing in APOE &#x25b;4-negative individuals with cerebral &#x3b2;-amyloidosis. Nat Commun. 2016;7:10918. doi:10.1038/ncomms10918</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10918</ArticleId><ArticleId IdType="pmc">PMC4786682</ArticleId><ArticleId IdType="pubmed">26948379</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol. 2007;27(1):22-31. doi:10.1055/s-2006-956752</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2006-956752</ArticleId><ArticleId IdType="pubmed">17226738</ArticleId></ArticleIdList></Reference><Reference><Citation>The Swedish BIOFINDER Study. http://biofinder.se/. Accessed May 24, 2019.</Citation></Reference><Reference><Citation>R&#xf3;zga M, Bittner T, Batrla R, Karl J. Preanalytical sample handling recommendations for Alzheimer&#x2019;s disease plasma biomarkers. Alzheimers Dement (Amst). 2019;11:291-300. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6446057</ArticleId><ArticleId IdType="pubmed">30984815</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. . Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282-1289. doi:10.1001/jamaneurol.2014.1358</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1358</ArticleId><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Zetterberg H, Mattsson N, et al. ; Swedish BioFINDER study group . CSF A&#x3b2;42/A&#x3b2;40 and A&#x3b2;42/A&#x3b2;38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3(3):154-165. doi:10.1002/acn3.274</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.274</ArticleId><ArticleId IdType="pmc">PMC4774260</ArticleId><ArticleId IdType="pubmed">27042676</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Hasselbalch SG, et al. . Pittsburgh compound B imaging and cerebrospinal fluid amyloid-&#x3b2; in a multicentre European memory clinic study. Brain. 2016;139(Pt 9):2540-2553. doi:10.1093/brain/aww160</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww160</ArticleId><ArticleId IdType="pmc">PMC4995359</ArticleId><ArticleId IdType="pubmed">27401520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Matzen A, Blennow K, et al. . Cerebrospinal fluid A&#x3b2;42/40 corresponds better than A&#x3b2;42 to amyloid PET in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2017;55(2):813-822. doi:10.3233/JAD-160722</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160722</ArticleId><ArticleId IdType="pmc">PMC5147502</ArticleId><ArticleId IdType="pubmed">27792012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid &#x3b2;-amyloid 1-42 cutoffs in a large memory clinic population. Alzheimers Res Ther. 2017;9(1):8. doi:10.1186/s13195-016-0233-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0233-7</ArticleId><ArticleId IdType="pmc">PMC5307885</ArticleId><ArticleId IdType="pubmed">28193256</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Sch&#xf6;ll M, Strandberg O, et al. . Earliest accumulation of &#x3b2;-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1214. doi:10.1038/s41467-017-01150-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01150-x</ArticleId><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308. doi:10.1001/archneur.56.3.303</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.56.3.303</ArticleId><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939-944. doi:10.1212/WNL.34.7.939</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Insel PS, Zetterberg H, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFINDER study . Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer&#x2019;s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374284</ArticleId><ArticleId IdType="pubmed">30365928</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsen E, Dahan A. Using Akaike&#x2019;s information theoretic criterion in mixed-effects modeling of pharmacokinetic data: a simulation study. F1000Res. 2013;2:71. doi:10.12688/f1000research.2-71.v1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.2-71.v1</ArticleId><ArticleId IdType="pmc">PMC4670010</ArticleId><ArticleId IdType="pubmed">26673949</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845. doi:10.2307/2531595</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Palmqvist S, Mackin RS, et al. . Assessing risk for preclinical &#x3b2;-amyloid pathology with APOE, cognitive, and demographic information. Alzheimers Dement (Amst). 2016;4:76-84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045949</ArticleId><ArticleId IdType="pubmed">27722193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Park KW, Kim TE, et al. . Elevation of the plasma A&#x3b2;40/A&#x3b2;42 ratio as a diagnostic marker of sporadic early-onset Alzheimer&#x2019;s disease. J Alzheimers Dis. 2015;48(4):1043-1050. doi:10.3233/JAD-143018</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-143018</ArticleId><ArticleId IdType="pubmed">26444752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Honig LS, Tang MX, et al. . Plasma A[beta]40 and A[beta]42 and Alzheimer&#x2019;s disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185-1190. doi:10.1212/01.WNL.0000091890.32140.8F</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000091890.32140.8F</ArticleId><ArticleId IdType="pubmed">14610118</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, et al. . Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989-997. doi:10.1016/j.jalz.2018.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Janelidze S, Hall S, et al. ; Swedish BioFINDER study . Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930-937. doi:10.1212/WNL.0000000000003680</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003680</ArticleId><ArticleId IdType="pmc">PMC5333515</ArticleId><ArticleId IdType="pubmed">28179466</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Insel PS, Zetterberg H, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFINDER study . Accurate risk estimation of &#x3b2;-amyloid positivity to identify prodromal Alzheimer&#x2019;s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2019;15(2):194-204. doi:10.1016/j.jalz.2018.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.08.014</ArticleId><ArticleId IdType="pmc">PMC6374284</ArticleId><ArticleId IdType="pubmed">30365928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31257024</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>LC3-Associated Endocytosis Facilitates &#x3b2;-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>536</StartPage><EndPage>551.e14</EndPage><MedlinePgn>536-551.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2019.05.056</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(19)30627-0</ELocationID><Abstract><AbstractText>The expression of some proteins in the autophagy pathway declines with age, which may impact neurodegeneration in diseases, including Alzheimer's Disease. We have identified a novel non-canonical function of several autophagy proteins in the conjugation of LC3 to Rab5<sup>+</sup>, clathrin<sup>+</sup> endosomes containing &#x3b2;-amyloid in a process of LC3-associated endocytosis (LANDO). We found that LANDO in microglia is a critical regulator of immune-mediated aggregate removal and microglial activation in a murine model of AD. Mice lacking LANDO but not canonical autophagy in the myeloid compartment or specifically in microglia have a robust increase in pro-inflammatory cytokine production in the hippocampus and increased levels of neurotoxic &#x3b2;-amyloid. This inflammation and &#x3b2;-amyloid deposition were associated with reactive microgliosis and tau hyperphosphorylation. LANDO-deficient AD mice displayed accelerated neurodegeneration, impaired neuronal signaling, and memory deficits. Our data support a protective role for LANDO in microglia in&#xa0;neurodegenerative pathologies resulting from &#x3b2;-amyloid deposition.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heckmann</LastName><ForeName>Bradlee L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teubner</LastName><ForeName>Brett J W</ForeName><Initials>BJW</Initials><AffiliationInfo><Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tummers</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada-Romero</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Lacie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Mao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guy</LastName><ForeName>Clifford S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakharenko</LastName><ForeName>Stanislav S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: douglas.green@stjude.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>L40 CA231423</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AI138492</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 CA231620</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC012833</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH097742</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI040646</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071187">Autophagy-Related Protein 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071183">Autophagy-Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018955">CD36 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C480860">Map1lc3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C428743">Rb1cc1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000601571">Rubcn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Cell. 2020 Dec 10;183(6):1733-1734. doi: 10.1016/j.cell.2020.11.033.</RefSource><PMID Version="1">33306957</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071187" MajorTopicYN="N">Autophagy-Related Protein 5</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071183" MajorTopicYN="N">Autophagy-Related Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018955" MajorTopicYN="N">CD36 Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="Y">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s Disease</Keyword><Keyword MajorTopicYN="N">LC3-associated endocytosis</Keyword><Keyword MajorTopicYN="N">LC3-associated phagocytosis</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">receptor-mediated endocytosis</Keyword><Keyword MajorTopicYN="N">tau pathology</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31257024</ArticleId><ArticleId IdType="mid">NIHMS1532619</ArticleId><ArticleId IdType="pmc">PMC6689199</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.05.056</ArticleId><ArticleId IdType="pii">S0092-8674(19)30627-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abram CL, Roberge GL, Hu Y, and Lowell CA (2014). Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. J Immunol Methods 408, 89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105345</ArticleId><ArticleId IdType="pubmed">24857755</ArticleId></ArticleIdList></Reference><Reference><Citation>Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, and Zipp F (2007). Neuronal damage in brain inflammation. Arch Neurol 64, 185&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296833</ArticleId></ArticleIdList></Reference><Reference><Citation>Belvindrah R, Nosten-Bertrand M, and Francis F (2014). Neuronal migration and its disorders affecting the CA3 region. Front Cell Neurosci 8, 63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941003</ArticleId><ArticleId IdType="pubmed">24624057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, et al. (2016). New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 113, E1738&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Briones A, Gagno S, Martisova E, Dobarro M, Aisa B, Solas M, Tordera R, and Ramirez M (2012). Stress-induced anhedonia is associated with an increase in Alzheimer's disease-related markers. Br J Pharmacol 165, 897&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312487</ArticleId><ArticleId IdType="pubmed">21797840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai B, Kasikara C, Doran AC, Ramakrishnan R, Birge RB, and Tabas I (2018). MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity. Sci Signal 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6171110</ArticleId><ArticleId IdType="pubmed">30254055</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z, Hussain MD, and Yan LJ (2014). Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci 124, 307&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23930978</ArticleId></ArticleIdList></Reference><Reference><Citation>Camenisch TD, Koller BH, Earp HS, and Matsushima GK (1999). A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. J Immunol 162, 3498&#x2013;3503.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092806</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy A, Dancourt J, Mugo B, O'Connor TJ, Isberg RR, Melia TJ, and Roy CR (2012). The Legionella effector RavZ inhibits host autophagy through irreversible Atg8 deconjugation. Science 338, 1072&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682818</ArticleId><ArticleId IdType="pubmed">23112293</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacurcio DJ, Pensalfini A, Jiang Y, and Nixon RA (2018). Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. Free Radic Biol Med 114, 40&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748263</ArticleId><ArticleId IdType="pubmed">28988799</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha LD, Yang M, Carter R, Guy C, Harris L, Crawford JC, Quarato G, Boada-Romero E, Kalkavan H, Johnson MDL, et al. (2018). LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance. Cell 175, 429&#x2013;441 e416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201245</ArticleId><ArticleId IdType="pubmed">30245008</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira CA, and Mantovani B (1988). Latrunculin A is a potent inhibitor of phagocytosis by macrophages. Life Sci 43, 1825&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">3200109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dheen ST, Kaur C, and Ling EA (2007). Microglial activation and its implications in the brain diseases. Curr Med Chem 14, 1189&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17504139</ArticleId></ArticleIdList></Reference><Reference><Citation>Doens D, and Fernandez PL (2014). Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. J Neuroinflammation 11, 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975152</ArticleId><ArticleId IdType="pubmed">24625061</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, and Vassar R (2013). Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegener 8, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejlerskov P, Ashkenazi A, and Rubinsztein DC (2019). Genetic enhancement of macroautophagy in vertebrate models of neurodegenerative diseases. Neurobiol Dis 122, 3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29625255</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng KE, Panas MD, Karlsson Hedestam GB, and McInerney GM (2010). A novel quantitative flow cytometry-based assay for autophagy. Autophagy 6, 634&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">20458170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro A, Qu W, Lukowicz A, Svedberg D, Johnson A, and Cvetanovic M (2018). Inhibition of NF-kappaB signaling in IKKbetaF/F;LysM Cre mice causes motor deficits but does not alter pathogenesis of Spinocerebellar ataxia type 1. PLoS One 13, e0200013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6033432</ArticleId><ArticleId IdType="pubmed">29975753</ArticleId></ArticleIdList></Reference><Reference><Citation>Frake RA, Ricketts T, Menzies FM, and Rubinsztein DC (2015). Autophagy and neurodegeneration. J Clin Invest 125, 65&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382230</ArticleId><ArticleId IdType="pubmed">25654552</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Gotz J, and Feany MB (2015). Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol 25, 46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4275400</ArticleId><ArticleId IdType="pubmed">25172552</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller JP, Stavenhagen JB, and Teeling JL (2014). New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Front Neurosci 8, 235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139653</ArticleId><ArticleId IdType="pubmed">25191216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras S, Earls LR, Howell S, Smeyne RJ, Zakharenko SS, and Pelletier S (2015). SCYL2 Protects CA3 Pyramidal Neurons from Excitotoxicity during Functional Maturation of the Mouse Hippocampus. J Neurosci 35, 10510&#x2013;10522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510291</ArticleId><ArticleId IdType="pubmed">26203146</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard SD, Jacquet M, Baranger K, Migliorati M, Escoffier G, Bernard A, Khrestchatisky M, Feron F, Rivera S, Roman FS, et al. (2014). Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease. Hippocampus 24, 762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">24596271</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, Brendecke SM, Kierdorf K, Staszewski O, Datta M, et al. (2013). A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci 16, 1618&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">24077561</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong CX, and Iqbal K (2008). Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15, 2321&#x2013;2328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656563</ArticleId><ArticleId IdType="pubmed">18855662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurley C, Nichols J, Liu S, Phulwani NK, Esen N, and Kielian T (2008). Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-gamma Agonists. PPAR Res 2008, 453120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435222</ArticleId><ArticleId IdType="pubmed">18584038</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris H, and Rubinsztein DC (2011). Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 8, 108&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">22187000</ArticleId></ArticleIdList></Reference><Reference><Citation>He C, Bartholomew CR, Zhou W, and Klionsky DJ (2009). Assaying autophagic activity in transgenic GFP-Lc3 and GFP-Gabarap zebrafish embryos. Autophagy 5, 520&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754832</ArticleId><ArticleId IdType="pubmed">19221467</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann BL, Boada-Romero E, Cunha LD, Magne J, and Green DR (2017). LC3-Associated Phagocytosis and Inflammation. J Mol Biol 429, 3561&#x2013;3576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743439</ArticleId><ArticleId IdType="pubmed">28847720</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann BL, and Green DR (2019). LC3-associated phagocytosis at a glance. J Cell Sci 132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432721</ArticleId><ArticleId IdType="pubmed">30787029</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann BL, Tummers B, and Green DR (2018). Crashing the computer: apoptosis vs. necroptosis in neuroinflammation. Cell Death Differ.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294765</ArticleId><ArticleId IdType="pubmed">30341422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogland IC, Houbolt C, van Westerloo DJ, van Gool WA, and van de Beek D (2015). Systemic inflammation and microglial activation: systematic review of animal experiments. J Neuroinflammation 12, 114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4470063</ArticleId><ArticleId IdType="pubmed">26048578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, and Yoshimori T (2004). LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 117, 2805&#x2013;2812.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169837</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S, Kalaany NY, Jacks T, Chan CS, Rabinowitz JD, et al. (2014). Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov 4, 914&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4125614</ArticleId><ArticleId IdType="pubmed">24875857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YS, and Joh TH (2006). Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38, 333&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">16953112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon DH, Kim S, Jung YO, Roh KH, Kim L, Kim BW, Hong SB, Lee IY, Song JH, Lee WC, et al. (2017). The 1:2 complex between RavZ and LC3 reveals a mechanism for deconjugation of LC3 on the phagophore membrane. Autophagy 13, 70&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5240826</ArticleId><ArticleId IdType="pubmed">27791457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz KM, and Nelson LH (2018). Microglia and Beyond: Innate Immune Cells As Regulators of Brain Development and Behavioral Function. Front Immunol 9, 698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5908908</ArticleId><ArticleId IdType="pubmed">29706957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski MM, Zheng B, Lu T, Yan Z, Py BF, Ng A, Xavier RJ, Li C, Yankner BA, Scherzer CR, et al. (2010). Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci U S A 107, 14164&#x2013;14169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922576</ArticleId><ArticleId IdType="pubmed">20660724</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu MY, Yin CY, Zhu LJ, Zhu XH, Xu C, Luo CX, Chen H, Zhu DY, and Zhou QG (2018). Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc 13, 1686&#x2013;1698.</Citation><ArticleIdList><ArticleId IdType="pubmed">29988104</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rube CE, Walter J, Heneka MT, Hartmann T, et al. (2012). TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. J Immunol 188, 1098&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">22198949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, O'Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, Mastroeni DF, Rogers J, Spencer B, Masliah E, et al. (2013). Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron 79, 873&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779465</ArticleId><ArticleId IdType="pubmed">24012002</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado V, Zoller T, Attaai A, and Spittau B (2016). Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice. Int J Mol Sci 17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4783885</ArticleId><ArticleId IdType="pubmed">26821015</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S (2016). Mechanisms of neuronal homeostasis: Autophagy in the axon. Brain Res 1649, 143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045311</ArticleId><ArticleId IdType="pubmed">27038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J, Almendinger J, Oberst A, Ness R, Dillon CP, Fitzgerald P, Hengartner MO, and Green DR (2011). Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc Natl Acad Sci U S A 108, 17396&#x2013;17401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198353</ArticleId><ArticleId IdType="pubmed">21969579</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J, Cunha LD, Park S, Yang M, Lu Q, Orchard R, Li QZ, Yan M, Janke L, Guy C, et al. (2016). Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells. Nature 533, 115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860026</ArticleId><ArticleId IdType="pubmed">27096368</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J, Malireddi RK, Lu Q, Cunha LD, Pelletier S, Gingras S, Orchard R, Guan JL, Tan H, Peng J, et al. (2015). Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat Cell Biol 17, 893&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612372</ArticleId><ArticleId IdType="pubmed">26098576</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N, Maejima I, Shirahama-Noda K, Ichimura T, Isobe T, et al. (2009). Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol 11, 385&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">19270696</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, Fullgrabe J, Jackson A, Jimenez Sanchez M, Karabiyik C, et al. (2017). Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. Neuron 93, 1015&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">28279350</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, and Maccioni RB (2014). Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 8, 112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001039</ArticleId><ArticleId IdType="pubmed">24795567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, and Griffin WS (2000). Interleukin-1 and the immunogenetics of Alzheimer disease. J Neuropathol Exp Neurol 59, 471&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833594</ArticleId><ArticleId IdType="pubmed">10850859</ArticleId></ArticleIdList></Reference><Reference><Citation>Naudin M, Mondon K, El-Hage W, Perriot E, Boudjarane M, Desmidt T, Lorette A, Belzung C, Hommet C, and Atanasova B (2015). Taste identification used as a potential discriminative test among depression and Alzheimers disease in elderly: A pilot study. Psychiatry Res 228, 228&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">25998001</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Hanger DP, Miller CC, and Lovestone S (2013). The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 4, 83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696910</ArticleId><ArticleId IdType="pubmed">23847585</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M (2009). Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Neurobiol Learn Mem 92, 455&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772829</ArticleId><ArticleId IdType="pubmed">19435612</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira CA, Kashman Y, and Mantovani B (1996). Effects of latrunculin A on immunological phagocytosis and macrophage spreading-associated changes in the F-actin/G-actin content of the cells. Chem Biol Interact 100, 141&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">8646787</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthgiess J, Gericke M, Immig K, Schulz A, Hirrlinger J, Bechmann I, and Eilers J (2016). Neurons exhibit Lyz2 promoter activity in vivo: Implications for using LysM-Cre mice in myeloid cell research. Eur J Immunol 46, 1529&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pubmed">27062494</ArticleId></ArticleIdList></Reference><Reference><Citation>Padurariu M, Ciobica A, Mavroudis I, Fotiou D, and Baloyannis S (2012). Hippocampal neuronal loss in the CA1 and CA3 areas of Alzheimer's disease patients. Psychiatr Danub 24, 152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">22706413</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, and Chen XC (2011). Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer's disease. Mol Neurodegener 6, 45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149591</ArticleId><ArticleId IdType="pubmed">21718498</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SK, Ratia K, Ba M, Valencik M, and Liebman SW (2016). Inhibition of Abeta42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs. Microb Cell 3, 53&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349104</ArticleId><ArticleId IdType="pubmed">28357335</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, and Holmes C (2014). Microglial priming in neurodegenerative disease. Nat Rev Neurol 10, 217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, et al. (2008). The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118, 2190&#x2013;2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391284</ArticleId><ArticleId IdType="pubmed">18497889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido-Salgado M, Vidal-Taboada JM, Garcia Diaz-Barriga G, Serratosa J, Valente T, Castillo P, Matalonga J, Straccia M, Canals JM, Valledor A, et al. (2017). Myeloid C/EBPbeta deficiency reshapes microglial gene expression and is protective in experimental autoimmune encephalomyelitis. J Neuroinflammation 14, 54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5356255</ArticleId><ArticleId IdType="pubmed">28302135</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaisiya M, Mardesic P, Pastore B, Tiribelli C, and Bellarosa C (2017). The activation of autophagy protects neurons and astrocytes against bilirubin-induced cytotoxicity. Neurosci Lett 661, 96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">28965934</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Savage JC, Hise AG, and Landreth GE (2009). CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 29, 11982&#x2013;11992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichman WE, and Coyne AC (1995). Depressive symptoms in Alzheimer's disease and multi-infarct dementia. J Geriatr Psychiatry Neurol 8, 96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">7794481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries M, and Sastre M (2016). Mechanisms of Abeta Clearance and Degradation by Glial Cells. Front Aging Neurosci 8, 160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932097</ArticleId><ArticleId IdType="pubmed">27458370</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Bento CF, and Deretic V (2015). Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med 212, 979&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493419</ArticleId><ArticleId IdType="pubmed">26101267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Marino G, and Kroemer G (2011). Autophagy and aging. Cell 146, 682&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">21884931</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Davies JE, Huang Z, Tunnacliffe A, and Rubinsztein DC (2007). Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 282, 5641&#x2013;5652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182613</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Ravikumar B, and Rubinsztein DC (2009). Autophagic clearance of aggregate-prone proteins associated with neurodegeneration. Methods Enzymol 453, 83&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">19216903</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, and Matsushima GK (2001). Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411, 207&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">11346799</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Griffin WS, and O'Banion MK (2008). The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5, 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2335091</ArticleId><ArticleId IdType="pubmed">18302763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, and O'Banion MK (2007). Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117, 1595&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, and Fukuchi K (2011). TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation 8, 92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169468</ArticleId><ArticleId IdType="pubmed">21827663</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorp E, Cui D, Schrijvers DM, Kuriakose G, and Tabas I (2008). Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe&#x2212;/&#x2212; mice. Arterioscler Thromb Vasc Biol 28, 1421&#x2013;1428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575060</ArticleId><ArticleId IdType="pubmed">18451332</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. (2017). TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell 170, 649&#x2013;663 e613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, and Holtzman DM (2014). Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 9, 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Liang H, and Zen K (2014). Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 5, 614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246889</ArticleId><ArticleId IdType="pubmed">25506346</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, Tan MS, Yu JT, and Tan L (2015a). Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med 3, 136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486922</ArticleId><ArticleId IdType="pubmed">26207229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. (2015b). TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. (2016). TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213, 667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb JL, Ravikumar B, Atkins J, Skepper JN, and Rubinsztein DC (2003). Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278, 25009&#x2013;25013.</Citation><ArticleIdList><ArticleId IdType="pubmed">12719433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson K, and El Khoury J (2012). Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. Int J Alzheimers Dis 2012, 489456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3362056</ArticleId><ArticleId IdType="pubmed">22666621</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A, and Simonsen A (2011). The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. Neurobiol Dis 43, 17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2998573</ArticleId><ArticleId IdType="pubmed">20732422</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J, Liu X, He Q, Zhou L, Yuan Z, and Zhao S (2016). Vps35-dependent recycling of Trem2 regulates microglial function. Traffic 17, 1286&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">27717139</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang QG, Wang RM, Scott E, Han D, Dong Y, Tu JY, Yang F, Reddy Sareddy G, Vadlamudi RK, and Brann DW (2013). Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain 136, 1432&#x2013;1445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634196</ArticleId><ArticleId IdType="pubmed">23474850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pina-Crespo JC, Zhang M, et al. (2018). TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function. Neuron 97, 1023&#x2013;1031 e1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31255487</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Transneuronal Propagation of Pathologic &#x3b1;-Synuclein from the Gut to the Brain Models Parkinson's Disease.</ArticleTitle><Pagination><StartPage>627</StartPage><EndPage>641.e7</EndPage><MedlinePgn>627-641.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.05.035</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)30488-X</ELocationID><Abstract><AbstractText>Analysis of human pathology led Braak to postulate that &#x3b1;-synuclein (&#x3b1;-syn) pathology could spread from the gut to brain via the vagus nerve. Here, we test this postulate by assessing &#x3b1;-synucleinopathy in the brain in a novel gut-to-brain &#x3b1;-syn transmission mouse model, where pathological &#x3b1;-syn preformed fibrils were injected into the&#xa0;duodenal and pyloric muscularis layer. Spread of pathologic &#x3b1;-syn in brain, as assessed by phosphorylation of serine 129 of &#x3b1;-syn, was observed first in the dorsal motor nucleus, then in caudal portions of the hindbrain, including the locus coeruleus, and much later in basolateral amygdala, dorsal raphe nucleus, and the substantia&#xa0;nigra pars compacta. Moreover, loss of dopaminergic neurons and motor and non-motor symptoms were observed in a similar temporal manner. Truncal vagotomy and &#x3b1;-syn deficiency prevented the gut-to-brain spread of &#x3b1;-synucleinopathy and associated neurodegeneration and behavioral deficits. This study supports the Braak hypothesis in the etiology of idiopathic Parkinson's disease (PD).</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sangjune</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Seung-Hwan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kam</LastName><ForeName>Tae-In</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panicker</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karuppagounder</LastName><ForeName>Senthilkumar S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Saebom</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jun Hee</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Wonjoong Richard</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kook</LastName><ForeName>Minjee</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foss</LastName><ForeName>Catherine A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Chentian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hojae</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Subhash</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurogastroenterology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasricha</LastName><ForeName>Pankaj J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Center for Neurogastroenterology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Gabsang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomper</LastName><ForeName>Martin G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Valina L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: tdawson@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Han Seok</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA. Electronic address: hko3@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS107404</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS098006</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Sep;15(9):491. doi: 10.1038/s41582-019-0241-x.</RefSource><PMID Version="1">31312039</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2019 Aug 21;103(4):547-549. doi: 10.1016/j.neuron.2019.07.031.</RefSource><PMID Version="1">31437447</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Endocrinol Metab. 2019 Oct;30(10):687-689. doi: 10.1016/j.tem.2019.08.001.</RefSource><PMID Version="1">31473011</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="Y">Axonal Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004386" MajorTopicYN="N">Duodenum</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009130" MajorTopicYN="N">Muscle, Smooth</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009425" MajorTopicYN="N">Nesting Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011708" MajorTopicYN="N">Pylorus</DescriptorName><QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045442" MajorTopicYN="N">Rotarod Performance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014628" MajorTopicYN="N">Vagotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014630" MajorTopicYN="N">Vagus Nerve</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Braak hypothesis</Keyword><Keyword MajorTopicYN="N">Lewy body pathology</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">gut to brain transmission</Keyword><Keyword MajorTopicYN="N">motor symptoms</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">non-motor symptoms</Keyword><Keyword MajorTopicYN="N">pre-formed fibrils</Keyword><Keyword MajorTopicYN="N">vagus nerve</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synuclein</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31255487</ArticleId><ArticleId IdType="mid">NIHMS1530676</ArticleId><ArticleId IdType="pmc">PMC6706297</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.05.035</ArticleId><ArticleId IdType="pii">S0896-6273(19)30488-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al. (2006). Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739&#x2013;29752.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias N, Mendez M, and Arias JL (2015). The importance of the context in the hippocampus and brain related areas throughout the performance of a fear conditioning task. Hippocampus 25, 1242&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pubmed">25675878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhardt N, Lieser MK, Hlusicka EB, Habelt B, Wieske F, Edemann-Callesen H, Garthe A, and Winter C (2018). Learning deficits in rats overexpressing the dopamine transporter. Sci Rep 8, 14173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154965</ArticleId><ArticleId IdType="pubmed">30242292</ArticleId></ArticleIdList></Reference><Reference><Citation>Berthoud HR, Carlson NR, and Powley TL (1991). Topography of efferent vagal innervation of the rat gastrointestinal tract. Am J Physiol 260, R200&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">1992820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevins RA, and Besheer J (2006). Object recognition in rats and mice: a one-trial-non-matching-to-sample learning task to study &#x2018;recognition memory&#x2019;. Nat Protoc 1, 1306&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406415</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, and Braak E (2003a). Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol Aging 24, 197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ghebremedhin E, Rub U, Bratzke H, and Del Tredici K (2004). Stages in the development of Parkinson&#x2019;s disease-related pathology. Cell Tissue Res 318, 121&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15338272</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Rub U, Gai WP, and Del Tredici K (2003b). Idiopathic Parkinson&#x2019;s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 110, 517&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12721813</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Sastre M, Bohl JR, de Vos RA, and Del Tredici K (2007). Parkinson&#x2019;s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 113, 421&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">17294202</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabresi P, Picconi B, Tozzi A, Ghiglieri V, and Di Filippo M (2014). Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 17, 1022&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">25065439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra R, Hiniker A, Kuo YM, Nussbaum RL, and Liddle RA (2017). Alpha-Synuclein in gut endocrine cells and its implications for Parkinson&#x2019;s disease. JCI Insight 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470880</ArticleId><ArticleId IdType="pubmed">28614796</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, Normark S, and Hultgren SJ (2002). Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295, 851&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838482</ArticleId><ArticleId IdType="pubmed">11823641</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri KR, and Schapira AH (2009). Non-motor symptoms of Parkinson&#x2019;s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8, 464&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">19375664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryan JF, Mombereau C, and Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29, 571&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">15890404</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cunha C, Angelucci ME, Canteras NS, Wonnacott S, and Takahashi RN (2002). The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson&#x2019;s disease memory disabilities. Cell Mol Neurobiol 22, 227&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11533768</ArticleId><ArticleId IdType="pubmed">12469866</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM (2006). Assessing nest building in mice. Nat Protoc 1, 1117&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406392</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaville C, Deurwaerdere PD, and Benazzouz A (2011). Noradrenaline and Parkinson&#x2019;s disease. Front Syst Neurosci 5, 31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103977</ArticleId><ArticleId IdType="pubmed">21647359</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, Oechsner M, Jost W, Reichmann H, and Schulz JB (2008). Lewy body dementia and Parkinson&#x2019;s disease with dementia. J Neurol 255 Suppl 5, 39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">18787881</ArticleId></ArticleIdList></Reference><Reference><Citation>Eagle AL, Wang H, and Robison AJ (2016). Sensitive Assessment of Hippocampal Learning Using Temporally Dissociated Passive Avoidance Task. Bio Protoc 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5672628</ArticleId><ArticleId IdType="pubmed">29119127</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Danielsson A, Axelsson H, and Qian BF (2000). Neuroendocrine peptide levels in the gastrointestinal tract of mice after unilateral cervical vagotomy. Regul Pept 88, 15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10706947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, and Chesselet MF (2004). Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24, 9434&#x2013;9440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730110</ArticleId><ArticleId IdType="pubmed">15496679</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, and Chesselet MF (2008). Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28, 247&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108548</ArticleId><ArticleId IdType="pubmed">18702696</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, and Lee VM (2004). Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10, 1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, and Keshavarzian A (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson&#x2019;s disease. PLoS One 6, e28032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3228722</ArticleId><ArticleId IdType="pubmed">22145021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, and Iwatsubo T (2002). Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4, 160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Furness JB (2012). The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 9, 286&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">22392290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, Marti MJ, Hernandez I, Valldeoriola F, Rene R, and Ribalta T (2014). Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 29, 1010&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">24395122</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, Gathagan RJ, Iba M, McBride JD, Trojanowski JQ, and Lee VM (2016). Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J Exp Med 213, 2635&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CH, Del Tredici K, and Braak H (2007). Parkinson&#x2019;s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33, 599&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194308</ArticleId><ArticleId IdType="pubmed">17961138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CH, Del Tredici K, and Braak H (2009). Parkinson&#x2019;s disease: the dual hit theory revisited. Ann N Y Acad Sci 1170, 615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">19686202</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T, Wang ZY, Roybon L, Melki R, and Li JY (2014). Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128, 805&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">25296989</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpowicz RJ Jr., Trojanowski JQ, and Lee VM (2019). Transmission of alpha-synuclein seeds in neurodegenerative disease: recent developments. Lab Invest.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609465</ArticleId><ArticleId IdType="pubmed">30760864</ArticleId></ArticleIdList></Reference><Reference><Citation>Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, and Ko HS (2014). The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson&#x2019;s disease. Sci Rep 4, 4874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007078</ArticleId><ArticleId IdType="pubmed">24786396</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingelhoefer L, and Reichmann H (2015). Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. Nat Rev Neurol 11, 625&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">26503923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD, and Nussbaum RL (2010). Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 19, 1633&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850613</ArticleId><ArticleId IdType="pubmed">20106867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon SH, Kim HC, Lee SY, and Jang CG (2009). Loganin improves learning and memory impairments induced by scopolamine in mice. Eur J Pharmacol 619, 44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">19666019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Desplats P, Sigurdson C, Tsigelny I, and Masliah E (2010). Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 6, 702&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4996353</ArticleId><ArticleId IdType="pubmed">21045796</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard BE, and Myint A (2006). Changes in the immune system in depression and dementia: causal or coincidental effects? Dialogues Clin Neurosci 8, 163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181774</ArticleId><ArticleId IdType="pubmed">16889103</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, Chen H, and Wirdefeldt K (2017). Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology 88, 1996&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5440238</ArticleId><ArticleId IdType="pubmed">28446653</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O&#x2019;Brien P, Trojanowski JQ, and Lee VM (2012). Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Song C, O&#x2019;Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, and Lee VM (2009). Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 106, 20051&#x2013;20056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredsson FP, Luk KC, Benskey MJ, Gezer A, Garcia J, Kuhn NC, Sandoval IM, Patterson JR, O&#x2019;Mara A, Yonkers R, and Kordower JH (2018). Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis 112, 106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890443</ArticleId><ArticleId IdType="pubmed">29341898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, et al. (2016). Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510615</ArticleId><ArticleId IdType="pubmed">27708076</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinho-Buzelli AR, Bonnyman AM, and Verrier MC (2015). The effects of aquatic therapy on mobility of individuals with neurological diseases: a systematic review. Clin Rehabil 29, 741&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">25394397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R (1990). The &#x201c;serotonin hypothesis&#x201d; for depression in Parkinson&#x2019;s disease. Adv Neurol 53, 163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">2239456</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi E, Wietzikoski S, Camplessei M, Silveira R, Takahashi RN, and Da Cunha C (2002). Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 58, 41&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12121811</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary OF, Ogbonnaya ES, Felice D, Levone BR, L CC, Fitzgerald P, Bravo JA, Forsythe P, Bienenstock J, Dinan TG, and Cryan JF (2018). The vagus nerve modulates BDNF expression and neurogenesis in the hippocampus. Eur Neuropsychopharmacol 28, 307&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">29426666</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, and Funk RH (2010). Progression of Parkinson&#x2019;s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5, e8762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808242</ArticleId><ArticleId IdType="pubmed">20098733</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O&#x2019;Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, et al. (2012). Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2, 898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510466</ArticleId><ArticleId IdType="pubmed">23205266</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellow S, and File SE (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24, 525&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">2871560</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer RF (2003). Gastrointestinal dysfunction in Parkinson&#x2019;s disease. Lancet Neurol 2, 107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849267</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps D, Brinkman NE, Keely SP, Anneken EM, Catron TR, Betancourt D, Wood CE, Espenschied ST, Rawls JF, and Tal T (2017). Microbial colonization is required for normal neurobehavioral development in zebrafish. Sci Rep 7, 11244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5593827</ArticleId><ArticleId IdType="pubmed">28894128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, and Berendse HW (2004). Idiopathic hyposmia as a preclinical sign of Parkinson&#x2019;s disease. Ann Neurol 56, 173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15293269</ArticleId></ArticleIdList></Reference><Reference><Citation>Porsolt RD, Anton G, Blavet N, and Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47, 379&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">204499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ressler KJ, and Mayberg HS (2007). Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 10, 1116&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2444035</ArticleId><ArticleId IdType="pubmed">17726478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, and Brundin P (2016). Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson&#x2019;s disease. J Exp Med 213, 1759&#x2013;1778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995088</ArticleId><ArticleId IdType="pubmed">27503075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers RC, Kita H, Butcher LL, and Novin D (1980). Afferent projections to the dorsal motor nucleus of the vagus. Brain Res Bull 5, 365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">7407633</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata K, Jin L, and Jha S (2010). Lack of promoter IV-driven BDNF transcription results in depression-like behavior. Genes Brain Behav 9, 712&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">20528954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, et al. (2016). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson&#x2019;s Disease. Cell 167, 1469&#x2013;1480 e1412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, and Vital MA (2010). Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson&#x2019;s disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 34, 1104&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">20547199</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarinana J, and Tonegawa S (2016). Differentiation of forebrain and hippocampal dopamine 1-class receptors, D1R and D5R, in spatial learning and memory. Hippocampus 26, 76&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583731</ArticleId><ArticleId IdType="pubmed">26174222</ArticleId></ArticleIdList></Reference><Reference><Citation>Song N, Liu J, Shaheen S, Du L, Proctor M, Roman J, and Yu J (2015). Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice. Sci Rep 5, 13419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542162</ArticleId><ArticleId IdType="pubmed">26289670</ArticleId></ArticleIdList></Reference><Reference><Citation>Song N, Wang W, Jia F, Du X, Xie A, He Q, Shen X, Zhang J, Rogers JT, Xie J, and Jiang H (2017). Assessments of plasma ghrelin levels in the early stages of parkinson&#x2019;s disease. Mov Disord 32, 1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">28681931</ArticleId></ArticleIdList></Reference><Reference><Citation>Steru L, Chermat R, Thierry B, and Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85, 367&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">3923523</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier DJ, Obeso JA, and Halliday GM (2017). Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18, 101&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5564322</ArticleId><ArticleId IdType="pubmed">28104909</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson E, Horvath-Puho E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, and Sorensen HT (2015). Vagotomy and subsequent risk of Parkinson&#x2019;s disease. Ann Neurol 78, 522&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">26031848</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, and Takahashi RN (2008). Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson&#x2019;s disease. Neuroscience 156, 830&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">18817851</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaga AK, Dong FN, Reisert J, and Zhao H (2017). Cilia- and Flagella-Associated Protein 69 Regulates Olfactory Transduction Kinetics in Mice. J Neurosci 37, 5699&#x2013;5710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469307</ArticleId><ArticleId IdType="pubmed">28495971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarutani A, Suzuki G, Shimozawa A, Nonaka T, Akiyama H, Hisanaga S, and Hasegawa M (2016). The Effect of Fragmented Pathogenic alpha-Synuclein Seeds on Prion-like Propagation. J Biol Chem 291, 18675&#x2013;18688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009244</ArticleId><ArticleId IdType="pubmed">27382062</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor TN, Greene JG, and Miller GW (2010). Behavioral phenotyping of mouse models of Parkinson&#x2019;s disease. Behav Brain Res 211, 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862121</ArticleId><ArticleId IdType="pubmed">20211655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ter Horst GJ, Toes GJ, and Van Willigen JD (1991). Locus coeruleus projections to the dorsal motor vagus nucleus in the rat. Neuroscience 45, 153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">1684412</ArticleId></ArticleIdList></Reference><Reference><Citation>Tysnes OB, Kenborg L, Herlofson K, Steding-Jessen M, Horn A, Olsen JH, and Reichmann H (2015). Does vagotomy reduce the risk of Parkinson&#x2019;s disease? Ann Neurol 78, 1011&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">26418122</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura N, Yagi H, Uemura MT, Hatanaka Y, Yamakado H, and Takahashi R (2018). Inoculation of alpha-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol Neurodegener 13, 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948849</ArticleId><ArticleId IdType="pubmed">29751824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, and Di Monte DA (2013). Caudo-rostral brain spreading of alpha-synuclein through vagal connections. EMBO Mol Med 5, 1119&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721477</ArticleId><ArticleId IdType="pubmed">23703938</ArticleId></ArticleIdList></Reference><Reference><Citation>Villageliu DN, Rasmussen S, and Lyte M (2018). A microbial endocrinology-based simulated small intestinal medium for the evaluation of neurochemical production by gut microbiota. FEMS Microbiol Ecol 94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29790946</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, and Lee VM (2014). Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal-cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite like aggregates. Nat Protoc 9, 2135&#x2013;2146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372899</ArticleId><ArticleId IdType="pubmed">25122523</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, and Lee VM (2011). Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorhees CV, and Williams MT (2006). Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1, 848&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895266</ArticleId><ArticleId IdType="pubmed">17406317</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Mori F, Tanji K, Orimo S, and Takahashi H (2010). Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 120, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">20532896</ArticleId></ArticleIdList></Reference><Reference><Citation>Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, and Uchida N (2012). Whole brain mapping of direct inputs to midbrain dopamine neurons. Neuron 74, 858&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">22681690</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DL, Grill HJ, Cummings DE, and Kaplan JM (2003). Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 144, 5184&#x2013;5187.</Citation><ArticleIdList><ArticleId IdType="pubmed">14525914</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CC, Lien CC, Hou WH, Chiang PM, and Tsai KJ (2016). Gain of BDNF Function in Engrafted Neural Stem Cells Promotes the Therapeutic Potential for Alzheimer&#x2019;s Disease. Sci Rep 6, 27358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893631</ArticleId><ArticleId IdType="pubmed">27264956</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31257031</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner.</ArticleTitle><Pagination><StartPage>686</StartPage><EndPage>698.e14</EndPage><MedlinePgn>686-698.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2019.05.054</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(19)30625-7</ELocationID><Abstract><AbstractText>Immune cells residing in white adipose tissue have&#xa0;been highlighted as important factors contributing to the pathogenesis of metabolic diseases, but the molecular regulators that drive adipose tissue immune cell remodeling during obesity remain largely unknown. Using index and transcriptional single-cell sorting, we comprehensively map all adipose tissue immune populations in both&#xa0;mice and humans during obesity. We describe a novel and conserved Trem2<sup>+</sup> lipid-associated macrophage (LAM) subset and identify markers, spatial localization, origin, and functional pathways associated with these cells. Genetic ablation of Trem2 in mice globally inhibits the downstream molecular LAM program, leading to adipocyte hypertrophy as well as systemic hypercholesterolemia, body fat accumulation, and glucose intolerance. These findings identify Trem2 signaling as a major pathway by which macrophages respond to loss of tissue-level lipid homeostasis, highlighting Trem2 as a key sensor of metabolic pathologies across multiple tissues and a potential therapeutic target in metabolic diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaitin</LastName><ForeName>Diego Adhemar</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adlung</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thaiss</LastName><ForeName>Christoph A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Assaf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Baoguo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Descamps</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleriot</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(&#x2217;)STAR), Biopolis, Singapore 138648, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhaoyuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deczkowska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keren-Shaul</LastName><ForeName>Hadas</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zmora</LastName><ForeName>Niv</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eldar</LastName><ForeName>Shai Meron</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Surgery, Tel-Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lubezky</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Surgery, Tel-Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibolet</LastName><ForeName>Oren</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Mitchell A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginhoux</LastName><ForeName>Florent</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(&#x2217;)STAR), Biopolis, Singapore 138648, Singapore; Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Hagit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elinav</LastName><ForeName>Eran</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: eran.elinav@weizmann.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amit</LastName><ForeName>Ido</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: ido.amit@weizmann.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 HD082842</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 DK116668</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR069589</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK050306</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK049780</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK019525</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D052436" MajorTopicYN="N">Adipose Tissue, White</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059305" MajorTopicYN="N">Diet, High-Fat</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018149" MajorTopicYN="N">Glucose Intolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050152" MajorTopicYN="N">Intra-Abdominal Fat</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">Trem2 pathway</Keyword><Keyword MajorTopicYN="N">fatty liver diseases</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">macrophages</Keyword><Keyword MajorTopicYN="N">metabolic diseases</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">single-cell genomics</Keyword><Keyword MajorTopicYN="N">systems biology</Keyword></KeywordList><CoiStatement>Declaration of Interests. A patent application has been filed related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31257031</ArticleId><ArticleId IdType="mid">NIHMS1561325</ArticleId><ArticleId IdType="pmc">PMC7068689</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.05.054</ArticleId><ArticleId IdType="pii">S0092-8674(19)30625-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bahary N, Leibel RL, Joseph L, and Friedman JM (1990). Molecular mapping of the mouse db mutation. Proc Natl Acad Sci U S A 87, 8642&#x2013;8646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55013</ArticleId><ArticleId IdType="pubmed">1978328</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran Y, Sebe-Pedros A, Lubling Y, Giladi A, Chomsky E, Meir Z, Hoichman M, Lifshitz A, and Tanay A (2018). MetaCell: analysis of single cell RNA-seq data using k-NN graph partitions. bioRxiv.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790056</ArticleId><ArticleId IdType="pubmed">31604482</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas SK, and Mantovani A (2012). Orchestration of metabolism by macrophages. Cell metabolism 15, 432&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482726</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulenouar S, Michelet X, Duquette D, Alvarez D, Hogan AE, Dold C, O'Connor D, Stutte S, Tavakkoli A, Winters D, et al. (2017). Adipose Type One Innate Lymphoid Cells Regulate Macrophage Homeostasis through Targeted Cytotoxicity. Immunity 46, 273&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">28228283</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D (2013). Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol Metab 24, 40&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3556486</ArticleId><ArticleId IdType="pubmed">23265946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakarov S, Lim HY, Tan L, Lim SY, See P, Lum J, Zhang XM, Foo S, Nakamizo S, Duan K, et al. (2019). Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science 363.</Citation><ArticleIdList><ArticleId IdType="pubmed">30872492</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, Benoist C, and Mathis D (2012). PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387339</ArticleId><ArticleId IdType="pubmed">22722857</ArticleId></ArticleIdList></Reference><Reference><Citation>Coats BR, Schoenfelt KQ, Barbosa-Lorenzi VC, Peris E, Cui C, Hoffman A, Zhou G, Fernandez S, Zhai L, Hall BA, et al. (2017). Metabolically Activated Adipose Tissue Macrophages Perform Detrimental and Beneficial Functions during Diet-Induced Obesity. Cell Rep 20, 3149&#x2013;3161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646237</ArticleId><ArticleId IdType="pubmed">28954231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochain C, Vafadarnejad E, Arampatzi P, Pelisek J, Winkels H, Ley K, Wolf D, Saliba AE, and Zernecke A (2018). Single-Cell RNA-Seq Reveals the Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine Atherosclerosis. Circ Res 122, 1661&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pubmed">29545365</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, and Amit I (2018). Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell 173, 1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, and Lempicki RA (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, P3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734009</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, et al. (2009). Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15, 930&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115752</ArticleId><ArticleId IdType="pubmed">19633656</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. (2013). TREM2 variants in Alzheimer's disease. The New England journal of medicine 368, 117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, Collins N, Dzutsev A, Shaik J, Morais da Fonseca D, Harrison OJ, Tamoutounour S, Byrd AL, et al. (2017). White Adipose Tissue Is a Reservoir for Memory T Cells and Promotes Protective Memory Responses to Infection. Immunity 47, 1154&#x2013;1168 e1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5773068</ArticleId><ArticleId IdType="pubmed">29221731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill DA, Lim HW, Kim YH, Ho WY, Foong YH, Nelson VL, Nguyen HCB, Chegireddy K, Kim J, Habertheuer A, et al. (2018). Distinct macrophage populations direct inflammatory versus physiological changes in adipose tissue. Proc Natl Acad Sci U S A 115, E5096&#x2013;E5105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984532</ArticleId><ArticleId IdType="pubmed">29760084</ArticleId></ArticleIdList></Reference><Reference><Citation>Honvo-Houeto E, and Truchet S (2015). Indirect Immunofluorescence on Frozen Sections of Mouse Mammary Gland. J Vis Exp.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692769</ArticleId><ArticleId IdType="pubmed">26650781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotamisligil GS (2017). Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">28179656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, Mildner A, Cohen N, Jung S, Tanay A, et al. (2014). Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343, 776&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412462</ArticleId><ArticleId IdType="pubmed">24531970</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. The New England journal of medicine 368, 107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanneganti TD, and Dixit VD (2012). Immunological complications of obesity. Nature immunology 13, 707&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">22814340</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell 169, 1276&#x2013;1290.e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, et al. (2016). Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. The New England journal of medicine 375, 2349&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338864</ArticleId><ArticleId IdType="pubmed">27959714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohlgruber AC, Gal-Oz ST, LaMarche NM, Shimazaki M, Duquette D, Nguyen HN, Mina AI, Paras T, Tavakkoli A, von Andrian U, et al. (2018). gammadelta T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. Nat Immunol 19, 464&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299914</ArticleId><ArticleId IdType="pubmed">29670241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Estevez E, Matthews VB, Neill B, White DA, Murphy AJ, et al. (2015). Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell metabolism 21, 403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">25738456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, Schoenfelt KQ, Kuzma JN, Larson I, Billing PS, et al. (2014). Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab 20, 614&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192131</ArticleId><ArticleId IdType="pubmed">25242226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, and Amit I (2014). Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB (2011). Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci 1243, 15&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564488</ArticleId><ArticleId IdType="pubmed">22211890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovren F, Teoh H, and Verma S (2015). Obesity and atherosclerosis: mechanistic insights. Can J Cardiol 31, 177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">25661552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch L, Hogan AE, Duquette D, Lester C, Banks A, LeClair K, Cohen DE, Ghosh A, Lu B, Corrigan M, et al. (2016). iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy. Cell Metab 24, 510&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5061124</ArticleId><ArticleId IdType="pubmed">27593966</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdougall CE, Wood EG, Loschko J, Scagliotti V, Cassidy FC, Robinson ME, Feldhahn N, Castellano L, Voisin MB, Marelli-Berg F, et al. (2018). Visceral Adipose Tissue Immune Homeostasis Is Regulated by the Crosstalk between Adipocytes and Dendritic Cell Subsets. Cell Metab 27, 588&#x2013;601 e584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846800</ArticleId><ArticleId IdType="pubmed">29514067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis D (2013). Immunological goings-on in visceral adipose tissue. Cell Metab 17, 851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264591</ArticleId><ArticleId IdType="pubmed">23747244</ArticleId></ArticleIdList></Reference><Reference><Citation>McNelis JC, and Olefsky JM (2014). Macrophages, immunity, and metabolic disease. Immunity 41, 36&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25035952</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura S, Manabe I, Takaki S, Nagasaki M, Otsu M, Yamashita H, Sugita J, Yoshimura K, Eto K, Komuro I, et al. (2013). Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue Inflammation. Cell Metab.</Citation><ArticleIdList><ArticleId IdType="pubmed">24209772</ArticleId></ArticleIdList></Reference><Reference><Citation>Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, et al. (2007). Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587297</ArticleId><ArticleId IdType="pubmed">17515919</ArticleId></ArticleIdList></Reference><Reference><Citation>Okabe Y, and Medzhitov R (2016). Tissue biology perspective on macrophages. Nature immunology 17, 9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26681457</ArticleId></ArticleIdList></Reference><Reference><Citation>Okin D, and Medzhitov R (2016). The Effect of Sustained Inflammation on Hepatic Mevalonate Pathway Results in Hyperglycemia. Cell 165, 343&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826308</ArticleId><ArticleId IdType="pubmed">26997483</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Yi JW, Kim EM, Yoon IJ, Lee EH, Lee HY, Ji KY, Lee KH, Jang JH, Oh SS, et al. (2015). Triggering receptor expressed on myeloid cells 2 (TREM2) promotes adipogenesis and diet-induced obesity. Diabetes 64, 117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">25114293</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen ED, and Spiegelman BM (2014). What we talk about when we talk about fat. Cell 156, 20&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934003</ArticleId><ArticleId IdType="pubmed">24439368</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielman LJ, Little JP, and Klegeris A (2014). Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. Journal of neuroimmunology 273, 8&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24969117</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens J, Oakkar EE, Cui Z, Cai J, and Truesdale KP (2015). US adults recommended for weight reduction by 1998 and 2013 obesity guidelines, NHANES 2007-2012. Obesity (Silver Spring) 23, 527&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">25684669</ArticleId></ArticleIdList></Reference><Reference><Citation>Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, Purdom E, and Dudoit S (2018). Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 19, 477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6007078</ArticleId><ArticleId IdType="pubmed">29914354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, et al. (2013). Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 62, 1623&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">23953944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, Nelson SM, Cowling R, Nagy K, Michael IP, et al. (2013). Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab 17, 61&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">23312284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Honda T, Yamakage H, Hata J, Yoshida D, Hirakawa Y, Shibata M, Inoue T, Kusakabe T, Satoh-Asahara N, et al. (2018). A potential novel pathological implication of serum soluble triggering receptor expressed on myeloid cell 2 in insulin resistance in a general Japanese population: The Hisayama study. Diabetes Res Clin Pract 146, 225&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">30339787</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, and Colonna M (2006). Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177, 3520&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. (2017). TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell 170, 649&#x2013;663 e613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer DA, Luck H, Tsai S, and Winer S (2016). The Intestinal Immune System in Obesity and Insulin Resistance. Cell Metab 23, 413&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">26853748</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, and Haass C (2016). TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8, 992&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Grijalva A, Skowronski A, van Eijk M, Serlie MJ, and Ferrante AW Jr. (2013). Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab 18, 816&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939841</ArticleId><ArticleId IdType="pubmed">24315368</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhaoyuan Liu, Y.G., Svetoslav Chakarov, Camille Bleriot, Xin Chen, Amanda Shin, Dress Regine J., Charles-Antoine Dutertre, Andreas Schlitzer, Jinmiao Chen, Honglin Wang, Zhiduo Liu, Bing Su and Florent Ginhoux (2019). Fate mapping via Ms4a3 expression history traces monocyte-derived cells. Cell, under revision.</Citation><ArticleIdList><ArticleId IdType="pubmed">31491389</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31268539</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.</ArticleTitle><Pagination><StartPage>e196562</StartPage><MedlinePgn>e196562</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e196562</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.6562</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The association between androgen deprivation therapy (ADT) exposure and dementia is uncertain.</AbstractText><AbstractText Label="OBJECTIVE">To analyze the association between ADT exposure and diagnosis of Alzheimer disease or dementia among elderly men with prostate cancer.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This retrospective cohort study used data from the National Cancer Institute's Surveillance, Epidemiology, and End Results-Medicare linked database. Participants were 154&#x202f;089 elderly men newly diagnosed with prostate cancer between 1996 and 2003. The analyses were conducted between November 1, 2018, and December 31, 2018.</AbstractText><AbstractText Label="EXPOSURE">Androgen deprivation therapy.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Patients receiving ADT within 2 years of prostate cancer diagnosis were identified. Survival analysis was used to determine the association between ADT exposure and diagnosis of Alzheimer disease or dementia in the follow-up period. Propensity score and instrumental variable approaches were used to minimize measured and unmeasured selection bias. The association by dose of ADT was also examined.</AbstractText><AbstractText Label="RESULTS">Of the 295&#x202f;733 men diagnosed with prostate cancer between 1996 and 2003, 154&#x202f;089 met the study criteria. Of these, 62&#x202f;330 (mean [SD] age, 76.0 [6.0] years) received ADT within 2 years of prostate cancer diagnosis, and 91&#x202f;759 (mean [SD] age, 74.3 [6.0] years) did not receive ADT. Mean (SD) follow-up was 8.3 (4.7) years. Exposure to ADT, compared with no ADT exposure, was associated with a diagnosis of Alzheimer disease (13.1% vs 9.4%; difference, 3.7%; 95% CI, 3.3%-3.9%; P&#x2009;&lt;&#x2009;.001; hazard ratio [HR], 1.14; 95% CI, 1.10-1.18) and dementia (21.6% vs 15.8%; difference, 5.8%; 95% CI, 5.4%-6.2%; P&#x2009;&lt;&#x2009;.001; HR, 1.20; 95% CI, 1.17-1.24). For 1 to 4 doses of ADT, the HR was 1.19 (95% CI, 1.15-1.24) for Alzheimer disease and 1.19 (95% CI, 1.15-1.23) for dementia. For 5 to 8 doses of ADT, the HR was 1.28 (95% CI, 1.22-1.35) for Alzheimer disease and 1.24 (95% CI, 1.19-1.29) for dementia. For more than 8 doses of ADT, the HR was 1.24 (95% CI, 1.16-1.34) for Alzheimer disease and 1.21 (95% CI, 1.15-1.28) for dementia. The number needed to harm was 18 patients (95% CI, 17-19 patients) and 10 patients (95% CI, 9.5-11 patients) for Alzheimer disease and dementia, respectively.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among elderly patients with prostate cancer, ADT exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jayadevappa</LastName><ForeName>Ravishankar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Perlman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perlman School of Medicine, Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perlman School of Medicine, Department of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatre</LastName><ForeName>Sumedha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Perlman School of Medicine, Department of Psychiatry, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malkowicz</LastName><ForeName>S Bruce</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Perlman School of Medicine, Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Ravi B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Perlman School of Medicine, Department of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzzo</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Perlman School of Medicine, Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wein</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Perlman School of Medicine, Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Malkowicz reported grants from the National Institutes of Health during the conduct of the study. Dr Wein reported personal fees from Avadel, Serenity, Urovant, Valencia, and Velicept outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31268539</ArticleId><ArticleId IdType="pmc">PMC6613289</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.6562</ArticleId><ArticleId IdType="pii">2737101</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):-. doi:10.3322/caac.21442</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21442</ArticleId><ArticleId IdType="pubmed">29313949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolla M, Gonzalez D, Warde P, et al. . Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300. doi:10.1056/NEJM199707313370502</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199707313370502</ArticleId><ArticleId IdType="pubmed">9233866</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821-827. doi:10.1001/jama.292.7.821</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.292.7.821</ArticleId><ArticleId IdType="pubmed">15315996</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipley WU, Seiferheld W, Lukka HR, et al. ; NRG Oncology RTOG . Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417-428. doi:10.1056/NEJMoa1607529</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1607529</ArticleId><ArticleId IdType="pmc">PMC5444881</ArticleId><ArticleId IdType="pubmed">28146658</ArticleId></ArticleIdList></Reference><Reference><Citation>Roach M III, DeSilvio M, Lawton C, et al. ; Radiation Therapy Oncology Group 9413 . Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21(10):1904-1911. doi:10.1200/JCO.2003.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2003.05.004</ArticleId><ArticleId IdType="pubmed">12743142</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-244. doi:10.1001/jama.294.2.238</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.294.2.238</ArticleId><ArticleId IdType="pubmed">16014598</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer TM, Armstrong AJ, Rathkopf DE, et al. ; PREVAIL Investigators . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433. doi:10.1056/NEJMoa1405095</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1405095</ArticleId><ArticleId IdType="pmc">PMC4418931</ArticleId><ArticleId IdType="pubmed">24881730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CJ, Smith MR, de Bono JS, et al. ; COU-AA-302 Investigators . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148. doi:10.1056/NEJMoa1209096</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1209096</ArticleId><ArticleId IdType="pmc">PMC3683570</ArticleId><ArticleId IdType="pubmed">23228172</ArticleId></ArticleIdList></Reference><Reference><Citation>Scher HI, Fizazi K, Saad F, et al. ; AFFIRM Investigators . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197. doi:10.1056/NEJMoa1207506</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1207506</ArticleId><ArticleId IdType="pubmed">22894553</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L. Androgen deprivation therapy and the risk of dementia in patients with prostate cancer. J Clin Oncol. 2017;35(2):201-207. doi:10.1200/JCO.2016.69.6203</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.69.6203</ArticleId><ArticleId IdType="pubmed">27870566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhan JH, Yang YH, Chang YH, Guu SJ, Tsai CC. Hormone therapy for prostate cancer increases the risk of Alzheimer&#x2019;s disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017;20(1):33-38. doi:10.1080/13685538.2016.1271782</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13685538.2016.1271782</ArticleId><ArticleId IdType="pubmed">28067607</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinty HL, Phillips KM, Jim HS, et al. . Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271-2280. doi:10.1007/s00520-014-2285-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-014-2285-1</ArticleId><ArticleId IdType="pmc">PMC4090762</ArticleId><ArticleId IdType="pubmed">24859915</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas. 2011;69(4):322-337. doi:10.1016/j.maturitas.2011.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2011.05.012</ArticleId><ArticleId IdType="pubmed">21696899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer&#x2019;s disease. Horm Behav. 2013;63(2):301-307. doi:10.1016/j.yhbeh.2012.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yhbeh.2012.04.006</ArticleId><ArticleId IdType="pmc">PMC3413783</ArticleId><ArticleId IdType="pubmed">22554955</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggins C, Hodges CU. Studies on prostate cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DD, Muralidhar V, Mahal BA, et al. . National trends and predictors of androgen deprivation therapy use in low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):338-343. doi:10.1016/j.ijrobp.2017.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2017.02.020</ArticleId><ArticleId IdType="pubmed">28463152</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico AV, Denham JW, Crook J, et al. . Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420-2425. doi:10.1200/JCO.2006.09.3369</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2006.09.3369</ArticleId><ArticleId IdType="pubmed">17557956</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan KA, Walker LM, Wassersug RJ, Thompson LMA, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer. 2015;121(24):4286-4299. doi:10.1002/cncr.29672</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.29672</ArticleId><ArticleId IdType="pubmed">26372364</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Almeida OP, Fonte J, et al. . Chemical andropause and amyloid-&#x3b2; peptide. JAMA. 2001;285(17):2195-2196. doi:10.1001/jama.285.17.2195-a</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.285.17.2195-a</ArticleId><ArticleId IdType="pubmed">11325319</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine GN, D&#x2019;Amico AV, Berger P, et al. ; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association . Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194-201. doi:10.3322/caac.20061</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.20061</ArticleId><ArticleId IdType="pmc">PMC3049943</ArticleId><ArticleId IdType="pubmed">20124400</ArticleId></ArticleIdList></Reference><Reference><Citation>Scailteux L-M, Naudet F, Alimi Q, Vincendeau S, Oger E. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: a systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine (Baltimore). 2016;95(24):e3873. doi:10.1097/MD.0000000000003873</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000003873</ArticleId><ArticleId IdType="pmc">PMC4998460</ArticleId><ArticleId IdType="pubmed">27310974</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388-2399. doi:10.1002/cncr.24283</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.24283</ArticleId><ArticleId IdType="pubmed">19399748</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazta&#xf1;aga M, Crook J. Androgen deprivation therapy: minimizing exposure and mitigating side effects. J Natl Compr Canc Netw. 2012;10(9):1088-1095. doi:10.6004/jnccn.2012.0115</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2012.0115</ArticleId><ArticleId IdType="pubmed">22956808</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JL, Klabunder CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data-content, research application and generalizability to the United States elderly population. Med Care. 2002;40(8):3-18. doi:10.1097/00005650-200208001-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-200208001-00002</ArticleId><ArticleId IdType="pubmed">12187163</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164. doi:10.1056/NEJMoa041943</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa041943</ArticleId><ArticleId IdType="pubmed">15647578</ArticleId></ArticleIdList></Reference><Reference><Citation>Klabunde C, Warren J, Legler J. Assessing comorbidity using claims data-an overview. Med Care. 2002;40(8):26-35. doi:10.1097/00005650-200208001-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-200208001-00004</ArticleId><ArticleId IdType="pubmed">12187165</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison PD. Logistic Regression&#x2014;Using the SAS System: Theory and Application. Cary, NC: SAS Institute Inc; 1999.</Citation></Reference><Reference><Citation>Spreeuwenberg MD, Bartak A, Croon MA, et al. . The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care. 2010;48(2):166-174. doi:10.1097/MLR.0b013e3181c1328f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3181c1328f</ArticleId><ArticleId IdType="pubmed">20068488</ArticleId></ArticleIdList></Reference><Reference><Citation>Green WH. Econometric Analysis. Upper Saddle River, NJ: Prentice Hall; 2000.</Citation></Reference><Reference><Citation>Johnston KM, Gustafson P, Levy AR, Grootendorst P. Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research. Stat Med. 2008;27(9):1539-1556. doi:10.1002/sim.3036</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3036</ArticleId><ArticleId IdType="pubmed">17847052</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid M, Sammon JD, Reznor G, et al. . Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int. 2016;118(2):221-229. doi:10.1111/bju.13203</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.13203</ArticleId><ArticleId IdType="pubmed">26074405</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez BD, Jim HSL, Booth-Jones M, et al. . Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021-2027. doi:10.1200/JCO.2014.60.1963</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.60.1963</ArticleId><ArticleId IdType="pmc">PMC4461804</ArticleId><ArticleId IdType="pubmed">25964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating NL, O&#x2019;Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. doi:10.1200/JCO.2006.06.2497</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2006.06.2497</ArticleId><ArticleId IdType="pubmed">16983113</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandaglia G, Sun M, Popa I, et al. . The impact of the androgen deprivation therapy on the risk of coronary heart disease in patients with non-metastatic prostate cancer: a population-based study. BJU Int. 2014;114(6b):E82-E89. doi:10.1111/bju.12732</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bju.12732</ArticleId><ArticleId IdType="pubmed">24612110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nead KT, Gaskin G, Chester C, et al. . Androgen deprivation therapy and future Alzheimer&#x2019;s disease risk. J Clin Oncol. 2016;34(6):566-571. doi:10.1200/JCO.2015.63.6266</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.63.6266</ArticleId><ArticleId IdType="pmc">PMC5070576</ArticleId><ArticleId IdType="pubmed">26644522</ArticleId></ArticleIdList></Reference><Reference><Citation>Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3(1):49-55. doi:10.1001/jamaoncol.2016.3662</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2016.3662</ArticleId><ArticleId IdType="pubmed">27737437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao LT, Lin HC, Chung SD, et al. . No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study. Asian J Androl. 2017;19(4):414-417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507085</ArticleId><ArticleId IdType="pubmed">27232853</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer&#x2019;s disease. Lancet. 2006;368(9533):387-403. doi:10.1016/S0140-6736(06)69113-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69113-7</ArticleId><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D. Alzheimer's and Parkinson's diseases: progress and new perspectives. Paper presented at: Eighth International Conference on AD/PD; March 14-18, 2007; Salzburg, Austria.</Citation></Reference><Reference><Citation>Rost K, Smith R, Matthews DB, Guise B. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med. 1994;3(4):333-337. doi:10.1001/archfami.3.4.333</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archfami.3.4.333</ArticleId><ArticleId IdType="pubmed">8012621</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MR, Saad F, Chowdhury S, et al. ; SPARTAN Investigators . Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1715546</ArticleId><ArticleId IdType="pubmed">29420164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M, Fizazi K, Saad F, et al. . Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1800536</ArticleId><ArticleId IdType="pmc">PMC8288034</ArticleId><ArticleId IdType="pubmed">29949494</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31273083</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><Issue>34</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Humanization of the entire murine <i>Mapt</i> gene provides a murine model of pathological human tau propagation.</ArticleTitle><Pagination><StartPage>12754</StartPage><EndPage>12765</EndPage><MedlinePgn>12754-12765</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.RA119.009487</ELocationID><Abstract><AbstractText>In cortical regions of brains from individuals with preclinical or clinical Alzheimer's disease (AD), extracellular &#x3b2;-amyloid (A&#x3b2;) deposition precedes the aggregation of pathological intracellular tau (the product of the gene microtubule-associated protein tau (<i>MAPT</i>)). To our knowledge, current mouse models of tauopathy reconstitute tau pathology by overexpressing mutant human tau protein. Here, through a homologous recombination approach that replaced the entire murine <i>Mapt</i> gene with the human ortholog, we developed knock-in mice with humanized <i>Mapt</i> to create an <i>in vivo</i> platform for studying human tauopathy. Of note, the humanized <i>Mapt</i> expressed all six tau isoforms present in humans. We next cross-bred the <i>MAPT</i> knock-in mice with single amyloid precursor protein (<i>App</i>) knock-in mice to investigate the A&#x3b2;-tau axis in AD etiology. The double-knock-in mice exhibited higher tau phosphorylation than did single <i>MAPT</i> knock-in mice but initially lacked apparent tauopathy and neurodegeneration, as observed in the single <i>App</i> knock-in mice. We further observed that tau humanization significantly accelerates cell-to-cell propagation of AD brain-derived pathological tau both in the absence and presence of A&#x3b2;-amyloidosis. In the presence of A&#x3b2;-amyloidosis, tau accumulation was intensified and closely associated with dystrophic neurites, consistently showing that A&#x3b2;-amyloidosis affects tau pathology. Our results also indicated that the pathological human tau interacts better with human tau than with murine tau, suggesting species-specific differences between these orthologous pathogenic proteins. We propose that the <i>MAPT</i> knock-in mice will make it feasible to investigate the behaviors and characteristics of human tau in an animal model.</AbstractText><CopyrightInformation>&#xa9; 2019 Saito et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9659-9251</Identifier><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan takashi.saito.aa@riken.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Pathobiology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi 464-8601, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihira</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuba</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaguri</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Shoko</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5778-4884</Identifier><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Sneha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaecho, Itabashi, Tokyo 173-0015, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan saido@brain.riken.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein (APP)</Keyword><Keyword MajorTopicYN="N">amyloid-beta (AB)</Keyword><Keyword MajorTopicYN="N">dystrophic neurite</Keyword><Keyword MajorTopicYN="N">humanized mouse model</Keyword><Keyword MajorTopicYN="N">knock-in</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">plaque deposit</Keyword><Keyword MajorTopicYN="N">tau propagation</Keyword><Keyword MajorTopicYN="N">tau protein (tau)</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList><CoiStatement>T. S., Y. M., S. H., and T. C. S. serve as advisor, director, researcher, and CEO, respectively, for RIKEN BIO Co. Ltd., which sublicenses animal models, <i>App</i> KI mice, to for-profit organizations, the proceeds from which are used for the identification of disease biomarkers</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31273083</ArticleId><ArticleId IdType="pmc">PMC6709628</ArticleId><ArticleId IdType="doi">10.1074/jbc.RA119.009487</ArticleId><ArticleId IdType="pii">S0021-9258(20)30308-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman R. J., Xiong C., Benzinger T. L., Fagan A. M., Goate A., Fox N. C., Marcus D. S., Cairns N. J., Xie X., Blazey T. M., Holtzman D. M., Santacruz A., Buckles V., Oliver A., Moulder K., et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795&#x2013;804 10.1056/NEJMoa1202753</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., and Hardy J. (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 10.15252/emmm.201606210</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J. L., Lee E. B., Xie S. X., Rennert L., Suh E., Bredenberg C., Caswell C., Van Deerlin V. M., Yan N., Yousef A., Hurtig H. I., Siderowf A., Grossman M., McMillan C. T., Miller B., et al. (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181&#x2013;2193 10.1093/brain/awy146</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy146</ArticleId><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M., Iwata N., Matsuba Y., Takano J., Suemoto T., Maeda J., Ji B., Ono M., Staufenbiel M., Suhara T., and Saido T. C. (2012) Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J. 26, 1204&#x2013;1217 10.1096/fj.11-187740</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-187740</ArticleId><ArticleId IdType="pubmed">22173972</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T., Matsuba Y., Mihira N., Takano J., Nilsson P., Itohara S., Iwata N., and Saido T. C. (2014) Single App knock-in mouse models of Alzheimer's disease. Nat. Neurosci. 17, 661&#x2013;663 10.1038/nn.3697</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3697</ArticleId><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T., Matsuba Y., Yamazaki N., Hashimoto S., and Saido T. C. (2016) Calpain activation in Alzheimer's model mice is an artifact of APP and presenilin overexpression. J. Neurosci. 36, 9933&#x2013;9936 10.1523/JNEUROSCI.1907-16.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1907-16.2016</ArticleId><ArticleId IdType="pmc">PMC5030353</ArticleId><ArticleId IdType="pubmed">27656030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H., Nilsson P., Hashimoto S., Nagata K., Saito T., De Strooper B., Hardy J., Vassar R., Winblad B., and Saido T. C. (2017) APP mouse models for Alzheimer's disease preclinical studies. EMBO J. 36, 2473&#x2013;2487 10.15252/embj.201797397</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797397</ArticleId><ArticleId IdType="pmc">PMC5579350</ArticleId><ArticleId IdType="pubmed">28768718</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Spillantini M. G., Jakes R., Rutherford D., and Crowther R. A. (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519&#x2013;526 10.1016/0896-6273(89)90210-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(89)90210-9</ArticleId><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J., Probst A., Spillantini M. G., Sch&#xe4;fer T., Jakes R., B&#xfc;rki K., and Goedert M. (1995) Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14, 1304&#x2013;1313 10.1002/j.1460-2075.1995.tb07116.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1995.tb07116.x</ArticleId><ArticleId IdType="pmc">PMC398215</ArticleId><ArticleId IdType="pubmed">7729409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo A., Misonou H., Matsuyama M., Nomori A., Wada-Kakuda S., Takashima A., Kawata M., Murayama S., Ihara Y., and Miyasaka T. (2019) Distribution of endogenous normal tau in the mouse brain. J. Comp. Neurol. 527, 985&#x2013;998 10.1002/cne.24577</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24577</ArticleId><ArticleId IdType="pmc">PMC6587864</ArticleId><ArticleId IdType="pubmed">30408165</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M. G., and Goedert M. (2013) Tau pathology and neurodegeneration. Lancet Neurol. 12, 609&#x2013;622 10.1016/S1474-4422(13)70090-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70090-5</ArticleId><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., and Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z., Guo J. L., McBride J. D., Narasimhan S., Kim H., Changolkar L., Zhang B., Gathagan R. J., Yue C., Dengler C., Stieber A., Nitla M., Coulter D. A., Abel T., Brunden K. R., et al. (2018) Amyloid-&#x3b2; plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 24, 29&#x2013;38 10.1038/nm.4443</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4443</ArticleId><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L., Bussi&#xe8;re T., Bu&#xe9;e-Scherrer V., Delacourte A., and Hof P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95&#x2013;130 10.1016/S0165-0173(00)00019-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(00)00019-9</ArticleId><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H., Nagata K., Sekiguchi M., Fujioka R., Matsuba Y., Hashimoto S., Sato K., Kurup D., Yokota T., and Saido T. C. (2018) Introduction of pathogenic mutations into the mouse Psen1 gene by Base Editor and Target-AID. Nat. Commun. 9, 2892 10.1038/s41467-018-05262-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05262-w</ArticleId><ArticleId IdType="pmc">PMC6057936</ArticleId><ArticleId IdType="pubmed">30042426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B. I., Geschwind D. H., Bird T. D., McKeel D., Goate A., Morris J. C., Wilhelmsen K. C., Schellenberg G. D., Trojanowski J. Q., and Lee V. M. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282, 1914&#x2013;1917 10.1126/science.282.5395.1914</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.282.5395.1914</ArticleId><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis A. (2005) Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim. Biophys. Acta 1739, 91&#x2013;103 10.1016/j.bbadis.2004.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2004.08.010</ArticleId><ArticleId IdType="pubmed">15615629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J. L., and Zheng H. (2017) Practical considerations for choosing a mouse model of Alzheimer's disease. Mol. Neurodegener. 12, 89 10.1186/s13024-017-0231-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0231-7</ArticleId><ArticleId IdType="pmc">PMC5741956</ArticleId><ArticleId IdType="pubmed">29273078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K., Leroy K., Heraud C., Kabova A., Yilmaz Z., Authelet M., Suain V., De Decker R., and Brion J. P. (2010) Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model. Biochem. Soc. Trans. 38, 1001&#x2013;1005 10.1042/BST0381001</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0381001</ArticleId><ArticleId IdType="pubmed">20658993</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liu L., Li M., Yao E., Hao J., Dong Y., Zheng X., and Liu X. (2018) Expression of human Tau40 in the medial entorhinal cortex impairs synaptic plasticity and associated cognitive functions in mice. Biochem. Biophys. Res. Commun. 496, 1006&#x2013;1012 10.1016/j.bbrc.2017.04.153</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.04.153</ArticleId><ArticleId IdType="pubmed">28472625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto S., Matsuba Y., Kamano N., Mihira N., Sahara N., Takano J., Muramatsu S. I., Saido T. C., and Saito T. (2019) Tau binding protein CAPON induces tau aggregation and neurodegeneration. Nat. Commun. 10, 2394 10.1038/s41467-019-10278-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10278-x</ArticleId><ArticleId IdType="pmc">PMC6546774</ArticleId><ArticleId IdType="pubmed">31160584</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y., Higuchi M., Zhang B., Huang S. M., Iwata N., Saido T. C., Maeda J., Suhara T., Trojanowski J. Q., and Lee V. M. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351 10.1016/j.neuron.2007.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover B. R., Reed M. N., Su J., Penrod R. D., Kotilinek L. A., Grant M. K., Pitstick R., Carlson G. A., Lanier L. M., Yuan L. L., Ashe K. H., and Liao D. (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067&#x2013;1081 10.1016/j.neuron.2010.11.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatz D. C., Rujescu D., Tang Y., Berendt F. J., Hartmann A. M., Faltraco F., Rosenberg C., Hulette C., Jellinger K., Hampel H., Riederer P., M&#xf6;ller H. J., Andreadis A., Henkel K., and Stamm S. (2006) The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J. Neurochem. 96, 635&#x2013;644 10.1111/j.1471-4159.2005.03552.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03552.x</ArticleId><ArticleId IdType="pubmed">16371011</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch K. M., DeVos S. L., Miller R. L., Chun S. J., Norrbom M., Wozniak D. F., Dawson H. N., Bennett C. F., Rigo F., and Miller T. M. (2016) Increased 4R-Tau induces pathological changes in a human-Tau mouse model. Neuron 90, 941&#x2013;947 10.1016/j.neuron.2016.04.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.042</ArticleId><ArticleId IdType="pmc">PMC5040069</ArticleId><ArticleId IdType="pubmed">27210553</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk K. C., Covell D. J., Kehm V. M., Zhang B., Song I. Y., Byrne M. D., Pitkin R. M., Decker S. C., Trojanowski J. Q., and Lee V. M. (2016) Molecular and biological compatibility with host &#x3b1;-synuclein influences fibril pathogenicity. Cell Rep. 16, 3373&#x2013;3387 10.1016/j.celrep.2016.08.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.08.053</ArticleId><ArticleId IdType="pmc">PMC5087609</ArticleId><ArticleId IdType="pubmed">27653697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B., Oblak A. L., Boeve B. F., Johnson K. A., Dickerson B. C., and Goedert M. (2015) Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol. 41, 24&#x2013;46 10.1111/nan.12213</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12213</ArticleId><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin L. O., Splinter E., Davis T. L., Urban R., He H., Braun R. E., Chesler E. J., Kumar V., van Min M., Ndukum J., Philip V. M., Reinholdt L. G., Svenson K., White J. K., Sasner M., Lutz C., and Murray S. A. (2019) Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis. Genome Res. 29, 494&#x2013;505 10.1101/gr.233866.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.233866.117</ArticleId><ArticleId IdType="pmc">PMC6396414</ArticleId><ArticleId IdType="pubmed">30659012</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Eisenberg D. S., and Crowther R. A. (2017) Propagation of tau aggregates and neurodegeneration. Annu. Rev. Neurosci. 40, 189&#x2013;210 10.1146/annurev-neuro-072116-031153</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031153</ArticleId><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar H., and Udgaonkar J. B. (2019) Mechanistic approaches to understand the prion-like propagation of aggregates of the human tau protein. Biochim. Biophys. Acta Proteins Proteom. 10.1016/j.bbapap.2019.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2019.04.004</ArticleId><ArticleId IdType="pubmed">30986567</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasili E., Dominguez-Meijide A., and Outeiro T. F. (2019) Spreading of &#x3b1;-synuclein and Tau: a systematic comparison of the mechanisms involved. Front. Mol. Neurosci. 12, 107 10.3389/fnmol.2019.00107</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00107</ArticleId><ArticleId IdType="pmc">PMC6494944</ArticleId><ArticleId IdType="pubmed">31105524</ArticleId></ArticleIdList></Reference><Reference><Citation>Puig B., Altmeppen H., and Glatzel M. (2014) The GPI-anchoring of PrP: implications in sorting and pathogenesis. Prion 8, 11&#x2013;18 10.4161/pri.27892</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.27892</ArticleId><ArticleId IdType="pmc">PMC7030901</ArticleId><ArticleId IdType="pubmed">24509692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M. S. (2012) The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica (Cairo) 2012, 796024 10.6064/2012/796024</Citation><ArticleIdList><ArticleId IdType="doi">10.6064/2012/796024</ArticleId><ArticleId IdType="pmc">PMC3820460</ArticleId><ArticleId IdType="pubmed">24278740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V. M., and Trojanowski J. Q. (1999) Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron 24, 507&#x2013;510 10.1016/S0896-6273(00)81106-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81106-X</ArticleId><ArticleId IdType="pubmed">10595503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambadipudi S., Biernat J., Riedel D., Mandelkow E., and Zweckstetter M. (2017) Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. Nat. Commun. 8, 275 10.1038/s41467-017-00480-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00480-0</ArticleId><ArticleId IdType="pmc">PMC5561136</ArticleId><ArticleId IdType="pubmed">28819146</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyko S., Qi X., Chen T.-H., Surewicz K., and Surewicz W. K. (2019) Liquid&#x2013;liquid phase separation of tau protein: the crucial role of electrostatic interactions. J. Biol. Chem. 274, 11054&#x2013;11059 10.1074/jbc.AC119.009198</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC119.009198</ArticleId><ArticleId IdType="pmc">PMC6643045</ArticleId><ArticleId IdType="pubmed">31097543</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanoska K., Volkerling A., Bertz J., Poljak A., Ke Y. D., Ittner L. M., and Ittner A. (2018) An N-terminal motif unique to primate tau enables differential protein&#x2013;protein interactions. J. Biol. Chem. 293, 3710&#x2013;3719 10.1074/jbc.RA118.001784</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.001784</ArticleId><ArticleId IdType="pmc">PMC5846163</ArticleId><ArticleId IdType="pubmed">29382714</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N., Mizukami H., Shirotani K., Takaki Y., Muramatsu S., Lu B., Gerard N. P., Gerard C., Ozawa K., and Saido T. C. (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-&#x3b2; peptide in mouse brain. J. Neurosci. 24, 991&#x2013;998 10.1523/JNEUROSCI.4792-03.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4792-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729819</ArticleId><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara S., and Saido T. C. (2005) Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J. Biol. Chem. 280, 15229&#x2013;15237 10.1074/jbc.M500939200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500939200</ArticleId><ArticleId IdType="pubmed">15699033</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T. C., Iwatsubo T., Mann D. M., Shimada H., Ihara Y., and Kawashima S. (1995) Dominant and differential deposition of distinct &#x3b2;-amyloid peptide species, A&#x3b2; N3(pE), in senile plaques. Neuron 14, 457&#x2013;466 10.1016/0896-6273(95)90301-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90301-1</ArticleId><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Enya M., Morishima-Kawashima M., Yoshimura M., Shinkai Y., Kusui K., Khan K., Games D., Schenk D., Sugihara S., Yamaguchi H., and Ihara Y. (1999) Appearance of sodium dodecyl sulfate-stable amyloid &#x3b2;-protein (A&#x3b2;) dimer in the cortex during aging. Am. J. Pathol. 154, 271&#x2013;279 10.1016/S0002-9440(10)65273-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65273-X</ArticleId><ArticleId IdType="pmc">PMC1853431</ArticleId><ArticleId IdType="pubmed">9916941</ArticleId></ArticleIdList></Reference><Reference><Citation>Iovino M., Patani R., Watts C., Chandran S., and Spillantini M. G. (2010) Human stem cell-derived neurons: a system to study human tau function and dysfunction. PLoS One 5, e13947 10.1371/journal.pone.0013947</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013947</ArticleId><ArticleId IdType="pmc">PMC2978712</ArticleId><ArticleId IdType="pubmed">21085657</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J. L., Narasimhan S., Changolkar L., He Z., Stieber A., Zhang B., Gathagan R. J., Iba M., McBride J. D., Trojanowski J. Q., and Lee V. M. (2016) Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. J. Exp. Med. 213, 2635&#x2013;2654 10.1084/jem.20160833</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160833</ArticleId><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S., and Lee V. M. Y. (2017) The use of mouse models to study cell-to-cell transmission of pathological tau. Methods Cell Biol. 141, 287&#x2013;305 10.1016/bs.mcb.2017.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.mcb.2017.06.009</ArticleId><ArticleId IdType="pmc">PMC5733800</ArticleId><ArticleId IdType="pubmed">28882308</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31301936</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>820</StartPage><EndPage>835.e7</EndPage><MedlinePgn>820-835.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.06.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)30560-4</ELocationID><Abstract><AbstractText>The microglial receptors CD33 and TREM2 have been associated with risk for Alzheimer's disease (AD). Here, we investigated crosstalk between CD33 and TREM2. We showed that knockout of CD33 attenuated amyloid beta (A&#x3b2;) pathology and improved cognition in 5xFAD mice, both of which were abrogated by additional TREM2 knockout. Knocking out TREM2 in 5xFAD mice exacerbated A&#x3b2; pathology and neurodegeneration but reduced Iba1<sup>+</sup> cell numbers, all of which could not be rescued by additional CD33 knockout. RNA-seq profiling of microglia revealed that genes related to phagocytosis and signaling (IL-6, IL-8, acute phase response) are upregulated in 5xFAD;CD33<sup>-/-</sup> and downregulated in 5xFAD;TREM2<sup>-/-</sup> mice. Differential gene expression in 5xFAD;CD33<sup>-/-</sup> microglia depended on the presence of TREM2, suggesting TREM2 acts downstream of CD33. Crosstalk between CD33 and TREM2 includes regulation of the IL-1&#x3b2;/IL-1RN axis and a gene set in the "receptor activity chemokine" cluster. Our results should facilitate AD therapeutics targeting these receptors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Griciuc</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Federico</LastName><ForeName>Anthony N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Innes</LastName><ForeName>Brendan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oram</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cereghetti</LastName><ForeName>Gea</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; Institute of Biochemistry, Department of Biology, ETH Z&#xfc;rich, 8093 Z&#xfc;rich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGinty</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anselmo</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadreyev</LastName><ForeName>Ruslan I</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickman</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Khoury</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. Electronic address: tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K99 AG049056</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG049056</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051506</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C571165">Cd33 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D063268">Sialic Acid Binding Ig-like Lectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2019 Sep 4;103(5):747-749. doi: 10.1016/j.neuron.2019.08.019.</RefSource><PMID Version="1">31487521</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000210" MajorTopicYN="N">Acute-Phase Reaction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063268" MajorTopicYN="N">Sialic Acid Binding Ig-like Lectin 3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">CD33</Keyword><Keyword MajorTopicYN="N">IL-1beta</Keyword><Keyword MajorTopicYN="N">RNA-seq</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">pathway analysis</Keyword><Keyword MajorTopicYN="N">transcriptomics</Keyword></KeywordList><CoiStatement>Declaration of interest. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31301936</ArticleId><ArticleId IdType="mid">NIHMS1532644</ArticleId><ArticleId IdType="pmc">PMC6728215</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.06.010</ArticleId><ArticleId IdType="pii">S0896-6273(19)30560-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. (2015). Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem 290, 26043&#x2013;26050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, DeVaux LB, and Farzan M (2015). The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem 290, 26033&#x2013;26042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Menachem-Zidon O, Ben-Menahem Y, Ben-Hur T, and Yirmiya R (2014). Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimer&#x2019;s disease model. Neuropsychopharmacology 39, 401&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870779</ArticleId><ArticleId IdType="pubmed">23954849</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, et al. (2008). Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet 83, 623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, et al. (2013). CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16, 848&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G, White CC, Winn PA, Cimpean M, Replogle JM, Glick LR, Cuerdon NE, Ryan KJ, Johnson KA, Schneider JA, et al. (2015). CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci 18, 1556&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682915</ArticleId><ArticleId IdType="pubmed">26414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocker PR, Paulson JC, and Varki A (2007). Siglecs and their roles in the immune system. Nat Rev Immunol 7, 255&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">17380156</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, and Goate AM (2017). Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener 12, 43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Paredes L, Casrouge A, Decalf J, de Andres C, Villar LM, Perez de Diego R, Alonso B, Alvarez Cermeno JC, Arroyo R, Tejera-Alhambra M, et al. (2017). Multimarker risk stratification approach at multiple sclerosis onset. Clin Immunol 181, 43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">28578025</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, and Tanzi RE (2013). Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. (2013). TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med 368, 117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE, and Sheng M (2018). Microglia in Alzheimer&#x2019;s disease. J Cell Biol 217, 459&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidary M, Rakhshi N, Pahlevan Kakhki M, Behmanesh M, Sanati MH, Sanadgol N, Kamaladini H, and Nikravesh A (2014). The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients. J Neurol Sci 343, 41&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24867167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrickx DAE, van Scheppingen J, van der Poel M, Bossers K, Schuurman KG, van Eden CG, Hol EM, Hamann J, and Huitinga I (2017). Gene Expression Profiling of Multiple Sclerosis Pathology Identifies Early Patterns of Demyelination Surrounding Chronic Active Lesions. Front Immunol 8, 1810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742619</ArticleId><ArticleId IdType="pubmed">29312322</ArticleId></ArticleIdList></Reference><Reference><Citation>Herran E, Perez-Gonzalez R, Igartua M, Pedraz JL, Carro E, and Hernandez RM (2013). VEGF-releasing biodegradable nanospheres administered by craniotomy: a novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer&#x2019;s disease. J Control Release 170, 111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, and El Khoury J (2008). Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci 28, 8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, and El Khoury J (2013). The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 16, 1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet 43, 429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, Yu Y, Yuan J, Zhao Y, and Cheng Y (2017). Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep 7, 9094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida A, Akita K, Mori Y, Tanida S, Toda M, Inoue M, and Nakada H (2014). Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33. J Biol Chem 289, 25341&#x2013;25350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155695</ArticleId><ArticleId IdType="pubmed">25059667</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, and Landreth GE (2017). Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. J Neurosci 37, 637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, et al. (2015). TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med 212, 287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. (2013). Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med 368, 107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, and Goate AM (2012). Expression of novel Alzheimer&#x2019;s disease risk genes in control and Alzheimer&#x2019;s disease brains. PLoS One 7, e50976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511432</ArticleId><ArticleId IdType="pubmed">23226438</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, et al. (2018). Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer&#x2019;s Disease Models. Neuron 97, 1032&#x2013;1048 e1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, et al. (2018). High-affinity interactions and signal transduction between Abeta oligomers and TREM2. EMBO Mol Med 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220267</ArticleId><ArticleId IdType="pubmed">30341064</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, and Holtzman DM (2017). TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A 114, 11524&#x2013;11529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Castano AP, Hudson TE, Nowlin BT, Lin SL, Bonventre JV, Swanson KD, and Duffield JS (2010). The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J 24, 4767&#x2013;4781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992370</ArticleId><ArticleId IdType="pubmed">20709912</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik M, Simpson JF, Parikh I, Wilfred BR, Fardo DW, Nelson PT, and Estus S (2013). CD33 Alzheimer&#x2019;s risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 33, 13320&#x2013;13325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742922</ArticleId><ArticleId IdType="pubmed">23946390</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico D, Isserlin R, Stueker O, Emili A, and Bader GD (2010). Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 5, e13984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981572</ArticleId><ArticleId IdType="pubmed">21085593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, et al. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet 43, 436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquarella C, Veronesi L, Napoli C, Castiglia P, Liguori G, Rizzetto R, Torre I, Righi E, Farruggia P, Tesauro M, et al. (2012). Microbial environmental contamination in Italian dental clinics: A multicenter study yielding recommendations for standardized sampling methods and threshold values. Sci Total Environ 420, 289&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">22335883</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M, Diamond B, Volpe BT, Aranow CB, Mackay MC, and Santiago-Schwarz F (2017). Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression. Sci Rep 7, 270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412647</ArticleId><ArticleId IdType="pubmed">28325905</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi RE, and Colonna M (2017). Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement 13, 381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, and Colonna M (2018). Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215, 745&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD, et al. (2016). sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. EMBO Mol Med 8, 466&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, and Neumann H (2005). Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201, 647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Shimazawa M, Kimura M, Takata M, Tsuruma K, Yamada M, Takahashi H, Hozumi I, Niwa J, Iguchi Y, et al. (2012). The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci Rep 2, 573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417778</ArticleId><ArticleId IdType="pubmed">22891158</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE (2012). The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE (2015). TREM2 and Risk of Alzheimer&#x2019;s Disease--Friend or Foe? N Engl J Med 372, 2564&#x2013;2565.</Citation><ArticleIdList><ArticleId IdType="pubmed">26107057</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, and Colonna M (2006). Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177, 3520&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. (2017). TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell 170, 649&#x2013;663 e613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, and Holtzman DM (2014). Altered microglial response to Abeta plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol Neurodegener 9, 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorhees CV, and Williams MT (2006). Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1, 848&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895266</ArticleId><ArticleId IdType="pubmed">17406317</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Whetzel AM, Serrano G, Sue LI, Beach TG, and Lue LF (2015). Association of CD33 polymorphism rs3865444 with Alzheimer&#x2019;s disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging 36, 571&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315751</ArticleId><ArticleId IdType="pubmed">25448602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. (2016). TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213, 667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Hansen DV, and Sheng M (2017). TREM2, Microglia, and Neurodegenerative Diseases. Trends Mol Med 23, 512&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">28442216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, and Sheng M (2016). TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron 91, 328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, and Grutzendler J (2016). TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 90, 724&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pina-Crespo JC, Zhang M, et al. (2018). TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function. Neuron 97, 1023&#x2013;1031 e1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Wang Z, Wang D, Wang Z, Martens YA, Wu L, Xu Y, Wang K, Li J, Huang R, et al. (2018). Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegener 13, 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870375</ArticleId><ArticleId IdType="pubmed">29587871</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31341278</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>572</Volume><Issue>7767</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>62</StartPage><EndPage>66</EndPage><MedlinePgn>62-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-019-1419-5</ELocationID><Abstract><AbstractText>Recent work has shown that meningeal lymphatic vessels (mLVs), mainly in the dorsal part of the skull, are involved in the clearance of cerebrospinal fluid (CSF), but the precise route of CSF drainage is still unknown. Here we reveal the importance of mLVs in the basal part of the skull for this process by visualizing their distinct anatomical location and characterizing their specialized morphological features, which facilitate the uptake and drainage of CSF. Unlike dorsal mLVs, basal mLVs have lymphatic valves and capillaries located adjacent to the subarachnoid space in mice. We also show that basal mLVs are hotspots for the clearance of CSF macromolecules and that both mLV integrity and CSF drainage are impaired with ageing. Our findings should increase the understanding of how mLVs contribute to the neuropathophysiological processes that are associated with ageing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ahn</LastName><ForeName>Ji Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cho</LastName><ForeName>Hyunsoo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Jun-Hee</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Bio and Brain Engineering, KAIST, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Shin Heun</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Program of Brain and Cognitive Engineering, KAIST, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ham</LastName><ForeName>Je-Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Bio and Brain Engineering, KAIST, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Intae</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Sang Heon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Seon Pyo</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Joo-Hye</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Young-Kwon</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Surgery, Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bio and Brain Engineering, KAIST, Daejeon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Brain and Cognitive Engineering, KAIST, Daejeon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sung-Hong</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Bio and Brain Engineering, KAIST, Daejeon, South Korea. sunghongpark@kaist.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Brain and Cognitive Engineering, KAIST, Daejeon, South Korea. sunghongpark@kaist.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Gou Young</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea. gykoh@kaist.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, South Korea. gykoh@kaist.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL121036</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL141857</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C082078">mesenchyme fork head 1 protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000098551">Prospero-Related Homeobox 1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040321">Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2019 Aug;572(7767):34-35. doi: 10.1038/d41586-019-02166-7.</RefSource><PMID Version="1">31358927</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosci Bull. 2020 May;36(5):557-560. doi: 10.1007/s12264-019-00456-8.</RefSource><PMID Version="1">31893342</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077502" MajorTopicYN="N">Glymphatic System</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019291" MajorTopicYN="N">Skull Base</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013346" MajorTopicYN="N">Subarachnoid Space</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040321" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000098551" MajorTopicYN="N">Prospero-Related Homeobox 1 Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31341278</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1419-5</ArticleId><ArticleId IdType="pii">10.1038/s41586-019-1419-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991&#x2013;999 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142290</ArticleId></ArticleIdList></Reference><Reference><Citation>Antila, S. et al. Development and plasticity of meningeal lymphatic vessels. J. Exp. Med. 214, 3645&#x2013;3667 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20170391</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita, S. et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0368-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau, A. et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21, 1380&#x2013;1391 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0227-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, T. K. et al. Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol. Neurodegener. 14, 11 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0312-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasoff-Conway, J. M. et al. Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457&#x2013;470 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.119</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita, S., Fu, Z. &amp; Kipnis, J. The meningeal lymphatic system: a new player in neurophysiology. Neuron 100, 375&#x2013;388 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, Q., Ineichen, B. V., Detmar, M. &amp; Proulx, S. T. Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice. Nat. Commun. 8, 1434 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01484-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Luki&#x107;, I. K., Glunci&#x107;, V., Ivki&#x107;, G., Hubenstorf, M. &amp; Marusi&#x107;, A. Virtual dissection: a lesson from the 18th century. Lancet 362, 2110&#x2013;2113 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)15114-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstmann, B. U., de Hollander, G., van Maanen, L., Alkemade, A. &amp; Keuken, M. C. Towards a mechanistic understanding of the human subcortex. Nat. Rev. Neurosci. 18, 57&#x2013;65 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.163</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova, T. V. &amp; Koh, G. Y. Organ-specific lymphatic vasculature: From development to pathophysiology. J. Exp. Med. 215, 35&#x2013;49 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171868</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund, A., Robciuc, M. R., Karaman, S., Makinen, T. &amp; Alitalo, K. Lymphatic system in cardiovascular medicine. Circ. Res. 118, 515&#x2013;530 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.306544</ArticleId></ArticleIdList></Reference><Reference><Citation>Margaris, K. N. &amp; Black, R. A. Modelling the lymphatic system: challenges and opportunities. J. R. Soc. Interface 9, 601&#x2013;612 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2011.0751</ArticleId></ArticleIdList></Reference><Reference><Citation>Brakenhielm, E. &amp; Alitalo, K. Cardiac lymphatics in health and disease. Nat. Rev. Cardiol. 16, 56&#x2013;68 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-018-0087-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Baluk, P. et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 204, 2349&#x2013;2362 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20062596</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, I. et al. Visualization of lymphatic vessels by Prox1-promoter directed GFP reporter in a bacterial artificial chromosome-based transgenic mouse. Blood 117, 362&#x2013;365 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-07-298562</ArticleId></ArticleIdList></Reference><Reference><Citation>Absinta, M. et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. eLife 6, e29738 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.29738</ArticleId></ArticleIdList></Reference><Reference><Citation>Gousopoulos, E., Proulx, S. T., Scholl, J., Uecker, M. &amp; Detmar, M. Prominent lymphatic vessel hyperplasia with progressive dysfunction and distinct immune cell infiltration in lymphedema. Am. J. Pathol. 186, 2193&#x2013;2203 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2016.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabine, A. et al. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev. Cell 22, 430&#x2013;445 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2011.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet, D. T. et al. Lymph flow regulates collecting lymphatic vessel maturation in vivo. J. Clin. Invest. 125, 2995&#x2013;3007 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI79386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabine, A. et al. FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature. J. Clin. Invest. 125, 3861&#x2013;3877 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI80454</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, H. et al. YAP and TAZ negatively regulate Prox1 during developmental and pathologic lymphangiogenesis. Circ. Res. 124, 225&#x2013;242 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313707</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolla, V. et al. Aging-related anatomical and biochemical changes in lymphatic collectors impair lymph transport, fluid homeostasis, and pathogen clearance. Aging Cell 14, 582&#x2013;594 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12330</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazigou, E. et al. Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice. J. Clin. Invest. 121, 2984&#x2013;2992 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI58050</ArticleId></ArticleIdList></Reference><Reference><Citation>Haiko, P. et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell. Biol. 28, 4843&#x2013;4850 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.02214-07</ArticleId></ArticleIdList></Reference><Reference><Citation>Yushkevich, P. A. et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31, 1116&#x2013;1128 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ineichen, B. V. et al. Direct, long-term intrathecal application of therapeutics to the rodent CNS. Nat. Protocols 12, 104&#x2013;131 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31375314</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Development of a Chimeric Model to Study and Manipulate Human Microglia In&#xa0;Vivo.</ArticleTitle><Pagination><StartPage>1016</StartPage><EndPage>1033.e10</EndPage><MedlinePgn>1016-1033.e10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.07.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)30600-2</ELocationID><Abstract><AbstractText>iPSC-derived microglia offer a powerful tool to study microglial homeostasis and disease-associated inflammatory responses. Yet, microglia are highly sensitive to their environment, exhibiting transcriptomic deficiencies when kept in isolation from the brain. Furthermore, species-specific genetic variations demonstrate that rodent microglia fail to fully recapitulate the human condition. To address this, we developed an approach to study human microglia within a surrogate brain environment. Transplantation of iPSC-derived hematopoietic-progenitors into the postnatal brain of humanized, immune-deficient mice results in context-dependent differentiation into microglia and other CNS macrophages, acquisition of an ex&#xa0;vivo human microglial gene signature, and responsiveness to both acute and chronic insults. Most notably, transplanted microglia exhibit robust transcriptional responses to A&#x3b2;-plaques that&#xa0;only partially overlap with that of murine microglia, revealing new, human-specific A&#x3b2;-responsive genes. We therefore have demonstrated that this chimeric model provides a powerful new system to examine the in&#xa0;vivo function of patient-derived and genetically modified microglia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hasselmann</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coburn</LastName><ForeName>Morgan A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>England</LastName><ForeName>Whitney</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa Velez</LastName><ForeName>Dario X</ForeName><Initials>DX</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiani Shabestari</LastName><ForeName>Sepideh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Christina H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolahdouzan</LastName><ForeName>Mahshad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Echeverria</LastName><ForeName>Karla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claes</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coufal</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Claudia Z</ForeName><Initials>CZ</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92696, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Christopher K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA 92093, USA; Department of Medicine, University of California, San Diego, San Diego, CA 92093-0651, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>Luke M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Neuroimmunology Unit, Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC H3A 2B4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Sunil P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA; Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spitale</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA; Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92696, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92696, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92696, USA; Center for the Neurobiology of Learning and Memory, University of California, Irvine, Irvine, CA 92697, USA. Electronic address: mblurton@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM008620</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048099</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 GM119164</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS109200</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 DA048813</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY028212</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA062203</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 EY029596</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021718</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 EY028046</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS082174</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR025496</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD010794</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000628668">CSF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000631512">CSF2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>81627-83-0</RegistryNumber><NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>83869-56-1</RegistryNumber><NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9014-42-0</RegistryNumber><NameOfSubstance UI="D013926">Thrombopoietin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Oct;15(10):558-559. doi: 10.1038/s41582-019-0252-7.</RefSource><PMID Version="1">31462751</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lab Anim (NY). 2020 Feb;49(2):49-51. doi: 10.1038/s41684-019-0465-9.</RefSource><PMID Version="1">31932736</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="Y">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="N">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013926" MajorTopicYN="N">Thrombopoietin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018183" MajorTopicYN="Y">Transplantation Chimera</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TREM-2</Keyword><Keyword MajorTopicYN="N">beta-amyloid</Keyword><Keyword MajorTopicYN="N">chimera</Keyword><Keyword MajorTopicYN="N">hematopoietic</Keyword><Keyword MajorTopicYN="N">humanized</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">pluripotent</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31375314</ArticleId><ArticleId IdType="mid">NIHMS1563396</ArticleId><ArticleId IdType="pmc">PMC7138101</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.07.002</ArticleId><ArticleId IdType="pii">S0896-6273(19)30600-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, et al. (2017). iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron 94, 278&#x2013;293 e279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Kachadoorian M, Carrasquillo MM, Karhade A, Manly L, Burgess JD, Wang C, Serie D, Wang X, Siuda J, et al. (2015). Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurol Genet 1, e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807909</ArticleId><ArticleId IdType="pubmed">27066552</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews S (2014). FastQC: a quality control tool for high throughput sequence data.</Citation></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett FC, Bennett ML, Yaqoob F, Mulinyawe SB, Grant GA, Hayden Gephart M, Plowey ED, and Barres BA (2018). A Combination of Ontogeny and CNS Environment Establishes Microglial Identity. Neuron 98, 1170&#x2013;1183 e1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023731</ArticleId><ArticleId IdType="pubmed">29861285</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, et al. (2016). New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 113, E1738&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, and Usadel B (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Boza-Serrano A, Ruiz R, Sanchez-Varo R, Garcia-Revilla J, Yang Y, Jimenez-Ferrer I, Paulus A, Wennstrom M, Vilalta A, Allendorf D, et al. (2019). Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer&#x2019;s disease. Acta Neuropathol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660511</ArticleId><ArticleId IdType="pubmed">31006066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray NL, Pimentel H, Melsted P, and Pachter L (2016). Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34, 525&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">27043002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushnell B (2018). BBMap.</Citation></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, and Satija R (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36, 411&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Capotondo A, Milazzo R, Garcia-Manteiga JM, Cavalca E, Montepeloso A, Garrison BS, Peviani M, Rossi DJ, and Biffi A (2017). Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells. Sci Adv 3, e1701211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5721728</ArticleId><ArticleId IdType="pubmed">29226242</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, and Gan WB (2005). ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8, 752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Golde TE, and Lagier-Tourenne C (2018). Animal models of neurodegenerative diseases. Nat Neurosci 21, 1370&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6615039</ArticleId><ArticleId IdType="pubmed">30250265</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lucia C, Rinchon A, Olmos-Alonso A, Riecken K, Fehse B, Boche D, Perry VH, and Gomez-Nicola D (2016). Microglia regulate hippocampal neurogenesis during chronic neurodegeneration. Brain Behav Immun 55, 179&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4907582</ArticleId><ArticleId IdType="pubmed">26541819</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, et al. (2014). Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. (2018). Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer&#x2019;s Disease Not Evident in Mouse Models. Cell Rep 22, 832&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold EM, Vasilevko V, Hasselmann J, Tiefenthaler C, Hoa D, Ranawaka K, Cribbs DH, and Cummings BJ (2018). Repeated Mild Closed Head Injuries Induce Long-Term White Matter Pathology and Neuronal Loss That Are Correlated With Behavioral Deficits. ASN Neuro 10, 1759091418781921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050992</ArticleId><ArticleId IdType="pubmed">29932344</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Wieghofer P, Jordao MJ, Prutek F, Hagemeyer N, Frenzel K, Amann L, Staszewski O, Kierdorf K, Krueger M, et al. (2016). Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat Immunol 17, 797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, Jaeger BN, O&#x2019;Connor C, Fitzpatrick C, Pasillas MP, et al. (2017). An environment-dependent transcriptional network specifies human microglia identity. Science 356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, and El Khoury J (2018). Microglia in neurodegeneration. Nat Neurosci 21, 1359&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, and Landreth GE (2017). Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. J Neurosci 37, 637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W, Kooijman L, Schetters S, Orre M, and Hol EM (2016). Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer&#x2019;s disease. Biochim Biophys Acta 1862, 1847&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pubmed">27425031</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Cruchaga C, and Goate AM (2014). Alzheimer&#x2019;s disease genetics: from the bench to the clinic. Neuron 83, 11&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120741</ArticleId><ArticleId IdType="pubmed">24991952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauppinen TM, Higashi Y, Suh SW, Escartin C, Nagasawa K, and Swanson RA (2008). Zinc triggers microglial activation. J Neurosci 28, 5827&#x2013;5835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680357</ArticleId><ArticleId IdType="pubmed">18509044</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, Bessy A, Cheneby J, Kulkarni SR, Tan G, et al. (2018). JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res 46, D260&#x2013;D266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753243</ArticleId><ArticleId IdType="pubmed">29140473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde R (2018). pheatmap: pretty heatmaps.</Citation></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, and Salzberg SL (2012). Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd S (1982). Least squares quantization in PCM. IEEE Transactions on Information Theory 28, 129&#x2013;137.</Citation></Reference><Reference><Citation>Love MI, Huber W, and Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, et al. (2016). The adaptive immune system restrains Alzheimer&#x2019;s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A 113, E1316&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="pubmed">26884167</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, and Blurton-Jones M (2018). Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener 13, 67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico D, Isserlin R, Stueker O, Emili A, and Bader GD (2010). Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 5, e13984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981572</ArticleId><ArticleId IdType="pubmed">21085593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, and Thomas PD (2017). PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 45, D183&#x2013;D189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210595</ArticleId><ArticleId IdType="pubmed">27899595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, and Helmchen F (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, and Holmes C (2014). Microglial priming in neurodegenerative disease. Nat Rev Neurol 10, 217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock JM, and Piers TM (2018). Modelling microglial function with induced pluripotent stem cells: an update. Nat Rev Neurosci 19, 445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">29977068</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Erny D, and Hagemeyer N (2017). Ontogeny and homeostasis of CNS myeloid cells. Nat Immunol 18, 385&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">28323268</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido-Salgado M, Vidal-Taboada JM, Barriga GG, Sola C, and Saura J (2018). RNA-Seq transcriptomic profiling of primary murine microglia treated with LPS or LPS + IFNgamma. Sci Rep 8, 16096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208373</ArticleId><ArticleId IdType="pubmed">30382133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathinam C, Poueymirou WT, Rojas J, Murphy AJ, Valenzuela DM, Yancopoulos GD, Rongvaux A, Eynon EE, Manz MG, and Flavell RA (2011). Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 118, 3119&#x2013;3128.</Citation><ArticleIdList><ArticleId IdType="pubmed">21791433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, and Smyth GK (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK, et al. (2014). Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32, 364&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017589</ArticleId><ArticleId IdType="pubmed">24633240</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, and Stevens B (2017). Microglia emerge as central players in brain disease. Nat Med 23, 1018&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Savchenko VL, McKanna JA, Nikonenko IR, and Skibo GG (2000). Microglia and astrocytes in the adult rat brain: comparative immunocytochemical analysis demonstrates the efficacy of lipocortin 1 immunoreactivity. Neuroscience 96, 195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683423</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider VA, Graves-Lindsay T, Howe K, Bouk N, Chen HC, Kitts PA, Murphy TD, Pruitt KD, Thibaud-Nissen F, Albracht D, et al. (2017). Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly. Genome Res 27, 849&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5411779</ArticleId><ArticleId IdType="pubmed">28396521</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, and Ideker T (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498&#x2013;2504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro LA, Perez ZD, Foresti ML, Arisi GM, and Ribak CE (2009). Morphological and ultrastructural features of Iba1-immunolabeled microglial cells in the hippocampal dentate gyrus. Brain Res 1266, 29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677570</ArticleId><ArticleId IdType="pubmed">19249294</ArticleId></ArticleIdList></Reference><Reference><Citation>Shitaka Y, Tran HT, Bennett RE, Sanchez L, Levy MA, Dikranian K, and Brody DL (2011). Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J Neuropathol Exp Neurol 70, 551&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118973</ArticleId><ArticleId IdType="pubmed">21666502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieff CA (1987). Hematopoietic growth factors. J Clin Invest 79, 1549&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424464</ArticleId><ArticleId IdType="pubmed">3034976</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI, and Robinson MD (2015). Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, and Colonna M (2018). Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215, 745&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. (2007). The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology, C. (2017). Expansion of the Gene Ontology knowledgebase and resources. Nucleic Acids Res 45, D331&#x2013;D338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210579</ArticleId><ArticleId IdType="pubmed">27899567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda Y, Gullipalli D, and Song WC (2016). Modeling complement-driven diseases in transgenic mice: Values and limitations. Immunobiology 221, 1080&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">27371974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, and Holtzman DM (2014). Altered microglial response to Abeta plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol Neurodegener 9, 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Varley AW, Coulthard MG, Meidell RS, Gerard RD, and Munford RS (1995). Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes. Proc Natl Acad Sci U S A 92, 5346&#x2013;5350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41691</ArticleId><ArticleId IdType="pubmed">7539915</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, et al. (2016). TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213, 667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster DE (2013). FOCIS.</Citation></Reference><Reference><Citation>Wickham H (2016). ggplot2: Elegant Graphics for Data, 2nd edn (Springer Nature; ).</Citation></Reference><Reference><Citation>Wu Y, Dissing-Olesen L, MacVicar BA, and Stevens B (2015). Microglia: Dynamic Mediators of Synapse Development and Plasticity. Trends Immunol 36, 605&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4841266</ArticleId><ArticleId IdType="pubmed">26431938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Raj D, Saiepour N, Van Dam D, Brouwer N, Holtman IR, Eggen BJL, Moller T, Tamm JA, Abdourahman A, et al. (2017). Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer&#x2019;s disease. Neurobiol Aging 55, 115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">28434692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, and Grutzendler J (2016). TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 92, 252&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, Cummins C, Gall A, Giron CG, et al. (2018). Ensembl 2018. Nucleic Acids Res 46, D754&#x2013;D761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753206</ArticleId><ArticleId IdType="pubmed">29155950</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31371569</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>17</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis.</ArticleTitle><Pagination><StartPage>e1647</StartPage><EndPage>e1659</EndPage><MedlinePgn>e1647-e1659</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000008081</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We examined whether plasma &#x3b2;-amyloid (A&#x3b2;)42/A&#x3b2;40, as measured by a high-precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p-tau181/A&#x3b2;42 as reference standards.</AbstractText><AbstractText Label="METHODS">Using an immunoprecipitation and liquid chromatography-mass spectrometry assay, we measured A&#x3b2;42/A&#x3b2;40 in plasma and CSF samples from 158 mostly cognitively normal individuals that were collected within 18 months of an amyloid PET scan.</AbstractText><AbstractText Label="RESULTS">Plasma A&#x3b2;42/A&#x3b2;40 had a high correspondence with amyloid PET status (receiver operating characteristic area under the curve [AUC] 0.88, 95% confidence interval [CI] 0.82-0.93) and CSF p-tau181/A&#x3b2;42 (AUC 0.85, 95% CI 0.79-0.92). The combination of plasma A&#x3b2;42/A&#x3b2;40, age, and <i>APOE</i> &#x3b5;4 status had a very high correspondence with amyloid PET (AUC 0.94, 95% CI 0.90-0.97). Individuals with a negative amyloid PET scan at baseline and a positive plasma A&#x3b2;42/A&#x3b2;40 (&lt;0.1218) had a 15-fold greater risk of conversion to amyloid PET-positive compared to individuals with a negative plasma A&#x3b2;42/A&#x3b2;40 (<i>p</i> = 0.01).</AbstractText><AbstractText Label="CONCLUSIONS">Plasma A&#x3b2;42/A&#x3b2;40, especially when combined with age and <i>APOE</i> &#x3b5;4 status, accurately diagnoses brain amyloidosis and can be used to screen cognitively normal individuals for brain amyloidosis. Individuals with a negative amyloid PET scan and positive plasma A&#x3b2;42/A&#x3b2;40 are at increased risk for converting to amyloid PET-positive. Plasma A&#x3b2;42/A&#x3b2;40 could be used in prevention trials to screen for individuals likely to be amyloid PET-positive and at risk for Alzheimer disease dementia.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class II evidence that plasma A&#x3b2;42/A&#x3b2;40 levels accurately determine amyloid PET status in cognitively normal research participants.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollinger</LastName><ForeName>James G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., J.G.B., V.O., K.G.M., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Knight Alzheimer's Disease Research Center (S.E.S., B.A.G., D.M.H., J.C.M., T.L.S.B., C.X., A.M.F., R.J.B.), Division of Biostatistics (Y.L., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (D.M.H., A.M.F., R.J.B.), Washington University School of Medicine, St. Louis, MO. batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2019 Oct 22;93(17):737-738. doi: 10.1212/WNL.0000000000008080.</RefSource><PMID Version="1">31371570</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31371569</ArticleId><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008081</ArticleId><ArticleId IdType="pii">WNL.0000000000008081</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80:1778&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte MM, Foster NL, Fleisher AS, et al. . Clinical use of amyloid-positron emission tomography neuroimaging: practical and bioethical considerations. Alzheimer's Demen 2015;1:358&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878065</ArticleId><ArticleId IdType="pubmed">27239516</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien JT, Herholz K. Amyloid imaging for dementia in clinical practice. BMC Med 2015;13:163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4499896</ArticleId><ArticleId IdType="pubmed">26170121</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Carrillo MC, Dean RA, et al. . Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's Demen 2015;1:412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879481</ArticleId><ArticleId IdType="pubmed">27239522</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease: are we on the right road? N Engl J Med 2014;370:377&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci translational Med 2014;6:228fs213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo MC, Brashear HR, Logovinsky V, et al. . Can we prevent Alzheimer's disease? Secondary &#x201c;prevention&#x201d; trials in Alzheimer's disease. Alzheimer's Dement 2013;9:123&#x2013;131 e121.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411394</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, Vellas B, Woodward M, et al. . Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med 2018;378:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Donohue M, Raman R, et al. . The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study: report of screening data results. Alzheimer's Dement 2018;14:P215&#x2013;P216.</Citation></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, et al. . Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's Dement 2017;13:841&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et al. . High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature 2018;554:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Roe CM, Villegas A, et al. . Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol 2003;54:163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Gray JD, Gordon BA, et al. . Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's Dement 2018;14:1460&#x2013;1469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119652</ArticleId><ArticleId IdType="pubmed">29501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Kasten T, Sigurdson W, Bateman RJ. Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics. Anal Biochem 2013;440:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749773</ArticleId><ArticleId IdType="pubmed">23714261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pino LK, Searle BC, Bollinger JG, Nunn B, MacLean B, MacCoss MJ. The Skyline ecosystem: informatics for quantitative mass spectrometry proteomics. Mass Spectrom Rev Epub 2017 Jul 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5799042</ArticleId><ArticleId IdType="pubmed">28691345</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, van der Kouwe A, Destrieux C, et al. . Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D'Angelo GM, Vlassenko AG, et al. . Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One 2013;8:e73377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. . Partial volume correction in quantitative amyloid imaging. Neuroimage 2015;107:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, McCue L, Jasielec MS, et al. . Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann Neurol 2016;80:379&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Gordon BA, Su Y, et al. . AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage 2017;161:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696044</ArticleId><ArticleId IdType="pubmed">28756238</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer's Dement 2015;11:1&#x2013;15 e11-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Flores S, Hornbeck RC, et al. . Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin 2018;19:406&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051499</ArticleId><ArticleId IdType="pubmed">30035025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson E. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209&#x2013;212.</Citation></Reference><Reference><Citation>Hirji K, Mehta C, Patel N. Computing distributions for exact logistic regression. J Am Stat Assoc 1987;82:1110&#x2013;1117.</Citation></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. . CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's Dement 2018;14:1470&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. Neurology 2009;72:8&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">19122025</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. . Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 2017;317:2305&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. . Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, et al. . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016;15:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemse E, van Uffelen K, Brix B, Engelborghs S, Vanderstichele H, Teunissen C. How to handle adsorption of cerebrospinal fluid amyloid beta (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Abeta42/Abeta40 ratio. Alzheimer's Dement 2017;13:885&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">28222302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Okereke OI, Xia W, Irizarry MC, et al. . Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis 2009;16:277&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737811</ArticleId><ArticleId IdType="pubmed">19221417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Kawarabayashi T, Seino Y, et al. . Aging and APOE-epsilon4 are determinative factors of plasma Abeta42 levels. Ann Clin Transl Neurol 2018;5:1184&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186936</ArticleId><ArticleId IdType="pubmed">30349853</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk IMW, Slot RE, Verfaillie SCJ, et al. . Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 2018;84:648&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6282982</ArticleId><ArticleId IdType="pubmed">30196548</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Vanderstichele H, Figurski M, et al. . Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011;122:401&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299300</ArticleId><ArticleId IdType="pubmed">21805181</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements: a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 2013;5:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706955</ArticleId><ArticleId IdType="pubmed">23470128</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Boccardi M, Barkhof F, et al. . Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol 2017;16:661&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">28721928</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31380975</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of White Matter Rarefaction, Arteriolosclerosis, and Tau With Dementia in Chronic Traumatic Encephalopathy.</ArticleTitle><Pagination><StartPage>1298</StartPage><EndPage>1308</EndPage><MedlinePgn>1298-1308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.2244</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive head impacts, including those from US football, that presents with cognitive and neuropsychiatric disturbances that can progress to dementia. Pathways to dementia in CTE are unclear and likely involve tau and nontau pathologic conditions.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the association of white matter rarefaction and cerebrovascular disease with dementia in deceased men older than 40 years who played football and had CTE.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This cross-sectional study involves analyses of data from the ongoing Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) Study, which is conducted via and included brain donors from the Veterans Affairs-Boston University-Concussion Legacy Foundation brain bank between 2008 and 2017. An original sample of 224 men who had played football and were neuropathologically diagnosed with CTE was reduced after exclusion of those younger than 40 years and those missing data.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">The number of years of football play as a proxy for repetitive head impacts.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Neuropathological assessment of white matter rarefaction and arteriolosclerosis severity (on a scale of 0-3, where 3 is severe); number of infarcts, microinfarcts, and microbleeds; and phosphorylated tau accumulation determined by CTE stage and semiquantitative rating of dorsolateral frontal cortex (DLFC) neurofibrillary tangles (NFTs) (none or mild vs moderate or severe). Informant-based retrospective clinical interviews determined dementia diagnoses via diagnostic consensus conferences.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 180 men were included. The mean (SD) age of the sample at death was 67.9 (12.7) years. Of 180, 120 [66.7%]) were found to have had dementia prior to death. Moderate to severe white matter rarefaction (84 of 180 [46.6%]) and arteriolosclerosis (85 of 180 [47.2%]) were common; infarcts, microinfarcts, and microbleeds were not. A simultaneous equations regression model controlling for age and race showed that more years of play was associated with more severe white matter rarefaction (&#x3b2;, 0.16 [95% CI, 0.02-0.29]; P&#x2009;=&#x2009;.03) and greater phosphorylated tau accumulation (DLFC NFTs: &#x3b2;, 0.15 [95% CI, 0.004-0.30]; P&#x2009;=&#x2009;.04; CTE stage: &#x3b2;, 0.27 [95% CI, 0.14-0.41]; P&#x2009;&lt;&#x2009;.001). White matter rarefaction (&#x3b2;, 0.16 [95% CI, 0.02-0.29]; P&#x2009;=&#x2009;.03) and DLFC NFTs (&#x3b2;, 0.16 [95% CI, 0.03-0.28]; P&#x2009;=&#x2009;.01) were associated with dementia. Arteriolosclerosis and years of play were not associated, but arteriolosclerosis was independently associated with dementia (&#x3b2;, 0.21 [95% CI, 0.07-0.35]; P&#x2009;=&#x2009;.003).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among older men who had played football and had CTE, more years of football play were associated with more severe white matter rarefaction and greater DLFC NFT burden. White matter rarefaction, arteriolosclerosis, and DLFC NFTs were independently associated with dementia. Dementia in CTE is likely a result of neuropathologic changes, including white matter rarefaction and phosphorylated tau, associated with repetitive head impact and pathologic changes not associated with head trauma, such as arteriolosclerosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alosco</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Thor D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bedford Veterans Affairs Medical Center, Bedford, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripodis</LastName><ForeName>Yorghos</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Alicia S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Bertrand Russell</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Posttraumatic Stress Disorder, VA Boston Healthcare, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lee E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical &amp; Computer Engineering, Boston University College of Engineering, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Boston University College of Engineering, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantu</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Concussion Legacy Foundation, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Emerson Hospital, Concord, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Douglas I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Braintree Rehabilitation Hospital, Braintree, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmisano</LastName><ForeName>Joseph N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherry</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahar</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Imaging, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McClean</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Rhoda</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, National Heart, Lung, and Blood Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mez</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Boston University Alzheimer's Disease Center and CTE Center, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bedford Veterans Affairs Medical Center, Bedford, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS102399</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 CX001038</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057902</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054156</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062348</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS093334</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamaneurol.2019.1089</RefSource></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Conflict of Interest Disclosures</b>: Dr Goldstein is a paid consultant to Johnson &amp; Johnson, Janssen Research &amp; Development LLC, and Rebiscan Inc and has received funding from the WWE (World Wrestling Entertainment) and Ivivi Health Sciences. Dr Stern has received research funding from Avid Radiopharmaceuticals Inc, is a member of the Mackey-White Committee of the National Football League Players Association, is a paid consultant to Biogen and Eli Lilly, receives royalties for published neuropsychological tests from Psychological Assessment Resources Inc, and is a member of the Board of Directors of King-Devick Technologies. Dr Cantu is a paid consultant to the National Football League Head Neck and Spine Committee, a vice president and chair of the scientific advisory committee of the National Operating Committee on Standards for Athletic Equipment, and a consultant to the Concussion Legacy Foundation; he also receives royalties from Houghton Mifflin Harcourt and compensation for expert legal opinion to the National Collegiate Athletic Association and National Hockey League and is a member of the Mackey-White Committee of the National Football League Players Association. Dr McKee is a member of the Mackey-White Committee of the National Football League Players Association and reports receiving grants from the National Institutes of Health and Department of Veteran Affairs and other funding from Buoniconti Foundation during the conduct of the study. Dr Alosco reported grants from National Institutes of Health/National Institute of Neurological Disorders and Stroke during the conduct of the study. Dr Katz reported grants from Boston University School of Medicine Department of Neurology during the conduct of the study. Dr Au reported grants from Cohen Veterans Bioscience, Pfizer, Biogen, and Evidation Health and personal fees from Optum Health, outside the submitted work. Dr Stern reported grants from the National Institutes of Health during the conduct of the study; personal fees from Biogen and Eli Lilly outside the submitted work; membership on the board of directors for King-Devick Technologies, with stock options; and royalties for published neuropsychological tests from Psychological Assessment Resources Inc. Dr Mez reported grants from the National Institutes of Health, Department of Defense, Alzheimer&#x2019;s Association, and Concussion Legacy Foundation during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31380975</ArticleId><ArticleId IdType="pmc">PMC6686769</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.2244</ArticleId><ArticleId IdType="pii">2739480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montenigro PH, Alosco ML, Martin BM, et al. . Cumulative head impact exposure predicts later-life depression, apathy, executive dysfunction, and cognitive impairment in former high school and college football players. J Neurotrauma. 2017;34(2):328-340. doi:10.1089/neu.2016.4413</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2016.4413</ArticleId><ArticleId IdType="pmc">PMC5220530</ArticleId><ArticleId IdType="pubmed">27029716</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stern RA, Nowinski CJ, et al. . The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(pt 1):43-64. doi:10.1093/brain/aws307</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws307</ArticleId><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Daneshvar DH, Kiernan PT, et al. . Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318(4):360-370. doi:10.1001/jama.2017.8334</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.8334</ArticleId><ArticleId IdType="pmc">PMC5807097</ArticleId><ArticleId IdType="pubmed">28742910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Ross OA, Cormier KA, et al. . Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol. 2015;130(6):877-889. doi:10.1007/s00401-015-1502-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1502-4</ArticleId><ArticleId IdType="pmc">PMC4655127</ArticleId><ArticleId IdType="pubmed">26518018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H, Morris HR, Neal JW, et al. . Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathol. 2017;133(3):337-352. doi:10.1007/s00401-017-1680-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1680-3</ArticleId><ArticleId IdType="pmc">PMC5325836</ArticleId><ArticleId IdType="pubmed">28205009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagge CA, Fisher AM, Minaeva OV, et al. . Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain. 2018;141(2):422-458. doi:10.1093/brain/awx350</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx350</ArticleId><ArticleId IdType="pmc">PMC5837414</ArticleId><ArticleId IdType="pubmed">29360998</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cairns NJ, Dickson DW, et al. ; TBI/CTE group . The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75-86. doi:10.1007/s00401-015-1515-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1515-z</ArticleId><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RA, Daneshvar DH, Baugh CM, et al. . Clinical presentation of chronic traumatic encephalopathy. Neurology. 2013;81(13):1122-1129. doi:10.1212/WNL.0b013e3182a55f7f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a55f7f</ArticleId><ArticleId IdType="pmc">PMC3795597</ArticleId><ArticleId IdType="pubmed">23966253</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Mez J, Tripodis Y, et al. . Age of first exposure to tackle football and chronic traumatic encephalopathy. Ann Neurol. 2018;83(5):886-901. doi:10.1002/ana.25245</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25245</ArticleId><ArticleId IdType="pmc">PMC6367933</ArticleId><ArticleId IdType="pubmed">29710395</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Mez J, Kowall NW, et al. . Cognitive reserve as a modifier of clinical expression in chronic traumatic encephalopathy: a preliminary examination. J Neuropsychiatry Clin Neurosci. 2017;29(1):6-12. doi:10.1176/appi.neuropsych.16030043</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.neuropsych.16030043</ArticleId><ArticleId IdType="pmc">PMC5288278</ArticleId><ArticleId IdType="pubmed">27539377</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Montenigro PH, Alvarez VE, et al. . Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol. 2015;130(1):21-34. doi:10.1007/s00401-015-1435-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1435-y</ArticleId><ArticleId IdType="pmc">PMC4529056</ArticleId><ArticleId IdType="pubmed">25943889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Stein TD, Tripodis Y, et al. . CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer&#x2019;s disease. PLoS One. 2017;12(9):e0185541. doi:10.1371/journal.pone.0185541</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0185541</ArticleId><ArticleId IdType="pmc">PMC5614644</ArticleId><ArticleId IdType="pubmed">28950005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Tripodis Y, Alvarez VE, et al. . Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun. 2016;4(1):112. doi:10.1186/s40478-016-0382-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0382-8</ArticleId><ArticleId IdType="pmc">PMC5084333</ArticleId><ArticleId IdType="pubmed">27793189</ArticleId></ArticleIdList></Reference><Reference><Citation>Holleran L, Kim JH, Gangolli M, et al. . Axonal disruption in white matter underlying cortical sulcus tau pathology in chronic traumatic encephalopathy. Acta Neuropathol. 2017;133(3):367-380. doi:10.1007/s00401-017-1686-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1686-x</ArticleId><ArticleId IdType="pubmed">28214960</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Duskin J, Besser LM, et al. . Modeling the relationships among late-life body mass index, cerebrovascular disease, and Alzheimer&#x2019;s disease neuropathology in an autopsy sample of 1,421 subjects from the National Alzheimer&#x2019;s Coordinating Center Data Set. J Alzheimers Dis. 2017;57(3):953-968. doi:10.3233/JAD-161205</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161205</ArticleId><ArticleId IdType="pmc">PMC5526463</ArticleId><ArticleId IdType="pubmed">28304301</ArticleId></ArticleIdList></Reference><Reference><Citation>Deramecourt V, Slade JY, Oakley AE, et al. . Staging and natural history of cerebrovascular pathology in dementia. Neurology. 2012;78(14):1043-1050. doi:10.1212/WNL.0b013e31824e8e7f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31824e8e7f</ArticleId><ArticleId IdType="pmc">PMC3317531</ArticleId><ArticleId IdType="pubmed">22377814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S115-S123. doi:10.1097/00002093-199912003-00017</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199912003-00017</ArticleId><ArticleId IdType="pubmed">10609690</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer&#x2019;s disease. Biochim Biophys Acta. 2016;1862(5):887-900. doi:10.1016/j.bbadis.2015.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2015.12.016</ArticleId><ArticleId IdType="pmc">PMC4821735</ArticleId><ArticleId IdType="pubmed">26705676</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Arnold SE, Raible K, et al. . Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer&#x2019;s Coordinating Centre. Brain. 2013;136(pt 9):2697-2706. doi:10.1093/brain/awt188</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt188</ArticleId><ArticleId IdType="pmc">PMC3858112</ArticleId><ArticleId IdType="pubmed">23842566</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738. doi:10.1038/nrn3114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3114</ArticleId><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Viqar F, Zimmerman ME, et al. ; Dominantly Inherited Alzheimer Network . White matter hyperintensities are a core feature of Alzheimer&#x2019;s disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol. 2016;79(6):929-939. doi:10.1002/ana.24647</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24647</ArticleId><ArticleId IdType="pmc">PMC4884146</ArticleId><ArticleId IdType="pubmed">27016429</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer&#x2019;s disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 2016;15(9):934-943. doi:10.1016/S1474-4422(16)30029-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30029-1</ArticleId><ArticleId IdType="pmc">PMC4969105</ArticleId><ArticleId IdType="pubmed">27312738</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron SL, Hein MJ, Lehman E, Gersic CM. Body mass index, playing position, race, and the cardiovascular mortality of retired professional football players. Am J Cardiol. 2012;109(6):889-896. doi:10.1016/j.amjcard.2011.10.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2011.10.050</ArticleId><ArticleId IdType="pubmed">22284915</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker AM, Vogel RA, Lincoln AE, et al. . Prevalence of cardiovascular disease risk factors among National Football League players. JAMA. 2009;301(20):2111-2119. doi:10.1001/jama.2009.716</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.716</ArticleId><ArticleId IdType="pubmed">19470988</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosco ML, Koerte IK, Tripodis Y, et al. . White matter signal abnormalities in former National Football League players. Alzheimers Dement (Amst). 2017;10:56-65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699890</ArticleId><ArticleId IdType="pubmed">29201991</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner RC, Possin KL, Hess CP, et al. . Evaluating and treating neurobehavioral symptoms in professional American football players: Lessons from a case series. Neurol Clin Pract. 2015;5(4):285-295. doi:10.1212/CPJ.0000000000000157</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000157</ArticleId><ArticleId IdType="pmc">PMC4549717</ArticleId><ArticleId IdType="pubmed">26336629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart J Jr, Kraut MA, Womack KB, et al. . Neuroimaging of cognitive dysfunction and depression in aging retired National Football League players: a cross-sectional study. JAMA Neurol. 2013;70(3):326-335. doi:10.1001/2013.jamaneurol.340</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamaneurol.340</ArticleId><ArticleId IdType="pmc">PMC4016798</ArticleId><ArticleId IdType="pubmed">23303193</ArticleId></ArticleIdList></Reference><Reference><Citation>Amen DG, Willeumier K, Omalu B, Newberg A, Raghavendra C, Raji CA. Perfusion neuroimaging abnormalities alone distinguish National Football League players from a healthy population. J Alzheimers Dis. 2016;53(1):237-241. doi:10.3233/JAD-160207</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160207</ArticleId><ArticleId IdType="pmc">PMC4942725</ArticleId><ArticleId IdType="pubmed">27128374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey DM, Jones DW, Sinnott A, et al. . Impaired cerebral haemodynamic function associated with chronic traumatic brain injury in professional boxers. Clin Sci (Lond). 2013;124(3):177-189. doi:10.1042/CS20120259</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20120259</ArticleId><ArticleId IdType="pubmed">22913765</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchi N, Bazarian JJ, Puvenna V, et al. . Consequences of repeated blood-brain barrier disruption in football players. PLoS One. 2013;8(3):e56805. doi:10.1371/journal.pone.0056805</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056805</ArticleId><ArticleId IdType="pmc">PMC3590196</ArticleId><ArticleId IdType="pubmed">23483891</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissberg I, Veksler R, Kamintsky L, et al. . Imaging blood-brain barrier dysfunction in football players. JAMA Neurol. 2014;71(11):1453-1455. doi:10.1001/jamaneurol.2014.2682</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2682</ArticleId><ArticleId IdType="pubmed">25383774</ArticleId></ArticleIdList></Reference><Reference><Citation>Filley CM, Kelly JP. White matter and cognition in traumatic brain injury. J Alzheimers Dis. 2018;65(2):345-362. doi:10.3233/JAD-180287</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180287</ArticleId><ArticleId IdType="pubmed">30040722</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med. 1973;3(3):270-303. doi:10.1017/S0033291700049588</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291700049588</ArticleId><ArticleId IdType="pubmed">4729191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Hof PR, Bouras C, et al. . Pathological alterations of the cerebral microvasculature in Alzheimer&#x2019;s disease and related dementing disorders. Acta Neuropathol. 1994;87(5):469-480. doi:10.1007/BF00294173</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00294173</ArticleId><ArticleId IdType="pubmed">8059599</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty CP, O&#x2019;Keefe E, Wallace E, et al. . Blood-brain barrier dysfunction as a hallmark pathology in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2016;75(7):656-662. doi:10.1093/jnen/nlw036</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlw036</ArticleId><ArticleId IdType="pmc">PMC4913433</ArticleId><ArticleId IdType="pubmed">27245243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Schweizer TA, Fischer CE, Munoz DG. The role of cerebrovascular disease on cognitive and functional status and psychosis in severe Alzheimer&#x2019;s disease. J Alzheimers Dis. 2017;55(1):381-389. doi:10.3233/JAD-160506</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160506</ArticleId><ArticleId IdType="pmc">PMC5115606</ArticleId><ArticleId IdType="pubmed">27662301</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Solomon TM, Daneshvar DH, et al. . Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. Alzheimers Res Ther. 2015;7(1):62. doi:10.1186/s13195-015-0148-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0148-8</ArticleId><ArticleId IdType="pmc">PMC4601147</ArticleId><ArticleId IdType="pubmed">26455775</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, Amaya MdelP, Cortes EP, Mancevska K, Keller CE. Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University. Cell Tissue Bank. 2008;9(3):247-258. doi:10.1007/s10561-008-9079-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10561-008-9079-y</ArticleId><ArticleId IdType="pmc">PMC2847415</ArticleId><ArticleId IdType="pubmed">18581261</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, Del Amaya MP, Keller CE. Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol. 2008;115(5):509-532. doi:10.1007/s00401-007-0311-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0311-9</ArticleId><ArticleId IdType="pmc">PMC2292479</ArticleId><ArticleId IdType="pubmed">17985145</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, van Belle G, et al. ; NIA-Alzheimer&#x2019;s Disease Centers . The National Alzheimer&#x2019;s Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord. 2004;18(4):270-277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Modeling. 1999;6:1-55. doi:10.1080/10705519909540118</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10705519909540118</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Walker L, Graham S, et al. . Parietal white matter lesions in Alzheimer&#x2019;s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol. 2017;134(3):459-473. doi:10.1007/s00401-017-1738-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1738-2</ArticleId><ArticleId IdType="pmc">PMC5563333</ArticleId><ArticleId IdType="pubmed">28638989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrami N, Sharma D, Rosenthal S, et al. . Subconcussive head impact exposure and white matter tract changes over a single season of youth football. Radiology. 2016;281(3):919-926. doi:10.1148/radiol.2016160564</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2016160564</ArticleId><ArticleId IdType="pmc">PMC5131834</ArticleId><ArticleId IdType="pubmed">27775478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzminski SJ, Clark MD, Fraser MA, et al. . White matter changes related to subconcussive impact frequency during a single season of high school football. AJNR Am J Neuroradiol. 2018;39(2):245-251. doi:10.3174/ajnr.A5489</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A5489</ArticleId><ArticleId IdType="pmc">PMC5812786</ArticleId><ArticleId IdType="pubmed">29269405</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayinger MC, Merchant-Borna K, Hufschmidt J, et al. . White matter alterations in college football players: a longitudinal diffusion tensor imaging study. Brain Imaging Behav. 2018;12(1):44-53. doi:10.1007/s11682-017-9672-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-017-9672-4</ArticleId><ArticleId IdType="pubmed">28092023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangolli M, Benetatos J, Esparza TJ, Fountain EM, Seneviratne S, Brody DL. Repetitive concussive and subconcussive injury in a human tau mouse model results in chronic cognitive dysfunction and disruption of white matter tracts, but not tau pathology. J Neurotrauma. 2019;36(5):735-755. doi:10.1089/neu.2018.5700</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2018.5700</ArticleId><ArticleId IdType="pmc">PMC6387572</ArticleId><ArticleId IdType="pubmed">30136628</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cantu RC, Nowinski CJ, et al. . Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009;68(7):709-735. doi:10.1097/NEN.0b013e3181a9d503</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181a9d503</ArticleId><ArticleId IdType="pmc">PMC2945234</ArticleId><ArticleId IdType="pubmed">19535999</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark MD, Varangis EML, Champagne AA, et al. . Effects of career duration, concussion history, and playing position on white matter microstructure and functional neural recruitment in former college and professional football athletes. Radiology. 2018;286(3):967-977. doi:10.1148/radiol.2017170539</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2017170539</ArticleId><ArticleId IdType="pmc">PMC5834225</ArticleId><ArticleId IdType="pubmed">29087238</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin JM, Wang Y, Minn I, et al. . Imaging of glial cell activation and white matter integrity in brains of active and recently retired National Football League players. JAMA Neurol. 2017;74(1):67-74. doi:10.1001/jamaneurol.2016.3764</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.3764</ArticleId><ArticleId IdType="pmc">PMC5504689</ArticleId><ArticleId IdType="pubmed">27893897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Arvanitakis Z, Boyle PA, de Toledo-Morrell L, Schneider JA. Selected findings from the Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2013;33(suppl 1):S397-S403. doi:10.3233/JAD-2012-129007</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-129007</ArticleId><ArticleId IdType="pmc">PMC3434299</ArticleId><ArticleId IdType="pubmed">22647261</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Zarow C, Mack WJ, et al. . Cognitive impact of subcortical vascular and Alzheimer&#x2019;s disease pathology. Ann Neurol. 2006;60(6):677-687. doi:10.1002/ana.21009</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21009</ArticleId><ArticleId IdType="pmc">PMC1851933</ArticleId><ArticleId IdType="pubmed">17192928</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the nun study. JAMA. 1997;277(10):813-817. doi:10.1001/jama.1997.03540340047031</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03540340047031</ArticleId><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos D, Wolters FJ, Darweesh SKL, et al. . Cerebral small vessel disease and the risk of dementia: a systematic review and meta-analysis of population-based evidence. Alzheimers Dement. 2018;14(11):1482-1492. doi:10.1016/j.jalz.2018.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.04.007</ArticleId><ArticleId IdType="pubmed">29792871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhrara M, Reiter DA, Bergeron CM, et al. . Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimers Dement. 2018;14(8):998-1004. doi:10.1016/j.jalz.2018.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.03.007</ArticleId><ArticleId IdType="pmc">PMC6097903</ArticleId><ArticleId IdType="pubmed">29679574</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenigro PH, Baugh CM, Daneshvar DH, et al. . Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther. 2014;6(5):68. doi:10.1186/s13195-014-0068-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0068-z</ArticleId><ArticleId IdType="pmc">PMC4288217</ArticleId><ArticleId IdType="pubmed">25580160</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahar I, Alosco ML, McKee AC. Psychiatric phenotypes in chronic traumatic encephalopathy. Neurosci Biobehav Rev. 2017;83:622-630. doi:10.1016/j.neubiorev.2017.08.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2017.08.023</ArticleId><ArticleId IdType="pubmed">28888534</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, et al. . Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol. 2007;66(12):1136-1146. doi:10.1097/nen.0b013e31815c5efb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31815c5efb</ArticleId><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83. doi:10.1002/ana.25123</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25123</ArticleId><ArticleId IdType="pmc">PMC5876116</ArticleId><ArticleId IdType="pubmed">29244218</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Hubbard RA, Keene CD, et al. . Mixed neuropathologies and associations with domain-specific cognitive decline. Neurology. 2017;89(17):1773-1781. doi:10.1212/WNL.0000000000004567</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004567</ArticleId><ArticleId IdType="pmc">PMC5664309</ArticleId><ArticleId IdType="pubmed">28939667</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenowitz WD, Hubbard RA, Keene CD, et al. . Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement. 2017;13(6):654-662. doi:10.1016/j.jalz.2016.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5438283</ArticleId><ArticleId IdType="pubmed">27870939</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171-186. doi:10.1007/s00401-017-1717-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1717-7</ArticleId><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain. 2016;139(11):2983-2993. doi:10.1093/brain/aww224</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneuse S, Schildcrout J, Crane P, Sonnen J, Breitner J, Larson E. Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology. 2009;32(3):229-239. doi:10.1159/000197389</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000197389</ArticleId><ArticleId IdType="pmc">PMC2698450</ArticleId><ArticleId IdType="pubmed">19176974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31395777</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>365</Volume><Issue>6453</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>A vicious cycle of &#x3b2; amyloid-dependent neuronal hyperactivation.</ArticleTitle><Pagination><StartPage>559</StartPage><EndPage>565</EndPage><MedlinePgn>559-565</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aay0198</ELocationID><Abstract><AbstractText>&#x3b2;-amyloid (A&#x3b2;)-dependent neuronal hyperactivity is believed to contribute to the circuit dysfunction that characterizes the early stages of Alzheimer's disease (AD). Although experimental evidence in support of this hypothesis continues to accrue, the underlying pathological mechanisms are not well understood. In this experiment, we used mouse models of A&#x3b2;-amyloidosis to show that hyperactivation is initiated by the suppression of glutamate reuptake. Hyperactivity occurred in neurons with preexisting baseline activity, whereas inactive neurons were generally resistant to A&#x3b2;-mediated hyperactivation. A&#x3b2;-containing AD brain extracts and purified A&#x3b2; dimers were able to sustain this vicious cycle. Our findings suggest a cellular mechanism of A&#x3b2;-dependent neuronal dysfunction that can be active before plaque formation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zott</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4537-7381</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Manuel M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-3475-2396</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0026-8026</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen-Engerer</LastName><ForeName>Hsing-Jung</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakmann</LastName><ForeName>Bert</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-0718-6261</Identifier><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konnerth</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9548-2676</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, 80802 Munich, Germany. arthur.konnerth@tum.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Technical University of Munich, 80802 Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046275</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2019 Aug 9;365(6453):540-541. doi: 10.1126/science.aay5188.</RefSource><PMID Version="1">31395769</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Oct;15(10):558-559. doi: 10.1038/s41582-019-0256-3.</RefSource><PMID Version="1">31462750</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: None of the authors have biomedical financial interests or potential conflicts of interest related to the work performed in the present study. Unrelated to the current study, D.M.W. is an advisor to CogRx and Regeneron, and has active collaborations with Medimmune, Sanofi, Gen2 and Roche. D.M.W. joined Biogen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31395777</ArticleId><ArticleId IdType="mid">NIHMS1042720</ArticleId><ArticleId IdType="pmc">PMC6690382</ArticleId><ArticleId IdType="doi">10.1126/science.aay0198</ArticleId><ArticleId IdType="pii">365/6453/559</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Hardy J, The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO molecular medicine 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM, Three dimensions of the amyloid hypothesis: time, space and &#x201c;wingmen&#x201d;. Nature Neuroscience 18, 800 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Karran E, The Cellular Phase of Alzheimer&#x2019;s Disease. Cell 164, 603&#x2013;615 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola KL, Klein WL, Amyloid &#x3b2; oligomers in Alzheimer&#x2019;s disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica 129, 183&#x2013;206 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390393</ArticleId><ArticleId IdType="pubmed">25604547</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L, Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci 17, 777&#x2013;792 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Zott B, Busche MA, Sperling RA, Konnerth A, What Happens with the Circuit in Alzheimer&#x2019;s Disease in Mice and Humans? Annual Review of Neuroscience 41, 277&#x2013;297 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6571139</ArticleId><ArticleId IdType="pubmed">29986165</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z et al., Human Brain-Derived A&#x3b2; Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. The Journal of neuroscience : the official journal of the Society for Neuroscience 37, 11947&#x2013;11966 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719975</ArticleId><ArticleId IdType="pubmed">29101243</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L et al., Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708&#x2013;721 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA et al., Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA neurology 70, 1158&#x2013;1166 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013391</ArticleId><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ et al., Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron 55, 697&#x2013;711 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA et al., Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 109, 8740&#x2013;8745 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA et al., Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science 321, 1686&#x2013;1689 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarosz-Griffiths HH, Noble E, Rushworth JV, Hooper NM, Amyloid-&#x3b2; Receptors: The Good, the Bad, and the Prion Protein. Journal of Biological Chemistry 291, 3174&#x2013;3183 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751366</ArticleId><ArticleId IdType="pubmed">26719327</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM et al., Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 2866&#x2013;2875 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM et al., Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106, 4012&#x2013;4017 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Um Ji W. et al., Metabotropic Glutamate Receptor 5 is a Coreceptor for Alzheimer A&#x3b2; Oligomer Bound to Cellular Prion Protein. Neuron 79, 887&#x2013;902 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3768018</ArticleId><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerdkrai C et al., Intracellular Ca2+ stores control in vivo neuronal hyperactivity in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 115, 1279&#x2013;1288 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819404</ArticleId><ArticleId IdType="pubmed">29358403</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al., Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788&#x2013;801 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al., Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. The Journal of neuroscience 31, 6627&#x2013;6638 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl JK et al., Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding A&#x3b2; plaques by iGluSnFR two-photon imaging. Nature Communications 7, 13441 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114608</ArticleId><ArticleId IdType="pubmed">27834383</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Shea SD et al., Intracerebroventricular Administration of Amyloid &#x3b2;-protein Oligomers Selectively Increases Dorsal Hippocampal Dialysate Glutamate Levels in the Awake Rat. Sensors (Basel, Switzerland) 8, 7428&#x2013;7437 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787453</ArticleId><ArticleId IdType="pubmed">27873937</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Alford M, Deteresa R, Mallory M, Deficient glutamate tranport is associated with neurodegeneration in Alzheimer&#x2019;s disease. Annals of Neurology 40, 759&#x2013;766 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8957017</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR, Glutamate transporter variants reduce glutamate uptake in Alzheimer&#x2019;s disease. Neurobiology of Aging 32, 553.e551&#x2013;553.e511 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20416976</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM et al., Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med 14, 837&#x2013;842 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B et al., Amyloid &#x3b2;-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils. The Journal of Neuroscience 30, 14411&#x2013;14419 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H et al., AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831&#x2013;843 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Manabe T, Wyllie DJ, Perkel DJ, Nicoll RA, Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. Journal of Neurophysiology 70, 1451&#x2013;1459 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">7904300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J et al., Soluble A&#x3b2; Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region. iScience 6, 138&#x2013;150 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137707</ArticleId><ArticleId IdType="pubmed">30240608</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvin JS et al., Stability, affinity, and chromatic variants of the glutamate sensor iGluSnFR. Nature Methods 15, 936&#x2013;939 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394230</ArticleId><ArticleId IdType="pubmed">30377363</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnth-Jensen N, Jabaudon D, Scanziani M, Cooperation between independent hippocampal synapses is controlled by glutamate uptake. Nature Neuroscience 5, 325 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11896395</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy-Royal C et al., Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission. Nature Neuroscience 18, 219 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25581361</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W et al., Diffusible, highly bioactive oligomers represent a critical minority of soluble A&#x3b2; in Alzheimer&#x2019;s disease brain. Acta Neuropathologica 136, 19&#x2013;40 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="pubmed">29687257</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlikova GG et al., Alzheimer brain-derived amyloid &#x3b2;-protein impairs synaptic remodeling and memory consolidation. Neurobiology of aging 34, 1315&#x2013;1327 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570694</ArticleId><ArticleId IdType="pubmed">23182244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM et al., The aqueous phase of Alzheimer&#x2019;s disease brain contains assemblies built from ~4 and ~7 kDa A&#x3b2; species. Alzheimer&#x2019;s &amp; dementia : the journal of the Alzheimer&#x2019;s Association 11, 1286&#x2013;1305 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4592782</ArticleId><ArticleId IdType="pubmed">25846299</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB et al., Interaction between prion protein and toxic amyloid &#x3b2; assemblies can be therapeutically targeted at multiple sites. Nature communications 2, 336 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G et al., Identification of neurotoxic cross-linked A&#x3b2; dimers in Alzheimer brain. Brain (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487330</ArticleId><ArticleId IdType="pubmed">31032851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M et al., An in vitro paradigm to assess potential anti-A&#x3b2; antibodies for Alzheimer&#x2019;s disease. Nature Communications 9, 2676 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041266</ArticleId><ArticleId IdType="pubmed">29992960</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K et al., Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer&#x2019;s disease. The Journal of experimental medicine 212, 319&#x2013;332 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354363</ArticleId><ArticleId IdType="pubmed">25711212</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumkehr J et al., Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer&#x2019;s disease. Neurobiology of aging 36, 2260&#x2013;2271 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25964214</ArticleId></ArticleIdList></Reference><Reference><Citation>Danysz W, Parsons CG, M&#xf6;bius H-J, St&#xf6;ffler A, Quack G, Neuroprotective and symptomatological action of memantine relevant for alzheimer&#x2019;s disease &#x2014; a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research 2, 85&#x2013;97 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">16787834</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Konnerth A, Neuronal hyperactivity--A key defect in Alzheimer&#x2019;s disease? Bioessays 37, 624&#x2013;632 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25773221</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin K, Paxinos G, The mouse brain in stereotaxic coordinates, compact. The coronal plates and diagrams.</Citation></Reference><Reference><Citation>Busche MA et al., Decreased amyloid-beta and increased neuronal hyperactivity by immunotherapy in Alzheimer&#x2019;s models. Nat Neurosci 18, 1725&#x2013;1727 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26551546</ArticleId></ArticleIdList></Reference><Reference><Citation>Stosiek C, Garaschuk O, Holthoff K, Konnerth A, In vivo two-photon calcium imaging of neuronal networks. Proceedings of the National Academy of Sciences 100, 7319 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165873</ArticleId><ArticleId IdType="pubmed">12777621</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada M, Takeuchi A, Hashizume M, Kitamura K, Kano M, A highly sensitive fluorescent indicator dye for calcium imaging of neural activity in vitro and in vivo. European Journal of Neuroscience 39, 1720&#x2013;1728 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232931</ArticleId><ArticleId IdType="pubmed">24405482</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin AD et al., BACE inhibition-dependent repair of Alzheimer&#x2019;s pathophysiology. Proc Natl Acad Sci U S A 114, 8631&#x2013;8636 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5559049</ArticleId><ArticleId IdType="pubmed">28739891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira JS et al., Co-agonists differentially tune GluN2B-NMDA receptor trafficking at hippocampal synapses. eLife 6, e25492 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466419</ArticleId><ArticleId IdType="pubmed">28598327</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocca G, Vicini S, Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. The Journal of physiology 507, 13&#x2013;24 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230772</ArticleId><ArticleId IdType="pubmed">9490809</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner S, Kakeyama M, Endo T, Yoshioka W, Tohyama C, Application of NeuroTrace staining in the fresh frozen brain samples to laser microdissection combined with quantitative RT-PCR analysis. BMC Research Notes 8, 252 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473849</ArticleId><ArticleId IdType="pubmed">26092293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31408138</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>322</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia.</ArticleTitle><Pagination><StartPage>535</StartPage><EndPage>545</EndPage><MedlinePgn>535-545</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.10575</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The association between late-life blood pressure (BP) and cognition may depend on the presence and chronicity of past hypertension. Late-life declines in blood pressure following prolonged hypertension may be associated with poor cognitive outcomes.</AbstractText><AbstractText Label="OBJECTIVE">To examine the association of midlife to late-life BP patterns with subsequent dementia, mild cognitive impairment, and cognitive decline.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Atherosclerosis Risk in Communities prospective population-based cohort study enrolled 4761 participants during midlife (visit 1, 1987-1989) and followed-up over 6 visits through 2016-2017 (visit 6). BP was examined over 24 years at 5 in-person visits between visits 1 and 5 (2011-2013). During visits 5 and 6, participants underwent detailed neurocognitive evaluation. The setting was 4 US communities: Washington County, Maryland; Forsyth County, North Carolina; Jackson, Mississippi; and Minneapolis, Minnesota. Follow-up ended on December 31, 2017.</AbstractText><AbstractText Label="EXPOSURES">Five groups based on longitudinal patterns of normotension, hypertension (&gt;140/90 mm Hg), and hypotension (&lt;90/60 mm Hg) at visits 1 to 5.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Primary outcome was dementia onset after visit 5, based on Ascertain Dementia-8 informant questionnaires, Six-Item Screener telephone assessments, hospital discharge and death certificate codes, and the visit 6 neurocognitive evaluation. Secondary outcome was mild cognitive impairment at visit 6, based on the neurocognitive evaluation.</AbstractText><AbstractText Label="RESULTS">Among 4761 participants (2821 [59%] women; 979 [21%] black race; visit 5 mean [SD] age, 75 [5] years; visit 1 mean age range, 44-66 years; visit 5 mean age range, 66-90 years), there were 516 (11%) incident dementia cases between visits 5 and 6. The dementia incidence rate for participants with normotension in midlife (n&#x2009;=&#x2009;833) and late life was 1.31 (95% CI, 1.00-1.72 per 100 person-years); for midlife normotension and late-life hypertension (n&#x2009;=&#x2009;1559), 1.99 (95% CI, 1.69-2.32 per 100 person-years); for midlife and late-life hypertension (n&#x2009;=&#x2009;1030), 2.83 (95% CI, 2.40-3.35 per 100 person-years); for midlife normotension and late-life hypotension (n&#x2009;=&#x2009;927), 2.07 (95% CI, 1.68-2.54 per 100 person-years); and for midlife hypertension and late-life hypotension (n&#x2009;=&#x2009;389), 4.26 (95% CI, 3.40-5.32 per 100 person-years). Participants in the midlife and late-life hypertension group (hazard ratio [HR], 1.49 [95% CI, 1.06-2.08]) and in the midlife hypertension and late-life hypotension group (HR, 1.62 [95% CI, 1.11-2.37]) had significantly increased risk of subsequent dementia compared with those who remained normotensive. Irrespective of late-life BP, sustained hypertension in midlife was associated with dementia risk (HR, 1.41 [95% CI, 1.17-1.71]). Compared with those who were normotensive in midlife and late life, only participants with midlife hypertension and late-life hypotension had higher risk of mild cognitive impairment (37 affected individuals (odds ratio, 1.65 [95% CI, 1.01-2.69]). There was no significant association of BP patterns with late-life cognitive change.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this community-based cohort with long-term follow-up, sustained hypertension in midlife to late life and a pattern of midlife hypertension and late-life hypotension, compared with midlife and late-life normal BP, were associated with increased risk for subsequent dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Keenan A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharrett</LastName><ForeName>A Richey</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Aozhou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Andrea L C</ForeName><Initials>ALC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutsey</LastName><ForeName>Pamela L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>School of Public Health, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandeen-Roche</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coresh</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Alden L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johns Hopkins Center on Aging and Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windham</LastName><ForeName>B Gwen</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>Melinda C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawlings</LastName><ForeName>Andreea M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Department of Medicine, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL096812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG050699</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096902</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL070825</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096899</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096814</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG052573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2019 Aug 13;322(6):512-513. doi: 10.1001/jama.2019.10849.</RefSource><PMID Version="1">31408120</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007022" MajorTopicYN="N">Hypotension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Gottesman reports serving as an associate editor for <i>Neurology</i>. Dr Knopman reports serving on a data safety monitoring board for the DIAN study, and being an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. Dr Walker reported receipt of grants from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute on Deafness and Other Communication Disorders (NIDCD) during the conduct of the study. Drs Sharrett, Bandeen-Roche, Coresh, and Windham reported receipt of grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Schneider reported receipt of grants from NIH/NINDS during the conduct of the study. Dr Albert reported receipt of grants from Johns Hopkins Univserity during the conduct of the study, and other (for consultancy) from Eli Lilly outside the submitted work. Dr Knopman reported receipt of personal fees from DIAN TU (member, data safety monitoring board), other from Biogen (clinical trial site primary investigator), and other from Eli Lilly (clinical trial site primary investigator) outside the submitted work. Dr Rawlings reported receipt of funding from the American Heart Association (17IFUNP33890036). Dr Gottesman reported other from the American Academy of Neurology outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31408138</ArticleId><ArticleId IdType="pmc">PMC6692677</ArticleId><ArticleId IdType="doi">10.1001/jama.2019.10575</ArticleId><ArticleId IdType="pii">2747672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19(3):24. doi:10.1007/s11906-017-0724-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-017-0724-3</ArticleId><ArticleId IdType="pmc">PMC6164165</ArticleId><ArticleId IdType="pubmed">28299725</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Albert M, et al. . Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014;71(10):1218-1227. doi:10.1001/jamaneurol.2014.1646</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1646</ArticleId><ArticleId IdType="pmc">PMC4226067</ArticleId><ArticleId IdType="pubmed">25090106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y, et al. . Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317(14):1443-1450. doi:10.1001/jama.2017.3090</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.3090</ArticleId><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, Sigurdsson S, Kjartansson O, et al. . Joint effect of mid- and late-life blood pressure on the brain. Neurology. 2014;82(24):2187-2195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113458</ArticleId><ArticleId IdType="pubmed">24898928</ArticleId></ArticleIdList></Reference><Reference><Citation>Glodzik L, Rusinek H, Pirraglia E, et al. . Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol Aging. 2014;35(1):64-71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799812</ArticleId><ArticleId IdType="pubmed">23969178</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Schneider ALC, Wruck L, et al. . Life-course blood pressure in relation to brain volumes. Alzheimers Dement. 2016;12(8):890-899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980244</ArticleId><ArticleId IdType="pubmed">27139841</ArticleId></ArticleIdList></Reference><Reference><Citation>The ARIC Investigators The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(4):687-702.</Citation><ArticleIdList><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-P, Zuo X-C, Huang Z-J, et al. . The impact of blood pressure on kidney function in the elderly. Kidney Blood Press Res. 2013;38(2-3):205-216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326667</ArticleId><ArticleId IdType="pubmed">24732208</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyetunji TA, Chang DC, Crompton JG, et al. . Redefining hypotension in the elderly. Arch Surg. 2011;146(7):865-869.</Citation><ArticleIdList><ArticleId IdType="pubmed">21768435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould CE, Beaudreau SA. Association between depression and anxiety on blood pressure dysregulation and pulse in the Health and Retirement Study. Int J Geriatr Psychiatry. 2013;28(10):1045-1053. doi:10.1002/gps.3926</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.3926</ArticleId><ArticleId IdType="pubmed">23335009</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Gottesman RF, Sharrett AR, et al. . Mild cognitive impairment and dementia prevalence. Alzheimers Dement (Amst). 2016;2:1-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772876</ArticleId><ArticleId IdType="pubmed">26949733</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden KM, Reed BR, Manly JJ, et al. . Cognitive decline in the elderly. Age Ageing. 2011;40(6):684-689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199215</ArticleId><ArticleId IdType="pubmed">21890481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Li Y, Bienias JL, Bennett DA. Cognitive decline in old age. Psychol Aging. 2006;21(4):774-789.</Citation><ArticleIdList><ArticleId IdType="pubmed">17201497</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association DSM-5: Diagnostic and Statistical Manual of Mental Disorders. 5th ed Washington, DC: American Psychiatric Association; 2013.</Citation></Reference><Reference><Citation>Carpenter CR, DesPain B, Keeling TN, Shah M, Rothenberger M. The Six-Item Screener and AD8 for the detection of cognitive impairment in geriatric emergency department patients. Ann Emerg Med. 2011;57(6):653-661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3213856</ArticleId><ArticleId IdType="pubmed">20855129</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant interview in dementia. Neurology. 2006;67(11):1942-1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159098</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider ALC, Sharrett AR, Gottesman RF, et al. . Normative data for 8 neuropsychological tests in older blacks and whites from the atherosclerosis risk in communities (ARIC) study. Alzheimer Dis Assoc Disord. 2015;29(1):32-44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206681</ArticleId><ArticleId IdType="pubmed">24759546</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Power MC, Albert MS, et al. . Application of latent variable methods to the study of cognitive decline when tests change over time. Epidemiology. 2015;26(6):878-887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4819068</ArticleId><ArticleId IdType="pubmed">26414855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Albert MS, Alonso A, et al. . Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246-1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710244</ArticleId><ArticleId IdType="pubmed">28783817</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedel J, H&#xe4;gele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29(6):1075-1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">6851096</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28(6):1379-1388.</Citation><ArticleIdList><ArticleId IdType="pubmed">7074948</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tang M-X, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol. 2007;64(12):1734-1740. doi:10.1001/archneur.64.12.1734</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.12.1734</ArticleId><ArticleId IdType="pmc">PMC2672564</ArticleId><ArticleId IdType="pubmed">18071036</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandav R, Dodge HH, DeKosky ST, Ganguli M. Blood pressure and cognitive impairment in India and the United States. Arch Neurol. 2003;60(8):1123-1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925370</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Weuve J, Gagne JJ, et al. . The association between blood pressure and incident Alzheimer disease. Epidemiology. 2011;22(5):646-659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640480</ArticleId><ArticleId IdType="pubmed">21705906</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Tchetgen EJT, Sparrow D, Schwartz J, Weisskopf MG. Blood pressure and cognition. Epidemiology. 2013;24(6):886-893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3818218</ArticleId><ArticleId IdType="pubmed">24030502</ArticleId></ArticleIdList></Reference><Reference><Citation>Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults. Stroke. 1998;29(11):2334-2340. doi:10.1161/01.STR.29.11.2334</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.29.11.2334</ArticleId><ArticleId IdType="pubmed">9804644</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Lernfelt B, Landahl S, et al. . 15-Year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609748</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, von Strauss E, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia. Stroke. 2004;35(8):1810-1815.</Citation><ArticleIdList><ArticleId IdType="pubmed">15232128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari AU. Modifications of the cardiovascular system with aging. Am J Geriatr Cardiol. 2002;11(1):30-33. doi:10.1111/1467-8446.00044-i1</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-8446.00044-i1</ArticleId><ArticleId IdType="pubmed">11773713</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738. doi:10.1038/nrn3114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3114</ArticleId><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Glodzik L, Rusinek H, Tsui W, et al. . Different relationship between systolic blood pressure and cerebral perfusion in subjects with and without hypertension. Hypertension. 2019;73(1):197-205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7986962</ArticleId><ArticleId IdType="pubmed">30571554</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, van der Graaf Y, Visseren FL, et al. . Hypertension and longitudinal changes in cerebral blood flow. Ann Neurol. 2012;71(6):825-833.</Citation><ArticleIdList><ArticleId IdType="pubmed">22447734</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike MA, Green KN, Blurton-Jones M, Laferla FM. Oligemic hypoperfusion differentially affects tau and amyloid-beta. Am J Pathol. 2010;177(1):300-310. doi:10.2353/ajpath.2010.090750</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.090750</ArticleId><ArticleId IdType="pmc">PMC2893673</ArticleId><ArticleId IdType="pubmed">20472896</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile MT, Poulet R, Di Pardo A, et al. . Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging. 2009;30(2):222-228.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JT Jr, Williamson JD, Whelton PK, et al. . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31410194</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1838-7640</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>17</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Theranostics</Title><ISOAbbreviation>Theranostics</ISOAbbreviation></Journal><ArticleTitle>Sex modulates the ApoE &#x3b5;4 effect on brain tau deposition measured by <sup>18</sup>F-AV-1451 PET in individuals with mild cognitive impairment.</ArticleTitle><Pagination><StartPage>4959</StartPage><EndPage>4970</EndPage><MedlinePgn>4959-4970</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.35366</ELocationID><Abstract><AbstractText>The strongest genetic risk factor for Alzheimer's disease (AD) is the Apolipoprotein E type 4 allele (ApoE &#x3b5;4). The interaction between sex and ApoE &#x3b5;4 carrier status on AD risk remains an area of intense investigation. We hypothesized that sex modulates the relationship between ApoE &#x3b5;4 carrier status and brain tau deposition (a quantitative endophenotype in AD) in individuals with mild cognitive impairment (MCI). <b>Methods</b>: Preprocessed <sup>18</sup>F-AV-1451 tau and <sup>18</sup>F-AV-45 amyloid PET images, T1-weighted structural magnetic resonance imaging (MRI) scans, demographic information, and cerebrospinal fluid (CSF) total tau (t-tau) and phosphorylated tau (p-tau) measurements from 108 MCI subjects in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database were included. After downloading pre-processed images from ADNI, an iterative reblurred Van Cittertiteration partial volume correction (PVC) method was applied to all PET images. MRIs were used for PET spatial normalization. Regions of interest (ROIs) were defined in standard space, and standardized uptake value ratio (SUVR) images relative to cerebellum were computed. ApoE &#x3b5;4 by sex interaction analyses on <sup>18</sup>F-AV-1451 and CSF tau (t-tau, p-tau) were assessed using generalized linear models. The association between <sup>18</sup>F-AV-1451 SUVR and CSF tau (t-tau, p-tau) was assessed. <b>Results</b>: After applying PVC and controlling for age, education level and global cortical <sup>18</sup>F-AV-45 SUVR, we found that the entorhinal cortex, amygdala, parahippocampal gyrus, posterior cingulate, and occipital ROIs exhibited a significant ApoE &#x3b5;4 by sex interaction effect (false discovery rate <i>P</i> &lt; 0.1) among MCI individuals. We also found a significant ApoE &#x3b5;4 by sex interaction effect on CSF t-tau and p-tau. <sup>18</sup>F-AV-1451 SUVR in the 5 ROIs with ApoE &#x3b5;4 by sex interaction was significantly correlated with CSF p-tau and t-tau. <b>Conclusions</b>: Our findings suggest that women are more susceptible to ApoE &#x3b5;4-associated accumulation of neurofibrillary tangles in MCI compared to males. Both CSF tau (p-tau, t-tau) and brain tau PET are robust quantitative biomarkers for studying ApoE &#x3b5;4 by sex effects on brain tau deposition in MCI participants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paranjpe</LastName><ForeName>Manish D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Harvard-MIT Program in Health Sciences and Technology, Harvard Medical School, Boston, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duy</LastName><ForeName>Phan Q</ForeName><Initials>PQ</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, Yale University School of Medicine, New Haven, CT, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Manu S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Xuanwu Hospital of Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rongfu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG053503</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057536</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007205</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Theranostics</MedlineTA><NlmUniqueID>101552395</NlmUniqueID><ISSNLinking>1838-7640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18F-AV-1451</Keyword><Keyword MajorTopicYN="N">ApoE &#x3b5;4</Keyword><Keyword MajorTopicYN="N">mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">partial volume correction</Keyword><Keyword MajorTopicYN="N">tau deposition</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31410194</ArticleId><ArticleId IdType="pmc">PMC6691387</ArticleId><ArticleId IdType="doi">10.7150/thno.35366</ArticleId><ArticleId IdType="pii">thnov09p4959</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L. et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993;342:710&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103823</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O. et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16:903&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65:1888&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380608</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M. et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 2008;70:1842&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676693</ArticleId><ArticleId IdType="pubmed">18401023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO. et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci. 2012;32:15181&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493562</ArticleId><ArticleId IdType="pubmed">23100439</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E. et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 1995;69:757&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596645</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranjpe MD, Chen X, Liu M, Paranjpe I, Leal JP, Wang R. et al. The effect of ApoE epsilon4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. Neuroimage Clin. 2019;22:101795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449776</ArticleId><ArticleId IdType="pubmed">30991617</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR. et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology. 1999;53:1992&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599770</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine K, Laws KR, Gale TM, Kondel TK. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol. 2012;34:989&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">22913619</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62:685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">15939846</ArticleId></ArticleIdList></Reference><Reference><Citation>Koran MEI, Wagener M, Hohman TJ, Alzheimer's Neuroimaging I. Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 2017;11:205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972701</ArticleId><ArticleId IdType="pubmed">26843008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD. et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord. 1999;13:216&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609670</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer's Disease Neuroimaging Initiative I. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75:563&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B. et al. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol. 2018;75:989&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142927</ArticleId><ArticleId IdType="pubmed">29801024</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D. et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Zhou Y, Chen X, Green E, Gupta N. et al. The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87:473&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP. et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74:807&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE. et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage. 2007;36:298&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2001263</ArticleId><ArticleId IdType="pubmed">17449282</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohka J, Reilhac A. Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method. Neuroimage. 2008;39:1570&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18077187</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Liu M, Ha L, Zhou Y, AsDNI, Weiner MW. et al. Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients. Frontiers in Neurology. 2019;10:486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6530456</ArticleId><ArticleId IdType="pubmed">31156534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W. et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009;29:14770&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810461</ArticleId><ArticleId IdType="pubmed">19940172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Klunk WE. Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis; 2014. p. 72. Pt A: 117-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226742</ArticleId><ArticleId IdType="pubmed">24825318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ. et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage. 2006;33:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16905334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer CY. Extension of Multiple Range Tests to Group Means with Unequal Numbers of Replications. Biometrics. 1956;12:307&#x2013;10.</Citation></Reference><Reference><Citation>Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured By Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol; 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6515599</ArticleId><ArticleId IdType="pubmed">30715078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J, Li S, Nielsen M, Carcione T, Liang WS, Shi J. Sirtuin 3 attenuates amyloid-beta induced neuronal hypometabolism. Aging (Albany NY) 2018;10:2874&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6224231</ArticleId><ArticleId IdType="pubmed">30362958</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K. et al. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett. 1996;203:33&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742040</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M. et al. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 1998;31:317&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809590</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Zolton J, Shaffner R, Schnell B, Crescentini R, Wu Y. et al. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J Neurosci Res. 2002;69:362&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12125077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME. et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018;24:647&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JH, Ritchie SJ, Bastin ME, Valdes Hernandez MC, Munoz Maniega S, Royle N. et al. Brain age predicts mortality. Mol Psychiatry. 2018;23:1385&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984097</ArticleId><ArticleId IdType="pubmed">28439103</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal MS, Blazey TM, Su Y, Couture LE, Durbin TJ, Bateman RJ. et al. Persistent metabolic youth in the aging female brain. Proc Natl Acad Sci U S A. 2019;116:3251&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386682</ArticleId><ArticleId IdType="pubmed">30718410</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S. et al. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142(4):1063&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439328</ArticleId><ArticleId IdType="pubmed">30753379</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M. An Overview on the Clinical Development of Tau-Based Therapeutics. Int J Mol Sci; 2018. p. 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5979300</ArticleId><ArticleId IdType="pubmed">29641484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls. J Alzheimers Dis. 2018;64:S555&#x2013;S65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6171771</ArticleId><ArticleId IdType="pubmed">29865056</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsolaki AC, Gatzima O, Daniilidou M, Lazarou E, Bamidis PD, Verykouki E. et al. Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: A Northern Greece Study. Neurodegener Dis. 2018;18:216&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30205398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN. et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">22179327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31416668</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP &#x3b2;-CTFs, Not A&#x3b2;.</ArticleTitle><Pagination><StartPage>256</StartPage><EndPage>270.e5</EndPage><MedlinePgn>256-270.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.07.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)30636-1</ELocationID><Abstract><AbstractText>Familial Alzheimer's disease (fAD) results from mutations in the amyloid precursor protein (APP) and presenilin (PSEN1 and PSEN2) genes. Here we leveraged recent advances in induced pluripotent stem cell (iPSC) and CRISPR/Cas9 genome editing technologies to generate a panel of isogenic knockin human iPSC lines carrying APP and/or PSEN1 mutations. Global transcriptomic and translatomic profiling revealed that fAD mutations have overlapping effects on the expression of AD-related and endocytosis-associated genes. Mutant neurons also increased Rab5+ early endosome size. APP and PSEN1 mutations had discordant effects on A&#x3b2; production but&#xa0;similar effects on APP &#x3b2; C-terminal fragments (&#x3b2;-CTFs), which accumulate in all mutant neurons. Importantly, endosomal dysfunction correlated with accumulation of &#x3b2;-CTFs, not A&#x3b2;, and could be rescued by pharmacological modulation of &#x3b2;-secretase (BACE). These data display the utility of our mutant iPSCs in studying AD-related phenotypes in a non-overexpression human-based system and support mounting evidence that &#x3b2;-CTF may be critical in AD pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwart</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregg</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheckel</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University of Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Elisabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro-oncology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquet</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duffield</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fak</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro-oncology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Olav</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darnell</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro-oncology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tessier-Lavigne</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA; Department of Biology, Stanford University, Stanford, CA 94305, USA. Electronic address: tessier3@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C427755">RAB5C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020696">rab5 GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2019 Oct;20(10):573. doi: 10.1038/s41583-019-0217-2.</RefSource><PMID Version="1">31467449</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2019 Dec 4;104(5):1022. doi: 10.1016/j.neuron.2019.11.010.</RefSource><PMID Version="1">31805257</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053141" MajorTopicYN="N">Organelle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020696" MajorTopicYN="N">rab5 GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">CRISPR/Cas9</Keyword><Keyword MajorTopicYN="N">Rab5</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">amyloid-beta</Keyword><Keyword MajorTopicYN="N">beta-C-terminal fragment</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cell</Keyword><Keyword MajorTopicYN="N">presenilin</Keyword><Keyword MajorTopicYN="N">&#x3b2;-CTF</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31416668</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.07.010</ArticleId><ArticleId IdType="pii">S0896-6273(19)30636-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31433986</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy.</ArticleTitle><Pagination><StartPage>2111</StartPage><EndPage>2123.e6</EndPage><MedlinePgn>2111-2123.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2019.07.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(19)30964-7</ELocationID><Abstract><AbstractText>Complement pathway overactivation can lead to neuronal damage in various neurological diseases. Although Alzheimer's disease (AD) is characterized by &#x3b2;-amyloid plaques and tau tangles, previous work examining complement has largely focused on amyloidosis models. We find that glial cells show increased expression of classical complement components and the central component C3 in mouse models of amyloidosis (PS2APP) and more extensively tauopathy (TauP301S). Blocking complement function by deleting C3 rescues plaque-associated synapse loss in PS2APP mice and ameliorates neuron loss and brain atrophy in TauP301S mice, improving neurophysiological and behavioral measurements. In addition, C3 protein is elevated in AD patient brains, including at synapses, and levels and processing of C3 are increased in AD patient CSF and correlate with tau. These results demonstrate that complement activation contributes to neurodegeneration caused by tau pathology and suggest that blocking C3 function might be protective in AD and other tauopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dejanovic</LastName><ForeName>Borislav</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandham</LastName><ForeName>Vineela D</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gogineni</LastName><ForeName>Alvin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmonds</LastName><ForeName>Rose</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schauer</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Karpagam</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huntley</LastName><ForeName>Melanie A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA; Department of Bioinformatics, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tzu-Ming</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedehus</LastName><ForeName>Maj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barck</LastName><ForeName>Kai H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stark</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>Oded</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meilandt</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elstrott</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>David V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carano</LastName><ForeName>Richard A D</ForeName><Initials>RAD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Imaging, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Jesse E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: hanson.jesse@gene.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">C3</Keyword><Keyword MajorTopicYN="N">amyloidosis</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">synapse</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31433986</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.07.060</ArticleId><ArticleId IdType="pii">S2211-1247(19)30964-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31959936</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain.</ArticleTitle><Pagination><StartPage>194</StartPage><EndPage>208</EndPage><MedlinePgn>194-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0566-1</ELocationID><Abstract><AbstractText>Microglia become progressively activated and seemingly dysfunctional with age, and genetic studies have linked these cells to the pathogenesis of a growing number of neurodegenerative diseases. Here we report a striking buildup of lipid droplets in microglia with aging in mouse and human brains. These cells, which we call 'lipid-droplet-accumulating microglia' (LDAM), are defective in phagocytosis, produce high levels of reactive oxygen species and secrete proinflammatory cytokines. RNA-sequencing analysis of LDAM revealed a transcriptional profile driven by innate inflammation that is distinct from previously reported microglial states. An unbiased CRISPR-Cas9 screen identified genetic modifiers of lipid droplet formation; surprisingly, variants of several of these genes, including progranulin (GRN), are causes of autosomal-dominant forms of human neurodegenerative diseases. We therefore propose that LDAM contribute to age-related and genetic forms of neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marschallinger</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iram</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zardeneta</LastName><ForeName>Macy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Song E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehallier</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7452-3785</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haney</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, School of Medicine, and Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pluvinage</LastName><ForeName>John V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathur</LastName><ForeName>Vidhu</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgens</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Genetics, School of Medicine, and Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Stanford ChEM-H and Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tevini</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felder</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0001-8266-5513</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity Research Unit, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolinski</LastName><ForeName>Heimo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, BioTechMed-Graz, University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertozzi</LastName><ForeName>Carolyn R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Stanford ChEM-H and Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassik</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, School of Medicine, and Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aigner</LastName><ForeName>Ludwig</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, School of Medicine, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Neurosciences Institute, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs, Palo Alto, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 HD084069</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM058867</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG000044</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AG053015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM058867</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2020 Feb;23(2):294. doi: 10.1038/s41593-020-0595-9.</RefSource><PMID Version="1">32005940</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Metab. 2020 Apr 7;31(4):664-666. doi: 10.1016/j.cmet.2020.03.015.</RefSource><PMID Version="1">32268112</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2020 Oct;23(10):1308. doi: 10.1038/s41593-020-0682-y.</RefSource><PMID Version="1">32719564</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="Y">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31959936</ArticleId><ArticleId IdType="mid">NIHMS1544918</ArticleId><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0566-1</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0566-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Barres BA &amp; Bennett ML Microglia: scapegoat, saboteur, or something else? Science 339, 156&#x2013;161, doi:10.1126/science.1227901 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227901</ArticleId><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI &amp; Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem Pharmacol 88, 594&#x2013;604, doi:10.1016/j.bcp.2014.01.008 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2014.01.008</ArticleId><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H. et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217, doi:10.1016/j.cell.2017.05.018 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S. et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569, doi:10.1016/j.immuni.2017.08.008 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q. et al. Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing. Neuron 101, 207&#x2013;223 e210, doi:10.1016/j.neuron.2018.12.006 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.12.006</ArticleId><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley P. Lipids in Alzheimer&#x2019;s disease: A century-old story. Biochim Biophys Acta 1801, 750&#x2013;753, doi:10.1016/j.bbalip.2010.05.004 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2010.05.004</ArticleId><ArticleId IdType="pubmed">20471492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler SD, Mayer EP &amp; Greenspan P. Foam cells and atherogenesis. Ann N Y Acad Sci 454, 79&#x2013;90 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3907470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozza PT &amp; Viola JP Lipid droplets in inflammation and cancer. Prostaglandins Leukot Essent Fatty Acids 82, 243&#x2013;250, doi:10.1016/j.plefa.2010.02.005 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2010.02.005</ArticleId><ArticleId IdType="pubmed">20206487</ArticleId></ArticleIdList></Reference><Reference><Citation>den Brok MH, Raaijmakers TK, Collado-Camps E. &amp; Adema GJ Lipid Droplets as Immune Modulators in Myeloid Cells. Trends Immunol 39, 380&#x2013;392, doi:10.1016/j.it.2018.01.012 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2018.01.012</ArticleId><ArticleId IdType="pubmed">29478771</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs BG et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472&#x2013;477, doi:10.1126/science.aaf6659 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6659</ArticleId><ArticleId IdType="pmc">PMC5112585</ArticleId><ArticleId IdType="pubmed">27789842</ArticleId></ArticleIdList></Reference><Reference><Citation>Castejon OJ, Castellano A, Arismendi GJ &amp; Medina Z. The inflammatory reaction in human traumatic oedematous cerebral cortex. J Submicrosc Cytol Pathol 37, 43&#x2013;52 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16136727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SC, Moore GR, Golenwsky G. &amp; Raine CS Multiple sclerosis: a role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J Neuropathol Exp Neurol 49, 122&#x2013;136 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2307980</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L. et al. Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 160, 177&#x2013;190, doi:10.1016/j.cell.2014.12.019 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.12.019</ArticleId><ArticleId IdType="pmc">PMC4377295</ArticleId><ArticleId IdType="pubmed">25594180</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro MK et al. Lipid-laden cells differentially distributed in the aging brain are functionally active and correspond to distinct phenotypes. Sci Rep 6, 23795, doi:10.1038/srep23795 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23795</ArticleId><ArticleId IdType="pmc">PMC4814830</ArticleId><ArticleId IdType="pubmed">27029648</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PK, Khatchadourian A, McKinney RA &amp; Maysinger D. Docosahexaenoic acid (DHA): a modulator of microglia activity and dendritic spine morphology. J Neuroinflammation 12, 34, doi:10.1186/s12974-015-0244-5 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0244-5</ArticleId><ArticleId IdType="pmc">PMC4344754</ArticleId><ArticleId IdType="pubmed">25889069</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatchadourian A, Bourque SD, Richard VR, Titorenko VI &amp; Maysinger D. Dynamics and regulation of lipid droplet formation in lipopolysaccharide (LPS)-stimulated microglia. Biochim Biophys Acta 1821, 607&#x2013;617, doi:10.1016/j.bbalip.2012.01.007 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2012.01.007</ArticleId><ArticleId IdType="pubmed">22289388</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris LA, Skinner JR &amp; Wolins NE Imaging of neutral lipids and neutral lipid associated proteins. Methods Cell Biol 116, 213&#x2013;226, doi:10.1016/B978-0-12-408051-5.00011-5 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-408051-5.00011-5</ArticleId><ArticleId IdType="pmc">PMC3870878</ArticleId><ArticleId IdType="pubmed">24099295</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Ramachandran PV &amp; Wang MC Shedding new light on lipid functions with CARS and SRS microscopy. Biochim Biophys Acta 1841, 1120&#x2013;1129, doi:10.1016/j.bbalip.2014.02.003 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2014.02.003</ArticleId><ArticleId IdType="pmc">PMC4285713</ArticleId><ArticleId IdType="pubmed">24576891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 113, E1738&#x2013;1746, doi:10.1073/pnas.1525528113 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525528113</ArticleId><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluvinage JV et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568, 187&#x2013;192, doi:10.1038/s41586-019-1088-4 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1088-4</ArticleId><ArticleId IdType="pmc">PMC6574119</ArticleId><ArticleId IdType="pubmed">30944478</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtman IR et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun 3, 31, doi:10.1186/s40478-015-0203-5 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0203-5</ArticleId><ArticleId IdType="pmc">PMC4489356</ArticleId><ArticleId IdType="pubmed">26001565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep 4, 385&#x2013;401, doi:10.1016/j.celrep.2013.06.018 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.018</ArticleId><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071, doi:10.1016/j.cell.2015.01.049 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50, 253&#x2013;271 e256, doi:10.1016/j.immuni.2018.11.004 (2019).15</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.11.004</ArticleId><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Namatame I, Tomoda H, Arai H, Inoue K. &amp; Omura S. Complete inhibition of mouse macrophage-derived foam cell formation by triacsin C. J Biochem 125, 319&#x2013;327 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9990129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn O. et al. Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism. Genome Biol 18, 56, doi:10.1186/s13059-017-1187-1 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-017-1187-1</ArticleId><ArticleId IdType="pmc">PMC5370449</ArticleId><ArticleId IdType="pubmed">28351387</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z. et al. Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci 32, 11706&#x2013;11715, doi:10.1523/JNEUROSCI.0730-12.2012 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0730-12.2012</ArticleId><ArticleId IdType="pmc">PMC4461442</ArticleId><ArticleId IdType="pubmed">22915113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabe K, Takano K, Moriyama M. &amp; Nakamura Y. Lipopolysaccharide-Stimulated Transglutaminase 2 Expression Enhances Endocytosis Activity in the Mouse Microglial Cell Line BV-2. Neuroimmunomodulation 22, 243&#x2013;249, doi:10.1159/000365484 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000365484</ArticleId><ArticleId IdType="pubmed">25301694</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef H. et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat Med 25, 988&#x2013;1000, doi:10.1038/s41591-019-0440-4 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0440-4</ArticleId><ArticleId IdType="pmc">PMC6642642</ArticleId><ArticleId IdType="pubmed">31086348</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgens DW et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat Commun 8, 15178, doi:10.1038/ncomms15178 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15178</ArticleId><ArticleId IdType="pmc">PMC5424143</ArticleId><ArticleId IdType="pubmed">28474669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamkaew A. et al. BODIPY dyes in photodynamic therapy. Chem Soc Rev 42, 77&#x2013;88, doi:10.1039/c2cs35216h (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c2cs35216h</ArticleId><ArticleId IdType="pmc">PMC3514588</ArticleId><ArticleId IdType="pubmed">23014776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. et al. Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes. J Biol Chem 283, 11501&#x2013;11508, doi:10.1074/jbc.M800642200 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800642200</ArticleId><ArticleId IdType="pmc">PMC2431074</ArticleId><ArticleId IdType="pubmed">18276590</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P. et al. S113R mutation in SLC33A1 leads to neurodegeneration and augmented BMP signaling in a mouse model. Dis Model Mech 10, 53&#x2013;62, doi:10.1242/dmm.026880 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.026880</ArticleId><ArticleId IdType="pmc">PMC5278525</ArticleId><ArticleId IdType="pubmed">27935820</ArticleId></ArticleIdList></Reference><Reference><Citation>Huey ED et al. Characteristics of frontotemporal dementia patients with a Progranulin mutation. Ann Neurol 60, 374&#x2013;380, doi:10.1002/ana.20969 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20969</ArticleId><ArticleId IdType="pmc">PMC2987739</ArticleId><ArticleId IdType="pubmed">16983677</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsika E. et al. Parkinson&#x2019;s disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum Mol Genet 23, 4621&#x2013;4638, doi:10.1093/hmg/ddu178 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu178</ArticleId><ArticleId IdType="pmc">PMC4119414</ArticleId><ArticleId IdType="pubmed">24740878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F. et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J 24, 4639&#x2013;4647, doi:10.1096/fj.10-161471 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-161471</ArticleId><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira-de-Abreu A. et al. Cross-talk between macrophage migration inhibitory factor and eotaxin in allergic eosinophil activation forms leukotriene C(4)-synthesizing lipid bodies. Am J Respir Cell Mol Biol 44, 509&#x2013;516, doi:10.1165/rcmb.2010-0004OC (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2010-0004OC</ArticleId><ArticleId IdType="pubmed">20539011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Xu B. &amp; Ge W. The Role of Lipid Bodies in the Microglial Aging Process and Related Diseases. Neurochem Res 42, 3140&#x2013;3148, doi:10.1007/s11064-017-2351-4 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-017-2351-4</ArticleId><ArticleId IdType="pubmed">28699057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambold AS, Cohen S. &amp; Lippincott-Schwartz J. Fatty acid trafficking in starved cells: regulation by lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics. Dev Cell 32, 678&#x2013;692, doi:10.1016/j.devcel.2015.01.029 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2015.01.029</ArticleId><ArticleId IdType="pmc">PMC4375018</ArticleId><ArticleId IdType="pubmed">25752962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N, Dearborn JT, Wozniak DF &amp; Cairns NJ Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol Dis 45, 395&#x2013;408, doi:10.1016/j.nbd.2011.08.029 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.08.029</ArticleId><ArticleId IdType="pmc">PMC3225509</ArticleId><ArticleId IdType="pubmed">21933710</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie E, Schulze A, Zechner R, Walther TC &amp; Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab 18, 153&#x2013;161, doi:10.1016/j.cmet.2013.05.017 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.05.017</ArticleId><ArticleId IdType="pmc">PMC3742569</ArticleId><ArticleId IdType="pubmed">23791484</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke AC &amp; Huff MW ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr Opin Lipidol 28, 193&#x2013;200, doi:10.1097/MOL.0000000000000390 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOL.0000000000000390</ArticleId><ArticleId IdType="pubmed">28059952</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L. et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science 359, 684&#x2013;688, doi:10.1126/science.aan4183 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan4183</ArticleId><ArticleId IdType="pubmed">29301957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Zhang J, Choi AM &amp; Kim HP Mitochondrial dysfunction induces formation of lipid droplets as a generalized response to stress. Oxid Med Cell Longev 2013, 327167, doi:10.1155/2013/327167 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/327167</ArticleId><ArticleId IdType="pmc">PMC3794647</ArticleId><ArticleId IdType="pubmed">24175011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadjar A. Role of metabolic programming in the modulation of microglia phagocytosis by lipids. Prostaglandins Leukot Essent Fatty Acids 135, 63&#x2013;73, doi:10.1016/j.plefa.2018.07.006 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2018.07.006</ArticleId><ArticleId IdType="pubmed">30103935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinetti-Gbaguidi G. et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ Res 108, 985&#x2013;995, doi:10.1161/CIRCRESAHA.110.233775 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.110.233775</ArticleId><ArticleId IdType="pmc">PMC3319502</ArticleId><ArticleId IdType="pubmed">21350215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandak PG et al. Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase. J Biol Chem 285, 20192&#x2013;20201, doi:10.1074/jbc.M110.107854 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.107854</ArticleId><ArticleId IdType="pmc">PMC2888432</ArticleId><ArticleId IdType="pubmed">20424161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaitin DA et al. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. Cell 178, 686&#x2013;698 e614, doi:10.1016/j.cell.2019.05.054 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.054</ArticleId><ArticleId IdType="pmc">PMC7068689</ArticleId><ArticleId IdType="pubmed">31257031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AD et al. Progranulin in the hematopoietic compartment protects mice from atherosclerosis. Atherosclerosis 277, 145&#x2013;154, doi:10.1016/j.atherosclerosis.2018.08.042 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2018.08.042</ArticleId><ArticleId IdType="pmc">PMC6432779</ArticleId><ArticleId IdType="pubmed">30212683</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers BM et al. Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency. Cell Rep 20, 2565&#x2013;2574, doi:10.1016/j.celrep.2017.08.056 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.056</ArticleId><ArticleId IdType="pmc">PMC5757843</ArticleId><ArticleId IdType="pubmed">28903038</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Perotin S, Alvarez-Buylla A. &amp; Garcia-Verdugo JM Identification and characterization of neural progenitor cells in the adult mammalian brain. Adv Anat Embryol Cell Biol 203, 1&#x2013;101, ix (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19552108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bligh EG &amp; Dyer WJ A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37, 911&#x2013;917, doi:10.1139/o59-099 (1959).</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/o59-099</ArticleId><ArticleId IdType="pubmed">13671378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ et al. Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures. Neuron 94, 759&#x2013;773 e758, doi:10.1016/j.neuron.2017.04.043 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Deans RM et al. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat Chem Biol 12, 361&#x2013;366, doi:10.1038/nchembio.2050 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.2050</ArticleId><ArticleId IdType="pmc">PMC4836973</ArticleId><ArticleId IdType="pubmed">27018887</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31408137</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>322</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions.</ArticleTitle><Pagination><StartPage>524</StartPage><EndPage>534</EndPage><MedlinePgn>524-534</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.10551</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The effect of intensive blood pressure lowering on brain health remains uncertain.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the association of intensive blood pressure treatment with cerebral white matter lesion and brain volumes.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A substudy of a multicenter randomized clinical trial of hypertensive adults 50 years or older without a history of diabetes or stroke at 27 sites in the United States. Randomization began on November 8, 2010. The overall trial was stopped early because of benefit for its primary outcome (a composite of cardiovascular events) and all-cause mortality on August 20, 2015. Brain magnetic resonance imaging (MRI) was performed on a subset of participants at baseline (n&#x2009;=&#x2009;670) and at 4 years of follow-up (n&#x2009;=&#x2009;449); final follow-up date was July 1, 2016.</AbstractText><AbstractText Label="INTERVENTIONS">Participants were randomized to a systolic blood pressure (SBP) goal of either less than 120 mm Hg (intensive treatment, n&#x2009;=&#x2009;355) or less than 140 mm Hg (standard treatment, n&#x2009;=&#x2009;315).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was change in total white matter lesion volume from baseline. Change in total brain volume was a secondary outcome.</AbstractText><AbstractText Label="RESULTS">Among 670 recruited patients who had baseline MRI (mean age, 67.3 [SD, 8.2] years; 40.4% women), 449 (67.0%) completed the follow-up MRI at a median of 3.97 years after randomization, after a median intervention period of 3.40 years. In the intensive treatment group, based on a robust linear mixed model, mean white matter lesion volume increased from 4.57 to 5.49 cm3 (difference, 0.92 cm3 [95% CI, 0.69 to 1.14]) vs an increase from 4.40 to 5.85 cm3 (difference, 1.45 cm3 [95% CI, 1.21 to 1.70]) in the standard treatment group (between-group difference in change, -0.54 cm3 [95% CI, -0.87 to -0.20]). Mean total brain volume decreased from 1134.5 to 1104.0 cm3 (difference, -30.6 cm3 [95% CI, -32.3 to -28.8]) in the intensive treatment group vs a decrease from 1134.0 to 1107.1 cm3 (difference, -26.9 cm3 [95% CI, 24.8 to 28.8]) in the standard treatment group (between-group difference in change, -3.7 cm3 [95% CI, -6.3 to -1.1]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among hypertensive adults, targeting an SBP of less than 120 mm Hg, compared with less than 140 mm Hg, was significantly associated with a smaller increase in cerebral white matter lesion volume and a greater decrease in total brain volume, although the differences were small.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT01206062.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>SPRINT MIND Investigators for the SPRINT Research Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Nasrallah</LastName><ForeName>Ilya M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajewski</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auchus</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Mississippi Medical Center, Jackson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chelune</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah School of Medicine, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Alfred K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Maryjo L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coker</LastName><ForeName>Laura H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cushman</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutler</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desiderio</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doshi</LastName><ForeName>Jimit</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erus</LastName><ForeName>Guray</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fine</LastName><ForeName>Larry J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Clinical Applications and Prevention Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaussoin</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Darrin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Karen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmel</LastName><ForeName>Paul L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurella Tamura</LastName><ForeName>Manjula</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Stanford University School of Medicine, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Cora E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martindale-Adams</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moy</LastName><ForeName>Claudia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Linda O</ForeName><Initials>LO</Initials><AffiliationInfo><Affiliation>Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oparil</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Mahboob</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reboussin</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocco</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Section of Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Bonnie C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Genentech, South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Still</LastName><ForeName>Carolyn H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Supiano</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, University of Utah School of Medicine, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Joni K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadley</LastName><ForeName>Virginia G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whelton</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Valerie M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolard</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Jackson T</ForeName><Initials>JT</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryan</LastName><ForeName>R Nick</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01206062</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002548</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000005</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000073</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024134</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000105</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000093</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000075</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 GM103337</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000064</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR013642</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000050</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025755</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000002</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001064</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2019 Aug 13;322(6):512-513. doi: 10.1001/jama.2019.10849.</RefSource><PMID Version="1">31408120</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Nasrallah reported receiving grants from the National Institutes of Health (NIH). Dr Pajewski reported receiving grants from NIH. Dr Auchus reported receiving grants from NIH/National Heart, Lung, and Blood Institute (NHLBI) (contract HHSN268200900047C, subaward 000336417-041). Dr Chelune reported receiving grants from University of Utah. Dr Cheung reported receiving grants from University of Utah and Veterans Affairs Salt Lake City Healthcare System. Dr Cushman reported receiving grants from NHLBI; personal fees from Sanofi; and nonfinancial support from Novartis. Dr Crowe reported receiving grants from NIH. Dr Davatzikos reported receiving grants from NIH. Dr Doshi reported receiving grants from NIH. Dr Erus reported receiving grants from the National Institute on Aging. Ms Gaussoin reported receiving other from NIH/NHLBI. Dr Johnson reported receiving grants from NHLBI. Dr Kimmel reported receiving royalties from Elsevier. Dr Lewis reported receiving grants from NIH. Dr Oparil reported receiving grants and nonfinancial support from NIH/NHLBI; personal fees from Actelion Clinical Research, Novo Nordisk, 98point6, George Clinical Pty Ltd/Actelion/Idorsia Pharmaceuticals, Pfizer, and ROX Medical; grants from George Clinical Pty Ltd/Actelion/Idorsia Pharmaceuticals, ROX Medical, Bayer, Idorsia Pharmaceuticals, and Novartis; and serving as editor in chief of <i>Current Hypertension Reports</i>. Dr Rahman reported receiving grants from NIH, Bayer, and Duke Clinical Research Institute. Dr Reboussin reported receiving grants from NIH. Dr Rocco reported receiving grants from NIH, Bayer, Boehringer Ingelheim, and GlaxoSmithKline and receiving personal fees from Abbvie, George Clinical, Beacon Bioscience, and Baxter. Dr Sachs reported receiving grants from NIH/NHLBI (contract HHSN268200900047C). Dr Sink reported receiving grants from NIH and through her institution from Biogen and vTv Therapeutics and that she was a full-time faculty member at Wake Forest School of Medicine during the conduct of SPRINT but is now a full-time employee of Genentech, a member of the Roche Group (Genentech had no involvement in SPRINT). Dr Still reported receiving grants from Case Western Reserve University. Dr Supiano reported receiving grants from NIH. Dr Wadley reported receiving grants from NIH. Ms Walker reported receiving grants from NIH. Dr Weiner reported receiving grants from University of Utah and receiving personal fees from Janssen Biopharmaceuticals. Dr Wilson reported receiving grants from Wake Forest University. Ms Woolard reported receiving grants from NIH/NHLBI (contract HHSN268200900047C). Dr J. Wright reported receiving grants from NIH. Dr C. Wright reported receiving grants from NIH. Dr Bryan reported receiving grants from NIH, having equity in GalileoCDS Inc, and having a licensed and issued patent for a System and Method for Medical Image Analysis and Probabilistic Diagnosis. No other authors reported disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31408137</ArticleId><ArticleId IdType="pmc">PMC6692679</ArticleId><ArticleId IdType="doi">10.1001/jama.2019.10551</ArticleId><ArticleId IdType="pii">2747671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wright JT Jr, Williamson JD, Whelton PK, et al. ; SPRINT Research Group . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1511939</ArticleId><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D, Cooper L, Cai J, et al. . Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: the ARIC study. Stroke. 1996;27(12):2262-2270. doi:10.1161/01.STR.27.12.2262</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.27.12.2262</ArticleId><ArticleId IdType="pubmed">8969791</ArticleId></ArticleIdList></Reference><Reference><Citation>Basile AM, Pantoni L, Pracucci G, et al. ; LADIS Study Group . Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes: the LADIS (Leukoaraiosis and Disability in the Elderly) study. Cerebrovasc Dis. 2006;21(5-6):315-322. doi:10.1159/000091536</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000091536</ArticleId><ArticleId IdType="pubmed">16490940</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer&#x2019;s disease prevalence. Lancet Neurol. 2011;10(9):819-828. doi:10.1016/S1474-4422(11)70072-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70072-2</ArticleId><ArticleId IdType="pmc">PMC3647614</ArticleId><ArticleId IdType="pubmed">21775213</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, et al. ; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0b013e3182299496</ArticleId><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdelho A, Madureira S, Ferro JM, et al. ; LADIS Study . Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly: the LADIS study. J Neurol Neurosurg Psychiatry. 2007;78(12):1325-1330. doi:10.1136/jnnp.2006.110361</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.110361</ArticleId><ArticleId IdType="pmc">PMC2095587</ArticleId><ArticleId IdType="pubmed">17470472</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222. doi:10.1056/NEJMoa022066</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa022066</ArticleId><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S115-S123. doi:10.1097/00002093-199912003-00017</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199912003-00017</ArticleId><ArticleId IdType="pubmed">10609690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalback W, Esh C, Casta&#xf1;o EM, et al. . Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer&#x2019;s disease. Neurol Res. 2004;26(5):525-539. doi:10.1179/016164104225017668</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164104225017668</ArticleId><ArticleId IdType="pubmed">15265270</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer&#x2019;s disease&#x2014;lessons from pathology. BMC Med. 2014;12:206. doi:10.1186/s12916-014-0206-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-014-0206-2</ArticleId><ArticleId IdType="pmc">PMC4226890</ArticleId><ArticleId IdType="pubmed">25385447</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufouil C, Chalmers J, Coskun O, et al. ; PROGRESS MRI Substudy Investigators . Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) magnetic resonance imaging substudy. Circulation. 2005;112(11):1644-1650. doi:10.1161/CIRCULATIONAHA.104.501163</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.501163</ArticleId><ArticleId IdType="pubmed">16145004</ArticleId></ArticleIdList></Reference><Reference><Citation>Saper CB. How low can you go? Ann Neurol. 2015;78(5):665-666. doi:10.1002/ana.24530</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24530</ArticleId><ArticleId IdType="pubmed">26395548</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Pajewski NM, Auchus AP, et al. ; SPRINT MIND Investigators for the SPRINT Research Group . Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553-561. doi:10.1001/jama.2018.21442</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.21442</ArticleId><ArticleId IdType="pmc">PMC6439590</ArticleId><ArticleId IdType="pubmed">30688979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosius WT, Sink KM, Foy CG, et al. ; SPRINT Study Research Group . The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532-546. doi:10.1177/1740774514537404</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774514537404</ArticleId><ArticleId IdType="pmc">PMC4156910</ArticleId><ArticleId IdType="pubmed">24902920</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KC, Whelton PK, Cushman WC, et al. ; SPRINT Research Group . Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2018;71(5):848-857. doi:10.1161/HYPERTENSIONAHA.117.10479</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.10479</ArticleId><ArticleId IdType="pmc">PMC5967644</ArticleId><ArticleId IdType="pubmed">29531173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17(1):87-97. doi:10.1109/42.668698</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/42.668698</ArticleId><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi J, Erus G, Ou Y, Gaonkar B, Davatzikos C. Multi-atlas skull-stripping. Acad Radiol. 2013;20(12):1566-1576. doi:10.1016/j.acra.2013.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2013.09.010</ArticleId><ArticleId IdType="pmc">PMC3880117</ArticleId><ArticleId IdType="pubmed">24200484</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi J, Erus G, Ou Y, et al. ; Alzheimer&#x2019;s Neuroimaging Initiative . MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration algorithms and parameters, and locally optimal atlas selection. Neuroimage. 2016;127:186-195. doi:10.1016/j.neuroimage.2015.11.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.11.073</ArticleId><ArticleId IdType="pmc">PMC4806537</ArticleId><ArticleId IdType="pubmed">26679328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronneberger O, Fischer P, Brox T. U-Net: convolutional networks for biomedical image segmentation In: Navab N, Hornegger J, Wells W, Frangi A, eds. Medical Image Computing and Computer-Assisted Intervention&#x2014;MICCAI 2015. Basel, Switzerland: Springer; 2015:234-241.</Citation></Reference><Reference><Citation>Szegedy C, Ioffe S, Vanhoucke V, Alemi AA Inception-v4, Inception-ResNet and the impact of residual connections on learning. In: Proceedings of the Thirty-First AAAI Conference on Artificial Intelligence (AAAI-17) Menlo Park, CA: Association for the Advancement of Artificial Intelligence; 2017:4278-4284.</Citation></Reference><Reference><Citation>Williamson JD, Supiano MA, Applegate WB, et al. ; SPRINT Research Group . Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged &#x2265;75 years: a randomized clinical trial. JAMA. 2016;315(24):2673-2682. doi:10.1001/jama.2016.7050</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.7050</ArticleId><ArticleId IdType="pmc">PMC4988796</ArticleId><ArticleId IdType="pubmed">27195814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Evans GW, Shorr RI, et al. . Syncope, hypotension, and falls in the treatment of hypertension: results from the randomized clinical systolic blood pressure intervention trial. J Am Geriatr Soc. 2018;66(4):679-686. doi:10.1111/jgs.15236</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15236</ArticleId><ArticleId IdType="pmc">PMC8045467</ArticleId><ArticleId IdType="pubmed">29601076</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Launer LJ, Bryan RN, et al. ; Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators . Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174(3):324-333. doi:10.1001/jamainternmed.2013.13656</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.13656</ArticleId><ArticleId IdType="pmc">PMC4423790</ArticleId><ArticleId IdType="pubmed">24493100</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbidge JB, Magee L, Robb AL. Alternative transformations to handle extreme values of the dependent variable. J Am Stat Assoc. 1988;83(401):123-127. doi:10.1080/01621459.1988.10478575</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1988.10478575</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller M. robustlmm: An R package for robust estimation of linear mixed-effects models. J Stat Softw. 2016;75(6):1-24. doi:10.18637/jss.v075.i06</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v075.i06</ArticleId><ArticleId IdType="pmc">PMC7351245</ArticleId><ArticleId IdType="pubmed">32655332</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw F-E, de Groot JC, Oudkerk M, et al. . Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125(pt 4):765-772. doi:10.1093/brain/awf077</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf077</ArticleId><ArticleId IdType="pubmed">11912110</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray AM, Hsu F-C, Williamson JD, et al. ; Action to Control Cardiovascular Risk in Diabetes Follow-On Memory in Diabetes (ACCORDION MIND) Investigators . ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia. 2017;60(1):69-80. doi:10.1007/s00125-016-4118-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4118-x</ArticleId><ArticleId IdType="pmc">PMC5633725</ArticleId><ArticleId IdType="pubmed">27766347</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael O, Schwarz C, Drucker D, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol. 2010;67(11):1370-1378. doi:10.1001/archneurol.2010.284</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.284</ArticleId><ArticleId IdType="pmc">PMC3082636</ArticleId><ArticleId IdType="pubmed">21060014</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaaren BFJ, Vernooij MW, de Boer R, et al. . High blood pressure and cerebral white matter lesion progression in the general population. Hypertension. 2013;61(6):1354-1359. doi:10.1161/HYPERTENSIONAHA.111.00430</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.111.00430</ArticleId><ArticleId IdType="pubmed">23529163</ArticleId></ArticleIdList></Reference><Reference><Citation>Enzinger C, Fazekas F, Matthews PM, et al. . Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005;64(10):1704-1711. doi:10.1212/01.WNL.0000161871.83614.BB</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000161871.83614.BB</ArticleId><ArticleId IdType="pubmed">15911795</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlek ALM, Visseren FLJ, Kappelle LJ, et al. ; SMART Study Group . Blood pressure and progression of cerebral atrophy in patients with vascular disease. Am J Hypertens. 2009;22(11):1183-1189. doi:10.1038/ajh.2009.166</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajh.2009.166</ArticleId><ArticleId IdType="pubmed">19745819</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochemsen HM, Muller M, Visseren FL, et al. ; SMART Study Group . Blood pressure and progression of brain atrophy: the SMART-MR Study. JAMA Neurol. 2013;70(8):1046-1053. doi:10.1001/jamaneurol.2013.217</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.217</ArticleId><ArticleId IdType="pubmed">23753860</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Shiung MM, Gunter JL, et al. . Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62(4):591-600. doi:10.1212/01.WNL.0000110315.26026.EF</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000110315.26026.EF</ArticleId><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Duning T, Kloska S, Steinstr&#xe4;ter O, Kugel H, Heindel W, Knecht S. Dehydration confounds the assessment of brain atrophy. Neurology. 2005;64(3):548-550. doi:10.1212/01.WNL.0000150542.16969.CC</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000150542.16969.CC</ArticleId><ArticleId IdType="pubmed">15699394</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31444142</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.</ArticleTitle><Pagination><StartPage>942</StartPage><EndPage>952</EndPage><MedlinePgn>942-952</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(19)30228-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(19)30228-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Midlife hypertension confers increased risk for cognitive impairment in late life. The sensitive period for risk exposure and extent that risk is mediated through amyloid or vascular-related mechanisms are poorly understood. We aimed to identify if, and when, blood pressure or change in blood pressure during adulthood were associated with late-life brain structure, pathology, and cognition.</AbstractText><AbstractText Label="METHODS">Participants were from Insight 46, a neuroscience substudy of the ongoing longitudinal Medical Research Council National Survey of Health and Development, a birth cohort that initially comprised 5362 individuals born throughout mainland Britain in one week in 1946. Participants aged 69-71 years received T1 and FLAIR volumetric MRI, florbetapir amyloid-PET imaging, and cognitive assessment at University College London (London, UK); all participants were dementia-free. Blood pressure measurements had been collected at ages 36, 43, 53, 60-64, and 69 years. We also calculated blood pressure change variables between ages. Primary outcome measures were white matter hyperintensity volume (WMHV) quantified from multimodal MRI using an automated method, amyloid-&#x3b2; positivity or negativity using a standardised uptake value ratio approach, whole-brain and hippocampal volumes quantified from 3D-T1 MRI, and a composite cognitive score-the Preclinical Alzheimer Cognitive Composite (PACC). We investigated associations between blood pressure and blood pressure changes at and between 36, 43, 53, 60-64, and 69 years of age with WMHV using generalised linear models with a gamma distribution and log link function, amyloid-&#x3b2; status using logistic regression, whole-brain volume and hippocampal volumes using linear regression, and PACC score using linear regression, with adjustment for potential confounders.</AbstractText><AbstractText Label="FINDINGS">Between May 28, 2015, and Jan 10, 2018, 502 individuals were assessed as part of Insight 46. 465 participants (238 [51%] men; mean age 70&#xb7;7 years [SD 0&#xb7;7]; 83 [18%] amyloid-&#x3b2;-positive) were included in imaging analyses. Higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) at age 53 years and greater increases in SBP and DBP between 43 and 53 years were positively associated with WMHV at 69-71 years of age (increase in mean WMHV per 10 mm Hg greater SBP 7%, 95% CI 1-14, p=0&#xb7;024; increase in mean WMHV per 10 mm Hg greater DBP 15%, 4-27, p=0&#xb7;0057; increase in mean WMHV per one SD change in SBP 15%, 3-29, p=0&#xb7;012; increase in mean WMHV per 1 SD change in DBP 15%, 3-30, p=0&#xb7;017). Higher DBP at 43 years of age was associated with smaller whole-brain volume at 69-71 years of age (-6&#xb7;9 mL per 10 mm Hg greater DBP, -11&#xb7;9 to -1&#xb7;9, p=0&#xb7;0068), as were greater increases in DBP between 36 and 43 years of age (-6&#xb7;5 mL per 1 SD change, -11&#xb7;1 to -1&#xb7;9, p=0&#xb7;0054). Greater increases in SBP between 36 and 43 years of age were associated with smaller hippocampal volumes at 69-71 years of age (-0&#xb7;03 mL per 1 SD change, -0&#xb7;06 to -0&#xb7;001, p=0&#xb7;043). Neither absolute blood pressure nor change in blood pressure predicted amyloid-&#x3b2; status or PACC score at 69-71 years of age.</AbstractText><AbstractText Label="INTERPRETATION">High and increasing blood pressure from early adulthood into midlife seems to be associated with increased WMHV and smaller brain volumes at 69-71 years of age. We found no evidence that blood pressure affected cognition or cerebral amyloid-&#x3b2; load at this age. Blood pressure monitoring and interventions might need to start around 40 years of age to maximise late-life brain health.</AbstractText><AbstractText Label="FUNDING">Alzheimer's Research UK, Medical Research Council, Dementias Platform UK, Wellcome Trust, Brain Research UK, Wolfson Foundation, Weston Brain Institute, Avid Radiopharmaceuticals.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudre</LastName><ForeName>Carole H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Ian B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Sarah-Naomi</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Medical Research Council Unit for Lifelong Health and Ageing at University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>Ashvini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray-Smith</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Research Council Unit for Lifelong Health and Ageing at University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchanan</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keuss</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coath</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Nuclear Medicine, University College London Hospitals, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Nuclear Medicine, University College London Hospitals, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modat</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Leonard Wolfson Experimental Neurology Centre and Academic Neuroradiological Unit, Department of Brain Repair and Rehabilitation, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crutch</LastName><ForeName>Sebastian J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Research Council Unit for Lifelong Health and Ageing at University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Research Council Unit for Lifelong Health and Ageing at University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute at University College London, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute at University College London, University College London, London, UK. Electronic address: j.schott@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_UU_00019/4</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/3</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00019/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PG/17/90/33415</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00019/3</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2019 Oct;18(10):906-908. doi: 10.1016/S1474-4422(19)30288-1.</RefSource><PMID Version="1">31444143</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2020 Jul;19(7):e6. doi: 10.1016/S1474-4422(20)30190-3.</RefSource><PMID Version="1">32562687</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016021" MajorTopicYN="N">Epidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007090" MajorTopicYN="N">Image Interpretation, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31444142</ArticleId><ArticleId IdType="pmc">PMC6744368</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(19)30228-5</ArticleId><ArticleId IdType="pii">S1474-4422(19)30228-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014. Dementia and risk reduction: an analysis of protective and modifiable factors. Alzheimer's Disease International. 2014. https://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf</Citation></Reference><Reference><Citation>Livingston G, Sommerlad A, Orgeta V. Dementia prevention, intervention, and care. Lancet. 2017;390:2673&#x2013;2734.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Tan L, Wang H-F. Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2015;86:1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">26294005</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Yaffe K, Biller J. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68:e67&#x2013;e94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5361411</ArticleId><ArticleId IdType="pubmed">27977393</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath ER, Beiser AS, DeCarli C. Blood pressure from mid- to and risk of incident dementia. Neurology. 2017;89:2447&#x2013;2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729797</ArticleId><ArticleId IdType="pubmed">29117954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuh D, Pierce M, Adams J. Cohort profile: updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. Int J Epidemiol. 2011;40:e1&#x2013;e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3043283</ArticleId><ArticleId IdType="pubmed">21345808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane CA, Parker TD, Cash DM. Study protocol: Insight 46&#x2014;a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol. 2017;17:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395844</ArticleId><ArticleId IdType="pubmed">28420323</ArticleId></ArticleIdList></Reference><Reference><Citation>James SN, Lane CA, Parker TD. Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. BMC Res Notes. 2018;11:885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293512</ArticleId><ArticleId IdType="pubmed">30545411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy R, Ghosh AK, Deanfield J, Kuh D, Hughes AD. Birthweight, childhood growth and left ventricular structure at age 60&#x2013;64 years in a British birth cohort study. Int J Epidemiol. 2016;45:1091&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841632</ArticleId><ArticleId IdType="pubmed">27413103</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Barnes J, Modat M. Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage. 2011;55:1091&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554789</ArticleId><ArticleId IdType="pubmed">21195780</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge Cardoso M, Leung K, Modat M. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal. 2013;17:671&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">23510558</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone IB, Leung KK, Clegg S. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. Neuroimage. 2015;104:366&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4265726</ArticleId><ArticleId IdType="pubmed">25255942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J, Ourselin S. Bayesian model selection for pathological neuroimaging data applied to white matter lesion segmentation. IEEE Trans Med Imaging. 2015;34:2079&#x2013;2102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25850086</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Psychological Corporation; San Antonio, TX: 1987. Manual for the Wechsler memory scale&#x2014;revised.</Citation></Reference><Reference><Citation>Papp KV, Amariglio RE, Dekhtyar M. Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer's disease trajectory. Clin Neuropsychol. 2014;28:771&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134419</ArticleId><ArticleId IdType="pubmed">24815535</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Psychological Corporation; New York, NY: 1981. Manual for the Wechsler adult intelligence scale&#x2014;revised.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A, Moebus S, M&#xf6;hlenkamp S. Algorithms for converting random-zero to automated oscillometric blood pressure values, and vice versa. Am J Epidemiol. 2006;164:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh AK, Hardy RJ, Francis DP. Midlife blood pressure change and left ventricular mass and remodelling in older age in the 1946 British birth cohort study. Eur Heart J. 2014;35:3287&#x2013;3295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4258225</ArticleId><ArticleId IdType="pubmed">25246483</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaysina D, Gardner MP, Richards M, Ben-Shlomo Y. Cortisol and cognitive function in midlife: the role of childhood cognition and educational attainment. Psychoneuroendocrinology. 2014;47:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103483</ArticleId><ArticleId IdType="pubmed">25001968</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, Sigurdsson S, Kjartansson O. Joint effect of mid- and late-life blood pressure on the brain: the AGES-Reykjavik Study. Neurology. 2014;82:2187&#x2013;2195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113458</ArticleId><ArticleId IdType="pubmed">24898928</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk factors for &#x3b2;-amyloid deposition in healthy aging. JAMA Neurol. 2013;70:600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968915</ArticleId><ArticleId IdType="pubmed">23553344</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbaum JBS, Chen K, Launer LJ. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012;33:827.e11&#x2013;827.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236809</ArticleId><ArticleId IdType="pubmed">21821316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider ALC, Zhou Y. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317:1443&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921896</ArticleId><ArticleId IdType="pubmed">28399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Knopman DS, Lesnick TG. Evaluation of amyloid protective factors and alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neurol. 2017;74:718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649401</ArticleId><ArticleId IdType="pubmed">28418521</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Davis-Plourde K, Himali JJ. Vascular risk at younger ages most strongly associates with current and future brain volume. Neurology. 2018;91:e1479&#x2013;e1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202941</ArticleId><ArticleId IdType="pubmed">30232248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA, Edmonds EC, Bangen KJ. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol. 2015;72:546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428938</ArticleId><ArticleId IdType="pubmed">25822631</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Hughes TM, White LR. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol. 2011;70:774&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241005</ArticleId><ArticleId IdType="pubmed">22162060</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274:1846&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500533</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Seshadri S, Beiser A. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146307</ArticleId><ArticleId IdType="pubmed">21810696</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano Y, Griswold M, Wang W. Long-term blood pressure level and variability from midlife to later life and subsequent cognitive change: the ARIC neurocognitive study. J Am Heart Assoc. 2018;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201456</ArticleId><ArticleId IdType="pubmed">30371241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Coresh J, Catellier DJ. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2010;41:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803313</ArticleId><ArticleId IdType="pubmed">19926835</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, Scheltens P, Jonker C, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology. 1998;51:319&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674838</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchet O, Celle S, Roche F. Blood pressure levels and brain volume reduction: a systematic review and meta-analysis. J Hypertens. 2013;31:1502&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pubmed">23811995</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin SS, Gustin W, Wong ND. Hemodynamic patterns of age-related changes in blood pressure. the Framingham Heart Study. Circulation. 1997;96:308&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236450</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Schneider ALC, Wruck L. Life-course blood pressure in relation to brain volumes. Alzheimers Dement. 2016;12:890&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980244</ArticleId><ArticleId IdType="pubmed">27139841</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Pajewski NM, Auchus AP. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439590</ArticleId><ArticleId IdType="pubmed">30688979</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra C. Associations between ambulatory blood pressure parameters and cerebral white matter lesions. Int J Hypertens. 2011;2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146988</ArticleId><ArticleId IdType="pubmed">21811670</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31434879</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model.</ArticleTitle><Pagination><StartPage>3758</StartPage><MedlinePgn>3758</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3758</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-11674-z</ELocationID><Abstract><AbstractText>Many risk genes for the development of Alzheimer's disease (AD) are exclusively or highly expressed in myeloid cells. Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for their survival. We designed and synthesized a highly selective brain-penetrant CSF1R inhibitor (PLX5622) allowing for extended and specific microglial elimination, preceding and during pathology development. We find that in the 5xFAD mouse model of AD, plaques fail to form in the parenchymal space following microglial depletion, except in areas containing surviving microglia. Instead, A&#x3b2; deposits in cortical blood vessels reminiscent of cerebral amyloid angiopathy. Altered gene expression in the 5xFAD hippocampus is also reversed by the absence of microglia. Transcriptional analyses of the residual plaque-forming microglia show they exhibit a disease-associated microglia profile. Collectively, we describe the structure, formulation, and efficacy of PLX5622, which allows for sustained microglial depletion and identify roles of microglia in initiating plaque pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spangenberg</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California Irvine (UCI), Irvine, CA, 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Severson</LastName><ForeName>Paul L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohsfield</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California Irvine (UCI), Irvine, CA, 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crapser</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California Irvine (UCI), Irvine, CA, 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiazhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burton</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spevak</LastName><ForeName>Wayne</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Nicole Y</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California Irvine (UCI), Irvine, CA, 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habets</LastName><ForeName>Gaston</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rymar</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Garson</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nespi</LastName><ForeName>Marika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Parmveer</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broome</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Prabha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollag</LastName><ForeName>Gideon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Brian L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-5320-3691</Identifier><AffiliationInfo><Affiliation>Plexxikon Inc, Berkeley, CA, 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California Irvine (UCI), Irvine, CA, 92697, USA. kngreen@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS083801</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG059367</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056768</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000604004">Csf1r protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009930">Organic Chemicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000630231">PLX5622</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016187">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009930" MajorTopicYN="N">Organic Chemicals</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016187" MajorTopicYN="N">Receptors, Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>P.L.Severson, J.Z., E.A.B., Y.Z., W.S., J.L., G.H., A.R., G.T., J.W., M.N., P.Singh, S.B., P.I., C.Z., G.B., and B.L.W. are employees of Plexxikon Inc.; the remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31434879</ArticleId><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-11674-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-11674-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Jr., et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216. doi: 10.1016/S1474-4422(12)70291-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. The amyloid hypothesis for Alzheimer&#x2019;s disease: a critical reappraisal. J. Neurochem. 2009;110:1129&#x2013;1134. doi: 10.1111/j.1471-4159.2009.06181.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06181.x</ArticleId><ArticleId IdType="pubmed">19457065</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Goate AM. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 2015;77:43&#x2013;51. doi: 10.1016/j.biopsych.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2014.05.006</ArticleId><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KL, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nat. Neurosci. 2017;20:1052&#x2013;1061. doi: 10.1038/nn.4587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4587</ArticleId><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J. Neurosci. 2008;28:8354&#x2013;8360. doi: 10.1523/JNEUROSCI.0616-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0616-08.2008</ArticleId><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Daria, A. et al. Young microglia restore amyloid plaque clearance of aged microglia. EMBO J (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5331757</ArticleId><ArticleId IdType="pubmed">28007893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellwig S, et al. Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-beta plaque formation in organotypic hippocampal slice cultures. Sci. Rep. 2015;5:14624. doi: 10.1038/srep14624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep14624</ArticleId><ArticleId IdType="pmc">PMC4586757</ArticleId><ArticleId IdType="pubmed">26416689</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, et al. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain. 2016;139:1265&#x2013;1281. doi: 10.1093/brain/aww016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, et al. Formation and maintenance of Alzheimer&#x2019;s disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 2009;12:1361&#x2013;1363. doi: 10.1038/nn.2432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2432</ArticleId><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355. doi: 10.1371/journal.pmed.0020355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0020355</ArticleId><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Chang PT. Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide. Brain Res. 2001;893:287&#x2013;291. doi: 10.1016/S0006-8993(00)03322-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(00)03322-9</ArticleId><ArticleId IdType="pubmed">11223020</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng BP, et al. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer&#x2019;s disease amyloid plaques in human brain preparations. Biochemistry. 1999;38:10424&#x2013;10431. doi: 10.1021/bi990718v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi990718v</ArticleId><ArticleId IdType="pubmed">10441137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl. Acad. Sci. USA. 2009;106:20324&#x2013;20329. doi: 10.1073/pnas.0911281106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911281106</ArticleId><ArticleId IdType="pmc">PMC2787156</ArticleId><ArticleId IdType="pubmed">19910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sole-Domenech, S., Cruz, D. L., Capetillo-Zarate, E. &amp; Maxfield, F. R. The endocytic pathway in microglia during health, aging and Alzheimer&#x2019;s disease. Ageing Res Rev (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127718</ArticleId><ArticleId IdType="pubmed">27421577</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397. doi: 10.1016/j.neuron.2014.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice RA, et al. Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus. J. Neurosci. 2015;35:9977&#x2013;9989. doi: 10.1523/JNEUROSCI.0336-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0336-15.2015</ArticleId><ArticleId IdType="pmc">PMC4495246</ArticleId><ArticleId IdType="pubmed">26156998</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc. Natl. Acad. Sci. USA. 2012;109:E197&#x2013;E205. doi: 10.1073/pnas.1111098109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1111098109</ArticleId><ArticleId IdType="pmc">PMC3268269</ArticleId><ArticleId IdType="pubmed">22167804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007;2:18. doi: 10.1186/1750-1326-2-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-2-18</ArticleId><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigaya Y, et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer&#x2019;s disease brain. Biochem Biophys. Res Commun. 2000;276:422&#x2013;427. doi: 10.1006/bbrc.2000.3490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2000.3490</ArticleId><ArticleId IdType="pubmed">11027491</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, et al. Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann. Neurol. 2013;73:584&#x2013;593. doi: 10.1002/ana.23845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23845</ArticleId><ArticleId IdType="pubmed">23495089</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 2004;279:20296&#x2013;20306. doi: 10.1074/jbc.M312946200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M312946200</ArticleId><ArticleId IdType="pubmed">14985348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Shi J, Smallman R, Iwatsubo T, Mann DM. Relationships in Alzheimer&#x2019;s disease between the extent of Abeta deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen. Neuropathol. Appl Neurobiol. 2006;32:332&#x2013;340. doi: 10.1111/j.1365-2990.2006.00732.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2006.00732.x</ArticleId><ArticleId IdType="pubmed">16640651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher NN, et al. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J. Neuroinflamm. 2015;12:139. doi: 10.1186/s12974-015-0366-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0366-9</ArticleId><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain. 2016;139:891&#x2013;907. doi: 10.1093/brain/awv379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv379</ArticleId><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol. Commun. 2015;3:70. doi: 10.1186/s40478-015-0250-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0250-y</ArticleId><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar, S. et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47:566&#x2013;581 e9. doi: 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew RJ, et al. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2017;114:E9665&#x2013;e9674. doi: 10.1073/pnas.1708568114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708568114</ArticleId><ArticleId IdType="pmc">PMC5692556</ArticleId><ArticleId IdType="pubmed">29078331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, et al. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer&#x2019;s disease. Neuroscience. 1992;48:763&#x2013;777. doi: 10.1016/0306-4522(92)90265-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(92)90265-4</ArticleId><ArticleId IdType="pubmed">1378573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S, et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer&#x2019;s disease amyloid plaques. Proc. Natl. Acad. Sci. USA. 2015;112:E3699&#x2013;E3708. doi: 10.1073/pnas.1510329112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510329112</ArticleId><ArticleId IdType="pmc">PMC4507205</ArticleId><ArticleId IdType="pubmed">26124111</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat. Commun. 2015;6:6176. doi: 10.1038/ncomms7176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7176</ArticleId><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 2016;213:667&#x2013;675. doi: 10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016;90:724&#x2013;739. doi: 10.1016/j.neuron.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi, A. R. et al. A limited capacity for microglial repopulation in the adult brain. Glia (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6269202</ArticleId><ArticleId IdType="pubmed">30370589</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290 e17. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore Monica R. P., Hohsfield Lindsay A., Kram&#xe1;r Enik&#xf6; A., Soreq Lilach, Lee Rafael J., Pham Stephanie T., Najafi Allison R., Spangenberg Elizabeth E., Wood Marcelo A., West Brian L., Green Kim N. Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice. Aging Cell. 2018;17(6):e12832. doi: 10.1111/acel.12832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12832</ArticleId><ArticleId IdType="pmc">PMC6260908</ArticleId><ArticleId IdType="pubmed">30276955</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice RA, et al. Microglial repopulation resolves inflammation and promotes brain recovery after injury. Glia. 2017;65:931&#x2013;944. doi: 10.1002/glia.23135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23135</ArticleId><ArticleId IdType="pmc">PMC5395311</ArticleId><ArticleId IdType="pubmed">28251674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger J, et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity. 2015;43:92&#x2013;106. doi: 10.1016/j.immuni.2015.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.012</ArticleId><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Faustino JV, et al. Microglial cells contribute to endogenous brain defenses after acute neonatal focal stroke. J. Neurosci. 2011;31:12992&#x2013;13001. doi: 10.1523/JNEUROSCI.2102-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2102-11.2011</ArticleId><ArticleId IdType="pmc">PMC3539822</ArticleId><ArticleId IdType="pubmed">21900578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 2011;44:200&#x2013;205. doi: 10.1038/ng.1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.1027</ArticleId><ArticleId IdType="pmc">PMC3267847</ArticleId><ArticleId IdType="pubmed">22197934</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada M, et al. Characteristic microglial features in patients with hereditary diffuse leukoencephalopathy with spheroids. Ann. Neurol. 2016;80:554&#x2013;565. doi: 10.1002/ana.24754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24754</ArticleId><ArticleId IdType="pubmed">27490250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Autosomal-dominant Alzheimer&#x2019;s disease: a review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2011;3:1. doi: 10.1186/alzrt59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt59</ArticleId><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009;66:1469&#x2013;1475. doi: 10.1001/archneurol.2009.269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.269</ArticleId><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer&#x2019;s disease. Biochem. Biophys. Acta. 2012;1822:370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264790</ArticleId><ArticleId IdType="pubmed">22108203</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann. Neurol. 2016;80:379&#x2013;387. doi: 10.1002/ana.24719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24719</ArticleId><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer&#x2019;s disease. Nat. Neurosci. 2010;13:411&#x2013;413. doi: 10.1038/nn.2511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2511</ArticleId><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="pubmed">20305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer&#x2019;s disease. Nat. Neurosci. 2018;21:941&#x2013;951. doi: 10.1038/s41593-018-0175-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0175-4</ArticleId><ArticleId IdType="pmc">PMC6800152</ArticleId><ArticleId IdType="pubmed">29950669</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann, B. L. et al. LC3-Associated Endocytosis Facilitates beta-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer&#x2019;s Disease. Cell (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689199</ArticleId><ArticleId IdType="pubmed">31257024</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraldo M, et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer&#x2019;s disease. Neurobiol. Aging. 2013;34:2077.e11&#x2013;8. doi: 10.1016/j.neurobiolaging.2013.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.02.016</ArticleId><ArticleId IdType="pmc">PMC3830921</ArticleId><ArticleId IdType="pubmed">23582655</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez Murcia JD, et al. Assessment of TREM2 rs75932628 association with Alzheimer&#x2019;s disease in a population-based sample: the Cache County Study. Neurobiol. Aging. 2013;34:2889.e11&#x2013;3. doi: 10.1016/j.neurobiolaging.2013.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.06.004</ArticleId><ArticleId IdType="pmc">PMC3779500</ArticleId><ArticleId IdType="pubmed">23855982</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussos P, et al. The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer&#x2019;s dementia. Alzheimers Dement. 2015;11:1163&#x2013;1170. doi: 10.1016/j.jalz.2014.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.10.013</ArticleId><ArticleId IdType="pmc">PMC4461564</ArticleId><ArticleId IdType="pubmed">25499537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 2014;9:20. doi: 10.1186/1750-1326-9-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C, et al. Microglia-derived ASC specks cross-seed amyloid-&#x3b2; in Alzheimer&#x2019;s disease. Nature. 2017;552:355&#x2013;361. doi: 10.1038/nature25158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25158</ArticleId><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik SH, Kang S, Son SM, Mook-Jung I. Microglia contributes to plaque growth by cell death due to uptake of amyloid beta in the brain of Alzheimer&#x2019;s disease mouse model. Glia. 2016;64:2274&#x2013;2290. doi: 10.1002/glia.23074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23074</ArticleId><ArticleId IdType="pubmed">27658617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer&#x2019;s amyloid beta-peptide by microglial cells. J. Biol. Chem. 1999;274:32301&#x2013;32308. doi: 10.1074/jbc.274.45.32301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.45.32301</ArticleId><ArticleId IdType="pubmed">10542270</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, Z., Taylor, J. M. &amp; Crack, P. J. The involvement of microglia in Alzheimer&#x2019;s disease: a new dog in the fight. Br. J. Pharmacol. (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715787</ArticleId><ArticleId IdType="pubmed">30445661</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap WD, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 2015;373:428&#x2013;437. doi: 10.1056/NEJMoa1411366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1411366</ArticleId><ArticleId IdType="pubmed">26222558</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of alzheimer&#x2019;s disease with plaques and tangles. Neuron. 2003;39:409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Khashwji H, Estrada T, Laferla FM. ST101 induces a novel 17 kDa APP cleavage that precludes Abeta generation in vivo. Ann. Neurol. 2011;69:831&#x2013;844. doi: 10.1002/ana.22325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22325</ArticleId><ArticleId IdType="pubmed">21416488</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41:e108. doi: 10.1093/nar/gkt214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt214</ArticleId><ArticleId IdType="pmc">PMC3664803</ArticleId><ArticleId IdType="pubmed">23558742</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: The R Foundation for Statistical Computing; 2017.</Citation></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140. doi: 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31442405</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Loss of Ataxin-1 Potentiates Alzheimer's Pathogenesis by Elevating Cerebral BACE1 Transcription.</ArticleTitle><Pagination><StartPage>1159</StartPage><EndPage>1175.e17</EndPage><MedlinePgn>1159-1175.e17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2019.07.043</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(19)30843-8</ELocationID><Abstract><AbstractText>Expansion of CAG trinucleotide repeats in ATXN1 causes spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disease that impairs coordination and cognition. While ATXN1 is associated with increased Alzheimer's disease (AD) risk, CAG repeat number in AD patients is not changed. Here, we investigated the consequences of ataxin-1 loss of function and discovered that knockout of Atxn1 reduced CIC-ETV4/5-mediated inhibition of Bace1 transcription, leading to increased BACE1 levels and enhanced amyloidogenic cleavage of APP, selectively in AD-vulnerable brain regions. Elevated BACE1 expression exacerbated A&#x3b2; deposition and gliosis in AD mouse models and impaired hippocampal neurogenesis and olfactory axonal targeting. In&#xa0;SCA1 mice, polyglutamine-expanded mutant ataxin-1 led to the increase of BACE1 post-transcriptionally, both in cerebrum and cerebellum, and caused axonal-targeting deficit and neurodegeneration in the hippocampal CA2 region. These findings suggest that loss of ataxin-1 elevates BACE1 expression and A&#x3b2; pathology, rendering it a potential contributor to AD risk and pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Jaehong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. Electronic address: suh.jaehong@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitschke</LastName><ForeName>Larissa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Integrative Molecular and Biomedical Sciences Graduate Program, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrick</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiMarzio</LastName><ForeName>Britt A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzhala</LastName><ForeName>Volodymyr</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Jun-Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oram</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yuejiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooli</LastName><ForeName>Basavaraj</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullin</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gennarino</LastName><ForeName>Vincenzo A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasco</LastName><ForeName>Wilma</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmahmann</LastName><ForeName>Jeremy D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Ataxia Unit, Cognitive Behavioral Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albers</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoghbi</LastName><ForeName>Huda Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Integrative Molecular and Biomedical Sciences Graduate Program, Baylor College of Medicine, Houston, TX 77030, USA; Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: hzoghbi@bcm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute of Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. Electronic address: tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041856</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD083092</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056775</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS027699</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067696">Ataxin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540571">Etv4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C513242">Etv5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050783">Proto-Oncogene Proteins c-ets</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067696" MajorTopicYN="N">Ataxin-1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056651" MajorTopicYN="N">CA2 Region, Hippocampal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050783" MajorTopicYN="N">Proto-Oncogene Proteins c-ets</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018911" MajorTopicYN="N">Trinucleotide Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">BACE1</Keyword><Keyword MajorTopicYN="N">CA2</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">ataxin-1</Keyword><Keyword MajorTopicYN="N">axonal targeting</Keyword><Keyword MajorTopicYN="N">hippocampal neurogenesis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">spinocerebellar ataxia type 1</Keyword></KeywordList><CoiStatement>DECLARATION OF INTERESTS. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31442405</ArticleId><ArticleId IdType="mid">NIHMS1536061</ArticleId><ArticleId IdType="pmc">PMC6726125</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.07.043</ArticleId><ArticleId IdType="pii">S0092-8674(19)30843-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asher M, Johnson A, Zecevic B, Pease D, and Cvetanovic M (2016). Ataxin-1 regulates proliferation of hippocampal neural precursors. Neuroscience 322, 54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">26876606</ArticleId></ArticleIdList></Reference><Reference><Citation>Barao S, Gartner A, Leyva-Diaz E, Demyanenko G, Munck S, Vanhoutvin T, Zhou L, Schachner M, Lopez-Bendito G, Maness PF, et al. (2015). Antagonistic Effects of BACE1 and APH1B-gamma-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse. Cell Rep 12, 1367&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820248</ArticleId><ArticleId IdType="pubmed">26299962</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnea G, O'Donnell S, Mancia F, Sun X, Nemes A, Mendelsohn M, and Axel R (2004). Odorant receptors on axon termini in the brain. Science 304, 1468.</Citation><ArticleIdList><ArticleId IdType="pubmed">15178793</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, et al. (2008). Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 83, 623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, and Tanzi RE (2012). The genetics of Alzheimer's disease. Prog Mol Biol Transl Sci 107, 79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Van Miegroet H, Gil A, Engelborghs S, De Deyn PP, Vandenberghe R, Van Broeckhoven C, and Sleegers K (2010). Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association. J Alzheimers Dis 19, 1169&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">20308783</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, et al. (2003). Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet 12, 23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Fulmore CA, Tartt AN, Simeon LR, Pavlova I, Poposka V, Rosoklija GB, Stankov A, Arango V, Dwork AJ, et al. (2018). Human Hippocampal Neurogenesis Persists throughout Aging. Cell Stem Cell 22, 589&#x2013;599 e585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5957089</ArticleId><ArticleId IdType="pubmed">29625071</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K, Bosch S, Globas C, Zuhlke C, Daum I, Klockgether T, and Dichgans J (2001). Executive dysfunction in spinocerebellar ataxia type 1. Eur Neurol 46, 43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11455183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, and Wong PC (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4, 233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Caille I, Allinquant B, Dupont E, Bouillot C, Langer A, Muller U, and Prochiantz A (2004). Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131, 2173&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, and Albers MW (2012a). The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep 2, 231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262176</ArticleId><ArticleId IdType="pubmed">22355745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC, Levites Y, Edwards SR, Golde TE, et al. (2012b). Abeta alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nat Commun 3, 1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529477</ArticleId><ArticleId IdType="pubmed">22910355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatila ZK, Kim E, Berle C, Bylykbashi E, Rompala A, Oram MK, Gupta D, Kwak SS, Kim YH, Kim DY, et al. (2018). BACE1 Regulates Proliferation and Neuronal Differentiation of Newborn Cells in the Adult Hippocampus in Mice. eNeuro 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6073981</ArticleId><ArticleId IdType="pubmed">30079376</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespo-Barreto J, Fryer JD, Shaw CA, Orr HT, and Zoghbi HY (2010). Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet 6, e1001021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900305</ArticleId><ArticleId IdType="pubmed">20628574</ArticleId></ArticleIdList></Reference><Reference><Citation>Culjkovic B, Stojkovic O, Savic D, Zamurovic N, Nesic M, Major T, Keckarevi D, Romac S, Zamurovi B, and Vukosavic S (2000). Comparison of the number of triplets in SCA1, MJD/SCA3, HD, SBMA, DRPLA, MD, FRAXA and FRDA genes in schizophrenic patients and a healthy population. Am J Med Genet 96, 884&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cvetanovic M, Hu YS, and Opal P (2017). Mutant Ataxin-1 Inhibits Neural Progenitor Cell Proliferation in SCA1. Cerebellum 16, 340&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510931</ArticleId><ArticleId IdType="pubmed">27306906</ArticleId></ArticleIdList></Reference><Reference><Citation>Demars MP, Hollands C, Zhao Kda T, and Lazarov O (2013). Soluble amyloid precursor protein-alpha rescues age-linked decline in neural progenitor cell proliferation. Neurobiol Aging 34, 2431&#x2013;2440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706568</ArticleId><ArticleId IdType="pubmed">23683827</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Lee S, Manly J, Andrews H, Schupf N, Doty RL, Stern Y, Zahodne LB, Louis ED, and Mayeux R (2015). Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology 84, 182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336090</ArticleId><ArticleId IdType="pubmed">25471394</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhilla Albers A, Asafu-Adjei J, Delaney MK, Kelly KE, Gomez-Isla T, Blacker D, Johnson KA, Sperling RA, Hyman BT, Betensky RA, et al. (2016). Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Ann Neurol 80, 846&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5177522</ArticleId><ArticleId IdType="pubmed">27696605</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzhala VI, and Staley KJ (2003). Excitatory actions of endogenously released GABA contribute to initiation of ictal epileptiform activity in the developing hippocampus. J Neurosci 23, 1840&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741948</ArticleId><ArticleId IdType="pubmed">12629188</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fancellu R, Paridi D, Tomasello C, Panzeri M, Castaldo A, Genitrini S, Soliveri P, and Girotti F (2013). Longitudinal study of cognitive and psychiatric functions in spinocerebellar ataxia types 1 and 2. J Neurol 260, 3134&#x2013;3143.</Citation><ArticleIdList><ArticleId IdType="pubmed">24122064</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann A, Shykind BM, Sosulski DL, Franks KM, Glinka ME, Mei DF, Sun Y, Kirkland J, Mendelsohn M, Albers MW, et al. (2008). Mice with a "monoclonal nose": perturbations in an olfactory map impair odor discrimination. Neuron 60, 1068&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732586</ArticleId><ArticleId IdType="pubmed">19109912</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Yu P, Kang H, Mandel-Brehm C, Carter AN, Crespo-Barreto J, Gao Y, Flora A, Shaw C, Orr HT, et al. (2011). Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science 334, 690&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232424</ArticleId><ArticleId IdType="pubmed">22053053</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, and Pedersen NL (2006). Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63, 168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. (2013). TREM2 variants in Alzheimer's disease. N Engl J Med 368, 117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, and Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, and Vassar R (2012). beta-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem 287, 38408&#x2013;38425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493884</ArticleId><ArticleId IdType="pubmed">22988240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitti FL, and Siegelbaum SA (2014). The hippocampal CA2 region is essential for social memory. Nature 508, 88&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000264</ArticleId><ArticleId IdType="pubmed">24572357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli BV, Kovacs-Vajna ZM, Mullin K, Blumenthal MA, Mattheisen M, Zhang C, Lange C, Mohapatra G, Bertram L, and Tanzi RE (2014). Rare autosomal copy number variations in early-onset familial Alzheimer's disease. Mol Psychiatry 19, 676&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">23752245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, He W, Luo X, Tsubota KE, and Yan R (2013). BACE1 regulates hippocampal astrogenesis via the Jagged1-Notch pathway. Cell Rep 4, 40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740554</ArticleId><ArticleId IdType="pubmed">23831026</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jodice C, Malaspina P, Persichetti F, Novelletto A, Spadaro M, Giunti P, Morocutti C, Terrenato L, Harding AE, and Frontali M (1994). Effect of trinucleotide repeat length and parental sex on phenotypic variation in spinocerebellar ataxia I. Am J Hum Genet 54, 959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1918191</ArticleId><ArticleId IdType="pubmed">8198139</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjomsson S, Huttenlocher J, Levey AI, Lah JJ, et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368, 107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju H, Kokubu H, and Lim J (2014). Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1. Mol Neurobiol 50, 866&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821199</ArticleId><ArticleId IdType="pubmed">24752589</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, and De Strooper B (2016). The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 139 Suppl 2, 237&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">27255958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai Y, Suenaga M, Watanabe H, and Sobue G (2009). Cognitive impairment in spinocerebellar degeneration. Eur Neurol 61, 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">19295212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura-Saito M, Yamazaki Y, Kaneko K, Kawaguchi N, Kanda H, Mukai H, Gotoh T, Motoi T, Fukayama M, Aburatani H, et al. (2006). Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet 15, 2125&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717057</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, Horvat V, Volk B, and Kempermann G (2010). Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS One 5, e8809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813284</ArticleId><ArticleId IdType="pubmed">20126454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohara K, Pignatelli M, Rivest AJ, Jung HY, Kitamura T, Suh J, Frank D, Kajikawa K, Mise N, Obata Y, et al. (2014). Cell type-specific genetic and optogenetic tools reveal hippocampal CA2 circuits. Nat Neurosci 17, 269&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004172</ArticleId><ArticleId IdType="pubmed">24336151</ArticleId></ArticleIdList></Reference><Reference><Citation>Koziol LF, Budding D, Andreasen N, D'Arrigo S, Bulgheroni S, Imamizu H, Ito M, Manto M, Marvel C, Parker K, et al. (2014). Consensus paper: the cerebellum's role in movement and cognition. Cerebellum 13, 151&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089997</ArticleId><ArticleId IdType="pubmed">23996631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, Fryer JD, Hyun ED, Duvick LA, Orr HT, Botas J, et al. (2006). ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127, 1335&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Fryer JD, Kang H, Crespo-Barreto J, Bowman AB, Gao Y, Kahle JJ, Hong JS, Kheradmand F, Orr HT, et al. (2011). ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveolarization. Dev Cell 21, 746&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253850</ArticleId><ArticleId IdType="pubmed">22014525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YI, Li Y, Mikesh M, Smith I, Nave KA, Schwab MH, and Thompson WJ (2016). Neuregulin1 displayed on motor axons regulates terminal Schwann cell-mediated synapse elimination at developing neuromuscular junctions. Proc Natl Acad Sci U S A 113, E479&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743767</ArticleId><ArticleId IdType="pubmed">26755586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr HT, and Zoghbi HY (2008). Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452, 713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377396</ArticleId><ArticleId IdType="pubmed">18337722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo RY, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai VG, Ying S, et al. (2016). Depression and clinical progression in spinocerebellar ataxias. Parkinsonism Relat Disord 22, 87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4695274</ArticleId><ArticleId IdType="pubmed">26644294</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. (2001). Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4, 231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Wu Y, Qiu Q, Scheerer H, Moran A, and Yu CR (2014). A developmental switch of axon targeting in the continuously regenerating mouse olfactory system. Science 344, 194&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">24723610</ArticleId></ArticleIdList></Reference><Reference><Citation>Manto M, and Marien P (2015). Schmahmann's syndrome - identification of the third cornerstone of clinical ataxiology. Cerebellum Ataxias 2, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552302</ArticleId><ArticleId IdType="pubmed">26331045</ArticleId></ArticleIdList></Reference><Reference><Citation>Matilla A, Roberson ED, Banff S, Morales J, Armstrong DL, Burright EN, Orr HT, Sweatt JD, Zoghbi HY, and Matzuk MM (1998). Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J Neurosci 18, 5508&#x2013;5516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793485</ArticleId><ArticleId IdType="pubmed">9651231</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jimenez EP, Flor-Garcia M, Terreros-Roncal J, Rabano A, Cafini F, Pallas-Bazarra N, Avila J, and Llorens-Martin M (2019). Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer's disease. Nat Med 25, 554&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriarty A, Cook A, Hunt H, Adams ME, Cipolotti L, and Giunti P (2016). A longitudinal investigation into cognition and disease progression in spinocerebellar ataxia types 1, 2, 3, 6, and 7. Orphanet J Rare Dis 11, 82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4917932</ArticleId><ArticleId IdType="pubmed">27333979</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, Chung MY, Banfi S, Kwiatkowski TJ Jr., Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, and Zoghbi HY (1993). Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4, 221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8358429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou-Yang MH, Kurz JE, Nomura T, Popovic J, Rajapaksha TW, Dong H, Contractor A, Chetkovich DM, Tourtellotte WG, and Vassar R (2018). Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Sci Transl Med 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11017370</ArticleId><ArticleId IdType="pubmed">30232227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, Legallic S, Paquet C, Bombois S, Pariente J, et al. (2012). High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry.</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Prox J, Bernreuther C, Altmeppen H, Grendel J, Glatzel M, D'Hooge R, Stroobants S, Ahmed T, Balschun D, Willem M, et al. (2013). Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions. J Neurosci 33, 12915&#x2013;12928, 12928a.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619719</ArticleId><ArticleId IdType="pubmed">23926248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajapaksha TW, Eimer WA, Bozza TC, and Vassar R (2011). The Alzheimer's beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol Neurodegener 6, 88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269394</ArticleId><ArticleId IdType="pubmed">22204380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux MWC, Tschumperlin T, Lu HC, Lackey EP, Bondar VV, Wan YW, Tan Q, Adamski CJ, Friedrich J, Twaroski K, et al. (2018). ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism. Neuron 97, 1235&#x2013;1243 e1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422678</ArticleId><ArticleId IdType="pubmed">29526553</ArticleId></ArticleIdList></Reference><Reference><Citation>Rub U, Burk K, Timmann D, den Dunnen W, Seidel K, Farrag K, Brunt E, Heinsen H, Egensperger R, Bornemann A, et al. (2012). Spinocerebellar ataxia type 1 (SCA1): new pathoanatomical and clinico-pathological insights. Neuropathol Appl Neurobiol 38, 665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">22309224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir KR, Eimer WA, Cole SL, and Vassar R (2015). Abeta reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener 10, 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297413</ArticleId><ArticleId IdType="pubmed">25567526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakano H (2010). Neural map formation in the mouse olfactory system. Neuron 67, 530&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">20797531</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer S, Wirths O, Multhaup G, and Bayer TA (2007). Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm (Vienna) 114, 387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17075721</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmahmann JD, and Sherman JC (1998). The cerebellar cognitive affective syndrome. Brain 121 (Pt 4), 561&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">9577385</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AS, Williams Avram SK, Cymerblit-Sabba A, Song J, and Young WS (2016). Targeted activation of the hippocampal CA2 area strongly enhances social memory. Mol Psychiatry 21, 1137&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4935650</ArticleId><ArticleId IdType="pubmed">26728562</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, et al. (2013). Dynamics of hippocampal neurogenesis in adult humans. Cell 153, 1219&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S, Stefansson H, Jonsson T, Johannsdottir H, Ingason A, Helgason H, Sulem P, Magnusson OT, Gudjonsson SA, Unnsteinsdottir U, et al. (2015). Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet 47, 445&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, and Tanzi RE (2013). ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron 80, 385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105199</ArticleId><ArticleId IdType="pubmed">24055016</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh J, Lyckman A, Wang L, Eckman EA, and Guenette SY (2011). FE65 proteins regulate NMDA receptor activation-induced amyloid precursor protein processing. J Neurochem 119, 377&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188680</ArticleId><ArticleId IdType="pubmed">21824144</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, Kim S, Shen L, Risacher SL, Foroud T, Pankratz N, Potkin SG, Huentelman MJ, Craig DW, Weiner MW, et al. (2011). Genomic Copy Number Analysis in Alzheimer's Disease and Mild Cognitive Impairment: An ADNI Study. Int J Alzheimers Dis 2011, 729478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109875</ArticleId><ArticleId IdType="pubmed">21660214</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, Shen L, Kim S, Inlow M, West JD, Faber KM, Foroud T, Mayeux R, and Saykin AJ (2012). Analysis of copy number variation in Alzheimer's disease: the NIALOAD/NCRAD Family Study. Curr Alzheimer Res 9, 801&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500615</ArticleId><ArticleId IdType="pubmed">22486522</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE (2012). The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Krall EB, Aguirre AJ, Kim M, Widlund HR, Doshi MB, Sicinska E, Sulahian R, Goodale A, Cowley GS, et al. (2017). ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Rep 18, 1543&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5313047</ArticleId><ArticleId IdType="pubmed">28178529</ArticleId></ArticleIdList></Reference><Reference><Citation>Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, Kano M, Atkinson R, Sun Y, Armstrong DL, et al. (2002). A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086639</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y, Meng S, Wang J, Li S, Liu J, Li H, Li T, Song W, and Zhou W (2014). Two novel DNA motifs are essential for BACE1 gene transcription. Sci Rep 4, 6864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4215305</ArticleId><ArticleId IdType="pubmed">25359283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153, 707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi HY, and Orr HT (2000). Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23, 217&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi HY, and Orr HT (2009). Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem 284, 7425&#x2013;7429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2658037</ArticleId><ArticleId IdType="pubmed">18957430</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31451782</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population.</ArticleTitle><Pagination><StartPage>1364</StartPage><EndPage>1369</EndPage><MedlinePgn>1364-1369</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-019-0547-7</ELocationID><Abstract><AbstractText>The exact etiology of dementia is still unclear, but both genetic and lifestyle factors are thought to be key drivers of this complex disease. The recognition of familial patterns of dementia has led to the discovery of genetic factors that have a role in the pathogenesis of dementia, including the apolipoprotein E (APOE) genotype and a large and still-growing number of genetic variants<sup>1,2</sup>. Beyond genetic architecture, several modifiable risk factors have been implicated in the development of dementia<sup>3</sup>. Prevention trials of measures to halt or delay cognitive decline are increasingly recruiting older individuals who are genetically predisposed to dementia. However, it remains unclear whether targeted health and lifestyle interventions can attenuate or even offset increased genetic risk. Here, we leverage long-term data on both genetic and modifiable risk factors from 6,352 individuals aged 55 years and older in the population-based Rotterdam Study. In this study, we demonstrate that, in individuals at low and intermediate genetic risk, favorable modifiable-risk profiles are related to a lower risk of dementia compared to unfavorable profiles. In contrast, these protective associations were not found in those at high genetic risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Licher</LastName><ForeName>Silvan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4586-4035</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands. s.licher@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karamuji&#x107;-&#x10c;omi&#x107;</LastName><ForeName>Hata</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voortman</LastName><ForeName>Trudy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leening</LastName><ForeName>Maarten J G</ForeName><Initials>MJG</Initials><Identifier Source="ORCID">0000-0002-4143-4839</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Kamran</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-0173-9571</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands. m.ikram@erasmusmc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands. m.ikram@erasmusmc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>678543</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Oct;15(10):560. doi: 10.1038/s41582-019-0266-1.</RefSource><PMID Version="1">31506591</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing Interests Statement</b>
. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31451782</ArticleId><ArticleId IdType="mid">EMS83726</ArticleId><ArticleId IdType="pmc">PMC6739225</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0547-7</ArticleId><ArticleId IdType="pii">10.1038/s41591-019-0547-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van der Lee SJ, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17:434&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">29555425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruijn RF, et al. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Med. 2015;13:132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4509699</ArticleId><ArticleId IdType="pubmed">26195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">25771249</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrieu S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;6:377&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">28359749</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll van Charante EP, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">27474376</ArticleId></ArticleIdList></Reference><Reference><Citation>Licher S, et al. Development and validation of a dementia risk prediction model in the general population: an analysis of three longitudinal studies. Am J Psychiatry. 2019;176(7):543&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">30525906</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bras J, Hardy J. SnapShot: genetics of Alzheimer's disease. Cell. 2013;155:968&#x2013;968 e961.</Citation><ArticleIdList><ArticleId IdType="pubmed">24209629</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A, et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 2018;75(4):462&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885273</ArticleId><ArticleId IdType="pubmed">29356827</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgart M, et al. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 2015;11:718&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">26045020</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673&#x2013;2734.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, et al. Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis. BMJ Open. 2019;9:e022846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6352772</ArticleId><ArticleId IdType="pubmed">30782689</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, et al. Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10128614</ArticleId><ArticleId IdType="pubmed">30421454</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization, W.H. Risk reduction of cognitive decline and dementia: WHO guidelines. WHO; Geneva: 2019. Vol. CC BY-NC-SA 3.0 IGO.</Citation><ArticleIdList><ArticleId IdType="pubmed">31219687</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy RM, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788299</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovio S, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005;4:705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Anttila T, et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ. 2004;329:539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516103</ArticleId><ArticleId IdType="pubmed">15304383</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen MH, et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement Geriatr Cogn Disord. 2006;22:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">16710090</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson IK, et al. Apolipoprotein E epsilon4 genotype and the temporal relationship between depression and dementia. Neurobiol Aging. 2015;36:1751&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380668</ArticleId><ArticleId IdType="pubmed">25670333</ArticleId></ArticleIdList></Reference><Reference><Citation>Podewils LJ, et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol. 2005;161:639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781953</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang TL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology. 2005;65:1409&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275829</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberger-Gateau P, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology. 2007;69:1921&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998483</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. J Am Geriatr Soc. 2004;52:540&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066068</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchant C, et al. The influence of smoking on the risk of Alzheimer's disease. Neurology. 1999;52:1408&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet. 1998;351:1840&#x2013;1843.</Citation><ArticleIdList><ArticleId IdType="pubmed">9652667</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay J, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, et al. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ. 2010;341:c3885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917002</ArticleId><ArticleId IdType="pubmed">20688841</ArticleId></ArticleIdList></Reference><Reference><Citation>Samieri C, et al. Association of cardiovascular health level in older age with cognitive decline and incident dementia. JAMA. 2018;320:657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142948</ArticleId><ArticleId IdType="pubmed">30140876</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med. 2008;12:2762&#x2013;2771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828889</ArticleId><ArticleId IdType="pubmed">18318693</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera AV, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375:2349&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338864</ArticleId><ArticleId IdType="pubmed">27959714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutten-Jacobs LC, et al. Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK Biobank participants. BMJ. 2018;363:k4168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199557</ArticleId><ArticleId IdType="pubmed">30355576</ArticleId></ArticleIdList></Reference><Reference><Citation>Voortman T, et al. Adherence to the 2015 Dutch dietary guidelines and risk of non-communicable diseases and mortality in the Rotterdam Study. Eur J Epidemiol. 2017;32:993&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684301</ArticleId><ArticleId IdType="pubmed">28825166</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig CL, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">12900694</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, et al. Gray matter maturation and cognition in children with different APOE epsilon genotypes. Neurology. 2016;87:585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977368</ArticleId><ArticleId IdType="pubmed">27412137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ornish D, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">1973470</ArticleId></ArticleIdList></Reference><Reference><Citation>Licher S, et al. Lifetime risk and multimorbidity of non-communicable diseases and disease-free life expectancy in the general population: A population-based cohort study. PLoS Med. 2019;16:e1002741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361416</ArticleId><ArticleId IdType="pubmed">30716101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016:CD003160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9346344</ArticleId><ArticleId IdType="pubmed">26727124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram MA, et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol. 2017;32:807&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662692</ArticleId><ArticleId IdType="pubmed">29064009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31481790</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Microtubules gate tau condensation to spatially regulate microtubule functions.</ArticleTitle><Pagination><StartPage>1078</StartPage><EndPage>1085</EndPage><MedlinePgn>1078-1085</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41556-019-0375-5</ELocationID><Abstract><AbstractText>Tau is an abundant microtubule-associated protein in neurons. Tau aggregation into insoluble fibrils is a hallmark of Alzheimer's disease and other types of dementia<sup>1</sup>, yet the physiological state of tau molecules within cells remains unclear. Using single-molecule imaging, we directly observe that the microtubule lattice regulates reversible tau self-association, leading to localized, dynamic condensation of tau molecules on the microtubule surface. Tau condensates form selectively permissible barriers, spatially regulating the activity of microtubule-severing enzymes and the movement of molecular motors through their boundaries. We propose that reversible self-association of tau molecules, gated by the microtubule lattice, is an important mechanism of the biological functions of tau, and that oligomerization of tau is a common property shared between the physiological and disease-associated forms of the molecule.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ruensern</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Aileen J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Tracy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jisoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Human Anatomy, School of Medicine, University of California, Davis, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowakowski</LastName><ForeName>Dan W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>N Molecular Systems, Inc., Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vershinin</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physics &amp; Astronomy, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sim&#xf3;</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8344-0313</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology and Human Anatomy, School of Medicine, University of California, Davis, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ori-McKenney</LastName><ForeName>Kassandra M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-2051-2495</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA, USA. kmorimckenney@ucdavis.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenney</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-8423-0852</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, University of California, Davis, Davis, CA, USA. rjmckenney@ucdavis.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM133688</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 HD080981</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS109176</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM124889</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS089428</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.3</RegistryNumber><NameOfSubstance UI="D000074181">Spastin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074181" MajorTopicYN="N">Spastin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Interests. Authors declare no financial and non-financial competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31481790</ArticleId><ArticleId IdType="mid">NIHMS1535155</ArticleId><ArticleId IdType="pmc">PMC6748660</ArticleId><ArticleId IdType="doi">10.1038/s41556-019-0375-5</ArticleId><ArticleId IdType="pii">10.1038/s41556-019-0375-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Eisenberg DS &amp; Crowther RA Propagation of Tau Aggregates and Neurodegeneration. Annu Rev Neurosci 40, 189&#x2013;210, doi:10.1146/annurev-neuro-072116-031153 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031153</ArticleId><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapitein LC &amp; Hoogenraad CC Building the Neuronal Microtubule Cytoskeleton. Neuron 87, 492&#x2013;506, doi:10.1016/j.neuron.2015.05.046 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.05.046</ArticleId><ArticleId IdType="pubmed">26247859</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XH &amp; Rhoades E Heterogeneous Tau-Tubulin Complexes Accelerate Microtubule Polymerization. Biophys J 112, 2567&#x2013;2574, doi:10.1016/j.bpj.2017.05.006 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2017.05.006</ArticleId><ArticleId IdType="pmc">PMC5479049</ArticleId><ArticleId IdType="pubmed">28636913</ArticleId></ArticleIdList></Reference><Reference><Citation>Makrides V et al. Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J Biol Chem 278, 33298&#x2013;33304, doi:10.1074/jbc.M305207200 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M305207200</ArticleId><ArticleId IdType="pubmed">12805366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Bennett RE, Amaral AS &amp; Hyman BT Studying tau protein propagation and pathology in the mouse brain using adeno-associated viruses. Methods Cell Biol 141, 307&#x2013;322, doi:10.1016/bs.mcb.2017.06.014 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.mcb.2017.06.014</ArticleId><ArticleId IdType="pubmed">28882310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Vega A et al. Local Nucleation of Microtubule Bundles through Tubulin Concentration into a Condensed Tau Phase. Cell reports 20, 2304&#x2013;2312, doi:10.1016/j.celrep.2017.08.042 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.042</ArticleId><ArticleId IdType="pmc">PMC5828996</ArticleId><ArticleId IdType="pubmed">28877466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambadipudi S, Biernat J, Riedel D, Mandelkow E &amp; Zweckstetter M Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. Nature communications 8, 275, doi:10.1038/s41467-017-00480-0 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00480-0</ArticleId><ArticleId IdType="pmc">PMC5561136</ArticleId><ArticleId IdType="pubmed">28819146</ArticleId></ArticleIdList></Reference><Reference><Citation>McVicker DP, Hoeprich GJ, Thompson AR &amp; Berger CL Tau interconverts between diffusive and stable populations on the microtubule surface in an isoform and lattice specific manner. Cytoskeleton 71, 184&#x2013;194, doi:10.1002/cm.21163 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cm.21163</ArticleId><ArticleId IdType="pmc">PMC4154625</ArticleId><ArticleId IdType="pubmed">24520046</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R, Ross JL, Goldman YE &amp; Holzbaur EL Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086&#x2013;1089 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs MH et al. Tau protein diffuses along the microtubule lattice. J Biol Chem 287, 38559&#x2013;38568, doi:10.1074/jbc.M112.369785 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.369785</ArticleId><ArticleId IdType="pmc">PMC3493901</ArticleId><ArticleId IdType="pubmed">23019339</ArticleId></ArticleIdList></Reference><Reference><Citation>Vershinin M, Carter BC, Razafsky DS, King SJ &amp; Gross SP Multiple-motor based transport and its regulation by Tau. Proc Natl Acad Sci U S A 104, 87&#x2013;92 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1765483</ArticleId><ArticleId IdType="pubmed">17190808</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy BY et al. Competition between microtubule-associated proteins directs motor transport. Nature communications 9, 1487, doi:10.1038/s41467-018-03909-2 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03909-2</ArticleId><ArticleId IdType="pmc">PMC5902456</ArticleId><ArticleId IdType="pubmed">29662074</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz A et al. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J 21, 4896&#x2013;4905 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126299</ArticleId><ArticleId IdType="pubmed">12234929</ArticleId></ArticleIdList></Reference><Reference><Citation>Vershinin M, Xu J, Razafsky DS, King SJ &amp; Gross SP Tuning microtubule-based transport through filamentous MAPs: the problem of dynein. Traffic 9, 882&#x2013;892 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958055</ArticleId><ArticleId IdType="pubmed">18373727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale RD Severing of stable microtubules by a mitotically activated protein in Xenopus egg extracts. Cell 64, 827&#x2013;839 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1671762</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang L, Yu W, Andreadis A, Luo M &amp; Baas PW Tau protects microtubules in the axon from severing by katanin. J Neurosci 26, 3120&#x2013;3129, doi:10.1523/JNEUROSCI.5392-05.2006 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5392-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674103</ArticleId><ArticleId IdType="pubmed">16554463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W et al. The microtubule-severing proteins spastin and katanin participate differently in the formation of axonal branches. Mol Biol Cell 19, 1485&#x2013;1498, doi:10.1091/mbc.E07-09-0878 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E07-09-0878</ArticleId><ArticleId IdType="pmc">PMC2291400</ArticleId><ArticleId IdType="pubmed">18234839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H &amp; Mandelkow EM Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia. Mol Neurodegener 10, 68, doi:10.1186/s13024-015-0064-1 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0064-1</ArticleId><ArticleId IdType="pmc">PMC4687341</ArticleId><ArticleId IdType="pubmed">26691836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger A, van Haren J, Ribeiro SA &amp; Wittmann T Doublecortin Is Excluded from Growing Microtubule Ends and Recognizes the GDP-Microtubule Lattice. Curr Biol 26, 1549&#x2013;1555, doi:10.1016/j.cub.2016.04.020 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2016.04.020</ArticleId><ArticleId IdType="pmc">PMC5023073</ArticleId><ArticleId IdType="pubmed">27238282</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan AR et al. Interactions between Tau and Different Conformations of Tubulin: Implications for Tau Function and Mechanism. J Mol Biol 429, 1424&#x2013;1438, doi:10.1016/j.jmb.2017.03.018 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2017.03.018</ArticleId><ArticleId IdType="pubmed">28322917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, LaFrance B &amp; Nogales E Separating the effects of nucleotide and EB binding on microtubule structure. Proc Natl Acad Sci U S A 115, E6191&#x2013;E6200, doi:10.1073/pnas.1802637115 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1802637115</ArticleId><ArticleId IdType="pmc">PMC6142192</ArticleId><ArticleId IdType="pubmed">29915050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellogg EH et al. Near-atomic model of microtubule-tau interactions. Science 360, 1242&#x2013;1246, doi:10.1126/science.aat1780 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat1780</ArticleId><ArticleId IdType="pmc">PMC6225777</ArticleId><ArticleId IdType="pubmed">29748322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara H, Yorifuji H, Sato-Yoshitake R &amp; Hirokawa N Competition between motor molecules (kinesin and cytoplasmic dynein) and fibrous microtubule-associated proteins in binding to microtubules. J Biol Chem 269, 3581&#x2013;3589 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8106402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S et al. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J 37, doi:10.15252/embj.201798049 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798049</ArticleId><ArticleId IdType="pmc">PMC5881631</ArticleId><ArticleId IdType="pubmed">29472250</ArticleId></ArticleIdList></Reference><Reference><Citation>Siahaan V et al. Kinetically distinct phases of tau on microtubules regulate kinesin motors and severing enzymes. Nature Cell Biology This Issue (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31481789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer A et al. Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice. J Neurosci 31, 18036&#x2013;18047, doi:10.1523/JNEUROSCI.4859-11.2011 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4859-11.2011</ArticleId><ArticleId IdType="pmc">PMC6634152</ArticleId><ArticleId IdType="pubmed">22159117</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Leon JA et al. Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein tau mutations which displays several phenotypes linked to neurodegeneration. Alzheimers Dement, doi:10.1016/j.jalz.2018.05.007 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.05.007</ArticleId><ArticleId IdType="pubmed">30036493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard KS et al. High yield derivation of enriched glutamatergic neurons from suspension-cultured mouse ESCs for neurotoxicology research. BMC Neurosci 13, 127, doi:10.1186/1471-2202-13-127 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-13-127</ArticleId><ArticleId IdType="pmc">PMC3573964</ArticleId><ArticleId IdType="pubmed">23095170</ArticleId></ArticleIdList></Reference><Reference><Citation>Konzack S, Thies E, Marx A, Mandelkow EM &amp; Mandelkow E Swimming against the tide: mobility of the microtubule-associated protein tau in neurons. J Neurosci 27, 9916&#x2013;9927, doi:10.1523/JNEUROSCI.0927-07.2007 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0927-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672630</ArticleId><ArticleId IdType="pubmed">17855606</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewidok B et al. Presence of a carboxy-terminal pseudorepeat and disease-like pseudohyperphosphorylation critically influence tau&#x2019;s interaction with microtubules in axon-like processes. Mol Biol Cell 27, 3537&#x2013;3549, doi:10.1091/mbc.E16-06-0402 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E16-06-0402</ArticleId><ArticleId IdType="pmc">PMC5221586</ArticleId><ArticleId IdType="pubmed">27582388</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenney RJ, Huynh W, Tanenbaum ME, Bhabha G &amp; Vale RD Activation of cytoplasmic dynein motility by dynactin-cargo adapter complexes. Science 345, 337&#x2013;341, doi:10.1126/science.1254198 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254198</ArticleId><ArticleId IdType="pmc">PMC4224444</ArticleId><ArticleId IdType="pubmed">25035494</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenney RJ, Huynh W, Vale RD &amp; Sirajuddin M Tyrosination of alpha-tubulin controls the initiation of processive dynein-dynactin motility. EMBO J, doi:10.15252/embj.201593071 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201593071</ArticleId><ArticleId IdType="pmc">PMC4888239</ArticleId><ArticleId IdType="pubmed">26968983</ArticleId></ArticleIdList></Reference><Reference><Citation>McVicker DP, Chrin LR &amp; Berger CL The nucleotide-binding state of microtubules modulates kinesin processivity and the ability of Tau to inhibit kinesin-mediated transport. J Biol Chem 286, 42873&#x2013;42880, doi:10.1074/jbc.M111.292987 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.292987</ArticleId><ArticleId IdType="pmc">PMC3234877</ArticleId><ArticleId IdType="pubmed">22039058</ArticleId></ArticleIdList></Reference><Reference><Citation>Urnavicius L et al. Cryo-EM shows how dynactin recruits two dyneins for faster movement. Nature 554, 202&#x2013;206, doi:10.1038/nature25462 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25462</ArticleId><ArticleId IdType="pmc">PMC5988349</ArticleId><ArticleId IdType="pubmed">29420470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez PA, Ackermann BE, Vershinin M &amp; McKenney RJ Differential effects of the dynein-regulatory factor Lissencephaly-1 on processive dynein-dynactin motility. J Biol Chem, doi:10.1074/jbc.M117.790048 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.790048</ArticleId><ArticleId IdType="pmc">PMC5519373</ArticleId><ArticleId IdType="pubmed">28576829</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumbach J et al. Lissencephaly-1 is a context-dependent regulator of the human dynein complex. Elife 6, doi:10.7554/eLife.21768 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.21768</ArticleId><ArticleId IdType="pmc">PMC5413349</ArticleId><ArticleId IdType="pubmed">28406398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ori-McKenney KM, Xu J, Gross SP &amp; Vallee RB A cytoplasmic dynein tail mutation impairs motor processivity. Nat Cell Biol 12, 1228&#x2013;1234, doi:10.1038/ncb2127 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2127</ArticleId><ArticleId IdType="pmc">PMC3385513</ArticleId><ArticleId IdType="pubmed">21102439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang HT, Schlager MA, Carter AP &amp; Bullock SL DYNC1H1 mutations associated with neurological diseases compromise processivity of dynein-dynactin-cargo adaptor complexes. Proc Natl Acad Sci U S A 114, E1597&#x2013;E1606, doi:10.1073/pnas.1620141114 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1620141114</ArticleId><ArticleId IdType="pmc">PMC5338514</ArticleId><ArticleId IdType="pubmed">28196890</ArticleId></ArticleIdList></Reference><Reference><Citation>White SR, Evans KJ, Lary J, Cole JL &amp; Lauring B Recognition of C-terminal amino acids in tubulin by pore loops in Spastin is important for microtubule severing. J Cell Biol 176, 995&#x2013;1005, doi:10.1083/jcb.200610072 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200610072</ArticleId><ArticleId IdType="pmc">PMC2064084</ArticleId><ArticleId IdType="pubmed">17389232</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper K et al. Oligomer formation of tau protein hyperphosphorylated in cells. J Biol Chem 289, 34389&#x2013;34407, doi:10.1074/jbc.M114.611368 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.611368</ArticleId><ArticleId IdType="pmc">PMC4256367</ArticleId><ArticleId IdType="pubmed">25339173</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31481789</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Kinetically distinct phases of tau on microtubules regulate kinesin motors and severing enzymes.</ArticleTitle><Pagination><StartPage>1086</StartPage><EndPage>1092</EndPage><MedlinePgn>1086-1092</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41556-019-0374-6</ELocationID><Abstract><AbstractText>Tau is an intrinsically disordered protein, which diffuses on microtubules<sup>1</sup>. In neurodegenerative diseases, collectively termed tauopathies, malfunction of tau and its detachment from axonal microtubules are correlated with axonal degeneration<sup>2</sup>. Tau can protect microtubules from microtubule-degrading enzymes such as katanin<sup>3</sup>. However, how tau carries out this regulatory function is still unclear. Here, using in vitro reconstitution, we show that tau molecules on microtubules cooperatively form cohesive islands that are kinetically distinct from tau molecules that individually diffuse on microtubules. Dependent on the tau concentration in solution, the islands reversibly grow or shrink by addition or release of tau molecules at their boundaries. Shielding microtubules from kinesin-1 motors and katanin, the islands exhibit regulatory qualities distinct from a comparably dense layer of diffusible tau. Superprocessive kinesin-8 motors penetrate the islands and cause their disassembly. Our results reveal a microtubule-dependent phase of tau that constitutes an adaptable protective layer on the microtubule surface. We anticipate that other intrinsically disordered axonal proteins display a similar cooperative behaviour and potentially compete with tau in regulating access to the microtubule surface.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Siahaan</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prague West, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Krattenmacher</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0002-0012</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prague West, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence Physics of Life, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0750-8515</Identifier><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence Physics of Life, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>B CUBE-Center for Molecular Bioengineering, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Vega</LastName><ForeName>Amayra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7558-6876</Identifier><AffiliationInfo><Affiliation>Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany. hernande@mpicbg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lansky</LastName><ForeName>Zdenek</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8474-053X</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prague West, Czech Republic. zdenek.lansky@ibt.cas.cz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2026-2238</Identifier><AffiliationInfo><Affiliation>Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prague West, Czech Republic. marcus.braun@ibt.cas.cz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>B CUBE-Center for Molecular Bioengineering, Technische Universit&#xe4;t Dresden, Dresden, Germany. marcus.braun@ibt.cas.cz.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.6.1.1</RegistryNumber><NameOfSubstance UI="D000074201">Katanin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074201" MajorTopicYN="N">Katanin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31481789</ArticleId><ArticleId IdType="doi">10.1038/s41556-019-0374-6</ArticleId><ArticleId IdType="pii">10.1038/s41556-019-0374-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hinrichs, M. H. et al. Tau protein diffuses along the microtubule lattice. J. Biol. Chem. 287, 38559&#x2013;38568 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.369785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneynsberg, A., Combs, B., Christensen, K., Morfini, G. &amp; Kanaan, N. M. Axonal degeneration in tauopathies: disease relevance and underlying mechanisms. Front. Neurosci. 11, 572 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00572</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang, L. Tau protects microtubules in the axon from severing by katanin. J. Neurosci. 26, 3120&#x2013;3129 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5392-05.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris, M., Maeda, S., Vossel, K. &amp; Mucke, L. The many faces of tau. Neuron 70, 410&#x2013;426 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.04.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, Y.-L. et al. Tau in neurodegenerative disease. Ann. Transl. Med. 6, 175&#x2013;175 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.04.23</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal, K., Liu, F. &amp; Gong, C.-X. Tau and neurodegenerative disease: the story so far. Nat. Rev. Neurol. 12, 15&#x2013;27 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.225</ArticleId></ArticleIdList></Reference><Reference><Citation>Drechsel, D. N., Hyman, A. A., Cobb, M. H. &amp; Kirschner, M. W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141&#x2013;1154 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.3.10.1141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary, A. R., Berger, F., Berger, C. L. &amp; Hendricks, A. G. Tau directs intracellular trafficking by regulating the forces exerted by kinesin and dynein teams. Traffic 19, 111&#x2013;121 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tra.12537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit, R., Ross, J. L., Goldman, Y. E. &amp; Holzbaur, E. L. F. Differential regulation of dynein and kinesin motor proteins by Tau. Science 319, 1086&#x2013;1089 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1152993</ArticleId></ArticleIdList></Reference><Reference><Citation>Vershinin, M., Carter, B. C., Razafsky, D. S., King, S. J. &amp; Gross, S. P. Multiple-motor based transport and its regulation by Tau. Proc. Natl Acad. Sci. USA 104, 87&#x2013;92 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607919104</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz, A. et al. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J. 21, 4896&#x2013;4905 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdf503</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek, B., Ebneth, A., Mandelkow, E. M. &amp; Mandelkow, E. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J. Cell Sci. 112, 2355&#x2013;2367 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10381391</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebneth, A. et al. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer&#x2019;s disease. J. Cell Biol. 143, 777&#x2013;794 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.143.3.777</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin, T. C., Berry, R. W. &amp; Binder, L. I. Tau polymerization: role of the amino terminus. Biochemistry 42, 2252&#x2013;2257 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0272510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, R. et al. Microtubules gate tau condensation to spatially regulate microtubule functions. Nat. Cell Biol. https://doi.org/10.1038/s41556-019-0375-5 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-019-0375-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Makrides, V., Massie, M. R., Feinstein, S. C. &amp; Lew, J. Evidence for two distinct binding sites for tau on microtubules. Proc. Natl Acad. Sci. USA 101, 6746&#x2013;6751 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400992101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann, S. et al. Tau protein liquid&#x2013;liquid phase separation can initiate tau aggregation. EMBO J. 37, e98049 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798049</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, R., Korten, T., Walter, W. J. &amp; Diez, S. Kinesin-1 motors can circumvent permanent roadblocks by side-shifting to neighboring protofilaments. Biophys. J. 108, 2249&#x2013;2257 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2015.03.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Telley, I. A., Bieling, P. &amp; Surrey, T. Obstacles on the microtubule reduce the processivity of Kinesin-1 in a minimal in vitro system and in cell extract. Biophys. J. 96, 3341&#x2013;3353 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2009.01.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, K. et al. Microtubule minus-end regulation at spindle poles by an ASPM&#x2013;katanin complex. Nat. Cell Biol. 19, 480&#x2013;492 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3511</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga, V., Leduc, C., Bormuth, V., Diez, S. &amp; Howard, J. Kinesin-8 motors act cooperatively to mediate length-dependent microtubule depolymerization. Cell 138, 1174&#x2013;1183 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.07.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Leduc, C. et al. Molecular crowding creates traffic jams of kinesin motors on microtubules. Proc. Natl Acad. Sci. USA 109, 6100&#x2013;6105 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1107281109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellogg, E. H. et al. Near-atomic model of microtubule&#x2013;tau interactions. Science 360, 1242&#x2013;1246 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat1780</ArticleId></ArticleIdList></Reference><Reference><Citation>McVicker, D. P., Hoeprich, G. J., Thompson, A. R. &amp; Berger, C. L. Tau interconverts between diffusive and stable populations on the microtubule surface in an isoform and lattice specific manner. Cytoskeleton 71, 184&#x2013;194 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cm.21163</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Vega, A. et al. Local nucleation of microtubule bundles through tubulin concentration into a condensed Tau phase. Cell Rep. 20, 2304&#x2013;2312 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechstedt, S. &amp; Brouhard, G. J. Doublecortin recognizes the 13-protofilament microtubule cooperatively and tracks microtubule ends. Dev. Cell 23, 181&#x2013;192 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2012.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sing, C. E., Olvera de la Cruz, M. &amp; Marko, J. F. Multiple-binding-site mechanism explains concentration-dependent unbinding rates of DNA-binding proteins. Nucleic Acids Res. 42, 3783&#x2013;3791 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansky, Z. et al. Diffusible crosslinkers generate directed forces in microtubule networks. Cell 160, 1159&#x2013;1168 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsonov, A., Yu, J.-Z., Rasenick, M. &amp; Popov, S. V. Tau interaction with microtubules in vivo. J. Cell Sci. 117, 6129&#x2013;6141 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.01531</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechstedt, S., Lu, K. &amp; Brouhard, G. J. Doublecortin recognizes the longitudinal curvature of the microtubule end and lattice. Curr. Biol. 24, 2366&#x2013;2375 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2014.08.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy, B. Y. et al. Competition between microtubule-associated proteins directs motor transport. Nat. Commun. 9, 1714 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03909-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra, A., Ruhnow, F., Girardo, S. &amp; Diez, S. Directionally biased sidestepping of Kip3/kinesin-8 is regulated by ATP waiting time and motor-microtubule interaction strength. Proc. Natl Acad. Sci. USA 115, E7950&#x2013;E7959 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1801820115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitzsche, B. et al. Studying kinesin motors by optical 3D-nanometry in gliding motility assays. Methods Cell Biol. 95, 247&#x2013;271 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-679X(10)95014-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun, M. et al. Adaptive braking by Ase1 prevents overlapping microtubules from sliding completely apart. Nat. Cell Biol. 13, 1259&#x2013;1264 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2323</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhnow, F., Zwicker, D. &amp; Diez, S. Tracking single particles and elongated filaments with nanometer precision. Biophys. J. 100, 2820&#x2013;2828 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2011.04.023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31484787</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>508</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaw1993</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaw1993</ELocationID><Abstract><AbstractText>Traumatic brain injury (TBI) can trigger progressive neurodegeneration, with tau pathology seen years after a single moderate-severe TBI. Identifying this type of posttraumatic pathology in vivo might help to understand the role of tau pathology in TBI pathophysiology. We used flortaucipir positron emission tomography (PET) to investigate whether tau pathology is present many years after a single TBI in humans. We examined PET data in relation to markers of neurodegeneration in the cerebrospinal fluid (CSF), structural magnetic resonance imaging measures, and cognitive performance. Cerebral flortaucipir binding was variable, with many participants with TBI showing increases in cortical and white matter regions. At the group level, flortaucipir binding was increased in the right occipital cortex in TBI when compared to healthy controls. Flortaucipir binding was associated with increased total tau, phosphorylated tau, and ubiquitin carboxyl-terminal hydrolase L1 CSF concentrations, as well as with reduced fractional anisotropy and white matter tissue density in TBI. Apolipoprotein E (<i>APOE</i>) &#x3b5;4 genotype affected the relationship between flortaucipir binding and time since injury, CSF &#x3b2; amyloid 1-42 (A&#x3b2;42) concentration, white matter tissue density, and longitudinal Mini-Mental State Examination scores in TBI. The results demonstrate that tau PET is a promising approach to investigating progressive neurodegeneration associated with tauopathy after TBI.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gorgoraptis</LastName><ForeName>Nikos</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2588-9235</Identifier><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lucia M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whittington</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8768-3366</Identifier><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Invicro London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Karl A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-1239-3414</Identifier><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maclean</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 0XH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLeod</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 0XH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Ewan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5983-526X</Identifier><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heslegrave</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7290-6405</Identifier><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal 431 80, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal 413 45, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passchier</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Invicro London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-1619-8328</Identifier><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunn</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0003-1181-5769</Identifier><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Invicro London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Tom M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-5278-9889</Identifier><AffiliationInfo><Affiliation>Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 0XH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0003-4995-2240</Identifier><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London W12 0NN, UK. david.sharp@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, Imperial College London, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L022141/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NIHR-RP-011-048</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C482860">UCHL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D043222">Ubiquitin Thiolesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="Y">Survivors</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043222" MajorTopicYN="N">Ubiquitin Thiolesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31484787</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaw1993</ArticleId><ArticleId IdType="pii">11/508/eaaw1993</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31492718</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>15</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial.</ArticleTitle><Pagination><StartPage>e1474</StartPage><EndPage>e1484</EndPage><MedlinePgn>e1474-e1484</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000008239</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Ladostigil reduces oxidative stress and microglial activation in aging rats. We assessed its safety and potential efficacy in a 3-year, randomized, double-blind, placebo-controlled phase 2 clinical trial in patients with mild cognitive impairment (MCI) and medial temporal lobe atrophy.</AbstractText><AbstractText Label="METHODS">Patients 55 to 85 years of age with MCI, Clinical Dementia Rating (CDR) score of 0.5, Mini-Mental State Examination (MMSE) score &gt;24, Wechsler Memory Scale-Revised Verbal Paired Associates I score &#x2264;18, and Medial Temporal Lobe Atrophy Scale score &gt;1 were stratified by <i>APOE</i> &#x3b5;4 genotype and randomly assigned (1:1) to ladostigil 10 mg/d or placebo. Primary outcomes were safety and onset of Alzheimer disease dementia. Secondary endpoints were Neuropsychological Test Battery (NTB) composite, Disability Assessment in Dementia (DAD), and Geriatric Depression Scale (GDS) scores. Exploratory outcomes were NTB component, CDR, and MMSE scores. Biomarkers included MRI-derived whole-brain, hippocampus, and entorhinal cortex volumes.</AbstractText><AbstractText Label="RESULTS">Two hundred ten patients from 15 sites in Austria, Germany, and Israel were randomly allocated to placebo (107 patients) or ladostigil (103 patients). After 36 months, 21 of 103 patients on placebo and 14 of 99 patients receiving ladostigil progressed to Alzheimer disease (log-rank test <i>p</i> = 0.162). There were no significant effects on the NTB composite, DAD, or GDS score. Whole-brain and hippocampus volumes decreased more in the placebo than in the ladostigil group (whole brain, <i>p</i> = 0.025, Cohen d = 0.43; hippocampus, <i>p</i> = 0.043, d = 0.43). Serious adverse events were reported by 28 of 107 patients treated with placebo and 26 of 103 with ladostigil.</AbstractText><AbstractText Label="CONCLUSION">Ladostigil was safe and well tolerated but did not delay progression to dementia. Its association with reduced brain and hippocampus volume loss suggests a potential effect on atrophy.</AbstractText><AbstractText Label="CLINICALTRIALSGOV IDENTIFIER">NCT01429623.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class II evidence that for patients with MCI and medial temporal lobe atrophy, ladostigil did not significantly decrease the risk of the development of Alzheimer disease.</AbstractText><CopyrightInformation>&#xa9; 2019 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-1875-3735</Identifier><AffiliationInfo><Affiliation>From the Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Avraham Pharmaceuticals, Ltd (Y.G.), Yavne; Bar Ilan University (J.R.), Ramat Gan, Israel; University of California (R.G.T.), San Diego; Department of Neurology (R.S., S.R.), Medical University, Graz, Austria; and Hebrew University (M.W.), Jerusalem, Israel. lschneid@usc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geffen</LastName><ForeName>Yona</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Avraham Pharmaceuticals, Ltd (Y.G.), Yavne; Bar Ilan University (J.R.), Ramat Gan, Israel; University of California (R.G.T.), San Diego; Department of Neurology (R.S., S.R.), Medical University, Graz, Austria; and Hebrew University (M.W.), Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinowitz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Avraham Pharmaceuticals, Ltd (Y.G.), Yavne; Bar Ilan University (J.R.), Ramat Gan, Israel; University of California (R.G.T.), San Diego; Department of Neurology (R.S., S.R.), Medical University, Graz, Austria; and Hebrew University (M.W.), Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>From the Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Avraham Pharmaceuticals, Ltd (Y.G.), Yavne; Bar Ilan University (J.R.), Ramat Gan, Israel; University of California (R.G.T.), San Diego; Department of Neurology (R.S., S.R.), Medical University, Graz, Austria; and Hebrew University (M.W.), Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Reinhold</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Avraham Pharmaceuticals, Ltd (Y.G.), Yavne; Bar Ilan University (J.R.), Ramat Gan, Israel; University of California (R.G.T.), San Diego; Department of Neurology (R.S., S.R.), Medical University, Graz, Austria; and Hebrew University (M.W.), Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ropele</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Avraham Pharmaceuticals, Ltd (Y.G.), Yavne; Bar Ilan University (J.R.), Ramat Gan, Israel; University of California (R.G.T.), San Diego; Department of Neurology (R.S., S.R.), Medical University, Graz, Austria; and Hebrew University (M.W.), Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstock</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Keck School of Medicine of the University of Southern California (L.S.S.), Los Angeles; Avraham Pharmaceuticals, Ltd (Y.G.), Yavne; Bar Ilan University (J.R.), Ramat Gan, Israel; University of California (R.G.T.), San Diego; Department of Neurology (R.S., S.R.), Medical University, Graz, Austria; and Hebrew University (M.W.), Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Ladostigil Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01429623</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423264">(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31492718</ArticleId><ArticleId IdType="pmc">PMC7010322</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008239</ArticleId><ArticleId IdType="pii">WNL.0000000000008239</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:555&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787840</ArticleId></ArticleIdList></Reference><Reference><Citation>Darreh-Shori T, Almkvist O, Guan ZZ, et al. . Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196650</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 2003;341:233&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697291</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock M, Luques L, Poltyrev T, Bejar C, Shoham S. Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol Aging 2011;32:1069&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">19625104</ArticleId></ArticleIdList></Reference><Reference><Citation>Panarsky R, Luques L, Weinstock M. Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells. J Neuroimmune Pharmacol 2012;7:488&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">22454040</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols NR, Day JR, Laping NJ, Johnson SA, Finch CE. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging 1993;14:421&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan Y, Maher FO, Martin DS, et al. . Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. J Biol Chem 2005;280:9354&#x2013;9362.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615726</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan TE, Xie Z, Goldsmith S, et al. . The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 1999;89:687&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">10199605</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005;37:289&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474976</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock M, Bejar C, Schorer-Apelbaum D, Panarsky R, Luques L, Shoham S. Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats. J Neuroimmune Pharmacol 2013;8:345&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">23325108</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher M, Nicolle MM. Animal models of normal aging: relationship between cognitive decline and markers in hippocampal circuitry. Behav Brain Res 1993;57:155&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">7906946</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, Edison P, Archer HA, et al. . Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009;72:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2817573</ArticleId><ArticleId IdType="pubmed">19122031</ArticleId></ArticleIdList></Reference><Reference><Citation>Parbo P, Ismail R, Hansen KV, et al. . Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. Brain 2017;140:2002&#x2013;2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">28575151</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoham S, Linial M, Weinstock M. Age-induced spatial memory deficits in rats are correlated with specific brain region alterations in microglial morphology and gene expression. J Neuroimmune Pharmacol 2019;14:251&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">30343448</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012:CD009132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464825</ArticleId><ArticleId IdType="pubmed">22972133</ArticleId></ArticleIdList></Reference><Reference><Citation>Haam J, Yakel JL. Cholinergic modulation of the hippocampal region and memory function. J Neurochem 2017;142(suppl 2):111&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645066</ArticleId><ArticleId IdType="pubmed">28791706</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale&#x2013;Revised: Manual. San Antonio: Psychological Corp, Harcourt Brace Jovanovich; 1987.</Citation></Reference><Reference><Citation>Scheltens P, Leys D, Barkhof F, et al. . Atrophy of medial temporal lobes on MRI in &#x201c;probable&#x201d; Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1015202</ArticleId><ArticleId IdType="pubmed">1431963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage DA, Sheikh JI. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantoni L, Inzitari D. Hachinski's ischemic score and the diagnosis of vascular dementia: a review. Ital J Neurol Sci 1993;14:539&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">8282525</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007;64:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846273</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H, Sauter A, Donald A, et al. . The Disability Assessment for Dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391090</ArticleId></ArticleIdList></Reference><Reference><Citation>Doniger GM, Simon ES. Construct Validity of NeuroTrax&#x2122;: Comparison with Paper-Based Tests. 2014. Available at: portal.neurotrax.com/docs/construct_validity.pdf. Accessed August 27, 2019.</Citation></Reference><Reference><Citation>Smith SM, Zhang Y, Jenkinson M, et al. . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001;20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. Freesurfer Neuroimage 2012;62:774&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Maclaren J, Han Z, Vos SB, Fischbein N, Bammer R. Reliability of brain volume measurements: a test-retest dataset. Sci Data 2014;1:140037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411010</ArticleId><ArticleId IdType="pubmed">25977792</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, et al. . Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Frisoni GB, Clark CM, et al. . Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007;64:108&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J, Arnold R, Dawson K, Nestor PJ, Hodges JR. Outcome in subgroups of mild cognitive impairment (MCI) is highly predictable using a simple algorithm. J Neurol 2009;256:1500&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">19434441</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">497341</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917&#x2013;2930.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325108</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. ICH harmonised tripartite guideline E6: guideline for Good Clinical Practice. 1996. Available at: fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf. Accessed September 19, 2011.</Citation></Reference><Reference><Citation>World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology 2013;80:648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590059</ArticleId><ArticleId IdType="pubmed">23303849</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins ND, van der Flier WA, Knol DL, et al. . The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimer's Res Ther 2014;6:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255389</ArticleId><ArticleId IdType="pubmed">25478019</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Chupin M, Hampel H, et al. . Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimers Dement 2015;11:1041&#x2013;1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">25596420</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen H, Solomon A, Visser PJ, et al. . 24-Month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol 2017;16:965&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697936</ArticleId><ArticleId IdType="pubmed">29097166</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, et al. . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen P, Boeve BF, et al. . Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013;74:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804562</ArticleId><ArticleId IdType="pubmed">23686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Boccardi M, Barkhof F, et al. . Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol 2017;16:661&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">28721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 2013;368:1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Kate M, Barkhof F, Boccardi M, et al. . Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging 2017;52:167&#x2013;182 e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28317647</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Gauthier S, Scinto L, et al. . Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024&#x2013;2035.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322263</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HH, Ferris S, Winblad B, et al. . Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509485</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31501572</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Cell-type-specific profiling of brain mitochondria reveals functional and molecular diversity.</ArticleTitle><Pagination><StartPage>1731</StartPage><EndPage>1742</EndPage><MedlinePgn>1731-1742</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0479-z</ELocationID><Abstract><AbstractText>Mitochondria vary in morphology and function in different tissues; however, little is known about their molecular diversity among cell types. Here we engineered MitoTag mice, which express a Cre recombinase-dependent green fluorescent protein targeted to the outer mitochondrial membrane, and developed an isolation approach to profile tagged mitochondria from defined cell types. We determined the mitochondrial proteome of the three major cerebellar cell types (Purkinje cells, granule cells and astrocytes) and identified hundreds of mitochondrial proteins that are differentially regulated. Thus, we provide markers of cell-type-specific mitochondria for the healthy and diseased mouse and human central nervous systems, including in amyotrophic lateral sclerosis and Alzheimer's disease. Based on proteomic predictions, we demonstrate that astrocytic mitochondria metabolize long-chain fatty acids more efficiently than neuronal mitochondria. We also characterize cell-type differences in mitochondrial calcium buffering via the mitochondrial calcium uniporter (Mcu) and identify regulator of microtubule dynamics protein 3 (Rmdn3) as a determinant of endoplasmic reticulum-mitochondria proximity in Purkinje cells. Our approach enables exploring mitochondrial diversity in many in vivo contexts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fecher</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7179-7323</Identifier><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Systemic Neurosciences, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Trov&#xf2;</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-3414-307X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, School of Medicine, Klinikum rechts der Isar and Institute for Advanced Study, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snaidero</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wettmarshausen</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gene Center Munich, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Diabetes and Obesity, Helmholtz Zentrum M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heink</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3276-6313</Identifier><AffiliationInfo><Affiliation>Experimental Neuroimmunology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Merck KGaA, Darmstadt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hn</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1694-9803</Identifier><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max-Delbr&#xfc;ck-Centrum f&#xfc;r Molekulare Medizin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karl</LastName><ForeName>Rosa Maria</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konnerth</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Integrated Protein Science, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korn</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3633-0955</Identifier><AffiliationInfo><Affiliation>Experimental Neuroimmunology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkler</LastName><ForeName>Doron</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0247-2007</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, School of Medicine, Klinikum rechts der Isar and Institute for Advanced Study, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perocchi</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Gene Center Munich, Ludwig-Maximilians University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Diabetes and Obesity, Helmholtz Zentrum M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misgeld</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9875-6794</Identifier><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany. thomas.misgeld@tum.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany. thomas.misgeld@tum.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Munich, Germany. thomas.misgeld@tum.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Integrated Protein Science, Munich, Germany. thomas.misgeld@tum.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2019 Nov;20(11):645. doi: 10.1038/s41583-019-0229-y.</RefSource><PMID Version="1">31554939</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31501572</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0479-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0479-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>MacIver, N. J., Michalek, R. D. &amp; Rathmell, J. C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259&#x2013;283 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23298210</ArticleId><ArticleId IdType="pmc">3606674</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, H. &amp; Chan, D. C. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. Cell Metab. 26, 39&#x2013;48 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28648983</ArticleId><ArticleId IdType="pmc">5539982</ArticleId></ArticleIdList></Reference><Reference><Citation>Misgeld, T. &amp; Schwarz, T. L. Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron 96, 651&#x2013;666 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29096078</ArticleId><ArticleId IdType="pmc">5687842</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine, M. J. &amp; Kittler, J. T. Mitochondria at the neuronal presynapse in health and disease. Nat. Rev. Neurosci. 19, 63&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29348666</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunnari, J. &amp; Suomalainen, A. Mitochondria: in sickness and in health. Cell 148, 1145&#x2013;1159 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22424226</ArticleId><ArticleId IdType="pmc">5381524</ArticleId></ArticleIdList></Reference><Reference><Citation>West, A. P., Shadel, G. S. &amp; Ghosh, S. Mitochondria in innate immune responses. Nat. Rev. Immunol. 11, 389&#x2013;402 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21597473</ArticleId><ArticleId IdType="pmc">4281487</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliarini, D. J. et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 134, 112&#x2013;123 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18614015</ArticleId><ArticleId IdType="pmc">2778844</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigeoka, T. et al. Dynamic axonal translation in developing and mature visual circuits. Cell 166, 181&#x2013;192 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27321671</ArticleId><ArticleId IdType="pmc">4930487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazalpour, A. et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet. 7, e1001393 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21695224</ArticleId><ArticleId IdType="pmc">3111477</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman, M. et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 135, 738&#x2013;748 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19013281</ArticleId><ArticleId IdType="pmc">2696821</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, W. W., Freinkman, E., Wang, T., Birsoy, K. &amp; Sabatini, D. M. Absolute quantification of matrix metabolites reveals the dynamics of mitochondrial metabolism. Cell 166, 1324&#x2013;1337.e1311 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27565352</ArticleId><ArticleId IdType="pmc">5030821</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Remaileh, M. et al. Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science 358, 807&#x2013;813 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29074583</ArticleId><ArticleId IdType="pmc">5704967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahier, A. et al. Affinity purification of cell-specific mitochondria from whole animals resolves patterns of genetic mosaicism. Nat. Cell Biol. 20, 352&#x2013;360 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29358705</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh, H. C. et al. Simultaneous transcriptional and epigenomic profiling from specific cell types within heterogeneous tissues in vivo. Cell Rep. 18, 1048&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28122230</ArticleId><ArticleId IdType="pmc">5291126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornig-Do, H. T. et al. Isolation of functional pure mitochondria by superparamagnetic microbeads. Anal. Biochem. 389, 1&#x2013;5 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19285029</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeusen, S., McCaffery, J. M. &amp; Nunnari, J. Mitochondrial fusion intermediates revealed in vitro. Science 305, 1747&#x2013;1752 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15297626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, K. et al. Cell type- and brain region-resolved mouse brain proteome. Nat. Neurosci. 18, 1819&#x2013;1831 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26523646</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo, S. E., Clauser, K. R. &amp; Mootha, V. K. MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucl. Acids Res. 44, D1251&#x2013;D1257 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26450961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, J. S. et al. Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell 132, 137&#x2013;148 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18191227</ArticleId><ArticleId IdType="pmc">18191227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato, K., Yoshida, S., Fujiwara, K., Tada, K. &amp; Tohyama, M. Glycine cleavage system in astrocytes. Brain Res. 567, 64&#x2013;70 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1815830</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake, S. et al. Identification and characterization of a novel mitochondrial tricarboxylate carrier. Biochem. Biophys. Res. Commun. 295, 463&#x2013;468 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12150972</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler, J. S. et al. Monoamine oxidase: radiotracer development and human studies. Methods 27, 263&#x2013;277 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12183115</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrova, V. Y., Drescher, D., Kujumdzieva, A. V. &amp; Schmitt, M. J. Dual targeting of yeast catalase a to peroxisomes and mitochondria. Biochem. J. 380, 393&#x2013;400 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14998369</ArticleId><ArticleId IdType="pmc">1224190</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan, J., Li, X., Issop, L., Culty, M. &amp; Papadopoulos, V. ACBD2/ECI2-mediated peroxisome-mitochondria interactions in Leydig cell steroid biosynthesis. Mol. Endocrinol. 30, 763&#x2013;782 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27167610</ArticleId><ArticleId IdType="pmc">5426581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shai, N. et al. Systematic mapping of contact sites reveals tethers and a function for the peroxisome-mitochondria contact. Nat. Commun. 9, 1761 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29720625</ArticleId><ArticleId IdType="pmc">5932058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha, S., Bheemsetty, V. A. &amp; Inamdar, M. S. A double helical motif in OCIAD2 is essential for its localization, interactions and STAT3 activation. Sci. Rep. 8, 7362 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29743632</ArticleId><ArticleId IdType="pmc">5943604</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughman, J. M. et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 476, 341&#x2013;345 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21685886</ArticleId><ArticleId IdType="pmc">3486726</ArticleId></ArticleIdList></Reference><Reference><Citation>De Stefani, D., Raffaello, A., Teardo, E., Szab&#xf2;, I. &amp; Rizzuto, R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476, 336&#x2013;340 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21685888</ArticleId><ArticleId IdType="pmc">4141877</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos, K. J. et al. VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. Hum. Mol. Genet. 21, 1299&#x2013;1311 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22131369</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmes, R. et al. ORP5/ORP8 localize to endoplasmic reticulum-mitochondria contacts and are involved in mitochondrial function. EMBO Rep. 17, 800&#x2013;810 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27113756</ArticleId><ArticleId IdType="pmc">5278607</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio, F. P., Boulting, G. L., Bobrowicz, S. &amp; Eggan, K. C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3, 637&#x2013;648 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nfeld, P. &amp; Reiser, G. Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. J. Cereb. Blood Flow. Metab. 33, 1493&#x2013;1499 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23921897</ArticleId><ArticleId IdType="pmc">3790936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert, D., Haller, R. G. &amp; Walton, M. E. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 23, 5928&#x2013;5935 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12843297</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch, M. et al. A fatty acid oxidation-dependent metabolic shift regulates adult neural stem cell activity. Cell Rep. 20, 2144&#x2013;2155 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28854364</ArticleId><ArticleId IdType="pmc">5583518</ArticleId></ArticleIdList></Reference><Reference><Citation>Eraso-Pichot, A. et al. GSEA of mouse and human mitochondriomes reveals fatty acid oxidation in astrocytes. Glia 66, 1724&#x2013;1735 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29575211</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington, J. L. &amp; Murphy, E. The mitochondrial calcium uniporter: mice can live and die without it. J. Mol. Cell. Cardiol. 78, 46&#x2013;53 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25451167</ArticleId></ArticleIdList></Reference><Reference><Citation>Paillard, M. et al. Tissue-Specific mitochondrial decoding of cytoplasmic Ca(2+) signals is controlled by the stoichiometry of MICU1/2 and MCU. Cell Rep. 18, 2291&#x2013;2300 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28273446</ArticleId><ArticleId IdType="pmc">5760244</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg-Bord, M., Shai, N., Schuldiner, M. &amp; Bohnert, M. A tether is a tether is a tether: tethering at membrane contact sites. Dev. Cell 39, 395&#x2013;409 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27875684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv, B. F. et al. Protein tyrosine phosphatase interacting protein 51 (PTPIP51) is a novel mitochondria protein with an N-terminal mitochondrial targeting sequence and induces apoptosis. Apoptosis 11, 1489&#x2013;1501 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16820967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangaraju, V., Lauterbach, M. &amp; Schuman, E. M. Spatially stable mitochondrial compartments fuel local translation during plasticity. Cell 176, 73&#x2013;84.e15 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30612742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, T. L. Jr., Kwon, S. K., Lee, A., Shaw, R. &amp; Polleux, F. MFF-dependent mitochondrial fission regulates presynaptic release and axon branching by limiting axonal mitochondria size. Nat. Commun. 9, 5008 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30479337</ArticleId><ArticleId IdType="pmc">6258764</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Castelao, B. et al. Cell-type-specific metabolic labeling of nascent proteomes in vivo. Nat. Biotechnol. 35, 1196&#x2013;1201 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29106408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C. L. et al. Proteomic mapping in live drosophila tissues using an engineered ascorbate peroxidase. Proc. Natl Acad. Sci. USA 112, 12093&#x2013;12098 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26362788</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayraktar, E. C. et al. MITO-Tag mice enable rapid isolation and multimodal profiling of mitochondria from specific cell types in vivo. Proc. Natl Acad. Sci. USA 116, 303&#x2013;312 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30541894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerschensteiner, M., Reuter, M. S., Lichtman, J. W. &amp; Misgeld, T. Ex vivo imaging of motor axon dynamics in murine triangularis sterni explants. Nat. Protoc. 3, 1645&#x2013;1653 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18833201</ArticleId><ArticleId IdType="pmc">2583328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiura, A., Mattie, S., Prudent, J. &amp; McBride, H. M. Newly born peroxisomes are a hybrid of mitochondrial and ER-derived pre-peroxisomes. Nature 542, 251&#x2013;254 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28146471</ArticleId></ArticleIdList></Reference><Reference><Citation>Meera, P., Pulst, S. M. &amp; Otis, T. S. Cellular and circuit mechanisms underlying spinocerebellar ataxias. J. Physiol. 594, 4653&#x2013;4660 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27198167</ArticleId><ArticleId IdType="pmc">4983629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaglia, T. et al. Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy. Proc. Natl Acad. Sci. USA 114, E9006&#x2013;E9015 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29073097</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, Z. et al. Mitochondrial Ca<sup>2+</sup> uniporter is a mitochondrial luminal redox sensor that augments MCU channel activity. Mol. Cell 65, 1014&#x2013;1028.e1017 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28262504</ArticleId><ArticleId IdType="pmc">5357178</ArticleId></ArticleIdList></Reference><Reference><Citation>Henzi, T. &amp; Schwaller, B. Antagonistic regulation of parvalbumin expression and mitochondrial calcium handling capacity in renal epithelial cells. PLoS One 10, e0142005 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26540196</ArticleId><ArticleId IdType="pmc">4634853</ArticleId></ArticleIdList></Reference><Reference><Citation>Suomalainen, A. &amp; Battersby, B. J. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat. Rev. Mol. Cell Biol. 19, 77&#x2013;92 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28792006</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshii, S. R., Kishi, C., Ishihara, N. &amp; Mizushima, N. Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J. Biol. Chem. 286, 19630&#x2013;19640 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21454557</ArticleId><ArticleId IdType="pmc">3103342</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie, C., Suzuki, H., Sakaguchi, M. &amp; Mihara, K. Characterization of signal that directs C-tail-anchored proteins to mammalian mitochondrial outer membrane. Mol. Biol. Cell 13, 1615&#x2013;1625 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12006657</ArticleId><ArticleId IdType="pmc">111131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitz, C., Steuber-Buchberger, P., Delic, S., Wurst, W. &amp; K&#xfc;hn, R. Generation of shRNA transgenic mice. Methods Mol. Biol. 530, 101&#x2013;129 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19266327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz, O., Wurst, W. &amp; K&#xfc;hn, R. Reversible and tissue-specific activation of MAP kinase signaling by tamoxifen in Braf(V637)ER(T2) mice. Genesis 51, 448&#x2013;455 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23441035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitz, C., Wurst, W. &amp; K&#xfc;hn, R. Conditional brain-specific knockdown of MAPK using Cre/loxP regulated RNA interference. Nucl. Acids Res. 35, e90 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17586814</ArticleId></ArticleIdList></Reference><Reference><Citation>Breckwoldt, M. O. et al. Multiparametric optical analysis of mitochondrial redox signals during neuronal physiology and pathology in vivo. Nat. Med. 20, 555&#x2013;560 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24747747</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorski, J. A. et al. Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J. Neurosci. 22, 6309&#x2013;6314 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12151506</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi, J. et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 13, 195&#x2013;204 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21284986</ArticleId><ArticleId IdType="pmc">3033043</ArticleId></ArticleIdList></Reference><Reference><Citation>Barski, J. J., Dethleffsen, K. &amp; Meyer, M. Cre recombinase expression in cerebellar purkinje cells. Genesis 28, 93&#x2013;98 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11105049</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;nfschilling, U. &amp; Reichardt, L. F. Cre-mediated recombination in rhombic lip derivatives. Genesis 33, 160&#x2013;169 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12203913</ArticleId><ArticleId IdType="pmc">2710124</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregorian, C. et al. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J. Neurosci. 29, 1874&#x2013;1886 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19211894</ArticleId><ArticleId IdType="pmc">2754186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, S. et al. Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J. Neurosci. 27, 9817&#x2013;9823 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17855595</ArticleId><ArticleId IdType="pmc">6672645</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, S. et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425, 917&#x2013;925 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14586460</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche, M. A. et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of alzheimer&#x2019;s disease. Science 321, 1686&#x2013;1689 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772&#x2013;1775 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez, C. I. et al. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat. Genet. 25, 139&#x2013;140 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10835623</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarnes, W. C. et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474, 337&#x2013;342 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21677750</ArticleId><ArticleId IdType="pmc">3572410</ArticleId></ArticleIdList></Reference><Reference><Citation>Brill, M. S. et al. Branch-specific microtubule destabilization mediates axon branch loss during neuromuscular synapse elimination. Neuron 92, 845&#x2013;856 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27773584</ArticleId><ArticleId IdType="pmc">5133389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleele, T. et al. An assay to image neuronal microtubule dynamics in mice. Nat. Commun. 5, 4827 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25219969</ArticleId><ArticleId IdType="pmc">4175586</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22743772</ArticleId><ArticleId IdType="pmc">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wettmarshausen, J. &amp; Perocchi, F. Isolation of functional mitochondria from cultured cells and mouse tissues. Methods Mol. Biol. 1567, 15&#x2013;32 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28276010</ArticleId></ArticleIdList></Reference><Reference><Citation>Franko, A. et al. Efficient isolation of pure and functional mitochondria from mouse tissues using automated tissue disruption and enrichment with anti-TOM22 magnetic beads. PLoS One 8, e82392 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24349272</ArticleId><ArticleId IdType="pmc">3861405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims, N. R. &amp; Anderson, M. F. Isolation of mitochondria from rat brain using percoll density gradient centrifugation. Nat. Protoc. 3, 1228&#x2013;1239 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18600228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. Isolation of brain mitochondria from neonatal mice. J. Neurochem. 119, 1253&#x2013;1261 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21985402</ArticleId><ArticleId IdType="pmc">3532608</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins, P. A., Ferrell, E. V. Jr., Pedersen, J. I. &amp; Hoefler, G. Peroxisomal fatty acid beta-oxidation in HepG2 cells. Arch. Biochem. Biophys. 289, 329&#x2013;336 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1654856</ArticleId></ArticleIdList></Reference><Reference><Citation>Demarquoy, J. &amp; Le Borgne, F. Crosstalk between mitochondria and peroxisomes. World J. Biol. Chem. 6, 301&#x2013;309 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26629313</ArticleId><ArticleId IdType="pmc">4657118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#x15b;niewski, J. R., Zougman, A., Nagaraj, N. &amp; Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359&#x2013;362 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19377485</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappsilber, J., Ishihama, Y. &amp; Mann, M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 75, 663&#x2013;670 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12585499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteom. 13, 2513&#x2013;2526 (2014).</Citation></Reference><Reference><Citation>Vizcaino, J. A. et al. update of the PRIDE database and its related tools. Nucl. Acids Res. 44, D447&#x2013;456 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26527722</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731&#x2013;740 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27348712</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox, J. &amp; Mann, M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinform. 13 (Suppl. 16), S12 (2012).</Citation></Reference><Reference><Citation>Goldberg, T. et al. LocTree3 prediction of localization. Nucl. Acids Res. 42, W350&#x2013;W355 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24848019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., Vasaikar, S., Shi, Z., Greer, M. &amp; Zhang, B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucl. Acids Res. 45, W130&#x2013;W137 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28472511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M., Goto, S., Sato, Y., Furumichi, M. &amp; Tanabe, M. KEGG for integration and interpretation of large-scale molecular data sets. Nucl. Acids Res. 40, D109&#x2013;D114 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22080510</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, J. B. et al. Molecular architecture of the chick vestibular hair bundle. Nat. Neurosci. 16, 365&#x2013;374 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23334578</ArticleId><ArticleId IdType="pmc">3581746</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida, Y. &amp; Takahashi, H. Rapid detection of Abeta deposits in APP transgenic mice by Hoechst 33342. Neurosci. Lett. 448, 279&#x2013;281 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18955112</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillberg, P. W. et al. Protein-retention expansion microscopy of cells and tissues labeled using standard fluorescent proteins and antibodies. Nat. Biotechnol. 34, 987&#x2013;992 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27376584</ArticleId><ArticleId IdType="pmc">5068827</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31501542</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2397-3374</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature human behaviour</Title><ISOAbbreviation>Nat Hum Behav</ISOAbbreviation></Journal><ArticleTitle>Rostral locus coeruleus integrity is associated with better memory performance in older adults.</ArticleTitle><Pagination><StartPage>1203</StartPage><EndPage>1214</EndPage><MedlinePgn>1203-1214</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41562-019-0715-2</ELocationID><Abstract><AbstractText>For decades, research into memory decline in human cognitive ageing has focused on neocortical regions, the hippocampus and dopaminergic neuromodulation. Recent findings indicate that the locus coeruleus (LC) and noradrenergic neuromodulation may also play an important role in shaping memory development in later life. However, technical challenges in quantification of LC integrity have hindered the study of LC-cognition associations in humans. Using high-resolution, neuromelanin-sensitive magnetic resonance imaging, we found that individual differences in learning and memory were positively associated with LC integrity across a variety of memory tasks in both younger (n&#x2009;=&#x2009;66) and older adults (n&#x2009;=&#x2009;228). Moreover, we observed functionally relevant age differences confined to rostral LC. Older adults with a more 'youth-like' rostral LC also showed higher memory performance. These findings link non-invasive, in vivo indices of LC integrity to memory in ageing and highlight the role of the LC norepinephrine system in the decline of cognition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-3525-0539</Identifier><AffiliationInfo><Affiliation>Center for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany. dahl@mpib-berlin.mpg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mather</LastName><ForeName>Mara</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4331-6112</Identifier><AffiliationInfo><Affiliation>Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;zel</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodammer</LastName><ForeName>Nils C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Center for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindenberger</LastName><ForeName>Ulman</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-8428-6453</Identifier><AffiliationInfo><Affiliation>Center for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck UCL Centre for Computational Psychiatry and Ageing Research, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck UCL Centre for Computational Psychiatry and Ageing Research, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hn</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Clinic Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lise Meitner Group for Environmental Neuroscience, Max Planck Institute for Human Development, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werkle-Bergner</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6399-9996</Identifier><AffiliationInfo><Affiliation>Center for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany. werkle@mpib-berlin.mpg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025340</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Hum Behav</MedlineTA><NlmUniqueID>101697750</NlmUniqueID><ISSNLinking>2397-3374</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Hum Behav. 2019 Nov;3(11):1143-1144. doi: 10.1038/s41562-019-0731-2.</RefSource><PMID Version="1">31501541</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31501542</ArticleId><ArticleId IdType="mid">NIHMS1067722</ArticleId><ArticleId IdType="pmc">PMC7203800</ArticleId><ArticleId IdType="doi">10.1038/s41562-019-0715-2</ArticleId><ArticleId IdType="pii">10.1038/s41562-019-0715-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nyberg L, L&#xf6;vd&#xe9;n M, Riklund K, Lindenberger U. &amp; B&#xe4;ckman L. Memory aging and brain maintenance. Trends Cogn. Sci 16, 292&#x2013;305 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22542563</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook T. et al. Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change&#x2014;Report of a National Institute of Mental Health Work Group. Dev. Neuropsychol 2, 261&#x2013;276 (1986).</Citation></Reference><Reference><Citation>Prince MJ et al. World Alzheimer Report 2015 - The global impact of dementia: An analysis of prevalence, incidence, cost and trends. (Alzheimer&#x2019;s Disease International, 2015).</Citation></Reference><Reference><Citation>Nyberg L. et al. Dopamine D2 receptor availability is linked to hippocampal&#x2013;caudate functional connectivity and episodic memory. Proc. Natl. Acad. Sci. U. S. A 113, 7918&#x2013;7923 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948341</ArticleId><ArticleId IdType="pubmed">27339132</ArticleId></ArticleIdList></Reference><Reference><Citation>Fandakova Y, Lindenberger U. &amp; Shing YL Deficits in process-specific prefrontal and hippocampal activations contribute to adult age differences in episodic memory interference. Cereb. Cortex 24, 1832&#x2013;1844 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23425890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenberger U. Human cognitive aging: Corriger la fortune? Science (80-. ). 346, 572&#x2013;578 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25359964</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie FM et al. Noradrenergic changes and memory loss in aged mice. Brain Res. 359, 292&#x2013;299 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">4075150</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E. &amp; Del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Marien MR, Colpaert FC &amp; Rosenquist AC Noradrenergic mechanisms in neurodegenerative diseases: A theory. Brain Res. Rev 45, 38&#x2013;78 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15063099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS et al. Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology 80, 1202&#x2013;1208 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691778</ArticleId><ArticleId IdType="pubmed">23486878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mather M. &amp; Harley CW The locus coeruleus: Essential for maintaining cognitive function and the aging brain. Trends Cogn. Sci 20, 214&#x2013;226 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761411</ArticleId><ArticleId IdType="pubmed">26895736</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Y. et al. Aging-associated formaldehyde-induced norepinephrine deficiency contributes to age-related memory decline. Aging Cell 19, 659&#x2013;668 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531079</ArticleId><ArticleId IdType="pubmed">25866202</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y. et al. Reversal of aging-related emotional memory deficits by norepinephrine via regulating the stability of surface AMPA receptors. Aging Cell 14, 170&#x2013;179 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364829</ArticleId><ArticleId IdType="pubmed">25564942</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT &amp; Goldman-Rakic PS Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230, 1273&#x2013;1276 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">2999977</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;mmerer D. et al. Locus coeruleus integrity in old age is selectively related to memories linked with salient negative events. Proc. Natl. Acad. Sci. U. S. A 115, 2228&#x2013;2233 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834676</ArticleId><ArticleId IdType="pubmed">29440429</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas P. et al. Locus coeruleus volume and cell population changes during Alzheimer&#x2019;s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimer&#x2019;s Dement. 13, 236&#x2013;246 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298942</ArticleId><ArticleId IdType="pubmed">27513978</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabadi E. Functional neuroanatomy of the central noradrenergic system. J. Psychopharmacol 27, 659&#x2013;693 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23761387</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes P, Regala J, Correia F. &amp; Gon&#xe7;alves-Ferreira AJ The human locus coeruleus 3-D stereotactic anatomy. Surg. Radiol. Anat 34, 879&#x2013;885 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22638719</ArticleId></ArticleIdList></Reference><Reference><Citation>German DC et al. The human locus coeruleus: Computer reconstruction of cellular distribution. J. Neurosci 8, 1776&#x2013;1788 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569207</ArticleId><ArticleId IdType="pubmed">3367220</ArticleId></ArticleIdList></Reference><Reference><Citation>Aston-Jones G. &amp; Waterhouse B. Locus coeruleus: From global projection system to adaptive regulation of behavior. Brain Res. 1645, 75&#x2013;78 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969192</ArticleId><ArticleId IdType="pubmed">26969408</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge CW &amp; Waterhouse BD The locus coeruleus-noradrenergic system: Modulation of behavioral state and state-dependent cognitive processes. Brain Res. Rev 42, 33&#x2013;84 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12668290</ArticleId></ArticleIdList></Reference><Reference><Citation>Manaye KF, McIntire DD, Mann DMA &amp; German DC Locus coeruleus cell loss in the aging human brain: A non-random process. J. Comp. Neurol 358, 79&#x2013;87 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7560278</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz LA &amp; Luo L. Organization of the locus coeruleus-norepinephrine system. Curr. Biol 25, R1051&#x2013;R1056 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26528750</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse BD &amp; Chandler DJ Heterogeneous organization and function of the central noradrenergic system. Brain Res. 1641, v&#x2013;x (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26746339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordway GA, Schwartz MA &amp; Frazer A. Brain norepinephrine: Neurobiology and therapeutics. (Cambridge University Press, 2007). doi:10.1017/CBO9780511544156</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/CBO9780511544156</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AFT &amp; Li BM Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 57, 1377&#x2013;1384 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15950011</ArticleId></ArticleIdList></Reference><Reference><Citation>Aston-Jones G. &amp; Cohen JD An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annu. Rev. Neurosci 28, 403&#x2013;450 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16022602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouret S. &amp; Sara SJ Network reset: A simplified overarching theory of locus coeruleus noradrenaline function. Trends Neurosci. 28, 574&#x2013;582 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16165227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mather M, Clewett D, Sakaki M. &amp; Harley CW Norepinephrine ignites local hotspots of neuronal excitation: How arousal amplifies selectivity in perception and memory. Behav. Brain Sci 39, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830137</ArticleId><ArticleId IdType="pubmed">26126507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieuwenhuis S. &amp; Jepma M. Investigating the role of the noradrenergic system in human cognition in Decision making, affect, and learning: Attention and performance XXIII (eds. Delgado M, Phelps E. &amp; Robbins T.) 367&#x2013;386 (Oxford University Press, 2011). doi:10.1093/acprof:oso/9780199600434.003.0017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/acprof:oso/9780199600434.003.0017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sara SJ Locus coeruleus in time with the making of memories. Curr. Opin. Neurobiol 35, 87&#x2013;94 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26241632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sara SJ The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci 10, 211&#x2013;223 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19190638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen N. The longevity of hippocampus-dependent memory is orchestrated by the locus coeruleus-noradrenergic system. Neural Plast. 2017, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485371</ArticleId><ArticleId IdType="pubmed">28695015</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Dell TJ, Connor SA, Guglietta R. &amp; Nguyen PV &#x3b2;-Adrenergic receptor signaling and modulation of long-term potentiation in the mammalian hippocampus. Learn. Mem 22, 461&#x2013;471 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4561407</ArticleId><ArticleId IdType="pubmed">26286656</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray N. Learning and memory: You only learn once. Nat. Rev. Neurosci 19, 59 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29348669</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara CG &amp; Dupret D. Two sources of dopamine for the hippocampus. Trends Neurosci. 40, 383&#x2013;384 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489110</ArticleId><ArticleId IdType="pubmed">28511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi T. et al. Locus coeruleus and dopaminergic consolidation of everyday memory. Nature 537, 357&#x2013;362 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5161591</ArticleId><ArticleId IdType="pubmed">27602521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Busch C. &amp; Bohl J. Unbiased estimation of neuronal numbers in the human nucleus coeruleus during aging. Neurobiol. Aging 18, 393&#x2013;399 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton PR, Pakkenberg B, Gundersen HJG &amp; Price DL Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals. J. Chem. Neuroanat 7, 185&#x2013;190 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7848573</ArticleId></ArticleIdList></Reference><Reference><Citation>Astafiev SV, Snyder AZ, Shulman GL &amp; Corbetta M. Comment on &#x2018;Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI&#x2019; and &#x2018;Homeostatic sleep pressure and responses to sustained attention in the suprachiasmatic area&#x2019;. Science (80-. ). 328, 309 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704136</ArticleId><ArticleId IdType="pubmed">20395497</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren NI, Lozar CT, Harris KC, Morgan PS &amp; Eckert MA In vivo mapping of the human locus coeruleus. Neuroimage 47, 1261&#x2013;1267 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671394</ArticleId><ArticleId IdType="pubmed">19524044</ArticleId></ArticleIdList></Reference><Reference><Citation>Zecca L. et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U. S. A 101, 9843&#x2013;9848 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470762</ArticleId><ArticleId IdType="pubmed">15210960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA &amp; Yates PO Lipoprotein pigments&#x2013;their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 97, 489&#x2013;498 (1974).</Citation><ArticleIdList><ArticleId IdType="pubmed">4423478</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcyniuk B, Mann DMA &amp; Yates PO The topography of nerve cell loss from the locus caeruleus in elderly persons. Neurobiol. Aging 10, 5&#x2013;9 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2755557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki M, Shibata E, Kudo K. &amp; Tohyama K. Neuromelanin-sensitive MRI: Basics, technique, and clinical applications. Clin. Neuroradiol 18, 147&#x2013;153 (2008).</Citation></Reference><Reference><Citation>Sasaki M. et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson&#x2019;s disease. Neuroreport 17, 1215&#x2013;1218 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16837857</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KY et al. Magnetic resonance imaging of the human locus coeruleus: A systematic review. Neurosci. Biobehav. Rev 83, 325&#x2013;355 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29107830</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren NI et al. Histologic validation of locus coeruleus MRI contrast in post-mortem tissue. Neuroimage 113, 235&#x2013;245 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649944</ArticleId><ArticleId IdType="pubmed">25791783</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Moss MB, Tanzi R. &amp; Jones K. Preclinical prediction of AD using neuropsychological tests. J. Int. Neuropsychol. Soc 7, 631&#x2013;639 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11459114</ArticleId></ArticleIdList></Reference><Reference><Citation>Belleville S, Fouquet C, Hudon C, Zomahoun HTV &amp; Croteau J. Neuropsychological measures that predict progression from mild cognitive impairment to Alzheimer&#x2019;s type dementia in older adults: A systematic review and meta-analysis. Neuropsychol. Rev 27, 328&#x2013;353 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754432</ArticleId><ArticleId IdType="pubmed">29019061</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradi E, Hallikainen I, H&#xe4;nninen T. &amp; Tohka J. Rey&#x2019;s Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimer&#x2019;s disease. NeuroImage Clin. 13, 415&#x2013;427 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233798</ArticleId><ArticleId IdType="pubmed">28116234</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenberg MR et al. Test performance and classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples. Arch. Clin. Neuropsychol 21, 693&#x2013;703 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16987634</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich D, Rast P. &amp; Martin M. Individual differences in verbal learning in old age in Handbook of cognitive aging: Interdisciplinary perspectives (eds. Hofer S. &amp; Alwin D.) 224&#x2013;243 (SAGE Publications, 2008). doi:10.4135/9781412976589.n14</Citation><ArticleIdList><ArticleId IdType="doi">10.4135/9781412976589.n14</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RN et al. A growth curve model of learning acquisition among cognitively normal older adults. Exp. Aging Res 31, 291&#x2013;312 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908897</ArticleId><ArticleId IdType="pubmed">16036723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich D. &amp; Rast P. Verbal learning changes in older adults across 18 months. Neuropsychol. Dev. Cogn. B. Aging. Neuropsychol. Cogn 16, 461&#x2013;484 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19365771</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle JJ Dynamic but structural equation modeling of repeated measures data in Handbook of multivariate experimental psychology (eds. Nesselroade JR &amp; Cattell RB) 561&#x2013;614 (Springer, 1988). doi:10.1007/978-1-4613-0893-5_17</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4613-0893-5_17</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran PJ, Obeidat K. &amp; Losardo D. Twelve frequently asked questions about growth curve modeling. J. Cogn. Dev 11, 121&#x2013;136 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131138</ArticleId><ArticleId IdType="pubmed">21743795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kievit RA et al. Developmental cognitive neuroscience using latent change score models: A tutorial and applications. Dev. Cogn. Neurosci (2017). doi:10.1016/j.dcn.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dcn.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC6614039</ArticleId><ArticleId IdType="pubmed">29325701</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TA Confirmatory factor analysis for applied research. New York:Guilford Press; (2006).</Citation></Reference><Reference><Citation>Eid M, Gollwitzer M. &amp; Schmitt M. Statistik und Forschungsmethoden: Lehrbuch. Grundlagen Psychologie (Beltz, 2015).</Citation></Reference><Reference><Citation>Betts MJ, Cardenas-Blanco A, Kanowski M, Jessen F. &amp; D&#xfc;zel E. In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. Neuroimage 163, 150&#x2013;159 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28943414</ArticleId></ArticleIdList></Reference><Reference><Citation>Maris E. &amp; Oostenveld R. Nonparametric statistical testing of EEG-and MEG-data. J. Neurosci. Methods 164, 177&#x2013;190 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17517438</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiger JH Beyond the F Test: Effect Size Confidence Intervals and Tests of Close Fit in the Analysis of Variance and Contrast Analysis. Psychol. Methods 9, 164&#x2013;182 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15137887</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiger JH Tests for comparing elements of a correlation matrix. Psychol. Bull 87, 245&#x2013;251 (1980).</Citation></Reference><Reference><Citation>Schmidt M. Rey Auditory Verbal Learning Test: A handbook. (Western Psychological Services, 2004).</Citation></Reference><Reference><Citation>Gifford KA et al. Associations between Verbal Learning Slope and Neuroimaging Markers across the Cognitive Aging Spectrum. J. Int. Neuropsychol. Soc 21, 455&#x2013;467 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4657447</ArticleId><ArticleId IdType="pubmed">26219209</ArticleId></ArticleIdList></Reference><Reference><Citation>Priovoulos N. et al. High-resolution in vivo imaging of human locus coeruleus by magnetization transfer MRI at 3T and 7T. Neuroimage 168, 127&#x2013;136 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28743460</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X. et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn. Reson. Imaging 32, 1301&#x2013;1306 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25086330</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley J, Huddleston DE, Liu CJ &amp; Hu X. Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI. Magn. Reson. Mater. Physics, Biol. Med 30, 121&#x2013;125 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27687624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tona KD et al. In vivo visualization of the locus coeruleus in humans: Quantifying the test&#x2013;retest reliability. Brain Struct. Funct 222, 4203&#x2013;4217 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686260</ArticleId><ArticleId IdType="pubmed">28647901</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinshenker D. Long road to ruin: Noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 41, 211&#x2013;223 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5878728</ArticleId><ArticleId IdType="pubmed">29475564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalermpalanupap T, Weinshenker D. &amp; Rorabaugh JM Down but not out: The consequences of pretangle tau in the locus coeruleus. Neural Plast. 2017, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5605916</ArticleId><ArticleId IdType="pubmed">29038736</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat. Rev. Neurosci 1 (2018). doi:10.1038/s41583-018-0067-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0067-3</ArticleId><ArticleId IdType="pmc">PMC7032048</ArticleId><ArticleId IdType="pubmed">30266970</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson IH A noradrenergic theory of cognitive reserve: Implications for Alzheimer&#x2019;s disease. Neurobiol. Aging 34, 298&#x2013;308 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22743090</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata E. et al. Age-related changes in locus coeruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn. Reson. Med. Sci 5, 197&#x2013;200 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17332710</ArticleId></ArticleIdList></Reference><Reference><Citation>Clewett DV et al. Neuromelanin marks the spot: Identifying a locus coeruleus biomarker of cognitive reserve in healthy aging. Neurobiol. Aging 37, 117&#x2013;126 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5134892</ArticleId><ArticleId IdType="pubmed">26521135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouret S. &amp; Sara SJ Locus coeruleus activation modulates firing rate and temporal organization of odour-induced single-cell responses in rat piriform cortex. Eur. J. Neurosci 16, 2371&#x2013;2382 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12492432</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries P. A mechanism for cognitive dynamics: Neuronal communication through neuronal coherence. Trends Cogn. Sci 9, 474&#x2013;480 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16150631</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S-C, Lindenberger U. &amp; Sikstrom S. Aging cognition: From neuromodulation to representation. Trends Cogn. Sci 5, 479&#x2013;486 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11684480</ArticleId></ArticleIdList></Reference><Reference><Citation>Shing YL et al. Episodic memory across the lifespan: The contributions of associative and strategic components. Neurosci. Biobehav. Rev 34, 1080&#x2013;1091 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19896974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenberg AJ et al. Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer&#x2019;s disease. Neuropathol. Appl. Neurobiol 43, 393&#x2013;408 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642282</ArticleId><ArticleId IdType="pubmed">28117917</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Del Tredici K, Thomas TL, Braak H. &amp; Diamond MI Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer&#x2019;s disease and PART. Acta Neuropathol. 136, 57 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015098</ArticleId><ArticleId IdType="pubmed">29752551</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinsen H. &amp; Grinberg LT On the origin of tau seeding activity in Alzheimer&#x2019;s disease. Acta Neuropathol. 1&#x2013;3 (2018). doi:10.1007/s00401-018-1890-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1890-3</ArticleId><ArticleId IdType="pmc">PMC6508082</ArticleId><ArticleId IdType="pubmed">30039213</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT &amp; Heinsen H. Light at the beginning of the tunnel? Investigating early mechanistic changes in Alzheimer&#x2019;s disease. Brain 140, 2770&#x2013;2773 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29088348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Lyness SA, Mortimer JA &amp; Chui HC Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol 60, 337 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12633144</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalermpalanupap T. et al. Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice. J. Neurosci 38, 74&#x2013;92 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761438</ArticleId><ArticleId IdType="pubmed">29133432</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts MJ, Ehrenberg AJ, H&#xe4;mmerer D. &amp; D&#xfc;zel E. Commentary: Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice. Front. Neurosci 12, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997818</ArticleId><ArticleId IdType="pubmed">29928191</ArticleId></ArticleIdList></Reference><Reference><Citation>Rorabaugh JM et al. Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer&#x2019;s disease. Brain 140, 3023&#x2013;3038 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841201</ArticleId><ArticleId IdType="pubmed">29053824</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE &amp; McHugh PR &#x2018;Mini-mental state&#x2019;. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 12, 189&#x2013;198 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Delius JAM, D&#xfc;zel S, Gerstorf D. &amp; Lindenberger U. Berlin Aging Studies (BASE and BASE-II) in Encyclopedia of geropsychology (ed. Pachana NA) 386&#x2013;395 (Springer, 2015). doi:10.1007/978-981-287-080-3_44-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-287-080-3_44-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstorf D. et al. The Berlin Aging Study II &#x2013; An overview. Gerontology 62, (2016).</Citation></Reference><Reference><Citation>Bertram L. et al. Cohort profile: The Berlin Aging Study II (BASE-II). Int. J. Epidemiol 43, 703&#x2013;712 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23505255</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;zel S. et al. Supplementary material for: The Subjective Health Horizon Questionnaire (SHH-Q): Assessing future time perspectives for facets of an active lifestyle. Gerontology 62, 345&#x2013;353 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26820307</ArticleId></ArticleIdList></Reference><Reference><Citation>von Oertzen T, Brandmaier AM &amp; Tsang S. Structural equation modeling with &#x3a9;nyx. Struct. Equ. Model 22, 148&#x2013;161 (2015).</Citation></Reference><Reference><Citation>Avants BB et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54, 2033&#x2013;2044 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065962</ArticleId><ArticleId IdType="pubmed">20851191</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Tustison N. &amp; Song G. Advanced Normalization Tools: V1.0. Insight J. 2, 1&#x2013;35 (2009).</Citation></Reference><Reference><Citation>Klein A. et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 46, 786&#x2013;802 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747506</ArticleId><ArticleId IdType="pubmed">19195496</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ Introduction: Experimental design and Statistical Parametric Mapping. Hum. Brain Funct 599&#x2013;632 (2003). doi:10.1016/B978-012693019-1/50024-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-012693019-1/50024-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl MJ, Ilg L, Li S-C, Passow S. &amp; Werkle-Bergner M. Diminished pre-stimulus alpha-lateralization suggests compromised self-initiated attentional control of auditory processing in old age. Neuroimage 197, 414&#x2013;424 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31054351</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31522977</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>PSEN1&#x394;E9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia.</ArticleTitle><Pagination><StartPage>669</StartPage><EndPage>683</EndPage><MedlinePgn>669-683</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2019.08.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(19)30298-X</ELocationID><Abstract><AbstractText>Here we elucidate the effect of Alzheimer disease (AD)-predisposing genetic backgrounds, APOE4, PSEN1&#x394;E9, and APPswe, on functionality of human microglia-like cells (iMGLs). We present a physiologically relevant high-yield protocol for producing iMGLs from induced pluripotent stem cells. Differentiation is directed with small molecules through primitive erythromyeloid progenitors to re-create microglial&#xa0;ontogeny from yolk sac. The iMGLs express microglial signature genes and respond to ADP with intracellular Ca<sup>2+</sup> release distinguishing&#xa0;them from macrophages. Using 16 iPSC lines from healthy donors, AD patients and isogenic controls, we reveal that the APOE4 genotype has a profound impact on several aspects of microglial functionality, whereas PSEN1&#x394;E9 and APPswe mutations trigger minor alterations. The APOE4 genotype impairs phagocytosis, migration, and metabolic activity of iMGLs but exacerbates their cytokine secretion. This indicates that APOE4 iMGLs are fundamentally unable to mount normal microglial functionality in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konttinen</LastName><ForeName>Henna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabral-da-Silva</LastName><ForeName>Mauricio E Castro</ForeName><Initials>MEC</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohtonen</LastName><ForeName>Sohvi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojciechowski</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shakirzyanova</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caligola</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Computer Science, University of Verona, Verona 37134, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giugno</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Computer Science, University of Verona, Verona 37134, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishchenko</LastName><ForeName>Yevheniia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Dami&#xe1;n</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia; Department of Surgery, the University of Melbourne, Melbourne, VIC 3002, Australia; Department of Anatomy and Neuroscience, the University of Melbourne, Melbourne, VIC 3002, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazaludeen</LastName><ForeName>Mohammad Feroze</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eamen</LastName><ForeName>Shaila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budia</LastName><ForeName>Mireia G&#xf3;mez</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagerlund</LastName><ForeName>Ilkka</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scoyni</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korhonen</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haapasalo</LastName><ForeName>Annakaisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Alex W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia; Department of Surgery, the University of Melbourne, Melbourne, VIC 3002, Australia; School of Medicine, Menzies Institute for Medical Research, University of Tasmania, Hobart, VIC 7005, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vickers</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wicking Dementia Research and Education Centre, University of Tasmania, Hobart, TAS 7000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Grady C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oksanen</LastName><ForeName>Minna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department NVS, Division of Neurogeriatrics, Karolinka Institutet, Stockholm 17176, Sweden; Theme Aging, Genetics Unit, Karolinska University Hospital-Solna, Stockholm 17176, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanninen</LastName><ForeName>Katja M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtonen</LastName><ForeName>Sarka</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Propson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology and the Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;bay</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC 3002, Australia; Department of Surgery, the University of Melbourne, Melbourne, VIC 3002, Australia; Department of Anatomy and Neuroscience, the University of Melbourne, Melbourne, VIC 3002, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koistinaho</LastName><ForeName>Jari</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland; Neuroscience Center, University of Helsinki, Helsinki 00014, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ooi</LastName><ForeName>Lezanne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Bioscience, Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malm</LastName><ForeName>Tarja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland. Electronic address: tarja.malm@uef.fi.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006410" MajorTopicYN="N">Hematopoiesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">APPswe</Keyword><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">E9</Keyword><Keyword MajorTopicYN="N">PSEN1&#x394;</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31522977</ArticleId><ArticleId IdType="pmc">PMC6829767</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2019.08.004</ArticleId><ArticleId IdType="pii">S2213-6711(19)30298-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abud E.M., Ramirez R.N., Martinez E.S., Healy L.M., Nguyen C.H.H., Newman S.A., Yeromin A.V., Scarfone V.M., Marsh S.E., Fimbres C. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94:278&#x2013;293.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagyinszky E., Youn Y.C., An S.S., Kim S. The genetics of Alzheimer's disease. Clin. Interv. Aging. 2014;9:535&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979693</ArticleId><ArticleId IdType="pubmed">24729694</ArticleId></ArticleIdList></Reference><Reference><Citation>Balez R., Steiner N., Engel M., Munoz S.S., Lum J.S., Wu Y., Wang D., Vallotton P., Sachdev P., O'Connor M. Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer's disease. Sci. Rep. 2016;6:31450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981845</ArticleId><ArticleId IdType="pubmed">27514990</ArticleId></ArticleIdList></Reference><Reference><Citation>Banati R.B., Gehrmann J., Czech C., Monning U., Jones L.L., Konig G., Beyreuther K., Kreutzberg G.W. Early and rapid de novo synthesis of Alzheimer beta A4-amyloid precursor protein (APP) in activated microglia. Glia. 1993;9:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7507467</ArticleId></ArticleIdList></Reference><Reference><Citation>Barroeta-Espar I., Weinstock L.D., Perez-Nievas B.G., Meltzer A.C., Siao Tick Chong M., Amaral A.C., Murray M.E., Moulder K.L., Morris J.C., Cairns N.J. Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiol. Dis. 2019;121:327&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437670</ArticleId><ArticleId IdType="pubmed">30336198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett M.L., Bennett F.C., Liddelow S.A., Ajami B., Zamanian J.L., Fernhoff N.B., Mulinyawe S.B., Bohlen C.J., Adil A., Tucker A. New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. U S A. 2016;113:E1738&#x2013;E1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Jedrychowski M.P., Moore C.S., Cialic R., Lanser A.J., Gabriely G., Koeglsperger T., Dake B., Wu P.M., Doykan C.E. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat. Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldeira C., Cunha C., Vaz A.R., Falcao A.S., Barateiro A., Seixas E., Fernandes A., Brites D. Key aging-associated alterations in primary microglia response to beta-amyloid stimulation. Front. Aging Neurosci. 2017;9:277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583148</ArticleId><ArticleId IdType="pubmed">28912710</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M., Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 2017;35:441&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167938</ArticleId><ArticleId IdType="pubmed">28226226</ArticleId></ArticleIdList></Reference><Reference><Citation>Crombie D.E., Daniszewski M., Liang H.H., Kulkarni T., Li F., Lidgerwood G.E., Conquest A., Hernandez D., Hung S.S., Gill K.P. Development of a modular automated system for maintenance and differentiation of adherent human pluripotent stem cells. SLAS Discov. 2017;22:1016&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">28287872</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R., Verkkoniemi A., Perez-Tur J., Mehta N., Baker M., Houlden H., Farrer M., Hutton M., Lincoln S., Hardy J. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 1998;4:452&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546792</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simone R., Niturad C.E., De Nuccio C., Ajmone-Cat M.A., Visentin S., Minghetti L. TGF-beta and LPS modulate ADP-induced migration of microglial cells through P2Y1 and P2Y12 receptor expression. J.&#xa0;Neurochem. 2010;115:450&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">20681951</ArticleId></ArticleIdList></Reference><Reference><Citation>Douvaras P., Sun B., Wang M., Kruglikov I., Lallos G., Zimmer M., Terrenoire C., Zhang B., Gandy S., Schadt E. Directed differentiation of human pluripotent stem cells to Microglia. Stem Cell Reports. 2017;8:1516&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470097</ArticleId><ArticleId IdType="pubmed">28528700</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel M., Balez R., Munoz S.S., Cabral-da-Silva M.C., Stevens C.H., Bax M., Do-Ha D., Sidhu K., Sachdev P., Ooi L. Viral-free generation and characterization of a human induced pluripotent stem cell line from dermal fibroblasts. Stem Cell Res. 2018;32:135&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">30278375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S., Castillo E., Frias E.S., Swanson R.A. Bioenergetic regulation of microglia. Glia. 2018;66:1200&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5903989</ArticleId><ArticleId IdType="pubmed">29219210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F., Lim S., Hoeffel G., Low D., Huber T. Origin and differentiation of microglia. Front. Cell Neurosci. 2013;7:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627983</ArticleId><ArticleId IdType="pubmed">23616747</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W., Sansom S.N., Buchrieser J., Newey S.E., Moore C.S., Nicholls F.J., Chintawar S., Schnell C., Antel J.P., Allen N.D. A highly efficient human pluripotent stem cell Microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Reports. 2017;8:1727&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470330</ArticleId><ArticleId IdType="pubmed">28591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann A., Kann O., Ohlemeyer C., Hanisch U.K., Kettenmann H. Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptor-evoked calcium signaling and control of release function. J.&#xa0;Neurosci. 2003;23:4410&#x2013;4419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740788</ArticleId><ArticleId IdType="pubmed">12805281</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmqvist S., Lehtonen S., Chumarina M., Puttonen K.A., Azevedo C., Lebedeva O., Ruponen M., Oksanen M., Djelloul M., Collin A. Creation of a library of induced pluripotent stem cells from Parkinsonian patients. NPJ Parkinson's Dis. 2016;2:16009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516589</ArticleId><ArticleId IdType="pubmed">28725696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayadev S., Case A., Alajajian B., Eastman A.J., Moller T., Garden G.A. Presenilin 2 influences miR146 level and activity in microglia. J.&#xa0;Neurochem. 2013;127:592&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4346352</ArticleId><ArticleId IdType="pubmed">23952003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy M., D'Souza S.L., Lynch-Kattman M., Schwantz S., Keller G. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood. 2007;109:2679&#x2013;2687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852226</ArticleId><ArticleId IdType="pubmed">17148580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K., Erny D., Goldmann T., Sander V., Schulz C., Perdiguero E.G., Wieghofer P., Heinrich A., Riemke P., Holscher C. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 2013;16:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J., Landreth G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J.&#xa0;Neurosci. 2005;25:8240&#x2013;8249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725530</ArticleId><ArticleId IdType="pubmed">16148231</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O'Loughlin E., Xu Y., Fanek Z. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert C., Ase A.R., Seguela P., Antel J.P. Distinct migratory and cytokine responses of human microglia and macrophages to ATP. Brain Behav. Immun. 2010;24:1241&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">20206681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzrein A.S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 1998;12:215&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9772027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavin Y., Winter D., Blecher-Gonen R., David E., Keren-Shaul H., Merad M., Jung S., Amit I. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437213</ArticleId><ArticleId IdType="pubmed">25480296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.Y., Landreth G.E. The role of microglia in amyloid clearance from the AD brain. J.&#xa0;Neural Transm. (Vienna) 2010;117:949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.T., Seo J., Gao F., Feldman H.M., Wen H.L., Penney J., Cam H.P., Gjoneska E., Raja W.K., Cheng J. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141&#x2013;1154.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Manocha G.D., Floden A.M., Rausch K., Kulas J.A., McGregor B.A., Rojanathammanee L., Puig K.R., Puig K.L., Karki S., Nichols M.R. APP regulates microglial phenotype in a mouse model of Alzheimer's disease. J.&#xa0;Neurosci. 2016;36:8471&#x2013;8486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978805</ArticleId><ArticleId IdType="pubmed">27511018</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaughey T., Liang H.H., Chen C., Fenwick E., Rees G., Wong R.C., Vickers J.C., Summers M.J., MacGregor C., Craig J.E. An interactive multimedia approach to improving informed consent for induced pluripotent stem cell research. Cell Stem Cell. 2016;18:307&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">26942850</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A., Coburn M., Tu C.H., Hasselmann J., Davtyan H., Blurton-Jones M. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener. 2018;13:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J., Li Y., Yuan B., Mitalipova M., Omer A., Corcoran S., Bakiasi G., Tsai L.H., Aubourg P., Ransohoff R.M. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med. 2016;22:1358&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1992;1:345&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz S.S., Balez R., Castro Cabral-da-Silva M.E., Berg T., Engel M., Bax M., Do-Ha D., Stevens C.H., Greenough M., Bush A. Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1. Stem Cell Res. 2018;31:227&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">30138848</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler Y., Alexandrovich A., Grigoriadis N., Hartmann T., Rao K.S., Shohami E., Stein R. Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia. 2008;56:552&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">18240300</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberstein T.J., Spitzer P., Klafki H.W., Linning P., Neff F., Knolker H.J., Lewczuk P., Wiltfang J., Kornhuber J., Maler J.M. Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Abeta peptides. Neurobiol. Dis. 2015;73:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25204716</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K., Matsumura Y., Sato Y., Okada A., Morizane A., Okamoto S., Hong H., Nakagawa M., Tanabe K., Tezuka K. A more efficient method to generate integration-free human iPS cells. Nat. Methods. 2011;8:409&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksanen M., Hyotylainen I., Voutilainen J., Puttonen K.A., Hamalainen R.H., Graff C., Lehtonen S., Koistinaho J. Generation of a human induced pluripotent stem cell line (LL008 1.4) from a familial Alzheimer's disease patient carrying a double KM670/671NL (Swedish) mutation in APP gene. Stem Cell Res. 2018;31:181&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">30099334</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksanen M., Petersen A.J., Naumenko N., Puttonen K., Lehtonen S., Gubert Olive M., Shakirzyanova A., Leskela S., Sarajarvi T., Viitanen M. PSEN1 mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer's disease. Stem Cell Reports. 2017;9:1885&#x2013;1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785689</ArticleId><ArticleId IdType="pubmed">29153989</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M., Patrick E., Villani A.C., Xu J., White C.C., Ryan K.J., Piehowski P., Kapasi A., Nejad P., Cimpean M. A transcriptomic atlas of aged human microglia. Nat. Commun. 2018;9:539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi L., Sidhu K., Poljak A., Sutherland G., O'Connor M.D., Sachdev P., Munch G. Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease. J.&#xa0;Neural Transm. (Vienna) 2013;120:103&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">22695755</ArticleId></ArticleIdList></Reference><Reference><Citation>Orihuela R., McPherson C.A., Harry G.J. Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 2016;173:649&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742299</ArticleId><ArticleId IdType="pubmed">25800044</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya H., Shen M.J., Ichikawa D.M., Sedlock A.B., Choi Y., Johnson K.R., Kim G., Brown M.A., Elkahloun A.G., Maric D. Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat. Neurosci. 2017;20:753&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404968</ArticleId><ArticleId IdType="pubmed">28253233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido-Salgado M., Vidal-Taboada J.M., Barriga G.G., Sola C., Saura J. RNA-Seq transcriptomic profiling of primary murine microglia treated with LPS or LPS&#xa0;+ IFNgamma. Sci. Rep. 2018;8:16096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208373</ArticleId><ArticleId IdType="pubmed">30382133</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu C., Puttonen K.A., Lindeberg H., Ruponen M., Hovatta O., Koistinaho J., Lammi M.J. Chondrogenic differentiation of human pluripotent stem cells in chondrocyte co-culture. Int. J. Biochem. Cell Biol. 2013;45:1802&#x2013;1812.</Citation><ArticleIdList><ArticleId IdType="pubmed">23735325</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J., Park T.I., Schweder P., Scotter J., Correia J., Smith A.M., Gibbons H.M., Oldfield R.L., Bergin P.S., Mee E.W. Isolation of highly enriched primary human microglia for functional studies. Sci. Rep. 2016;6:19371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725991</ArticleId><ArticleId IdType="pubmed">26778406</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo K., Glass C.K. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 2011;11:775&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">22025055</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in&#xa0;vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M.P., Hou Z., Propson N.E., Zhang J., Engstrom C.J., Santos Costa V., Jiang P., Nguyen B.K., Bolin J.M., Daly W. Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. Proc. Natl. Acad. Sci. U S A. 2015;112:12516&#x2013;12521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603492</ArticleId><ArticleId IdType="pubmed">26392547</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998;8:447&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Holtzman D.M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 2018;18:759&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J.A., Das A., Ray S.K., Banik N.L. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res. Bull. 2012;87:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9827422</ArticleId><ArticleId IdType="pubmed">22024597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturgeon C.M., Ditadi A., Awong G., Kennedy M., Keller G. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells. Nat. Biotechnol. 2014;32:554&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152856</ArticleId><ArticleId IdType="pubmed">24837661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta T.T., Dikmen H.O., Schilling S., Chausse B., Lewen A., Hollnagel J.O., Kann O. Priming of microglia with IFN-gamma slows neuronal gamma oscillations in&#xa0;situ. Proc. Natl. Acad. Sci. U S A. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410786</ArticleId><ArticleId IdType="pubmed">30782788</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend K.P., Town T., Mori T., Lue L.F., Shytle D., Sanberg P.R., Morgan D., Fernandez F., Flavell R.A., Tan J. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur. J. Immunol. 2005;35:901&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688347</ArticleId></ArticleIdList></Reference><Reference><Citation>Uenishi G., Theisen D., Lee J.H., Kumar A., Raymond M., Vodyanik M., Swanson S., Stewart R., Thomson J., Slukvin I. Tenascin C promotes hematoendothelial development&#xa0;and T lymphoid commitment from human pluripotent stem cells in chemically defined conditions. Stem Cell Reports. 2014;3:1073&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263995</ArticleId><ArticleId IdType="pubmed">25448067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland T.K., Song W.M., Huang S.C., Ulrich J.D., Sergushichev A., Beatty W.L., Loboda A.A., Zhou Y., Cairns N.J., Kambal A. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell. 2017;170:649&#x2013;663.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.Y., Tan M.S., Yu J.T., Tan L. Role of pro-inflammatory&#xa0;cytokines released from microglia in Alzheimer's disease. Ann. Transl. Med. 2015;3:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486922</ArticleId><ArticleId IdType="pubmed">26207229</ArticleId></ArticleIdList></Reference><Reference><Citation>Weuve J., Hebert L.E., Scherr P.A., Evans D.A. Deaths in the United States among persons with Alzheimer's disease (2010-2050) Alzheimers Dement. 2014;10:e40&#x2013;e46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976898</ArticleId><ArticleId IdType="pubmed">24698031</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Zhang L., Liu G., Jiang N., Zhou W., Zhang Y. Pathological changes in alzheimer's disease analyzed using induced pluripotent stem cell-derived human Microglia-like cells. J.&#xa0;Alzheimers Dis. 2019;67:357&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">30562902</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen K., Sloan S.A., Bennett M.L., Scholze A.R., O'Keeffe S., Phatnani H.P., Guarnieri P., Caneda C., Ruderisch N. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J.&#xa0;Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Li X., Huang T., Jiang L.L., Tan Z., Zhang M., Cheng I.H., Wang X., Bu G., Zhang Y.W. Intracellular trafficking of TREM2 is regulated by presenilin 1. Exp. Mol. Med. 2017;49:e405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5750471</ArticleId><ArticleId IdType="pubmed">29611543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31524631</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.</ArticleTitle><Pagination><StartPage>4539</StartPage><EndPage>4549</EndPage><MedlinePgn>4539-4549</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI129987</ELocationID><ELocationID EIdType="pii" ValidYN="Y">129987</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is a common neurodegenerative disease that lacks therapies to prevent progressive neurodegeneration. Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enhances the activity of phosphoglycerate kinase 1 (PGK1), thereby stimulating glycolysis and increasing cellular ATP levels. Therefore, we asked whether enhancement of PGK1 activity would change the course of PD. In toxin-induced and genetic PD models in mice, rats, flies, and induced pluripotent stem cells, TZ increased brain ATP levels and slowed or prevented neuron loss. The drug increased dopamine levels and partially restored motor function. Because TZ is prescribed clinically, we also interrogated 2 distinct human databases. We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs. These findings suggest that enhancing PGK1 activity and increasing glycolysis may slow neurodegeneration in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Hypoxia Medicine, Xuanwu Hospital and Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Membrane Biology, School of Life Sciences, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmering</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Jordan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departments of Pharmaceutical Care and Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Carasa</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat and Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Consiglio</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospitalet de Llobregat and Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raya</LastName><ForeName>Angel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center of Regenerative Medicine in Barcelona (CMRB) and Networking Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituci&#xf3; Catalana de Recerca i Estudis Avan&#xe7;ats (ICREA), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polgreen</LastName><ForeName>Philip M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Departments of Internal Medicine and Epidemiology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayanan</LastName><ForeName>Nandakumar S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yanpeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Hypoxia Medicine, Xuanwu Hospital and Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhiguo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Hypoxia Medicine, Xuanwu Hospital and Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Wenting</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Hypoxia Medicine, Xuanwu Hospital and Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Chunyue</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Lifang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Xunming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Hypoxia Medicine, Xuanwu Hospital and Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welsh</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Departments of Internal Medicine, Neurology, and Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR002536</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL091842</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8L5014XET7</RegistryNumber><NameOfSubstance UI="C041226">Terazosin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.2.3</RegistryNumber><NameOfSubstance UI="C577282">PGK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.2.3</RegistryNumber><NameOfSubstance UI="D010735">Phosphoglycerate Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>XM03YJ541D</RegistryNumber><NameOfSubstance UI="D011224">Prazosin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2019 Nov;15(11):621. doi: 10.1038/s41582-019-0274-1.</RefSource><PMID Version="1">31578529</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2020 Jan;35(1):81. doi: 10.1002/mds.27934.</RefSource><PMID Version="1">31782816</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010735" MajorTopicYN="N">Phosphoglycerate Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011224" MajorTopicYN="N">Prazosin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neuroscience</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> The authors have declared that no conflict of interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31524631</ArticleId><ArticleId IdType="pmc">PMC6763248</ArticleId><ArticleId IdType="doi">10.1172/JCI129987</ArticleId><ArticleId IdType="pii">129987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2016 Neurology Collaborators Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459&#x2013;480. doi: 10.1016/S1474-4422(18)30499-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30499-X</ArticleId><ArticleId IdType="pmc">PMC6459001</ArticleId><ArticleId IdType="pubmed">30879893</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S. The history of dopamine and levodopa in the treatment of Parkinson&#x2019;s disease. Mov Disord. 2008;23(Suppl 3):S497&#x2013;S508.</Citation><ArticleIdList><ArticleId IdType="pubmed">18781671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri KR, Odin P. The challenge of non-motor symptoms in Parkinson&#x2019;s disease. Prog Brain Res. 2010;184:325&#x2013;341. doi: 10.1016/S0079-6123(10)84017-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6123(10)84017-8</ArticleId><ArticleId IdType="pubmed">20887883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia LV, Lang AE. Parkinson&#x2019;s disease. Lancet. 2015;386(9996):896&#x2013;912. doi: 10.1016/S0140-6736(14)61393-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61393-3</ArticleId><ArticleId IdType="pubmed">25904081</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson&#x2019;s disease: Targets for potential treatments. Transl Neurodegener. 2017;6:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655877</ArticleId><ArticleId IdType="pubmed">29090092</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson&#x2019;s disease: Separating the wheat from the chaff. J Parkinsons Dis. 2017;7(s1):S71&#x2013;S85. doi: 10.3233/JPD-179001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-179001</ArticleId><ArticleId IdType="pmc">PMC5345633</ArticleId><ArticleId IdType="pubmed">28282810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunn BH, Cragg SJ, Bolam JP, Spillantini MG, Wade-Martins R. Impaired intracellular trafficking defines early Parkinson&#x2019;s disease. Trends Neurosci. 2015;38(3):178&#x2013;188. doi: 10.1016/j.tins.2014.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.12.009</ArticleId><ArticleId IdType="pmc">PMC4740565</ArticleId><ArticleId IdType="pubmed">25639775</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. Triggers, facilitators, and aggravators: Redefining Parkinson&#x2019;s disease pathogenesis. Trends Neurosci. 2019;42(1):4&#x2013;13. doi: 10.1016/j.tins.2018.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2018.09.007</ArticleId><ArticleId IdType="pmc">PMC6623978</ArticleId><ArticleId IdType="pubmed">30342839</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson&#x2019;s disease. Rev Neurol (Paris) 2018;174(9):628&#x2013;643. doi: 10.1016/j.neurol.2018.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2018.08.004</ArticleId><ArticleId IdType="pubmed">30245141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;newald A, Kumar KR, Sue CM. New insights into the complex role of mitochondria in Parkinson&#x2019;s disease. Prog Neurobiol. 2019;177:73&#x2013;93. doi: 10.1016/j.pneurobio.2018.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2018.09.003</ArticleId><ArticleId IdType="pubmed">30219247</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena U. Bioenergetics failure in neurodegenerative diseases: back to the future. Expert Opin Ther Targets. 2012;16(4):351&#x2013;354. doi: 10.1517/14728222.2012.664135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2012.664135</ArticleId><ArticleId IdType="pubmed">22339293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer S. Brain glucose and energy metabolism during normal aging. Aging (Milano) 1990;2(3):245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">1982730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CC, et al. Risk factors for myopia progression in second-grade primary school children in Taipei: a population-based cohort study. Br J Ophthalmol. 2017;101(12):1611&#x2013;1617. doi: 10.1136/bjophthalmol-2016-309299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2016-309299</ArticleId><ArticleId IdType="pubmed">28315834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH. Mitochondrial complex I deficiency in Parkinson&#x2019;s disease. Adv Neurol. 1993;60:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">8420145</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson&#x2019;s disease. J Biomed Biotechnol. 2012;2012:845618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321500</ArticleId><ArticleId IdType="pubmed">22536024</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson&#x2019;s disease. Lancet Neurol. 2008;7(1):97&#x2013;109. doi: 10.1016/S1474-4422(07)70327-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70327-7</ArticleId><ArticleId IdType="pubmed">18093566</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson&#x2019;s disease. FEBS J. 2018;285(19):3657&#x2013;3668. doi: 10.1111/febs.14607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.14607</ArticleId><ArticleId IdType="pmc">PMC6546423</ArticleId><ArticleId IdType="pubmed">30028088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, et al. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. Nat Chem Biol. 2015;11(1):19&#x2013;25. doi: 10.1038/nchembio.1657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1657</ArticleId><ArticleId IdType="pmc">PMC4412158</ArticleId><ArticleId IdType="pubmed">25383758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilt TJ, Howe W, MacDonald R. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int. 2002;89(3):214&#x2013;225. doi: 10.1046/j.1464-4096.2001.02537.x-i1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-4096.2001.02537.x-i1</ArticleId><ArticleId IdType="pubmed">11856101</ArticleId></ArticleIdList></Reference><Reference><Citation>Compan V, et al. Monitoring mitochondrial pyruvate carrier activity in real time using a BRET-based biosensor: investigation of the Warburg effect. Mol Cell. 2015;59(3):491&#x2013;501. doi: 10.1016/j.molcel.2015.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.06.035</ArticleId><ArticleId IdType="pubmed">26253029</ArticleId></ArticleIdList></Reference><Reference><Citation>Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 1984;224(4656):1451&#x2013;1453. doi: 10.1126/science.6610213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6610213</ArticleId><ArticleId IdType="pubmed">6610213</ArticleId></ArticleIdList></Reference><Reference><Citation>Przedborski S, et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2000;16(2):135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">12671216</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson L, Yang Q, Szustakowski JD, Gullicksen PS, Halse R. Pyruvate induces mitochondrial biogenesis by a PGC-1 alpha-independent mechanism. Am J Physiol, Cell Physiol. 2007;292(5):C1599&#x2013;C1605. doi: 10.1152/ajpcell.00428.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00428.2006</ArticleId><ArticleId IdType="pubmed">17182725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. 1968;5(1):107&#x2013;110. doi: 10.1016/0014-2999(68)90164-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(68)90164-7</ArticleId><ArticleId IdType="pubmed">5718510</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Lee T, Leong SK. Time course of dopaminergic cell death and changes in iron, ferritin and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning. Free Radic Res. 1999;31(2):103&#x2013;112. doi: 10.1080/10715769900301611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715769900301611</ArticleId><ArticleId IdType="pubmed">10490239</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms AS, et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson&#x2019;s disease. Mol Ther. 2011;19(1):46&#x2013;52. doi: 10.1038/mt.2010.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.217</ArticleId><ArticleId IdType="pmc">PMC3017447</ArticleId><ArticleId IdType="pubmed">20959812</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan WJ, et al. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci. 2008;9:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533664</ArticleId><ArticleId IdType="pubmed">18671880</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Potential pathways of abnormal tau and &#x3b1;-synuclein dissemination in sporadic Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Cold Spring Harb Perspect Biol. 2016;8(11):a023630. doi: 10.1101/cshperspect.a023630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a023630</ArticleId><ArticleId IdType="pmc">PMC5088528</ArticleId><ArticleId IdType="pubmed">27580631</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson&#x2019;s disease in Drosophila melanogaster. J Neurosci. 2004;24(48):10993&#x2013;10998. doi: 10.1523/JNEUROSCI.2993-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2993-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730201</ArticleId><ArticleId IdType="pubmed">15574749</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd PJ, et al. Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genet. 2017;13(4):e1006744. doi: 10.1371/journal.pgen.1006744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006744</ArticleId><ArticleId IdType="pmc">PMC5417717</ArticleId><ArticleId IdType="pubmed">28426667</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark IE, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441(7097):1162&#x2013;1166. doi: 10.1038/nature04779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04779</ArticleId><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai PI, et al. PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions. Mol Cell. 2018;69(5):744&#x2013;756.e6. doi: 10.1016/j.molcel.2018.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.01.026</ArticleId><ArticleId IdType="pubmed">29456190</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun J, et al. Loss-of-function analysis suggests that Omi/HtrA2 is not an essential component of the PINK1/PARKIN pathway in vivo. J Neurosci. 2008;28(53):14500&#x2013;14510. doi: 10.1523/JNEUROSCI.5141-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5141-08.2008</ArticleId><ArticleId IdType="pmc">PMC2718055</ArticleId><ArticleId IdType="pubmed">19118185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SB, Kim W, Lee S, Chung J. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun. 2007;358(2):534&#x2013;539. doi: 10.1016/j.bbrc.2007.04.156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.04.156</ArticleId><ArticleId IdType="pubmed">17498648</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601&#x2013;607. doi: 10.1016/j.neuron.2004.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.11.005</ArticleId><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x2019;s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469&#x2013;6473. doi: 10.1073/pnas.95.11.6469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6469</ArticleId><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68(5):568&#x2013;578. doi: 10.1002/jnr.10231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10231</ArticleId><ArticleId IdType="pubmed">12111846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM. Genetics of Parkinson&#x2019;s disease. Mol Cell Probes. 2016;30(6):386&#x2013;396. doi: 10.1016/j.mcp.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2016.11.001</ArticleId><ArticleId IdType="pubmed">27818248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HN, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8(3):267&#x2013;280. doi: 10.1016/j.stem.2011.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2011.01.013</ArticleId><ArticleId IdType="pmc">PMC3578553</ArticleId><ArticleId IdType="pubmed">21362567</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72(5):432&#x2013;438. doi: 10.1212/01.wnl.0000341769.50075.bb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000341769.50075.bb</ArticleId><ArticleId IdType="pmc">PMC2676726</ArticleId><ArticleId IdType="pubmed">19188574</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson&#x2019;s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129&#x2013;2170. doi: 10.1002/mds.22340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22340</ArticleId><ArticleId IdType="pubmed">19025984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. Insulin and mTOR pathway regulate HDAC3-mediated deacetylation and activation of PGK1. PLoS Biol. 2015;13(9):e1002243. doi: 10.1371/journal.pbio.1002243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002243</ArticleId><ArticleId IdType="pmc">PMC4565669</ArticleId><ArticleId IdType="pubmed">26356530</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanon A, Pramstaller PP, Hicks AA, Pichler I. Environmental and genetic variables influencing mitochondrial health and Parkinson&#x2019;s disease penetrance. Parkinsons Dis. 2018;2018:8684906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863306</ArticleId><ArticleId IdType="pubmed">29707191</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, et al. ATP as a biological hydrotrope. Science. 2017;356(6339):753&#x2013;756. doi: 10.1126/science.aaf6846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6846</ArticleId><ArticleId IdType="pubmed">28522535</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes MH, Peuchen EH, Dovichi NJ, Weeks DL. Dual roles for ATP in the regulation of phase separated protein aggregates in Xenopus oocyte nucleoli. Elife. 2018;7:e35224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050040</ArticleId><ArticleId IdType="pubmed">30015615</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018;21(10):1370&#x2013;1379. doi: 10.1038/s41593-018-0236-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0236-8</ArticleId><ArticleId IdType="pmc">PMC6615039</ArticleId><ArticleId IdType="pubmed">30250265</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009;55(4):129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">19886768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk JK, Konen JC, Shihabi Z, Rocco MV, Summerson JH. Effects of terazosin on glycemic control, cholesterol, and microalbuminuria in patients with non&#x2013;insulin-dependent diabetes mellitus and hypertension. Am J Ther. 1996;3(9):616&#x2013;621. doi: 10.1097/00045391-199609000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00045391-199609000-00003</ArticleId><ArticleId IdType="pubmed">11862301</ArticleId></ArticleIdList></Reference><Reference><Citation>Shionoiri H, et al. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study. Am J Med Sci. 1994;307(Suppl 1):S91&#x2013;S95.</Citation><ArticleIdList><ArticleId IdType="pubmed">7908168</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyda HN, Procyshyn RM, Pang CC, Barr AM. Peripheral adrenoceptors: the impetus behind glucose dysregulation and insulin resistance. J Neuroendocrinol. 2013;25(3):217&#x2013;228. doi: 10.1111/jne.12002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jne.12002</ArticleId><ArticleId IdType="pubmed">23140239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue S, et al. Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism? NPJ Parkinsons Dis. 2017;3:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5459803</ArticleId><ArticleId IdType="pubmed">28649613</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotiriou E, Greene P, Krishna S, Hirano M, DiMauro S. Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve. 2010;41(5):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285082</ArticleId><ArticleId IdType="pubmed">20151463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson&#x2019;s disease than women? J Neurol Neurosurg Psychiatry. 2004;75(4):637&#x2013;639. doi: 10.1136/jnnp.2003.020982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.020982</ArticleId><ArticleId IdType="pmc">PMC1739032</ArticleId><ArticleId IdType="pubmed">15026515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer&#x2019;s pathology in female mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2009;106(34):14670&#x2013;14675. doi: 10.1073/pnas.0903563106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903563106</ArticleId><ArticleId IdType="pmc">PMC2732886</ArticleId><ArticleId IdType="pubmed">19667196</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31542321</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Pathogenic Tau Impairs Axon Initial Segment Plasticity and Excitability Homeostasis.</ArticleTitle><Pagination><StartPage>458</StartPage><EndPage>470.e5</EndPage><MedlinePgn>458-470.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2019.08.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(19)30692-0</ELocationID><Abstract><AbstractText>Dysregulation of neuronal excitability underlies the pathogenesis of tauopathies, including frontotemporal dementia (FTD) with tau inclusions. A majority of FTD-causing tau mutations are located in the microtubule-binding domain, but how these mutations alter neuronal excitability is largely unknown. Here, using CRISPR/Cas9-based gene editing in human pluripotent stem cell (iPSC)-derived neurons and isogenic controls, we show that the FTD-causing V337M tau mutation impairs activity-dependent plasticity of the cytoskeleton in the axon initial segment (AIS). Extracellular recordings by multi-electrode arrays (MEAs) revealed that the V337M tau mutation in human neurons leads to an abnormal increase in neuronal activity in response to chronic depolarization. Stochastic optical reconstruction microscopy of human neurons with this mutation showed that AIS plasticity is impaired by the abnormal accumulation of end-binding protein 3 (EB3) in the AIS submembrane region. These findings expand our understanding of how FTD-causing tau mutations dysregulate components of the neuronal cytoskeleton, leading to network dysfunction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>Peter Dongmin</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Cindy Tzu-Ling</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Weill Cornell Medical Center, New York, NY10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>Tara E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camargo</LastName><ForeName>Carolina M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arhar</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Sue-Ann</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freilich</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baik</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physics, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Manni</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Shiaoching</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Weill Cornell Medical Center, New York, NY10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neurobiology, University of Alabama, Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gestwicki</LastName><ForeName>Jason E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: lig2033@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG057497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS059690</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG057862</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG046374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054214</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM064337</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C403664">MAPRE3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2019 Nov 6;104(3):429-430. doi: 10.1016/j.neuron.2019.10.021.</RefSource><PMID Version="1">31697915</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000071040" MajorTopicYN="N">Axon Initial Segment</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055724" MajorTopicYN="N">Electrophysiological Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EB3</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">axon initial segment</Keyword><Keyword MajorTopicYN="N">cytoskeleton</Keyword><Keyword MajorTopicYN="N">homeostasis</Keyword><Keyword MajorTopicYN="N">neuronal activity</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31542321</ArticleId><ArticleId IdType="mid">NIHMS1537566</ArticleId><ArticleId IdType="pmc">PMC6880876</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.08.008</ArticleId><ArticleId IdType="pii">S0896-6273(19)30692-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ban H, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, Takada N, Inoue M, Hasegawa M, Kawamata S, et al. (2011). Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A 108, 14234&#x2013;14239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161531</ArticleId><ArticleId IdType="pubmed">21821793</ArticleId></ArticleIdList></Reference><Reference><Citation>Barre P, and Eliezer D (2013). Structural transitions in tau k18 on micelle binding suggest a hierarchy in the efficacy of individual microtubule-binding repeats in filament nucleation. Protein Sci 22, 1037&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832040</ArticleId><ArticleId IdType="pubmed">23740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Beagle AJ, Darwish SM, Ranasinghe KG, La AL, Karageorgiou E, and Vossel KA (2017). Relative Incidence of Seizures and Myoclonus in Alzheimer&#x2019;s Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia. J Alzheimers Dis 60, 211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608587</ArticleId><ArticleId IdType="pubmed">28826176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender KJ, and Trussell LO (2009). Axon initial segment Ca2+ channels influence action potential generation and timing. Neuron 61, 259&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730113</ArticleId><ArticleId IdType="pubmed">19186168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges DC, Tovar KR, Wu B, Hansma PK, and Kosik KS (2018). MEA Viewer: A high- performance interactive application for visualizing electrophysiological data. PLoS One 13, e0192477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806868</ArticleId><ArticleId IdType="pubmed">29425223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chand AN, Galliano E, Chesters RA, and Grubb MS (2015). A distinct subtype of dopaminergic interneuron displays inverted structural plasticity at the axon initial segment. J Neurosci 35, 1573&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308603</ArticleId><ArticleId IdType="pubmed">25632134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cao J, Xiong M, Petersen AJ, Dong Y, Tao Y, Huang CT, Du Z, and Zhang SC (2015). Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9. Cell Stem Cell 17, 233&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530040</ArticleId><ArticleId IdType="pubmed">26145478</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde C, and Caceres A (2009). Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10, 319&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">19377501</ArticleId></ArticleIdList></Reference><Reference><Citation>Crimins JL, Rocher AB, and Luebke JI (2012). Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. Acta Neuropathol 124, 777&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509230</ArticleId><ArticleId IdType="pubmed">22976049</ArticleId></ArticleIdList></Reference><Reference><Citation>Czogalla A, and Sikorski AF (2005). Spectrin and calpain: a &#x2018;target&#x2019; and a &#x2018;sniper&#x2019; in the pathology of neuronal cells. Cell Mol Life Sci 62, 1913&#x2013;1924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11139101</ArticleId><ArticleId IdType="pubmed">15990959</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, et al. (2013). Antisense reduction of tau in adult mice protects against seizures. J Neurosci 33, 12887&#x2013;12897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, et al. (2005). Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65, 404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MD, Dumitrescu AS, Kruijssen DLH, Taylor SE, and Grubb MS (2015). Rapid Modulation of Axon Initial Segment Length Influences Repetitive Spike Firing. Cell Rep 13, 1233&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646840</ArticleId><ArticleId IdType="pubmed">26526995</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MD, Sammons RP, Lebron S, Dumitrescu AS, Watkins TB, Uebele VN, Renger JJ, and Grubb MS (2013). Calcineurin signaling mediates activity-dependent relocation of the axon initial segment. J Neurosci 33, 6950&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743026</ArticleId><ArticleId IdType="pubmed">23595753</ArticleId></ArticleIdList></Reference><Reference><Citation>Freal A, Fassier C, Le Bras B, Bullier E, De Gois S, Hazan J, Hoogenraad CC, and Couraud F (2016). Cooperative Interactions between 480 kDa Ankyrin-G and EB Proteins Assemble the Axon Initial Segment. J Neurosci 36, 4421&#x2013;4433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601828</ArticleId><ArticleId IdType="pubmed">27098687</ArticleId></ArticleIdList></Reference><Reference><Citation>Galjart N (2010). Plus-end-tracking proteins and their interactions at microtubule ends. Curr Biol 20, R528&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">20620909</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Cabrero AM, Guerrero-Lopez R, Giraldez BG, Llorens-Martin M, Avila J, Serratosa JM, and Sanchez MP (2013). Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis 58, 200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774255</ArticleId></ArticleIdList></Reference><Reference><Citation>Geyer M, Huang F, Sun Y, Vogel SM, Malik AB, Taylor CW, and Komarova YA (2015). Microtubule-Associated Protein EB3 Regulates IP3 Receptor Clustering and Ca(2+) Signaling in Endothelial Cells. Cell Rep 12, 79&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487770</ArticleId><ArticleId IdType="pubmed">26119739</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Crowther RA, and Spillantini MG (1998). Tau mutations cause frontotemporal dementias. Neuron 21, 955&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856453</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubb MS, and Burrone J (2010). Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability. Nature 465, 1070&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196626</ArticleId><ArticleId IdType="pubmed">20543823</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubb MS, Shu Y, Kuba H, Rasband MN, Wimmer VC, and Bender KJ (2011). Short- and long-term plasticity at the axon initial segment. J Neurosci 31, 16049&#x2013;16055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232445</ArticleId><ArticleId IdType="pubmed">22072655</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall AM, Throesch BT, Buckingham SC, Markwardt SJ, Peng Y, Wang Q, Hoffman DA, and Roberson ED (2015). Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer&#x2019;s disease. J Neurosci 35, 6221&#x2013;6230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397611</ArticleId><ArticleId IdType="pubmed">25878292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch RJ, Wei Y, Xia D, and Gotz J (2017). Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. Acta Neuropathol 133, 717&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389999</ArticleId><ArticleId IdType="pubmed">28091722</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, and Noebels JL (2013). Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci 33, 1651&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711605</ArticleId><ArticleId IdType="pubmed">23345237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A, et al. (1998). Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282, 1914&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Horschitz S, Matthaus F, Gross A, Rosner J, Galach M, Greffrath W, Treede RD, Utikal J, Schloss P, and Meyer-Lindenberg A (2015). Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neurons. Stem Cell Res 15, 30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">26001168</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B, Wang W, Bates M, and Zhuang X (2008). Three-dimensional super-resolution imaging by stochastic optical reconstruction microscopy. Science 319, 810&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633023</ArticleId><ArticleId IdType="pubmed">18174397</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al. (1998). Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, Akoury E, Abisambra JF, O&#x2019;Leary JC 3rd, Thompson AD, Blair LJ, Jin Y, Bacon J, Nordhues BA, Cockman M, et al. (2013). Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J 27, 1450&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606536</ArticleId><ArticleId IdType="pubmed">23271055</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones SL, Korobova F, and Svitkina T (2014). Axon initial segment cytoskeleton comprises a multiprotein submembranous coat containing sparse actin filaments. J Cell Biol 205, 67&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3987141</ArticleId><ArticleId IdType="pubmed">24711503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kevenaar JT, and Hoogenraad CC (2015). The axonal cytoskeleton: from organization to function. Front Mol Neurosci 8, 44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4536388</ArticleId><ArticleId IdType="pubmed">26321907</ArticleId></ArticleIdList></Reference><Reference><Citation>Komarova YA, Huang F, Geyer M, Daneshjou N, Garcia A, Idalino L, Kreutz B, Mehta D, and Malik AB (2012). VE-cadherin signaling induces EB3 phosphorylation to suppress microtubule growth and assemble adherens junctions. Mol Cell 48, 914&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3627495</ArticleId><ArticleId IdType="pubmed">23159740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba H, Oichi Y, and Ohmori H (2010). Presynaptic activity regulates Na(+) channel distribution at the axon initial segment. Nature 465, 1075&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">20543825</ArticleId></ArticleIdList></Reference><Reference><Citation>Leterrier C, Potier J, Caillol G, Debarnot C, Rueda Boroni F, and Dargent B (2015). Nanoscale Architecture of the Axon Initial Segment Reveals an Organized and Robust Scaffold. Cell Rep 13, 2781&#x2013;2793.</Citation><ArticleIdList><ArticleId IdType="pubmed">26711344</ArticleId></ArticleIdList></Reference><Reference><Citation>Leterrier C, Vacher H, Fache MP, d&#x2019;Ortoli SA, Castets F, Autillo-Touati A, and Dargent B (2011). End-binding proteins EB3 and EB1 link microtubules to ankyrin G in the axon initial segment. Proc Natl Acad Sci U S A 108, 8826&#x2013;8831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102358</ArticleId><ArticleId IdType="pubmed">21551097</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Kumar Y, Zempel H, Mandelkow EM, Biernat J, and Mandelkow E (2011). Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J 30, 4825&#x2013;4837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243615</ArticleId><ArticleId IdType="pubmed">22009197</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, Djukic B, Taneja P, Yu GQ, Lo I, Davis A, Craft R, Guo W, Wang X, Kim D, et al. (2016). Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep 17, 530&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka Y, Chan AH, Judge LM, Yoo J, Huang M, Nguyen TD, Lizarraga PP, So PL, and Conklin BR (2014). Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat Methods 11, 291&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063274</ArticleId><ArticleId IdType="pubmed">24509632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok SA, Condello C, Freilich R, Gillies A, Arhar T, Oroz J, Kadavath H, Julien O, Assimon VA, Rauch JN, et al. (2018). Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 25, 384&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942583</ArticleId><ArticleId IdType="pubmed">29728653</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Maeda S, Vossel K, and Mucke L (2011). The many faces of tau. Neuron 70, 410&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Olazaran J, Prieto J, Cruz I, and Esteban A (2010). Cortical excitability in very mild Alzheimer&#x2019;s disease: a long-term follow-up study. J Neurol 257, 2078&#x2013;2085.</Citation><ArticleIdList><ArticleId IdType="pubmed">20680325</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Yan R, Li W, and Xu K (2018). Super-resolution microscopy reveals the native ultrastructure of the erythrocyte cytoskeleton. Cell Rep 22, 1151&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">29386104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Rios S, Denarier E, Prezel E, Vinit A, Stoppin-Mellet V, Devred F, Barbier P, Peyrot V, Sayas CL, Avila J, et al. (2016). Tau antagonizes end-binding protein tracking at microtubule ends through a phosphorylation-dependent mechanism. Mol Biol Cell 27, 2924&#x2013;2934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042579</ArticleId><ArticleId IdType="pubmed">27466319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, and Zhang F (2013). Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasband MN (2010). The axon initial segment and the maintenance of neuronal polarity. Nat Rev Neurosci 11, 552&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">20631711</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, et al. (2011). Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer&#x2019;s disease. J Neurosci 31, 700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, and Mucke L (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science 316, 750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi G, and Tagliavini F (2015). Frontotemporal lobar degeneration: old knowledge and new insight into the pathogenetic mechanisms of tau mutations. Front Aging Neurosci 7, 192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604311</ArticleId><ArticleId IdType="pubmed">26528178</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust MJ, Bates M, and Zhuang XW (2006). Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). Nature Methods 3, 793&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700296</ArticleId><ArticleId IdType="pubmed">16896339</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayas CL, Tortosa E, Bollati F, Ramirez-Rios S, Arnal I, and Avila J (2015). Tau regulates the localization and function of End-binding proteins 1 and 3 in developing neuronal cells. J Neurochem 133, 653&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">25761518</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Jha S, Liu F, Akella T, McCullough LD, and Rasband MN (2009). Disruption of the axon initial segment cytoskeleton is a new mechanism for neuronal injury. J Neurosci 29, 13242&#x2013;13254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801423</ArticleId><ArticleId IdType="pubmed">19846712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn PD, Tracy TE, Son HI, Zhou Y, Leite RE, Miller BL, Seeley WW, Grinberg LT, and Gan L (2016). Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Molecular neurodegeneration 11, 47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4928318</ArticleId><ArticleId IdType="pubmed">27356871</ArticleId></ArticleIdList></Reference><Reference><Citation>Stols L, Gu M, Dieckman L, Raffen R, Collart FR, and Donnelly MI (2002). A new vector for high-throughput, ligation-independent cloning encoding a tobacco etch virus protease cleavage site. Protein Expr Purif 25, 8&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">12071693</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone MB, and Veatch SL (2015). Steady-state cross-correlations for live two-colour superresolution localization data sets. Nat Commun 6, 7347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4467025</ArticleId><ArticleId IdType="pubmed">26066572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Wu Y, Gu M, Liu Z, Ma Y, Li J, and Zhang Y (2014). Selective filtering defect at the axon initial segment in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci U S A 111, 14271&#x2013;14276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191768</ArticleId><ArticleId IdType="pubmed">25232037</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, and Yamanaka S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovar KR, Bridges DC, Wu B, Randall C, Audouard M, Jang J, Hansma PK, and Kosik KS (2017). Recording action potential propagation in single axons using multi-electrode arrays. bioRxiv.</Citation><ArticleIdList><ArticleId IdType="pubmed">29641308</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsushima H, Emanuele M, Polenghi A, Esposito A, Vassalli M, Barberis A, Difato F, and Chieregatti E (2015). HDAC6 and RhoA are novel players in Abeta-driven disruption of neuronal polarity. Nature communications 6, 7781.</Citation><ArticleIdList><ArticleId IdType="pubmed">26198811</ArticleId></ArticleIdList></Reference><Reference><Citation>Veatch SL, Machta BB, Shelby SA, Chiang EN, Holowka DA, and Baird BA (2012). Correlation functions quantify super-resolution images and estimate apparent clustering due to over-counting. PLoS One 7, e31457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288038</ArticleId><ArticleId IdType="pubmed">22384026</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, et al. (2013). Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70, 1158&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013391</ArticleId><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G et al. (2014). Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep 7, 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ward ME, Chen R, Liu K, Tracy TE, Chen X, Xie M, Sohn PD, Ludwig C, Meyer-Franke A, et al. (2017). Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening. Stem Cell Reports 9, 1221&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639430</ArticleId><ArticleId IdType="pubmed">28966121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, and Mandelkow E (2016). Tau in physiology and pathology. Nat Rev Neurosci 17, 521.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojcik M, Hauser M, Li W, Moon S, and Xu K (2015). Graphene-enabled electron microscopy and correlated super-resolution microscopy of wet cells. Nature Commun 6, 7384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490578</ArticleId><ArticleId IdType="pubmed">26066680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada R, and Kuba H (2016). Structural and Functional Plasticity at the Axon Initial Segment. Front Cell Neurosci 10, 250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078684</ArticleId><ArticleId IdType="pubmed">27826229</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Ogawa Y, Hedstrom KL, and Rasband MN (2007). betaIV spectrin is recruited to axon initial segments and nodes of Ranvier by ankyrinG. J Cell Biol 176, 509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063985</ArticleId><ArticleId IdType="pubmed">17283186</ArticleId></ArticleIdList></Reference><Reference><Citation>Young ZT, Rauch JN, Assimon VA, Jinwal UK, Ahn M, Li X, Dunyak BM, Ahmad A, Carlson GA, Srinivasan SR, et al. (2016). Stabilizing the Hsp70-Tau Complex Promotes Turnover in Models of Tauopathy. Cell Chem Biol 23, 992&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4992411</ArticleId><ArticleId IdType="pubmed">27499529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Dennissen FJA, Kumar Y, Luedtke J, Biernat J, Mandelkow EM, and Mandelkow E (2017). Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. J Biol Chem 292, 12192&#x2013;12207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519369</ArticleId><ArticleId IdType="pubmed">28536263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy J, et al. (2013). Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31543469</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs.</ArticleTitle><Pagination><StartPage>684</StartPage><EndPage>699</EndPage><MedlinePgn>684-699</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2019.08.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(19)30305-4</ELocationID><Abstract><AbstractText>Mutations in the microtubule-associated protein tau (MAPT) gene are known to cause familial frontotemporal dementia (FTD). The R406W tau mutation is a unique missense mutation whose patients have been reported to exhibit Alzheimer's disease (AD)-like phenotypes rather than the more typical FTD phenotypes. In this study, we established patient-derived induced pluripotent stem cell (iPSC) models to investigate the disease pathology induced by the R406W mutation. We generated iPSCs from patients and established isogenic lines using CRISPR/Cas9. The iPSCs were induced into cerebral organoids, which were dissociated into cortical neurons with high purity. In this neuronal culture, the mutant tau protein exhibited reduced phosphorylation levels and was increasingly fragmented by calpain. Furthermore, the mutant tau protein was mislocalized and the axons of the patient-derived neurons displayed morphological and functional abnormalities, which were rescued by microtubule stabilization. The findings of our study provide mechanistic insight into tau pathology and a potential for therapeutic intervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Department of Biomedical Chemistry, School of International Health, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiozawa</LastName><ForeName>Seiji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: shiozawa@keio.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuboi</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University, 65 Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amano</LastName><ForeName>Mutsuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University, 65 Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Hirotaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Sumihiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Taeko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 266-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimatsu</LastName><ForeName>Sho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kisa</LastName><ForeName>Fumihiko</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyasaka</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe-shi, Kyoto 610-0394, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Science, Gakushuin University, Toshima-ku, Tokyo 171-8588, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahara</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 266-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hisanaga</LastName><ForeName>Shin-Ichi</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Graduate School of Science, Tokyo Metropolitan University, 1-1 Minami-Osawa, Hachioji-shi, Tokyo 192-0397, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, 1-757 Asahimachidori, Chuo-ku, Niigata 951-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaibuchi</LastName><ForeName>Kozo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University, 65 Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: hidokano@keio.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG046374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D010770">Phosphotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="Y">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010770" MajorTopicYN="N">Phosphotransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">disease modeling</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31543469</ArticleId><ArticleId IdType="pmc">PMC6829766</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2019.08.011</ArticleId><ArticleId IdType="pii">S2213-6711(19)30305-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen H.H., Liu P., Auger P., Lee S.H., Adolfsson O., Rey-Bellet L., Lafrance-Vanasse J., Friedman B.A., Pihlgren M., Muhs A. Calpain-mediated tau fragmentation is altered in Alzheimer&#x2019;s disease progression. Sci. Rep. 2018;8:16725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233188</ArticleId><ArticleId IdType="pubmed">30425303</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesser A., Pritchard S., Johnson G.V. Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front. Neurol. 2013;4:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759803</ArticleId><ArticleId IdType="pubmed">24027553</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.H., Kim Y.H., Hebisch M., Sliwinski C., Lee S., D&#x2019;Avanzo C., Klee J.B. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature. 2014;515:274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayanandan R., Van Slegtenhorst M., Mack T.G.A., Ko L., Yen S.H., Leroy K., Lovestone S. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 1999;446:228&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10100846</ArticleId></ArticleIdList></Reference><Reference><Citation>Denk F., Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol. Aging. 2009;30:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806682</ArticleId><ArticleId IdType="pubmed">17590238</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure M., Ko L.W., Yen S., Nacharaju P., Easson C., Lewis J., van Slegtenhorst M., Hutton M., Yen S.H. Missense tau mutations identified in FTDP-17 have a small effect on tau&#x2013;microtubule interactions. Brain Res. 2000;853:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10627302</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit R., Ross J.L., Goldman Y.E., Holzbaur E.L. Differential regulation of dynein and kinesin motor proteins by tau. Science. 2008;319:1086&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866193</ArticleId><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster N.L., Wilhelmsen K., Sima A.A., Jones M.Z., D'Amato C.J., Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann. Neurol. 1997;41:706&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">9189031</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S., Timm T., Mandelkow E.M., Mandelkow E., Wang Y. Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol. Aging. 2011;32:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B., Wszolek Z.K., Boeve B.F. Frontotemporal dementia and parkinsonism linked to chromosome 17. In: Dickson D., Weller Roy O., editors. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Second Edition. Wiley-Blackwell (an imprint of John Wiley &amp; Sons Ltd); 2011. pp. 110&#x2013;134.</Citation></Reference><Reference><Citation>Ghetti B., Oblak A.L., Boeve B.F., Johnson K.A., Dickerson B.C., Goedert M. Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol. 2015;41:24&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Smith M.J., Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 1998;437:207&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B.I., Geschwind D.H., Bird T.D., McKeel D., Goate A. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Hackett J. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichiyanagi N., Fujimori K., Yano M., Ishihara-Fujisaki C., Sone T., Akiyama T., Okada Y., Akamatsu W., Matsumoto T., Ishikawa M. Establishment of in&#xa0;vitro FUS-associated familial amyotrophic lateral sclerosis model using human induced pluripotent stem cells. Stem Cell Reports. 2016;6:496&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4834049</ArticleId><ArticleId IdType="pubmed">26997647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M., Kawarai T., Kawarabayashi T., Matsubara E., Murakami T., Sasaki A., Hasegawa M. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am. J. Pathol. 2005;166:521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602315</ArticleId><ArticleId IdType="pubmed">15681835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi T., Imamura T., Kawase Y., Kitade Y., Tsuchiya M., Tokutake T., Sugishita M. Evidence for a common founder&#xa0;and clinical characteristics of Japanese families with the MAPT R406W mutation. Dement. Geriatr. Cogn. Disord. Extra. 2011;1:267&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235940</ArticleId><ArticleId IdType="pubmed">22545037</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Sahara N., Kanaan N.M., Tsukita K., Kondo T., Kutoku Y., Ohsawa Y., Sunada Y., Kawakami K., Hotta A. Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Sci. Rep. 2016;6:34904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056519</ArticleId><ArticleId IdType="pubmed">27721502</ArticleId></ArticleIdList></Reference><Reference><Citation>Iovino M., Agathou S., Gonz&#xe1;lez-Rueda A., Del Castillo Velasco-Herrera M., Borroni B., Alberici A., Lynch T., O'Dowd S., Geti I., Gaffney D. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations. Brain. 2015;138:3345&#x2013;3359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620511</ArticleId><ArticleId IdType="pubmed">26220942</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Wen N., Li Z., Dube U., Del Aguila J., Budde J., Martinez R., Hsu S., Fernandez M.V., Cairns N.J. Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP. Transl. Psychiatry. 2018;8:265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293323</ArticleId><ArticleId IdType="pubmed">30546007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadoshima T., Sakaguchi H., Nakano T., Soen M., Ando S., Eiraku M., Sasai Y. Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. Proc. Natl. Acad. Sci. U S A. 2013;110:20284&#x2013;20289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864329</ArticleId><ArticleId IdType="pubmed">24277810</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopeikina K.J., Carlson G.A., Pitstick R., Ludvigson A.E., Peters A., Luebke J.I., Koffie R.M., Frosch M.P., Hyman B.T., Spires-Jones T.L. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am. J. Pathol. 2011;179:2071&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181340</ArticleId><ArticleId IdType="pubmed">21854751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowall N.W., Kosik K.S. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Ann. Neurol. 1987;22:639&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">3122646</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy P.K., Johnson G.V. Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model. J.&#xa0;Biochem. 2004;279:7893&#x2013;7900.</Citation><ArticleIdList><ArticleId IdType="pubmed">14660557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Knoblich J.A. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S., Haque M.M., Kim D., Kim D.J., Kim Y.K. Cell-based models to investigate Tau aggregation. Comput. Struct. Biotechnol. J. 2014;12:7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4262059</ArticleId><ArticleId IdType="pubmed">25505502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura N., Yamazaki T., Ihara Y. Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) Am. J. Pathol. 1999;154:1649&#x2013;1656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866642</ArticleId><ArticleId IdType="pubmed">10362789</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyasaka T., Morishima-Kawashima M., Ravid R., Heutink P., van Swieten J.C., Nagashima K., Ihara Y. Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation. Am. J. Pathol. 2001;158:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850291</ArticleId><ArticleId IdType="pubmed">11159174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamoto F.K., Okamoto S., Mitsui J., Sone T., Ishikawa M., Yamamoto Y., Kanegae Y., Nakatake Y., Imaizumi K., Ishiura H. The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy. Sci. Rep. 2018;8:14215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155102</ArticleId><ArticleId IdType="pubmed">30242188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimsanor N., Poulsen U., Rasmussen M.A., Clausen C., Mau-Holzmann U.A., Nielsen J.E., Nielsen T.T., Hyttel P., Holst B., Schmid B. Generation of an isogenic, gene-corrected iPSC line from a pre-symptomatic 28-year-old woman with an R406W mutation in the microtubule associated protein tau (MAPT) gene. Stem Cell Res. 2016;17:600&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">27934590</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimsanor N., Poulsen U., Rasmussen M.A., Clausen C., Mau-Holzmann U.A., Nielsen J.E., Schmid B. Generation of an isogenic, gene-corrected iPSC line from a symptomatic 59-year-old female patient with frontotemporal dementia caused by an R406W mutation in the microtubule associated protein tau (MAPT) gene. Stem Cell Res. 2016;17:576&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">27934586</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K., Yamakawa T., Matsumura Y., Sato Y., Amano N., Watanabe A., Yamanaka S. An efficient nonviral method to&#xa0;generate integration-free human-induced pluripotent stem cells&#xa0;from cord blood and peripheral blood cells. Stem Cells. 2013;31:458&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">23193063</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M., Lim F., Arrasate M., Avila J. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J.&#xa0;Neurochem. 2000;74:2583&#x2013;2589.</Citation><ArticleIdList><ArticleId IdType="pubmed">10820221</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Schellenberg G.D. Tau is a candidate gene&#xa0;for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrato G., Nguyen T., Macosko E.Z., Sherwood J.L., Yang S.M., Berger D.R., Maria N., Scholvin J., Goldman M., Kinney J.P. Cell diversity and network dynamics in photosensitive human brain organoids. Nature. 2017;545:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5659341</ArticleId><ArticleId IdType="pubmed">28445462</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen M.A., Hjermind L.E., Hasholt L.F., Waldemar G., Nielsen J.E., Clausen C., Holst B. Induced pluripotent stem cells (iPSCs) derived from a pre-symptomatic carrier of a R406W mutation in microtubule-associated protein tau (MAPT) causing frontotemporal dementia. Stem Cell Res. 2016;16:105&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">27345791</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen M.A., Hjermind L.E., Hasholt L.F., Waldemar G., Nielsen J.E., Clausen C., Holst B. Induced pluripotent stem cells (iPSCs) derived from a patient with frontotemporal dementia caused by a R406W mutation in microtubule-associated protein tau (MAPT) Stem Cell Res. 2016;16:75&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">27345789</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds C.H., Betts J.C., Blackstock W.P., Nebreda A.R., Anderton B.H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry. J.&#xa0;Neurochem. 2000;74:1587&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737616</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P., Van Swieten J.C., Joosse M., Hasegawa M., Stevens M., Tibben A., Goedert M. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in The Netherlands. Am. J. Hum. Genet. 1999;64:414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377751</ArticleId><ArticleId IdType="pubmed">9973279</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Mart&#xed;n T., Pooler A.M., Lau D.H., M&#xf3;rotz G.M., De Vos K.J., Gilley J., Coleman M.P., Hanger D.P. Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons. Neurobiol. Dis. 2016;85:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684147</ArticleId><ArticleId IdType="pubmed">26459111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue F., Saito T., Sato Y., Asada A., Ishiguro K., Hasegawa M., Hisanaga S.I. Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39. J.&#xa0;Biol. Chem. 2005;280:31522&#x2013;31529.</Citation><ArticleIdList><ArticleId IdType="pubmed">15994305</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz T.L. Mitochondrial trafficking in neurons. Cold Spring Harb. Perspect. Biol. 2013;5:a011304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660831</ArticleId><ArticleId IdType="pubmed">23732472</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U&#xa0;S A. 1998;95:7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Swieten J.C., Stevens M., Rosso S.M., Rizzu P., Joosse M., De Koning I., Heutink P. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann. Neurol. 1999;46:617&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514099</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y., Miyasaka T., Chui D.H., Akagi T., Mishima K.I., Iwasaki K., Planel E. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U S A. 2002;99:13896&#x2013;13901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129794</ArticleId><ArticleId IdType="pubmed">12368474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y., Planel E., Chui D.H., Sato S., Miyasaka T., Sahara N., Takashima A. c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. FASEB J. 2006;20:762&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">16478768</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Mandelkow E. Tau in physiology and pathology. Nat. Rev. Neurosci. 2016;17:22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusa K., Zhou L., Li M.A., Bradley A., Craig N.L. A hyperactive piggyBac transposase for mammalian applications. Proc. Natl. Acad. Sci. U S A. 2011;108:1531&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3029773</ArticleId><ArticleId IdType="pubmed">21205896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Higuchi M., Yoshiyama Y., Ishihara T., Forman M.S., Martinez D., Joyce S., Trojanowski J.Q., Lee V.M.Y. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J.&#xa0;Neurosci. 2004;24:4657&#x2013;4667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729383</ArticleId><ArticleId IdType="pubmed">15140937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Pak C., Han Y., Ahlenius H., Zhang Z., Chanda S., Marro S., Patzke C., Acuna C., Covy J. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31551592</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration.</ArticleTitle><Pagination><StartPage>1635</StartPage><EndPage>1648</EndPage><MedlinePgn>1635-1648</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0486-0</ELocationID><Abstract><AbstractText>In neurodegenerative diseases, debris of dead neurons are thought to trigger glia-mediated neuroinflammation, thus increasing neuronal death. Here we show that the expression of neurotoxic proteins associated with these diseases in microglia alone is sufficient to directly trigger death of naive neurons and to propagate neuronal death through activation of naive astrocytes to the A1 state. Injury propagation is mediated, in great part, by the release of fragmented and dysfunctional microglial mitochondria into the neuronal milieu. The amount of damaged mitochondria released from microglia relative to functional mitochondria and the consequent neuronal injury are determined by Fis1-mediated mitochondrial fragmentation within the glial cells. The propagation of the inflammatory response and neuronal cell death by extracellular dysfunctional mitochondria suggests a potential new intervention for neurodegeneration-one that inhibits mitochondrial fragmentation in microglia, thus inhibiting the release of dysfunctional mitochondria into the extracellular milieu of the brain, without affecting the release of healthy neuroprotective mitochondria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Amit U</ForeName><Initials>AU</Initials><Identifier Source="ORCID">0000-0002-2472-7672</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Paras S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-0840-1437</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Physiology and Neuroscience Institute, New York University Langone Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haileselassie</LastName><ForeName>Bereketeab</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics Division of Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Katrin I</ForeName><Initials>KI</Initials><Identifier Source="ORCID">0000-0001-8391-4155</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorn</LastName><ForeName>Gerald W</ForeName><Initials>GW</Initials><Suffix>2nd</Suffix><AffiliationInfo><Affiliation>Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochly-Rosen</LastName><ForeName>Daria</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6691-8733</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA. mochly@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL052141</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 HL135736</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058047</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561064">FIS1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="C486391">Dnm1l protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="D034281">Dynamins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2021 Feb;24(2):289. doi: 10.1038/s41593-020-00774-5.</RefSource><PMID Version="1">33324000</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. Patents on P110 and its utility in HD, ALS and other neurodegenerative diseases have been filed by D.M&#x2010;R and A.U.J. The other authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31551592</ArticleId><ArticleId IdType="mid">NIHMS1536715</ArticleId><ArticleId IdType="pmc">PMC6764589</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0486-0</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0486-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A &amp; O&#x2019;Connor T Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 9, 237&#x2013;248 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20190788</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature 535, 551&#x2013;555 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968589</ArticleId><ArticleId IdType="pubmed">27466127</ArticleId></ArticleIdList></Reference><Reference><Citation>Belanger M &amp; Magistretti PJ The role of astroglia in neuroprotection. Dialogues Clin Neurosci 11, 281&#x2013;295 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181926</ArticleId><ArticleId IdType="pubmed">19877496</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z &amp; Trapp BD Microglia and neuroprotection. J Neurochem 136 Suppl 1, 10&#x2013;17 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25693054</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A &amp; Glass CK The choreography of neuroinflammation in Huntington&#x2019;s disease. Trends Immunol 36, 364&#x2013;373 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786070</ArticleId><ArticleId IdType="pubmed">26001312</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol 14, 388&#x2013;405 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J &amp; Wang F Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. Front Immunol 8, 1005 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM How neuroinflammation contributes to neurodegeneration. Science 353, 777&#x2013;783 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K, Nakamura K, Iijima M &amp; Sesaki H Mitochondrial dynamics in neurodegeneration. Trends Cell Biol. 23, 64&#x2013;71 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558617</ArticleId><ArticleId IdType="pubmed">23159640</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH Increased mitochondrial fission and neuronal dysfunction in Huntington&#x2019;s disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today 19, 951&#x2013;955 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191657</ArticleId><ArticleId IdType="pubmed">24681059</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AU, et al. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol Med 10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840540</ArticleId><ArticleId IdType="pubmed">29335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil B &amp; Lievens JC Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway? Neural Regen Res 12, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558479</ArticleId><ArticleId IdType="pubmed">28852382</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, et al. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev 67, 103&#x2013;118 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061980</ArticleId><ArticleId IdType="pubmed">21145355</ArticleId></ArticleIdList></Reference><Reference><Citation>Knott AB, Perkins G, Schwarzenbacher R &amp; Bossy-Wetzel E Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9, 505&#x2013;518 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711514</ArticleId><ArticleId IdType="pubmed">18568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Qvit N, Su YC &amp; Mochly-Rosen D A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci 126, 789&#x2013;802 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619809</ArticleId><ArticleId IdType="pubmed">23239023</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohm J, et al. Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ 19, 1446&#x2013;1458 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422469</ArticleId><ArticleId IdType="pubmed">22388349</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AU, Saw NL, Shamloo M &amp; Mochly-Rosen D Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer&#x2019;s disease. Oncotarget 9, 6128&#x2013;6143 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814200</ArticleId><ArticleId IdType="pubmed">29464060</ArticleId></ArticleIdList></Reference><Reference><Citation>Disatnik MH, et al. Potential biomarkers to follow the progression and treatment response of Huntington&#x2019;s disease. J Exp Med 213, 2655&#x2013;2669 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110026</ArticleId><ArticleId IdType="pubmed">27821553</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, et al. Inhibition of mitochondrial fragmentation diminishes Huntington&#x2019;s disease-associated neurodegeneration. J Clin Invest 123, 5371&#x2013;5388 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859413</ArticleId><ArticleId IdType="pubmed">24231356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P &amp; Chan DC Metabolic regulation of mitochondrial dynamics. J Cell Biol 212, 379&#x2013;387 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754720</ArticleId><ArticleId IdType="pubmed">26858267</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci 17, 513&#x2013;521 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113004</ArticleId><ArticleId IdType="pubmed">24584051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson&#x2019;s disease. NPJ Parkinsons Dis 3, 30 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645400</ArticleId><ArticleId IdType="pubmed">29057315</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Hao W, Dawson A, Liu S &amp; Fassbender K Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J Biol Chem 284, 3691&#x2013;3699 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19091752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondag CM, Dhawan G &amp; Combs CK Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 6, 1 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632990</ArticleId><ArticleId IdType="pubmed">19123954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornfeld OS, et al. Interaction of mitochondrial fission factor with dynamin related protein 1 governs physiological mitochondrial function in vivo. Sci Rep 8, 14034 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6145916</ArticleId><ArticleId IdType="pubmed">30232469</ArticleId></ArticleIdList></Reference><Reference><Citation>Falchi AM, et al. Astrocytes shed large membrane vesicles that contain mitochondria, lipid droplets and ATP. Histochem Cell Biol 139, 221&#x2013;231 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23108569</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogvadze V, Orrenius S &amp; Zhivotovsky B Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta 1757, 639&#x2013;647 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16678785</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan KJ, et al. A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Sci Transl Med 9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5945290</ArticleId><ArticleId IdType="pubmed">29263232</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy-Stone A, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 14, 193&#x2013;204 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267902</ArticleId><ArticleId IdType="pubmed">18267088</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates D Neurodegenerative disease: Factoring in astrocytes. Nat Rev Neurosci 16, 67 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25601774</ArticleId></ArticleIdList></Reference><Reference><Citation>West AP, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520, 553&#x2013;557 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409480</ArticleId><ArticleId IdType="pubmed">25642965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560, 198&#x2013;203 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6329306</ArticleId><ArticleId IdType="pubmed">30046112</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou SH, et al. Extracellular mitochondria in cerebrospinal fluid and neurological recovery after subarachnoid hemorrhage. Stroke 48, 2231&#x2013;2237 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526718</ArticleId><ArticleId IdType="pubmed">28663512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zussman B, Weiner G &amp; Ducruet A Mitochondrial transfer into the cerebrospinal fluid in the setting of subarachnoid hemorrhage. Neurosurgery 82, N11&#x2013;N13 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29244132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K, et al. Protective effects of endothelial progenitor cell-derived extracellular mitochondria in brain endothelium. Stem Cells 36, 1404&#x2013;1410 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407639</ArticleId><ArticleId IdType="pubmed">29781122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K, et al. Extracellular mitochondria for therapy and diagnosis in acute central nervous system injury. JAMA Neurol 75, 119&#x2013;122 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8305970</ArticleId><ArticleId IdType="pubmed">29159397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins HM, et al. Extracellular mitochondria and mitochondrial components act as damage-associated molecular pattern molecules in the mouse brain. J Neuroimmune Pharmacol 11, 622&#x2013;628 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097888</ArticleId><ArticleId IdType="pubmed">27562848</ArticleId></ArticleIdList></Reference><Reference><Citation>Labzin LI, Heneka MT &amp; Latz E Innate immunity and neurodegeneration. Annu Rev Med 69, 437&#x2013;449 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29106805</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC &amp; Gage FH Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918&#x2013;934 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>van Niel G, D&#x2019;Angelo G &amp; Raposo G Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19, 213&#x2013;228 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29339798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai RC, et al. MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA. J Extracell Vesicles 5, 29828 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770866</ArticleId><ArticleId IdType="pubmed">26928672</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AR, Robinson MB, Gifondorwa DJ, Tytell M &amp; Milligan CE Regulation of heat shock protein 70 release in astrocytes: role of signaling kinases. Dev Neurobiol 67, 1815&#x2013;1829 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17701989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, et al. Wnt3a induces exosome secretion from primary cultured rat microglia. BMC Neurosci 13, 144 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541220</ArticleId><ArticleId IdType="pubmed">23173708</ArticleId></ArticleIdList></Reference><Reference><Citation>Glebov K, et al. Serotonin stimulates secretion of exosomes from microglia cells. Glia 63, 626&#x2013;634 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25451814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hessvik NP &amp; Llorente A Current knowledge on exosome biogenesis and release. Cell Mol Life Sci 75, 193&#x2013;208 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5756260</ArticleId><ArticleId IdType="pubmed">28733901</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MN, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 18, 759&#x2013;765 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727429</ArticleId><ArticleId IdType="pubmed">22504485</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens JC, et al. Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag--implications for research into amyotrophic lateral sclerosis (ALS). PLoS One 5, e9541 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833207</ArticleId><ArticleId IdType="pubmed">20221404</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhas PS, et al. Macrophage de novo NAD(+) synthesis specifies immune function in aging and inflammation. Nat Immunol 20, 50&#x2013;63 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768398</ArticleId><ArticleId IdType="pubmed">30478397</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente AJ, Maddalena LA, Robb EL, Moradi F &amp; Stuart JA A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture. Acta Histochem 119, 315&#x2013;326 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28314612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31554740</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>511</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle><i>Lrrk2</i> alleles modulate inflammation during microbial infection of mice in a sex-dependent manner.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaas9292</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aas9292</ELocationID><Abstract><AbstractText>Variants in the leucine-rich repeat kinase-2 (<i>LRRK2</i>) gene are associated with Parkinson's disease, leprosy, and Crohn's disease, three disorders with inflammation as an important component. Because of its high expression in granulocytes and CD68-positive cells, LRRK2 may have a function in innate immunity. We tested this hypothesis in two ways. First, adult mice were intravenously inoculated with <i>Salmonella typhimurium</i>, resulting in sepsis. Second, newborn mouse pups were intranasally infected with reovirus (serotype 3 Dearing), which induced encephalitis. In both mouse models, wild-type Lrrk2 expression was protective and showed a sex effect, with female Lrrk2-deficient animals not controlling infection as well as males. Mice expressing Lrrk2 carrying the Parkinson's disease-linked p.G2019S mutation controlled infection better, with reduced bacterial growth and longer animal survival during sepsis. This gain-of-function effect conferred by the p.G2019S mutation was mediated by myeloid cells and was abolished in animals expressing a kinase-dead Lrrk2 variant, p.D1994S. Mouse pups with reovirus-induced encephalitis that expressed the p.G2019S Lrrk2 mutation showed increased mortality despite lower viral titers. The p.G2019S mutant Lrrk2 augmented immune cell chemotaxis and generated more reactive oxygen species during virulent infection. Reovirus-infected brains from mice expressing the p.G2019S mutant Lrrk2 contained higher concentrations of &#x3b1;-synuclein. Animals expressing one or two p.D1994S <i>Lrrk2</i> alleles showed lower mortality from reovirus-induced encephalitis. Thus, <i>Lrrk2</i> alleles may alter the course of microbial infections by modulating inflammation, and this may be dependent on the sex and genotype of the host as well as the type of pathogen.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shutinoski</LastName><ForeName>Bojan</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4669-5656</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakimi</LastName><ForeName>Mansoureh</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6011-8719</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmsen</LastName><ForeName>Irene E</ForeName><Initials>IE</Initials><Identifier Source="ORCID">0000-0001-9056-1706</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunn</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0876-8017</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Carleton University, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0814-7088</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lengacher</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2536-1895</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yi Yuan</ForeName><Initials>YY</Initials><Identifier Source="ORCID">0000-0003-4997-3412</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5765-2371</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7453-2232</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hake-Volling</LastName><ForeName>Quinton</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-6002-7684</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Kodsi</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8896-0043</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1565-2477</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alikashani</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9035-0615</Identifier><AffiliationInfo><Affiliation>Research Centre, Montreal Heart Institute, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beauchamp</LastName><ForeName>Claudine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research Centre, Montreal Heart Institute, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majithia</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coombs</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7667-8430</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimshek</LastName><ForeName>Derya</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8602-7850</Identifier><AffiliationInfo><Affiliation>Novartis Institutes of BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcogliese</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials><Identifier Source="ORCID">0000-0002-8011-7852</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-4490-3784</Identifier><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rioux</LastName><ForeName>John D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0001-7560-8326</Identifier><AffiliationInfo><Affiliation>Research Centre, Montreal Heart Institute, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philpott</LastName><ForeName>Dana J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Immunology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woulfe</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayley</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Carleton University, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sad</LastName><ForeName>Subash</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Julianna J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-2997-5162</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Earl G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlossmacher</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-0394-0300</Identifier><AffiliationInfo><Affiliation>Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. mschlossmacher@ohri.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002633" MajorTopicYN="N">Chemotaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007962" MajorTopicYN="N">Leukocytes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012087" MajorTopicYN="N">Reoviridae</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012486" MajorTopicYN="N">Salmonella typhimurium</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31554740</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aas9292</ArticleId><ArticleId IdType="pii">11/511/eaas9292</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31570577</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>116</Volume><Issue>42</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta impairs TOM1-mediated IL-1R1 signaling.</ArticleTitle><Pagination><StartPage>21198</StartPage><EndPage>21206</EndPage><MedlinePgn>21198-21206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1914088116</ELocationID><Abstract><AbstractText>Defects in interleukin-1&#x3b2; (IL-1&#x3b2;)-mediated cellular responses contribute to Alzheimer's disease (AD). To decipher the mechanism associated with its pathogenesis, we investigated the molecular events associated with the termination of IL-1&#x3b2; inflammatory responses by focusing on the role played by the target of Myb1 (TOM1), a negative regulator of the interleukin-1&#x3b2; receptor-1 (IL-1R1). We first show that TOM1 steady-state levels are reduced in human AD hippocampi and in the brain of an AD mouse model versus respective controls. Experimentally reducing TOM1 affected microglia activity, substantially increased amyloid-beta levels, and impaired cognition, whereas enhancing its levels was therapeutic. These data show that reparation of the TOM1-signaling pathway represents a therapeutic target for brain inflammatory disorders such as AD. A better understanding of the age-related changes in the immune system will allow us to craft therapies to limit detrimental aspects of inflammation, with the broader purpose of sharply reducing the number of people afflicted by AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Alessandra Cadete</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-8447-6756</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Arboledas</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga-IBIMA, Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), University of M&#xe1;laga, M&#xe1;laga 29010, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forner</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Ortiz</LastName><ForeName>Carlos J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0003-2688-947X</Identifier><AffiliationInfo><Affiliation>Center for Occupational and Environmental Health, School of Medicine, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danhash</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Javonillo</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Jordan-Vu</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tram</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trujillo-Estrada</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga-IBIMA, Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), University of M&#xe1;laga, M&#xe1;laga 29010, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Cunha</LastName><ForeName>Celia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ager</LastName><ForeName>Rahasson R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davila</LastName><ForeName>Jose C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-7016-288X</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga-IBIMA, Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), University of M&#xe1;laga, M&#xe1;laga 29010, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitazawa</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Occupational and Environmental Health, School of Medicine, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga-IBIMA, Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), University of M&#xe1;laga, M&#xe1;laga 29010, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baglietto-Vargas</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1441-3175</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga-IBIMA, Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), University of M&#xe1;laga, M&#xe1;laga 29010, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medeiros</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697; rodrigo.medeiros@neurula.org laferla@uci.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697; rodrigo.medeiros@neurula.org laferla@uci.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA 92697.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 ES024331</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048099</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG054884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS082174</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23860. doi: 10.1073/pnas.1918411116.</RefSource><PMID Version="1">31740603</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):3917-3919. doi: 10.1073/pnas.1917743117.</RefSource><PMID Version="1">32047040</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):3915-3916. doi: 10.1073/pnas.1917589117.</RefSource><PMID Version="1">32047041</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3xTg-AD</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">IL-1R1</Keyword><Keyword MajorTopicYN="N">TOM1</Keyword><Keyword MajorTopicYN="N">target of Myb1</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31570577</ArticleId><ArticleId IdType="pmc">PMC6800331</ArticleId><ArticleId IdType="doi">10.1073/pnas.1914088116</ArticleId><ArticleId IdType="pii">1914088116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shaw A. C., Goldstein D. R., Montgomery R. R., Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13, 875&#x2013;887 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096436</ArticleId><ArticleId IdType="pubmed">24157572</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnardottir H. H., Dalli J., Colas R. A., Shinohara M., Serhan C. N., Aging delays resolution of acute inflammation in mice: Reprogramming the host response with novel nano-proresolving medicines. J. Immunol. 193, 4235&#x2013;4244 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185223</ArticleId><ArticleId IdType="pubmed">25217168</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C., Garagnani P., Parini P., Giuliani C., Santoro A., Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576&#x2013;590 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30046148</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe E. A., et al. , Inflammation: The link between comorbidities, genetics, and Alzheimer&#x2019;s disease. J. Neuroinflammation 15, 276 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154824</ArticleId><ArticleId IdType="pubmed">30249283</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Spencer N. Y., Pantazis N. J., Engelhardt J. F., Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity. J. Biol. Chem. 286, 40151&#x2013;40162 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220533</ArticleId><ArticleId IdType="pubmed">21937428</ArticleId></ArticleIdList></Reference><Reference><Citation>Neefjes J., van der Kant R., Stuck in traffic: An emerging theme in diseases of the nervous system. Trends Neurosci. 37, 66&#x2013;76 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24411104</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Soetandyo N., Wang Q., Ye Y., The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta 1793, 346&#x2013;353 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657479</ArticleId><ArticleId IdType="pubmed">18952128</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodeller F., Gottar M., Huesken D., Iourgenko V., Cenni B., The lysosomal transmembrane protein 9B regulates the activity of inflammatory signaling pathways. J. Biol. Chem. 283, 21487&#x2013;21494 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18541524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cendrowski J., Mami&#x144;ska A., Miaczynska M., Endocytic regulation of cytokine receptor signaling. Cytokine Growth Factor Rev. 32, 63&#x2013;73 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27461871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M., Oddo S., Yamasaki T. R., Green K. N., LaFerla F. M., Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer&#x2019;s disease. J. Neurosci. 25, 8843&#x2013;8853 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725603</ArticleId><ArticleId IdType="pubmed">16192374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazawa M., et al. , Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal &#x3b2;-catenin pathway function in an Alzheimer&#x2019;s disease model. J. Immunol. 187, 6539&#x2013;6549 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072218</ArticleId><ArticleId IdType="pubmed">22095718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciacca F. L., et al. , Interleukin-1B polymorphism is associated with age at onset of Alzheimer&#x2019;s disease. Neurobiol. Aging 24, 927&#x2013;931 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12928052</ArticleId></ArticleIdList></Reference><Reference><Citation>Licastro F., et al. , Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer&#x2019;s disease: Peripheral inflammation or signals from the brain? J. Neuroimmunol. 103, 97&#x2013;102 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10674995</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Liu L., Barger S. W., Griffin W. S., Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23, 1605&#x2013;1611 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833596</ArticleId><ArticleId IdType="pubmed">12629164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A., Kim H. J., Shin A. H., Thayer S. A., Synapse loss induced by interleukin-1&#x3b2; requires pre- and post-synaptic mechanisms. J. Neuroimmune Pharmacol. 7, 571&#x2013;578 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415563</ArticleId><ArticleId IdType="pubmed">22311599</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., et al. , Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hein A. M., et al. , Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav. Immun. 24, 243&#x2013;253 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818290</ArticleId><ArticleId IdType="pubmed">19825412</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto G. A., et al. , Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1&#x3b2; in the aged hippocampus. Proc. Natl. Acad. Sci. U.S.A. 112, E5078&#x2013;E5087 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568670</ArticleId><ArticleId IdType="pubmed">26305968</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran B. P., Murray H. J., O&#x2019;Connor J. J., A role for c-Jun N-terminal kinase in the inhibition of long-term potentiation by interleukin-1beta and long-term depression in the rat dentate gyrus in vitro. Neuroscience 118, 347&#x2013;357 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12699771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly A., et al. , Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. J. Biol. Chem. 278, 19453&#x2013;19462 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12609991</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Smith D. E., Ib&#xe1;&#xf1;ez-Sandoval O., Sims J. E., Friedman W. J., Neuron-specific effects of interleukin-1&#x3b2; are mediated by a novel isoform of the IL-1 receptor accessory protein. J. Neurosci. 31, 18048&#x2013;18059 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261076</ArticleId><ArticleId IdType="pubmed">22159118</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson S. L., Immune dysregulation and cognitive vulnerability in the aging brain: Interactions of microglia, IL-1beta, BDNF and synaptic plasticity. Neuropharmacology 96, 11&#x2013;18 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475415</ArticleId><ArticleId IdType="pubmed">25549562</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns K., et al. , Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat. Cell Biol. 2, 346&#x2013;351 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10854325</ArticleId></ArticleIdList></Reference><Reference><Citation>Didierlaurent A., et al. , Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell. Biol. 26, 735&#x2013;742 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347014</ArticleId><ArticleId IdType="pubmed">16428431</ArticleId></ArticleIdList></Reference><Reference><Citation>Brissoni B., et al. , Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr. Biol. 16, 2265&#x2013;2270 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17113392</ArticleId></ArticleIdList></Reference><Reference><Citation>Qwarnstrom E. E., Page R. C., Gillis S., Dower S. K., Binding, internalization, and intracellular localization of interleukin-1 beta in human diploid fibroblasts. J. Biol. Chem. 263, 8261&#x2013;8269 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2967293</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S., et al. , Tom1 modulates binding of tollip to phosphatidylinositol 3-phosphate via a coupled folding and binding mechanism. Structure 23, 1910&#x2013;1920 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26320582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Liu N. S., Seet L. F., Hong W., The emerging role of VHS domain-containing Tom1, Tom1L1 and Tom1L2 in membrane trafficking. Traffic 11, 1119&#x2013;1128 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20604899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S., Casey A. E., Sargeant T. J., M&#xe4;kinen V. P., Genetic variation within endolysosomal system is associated with late-onset Alzheimer&#x2019;s disease. Brain 141, 2711&#x2013;2720 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30124770</ArticleId></ArticleIdList></Reference><Reference><Citation>Omtri R. S., et al. , Differential effects of Alzheimer&#x2019;s disease A&#x3b2;40 and 42 on endocytosis and intraneuronal trafficking. Neuroscience 373, 159&#x2013;168 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29337241</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda A. M., et al. , Neuronal lysosomal dysfunction releases exosomes harboring APP C-terminal fragments and unique lipid signatures. Nat. Commun. 9, 291 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5773483</ArticleId><ArticleId IdType="pubmed">29348617</ArticleId></ArticleIdList></Reference><Reference><Citation>French R. A., et al. , Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. J. Neuroimmunol. 93, 194&#x2013;202 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10378883</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinteaux E., Parker L. C., Rothwell N. J., Luheshi G. N., Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J. Neurochem. 83, 754&#x2013;763 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12421347</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves S., et al. , Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer&#x2019;s disease mice. Brain 140, 826&#x2013;842 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28003243</ArticleId></ArticleIdList></Reference><Reference><Citation>Makioka K., et al. , Immunolocalization of Tom1 in relation to protein degradation systems in Alzheimer&#x2019;s disease. J. Neurol. Sci. 365, 101&#x2013;107 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27206884</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N., Figueiredo-Pereira M. E., Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: Association with sequestosome 1/p62. J. Biol. Chem. 286, 22426&#x2013;22440 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121389</ArticleId><ArticleId IdType="pubmed">21536669</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu J. R., Geetha T., Wooten M. W., Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J. Neurochem. 94, 192&#x2013;203 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15953362</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A., Ferreira E., Branca C., Oddo S., p62 improves AD-like pathology by increasing autophagy. Mol. Psychiatry 22, 865&#x2013;873 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479312</ArticleId><ArticleId IdType="pubmed">27573878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Mart&#xed;nez S., A new perspective on the role of the CREB family of transcription factors in memory consolidation via adult hippocampal neurogenesis. Front. Mol. Neurosci. 8, 46 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549561</ArticleId><ArticleId IdType="pubmed">26379491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu J. S., Li W. P., Yao Z. B., Zhou X. F., Deprivation of endogenous brain-derived neurotrophic factor results in impairment of spatial learning and memory in adult rats. Brain Res. 835, 259&#x2013;265 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10415381</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli F., Berry A., Chiarotti F., Alleva E., Intrahippocampal administration of BDNF in adult rats affects short-term behavioral plasticity in the Morris water maze and performance in the elevated plus-maze. Hippocampus 14, 802&#x2013;807 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15382250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Barber K. D., Yan B., Clash of the cytokine titans: Counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell. Mol. Immunol. 14, 22&#x2013;35 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5214938</ArticleId><ArticleId IdType="pubmed">27264686</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M. G., et al. , IL-1beta processing in host defense: Beyond the inflammasomes. PLoS Pathog. 6, e1000661 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829053</ArticleId><ArticleId IdType="pubmed">20195505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson R. M., Rothwell N. J., Le Feuvre R. A., CNS injury: The role of the cytokine IL-1. Vet. J. 168, 230&#x2013;237 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15501140</ArticleId></ArticleIdList></Reference><Reference><Citation>Depino A., Ferrari C., Pott Godoy M. C., Tarelli R., Pitossi F. J., Differential effects of interleukin-1beta on neurotoxicity, cytokine induction and glial reaction in specific brain regions. J. Neuroimmunol. 168, 96&#x2013;110 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16112750</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel S. S., et al. , Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 117, 1595&#x2013;1604 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakami M., Yokosawa H., Tom1 (target of Myb 1) is a novel negative regulator of interleukin-1- and tumor necrosis factor-induced signaling pathways. Biol. Pharm. Bull. 27, 564&#x2013;566 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15056867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A., Abiega O., Shahraz A., Neumann H., Janus-faced microglia: Beneficial and detrimental consequences of microglial phagocytosis. Front. Cell. Neurosci. 7, 6 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558702</ArticleId><ArticleId IdType="pubmed">23386811</ArticleId></ArticleIdList></Reference><Reference><Citation>Parajuli B., et al. , Oligomeric amyloid &#x3b2; induces IL-1&#x3b2; processing via production of ROS: Implication in Alzheimer&#x2019;s disease. Cell Death Dis. 4, e975 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877570</ArticleId><ArticleId IdType="pubmed">24357806</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft J. M., Watterson D. M., Hirsch E., Van Eldik L. J., Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J. Neuroinflammation 2, 15 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1190207</ArticleId><ArticleId IdType="pubmed">15967035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X. D., et al. , Microglial phagocytosis induced by fibrillar &#x3b2;-amyloid is attenuated by oligomeric &#x3b2;-amyloid: Implications for Alzheimer&#x2019;s disease. Mol. Neurodegener. 6, 45 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149591</ArticleId><ArticleId IdType="pubmed">21718498</ArticleId></ArticleIdList></Reference><Reference><Citation>Platta H. W., Stenmark H., Endocytosis and signaling. Curr. Opin. Cell Biol. 23, 393&#x2013;403 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21474295</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh Y., et al. , Tollip and Tom1 form a complex and recruit ubiquitin-conjugated proteins onto early endosomes. J. Biol. Chem. 279, 24435&#x2013;24443 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15047686</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakami M., Yoshimori T., Yokosawa H., Tom1, a VHS domain-containing protein, interacts with tollip, ubiquitin, and clathrin. J. Biol. Chem. 278, 52865&#x2013;52872 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14563850</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Zabala A., Sierra-Torre V., Sierra A., Autophagy and microglia: Novel partners in neurodegeneration and aging. Int. J. Mol. Sci. 18, E598 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5372614</ArticleId><ArticleId IdType="pubmed">28282924</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois A., et al. , Involvement of interleukin-1&#x3b2; in the autophagic process of microglia: Relevance to Alzheimer&#x2019;s disease. J. Neuroinflammation 10, 151 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3878742</ArticleId><ArticleId IdType="pubmed">24330807</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte L. S., Lau A. A., Hemsley K. M., Hopwood J. J., Sargeant T. J., Endo-lysosomal and autophagic dysfunction: A driving factor in Alzheimer&#x2019;s disease? J. Neurochem. 140, 703&#x2013;717 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28027395</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmukler E., Michaelson D. M., Pinkas-Kramarski R., The interplay between apolipoprotein E4 and the autophagic-endocytic-lysosomal axis. Mol. Neurobiol. 55, 6863&#x2013;6880 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29353455</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo E. H., Squazzo S. L., Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386&#x2013;17389 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R. A., Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol. Aging 26, 373&#x2013;382 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh W. H., Chia P. Z. C., Hossain M. I., Gleeson P. A., GGA1 regulates signal-dependent sorting of BACE1 to recycling endosomes, which moderates A&#x3b2; production. Mol. Biol. Cell 29, 191&#x2013;208 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909931</ArticleId><ArticleId IdType="pubmed">29142073</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiba Y., et al. , GAT (GGA and Tom1) domain responsible for ubiquitin binding and ubiquitination. J. Biol. Chem. 279, 7105&#x2013;7111 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14660606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwon Y., et al. , TOM1 regulates neuronal accumulation of amyloid-&#x3b2; oligomers by Fc&#x3b3;RIIb2 variant in Alzheimer&#x2019;s disease. J. Neurosci. 38, 9001&#x2013;9018 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705977</ArticleId><ArticleId IdType="pubmed">30185465</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M., et al. , Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 106, 13594&#x2013;13599 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715325</ArticleId><ArticleId IdType="pubmed">19633196</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A., et al. , Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener. 13, 67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein W. L., Abeta toxicity in Alzheimer&#x2019;s disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345&#x2013;352 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglietto-Vargas D., Medeiros R., Martinez-Coria H., LaFerla F. M., Green K. N., Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol. Psychiatry 74, 357&#x2013;366 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633722</ArticleId><ArticleId IdType="pubmed">23312564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Arboledas A., et al. , Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer&#x2019;s disease. Glia 66, 637&#x2013;653 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814816</ArticleId><ArticleId IdType="pubmed">29178139</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31551603</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Common brain disorders are associated with heritable patterns of apparent aging of the brain.</ArticleTitle><Pagination><StartPage>1617</StartPage><EndPage>1623</EndPage><MedlinePgn>1617-1623</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0471-7</ELocationID><Abstract><AbstractText>Common risk factors for psychiatric and other brain disorders are likely to converge on biological pathways influencing the development and maintenance of brain structure and function across life. Using structural MRI data from 45,615 individuals aged 3-96 years, we demonstrate distinct patterns of apparent brain aging in several brain disorders and reveal genetic pleiotropy between apparent brain aging in healthy individuals and common brain disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaufmann</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4003-1018</Identifier><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. bias.kaufmann@medisin.uio.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Meer</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0466-386X</Identifier><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Mental Health and Neuroscience Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doan</LastName><ForeName>Nhat Trung</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Emanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lund</LastName><ForeName>Martina J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agartz</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry Diakonhjemmet Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Psychiatry Research, Department of Clinical Neuroscience Karolinska Institutet &amp; Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aln&#xe6;s</LastName><ForeName>Dag</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7361-5418</Identifier><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barch</LastName><ForeName>Deanna M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry Washington, University in St. Louis, St. Louis, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology Washington, University in St. Louis, St. Louis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baur-Streubel</LastName><ForeName>Ramona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychology I, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertolino</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry Bari University Hospital, Bari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Medical Science, Neuroscience and Sense Organs University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bettella</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>Mona K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Radiology and Nuclear Medicine, Section of Neuroradiology Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf8;en</LastName><ForeName>Erlend</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry Diakonhjemmet Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychosomatic and CL Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borgwardt</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5792-3987</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry (UPK), University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatics and Psychotherapy University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychiatry King's College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Christine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buitelaar</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8288-7757</Identifier><AffiliationInfo><Affiliation>Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celius</LastName><ForeName>Elisabeth G</ForeName><Initials>EG</Initials><Identifier Source="ORCID">0000-0002-9127-6488</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervenka</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Psychiatry Research, Department of Clinical Neuroscience Karolinska Institutet &amp; Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conzelmann</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C&#xf3;rdova-Palomera</LastName><ForeName>Aldo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Center for Multimodal Imaging and Genetics, University of California at San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Quervain</LastName><ForeName>Dominique J F</ForeName><Initials>DJF</Initials><AffiliationInfo><Affiliation>Division of Cognitive Neuroscience, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transfaculty Research Platform Molecular and Cognitive Neurosciences University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Carlo</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5150-5274</Identifier><AffiliationInfo><Affiliation>Department of Basic Medical Science, Neuroscience and Sense Organs University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8140-8061</Identifier><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xf8;rum</LastName><ForeName>Erlend S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnaas Rehabilitation Hospital HT, Nesodden, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenacher</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elvs&#xe5;shagen</LastName><ForeName>Torbj&#xf8;rn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espeseth</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9076-6365</Identifier><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatouros-Bergman</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Psychiatry Research, Department of Clinical Neuroscience Karolinska Institutet &amp; Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flyckt</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Psychiatry Research, Department of Clinical Neuroscience Karolinska Institutet &amp; Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4375-6572</Identifier><AffiliationInfo><Affiliation>Departments of Human Genetics and Psychiatry, Donders Institute for Brain, Cognition and Behaviour Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frei</LastName><ForeName>Oleksandr</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haatveit</LastName><ForeName>Beathe</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe5;berg</LastName><ForeName>Asta K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science Norwegian, University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine St. Olavs Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harbo</LastName><ForeName>Hanne F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Catharina A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heslenfeld</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Neuropsychology section Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cognitive Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoekstra</LastName><ForeName>Pieter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf8;gest&#xf8;l</LastName><ForeName>Einar A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jernigan</LastName><ForeName>Terry L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Center for Human Development, University of California, San Diego, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Psychiatry and Radiology, University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonassen</LastName><ForeName>Rune</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;nsson</LastName><ForeName>Erik G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Psychiatry Research, Department of Clinical Neuroscience Karolinska Institutet &amp; Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Karolinska Schizophrenia Project (KaSP)</CollectiveName></Author><Author ValidYN="Y"><LastName>Kirsch</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0817-1248</Identifier><AffiliationInfo><Affiliation>Department of Clinical Psychology Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bernstein Center for Computational Neuroscience Heidelberg/Mannheim, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolsk&#xe5;r</LastName><ForeName>Knut K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnaas Rehabilitation Hospital HT, Nesodden, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landr&#xf8;</LastName><ForeName>Nils Inge</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry Diakonhjemmet Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Hellard</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesch</LastName><ForeName>Klaus-Peter</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0001-8348-153X</Identifier><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Center of Mental Health, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School for Mental Health and Neuroscience (MHeNS) Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Warneford Hospital University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundervold</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0032-4182</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundervold</LastName><ForeName>Astri J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-6819-6164</Identifier><AffiliationInfo><Affiliation>Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maglanoc</LastName><ForeName>Luigi A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malt</LastName><ForeName>Ulrik F</ForeName><Initials>UF</Initials><Identifier Source="ORCID">0000-0002-9881-2511</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research and Education, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melle</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Lindenberg</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5619-1123</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moberget</LastName><ForeName>Torgeir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norbom</LastName><ForeName>Linn B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordvik</LastName><ForeName>Jan Egil</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>CatoSenteret Rehabilitation Center Son, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departments of Radiation Sciences and Integrative Medical Biology, Ume&#xe5; Center for Functional Brain Imaging Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oosterlaan</LastName><ForeName>Jaap</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Neuropsychology section Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emma Children's Hospital, Amsterdam UMC University of Amsterdam and Vrije Universiteit Amsterdam, Emma Neuroscience Group, Department of Pediatrics, Amsterdam Reproduction &amp; Development, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papalino</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Basic Medical Science, Neuroscience and Sense Organs University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papassotiropoulos</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cognitive Neuroscience, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Molecular Neuroscience University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Life Sciences Training Facility, Department Biozentrum University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauli</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0692-6720</Identifier><AffiliationInfo><Affiliation>Department of Psychology I, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pergola</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9193-1841</Identifier><AffiliationInfo><Affiliation>Department of Basic Medical Science, Neuroscience and Sense Organs University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Persson</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Genevi&#xe8;ve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnaas Rehabilitation Hospital HT, Nesodden, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rokicki</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Anne-Marthe</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnaas Rehabilitation Hospital HT, Nesodden, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selb&#xe6;k</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shadrin</LastName><ForeName>Alexey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smeland</LastName><ForeName>Olav B</ForeName><Initials>OB</Initials><Identifier Source="ORCID">0000-0002-3761-5215</Identifier><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Clinical Medicine University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurocenter, Neurology Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sowa</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Radiology and Nuclear Medicine, Section of Neuroradiology Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steen</LastName><ForeName>Vidar M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. E. Martens Research Group for Biological Psychiatry, Department of Medical Genetics Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1st Department of Neurology Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrichsen</LastName><ForeName>Kristine M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnaas Rehabilitation Hospital HT, Nesodden, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>UMR Inserm 1027, CHU Toulouse, UPS, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3870-3388</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westman</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3115-2977</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatics and Psychotherapy University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Georg C</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0001-9411-3169</Identifier><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Center of Mental Health, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zink</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>District hospital Ansbach, Ansbach, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0002-4461-3568</Identifier><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westlye</LastName><ForeName>Lars T</ForeName><Initials>LT</Initials><Identifier Source="ORCID">0000-0001-8644-956X</Identifier><AffiliationInfo><Affiliation>NORMENT, Division of Mental Health and Addiction Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. l.t.westlye@psykologi.uio.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Oslo, Oslo, Norway. l.t.westlye@psykologi.uio.no.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>802998</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2020 Feb;23(2):295. doi: 10.1038/s41593-019-0553-6.</RefSource><PMID Version="1">31848485</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests</b>. Some authors received educational speaker&#x2019;s honorarium from Lundbeck (O.A. Andreassen, A. Bertolino, T. Elvs&#xe5;shagen, M. Zink, N. I. Landr&#xf8;), Sunovion (O.A. Andreassen), Shire (B. Franke), Medice (B. Franke), Otsuka (A. Bertolino, M. Zink) and Jannsen (A. Bertolino), Roche (M. Zink), Ferrer (M. Zink), Trommsdorff (M. Zink), Servier (M. Zink), all of these unrelated to this work. A. Bertolino is a stockholder of Hoffmann-La Roche Ltd and has received consultant fees from Biogen Idec. E. G. Celius and H. F. Harbo have received travel support, honoraria for advice and lecturing from Almirall (Celius), Biogen Idec (both), Genzyme (both), Merck (both), Novartis(both), Roche (both), Sanofi-Aventis (both) and Teva (both). They have received unrestricted research grants from Novartis (Celius, Harbo), Biogen Idec (Celius) and Genzyme (Celius). G. Pergola has been the academic supervisor of a Roche collaboration grant (years 2015-16) that funds his salary. None of the mentioned external parties had any role in the analysis, writing or decision to publish this work. Other authors declare no competing financial interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Farde</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flyckt</LastName><ForeName>Lena</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engberg</LastName><ForeName>G&#xf6;ran</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erhardt</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fatouros-Bergman</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cervenka</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwieler</LastName><ForeName>Lilly</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piehl</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agartz</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collste</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Victorsson</LastName><ForeName>Pauliina</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malmqvist</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedberg</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orhan</LastName><ForeName>Funda</ForeName><Initials>F</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31551603</ArticleId><ArticleId IdType="mid">EMS83795</ArticleId><ArticleId IdType="pmc">PMC6823048</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0471-7</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0471-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. World Health Statistics 2016. 2016.</Citation></Reference><Reference><Citation>Insel TR, Cuthbert BN. Brain disorders? Precisely. Science. 2015;348:499&#x2013;500. doi: 10.1126/science.aab2358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab2358</ArticleId><ArticleId IdType="pubmed">25931539</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, et al. No health without mental health. Lancet. 2007;370:859&#x2013;877. doi: 10.1016/S0140-6736(07)61238-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61238-0</ArticleId><ArticleId IdType="pubmed">17804063</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikshak NN, Gandal MJ, Geschwind DH. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat Rev Genet. 2015;16:441&#x2013;458. doi: 10.1038/nrg3934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3934</ArticleId><ArticleId IdType="pmc">PMC4699316</ArticleId><ArticleId IdType="pubmed">26149713</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin O. Developmental timing and critical windows for the treatment of psychiatric disorders. Nat Med. 2016;22:1229&#x2013;1238. doi: 10.1038/nm.4225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4225</ArticleId><ArticleId IdType="pubmed">27783067</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel TR. Rethinking schizophrenia. Nature. 2010;468:187&#x2013;193. doi: 10.1038/Nature09552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/Nature09552</ArticleId><ArticleId IdType="pubmed">21068826</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubert-Broche B, et al. Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology. 2014;83:2140&#x2013;2146. doi: 10.1212/WNL.0000000000001045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001045</ArticleId><ArticleId IdType="pmc">PMC4276405</ArticleId><ArticleId IdType="pubmed">25378667</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, et al. Alzheimer's disease. Nat Rev Dis Primers. 2015;1 doi: 10.1038/nrdp.2015.56. 15056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.56</ArticleId><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NU, et al. Prediction of individual brain maturity using fMRI. Science. 2010;329:1358&#x2013;1361. doi: 10.1126/science.1194144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194144</ArticleId><ArticleId IdType="pmc">PMC3135376</ArticleId><ArticleId IdType="pubmed">20829489</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke K, Ziegler G, Kloppel S, Gaser C. Alzheimer's Disease Neuroimaging, I. Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. Neuroimage. 2010;50:883&#x2013;892. doi: 10.1016/j.neuroimage.2010.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.01.005</ArticleId><ArticleId IdType="pubmed">20070949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JH, Franke K. Predicting Age Using Neuroimaging: Innovative Brain Ageing Biomarkers. Trends Neurosci. 2017;40:681&#x2013;690. doi: 10.1016/j.tins.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2017.10.001</ArticleId><ArticleId IdType="pubmed">29074032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie SJ, et al. Sex Differences in the Adult Human Brain: Evidence from 5216 UK Biobank Participants. Cereb Cortex. 2018;28:2959&#x2013;2975. doi: 10.1093/cercor/bhy109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhy109</ArticleId><ArticleId IdType="pmc">PMC6041980</ArticleId><ArticleId IdType="pubmed">29771288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JH, et al. Predicting brain age with deep learning from raw imaging data results in a reliable and heritable biomarker. Neuroimage. 2017;163:115&#x2013;124. doi: 10.1016/j.neuroimage.2017.07.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.07.059</ArticleId><ArticleId IdType="pubmed">28765056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal V, et al. Genome-wide association study results for educational attainment aid in identifying genetic heterogeneity of schizophrenia. Nature Communications. 2018;9:3078. doi: 10.1038/s41467-018-05510-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05510-z</ArticleId><ArticleId IdType="pmc">PMC6079028</ArticleId><ArticleId IdType="pubmed">30082721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophrenia research. 2010;117:1&#x2013;12. doi: 10.1016/j.schres.2009.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2009.12.022</ArticleId><ArticleId IdType="pubmed">20071149</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernigan TL, Salmon DP, Butters N, Hesselink JR. Cerebral structure on MRI, Part II: Specific changes in Alzheimer's and Huntington's diseases. Biological psychiatry. 1991;29:68&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">1825793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfers T, et al. Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models. Jama Psychiat. 2018;75:1146&#x2013;1155. doi: 10.1001/jamapsychiatry.2018.2467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2018.2467</ArticleId><ArticleId IdType="pmc">PMC6248110</ArticleId><ArticleId IdType="pubmed">30304337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecker C, Bookheimer SY, Murphy DG. Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan. Lancet Neurol. 2015;14:1121&#x2013;1134. doi: 10.1016/S1474-4422(15)00050-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00050-2</ArticleId><ArticleId IdType="pubmed">25891007</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraone SV, et al. Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers. 2015;1 doi: 10.1038/nrdp.2015.20. 15020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.20</ArticleId><ArticleId IdType="pubmed">27189265</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Molecular psychiatry. 2015;20:207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356743</ArticleId><ArticleId IdType="pubmed">24468824</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355. doi: 10.1016/S0896-6273(02)00569-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00569-X</ArticleId><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen AFG, et al. Quantitative assessment of structural image quality. Neuroimage. 2018;169:407&#x2013;418. doi: 10.1016/j.neuroimage.2017.12.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.12.059</ArticleId><ArticleId IdType="pmc">PMC5856621</ArticleId><ArticleId IdType="pubmed">29278774</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Nichols TE. Statistical Challenges in "Big Data" Human Neuroimaging. Neuron. 2018;97:263&#x2013;268. doi: 10.1016/j.neuron.2017.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.12.018</ArticleId><ArticleId IdType="pubmed">29346749</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser MF, et al. A multi-modal parcellation of human cerebral cortex. Nature. 2016;536:171&#x2013;178. doi: 10.1038/nature18933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18933</ArticleId><ArticleId IdType="pmc">PMC4990127</ArticleId><ArticleId IdType="pubmed">27437579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho D, Imai K, King G, Stuart E. A. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. Journal of Statistical Software. 2011;42:1&#x2013;28.</Citation></Reference><Reference><Citation>Chen T, Guestrin C. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; San Francisco, California, USA: ACM; 2016. pp. 785&#x2013;794.</Citation></Reference><Reference><Citation>Tianqi C, Tong H, Benesty M, Khotilovich V, Tang Y. R package v0.4-2. 2015. Xgboost: extreme gradient boosting.</Citation></Reference><Reference><Citation>Le TT, et al. A Nonlinear Simulation Framework Supports Adjusting for Age When Analyzing BrainAGE. Front Aging Neurosci. 2018;10:317. doi: 10.3389/fnagi.2018.00317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00317</ArticleId><ArticleId IdType="pmc">PMC6208001</ArticleId><ArticleId IdType="pubmed">30405393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuber V, Strimmer K. Care. R package v 1.1.10. 2017. Care. R package v 1.1.10.</Citation></Reference><Reference><Citation>Cole JH, et al. Brain age predicts mortality. Molecular psychiatry. 2018;23:1385&#x2013;1392. doi: 10.1038/mp.2017.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.62</ArticleId><ArticleId IdType="pmc">PMC5984097</ArticleId><ArticleId IdType="pubmed">28439103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82:591&#x2013;605. doi: 10.1111/j.1469-185X.2007.00027.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-185X.2007.00027.x</ArticleId><ArticleId IdType="pubmed">17944619</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analysis in R with the metafor package. Journal of Statistical Software. 2010;36:1&#x2013;48.</Citation></Reference><Reference><Citation>Warnes GR, et al. R Package gplots: Various R Programming Tools for Plotting Data. 2016.</Citation></Reference><Reference><Citation>Gu Z. R Package circlize: Circular Visualization. 2017.</Citation></Reference><Reference><Citation>Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203&#x2013;209. doi: 10.1038/s41586-018-0579-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0579-z</ArticleId><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics. 2007;81:559&#x2013;575. doi: 10.1086/519795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nature genetics. 2015;47:291&#x2013;295. doi: 10.1038/ng.3211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3211</ArticleId><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B, et al. An atlas of genetic correlations across human diseases and traits. Nature genetics. 2015;47:1236&#x2013;1241. doi: 10.1038/ng.3406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3406</ArticleId><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols T, Brett M, Andersson J, Wager T, Poline J-B. Valid conjunction inference with the minimum statistic. Neuroimage. 2005;25:653&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808966</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. The American Journal of Human Genetics. 2013;92:197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567279</ArticleId><ArticleId IdType="pubmed">23375658</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove J, et al. Identification of common genetic risk variants for autism spectrum disorder. Nature genetics. 2019;51:431&#x2013;444. doi: 10.1038/s41588-019-0344-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0344-8</ArticleId><ArticleId IdType="pmc">PMC6454898</ArticleId><ArticleId IdType="pubmed">30804558</ArticleId></ArticleIdList></Reference><Reference><Citation>Demontis D, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature genetics. 2018 doi: 10.1038/s41588-018-0269-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0269-7</ArticleId><ArticleId IdType="pmc">PMC6481311</ArticleId><ArticleId IdType="pubmed">30478444</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophrenia Working Group of the PGC et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421. doi: 10.1038/nature13595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13595</ArticleId><ArticleId IdType="pmc">PMC4112379</ArticleId><ArticleId IdType="pubmed">25056061</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl EA, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature genetics. 2019;51:793&#x2013;803. doi: 10.1038/s41588-019-0397-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0397-8</ArticleId><ArticleId IdType="pmc">PMC6956732</ArticleId><ArticleId IdType="pubmed">31043756</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsopoulos N, et al. The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility. bioRxiv. 2017 doi: 10.1101/143933. 143933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/143933</ArticleId><ArticleId IdType="pmc">PMC7241648</ArticleId><ArticleId IdType="pubmed">31604244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray NR, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature genetics. 2018;50:668&#x2013;681. doi: 10.1038/s41588-018-0090-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0090-3</ArticleId><ArticleId IdType="pmc">PMC5934326</ArticleId><ArticleId IdType="pubmed">29700475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature genetics. 2013;45:1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, et al. The ensembl variant effect predictor. Genome biology. 2016;17:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen G, Karterud S. The symptom and function dimensions of the Global Assessment of Functioning (GAF) scale. Comprehensive Psychiatry. 2012;53:292&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">21632038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987;13:261.</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33:1444&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">6685237</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2013.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32211502</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-8729</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia (Amsterdam, Netherlands)</Title><ISOAbbreviation>Alzheimers Dement (Amst)</ISOAbbreviation></Journal><ArticleTitle>Amyloid duration is associated with preclinical cognitive decline and tau PET.</ArticleTitle><Pagination><StartPage>e12007</StartPage><MedlinePgn>e12007</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12007</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/dad2.12007</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">This study applies a novel algorithm to longitudinal amyloid positron emission tomography (PET) imaging to identify age-heterogeneous amyloid trajectory groups, estimate the age and duration (chronicity) of amyloid positivity, and investigate chronicity in relation to cognitive decline and tau burden.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cognitively unimpaired participants (<i>n</i> = 257) underwent one to four amyloid PET scans (Pittsburgh Compound B, PiB). Group-based trajectory modeling was applied to participants with longitudinal scans (<i>n</i> = 171) to identify and model amyloid trajectory groups, which were combined with Bayes theorem to estimate age and chronicity of amyloid positivity. Relationships between chronicity, cognition, clinical progression, and tau PET (MK-6240) were investigated using regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Chronicity explained more heterogeneity in amyloid burden than age and binary amyloid status. Chronicity was associated with faster cognitive decline, increased risk of abnormal cognition, and higher entorhinal tau.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Amyloid chronicity provides unique information about cognitive decline and neurofibrillary tangle development and may be useful to investigate preclinical Alzheimer's disease.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring published by Wiley Periodicals, Inc. on behalf of the Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koscik</LastName><ForeName>Rebecca L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betthauser</LastName><ForeName>Tobey J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonaitis</LastName><ForeName>Erin M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allison</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Lindsay R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Bruce P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cody</LastName><ForeName>Karly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engle</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Medical Physics University of Wisconsin-Madison Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnhart</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Medical Physics University of Wisconsin-Madison Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Charles K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Nathaniel A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christian</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Physics University of Wisconsin-Madison Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Waisman Laboratory for Brain Imaging and Behavior University of Wisconsin-Madison Madison Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG037639</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR002375</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025245</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090256</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062285</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement (Amst)</MedlineTA><NlmUniqueID>101654604</NlmUniqueID><ISSNLinking>2352-8729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">beta&#x2010;amyloid</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">chronicity</Keyword><Keyword MajorTopicYN="N">group&#x2010;based trajectory modeling</Keyword><Keyword MajorTopicYN="N">positron emission tomography</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">trajectory modeling</Keyword></KeywordList><CoiStatement>[18F]MK&#x2010;6240 precursor and reference standard used in this study were provided by Cerveau Technologies. Dr. Sterling C. Johnson is principal investigator for a separate ongoing study using MK&#x2010;6240 sponsored by Cerveau Technologies. Dr. Sterling C. Johnson served on an advisory board for Roche Diagnostics in 2018. Dr. Howard Rowley is a consultant for GE HealthCare and has equity interest in ImageMoverMD. None of the other authors has any relevant disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32211502</ArticleId><ArticleId IdType="pmc">PMC7085284</ArticleId><ArticleId IdType="doi">10.1002/dad2.12007</ArticleId><ArticleId IdType="pii">DAD212007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Jr. , Knopman DS, Jagust WJ, et&#xa0;al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr. , Knopman DS, Jagust WJ, et&#xa0;al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119&#x2010;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et&#xa0;al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795&#x2010;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et&#xa0;al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2010;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr. , Lowe VJ, Weigand SD, et&#xa0;al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(5):1355&#x2010;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et&#xa0;al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#x2010;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, et&#xa0;al. NIA&#x2010;AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc. 2018;14(4):535&#x2010;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LR, Berman SE, Norton D, et&#xa0;al. Age&#x2010;accelerated cognitive decline in asymptomatic adults with CSF &#x3b2;&#x2010;amyloid. Neurology. 2018;90(15):e1306&#x2010;e1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5894934</ArticleId><ArticleId IdType="pubmed">29523644</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LR, Racine AM, Koscik RL, et&#xa0;al. Beta&#x2010;amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement. 2016;12(7):805&#x2010;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947439</ArticleId><ArticleId IdType="pubmed">26806386</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun C&#x2010;K, Weiner MW, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305&#x2010;2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, et&#xa0;al. Amyloid&#x2010;&#x3b2;&#x2013;associated clinical decline occurs only in the presence of elevated p&#x2010;tau. Arch Neurol. 2012;69(6):709&#x2010;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino EC, Schultz AP, et&#xa0;al. The impact of amyloid&#x2010;beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85(2):181&#x2010;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, Prince JL, Wong DF, Resnick SM, Jedynak BM. A multivariate nonlinear mixed effects model for longitudinal image analysis: application to amyloid imaging. Neuroimage. 2016;134:658&#x2010;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4912927</ArticleId><ArticleId IdType="pubmed">27095307</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Lesnick TG, et&#xa0;al. Brain &#x3b2;&#x2010;amyloid load approaches a plateau. Neurology. 2013;80(10):890&#x2010;896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Ossenkoppele R, Gessert D, et&#xa0;al. Time to amyloid positivity and preclinical changes in brain metabolism, atrophy, and cognition: evidence for emerging amyloid pathology in Alzheimer's disease. Front Neurosci. 2017;11:281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434146</ArticleId><ArticleId IdType="pubmed">28567001</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittington A, Sharp DJ, Gunn RN, Initiative ADN. Spatiotemporal distribution of &#x3b2;&#x2010;amyloid in Alzheimer disease is the result of heterogeneous regional carrying capacities. J Nucl Med. 2018;59(5):822&#x2010;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932528</ArticleId><ArticleId IdType="pubmed">29146694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29(3):374&#x2010;393.</Citation></Reference><Reference><Citation>Nagin DS. Analyzing developmental trajectories: a semiparametric, group&#x2010;based approach. Psychol Methods. 1999;4(2):139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11285809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostetler ED, Walji AM, Zeng Z, et&#xa0;al. Preclinical characterization of 18F&#x2010;MK&#x2010;6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599&#x2010;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">27230925</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Cody KA, Zammit MD, et&#xa0;al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F&#x2010;MK&#x2010;6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93&#x2010;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354223</ArticleId><ArticleId IdType="pubmed">29777006</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Koscik RL, Jonaitis EM, et&#xa0;al. The Wisconsin registry for Alzheimer's prevention: a review of findings and current directions. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:130&#x2010;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5755749</ArticleId><ArticleId IdType="pubmed">29322089</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonaitis EM, Koscik RL, Clark LR, et&#xa0;al. Measuring longitudinal cognition: individual tests versus composites. Alzheimers Dement Diagn Assess Dis Monit. 2019;11:74&#x2010;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816509</ArticleId><ArticleId IdType="pubmed">31673596</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. L'examen psychologique dans les cas d'enc&#xe9;phalopathie traumatique (Les problems.). Arch Psychol. 1941;28:215&#x2010;285.</Citation></Reference><Reference><Citation>Wechsler D. WMS&#x2010;R: Wechsler Memory Scale&#x2010;Revised. New York, NY: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Wechsler D. WAIS&#x2010;III: Wechsler Adult Intelligence Scale. New York, NY: Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, et&#xa0;al. Binding of the positron emission tomography tracer Pittsburgh compound&#x2010;B reflects the amount of amyloid&#x2010;&#x3b2; in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25(46):10598&#x2010;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, Bendlin BB, Racine AM, et&#xa0;al. Amyloid burden is associated with self&#x2010;reported sleep in nondemented late middle&#x2010;aged adults. Neurobiol Aging. 2015;36(9):2568&#x2010;2576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4523445</ArticleId><ArticleId IdType="pubmed">26059712</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine AM, Clark LR, Berman SE, et&#xa0;al. Associations between performance on an abbreviated CogState battery, other measures of cognitive function, and biomarkers in people at risk for Alzheimer's disease. J Alzheimers Dis. 2016;54(4):1395&#x2010;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074904</ArticleId><ArticleId IdType="pubmed">27589532</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Christian BT, Okonkwo OC, et&#xa0;al. Amyloid burden and neural function in people at risk for Alzheimer's disease. Neurobiol Aging. 2014;35(3):576&#x2010;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018215</ArticleId><ArticleId IdType="pubmed">24269021</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BL, Nagin DS. Advances in group&#x2010;based trajectory modeling and an SAS procedure for estimating them. Sociol Methods Res. 2007;35(4):542&#x2010;571.</Citation></Reference><Reference><Citation>Nagin DS, Odgers CL. Group&#x2010;based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109&#x2010;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">20192788</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh ML. Interrater reliability: the kappa statistic. Biochem Medica Biochem Medica. 2012;22(3):276&#x2010;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900052</ArticleId><ArticleId IdType="pubmed">23092060</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham KP, Anderson DR, Huyvaert KP. AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons. Behav Ecol Sociobiol. 2011;65(1):23&#x2010;35.</Citation></Reference><Reference><Citation>Koscik RL, Jonaitis EM, Clark LR, et&#xa0;al. Longitudinal standards for mid&#x2010;life cognitive performance: identifying abnormal within&#x2010;person changes in the Wisconsin Registry for Alzheimer's Prevention. J Int Neuropsychol Soc. 2019;25(1):1&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349483</ArticleId><ArticleId IdType="pubmed">30482257</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittington A, Sharp D, Gunn R. Spatiotemporal distribution of &#x3b2;&#x2010;amyloid in Alzheimer's disease results from heterogeneous regional carrying capacities. J Nucl Med. 2016;57(supplement 2):346&#x2010;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932528</ArticleId><ArticleId IdType="pubmed">29146694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, An Y, Zhou Y, et&#xa0;al. Individual estimates of age at detectable amyloid onset for risk factor assessment. Alzheimers Dement. 2016;12(4):373&#x2010;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4841700</ArticleId><ArticleId IdType="pubmed">26588863</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedynak BM, Lang A, Liu B, et&#xa0;al. A computational neurodegenerative disease progression score: method and results with the Alzheimer's Disease Neuroimaging Initiative Cohort. Neuroimage. 2012;63(3):1478&#x2010;1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472161</ArticleId><ArticleId IdType="pubmed">22885136</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, et&#xa0;al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509&#x2010;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et&#xa0;al. Episodic memory loss is related to hippocampal&#x2010;mediated &#x3b2;&#x2010;amyloid deposition in elderly subjects. Brain. 2008;132(5):1310&#x2010;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, et&#xa0;al. &#x3b2;&#x2010;amyloid imaging and memory in non&#x2010;demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(11):2837&#x2010;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Betthauser TJ, Koscik RL, Jonaitis EM, et&#xa0;al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle&#x2010;age. Brain. January 2020;143(1):320&#x2010;335, 10.1093/brain/awz378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz378</ArticleId><ArticleId IdType="pmc">PMC6935717</ArticleId><ArticleId IdType="pubmed">31886494</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31591557</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations.</ArticleTitle><Pagination><StartPage>1903</StartPage><EndPage>1912</EndPage><MedlinePgn>1903-1912</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-019-0501-5</ELocationID><Abstract><AbstractText>Parietal cortex RNA-sequencing (RNA-seq) data were generated from individuals with and without Alzheimer disease (AD; n<sub>control</sub>&#x2009;=&#x2009;13; n<sub>AD</sub>&#x2009;=&#x2009;83) from the Knight Alzheimer Disease Research Center (Knight ADRC). Using this and an independent (Mount Sinai Brain Bank (MSBB)) AD RNA-seq dataset, cortical circular RNA (circRNA) expression was quantified in the context of AD. Significant associations were identified between circRNA expression and AD diagnosis, clinical dementia severity and neuropathological severity. It was demonstrated that most circRNA-AD associations are independent of changes in cognate linear messenger RNA expression or estimated brain cell-type proportions. Evidence was provided for circRNA expression changes occurring early in presymptomatic AD and in autosomal dominant AD. It was also observed that AD-associated circRNAs co-expressed with known AD genes. Finally, potential microRNA-binding sites were identified in AD-associated circRNAs for miRNAs predicted to target AD genes. Together, these results highlight the importance of analyzing non-linear RNAs and support future studies exploring the potential roles of circRNAs in AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dube</LastName><ForeName>Umber</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-9324-1927</Identifier><AffiliationInfo><Affiliation>Medical Scientist Training Program, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del-Aguila</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zeran</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-7434-6499</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budde</LastName><ForeName>John P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-7778-7276</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibanez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Maria Victoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentsch</LastName><ForeName>Jen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fengxian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network (DIAN)</CollectiveName></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alpert Medical School of Brown University, 345 Blackstone Boulevard, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute, the University of Melbourne. Level 1, Howard Florey Laboratories, Royal Parade, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jae-Hong</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders. Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0276-2899</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid Ave. CB8134, St. Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders. Washington University School of Medicine, St. Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics, Washington University School of Medicine, St. Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG046374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057777</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058922</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG064877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079962">RNA, Circular</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001271" MajorTopicYN="Y">Atlases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079962" MajorTopicYN="N">RNA, Circular</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: CC receives research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Allegri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amtashar</LastName><ForeName>Fatima</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodge</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandon</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buck</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chea</LastName><ForeName>Sochenda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chrem</LastName><ForeName>Patricio</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cinco</LastName><ForeName>Jake</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clifford</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Mello</LastName><ForeName>Mirelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donahue</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Douglas</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edigo</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Marty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrar</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flynn</LastName><ForeName>Gigi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujii</LastName><ForeName>Hisako</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gant</LastName><ForeName>Cortaiga</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardener</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gurney</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirohara</LastName><ForeName>Mie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornbeck</LastName><ForeName>Russ</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiBari</LastName><ForeName>Siri Houeland</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Snezana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerome</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasuga</LastName><ForeName>Kensaku</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawarabayashi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>Elke</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laske</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Neal Scott</ForeName><Initials>NS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maue-Dreyfus</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoya</LastName><ForeName>Lucy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamatsu</LastName><ForeName>Akem</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neimeyer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roh</LastName><ForeName>Jee Hoon</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimada</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiroto</LastName><ForeName>Tomoyo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoji</LastName><ForeName>Mikio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sohrabi</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sparks</LastName><ForeName>Paige</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kazushi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swisher</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfsberger</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiong</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31591557</ArticleId><ArticleId IdType="mid">NIHMS1537925</ArticleId><ArticleId IdType="pmc">PMC6858549</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0501-5</ArticleId><ArticleId IdType="pii">10.1038/s41593-019-0501-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barrett SP &amp; Salzman J Circular RNAs: analysis, expression and potential functions. Development 143, 1838&#x2013;1847 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920157</ArticleId><ArticleId IdType="pubmed">27246710</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Yang L &amp; Chen L-L The Biogenesis, Functions, and Challenges of Circular RNAs. Mol. Cell 71, 428&#x2013;442 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30057200</ArticleId></ArticleIdList></Reference><Reference><Citation>Westholm JO et al. Genome-wide Analysis of Drosophila Circular RNAs Reveals Their Structural and Sequence Properties and Age-Dependent Neural Accumulation. Cell Rep. 9, 1966&#x2013;1980 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4279448</ArticleId><ArticleId IdType="pubmed">25544350</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruner H, Cort&#xe9;s-L&#xf3;pez M, Cooper DA, Bauer M &amp; Miura P CircRNA accumulation in the aging mouse brain. Sci. Rep 6, 38907 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5153657</ArticleId><ArticleId IdType="pubmed">27958329</ArticleId></ArticleIdList></Reference><Reference><Citation>Memczak S et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333&#x2013;338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23446348</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman J, Gawad C, Wang PL, Lacayo N &amp; Brown PO Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PloS One 7, e30733 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270023</ArticleId><ArticleId IdType="pubmed">22319583</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass PG et al. A map of human circular RNAs in clinically relevant tissues. J. Mol. Med 1&#x2013;11 (2017). doi:10.1007/s00109-017-1582-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-017-1582-9</ArticleId><ArticleId IdType="pmc">PMC5660143</ArticleId><ArticleId IdType="pubmed">28842720</ArticleId></ArticleIdList></Reference><Reference><Citation>You X et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat. Neurosci 18, 603&#x2013;610 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376664</ArticleId><ArticleId IdType="pubmed">25714049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashwal-Fluss R et al. circRNA biogenesis competes with pre-mRNA splicing. Mol. Cell 56, 55&#x2013;66 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25242144</ArticleId></ArticleIdList></Reference><Reference><Citation>Rybak-Wolf A et al. Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. Mol. Cell 58, 870&#x2013;885 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25921068</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D et al. The Output of Protein-Coding Genes Shifts to Circular RNAs When the Pre-mRNA Processing Machinery Is Limiting. Mol. Cell 0, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728686</ArticleId><ArticleId IdType="pubmed">29174924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ven&#xf8; MT et al. Spatio-temporal regulation of circular RNA expression during porcine embryonic brain development. Genome Biol. 16, 245 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635978</ArticleId><ArticleId IdType="pubmed">26541409</ArticleId></ArticleIdList></Reference><Reference><Citation>Legnini I et al. Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis. Mol. Cell 66, 22&#x2013;37.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5387670</ArticleId><ArticleId IdType="pubmed">28344082</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamudurti NR et al. Translation of CircRNAs. Mol. Cell 66, 9&#x2013;21.e7 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5387669</ArticleId><ArticleId IdType="pubmed">28344080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen TB et al. Natural RNA circles function as efficient microRNA sponges. Nature 495, 384&#x2013;388 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23446346</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P et al. Alzheimer&#x2019;s disease. The Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H &amp; Del Tredici K Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. (Berl.) 112, 389&#x2013;404 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM et al. Expression of novel Alzheimer&#x2019;s disease risk genes in control and Alzheimer&#x2019;s disease brains. PloS One 7, e50976 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511432</ArticleId><ArticleId IdType="pubmed">23226438</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x2019;s disease susceptibility. Nat. Genet 50, 1584 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354244</ArticleId><ArticleId IdType="pubmed">30297968</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J &amp; Sleegers K Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics. Trends Genet. TIG 34, 434&#x2013;447 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29573818</ArticleId></ArticleIdList></Reference><Reference><Citation>Piwecka M et al. Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. Science 357, eaam8526 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28798046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ Circular RNA (circRNA) in Alzheimer&#x2019;s disease (AD). Front. Genet 4, (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875874</ArticleId><ArticleId IdType="pubmed">24427167</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS Diagnosis of Alzheimer&#x2019;s disease. Arch. Neurol 42, 1097&#x2013;1105 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Sci. Data 5, 180185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma. Oxf. Engl 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrow J et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res. 22, 1760&#x2013;1774 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431492</ArticleId><ArticleId IdType="pubmed">22955987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, Metge F &amp; Dieterich C Specific identification and quantification of circular RNAs from sequencing data. Bioinforma. Oxf. Engl 32, 1094&#x2013;1096 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26556385</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W &amp; Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L et al. Measure transcript integrity using RNA-seq data. BMC Bioinformatics 17, 58 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739097</ArticleId><ArticleId IdType="pubmed">26842848</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett SP, Parker KR, Horn C, Mata M &amp; Salzman J ciRS-7 exonic sequence is embedded in a long non-coding RNA locus. PLoS Genet. 13, e1007114 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745005</ArticleId><ArticleId IdType="pubmed">29236709</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z et al. Genetic variants associated with Alzheimer&#x2019;s disease confer different cerebral cortex cell-type population structure. Genome Med. 10, 43 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5992755</ArticleId><ArticleId IdType="pubmed">29880032</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter J &amp; Bithell J Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat. Med 19, 1141&#x2013;1164 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10797513</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter ML et al. Executive deficits are related to the inferior frontal junction in early dementia. Brain 135, 201&#x2013;215 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267982</ArticleId><ArticleId IdType="pubmed">22184615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. Autosomal-dominant Alzheimer&#x2019;s disease: a review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res. Ther 3, 1 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Relative Importance for Linear Regression in R: The Package relaimpo | Groemping | Journal of Statistical Software. doi:10.18637/jss.v017.i01</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v017.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W-M &amp; Zhang B Multiscale Embedded Gene Co-expression Network Analysis. PLOS Comput. Biol 11, e1004574 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664553</ArticleId><ArticleId IdType="pubmed">26618778</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P &amp; Horvath S WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y et al. Circular RNA DLGAP4 Ameliorates Ischemic Stroke Outcomes by Targeting miR-143 to Regulate Endothelial-Mesenchymal Transition Associated with Blood-Brain Barrier Integrity. J. Neurosci. Off. J. Soc. Neurosci 38, 32&#x2013;50 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705810</ArticleId><ArticleId IdType="pubmed">29114076</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V, Bell GW, Nam J-W &amp; Bartel DP Predicting effective microRNA target sites in mammalian mRNAs. eLife 4, e05005 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532895</ArticleId><ArticleId IdType="pubmed">26267216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y et al. MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett. 586, 3608&#x2013;3612 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22967897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TI &amp; Young RA Transcriptional Regulation and Its Misregulation in Disease. Cell 152, 1237&#x2013;1251 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640494</ArticleId><ArticleId IdType="pubmed">23498934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kljajevic V, Grothe MJ, Ewers M &amp; Teipel S Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer&#x2019;s disease. Neurobiol. Aging 35, 1973&#x2013;1981 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24811241</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang WS et al. Alzheimer&#x2019;s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc. Natl. Acad. Sci 105, 4441&#x2013;4446 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2393743</ArticleId><ArticleId IdType="pubmed">18332434</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins M et al. Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E &#x25b;4 Carriers. J. Alzheimers Dis 53, 95&#x2013;106</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4942726</ArticleId><ArticleId IdType="pubmed">27128370</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R et al. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer&#x2019;s Disease Patient with Presenilin-1 Mutation. J. Alzheimers Dis. JAD 51, 339&#x2013;343 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26836192</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer&#x2019;s disease. J. Nucl. Med. Off. Publ. Soc. Nucl. Med 47, 1778&#x2013;1786 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 25, 981&#x2013;984 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4528056</ArticleId><ArticleId IdType="pubmed">26138677</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>METHODS-only - REFERENCES</Title><Reference><Citation>Pine PS et al. Evaluation of the External RNA Controls Consortium (ERCC) reference material using a modified Latin square design. BMC Biotechnol. 16, 54 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4921035</ArticleId><ArticleId IdType="pubmed">27342544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 4, 7 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs RA et al. The International HapMap Project. Nature 426, 789&#x2013;796 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14685227</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang C et al. Template switching causes artificial junction formation and false identification of circular RNAs. bioRxiv 259556 (2018). doi:10.1101/259556</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/259556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gla&#x17e;ar P, Papavasileiou P &amp; Rajewsky N circBase: a database for circular RNAs. RNA (2014). doi:10.1261/rna.043687.113</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.043687.113</ArticleId><ArticleId IdType="pmc">PMC4201819</ArticleId><ArticleId IdType="pubmed">25234927</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA &amp; Kingsford C Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference. Nat. Methods 14, 417&#x2013;419 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang S &amp; Li W RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184&#x2013;2185 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22743226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Zhao Y &amp; Zhang B Efficient Test and Visualization of Multi-Set Intersections. Sci. Rep 5, 16923 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658477</ArticleId><ArticleId IdType="pubmed">26603754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chella Krishnan K et al. Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease. Cell Syst. 6, 103&#x2013;115.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5799036</ArticleId><ArticleId IdType="pubmed">29361464</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Taskesen E, van Bochoven, A. &amp; Posthuma D Functional mapping and annotation of genetic associations with FUMA. Nat. Commun 8, 1826 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705698</ArticleId><ArticleId IdType="pubmed">29184056</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria: 
https://www.R-project.org/ (2018).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>